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Abstract 1 
Abstract 
Developed countries' publicly funded health care systems all share the similar task of deciding 
which pharmaceuticals should be reimbursed. OECD countries' pharmaceutical reimbursement 
systems achieve this task through a number of institutions some of which use Health Technology 
Assessment (HTA) including health economic analysis to inform decision-making. The 
reimbursement decisions influence the health outcomes of patients, produce Signals of the 
demand curve to manufacturers and may have political consequences. The overall aim of this 
thesis is to examine the use of health economic analysis in OECD countries' reimbursement 
systems and the contribution of health economic analysis and other factors to decision-making. 
Chapter 2 provides a literature review of previous quantitative and qualitative studies examining 
the factors contributing to reimbursement decision-making in OECD countries. The review 
identified limited evidence for comparisons across OECD countries and outlined the 
methodological limitations of identifying influence. Chapters 3 and 4 categorise OECD 
reimbursement systems using a published framework. Application of the framework identified 
that Health Economic analysis is used by agencies operating in heterogeneous reimbursement 
systems with respect to the objectives, other institutions, processes, guidelines, interpretation 
and other factors considered alongside health economic analysis. Chapter 5 uses regression 
analysis to examine decisions by those agencies that similarly use clinical evidence and health 
economic analysis, and identifies common factors across four countries. Chapter 6 uses a 
qualitative methodology to match decisions for an agency using health economic analysis in 
comparison to one not and found evidence of the influence of health economic analysis alongside 
other evidence and process factors. Finally, chapter 7 concludes by outlining the differential 
contribution of health economic analysis depending on how it is used by the systems. The 
limitations are discussed and recommendations provided for further research. 
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Chapter 1: Introduction 
1.1 Pharmaceutical market and its structure 
Developed countries' health care systems typically aim to provide universal and equitable access 
to health care in order to improve the health of their populations. Each country's public health 
system must decide which treatments to provide and pay for, with or without conditions, given 
the limited resources available to meet their objectives. Pharmaceuticals are one form of 
treatment option to meet these requirements and are produced by manufacturers located 
globally. Pharmaceutical global sales were reported by IMS Health to be $875bn US dollars in 
2010, representing growth of 4.1% since 2009. The US is the largest market with 38% of sales, 
followed by Europe with 29% and Asia, Africa and Australasia with 15% of sales (IMS Health, 
2011). Pharmaceutical research and development is complex, risky and highly regulated by 
governments. It takes between 12 to 13 years (EFPIA, 2011) to bring a pharmaceutical to market 
for which the latest estimates of costs per product to reach market are around $1.2 billion for a 
biopharmaceutical and $1.3 billion US Dollars for traditional pharmaceuticals (DiMasi and 
Grabowski, 2007). 
There has been speculation on whether pharmaceuticals influence mortality and some evidence 
that the relationship between pharmaceutical innovation and mortality may have declined over 
time (Weisbrod, 1991, Beltran-Sanchez et aI., 2008). Other studies report an association between 
new medicines and mortality and the quality of life of societies. A recent US study based on 40 
years of data demonstrates that there is a significant relationship between pharmaceutical 
innovation and yearly fluctuations in life expectancy at birth, which is robust to controls for 
income as well as other forms of medical spending (Schnittker and Karandinos, 2010). In an 
earlier study, the impact of new medicines launches on life expectancy in 52 countries during the 
period between 1986 and 2000 demonstrated important positive impacts upon health. The 
analysis demonstrated a relationship between the number of New Chemical Entities (NCEs) 
introduced and the impact on life expectancy. The period showed that life expectancy increased 
by almost two years across the sample of countries, of which 40% (3 weeks per year) may be 
accountable to the introduction of the NCEs during this period (lichtenberg, 2005). These 
analyses do not take into account the fact that scientific advances result in both new medicines 
and changes in behaviour. Behavioural changes such as reduced smoking rates and other 
innovations may be just as important in explaining the association. 
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The pharmaceutical market is highly regulated and requires manufacturers to make large sunk 
costs. Governments provide pharmaceutical manufacturers with incentives to innovate by the use 
of patents. A patent provides protection for the invention of a new medicine for a limited period 
of time, commonly 20 years. Patents are necessary to provide pharmaceutical manufacturers with 
legal protection to achieve a price sufficient to recover Research and Development (R&D) costs 
and provide incentives for the creation of new and innovative medicines. The pharmaceutical 
manufacturer is assumed to maximise global profits. The patent system guarantees the monopoly 
status of the manufacturer for a set period of time but the final value is determined by 
consumers, which in the case of the public reimbursement system is usually a single 
reimbursement or payer body which can be referred to as a monopsony buyer (Puig-Junoy, 2005). 
A market characterised by a single seller (monopoly) and a single buyer (monopsony) is known as 
a bilateral monopoly, where the buyer will tend to drive for a lower price and the seller a higher 
price. The price is indeterminate within a wide range of prices which may take the extreme values 
set between the price set by a single manufacturer where there are a number of competitive 
purchasers (where the manufacturer retains all the benefit) and the price that a monopsonist 
buyer would impose on a number of competitive manufacturers (where the health system retains 
all the benefit), (Scherer, 1970). The price indeterminacy problem can be overcome using game 
theory (Nash, 1950, Rubinstein, 1982). The situation between the monopoly manufacturer and 
the monopsony reimbursement institution represents a bargaining game and the price and 
reimbursement coverage will be determined by their relative bargaining power (Hawkins and 
Scott, 2011). There are different decision processes in countries' reimbursement systems that set 
the rules for bargaining. 
Claxton argues that reimbursement institutions that use health economic analysis can provide 
clear signals of the 'demand curve' by being explicit about the threshold range (the opportunity 
cost or value of displaced health service activities) and where possible considering cost-
effectiveness by subgroups within indications where there is elastic demand rather than average 
cost-effectiveness of the entire population (Claxton, 2007, Claxton et aI., 2008). If the 
manufacturer is able to price at the average cost effectiveness all the benefit will be accrued to 
the manufacturer, assuming that price has been set in accordance to the threshold. This is 
represented as P*/Q* in the diagram reproduced from (Claxton, 2007) where the demand curve is 
perfectly price elastic. If subgroups have differential effectiveness within the indication, an elastic 
demand curve can be specified as in Figure 1.1 (diagram b). The manufacturer can choose a price 
for which they would be prepared to supply the market taking into account their average costs 
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and the impact on the local market profit and influence on prices in other countries 
reimbursement systems (either Pl, P2, or P3). Restrictions on reimbursement in relation to the 
marketing authorisation can then be read off the demand curve in relation to the manufacturers 
choice of price, i.e. higher prices result in more restrictive decisions when there is evidence of the 
medicines differential effectiveness across subgroups (as illustrated by Pl/Ql, P2/Q2 and P3/Q3), 
(Claxton, 2007). The final reimbursement decision and price will depend on the ability of the 
system to ensure marginal pricing by subgroup where appropriate and the pricing process 
followed within each country (prices are set freely by the manufacturer, statutory pricing or 
negotiated prices). 
Figure 1.1: Demand curve reproduced from figure 1 (Claxton, 2007) 
Price Price 
Pi ~. 
A 
P* P2 t----.........,.,-..., 
B C 
P3 r.~=~~===~~-~ 
Q* Ql Q2 Q3 
Quantity Quantity 
1.2 The Journey from laboratory bench to reimbursement (fourth hurdle) 
Following a patent application a new medicine will have gone through approximately ten years of 
research and development which includes pre-clinical testing (Pharmacology, acute and chronic 
toxicity) and clinical research (Phase I, Phase" and Phase III trials) (EFPIA, 2011). A new medicine 
must gain a regulatory licence/marketing authorisation before it can be considered by the 
reimbursement system. The manufacturer must obtain a new licence by providing evidence of the 
medicine's quality, safety and efficacy. This is not sufficient in many countries to obtain 
reimbursement of the medicine in the public system and the manufacturer must provide evidence 
in a further step called the 'fourth hurdle'. The 'fourth hurdle' is a term used by many 
stakeholders to describe the stage by which the system judges whether the medicine should be 
reimbursed by the public system after obtaining a regulatory licence (Hutton et aI., 2006). This is 
recognised by many stakeholders to refer to this stage but the term is sometimes used to describe 
different analytical techniques or methods used by countries systems such as Health Technology 
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Assessment (HTA) (Maynard and McDaid, 2003, Hutton et aL, 2006), comparative effectiveness 
(Honig, 2011) or economic analysis (Hill et aL, 1997, Drummond, 2003, Taylor et aL, 2004) to 
Inform reimbursement decisions. 
There is a belief that the formal use of evidence and analytical methods to inform the decisions 
for reimbursement improves decision-making for pharmaceutical reimbursement (Culyer and 
lomas, 2006). There is currently a lack of evidence across international reimbursement systems of 
whether such evidence improves decision-making. The practical use of evidence in decision-
making has been criticised on a number of occasions because of the divergence between theory 
and use in real life practice (Birch and Gafni 2002, Birch and Gafni 2006 & Birch and Gafni 2007). 
In particular the health economic analysis framework has been criticised on the basis of its 
theoretical assumptions, whether empirical studies can truly identify the opportunity cost and the 
practical problems of the opportunity cost varying across different parts of the health system. A 
central theoretical focus has been with respect to the maximisation of health and improvements 
in allocative efficiency where Improvements in health are defined as the welfare maximand. 
Allocative efficiency Is the situation in which resources are allocated so as to maximise the welfare 
(health) of the community or in other words achieving the right mixture of healthcare 
programmes to maximise the health of society (Palmer and Torgerson, 1999). The examination of 
whether such evidence improves decision-making requires convergence between theory and 
practical application, alongside evolution of the explicit criteria important for each system in 
which the economic analysis is used. The uncertainty over many of these practical difficulties 
means that it is difficult to assess whether the use of such analysis leads to improvements in 
allocative efficiency and other criteria deemed important by each system. An examination of 
whether such evidence improves deCision-making requires study firstly of the factors driving 
decisions In each country, consideration of the desirability of each of these factors and the 
Improvement In welfare resulting from better decisions by using such analysis. 
Most developed countries health systems have established national reimbursement agencies that 
appraise and make decisions on the availability of new medicines in their health systems (Hutton 
et aL, 2006). An appraisal is defined as the activity of judging on the basis of the current 
Information and a variety of analytical methods according to stated criteria, the value of the 
medicine prior to the medicines use (ex ante) and proposing recommendations (either mandatory 
or advisory) for Its future use. The analytical methods referred to in this thesis are similar to those 
broadly described In (Dowie, 1997) for which evaluation (ex post) was said to include Intuitive 
judgement, Randomised Controlled Trials (RCTs), observational studies and decision analytic 
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models. The term evaluation will only be used to refer in this thesis to those medicines that are 
judged using analytical methods, evidence and other factors after being in use for a period of 
time. There are five common process stages which each fourth hurdle system can be observed to 
broadly follow such as identification of the question and definition, evidence generation, evidence 
synthesis, deliberation and the decision (Hutton et aI., 2008). 
HTA has been an increasingly prominent source of information considered amongst other 
factors/criteria when reimbursement agencies appraise medicines for use in developed countries 
(Banta, 2003, Neumann, 2009, O'Donnell et aI., 2009, Sorenson et aI., 2008). HTA was first 
introduced in the US with the formation ofthe US Office of Technology Assessment (OTA) in 1972, 
(Banta and luce, 1993). The seminal report written by the Committee for Evaluating Medical 
Technologies in Washington defined HTA as "any process and reporting of properties of a medical 
technology used in health care such as safety, efficacy, feasibility and indication of use, cost, cost-
effectiveness as well as social, economic and ethical consequences whether intended or 
unintended", (Mosteller et aI., 1986). There have been a number of other broadly similar 
definitions published since then (Facey et aI., 2006, Banta and Luce, 1993). The definition adopted 
by Health Technology Assessment International (HTAi) is "The systematic evaluation of properties, 
effects, and/or impacts of health care technology. It may address the direct, intended 
consequences of technologies as well as their indirect, unintended consequences. Its main 
purpose is to inform technology-related policymaking in health care. HTA is conducted by 
interdisciplinary groups using explicit analytical frameworks drawing from a variety of methods." 
(HTAi, 2011). HTA is therefore a scientific field, which seeks to inform decision-making on the use 
of technologies and broadly covers five main areas; clinical effectiveness, cost-effectiveness, 
social, ethical and legal aspects. A recent study aimed to clarify the definition of HTA because of 
the lack of consistency of the use of terms across jurisdictions and distinguish the activity from 
Evidence Based Medicine (EBM) and Comparative effectiveness research (CER). luce and 
colleagues proposed more speCific terminology for HTA and state that it answers the question of 
"is it worth it?" and they define this as Ita method of evidence synthesis that considers evidence 
regarding clinical-effectiveness, safety, cost-effectiveness and, when broadly applied, includes 
social, ethical and legal aspects of the use of technologies. The precise balance of these inputs 
depends on the purpose of each individual HTA. A major use of HTAs is informing reimbursement 
and coverage decisions, in which case HTAs should include benefit-harm assessment and 
economic evaluation.", (Luce et aI., 2010). 
18 Chapter 1: Introduction 
There is variation across countries national reimbursement agencies with regards to either 
requiring a full HTA or partial HTA and this may be provided by the manufacturer, a third party 
independent group or by both of these groups. The term HTA agency is used to describe a range 
of bodies, which may apply full HTA or use a range of components of HTA assessing different 
technologies for different purposes. The International Network of Agencies for Health Technology 
Assessment (INAHTA) has S4 member agencies from 26 countries and organisations can become 
members if they assess technologies in health care and are non-profit public organisations 
relating to regional or national governments. Health economic analysis is an important 
component of HTA and many systems use this formally in their relevant process to consider the 
consequences of a decision. 
1.3 Health economic analysis (appraisal and evaluation) 
In order to understand the importance of heath economic analysis and other factors, a clear 
definition of what is meant by the term health economic analysis is required. Health economic 
analysis (economic evaluation or appraisal) aims to provide a framework for organising and 
addressing as many of these consequences as possible and providing justification of the explicit 
value judgements in decision-making. In a recent bibliometric tour of the past 40 years of health 
economics, 'Economic Evaluation in Health care' represents the second largest topic with respect 
to the Top 300 most highly cited articles in Health Economics (Wagstaff and Culyer, 2011). The 
Google Ngram viewer shows the use of the term 'health economic evaluation' begun to appear in 
books in the late 1990s. Drummond et 01. provides the distinguishing characteristics of health care 
evaluation and differentiates between full economic evaluation and partial evaluation. Partial 
evaluation includes efficacy, effectiveness evaluation, cost-analysis and cost outcome description. 
The term economic evaluation with respect to health was defined as the "the comparative 
analysis of alternative courses of action in terms of both their costs and consequences." 
(Drummond et al., 1987). This includes four types of health economic analysis, cost-minimisation 
analysis, cost-effectiveness analysis, cost-utility analysis and cost-benefit analysis. 
The definition of health economic evaluation does not include a time dimension for the analysis 
with respect to the technology or programs implementation and therefore does not directly 
distinguish between appraisal and evaluation. The UK Treasury Green Book defines appraisal as 
the assessment and judgement of whether a proposal is worthwhile before the implementation 
of a project proposal. In contrast evaluation uses similar techniques (economic analysis) to 
appraisal but uses data directly after the implementation of the proposal and can feedback for 
Improving the assessment of new proposals (HM Treasury, 2011). The differentiation between 
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health economic appraisal and health economic evaluation are often not made clear and the 
terms are used interchangeably to mean those aspects of full evaluation as described by 
Drummond et al. data available at appraisal may provide different results to that available at an 
evaluation stage. The term health economic appraisal will be used in this thesis to refer to 
whether a medicine will be cost-effective in practice whereas health economic evaluation will 
refer to whether a medicine has been cost-effective in practice. However, the same techniques of 
economic analysis are used in health economic appraisal and health economic evaluation which 
include cost-minimisation analysis, cost-effectiveness analysis, cost-utility analysis and cost-
benefit analysis. These types of analysis may be required by reimbursement agencies to provide 
the economic case for a new or existing medicine. 
Cost-benefit analysis is the cornerstone of the Welfare Economists approach to addreSSing 
problems in public policy (Brouwer et aI., 2008). The origins of cost-benefit analysis can be traced 
back to Jules Dupuit in 1849 in his theoretical study of toll bridges (Ekelund, 1968) and the 
concept was then formalised in economics by Alfred Marshall in 1890, (Marshall, 1920). Cost-
benefit analysis was defined by Sugden and Williams as: 'requiring the identification of all the 
effects of the project on the individual welfare of all members of the community. It then requires 
these effects to be measured in some common units so that aggregate benefits can be compared 
with aggregate costs.' {p89 (Sugden and Williams, 1978)). It therefore compares whether the 
monetised benefits of a medicine exceed the monetised costs. Cost-benefit analysis is grounded 
in welfare economics and the Pareto improvement criterion - if the reallocation makes at least 
one individual better off and no one worse off, ceteris paribus, this represents a Pareto 
improvement. The benefits of a project can be measured in terms of the changes in individual's 
welfare through a monetary valuation of the health effects. 
There are three approaches to assigning a monetary valuation to health outcomes either through 
the human capital approach, revealed preferences (value of a statistical life year) or stated 
preferences through a contingent valuation approach (willingness-to-pay survey). The political 
undesirability of measuring health benefits in monetary terms made way for the growth in a 
second approach called cost-effectiveness analysis which measures the benefits in some other 
units. The first cost-effectiveness analysis in health appeared in the 1960's (Backhouse et aI., 
1992, Elixhauser et aI., 1993, Warner and Hutton, 1980, Culyer et al., 1977). The first published 
cost-effectiveness analyses were on the economics of syphilis control programs, (Klarman, 1965) 
and the cost-effectiveness of contraceptives with respect to population growth (Enke, 1966). 
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Cost-effectiveness analysis in its broadest sense is a method designed to assess the comparative 
impact of expenditures on different health expenditures (Gold et aI., 1996) assuming that for any 
given level of resources society aims to maximise the total health benefit of the population 
(Weinstein and Stason, 1977). The analysis produces a cost per unit of health effect (effectiveness 
data but new medicines often rely on efficacy data and assumptions on potential effectiveness) 
from a medicine when compared to an alternative (per life year, per natural unit treatment 
specific), otherwise known as an Incremental Cost-effectiveness Ratio (ICER). The use of cost-
effectiveness analysis may be treatment specific and may not allow comparisons between 
different treatments for different diseases but cannot address the issue of opportunity cost of 
funding a new medicine across diseases. 
In contrast, cost-utility analysis allows various different outcomes to be combined into one single 
composite outcome and allows comparisons across different diseases areas and treatment 
programmes. Cost-utility analysis is a method where the costs are identical to cost-effectiveness 
analysis but the units of health effect differ and are measured in quality-adjusted life-years 
(QAlYs) gained (effectiveness). Cost-utility analysis was first used in a study of the treatment of 
patients with chronic renal disease where those patients on dialysis were given a quarter of a life 
year reduction in life year gained in comparison to those patients with an effective transplanted 
kidney (Klarman et aI., 1968). This study at the time did not refer to this as the QALY. The formal 
definition of cost-utility analysis is 'a form of evaluation that focuses on the quality of the health 
outcome produced or forgone by health programmes or treatments (Drummond et aI., 1997). The 
incremental cost effectiveness estimates (leER) using this approach are expressed in the form of a 
cost-per QALY gained. This value must then be compared against a cost-effectiveness threshold 
which may be established through empirical data and the method for establishing this will depend 
upon the system (opportunity cost of the least efficient funded treatment or willingness to pay). 
Cost-minimisation analysis concerns the analysis of two treatments that have equivalent efficacy 
by a trial finding no statistically significant difference or effectiveness (where data available) and 
involves a comparison of the costs of the two treatments. A cost-analysis may become a cost-
minimisation analysis if there is evidence that the treatments are equivalent in their 
consequences (Drummond et aI., 1997). In the third edition of the book Drummond dropped cost-
minimisation as a form of full evaluation technique because of uncertainty around determining 
whether two treatments are broadly equivalent with respect to either costs or effects. Cost-
minimisation is not a study design that can be determined in advance and the authors suggest 
that the type of analysis is only justifiable ~hen the technologies are near identical (Drummond et 
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aI., 2005). A recent study has demonstrated that when CMA is used it is likely to bias estimates of 
uncertainty and leads to overestimate or underestimates of the probability that the treatment is 
cost-effective. The study suggests cost-effectiveness analysis is almost always required to guard 
against biased estimates of the uncertainty (Dakin and Wordsworth, 2011). 
1.4 The contribution of health economic analysis and other factors in heterogeneous 
reimbursement systems 
Only a few, on average, of every 10,000 substances synthesised in research laboratories, will 
successfully pass all the research and development stages to become a medicine marketed to 
patients (EFPIA, 2011). Manufacturers require stability and predictability to develop successful 
new medicines. Public reimbursement systems need to provide clear signals of their demand for 
medicines so that manufacturers can make efficient investment decisions in the light of the 
uncertainty. 
Figure 1.2: Diagram of reimbursement system factors 
Reimbursement System 1: 
Process 
Factors 1 
= Evidence Factor 
r=l U = Non-evidence Factor 
-. = Process Factor 
} Appraisal factors 
Reimbursement System 2: 
Process 
Factors 2 
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Reimbursement agencies can provide stability and predictability by clearly communicating the 
process and requirements, the main decision factors and details of their deliberations so that 
manufacturers and other stakeholders can understand the determinants of the decisions. The 
factors or determinants of medicine reimbursement decisions can be investigated within 
countries and across countries when such details are provided. A factor can be considered either 
as an evidence or non-evidence factor that are important in the appraisal or a factor with respect 
to technology assessment process. An 'evidence factor' - a characteristic of the medicines 
evidence (safety, clinical efficacy, clinical effectiveness and cost-effectiveness), 'non-evidence 
factor' - other value judgement applied because of a characteristics of the medicine that 
influences the decision (medicine treats severe illness, end of life medicine, orphan medicine, 
innovative medicine). These factors are potentially not backed by evidence but are a form of value 
that Williams referred to as postulated by the decision-maker in the political process (Williams, 
1972). The third category is a 'process factor' - characteristic of the process of assessment or 
appraisal (Within countries: different committees, time period, different processes and across 
Countries: Differences in categorisation of the reimbursement system) that the medicine 
undergoes which effects or influences the reimbursement decision (Figure 1.2). 
An understanding of the similarities and differences of the influence of factors on decisions is 
important for manufacturers as it enables them to select new molecules, develop medicines with 
appropriate clinical strategies and produce effective and profitable medicines with the correct 
evidence requirements for each reimbursement system. An understanding of the relative 
importance of the factors within and across countries is important for policy makers to help to 
identify the desirability of differences in their system with respect to the overall operation and 
objectives of the system. This enables the policy makers to legitimately communicate the 
rationale for decisions to patients to enable patients to understand any differences in decisions 
for medicines that may occur across public reimbursement systems. 
The definition of what constitutes the influence of a factor on the reimbursement decision is 
important because there are many potential interpretations of the term 'influence'. Buxton 
considered this issue and the problem of the 'missing counterfactuai' to determine the influence 
of economic evaluation on health policy in the United Kingdom. 'The consistency of a subsequent 
health policy with the conclusions of the study does not necessarily indicate that the study has 
influenced the policy. The consistency may be a happy coincidence, with the evaluation used 
rather as a drunken man may use a lamp post - more for support than illumination' (Buxton, 
2006). With respect to the influence of factors on reimbursement decisions in countries 
reimbursement systems this can be interpreted to mean: 
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1. The observation that reimbursement system states that the factor is considered, 
regardless of the reimbursement decision. Or; 
2. Influence may be considered where a factor (cost-effectiveness considered) is found 
consistently to be attributable to a certain decision outcome (correlate influence). Or; 
3. Influence maybe considered with respect to the causal influence of a factor on the 
decision, in the situation where the counterfactual is evident where the factor is not 
present (not considering cost-effectiveness evidence) and the reimbursement decision 
and compared with the decision where the factor is considered (considering cost-
effectiveness evidence) and the reimbursement decision, ceteris paribus. 
The second and third will be used to define what constitutes influence in this study, with 
preference for the third definition of the causal influence. However, the third definition is 
impossible to observe in practice. This requires a study with experimental design such as a 
randomised trial or statistical analysis that can correct for the counterfactuaL A randomised trial 
at country level would not be possible and a study assessing the influence of the use of health 
economic analysis would require two "identical twin reimbursement agencies" operating with 
identical reimbursement systems in which health economic evidence would be considered by one 
of the agencies for the medicine and would not be considered by its twin. The influence could 
then be assessed by the differences in reimbursement decisions between the two. 
The literature acknowledges that HTA and economic analysis supports and informs 
reimbursement decisions (Oliver et aL, 2004, Drummond et aL, 2008, Annemans et aI., 2010). 
However, few empirical studies have been conducted to discover the relative influence of the 
evidence and other factors in reimbursement decisions within countries and comparisons of these 
between countries. An initial search of the literature reveals a focus has been made on the use of 
evidence in reimbursement decisions within Australia, Canada and England. Factors may have 
similar effects in some countries, differential effects in some and have no influence in other 
countries on reimbursement decisions. Cross-country comparisons of the similarities and 
differences in the determinants of reimbursement decisions are scarce. One study focuses on a 
comparison of the clinical and cost-effectiveness evidence used in reimbursement decisions for 
Australia, Canada and England that there are a limited number of common medicines across 
countries and concludes some of the variation in reimbursement decisions may be explained by 
differences in process (Clement et aL, 2009). 
The empirical literature appears to focus on the influence of evidence. Evidence covers a number 
of factors in the appraisal of medicines for reimbursement but other non-evidentiary factors that 
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may influence reimbursement (Berg et aJ., 2004, Neumann, 2009). Every reimbursement system 
operates in the social and political priorities of the country, decision structures and resources 
available. These are complex systems and other characteristics of the systems such as the 
objectives; processes and other factors may be influential upon the reimbursement decisions. 
There is considerable variation in the processes and types of institutions involved within the 
systems that incorporate HTA in the appraisal of medicines (Hutton et aI., 2008). Of the few 
studies available, many focus on categorising a small number of selected reimbursement systems 
and considering these with respect to the influence of differences in the use of evidence to inform 
reimbursement (Belgian Health Care Knowledge Centre, 2010). 
The process differences across countries may have considerable influence in explaining 
differences between countries reimbursement decisions and the relative importance of factors. 
For example, consider the hypothetical scenario where two systems are similar on all 
characteristics and the manufacturer presents the same evidence but they differ in an aspect of 
process, two separate committees conduct assessment and appraisal in one system and by a 
single committee in the other, it Is conceivable that these two systems may reach different 
decisions because of differences in the committees representatives. The process may also modify 
the effect of other factors. The evidence maybe revised by a third party independent assessment 
of the cost-effectiveness which results in different cost-effectiveness estimates leading to a 
difference in the relative influence of the cost-effectiveness evidence in comparison to a system 
without such third party assessment. The third party assessment provides a further perspective 
on the evidence. 
The first stage in examining the influence of differences in process on decisions requires 
considering the characteristics of reimbursement systems. It is not anticipated that any of the 
systems will be identical with respect to all characteristics of the reimbursement system but it is 
expected that some will share more similarities than others. Where countries share similarities it 
would be expected that there would be more convergence in decisions than those that were 
dissimilar, assuming similar evidence. An understanding of the importance of process requires 
comparison of decisions across countries of the decisions and factors important within each 
respective country. This thesis will focus on the use of evidence and the specific contribution of 
health economic evidence, accounting for differences in reimbursement process across systems. 
This will be undertaken by considering the similarities and differences in reimbursement systems, 
the differences and similarities In the use of economic evidence and the empirical contribution of 
economic evidence alongside other factors in reimbursement decision-making. 
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1.5 Aims and objectives 
Reimbursement systems are complex and the literature describes differences in the use of 
evidence within countries but has not focused on the influence of differences in other factors 
within countries and in process within and across countries on reimbursement decisions. The 
overall aim of the thesis is to examine the influence of health economic analysis and other factors 
on medicine reimbursement decisions within and across countries. In order to recognise this it is 
necessary to categorise DECO reimbursement systems to understand the similarities and 
differences across systems. Each reimbursement system produces decisions on medicines that are 
paid for by the public health system. An understanding of the influence of the broad factors 
affecting reimbursement decisions for pharmaceuticals will help to understand the role of health 
economic evidence in countries that share similarities and differences in processes and the 
information used in decision-making. This aim will be investigated by considering the following 
research questions (objectives): 
1. What factors have been considered in empirical studies assessing the influence upon 
reimbursement decisions? What is the influence of these factors on decisions in these 
countries? 
2. What are the similarities and differences in reimbursement systems in DECO countries 
and what are the stated criteria in the appraisal of medicines in these systems? 
3. What is the common influence of health economic analysis and other factors in countries 
with broadly similar reimbursement systems that use health economic analysis? 
4. What is the influence of health economic evidence in a country using cost-effectiveness 
evidence in comparison to a system using solely clinical effectiveness evidence? 
Research Question 1: What factors have been considered in empirical studies assessing the 
influence upon reimbursement decisions? What is the influence of these factors on decisions in 
these countries? 
The influence of factors in reimbursement decisions maybe considered through either a 
qualitative or quantitative study. A systematic review will be performed in chapter four to identify 
empirical studies that have analysed the impact of factors on reimbursement decisions in DECO 
countries. This will consider the factors that have been considered across countries and the 
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resulting influence of these factors within countries. A comparison will be made against the stated 
criteria provided by the reimbursement systems in the appraisal of medicines identified in chapter 
4. This will identify countries that have not been studied and the opportunity to conduct useful 
cross-country comparisons where sufficient information is available on the reimbursement 
decisions 
Research Question 2: What are the similarities and difference in reimbursement systems in OECD 
Countries and what are the stated factors in the appraisal of medicines in these systems? 
Chapter 3 and 4 will provide a categorisation of the entire reimbursement system using the 
framework for classifying fourth hurdle systems (Hutton et aI., 2006). The framework considers 
the establishment, objectives, implementation and accountability of the system (policy 
implementation level) as a distinct set of characteristics of the entire system from how decisions 
are made with the systems for individual technologies (individual technology decision level). The 
chapters aim to consider the similarities and differences between OECD countries processes and 
stated criteria in the appraisal of medicines. It is anticipated that some systems will be more 
transparent than others and provide details of the characteristics of the system and details of the 
deliberations for the decisions. This will also inform the feasibility of conducting an empirical 
analysis of the factors influencing decisions in OECD countries. 
Research Question 3: What is the common influence of health economic analysis and other 
factors in countries with similarities in reimbursement systems that use health economic analysis? 
Countries sharing broad similarities with the reimbursement system will be investigated through 
the categorisation of systems and the previous empirical research in this area. Those agencies 
providing similar evidence requirements and use of health economic evidence and similarities in 
the reimbursement system will be studied alongside other factors to establish whether there are 
common factors that can be identified regardless of potential variation in the process. A 
quantitative regression analysis will be considered introducing new factors by providing variables 
to account for factors previously studied in countries and new factors. The study will aim to 
investigate whether there are common factors that are influential over and above any differences 
in process observed across the countries. This will require sufficient reporting of the evidence 
assessment and appraisal within countries and there will be a trade off between more 
information on factors in a smaller sample of countries and including as many countries as 
possible with less information or no information on factors where health economic analysis is 
used in decision-making. 
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Research Question 4: What is the influence of health economic evidence in a country using cost-
effectiveness evidence in comparison to a system using solely clinical evidence? 
Health Economic evidence can be used by the reimbursement agencies to provide an indication of 
the demand curve for medicines and the manufacturer can select or propose a price. The rules of 
the game are different in countries that do not use health economic analysis where other criteria 
are set to appraise the medicine and decide reimbursement. A comparison of reimbursement 
decisions will be performed between a reimbursement system that uses health economic 
evidence and one that only considers clinical evidence, where sufficient documentation of the 
assessment and deliberations are publically available. A qualitative study will be performed on the 
influence of health economic analysis alongside any observed variation in other factors in the 
decision-making. This will identify common medicines assessed between the agencies and 
consider whether health economic analysis can explain these differences or whether other factors 
may explain the differences in decisions between the two systems. 
1.6 OECD reimbursement systems 
The study focuses on countries reimbursement systems in the Organisation for Economic Co-
operation and Development (OECD). The OECD was established in 1961 and provides information 
to help government's foster prosperity and fight poverty through economic growth and financial 
stability. There are 34 (36 including the countries of the United Kingdom, Scotland, Wales and 
England) mem ber countries of the OECD as of July 2011. 
The OECD countries which will be considered within this research are listed below: 
1. Australia 
2. Austria 
3. Belgium 
4. Czech Republic 
5. Canada 
6. Chile 
7. Denmark 
8. Estonia 
9. Finland 
10. France 
11. Germany 
12. Greece 
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13. Iceland 
14. Ireland 
15. Israel 
16. It~ly 
17. Japan 
18. Hungary 
19. Korea 
20. Luxembourg 
21. Mexico 
22. Netherlands 
23. New Zealand 
24. Norway 
25. Poland 
26. Portugal 
27. Slovak Republic 
28. Slovenia 
29. Spain 
30. Sweden 
31. Switzerland 
32. Turkey 
33. United Kingdom - England and Wales 
34. United Kingdom - Scotland 
35. United States of America 
1.7 Summary 
This chapter has outlined the importance of understanding the influence of health economic 
analysis and other factors within and across countries to explain similarities and differences in 
access to medicines reimbursed by the public health system. Chapter 2 will provide a systematic 
review of the current evidence of the influence of factors internationally. Chapter 3 and 4 will 
identify the impact of system and process differences on the use and interpretation of health 
economic analysis and other factors. Two further chapters will provide two empirical analyses of 
the use of health economic analysis in different countries. Chapter 5 will explore the common 
factors for decisions using a multinomial regression analysis in systems using both clinical-
effectiveness and cost-effectiveness evidence. Chapter 6 will consider the contribution of formal 
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health economic analysis on decisions in a process using such analysis in Scotland in comparison 
to a process not routinely using such analysis in France. The final chapter will provide a discussion 
of the use and influence of health economic analysis in heterogeneous reimbursement systems 
and provide the limitations and some ideas for further research. 
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Chapter 2: Systematic Review of Factors 
Influencing Pharmaceutical Reimbursement 
Decisions in OECD countries' 
Abstract 
Objective: Chapter 1 introduced examples of the many factors that influence pharmaceutical 
reimbursement decisions. This chapter aims to determine the factors considered in empirical 
studies and the influence of these factors on the reimbursement decisions of government funded 
reimbursement bodies in OECD countries'. 
Methods: A search of MEDLlNE, EMBASE, EconLit, Health Management Information Consortium, 
NHS EED and REPEC Economic working papers until July 2010 was conducted. A hand search of 
the International Journal of Technology Assessment in Health Care was undertaken (1990-2010). 
A citation search was undertaken for one highly cited article. The following study designs were 
eligible: experimental, quasi-experimental, retrospective, prospective, case series and surveys or 
questionnaires design. The influential factors were reviewed across and within OECD countries 
and the validity of study findings critically appraised. 
Results: The search identified 13 quantitative studies and 19 qualitative studies. The quantitative 
studies considered the correlation between factors and decisions either through regression 
analysis of retrospective decisions or discrete choice experiments. Cost-effectiveness was found 
to be consistently influential for reimbursement decision-making in Australia, England, Canada 
and the Netherlands. There was variation in the definition of clinical considerations and other 
factors in studies conducted in countries. This limited comparability within and across countries. 
Studies reported mixed evidence of the influence of the quality, quantity and type of clinical 
evidence, appropriate economic analysis, economic analysiS uncertainty, lack of alternative 
therapy and severity of disease on reimbursement decisions. Qualitative studies reported 
narrative descriptions, case studies and interviews with decision-makers. These studies supported 
the influence of cost-effectiveness found in the quantitative evidence. Additional factors were 
described to influence decisions in the qualitative studies, namely, the composition of the 
decision panel, committee deliberations, stakeholder involvement and lobbying upon decisions. 
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Conclusion: There is limited evidence of the influence of factors on reimbursement decisions in a 
few DECO countries with established reimbursement processes and qualitative evidence 
highlights some potential factors that have not been included in quantitative studies. Wider 
investigation of the factors influential in other countries would allow comparison of the 
similarities and differences across DECO countries. 
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2.1 Introduction 
Developed countries' health care systems typically aim to provide universal and equitable access 
to health care. In the last 30 years, a rise in the diffusion of new medicines and resulting pressure 
on healthcare budgets has led countries with public systems to explicitly decide which medicines 
should be funded. Some countries have developed explicit procedures and established national 
reimbursement agencies using formal HTA (or elements of HTA) along with other factors to make 
such decisions. The introduction of evidence requirements and the resulting emergence of HTA 
have improved the transparency of countries reimbursement decision-making. Examples of some 
established reimbursement agencies using elements of HTA are contained in Table 2.1. 
Table 2.1: Examples of reimbursement agencies and institutions 
country National Reimbursement Institute/agency/entity 
England and Wales National Institute for Health and Clinical Excellence (NICE) 
Australia Pharmaceutical Benefits Advisory Committee (PBAC) 
Scotland Scottish Medicines Consortium (SMC) 
Canada Canadian Agency for Drugs and Technologies in Health (CADTH) 
Germany Joint Federal Committee (G-BA) and IQWIG 
France Haute Autorite de sante (HAS) 
Sweden Pharmaceutical Benefits Board (TlV) 
Netherlands Dutch Health Insurance Boards (CVZ) 
New Zealand Pharmaceutical Management Agency (PHARMAC) 
The objectives of different systems vary but all aim to make evidence informed recommendations 
or mandatory decisions on whether a medicine should be included on each country's formulary or 
list of medicines for reimbursement by their respective government funded schemes. The 
reimbursement processes include an assessment of the evidence provided by the manufacturer 
or other source, followed by an appraisal of the evidence by experts. The appraisals involve 
judgements regarding the evidence and analysis of the value of a new medicine in comparison 
with the available alternatives. The countries reimbursement processes vary with respect to the 
extent by which the assessment phase of the process can be distinguished from the appraisal. 
There is variation in the factors considered by reimbursement agencies (Hutton et aI., 2006) and 
this may explain the variation in reimbursement recommendations for the same medicines across 
countries (Clement et aI., 2009). 
The first chapter identified that the influence of health economic appraisal/evaluation can only be 
identified in countries reimbursement systems by controlling for all factors influencing the 
appraisal and final decision of the reimbursement agency. The previous chapter broadly 
categorised these factors into evidence factors, non-evidence factors and process factors. The 
evidence factors included clinical evidence factors, economic evidence factors and the other 
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economic evidence factors such as budget impact and productivity savings. Studies may explore 
these factors through the consideration of a single reimbursement system or by comparing the 
decisions and factors in cross country comparisons. This chapter aims to consider the factors that 
have already been studied with respect to factors influencing the reimbursement decisions within 
and across national government funded medicine reimbursement systems. 
An understanding of the factors studied within and across OECD countries will be important for 
identifying current international comparisons of reimbursement systems, the challenges of 
constructing factors across countries and potential solutions, the weight of evidence and other 
factors to explain differences in reimbursement decisions across countries and the limitations of 
the different methodologies currently available to consider the question of factors influencing 
reimbursement decisions. Further to this the identification of differences between appraisal 
components and the influence of process factors would help to clarify certain differences 
between agencies and establish the respective importance and desirability of specific 
combinations in methods, processes and procedures for reimbursement agencies in different 
health systems. This would help to understand how the procedures influence the decisions 
arrived at for new drugs and further understand the dynamics and evolution of these system The 
review. will help to identify further research to understand the similarities and differences 
between the factors internationally. 
2.1.1 Previous relevant systematic literature reviews 
An initial search was conducted of the Cochrane CENTRAL database and the International Journal 
of Technology Assessment in Health Care to identify any previous systematic reviews on this 
topic. The search did not identify any systematic reviews that consider the use of factors in the 
appraisal of medicines on reimbursement decisions. There have been two systematic reviews and 
one intervention protocol, which consider the influence of methods and factors on 
pharmaceutical reimbursement systems. 
Williams et al. performed a study, which identified the ways, and extent to which economic 
analysis is used in health policy decision-making through a systematic review and qualitative data 
collection of heath policy decisions broader than pharmaceuticals (Williams et aI., 2008). The 
review also considered the factors associated with the utilisation of economic evaluation findings. 
The search strategy for this systematic review considered evidence between 1966 and 2002 for 
England and Wales. The review considered the use of economic evaluation in policy-making, 
health and non-health literature on the use of economic analysis in policy-making and studies that 
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have considered the actual and perceived barriers to economic analysis. There were few 
systematic reviews of the evidence for this question and the primary studies identified suffered 
from methodological concerns. The review identified a number of factors limiting the emphasis 
on economic analysis that included the lack of a clear objective for the committees and their 
relationship with the structures and process, satisfying a number of interests in an explicit political 
decision-making process and the absence of a specifically defined budget. The study illustrated 
that more primary studies are required to identify the extent of which economic analysis informs 
health policy deciSion-making. The study also suggested that a formal process should be set out to 
clarify the objectives of the healthcare system/reimbursement system seeks from investments in 
healthcare. 
Eddama and Coast conducted a systematic review with the objective of understanding the use of 
economic evaluation at a local level (Eddama and Coast, 2009). The study identified a total of 40 
empirical studies and found that there has been an increase in the use of economic evaluation 
overtime, especially in the UK. The review highlighted that there is little known of the influence of 
economic evaluation at the local level. The authors suggested that further qualitative research 
may be helpful in understanding further the impact of economic evaluation. The perspective of 
this chapter will be from the national level rather than local or regional level. 
2.2 Literature review methodology 
2.2.1 Objective 
To determine the formal appraisal and process factors in empirical studies considering the 
influence of these factors on medicine reimbursement decisions in OECD countries and the 
influence of these factors on reimbursement decisions in these countries. 
The objective has been split into two sub-objectives with a number of respective questions to be 
addressed: 
1. To determine the formal appraisal and process factors that have been considered to influence 
reimbursement decisions or recommendations in OECD countries. 
a. What methodologies are used to consider the influence of factors on decisions? 
b. What is the definition of influence within studies? 
c. What factors are included in studies considering influence? 
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2. To determine the influence of formal appraisal and process on the reimbursement in OECD 
countries government funded reimbursement bodies. 
2.2.2 Types of studies 
A review of systematic reviews was conducted to identify whether this topic is original and to 
identify other studies to include in this review. 
Influence is defined in Oxford Online Dictionary as "the capacity to have an effect on the 
character, or behaviour of someone or something, or the effect itself', (Oxford Online 
Dictionaries, 2011). In the context of reimbursement decision-making the term influence refers to 
the extent by which appraisal factors within a country or process factors within or across 
countries effect a medicines reimbursement decision outcome. Influence maybe identified by: 
1. Influence may be considered where a factor (cost-effectiveness estimate) is found 
consistently to be attributable to a certain decision outcome (correlate influence). Or; 
2. Influence maybe considered with respect to the causal influence of a factor on the decision, 
in the situation where the counterfactual is evident where the factor is not present (not 
considering cost-effectiveness evidence) and the reimbursement decision and compared 
with the decision where the factor is considered (considering cost-effectiveness evidence) 
and the reimbursement decision, ceteris paribus. 
In development of the review methodology the reviewer did not expect to find RCTs studies 
because of the difficulties pragmatically in randomising different appraisal factors and processes 
between different national reimbursement systems. In the light of this a variety of research 
designs were included to address the research questions: 
1. Experimental study designs; 
2. Quasi-experimental study designs using statistical approaches to identify the impact of 
factors; 
3. Retrospective study designs; 
4. Prospective study designs; 
S. Case series; 
6. Surveyor questionnaire based studies in relation to a number of countries' reimbursement 
decisions. 
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A study with a single reimbursement recommendation or decision (case report) was not 
considered in this review because this type of study does not allow the identification of the 
relationship between factors and may not be representative of the general decisions made by a 
reimbursement body at a particular period of time/over decision periods. 
2.2.3 Study population 
The study population includes national institutions, bodies or entities that consider elements of 
HTA evidence to produce formal reimbursement recommendations or decisions for medicines. 
The term "reimbursement" is defined as the payment for new medicines under a government 
funded scheme. This may include studies that investigate the influence of factors on 
reimbursement decisions within single countries or cross-country comparisons. The study 
population would not include studies of reimbursement decisions of privately funded agencies or 
those HTA reports produced for information only and do not have a practical reimbursement 
purpose. 
2.2.4 Types of Intervention 
A factor can be described as a component of appraisal or relevant characteristic of the decision-
making process that influences the medicine reimbursement decisions within or across countries. 
2.2.4.1 Formal appraisal factors 
Many reimbursement systems include one or more committees that judge the characteristics of a 
medicine with respect to criteria. The criteria mayor may not be explicitly stated. Appraisals 
factors can either be evidence based or non -evidence based. Evidence based appraisal factors 
include the elements of formal identification, gathering, synthesis and analysis of the evidence 
that are judged by a committee for the purpose of reaching a reimbursement recommendation or 
decision for a new medicine. The evidence includes those elements of HTA such as clinical 
evidence, economic evidence and budget impact. The non-evidence based factors judged by a 
committee include social value judgements, respective patient information, public perceptions of 
the decisions, political considerations such as location of industry and other economic 
considerations. 
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2.2.4.2 Process factors 
The reimbursement decision for individual medicines may be influenced by the characteristics of 
the process by which a medicine is assessed and appraised. Variation in process may impact upon 
how a medicine is viewed by the committee or individuals tasked with appraising a medicine for 
reimbursement. Process factors may vary within countries for each medicine appraised such as 
the time taken to complete the decision, type of process followed (e.g. Single Technology 
Appraisal (STA) or Multiple Technology Appraisal (MTA) in the case of NICE) or decision appealed 
by stakeholders or processes may only vary at the country reimbursement level such as freedom 
to set price, independent assessment, number of reimbursement process stages and number of 
committees informing the decision. The influence of country level process factors on decisions 
can only be completely investigated within studies including a comparison of countries. 
2.2.5 Types of outcome measures 
A study was included if it reported the following details: 
A description of appraisal factors considered by the reimbursement body/institution/entity AND: 
A quantitative report of the factors involved in the appraisal/evaluation for the reimbursement or 
recommendation of medicines. Such as: 
OR: 
• The number of decisions, percentage or proportion influenced by each of the factors used 
by the reimbursement body. 
A qualitative report of the factors involved in the appraisal/evaluation for the reimbursement or 
recommendation of medicines. Such as: 
• A ranking or more detailed analysis of data from a questionnaire or survey of the 
influence of factors on reimbursement decisions or recommendations. 
2.2.6 Study exclusion 
A study inclusion and exclusion form was completed for each of the studies and the template is 
included in Box A2.1. The following studies were excluded: 
1. Editorials or discussion papers were excluded if they did not report a data analysis. 
2. Studies that consider factors at the local or regional deCision-making level 
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3. Studies that explain or report one pharmaceutical reimbursement decision. 
4. Studies conducted before 1990. 
2.2.7 Critical appraisal of Included studies for validity of results and risk of bias 
2.2.7.1 Quantitative studies validity and reliability (risk of bias) 
Buxton describes the influence of an economic evaluation on decision-making and discusses what 
constitutes influence (Buxton, 2006). In order to assess the influence of a factor on a 
reimbursement decision an understanding of the counterfactual is required. For example, the 
counterfactual would be the policy or decision if the factor had not been present. The gold 
standard study design would be an experimental study where all factors are quantifiable and 
measurable and the effect of changes can be observed. This can theoretically be achieved 
through either an RCT or through an observational study using advanced statistical methods 
(instrumental variables and propensity score matching) to overcome the issues of 
confounding!endogeneity. A confounding variable is related both to the outcome variable 
(reimbursement decision) and to the independent variable of interest (factors such as economic 
evaluation) and is not part of the causal pathway between them (Bowling and Ebrahim, 2008). An 
understanding of the counterfactual allows consideration of whether the observed association 
between a factor and the reimbursement decisions are causal or spurious and therefore related 
by an underlying separate factor. 
The Cochrane handbook suggests that a focus should be made on the risk of bias in the results 
rather than the methodological quality of quantitative studies included (Higgins and Green, 2011). 
The Cochrane framework will be used for an assessment of risk of bias for those studies that are 
of an experimental design. The framework applied by the Cochrane collaboration using the 
assessment of risk of bias tools which consider selection bias, performance bias, attrition bias, 
detection bias and reporting bias. The purpose of the tool is for consideration of risk of bias in 
healthcare interventions and the tool will be tailored to consider the risk of bias for the purpose 
of this thesis. 
The potential value for using the risk of bias tool for those studies that are non-experimental is 
more of a contested issue, especially for those studies of a qualitative nature. The quantitative 
non-experimental studies will be critiqued separately from the qualitative studies. The validity of 
the results of observational studies using econometrics techniques will be reviewed with respect 
to a number of criteria. 
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The key characteristics of a good regression model are summarised in Essential Econometrics 
(Gujarati, 1999). Gujarati states that a model can be critically appraised by considering the 
following general criteria: 
o Parsimonious: A regression model can never completely capture the decision-making 
environment. The regression model should be kept as simple as possible; 
o Goodness of fit: The regression analysis should explain as much of the variation in the 
dependent variable as is possible by the included explanatory variables (factors); 
o Theoretical consistency: The model should have a theoretical underpinning to the 
inclusion and construct of the factors in the regression analysis; 
o Predictive power: The models predictions should be borne out by the actual experience in 
reimbursement decision-making. 
These criteria can be used to consider the validity of the results provided by the regression 
analysis. The robustness of the quantitative observational studies will be assessed with respect to 
the following speCific criteria and regression diagnostic tests such as (Greene, 2003, Gujarati, 
1999): 
• Reporting ofthe definition of influence and appropriate statistical methods; 
• Regression model specification: 
o Dependent variable and construct of independent factors: Data and construct of 
methods justified (attempts to minimise subjectivity and measurement error); 
o Sample size: are there sufficient reimbursement decisions given the number of 
factors to provide robust evidence of the association or causal impact of the 
factor on the reimbursement decision; 
o Model Goodness of fit: The measure will depend on the type of statistical analysis 
used in the regression model; 
o Omitted relevant variables (under-fitting the model) are a type of specification 
error; 
o Sample selection bias in which there are missing data for the dependent variable 
(selected sample of decisions for medicines); 
o Testing of regression model assumptions used in each of the studies. 
• External validity of the results to other reimbursement decisions made by the agency. 
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2.2.7.2 Qualitative studies validity and reliability: 
The application of quality guidelines to qualitative studies is controversial because no one set of 
guidelines can be definitive for these types of studies (Mays and Pope, 2000, Centre for Reviews 
and Dissemination, 2009). A descriptive critique will be made of the qualitative studies included 
with respect to the validity and reliability of the results. The suggested questions proposed by 
(Mays and Pope, 2000) will be considered when assessing the validity of the qualitative studies: 
• Clarity of research question on influence; 
• Appropriateness of study design; 
• Sampling; 
• Data collection and analysis; 
• Reflexivity of the account given by the researchers undertaking the study. 
2.2.8 Data extraction 
The data will be extracted for experimental studies and non-experimental studies through a data 
collection form. A formal data collection form was used to capture the characteristics and results 
of the studies and the template is included in Table A2.1. The data was extracted by MWB for 
each of the included studies and the definition of the factors and results were double checked by 
MWB to minimise errors in recording and interpretation of the data from each study. The data 
extraction form included the following elements: 
• Study details 
o . Study 10; 
o Report 10; 
o Review author 10; 
o Citation and contact details. 
• Methods 
o Quantitative! Qualitative study; 
o Agencies compared; 
o Study design; 
o AnalysiS type!Statistical!narrative!interviews!focus groups; 
o Methods relating to eith~r experimental study design or non-experimental study 
design. 
• Reimbursement decisions 
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o Total number of reimbursement decisions; 
o Characteristics of reimbursement decisions. 
• Interventions 
o Types of factors considered; 
o Definition of the variables for each factor (quantitative studies); 
o Definition of influence (quantitative studies). 
• Outcomes 
o Decision outcome and date decision made. 
• Results 
o Factors influencing decisions. 
2.2.9 Data analysis 
The studies will first be grouped by quantitative and qualitative studies by country or by country 
comparison. A textual description of each of the studies included in the review and the 
characteristics systematically assessed in a table so that the same Information is extracted on 
each of the studies. 
2.2.9.1 Quantitative studies: 
The quantitative studies will be categorised and the results reported separately for country 
comparisons and within country analyses of decisions and factors in reimbursement systems 
(Table 2.2): 
• A consideration of the definition of factors and variables assessed for each country by 
type of factor; 
• Definition of influence; 
• Number of decisions assessed by each study; 
• The statistical methods for assessing influence; 
• Decision outcome. 
The description of influence of each factor will be described within and across the countries in a 
separate section. 
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antitative extraction for the definition of factors 
2.2.9.2 Qualitative studies: 
The qualitative studies will be categorised and the results reported separately for country 
comparisons and within country analyses of decisions and factors in reimbursement systems: 
• A description of the factors considered by type of factor; 
• Number of decisions for each study; 
• Methodology used; 
• Description of the influence of the factor. 
A comparison will be made across the quantitative and qualitative studies to assess consistency of 
findings within and across countries. 
2.2.10 Search methods for Identification of studies 
An initial broad search of evaluative approaches informing pharmaceutical recommendations was 
performed. 
2.2.10.1 Resources to search: 
• Medline; 
• EMBASE; 
• Econlit; 
• HMIC Health Management database; 
• NHS EEO; 
• REPEC Economic Working Papers; 
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• HTAi conferences abstracts; 
• WHO; 
• OECD reimbursement bodies' websites (e.g. NICE); 
• EUnetHTA website. 
2.2.10.2 Key journals search 
The following key journal was searched between 1990 and 2010: 
• International Journal of Technology Assessment in Health Care (UTAHC). 
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2.2.10.3 Identification of reimbursement institutions/bodies/entities 
Table 2.3: Country and Reimbursement Institution and abbreviation 
OECD country Reimbursement Institution/Body/Entity Abbreviation 
Australia Pharmaceutical Benefits Advisory Committee PBAC 
Austria Pharmaceutical Evaluation Board HEK 
Belgium Committee for Drug reimbursement (CRM) CRM 
Canada CADTH Common Drug Review (CDR) decision at a provincial level CADTH CDR 
Chile Not identified 
-
Czech Republic Ministry of Finance 
-
Denmark Danish Medicines Agency DMA 
laegemiddel stryrelsen 
Finland Ministry of Social Affairs and Health PPB 
Pharmaceutical Pricing Board (PPB) 
France Haute Authorite de sante HAS 
French National Authority for Health 
Germany IQWIG IQWIG/GBA 
Institute for Quality and Efficiency In Health Care 
Institut fUr Qualitlit und Wirtschaftlichkeit 1m Gesundheitswesen 
Federal Joint Committee 
Greece Reimbursement and Medicinal Products EDAF 
Hungary National Health Insurance Fund Administration NHIFA 
Iceland Ministry of SOCial affairs and health -
Tryggingastofnun rikisins (Icelandic Health Insurance) 
Ireland National Centre for Pharmacoeconomlcs NCPE 
Italy Italian Medicines Agency (Agenzia Italiana del Farmaco) AIFA 
Japan Ministry of Health, labour and Welfare MHlW 
Korea Health Insurance Review Agency HIRA 
luxembourg Direction de la sante -
Health Directorate 
Mexico Council CENETEC 
Centro Nacional de Excelencia Tecnol6gica en Salud 
National Center of Excellence In Health Technology 
Netherlands National Insurance Health Boards (CVZ) CVZ 
college voor zorgverzekeringen 
New Zealand Pharmaceutical Management Agency PHARMAC 
Norway Norwegian Medicines Agency 
-
Statens legemiddelverk 
Poland Health Technology Assessment Agency AOTM/ AHTAPol 
Portugal National Institute for Pharmacies and Medicines INFARMED 
Instituto Nacional da farmacia e do medicamento 
Slovak Republic Ministry of Health 
-
Spain Ministry of Health 
-
Agencia d'Avaluaci6 de Tecnologia I Recerca Mediques de Catalunya 
Sweden Dental and Pharmaceutical Benefits Board TLV 
Switzerland Federal Office of Public Health FOPH 
Turkey Social Insurance agency 
-
United Kingdom National Institute for Health and Clinical Excellence (NICE), Scottish NICE, SMC 
(England, Wales, Medicines Consortium (SMC) 
Scotland) 
United States Medicare evidence development and coverage advisory committee 
-
Israel Oolned Not included (Became an OECD country after search strategy -
September 2010) conducted) 
Estonia Oolned Not Included (Became an OECD country after search strategy -
December 2010) conducted) 
Slovenia Oolned July Not included (Became an .OECD country after search strategy 
-
2010) conducted) 
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There were 33 OECD countries when the search strategy was undertaken. Since 2010, 3 new 
countries gained membership of the OECD and as of September 2011 there are 36 OECD 
countries. Table 2.3 identifies the reimbursement institution/body/entity that is involved in 
appraising evidence for reimbursement decisions. These details were included in the search 
strategy in the next section. 
2.2.11 Search strategy 
The identification of the reimbursement agencies informed the search strategy for the systematic 
review to identify the population and intervention (Table 2.4). 
Table 2.4: Population and Intervention 
Population Intervention 
Reimbursement Decision$ 
Payer Allocatlon$ 
Drug coverage Advice 
Reimbursement mechanlsms/ List 
Pharmaceutical benefits advisory committee lists 
Pbac Recomend$.tl,ab 
Committee for drug reimbursement Recommend$ 
Danish medicines agency Apprais$ 
haute autorit$ de sant$. Drug approval/ 
french national authority for health 
reimbursement and medicinal products 
edaf 
ministry of social affairs and health 
Italian medicines agency 
agenzla Italiana del farmaco 
aifa 
health Insurance review agency 
national centS of excellence In health technology 
centro nacional de excelencla tecnologica en salud 
cenetec 
~harmaceutical management agency 
pharmac 
health technology assessment agency 
aotm 
ministry of health adj20 slovak republic 
dental adj6 pharmaceutical benefits board 
pharmaceutical adj20 tlv 
social Insurance agency adj20 turkey 
medicare adj20 coverage advisory committee 
Institute for Quality and Efficiency In Health Care 
Institut fur Qualitat und Wirtschaftlichkeit 1m Gesundheitswesen 
Iqwig 
national health Insurance fund administration adj20 hungary 
national centre for pharmacoeconomics 
ncpe 
ministry of health adj5 labour and welfare adj20 Japan 
direction de la sant$. 
national Insurance health boards 
college voor zorgverzekerlngen 
cvz adj20 netherlands 
norwegian medicines agency (statens legemiddelvern) 
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Table 2.4 Continued .••• / 
national Institute for pharmacies and medicines 
Instltuto nacional da farmacia e do medicamento 
agencla d'Avaluaclo de tecnologla I recerca mediques de catalunya 
federal office of public health adj20 switzerland 
national Institute adj6 clinical e)(cellence 
scottish medicines consortium 
Nice 
smc 
A preliminary search strategy was run and the first 100 studies from 2010 and 100 for 2009 were 
taken to identify new search terms from the studies selected. The final search strategies for 
Medline, Embase, Econlit, HMIC, NHSEED and REPEC are reported in the Box A2.3. 
2.2.12 Grey literature searches 
Table 2.5 documents the websites searched and Table 2.6 displays the results (21July 2010). 
Table 2.5: Websites searched (21July2010) 
International Health Economics http://eche2010.abstractbook.org/presentations/ 
Association IHEA 
National Institute for Health and http://www.nice.org.uk/ 
Clinical Excellence (NICE) 
REPEC http://ideas.repec.org/ 
Google Scholar search http://scholar.google.co.uk/ 
ISPOR http://www.ispor.org/ 
HTAI http://www.htai.org 
EUnetHTA http://www.eunethta.net/ 
Table 2 6' Website search results ..
Internet Search Website 
IHEA 1 
REPEC 0 
Scholar 2 
Total 3 
2.2.13 Citation searches 
A citation search was conducted for one of the seminal quantitative regression studies of NICE 
decision-making that has been highly cited (Devlin and Parkin, 2004). The search identified the 
following two additional studies: 
(Raftery, 2006) and (Williams and Bryan, 2007). 
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2.3 Literature review results 
Table 2.7 identified the databases searched and the number of hits and Table 2.8 provides details 
of the number of studies finally included. 
Table 2.7: Database searches conducted (July 2010) 
Database Search Number of Hits 
Medline Search hits (06/07/2010) 3,423 
Medline within database duplicates 83 
Medline hits 3,340 
Embase Search hits (06/07/2010) 3,837 
Embase within database duplicates 27 
Embase hits 3810 
EconLit Search hits (06/07/2010) 401 
Econlit within database duplicates 6 
Econlit hits 395 
HMIC Search hits (06/07/2010) 749 
HMIC within database duplicates 25 
HMIC hits 724 
NHSEED REPEC Search hits (06/07/2010) 101 
NHSEED within database duplicates 1 
NHSEED hits 100 
Total combined database hits 8369 
Table 2.8: Studies Included and reference list searches 
Hits 
Database search hits 8369 
Internet search 3 
Citation list search 2 
Total hits 8374 
Duplicates across database 2468 
Exclude title/abstract 5850 
Full Text 56 
Full text retrieved 56 
Not Retrieved (Not English language) 4 
Full Text excluded 21 
Full Text included 31 
Total Included 31 
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Figure 2.1: Study selection flow diagram 
Total record identified from 
electronic database searches 
after duplicates removed 
(n =5,901) 
Excluded on title/abstract 
(n=5,850) 
Full copies retrieved and 
assessed for eligibility 
(n=51) 
Studies identified from grey 
literature/internet (n= 3) 
Excluded (n=21) 
Studies Identified by citation 
search (n= 2) No data on decisions (n=9) Factors not related to decision (n=5) 
Local level decision (n=5) 
Single medicine decision (n=1) 
Timeliness of local vs national (n=1) 
-I Foreign Language (n=4) 
Studies Included in the review 
(n= 31) 
Figure 2.1 illustrates the flow chart of the study selection process. The database search identified 
a total of 8,369 hits and resulted in 5,901 individual studies after 2,468 duplicates were removed 
from across the databases. The title and abstract were initially screened against the study 
1 
Chapter 2: Review of Empirical Evidence 49 
inclusion criteria and 5,850 studies were excluded. This stage identified Sl studies that were 
potentially relevant. In addition 3 studies were obtained through grey literature searching and 2 
studies through citation searching. After review of the full text 2S studies were excluded and a 
detailed description of the exclusion reasons can be found in Table A2.2 and Box A2.2. There were 
31 studies included in the final review. The data extracted from the quantitative and qualitative 
studies can be found in Tables A2.3 and A2.4. 
Table 2.9: Studies included by type and country 
Category Quantitative Qualitative Total 
Cross-country comparisons 1 S* 5* 
Reimbursement factors in Australia 4 1 5 
Reimbursement factors in Belgium 1 0 1 
Reimbursement factors in Canada 0 1 1 
Reimbursement factors in England 5 7 12 
Reimbursement factors in Finland 0 1 1 
Reimbursement factors in the Netherlands 1 2 3 
Reimbursement factors in Sweden 0 2 2 
Reimbursement factors in USA 1 0 1 
Total number of studies Included 13* 19* 31 
·One study uses both a Quantitative and Qualitative approach and appears in both the quantitative and qualitative 
columns (Total sums to 32 examples of quantitative and qualitative methods because of one mixed method study). 
Table 2.9 show the studies by country and type of methodology. The search identified a total of 
13 quantitative studies and 19 qualitative studies that included 5 cross country comparisons 
studies and 26 country specific studies. The empirical studies included analysis for elements of ten 
OECD countries reimbursement systems. A number of studies that used both qualitative· and 
quantitative methodology were excluded for Canada because they either related directly to 
decision-making at the provincial level or they were concerned with the linkage of the national 
decision-making body (CADTH CDR) with the provincial reimbursement decision-making: 
• Australia (Pharmaceutical Benefits Advisory Committee); 
• Belgium (Committee for Reimbursement of Medicines); 
• Canada (CADTH CDR); 
• England and Wales (National Institute for Health and Clinical Excellence); 
• Finland (Ministry of Health and Social Affairs); 
• Netherlands (Dutch Health Boards, CVZ); 
• New Zealand (Pharmaceutical Management Agency, PHARMAC); 
• Sweden (Dental and Pharmaceutical Board, TLV); 
• Scotland (Scottish Medicines Consortium, SMC); 
• USA (Medicare). 
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Comparisons of reimbursement systems were provided for Australia, Canada, England, New 
Zealand and Scotland. Table 2.10 shows the country comparisons conducted across countries. 
Two studies compared the NICE in England with the SMC in Scotland, one study compared PBAC 
in Australia with CADTH CDR in Canada and NICE in England, one compared PBAC in Australia with 
CADTH CDR in Canada and SMC in Scotland and another compared PBAC in Australia with NICE in 
England and PHARMAC in New Zealand. 
The quantitative and qualitative studies were analysed with respect to the factors considered 
Influential within countries. The evidence is classified into quantitative evidence, for which 
quantities and relationships between attributes have been estimated following a set of statistical 
methods, and qualitative evidence, for which data has been collected in a narrative and non-
numeric form. 
The quantitative studies identified are described in the following sections: 
• Overview of quantitative methodology studies; 
• Characteristics and definition of influence by countries considered; 
• Influence of factors on decision outcomes in studies identified. 
2.3.1 Overview of quantitative methodology studies Identified 
The search Identified thirteen studies that used a quantitative methodology to consider the 
association between factors and decisions in reimbursement systems in six countries (institutions, 
agency or entity): 
• Australia (PBAC); 
• Belgium (CRM); 
• Canada (CADTH CDR); 
• England (NICE); 
• Netherlands (CVZ); 
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• US (Medicare). 
A summary of the quantitative studies is provided with respect to the country (institutions), 
number of observations, methodology, decision outcomes, study observation period and factors 
considered to influence decisions in Table A2.S. The quantitative studies identified can be 
grouped into two frameworks of study, those that are revealed preference studies and those that 
are stated preference studies. The revealed preference studies are those in which previous 
decisions made by the reimbursement system reveal the factors influencing decisions. The stated 
preference studies are where committee members are asked to state the impact of factors on the 
decision outcome in the respective system. Eleven of the studies used a revealed preference 
framework and two of the studies used a stated preference framework. 
2.3.1.1 Revealed preference framework 
The revealed preference framework was used in thirteen studies considering one reimbursement 
system and one of these studies compared three reimbursement systems. These studies focused 
on a retrospective analysis using past decisions made by the national agency responsible and the 
factors that can be identified to explain these decisions. The sample of decisions considered in 
the analyses varied from 33 to 824, and the studies covered different periods between 1991 and 
2009. 
The studies used a range of statistical methods from simple Chi squared tests, logistic regression, 
probit regression and multiple logistic regression models (MNLM) to consider the association of 
factors on the decision outcome. The studies used univariate analysis in six of the studies and 
multivariate analyses were used in five of the studies. Multiple factors were included in seven of 
the studies. Multinomial decision outcomes - at least one more category than recommend and 
not recommend - were used in two studies. 
The factors have been grouped into the general categories of factors considered. Evidence factors 
were considered across all eleven of the studies with respect to the clinical evidence and 
economic evidence. Non evidential factors were considered in six of the studies (Characteristics of 
the disease, burden, medicine type such as cancer medicine, other alternative). Process factors 
were considered in six of the studies (resubmission, application type, history of drug submission, 
stakeholder involvement and STA process). 
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2.3.1.2 Stated preference framework 
There were two studies using a stated preference framework, one with a sample of NICE 
committee members in England and one with a sample of health policy makers in the Netherlands 
(including members of CVZ). The studies used a discrete choice experiment methodology to 
overcome some of the disadvantages of revealed preference studies such as the reliance on the 
reporting documented for each decision and the difficulty in accounting for wider factors because 
of the lack of reporting of some qualitative aspects of decision-making. These studies have more 
of an emphasis on the influence of non-evidence factors on the decisions such as disease severity, 
age of patient and availability of other treatments. These are factors that may be either applied to 
the evidence or considered separately from the evidence in the appraisal and resulting 
reimbursement decision. 
2.3.2 Reimbursement factors investigated In quantitative country comparisons 
Table 2.11: Cross country comparison (Clement et al., 2009) 
Institutions (Year) 
Table 2.11 describes the characteristics of the study and the definitions of each factor included in 
(Clement et aI., 2009). There was one study that used a mixed methodology of qualitative and 
quantitative methods for reimbursement decisions in Australia (PBAC), Canada (CADTH CDR) and 
England (NICE), (Clement et aI., 2009). The study aimed to describe the influence of effectiveness 
and cost-effectiveness evidence and other factors on decisions between 2001 and 2008. However, 
the study does not explicitly describe the meaning of the term influence. The authors stated: 
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Using a retrospective analysis of past decisions, we describe how these committees use 
evidence on effectiveness and cost-effectiveness (including any barriers to such use), and 
what additional factors have influenced deCisions, and explore how these issues maybe 
associated with listing decisions. (p.1438) 
The study used Chi squared tests to identify how key factors were associated with the likelihood 
of listing (The authors report that Chi square tests are used to consider differences across factors 
and countries but the tests were not reported for the association with the listing. Contact with the 
authors confirmed that Chi square tests were used but not reported in the study). The agencies 
were selected because they consider both effectiveness and cost-effectiveness, provide 
documents in English and are reported to be similar in their underlying populations and public 
insurance coverage. The study analysed the composition of all medicine decisions produced by 
the agencies within and across countries with respect to a binary decision outcome (list/do not 
list) and each factor in a univariate analysis: the clinical evidence (clinical uncertainty, weight of 
clinical evidence, study endpoints), economic evidence (cost-effectiveness estimates, type of 
economic analysis, economic uncertainty), one non-evidence factor (life threatening disease) and 
one process factor (resubmission). 
2.3.3 Reimbursement factors investigated in quantitative single country studies 
2.3.3.1 Studies Investigating reimbursement factors in Australia: 
There were four quantitative studies that considered the influence of factors for the national 
reimbursement recommendations for PBAC in Australia (Table A2.6). They shared similarities in 
the decision outcomes and definition of influence by correlation between the factor and the 
decision outcomes. Two studies adopted a regression approach whereas the other two studies 
considered the impact of one factor upon the decision outcome. The studies shared differences In 
the sample of the medicines appraised and factors included and definitions of these factors when 
the same factor was used across the studies. 
Two studies considered the influence of single factors on decision outcomes for those medicines 
that were submitted to PBAC with a cost-utility analysis (George et aI., 2001, Scuffham et aI., 
2008). The aim of one study was to generate a league table of 355 medicines considered by PBAC 
between 1991 and 1996, (George et aI., 2001). This study compared 26 estimates of cost per life 
year gained and 9 estimates of cost per QALY separately for those that were recommended for 
listing and those that were not by using a Mann-Whitney test to consider whether any difference 
was statistically significant. A ranking of the estimates of cost effectiveness was provided to elicit 
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a threshold value for PBAC. The second study compared the listing rates observed for different 
types of methods for obtaining QALY weights for 49 submissions provided to PBAC between 2002 
and 2004. There were three categories of QAl Y weights namely, multi-attribute utility 
instruments, health state valuation and non-preference based (Scuffham et aI., 2008). 
One study considered whether cancer medicines were less likely to be recommended by PBAC by 
controlling for the influence of other factors for 243 binary decisions made between 2005 and 
2008, (Chim et aI., 2010). Chim et 01. conducted both a univariate and multivariate analysis of the 
factors influencing PBAC decisions. The study analysed the univariate association between clinical 
evidence, economic evidence, non evidence and process factors and performs a multivariate 
logistic regression analysis using the statistically significant associations found in the univariate 
analysis. The multivariate analysis includes the medicine type (cancer/non-cancer), application 
type, estimated cost to the PBS and cost-effectiveness estimate. The study used a unique set of 
variables to characterise the clinical evidence, including whether the PBAC accepted the 
manufacturers claim for the effectiveness of the comparator and the clinical claim. The authors 
included a variable for whether the PBAC accepted the claims in the economic analysis and similar 
to some of the other studies considering PBAC included the type of economic analYSiS, cost-
effectiveness estimate and budget impact estimate. The study also uniquely included two non-
evidence factors that were the number of patients per year the medicine treats and whether the 
medicine was used to treat cancer or another disease. 
One study considers the role of value for money amongst other factors through a retrospective 
analysis of 103 PBAC binary decisions produced between 1994 and 2004, (Harris et aI., 2008). The 
correlative Influence and relative weight of factors is considered using a probit regression model 
that produces a Nmarginal effect". The marginal effect estimates the change in the probability of 
listing for a unit change in each of the variables, holding the other variables constant at their 
mean. The study includes variables for clinical evidence, economic evidence, non-evidence factors 
and process factors. The study uniquely defines aspects of the clinical evidence by focusing on the 
quality of the clinical evidence through a categorical variable for clinical significance, precision of 
clinical evidence, type of clinical evidence, quality of studies and the relevance of the evidence. 
Similar to other studies for PBAC, a variable was included to consider the influence of the 
medicines cost-effectiveness estimate and a continuous variable for the budget impact. A single 
process factor is included that controls for whether the submission was a resubmission. 
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2.3.3.2 Reimbursement factors investigated in Belgium 
Decision outcome (Number) 
Influence (Methods) 
Categorisation of those medicines In the Hlimlted PVII1lpnrp-
new medical entitles and new Indications In com line extensions. 
Indication of added therapeutic The approval of therapeutic value in class 1 submissions only by a positive 
value active control su trial. 
Table 2.12 describes the characteristics of the study and the definitions of each factor included in 
(Van Wilder and Dupont, 2008). The study considered decisions made by the Belgium 
reimbursement decision-making body called the National Insurance Agency and aimed to assess 
whether evidence of therapeutic value were associated with reimbursement decision-making in 
Belgium (Van Wilder and Dupont, 2008). The study considered the difference in 
recommendations for those medicines categorised as new indications and those categorised as 
line extensions using a Pearson Chi squared test in 824 reimbursement decisions between 2002 
and 2004. The influence of the clinical evidence was defined in terms of the impact of the 
evidence on the reimbursement decision by the correlation between the decision and the extent 
of the available evidence on the effectiveness for all medicines. The influence was also 
investigated by the Pearson chi-square for correlation between the decision and the medicine 
having added therapeutic value in those medicines categorised as Class 1. 
2.3.3.3 Reimbursement factors investigated in England 
There were four quantitative empirical studies that considered retrospective NICE decisions in 
England covering different periods of time, with different samples of recommendations using 
different factors (Table A2.7). There was greater consistency in the factor definitions for some 
aspects of the clinical evidence (number of RCTs), economic evidence (cost-effectiveness 
estimates), and process factors (date of decision and stakeholder involvement) in some of the 
retrospective studies of reimbursement decisions. Three of the studies used discrete choice 
regression modelling and the other used a Fisher exact statistical significance test for two 
categorical groups. The samples of decisions included all technologies following the technology 
~ppraisal process by NICE rather than specifically pharmaceuticals in three of the studies. A fourth 
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retrospective study considered cancer medicines only and uniquely considered the influence on 
decisions of a change in the NICE process. 
One study used a logistic regression analysis for the first 33 NICE decisions between 1999 and 
2002 to understand the influence of cost-effectiveness analysis and other factors (Devlin and 
Parkin, 2004). The study aimed to explore NICEs cost-effectiveness threshold and the tradeoffs 
and weight between cost-effectiveness and other factors influencing decisions. The factors 
relevant to NICE decision-making were identified by a description of the cost-effectiveness 
threshold in the context of NICE and considered with respect to all technologies (medicines and 
other technologies). The binary regression model included six explanatory variables; continuous 
variables for the ICER value, uncertainty surrounding the cost-effectiveness evidence, burden of 
disease, impact on the NHS budget and categorical variables for other available therapy and other 
factors. The meaning of the term influence is not defined explicitly within the study but a 
statement was made with respect to the aim of the study that: 
The aim of this paper is to consider the factors that operate to influence NICE decisions, 
to explore systematically the influence of each and to establish the characteristics of the 
cost-effectiveness threshold, if it exists. (p.438) 
The author's use of the term alongside the methodology used implies that influence in this study 
is the correlate association between the factor and deciSion, controlling for other factors without 
explicit consideration of the counterlactual. 
A multinomial decision outcome (recommend, restrict, not recommend) was used for the first 
time in one study to provide a more realistic description of 94 NICE decisions for technologies 
considered between 1999 and 2003 (Dakin et aI., 2006). A model of NICE decision-making was 
developed to identify the determinants of decisions through the identification of two broad sets 
of factors, the inputs into decision-making and the factors pertaining to the decision process used 
by NICE. A multinomial regression technique was used to evaluate the impact of evidence factors, 
quantity and quality of the clinical evidence, cost-effectiveness estimates and budget impact. Non 
evidence factors were included in relation to existence of alternatives and the technology type. 
Two process factors were included with respect to the decision date and patient group 
submissions. The terms "impact" and "influence" are used interchangeably in the study but are 
not directly defined with respect to the methodology used. The definition of influence is implied 
by the analysis to be the observation of an association between the factor and decision 
controlling for the other factors included. 
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A further study was identified as a conference abstract that considers the influence of cost-
effectiveness and other factors on a large sample of NICE decisions between the period 1999 and 
2009 (Devlin et aL, 2010). The study considers 184 NICE technology appraisals and innovatively 
approaches the analysis by breaking down into a number of binary decisions for each indication or 
defined patient group resulting in more than 600 binary decisions. The study reports use of 
regression analysis to identify the threshold and influence of other factors in NICE decisions. 
Influence or impact on decisions is not defined within the conference abstract. The study includes 
explanatory variables for the clinical evidence and cost-effectiveness evidence and includes non-
evidence factors such as characteristics of the patients, disease or treatment and contextual 
factors affecting the conduct of the technology appraisal such as patient group involvement. The 
factors affecting the conduct of the technology appraisal are referred to as process factors In 
other studies. The results are not reported in the abstract because this is reported as work In 
progress. 
A fourth study uniquely considers the impact of a change in process on the S6 decisions made 
between 2000 and 2006 for cancer medicines by NICE (Mason and Drummond, 2009). A structural 
break analysis is presented for the period before NICE introduced the STA process (2000-2006) to 
the period between which the STA process was introduced and in operation (2006-2008). The STA 
process was Introduced to speed up the time that technology appraisals were completed in to six 
months and removed the requirement for an independent analYSis by an academic assessment 
group. The analysiS compares the multinomial recommendations (recommended, restricted, not 
recommended) for the first period with the second period by using the generalised Fisher exact 
test to determine whether the differences were statistically significant. This explores the extent 
of the change in the process in explaining differences in the decisions over the time period. 
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rs to recommend a technologv (Stated 
The mean age of the population who will benefit from the Intervention 
(Categorical: Children (less than 18 years, working 18 to 64 years, Retired more 
than 64 
An Index utilitV score of patients prior to receiving the Intervention 1 
representing perfect health and zero representing dead. (Categorical, 0.25, 0.50, 
therapies are available to manage the condition 
A fifth study performed a discrete choice experiment of stated decision-maker preferences with a . 
binary outcome for the decision rather than considering retrospective decisions (Tappenden et 
al., 2007). The study used a logistic regression to understand 37 committee members preferences 
for a number of factors including the incremental cost-effectiveness estimate, the degree of 
uncertainty surrounding the cost-effectiveness and health outcomes, the age of the beneficiaries, 
baseline health related quality of life and the availability of alternative therapies when 
considering the decisions for technologies considered by NICE (Table 2.13). 
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2.3.3.4 Reimbursement factors Investigated In Netherlands 
Table 2.14: Characteristics of 
The search identified one study (Table 2.14) that conducted a discrete choice experiment 
between 2007 and 2008 that specifically considered the factors in decision-making by 62 Dutch 
health care professionals (including members from the Dutch Health Board, CVZ). The study 
included a number of factors relating to the decision outcome of a choice preference between 
two treatments including clinical considerations such as the QAlY gains and composition of health 
gain, economic considerations such as ICER value, uncertainty around ICER and budget impact, 
productivity savings and disease severity (Koopmanschap et aI., 2010). 
2.3.3.5 Reimbursement factors investigated in the USA for the Centre for Medicare and 
Medicaid Services (CMS): 
There was one study that identified the influence of clinical evidence and the quality of the 
evidence for Medicare coverage decisions in 69 technologies (5 of which were for medicines) for 
between 1999 and 2003, (Neumann et aI., 2005). The study focuses on the level of evidence as 
described as good if it included consistent results from well designed, well conducted studies In 
representative populations, fair if evidence was sufficient to determine the effect of health 
outcomes but strength was limited by the number, quality or consistency of individual studies and 
poor studies were identified if the evidence was insufficient to assess the effects on health 
outcomes because of the limited number of power studies, flaws in design or lack of information 
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on important health outcomes. A statistical test comparison between poor and good quality 
evidence was conducted in this study (Table 2.15). 
Table 2.15: Characteristics of 
contractor discretion, not 
Categorical: 0-3 months, 3-6 months, 6-9 months, 9-12 months and more than 12 
months 
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2.3.4 Influence of factors within and across countries 
The comparison of influence of a factor across studies for a country's reimbursement system and 
across studies conducted in different countries can only be examined in relation to the direction 
of the association with the decision and whether this was found to be statistically significant. This 
is because even where the same factor is constructed, methodological differences in the 
statistical analysis performed and decision outcomes used do not allow a comparison of the 
relative magnitude of each factor across countries systems. The association and statistical 
significance of factors considered in each country can be found in Table A2.S. Tables 2.16, 2.17 
and 2.18 detail a summary of the direction of effect of each study for each of the factors based on 
the statistical significance in the quantitative studies. The influence of each factor is considered in 
the influence of a factor on a recommended decision or decision to list a medicine. The factors are 
considered within the follow groups: 
• Evidence Factors (clinical and economic evidence); 
• Non-evidence factors (age of patient, disease); 
• Process Factors (resubmission, time period of decision). 
The following section details those factors where a statistical association was found with the 
factor and decision in all studies and countries for which the factor was considered. The second 
group of factors concerns where there is mixed evidence of the association of the factors and 
reimbursement decisions within studies for a single reimbursement system and across countries 
reimbursement systems. 
2.3.4.1 Consistency of the Influence of factor across quantitative studies and countries 
• Clinical evidence considerations - Size of Clinical Effect 
There were two studies for national reimbursement decision's In Australia (PBAC), (Harris et aI., 
2008) and Belgium (CRM) where the size of the clinical effect was statistically significantly 
associated with the decision (Van Wilder and Dupont, 200S). The study conducted in Australia 
considered the clinical effect in a multivariate analysis whereas the Belgium study specifically 
considered the univariate difference in the proportion of positive and negative decisions. A 
further study considering PBAC in Australia provided a univariate analysis of the influence of the 
manufacturers' clinical claim on the decision and found this to be statistically associated with 
recommending the medicine (Chim et aI., 2010). 
• Economic evidence considerations -Incremental Cost-effectiveness Ratio (ICER) 
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In all eight studies that considered the impact of the ICER value on the reimbursement decision in 
Australia (PBAC), England (NICE), Canada (CDR) and the Netherlands (CVZ), a higher ICER value 
was found to be statistically significantly negatively associated with the decision to list (Chim et 
aL, 2010, Clement et aL, 2009, Dakin et aL, 2006, Devlin and Parkin, 2004, George et aL, 2001, 
Harris et aL, 2008, Koopmanschap et aL, 2010, Tappenden et aL, 2007). These studies used 
different decision outcomes and a variety of methods, univariate statistical tests, multivariate 
probit regression models, multivariate logistic regression models, multinomial logistic regression 
models and discrete choice experiments using multinomial regression models. Two of the studies 
consider a cost per QAl Y threshold for decision-making. One study reports a threshold range for 
decisions of between £34,000 per QAlY and £47,000 for NICE for past NICE decisions in 1999 and 
2002, (Devlin and Parkin, 2004). A study conducted in the Netherlands reports a threshold of 
EUR093,000 per QAlY for high severity and EUR010-15,000 threshold for low severity disease for 
stated preferences of decision-makers between 2007 to 2008, (Koopmanschap et aL, 2010). 
2.3.4.2 Mixed evidence of association with reimbursement decisions across studies and 
countries 
• Clinical evidence considerations - Quality and quantity of clinical evidence 
There were six studies that analyse attributes relating to the quality and quantity of clinical 
evidence and there were multiple measures used within each study. The studies used composite 
scores to assess the overall quality of studies and the association with reimbursement decisions 
and specific characteristics of the quality and quantity of clinical evidence. There are difficulties in 
making comparisons within and across studies in this review of the association of the impact of 
quality and quantity of clinical evidence because these measures have different constructs and 
each construct has been considered exclusively in each study for the countries of interest. 
Four of the studies consider composite measures of the quality of evidence, one using a measure 
of clinical uncertainty that includes the type of trial, comparator and endpoint for studies 
assessed by NICE, PBAC and CDR (Clement et aL, 2009), one using the mean Jadad score for trials 
assessed by NICE, (Dakin et aL, 2006), one using a 12 item checklist for the quality of studies for 
PBAC decision-making, (Harris et aI., 2008) and the consideration of well designed and conducted 
RCTs for Medicare decision-making in US (Neumann et aL, 2005). The two studies that considered 
NICE decision-making used two different measures found no association. The US study of 
Medicare found that technologies (including pharmaceuticals) with good evidence were 
statistically significantly more likely to be listed than those with fair or poor evidence, although 
this study only included 5 medicines in the sample for Medicare decisions. The study considering 
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clinical uncertainty found that the presence of high levels led to a lower probability of listing in 
Australia and Canada. In a study that specifically considered PBAC decision-making in Australia, 
the use of 12 item quality checklist was not found to be associated with the decision outcome. 
Three of the studies considered eight specific characteristics of the quantity and quality of 
evidence and number of RCTs and number of systematic reviews were found to be statistically 
significant in NICE decision-making, (Dakin et aL, 2006), whereas a relevant clinical endpoint was 
found to be associated with a higher probability of listing in PBAC decisions in Australia and CDR 
decisions in Canada (Clement et aI., 2009). There was no association found for RCT significance 
and RCT size for NICE decision-making, appropriate comparator and population and type of 
evidence (randomised, observational) for NICE and PBAC decisions and precision of treatment 
effect in PBAC decisions. 
• Economic evidence considerations - General requirements for economic analysis 
There were seven studies that considered the influence of different requirements for economic 
analysis for PBAC decision-making in Australia, CDR decision-making in Canada, NICE decision-
making in England and reimbursement decision-making in the Netherlands. The measures broadly 
relate to composite measures of the quality or robustness of the economic evaluation, 
uncertainty surrounding the ICER estimates and other specific characteristics of the economic 
evaluations. 
Two studies considered a composite measure of the robustness of the economic analysis. One 
labels this as 'economic uncertainty' on three levels of considerable, some and no uncertainty and 
finds that considerable economic uncertainty is associated with a lower probability of listing for 
PBAC deCision-making and CDR decision-making but finds no association for NICE decision-making 
(Clement et aI., 2009). 
Four studies considered measures of uncertainty around the ICER and consistently found an 
association with the decision outcome. Two studies using discrete choice regression models found 
that higher levels of uncertainty (The NICE study considered the ratio of the range of cost-
effectiveness divided by the average cost-effectiveness and the PBAC study considered the upper 
limit of the sensitivity analysis) were statistically significantly less likely to be listed for NICE and 
PBAC decision-making (Devlin and Parkin, 2004, Harris et aL, 2008). The two discrete choice 
experiments performed in England (degree of uncertainty concerning costs and effects), 
(Tappenden et aL, 2007) and in the Netherlands (probability that the cost per QAl Y will be at least 
doubled as compared to the average cost-effectiveness), (Koopmanschap et aI., 2010) found that 
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higher levels of each attribute were statistically associated with a lower probability of choice of 
the intervention. 
Three studies considered other characteristics relating to the economic evaluations. A study of 
NICE decision-making found that the type of economic evaluation (cost-utility analysis) was 
statistically significantly more likely to be not recommended in comparison to recommended 
(Dakin et aI., 2006). A study for PBAC in Australia also found a similar relationship between cost-
minimisation and no economic evaluation statistically associated with a recommendation in 
comparison to cost-effectiveness analysis and cost-utility analysis in a univariate analysis (Chim et 
aI., 2010). This was an unexpected finding and possible explanations were suggested with regards 
to decision-makers using the same threshold for cost-effectiveness and cost-utility analysis, it may 
imply a 'rule of rescue' where decision-makers place more value on increased quantity of life 
rather than quality, the use of quality weights may increase the uncertainty around the CQG. A 
study of PBAC decision-making considered appropriate model structure, robust translation of 
clinical outcomes with quality of life, modelled cost outcomes and did not find any of these 
factors to be statistically associated with decisions (Harris et aI., 2008). The researchers of one 
study judged whether the PBAC judged the economic claim to be acceptable and found that this 
was statistically associated with the decision in a univariate analysis but found this to be 
statistically insignificant in a multivariate analysis (Chim et aI., 2010). A further study found 
evidence of a statistically significant lower probability of listing for those submissions that used 
non-preference based utility weights (Scuffham et aI., 2008). 
• Economic evidence considerations - Budget Impact 
Budget impact was included as a factor in the decision-making in studies for PBAC in Australia, 
NICE in England, and reimbursement decision-making in the Netherlands. There was a negative 
association between increases in the size of the budget impact and a listing decision in two 
studies considering decision-making in Australia and one study in the Netherlands (Chim et aI., 
2010, Harris et aI., 2008, Koopmanschap et aI., 2010). One study performed for NICE England 
found no statistically significant association between budget impact and the listing decision (Dakin 
et aI., 2006), which would be the result expected given that budget impact is not directly taken 
into account by the NICE committee. 
2.3.4.3 Mixed evidence of non-evidence factors across studies and countries 
• Lack of alternative therapy 
Chapter 2: Review of Empirical Evidence 65 
There were four studies that considered this factor, one for PBAC decision-making in Australia and 
three for NICE decision-making in England. There was no association found between lack of 
alternative therapies in PBAC decision-making (Harris et aI., 2008). There was mixed evidence of 
an association for NICE decision-making, two studies using different methods, found a positive 
association with the decision to list, one of which considered past NICE decisions (Devlin and 
Parkin, 2004) and one a stated preference of NICE decision-makers (Tappenden et aI., 2007). A 
third study found no association between lack of alternative therapies for NICE decision-making 
and this may be because this study focused on a larger number of explanatory factors than the 
other two studies for NICE decision-making (Dakin et aI., 2006). 
• Severity of disease and life threatening conditions 
There were two studies that considered the association between whether the disease was 
classified as life threatening and the decision outcomes for PBAC decisions in Australia, NICE 
decisions in England, CDR decisions in Canada and one study that considered severity of disease in 
the Netherlands. One of the studies found no association between disease severity and listing 
decision for PBAC in Australia, NICE in England and CDR decisions in Canada for decisions between 
2001 and 2008, (Clement et aI., 2009). In contrast, a probit regression model of past PBAC 
decision-making in Australia that featured a subset of the decisions in the first study for the 
period 1994 to 2004 found there to be a positive association between disease severity and listing 
(Harris et al., 2008). The stated preference study conducted in the Netherlands found severity to 
be positively linked to choice of intervention (Koopmanschap et aI., 2010). 
• Other non-evidence factors 
One study conducted with decision-makers in the Netherlands considered other factors such as 
the number of QAlYs gained per patient, the composition of the health gain and the cost of 
absence per year (Koopmanschap et aI., 2010). The study found a statistically significant positive 
association between the number of QALYs gained and the choice of the intervention. There was a 
preference for those interventions that had quality of life improvements over extension of life 
with improved quality. The study found no association between productivity savings and the 
preference to list an intervention. 
A second study aimed to consider the hypothesis that cancer medicines were less likely to be 
recommended other things remaining equal (ceteris paribus) (Chim et aI., 2010). The study found 
that after adjusting for other factors there was no difference between the recommendation rates 
for cancer medicines and non-cancer medicines in the multivariate analysis. 
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2.3.4.4 Mixed evidence of the Influence of process factors across studies 
• Patient group Impact 
There was one study that considered whether the presence of a patient group submission was 
associated with NICE decision-making in England (Dakin et aI., 2006). This was identified as 
whether a patient organisation was listed at the end of the guidance document and categorised 
for each decision as a categorical submission/no submission variable. The presence of a patient 
group had a large statistical effect on the odds of being the medicine being recommended in 
comparison to restricted. The study notes that this result may have been due to only three 
appraisals reporting an ICER value but lacking a patient group submission and were not 
recommended for use. The very small sample of decisions not reporting a patient group 
submission may undermine the reliability of this finding. 
• Resubmlsslon 
One study found that a medicine that had been previously considered for the same indication by 
PBAC in Australia was statistically significantly more likely to be listed than one that had not been 
previously considered (Harris et aI., 2008). In contrast a second study on PBAC found there to be 
no association between resubmission and the listing outcome in both the univariate and 
multivariate analysis (Chim et aI., 2010). The results of the association between resubmission and 
the listing decisions were not reported in any of the other quantitative studies for other countries, 
although considered in one study for Australia, Canada and England (Clement et aI., 2009). 
• Reimbursement time period 
There were two studies considering the effect of time on NICE decision-making in England and 
Wales over two different time periods. The first study considers NICE decision-making between 
1999 and 2005 and finds that the later appraisals were more likely to be not recommended (Dakin 
et aI., 2006). A second study found that the introduction of the Single Technology Appraisal 
process in 2006 partly explained the Increase in negative decisions after 2006 but the differences 
were not found to be statistically significant. Mason and Drummond concluded that the higher 
rejection rates may be explained by an absence of evidence on cost-effectiveness where the 
manufacturer decides to terminate the NICE STA (Mason and Drummond, 2009). 
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Table 2.16: Clinical evidence factors by influence on recommendation 
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NR=not reported) 
68 Chapter 2: Review of the Empirical Evidence 
Table 2.17: Economic evidence factors and Influence on recommendations 
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Table 2.18: Non evidence and process factors influence on recommendations 
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2.3.5 Qualitative studies results 
2.3.5.1 Cross country comparisons 
The search identified five cross country comparisons of national reimbursement decision-making 
bodies covering the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, Canadian 
Agency for Drug and Technologies in Health (CADTH) in Canada, National Institute for Health and 
Clinical Excellence (NICE) in England, Pharmaceutical Management Agency (PHARMAC) in New 
Zealand and Scottish Medicines Consortium (SMC) in Scotland (Barbieri et aI., 2009, Cairns, 2006, 
Clement et aI., 2009, lexchin and Mintzes, 2008, Raftery, 2008). 
Two studies conduct a narrative retrospective comparison of decisions between SMC and NICE 
decision-making, the earlier study considers the process similarities and differences and provides 
a comparison of medicines licensed for the same indications and the respective reimbursement 
decisions (Cairns, 2006). The second study is an extension of the first that considers the influence 
third party assessment on decisions (Barbieri et aI., 2009). The studies both argue that there are 
some similarities between the two agencies which allow comparison such as both agencies being 
part of the NHS in England reflecting the system objectives and few differences between the 
agencies guidance on economic evaluation. The earlier study concluded that there were broadly 
similar decisions made with a few noted differences, whereas the extension study considered 
there to be a trend towards more restrictive NICE decisions in comparison to the SMC. The studies 
attributed these differences to the extent of the assessment and timing of the decisions. Both 
studies identify the difficulties with making comparisons such as the limited number of 
comparative decisions, time differences and potential to collect evidence, process differences and 
the potential interdependency between the two agencies. The two studies both consider the 
trends in decision-making and identify the complexities with considering the impact or influence 
of different processes or criteria but do not consider whether other factors contribute to the 
decisions made by the two agencies. These studies suggest that independent third party 
assessment impacts upon the reimbursement decision. 
Process factors: 
• The use of third party assessment in the process of assessment of medicines results in 
differences in the restrictions applied by the SMC in Scotland and NICE in England 
(Barbieri et aI., 2009). NICE was more restrictive on some occasions and SMC on other 
occasions. 
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• The fundamental differences in the process are reported to be the timing of production of 
the guidance and extent of the evaluation performed between NICE and the SMC. A study 
finds general agreement in decisions but differences in any restrictions on use (Cairns, 
2006). 
There were three studies that made cross country narrative comparisons of reimbursement 
decisions made between countries which were perceived to have similarities with regards their 
health care systems and processes and criteria in considering evidence. One study considered 19 
common medicines for the same indication for NICE, PBAC and CDR (Clement et aI., 2009), 
another considered 29 common medicines across CDR, PBAC and SMC (Lexchin and Mintzes, 
2008), and a further study considered 10 common medicines across PBAC, NICE and PHARMAC in 
New Zealand (Raftery, 2008). The other two studies included New Zealand and Scotland in their 
comparison of decisions. The three studies attributed differences in the decisions, three with 
respect to process and three with respect to the characteristics of the medicines considered: 
Process factors: 
• Differences in the decision outcomes across countries (Lexchin and Mintzes, 2008); 
• Different processes for identifying subgroups by cost-effectiveness in NICE decision-
making and price negotiation by PBAC to ensure cost-effectiveness (Clement et aI., 2009). 
Evidence based factors: 
• Pharmacoeconomics used in the evaluation in PBAC (Australia), CDR (Canada) and SMC 
(Scotland), (Lexchin and Mintzes, 2008). 
Non-evidence based factors: 
• The composition of the decision panel (Lexchin and Mintzes, 2008); 
• Nature of disease treated and severity of disease (Lexchin and Mintzes, 2008, Raftery, 
2008); 
• Number of drugs in a therapeutic class (Clement et aI., 2009); 
• Prevalence of disease that the drug is designed to treat (Lexchin and Mintzes, 2008). 
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2.3.5.2 Qualitative studies for Australia 
One study provided a narrative comparison of decisions made by PBAC for twelve cases studies of 
medicines that met the cost-effectiveness requirements and were listed, decisions not to list 
based on evaluation of effectiveness, listing of some products despite limited cost-effectiveness, 
listing on the basis of limited evidence conditional on further monitoring (Hailey, 1997). This study 
was conducted in a period where economic analysis provided in the submission was voluntary in 
1991 and then requested as a compulsory requirement in 1993. The study found that clinical 
effectiveness and cost-effectiveness are important but other considerations may become 
important for those with limited evidence of cost-effectiveness such as the nature of the 
condition (life threatening), the public profile that it generates and budget impact. 
• Clinical-effectiveness; 
• Cost-effectiveness; 
• Budget impact; 
• Life threatening disease; 
• Patient group lobbying. 
2.3.5.3 Qualitative studies for Canada 
One study performed a narrative analysiS of the first 62 recommendations of the Common Drug 
Review (CDR) for the period of between 2003 and 2007 and a focus group of decision-makers on 
the use of economic analysis in decision-making (Rocchi et aI., 2008). The most frequently cited 
factors for the reasons for recommendation found in the documentation with respect to the 
clinical evidence were: 
• Type of outcome (surrogate, intermediate, final); 
• Magnitude of the benefit versus comparator; 
• Choice of comparator; 
• Trial duration; 
• Generalisability of the trial population; 
• Trial size; 
• Comparative safety for the clinical evidence. 
The factors described for reason in relation to the economic evidence 
• Price; 
• Quality of model; 
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• Clinical benefit used in model; 
• ICER. 
The following factors were not cited as important across the recommendations: 
• Type of disease; 
• Prevalence of the disease; 
• Equity; 
• Rule of rescue; 
• Lack of alternatives; 
• Budget impact; 
• Appropriateness of utilisation; 
• Innovative drug. 
There were some reimbursement recommendations that were seen to be inconsistent with 
respect to clinical evidence, economic evidence and this was attributed to lack of transparency or 
context-sensitive interpretations. The focus group discussion suggested that economic evidence 
does not dictate or predict the reimbursement decision, but instead can be one of several pieces 
of information that contribute to a decision. The discussions also repeatedly acknowledged the 
decision-making tasks as complex and it is sometimes difficult to reconcile competing interests. 
This may mean that every decision is unique and must be considered in the specific context. The 
discussion suggested a hierarchy for health gain or diseases of which merit additional funding 
over others. There were often problems found with the submitted economic evidence, but when 
this was deemed to be helpful, it was described whether this was considered an attractive level of 
cost-effectiveness. The inconsistencies in the cost-effectiveness maybe where there are other 
factors that are considered in the analysiS. The study concluded that decision-makers in Canada 
struggle with assigning a consistent weight to evidence and non-evidentiary factors. 
The literature search identified a number of studies that considered reimbursement decision-
making at a provincial level but these were deemed to fall outside of the inclusion criteria for this 
review because they were considered regional decision-making. These studies can be identified In 
Table A2.2 that describes the reasons for exclusion and the full references of excluded studies can 
be found in Box A2.2. 
2.3.5.4 Qualitative studies for England and Wales 
There were seven studies identified with regards the influence of factors upon decision-making 
(Andronis et aI., 2009, Bryan et aI., 2007, Raftery, 2006, Raftery, 2009, Williams et aI., 2007, 
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Williams et aL, 2008, Williams and Bryan, 2007, Wirtz et aL, 2005). The studies referred to NICE 
national decision-making with the exception of one study that referred to local formulary 
decision-making that included pharmaceuticals. These were categorised into the following two 
groups of studies: 
• Evaluation of NICE process changes; 
• The use of cost-effectiveness analysis in NICE decision-making; 
• Other decision-making factors. 
Evaluation of NICE process changes and additional appraisal factor 
One study considered the impact of end of life guidance by applying the guidance to past 
decisions to not recommend a drug because the drug was not deemed to be cost-effective 
(Raftery, 2009). The introduction of supplementary end of life guidance can be viewed as an 
additional appraisal factor (non-evidence) and a change to the NICE process for considering such 
medicines that meet the criteria. The study found that very few of the drugs would have met the 
criteria imposed and therefore the process change is thought to be unlikely to impact decisions. 
The imposition of such a special consideration under the end of life guidance sets a precedent for 
other groups to seek changes in process when this is politically deemed acceptable. Both of these 
studies considered the process change in a relatively small group of decisions and there may be 
doubt regarding the generalisability of such findings. 
The use of cost-effectiveness analysis in NICE decision-making 
There were four studies that qualitatively considered the impact of NICE decision-making using a 
qualitative approach through interview or focus groups of the impact of economic evaluation 
(Bryan et aL, 2007, Williams et aL, 2007, Williams et aI., 2008). The studies considered the impact 
of economics on decision-making by considering the ways in which economic analysis was used in 
decision-making, the value of economic analysis and the types of stakeholders' influential on the 
decision-making committee. At a national level the studies concluded that economic analysis was 
highly integrated into the decision process with an ordinal approach to considering clinical and 
cost-effectiveness information. The decision-makers reported that cost-effectiveness analysis 
allows them to structure and provide a framework to the considerations within the decision 
problem. 
There was one study that considered the first 86 guidance produced by NICE that examined the 
clinical and cost-effectiveness of technologies (Raftery, 2006). The study found that of the 
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negative recommendations, nearly two thirds were due to insufficient evidence and the rest were 
categorised as due to unacceptable cost-effectiveness. The highest cost per QALY accepted in this 
period was £39,000 for riluzole to treat motor neurone disease. The study found some evidence 
of prioritising life saving therapies through the 'rule of rescue', (Raftery, 2006). Following this 
study, political sensitivity and discomfort resulted because of the rejection by NICE of a number of 
cancer medicines. NICE introduced new supplementary guidance for end of life medicines in 
January 2009. Raftery reviewed the criteria for medicines undergoing NICE supplementary 
guidance following the guidance for 11 medicines (final and provisional guidance) for which the 
results are discussed in the previous section (Raftery, 2009). 
There was a further that employed a mix of stated and revealed preference methods for 
identifying the impact of sensitivity analysis, by consideration of 15 MTA NICE documented 
guidance and by a sample of 28 NICE committee members (Andronis et aI., 2009). The study 
observed that uncertainty was explicitly noted as a justification to not recommend two 
technologies in the sample. The interviews reinforced this as an influence as it was suggested that 
the width of the confidence intervals around the ICER should impact the coverage decision (when 
uncertainty is greater decisions should tend towards being negative. Uncertainty is therefore a 
factor considered by NICE when arriving at a coverage decision. 
Other decision-making factors 
There was one study which used 20 interviews to consider the other aspects of decision-making 
which have not been captured in previous studies (Wirtz et aI., 2005). The interviews were 
conducted with a number of decision-makers and stakeholders in the NHS and included three 
drug therapies, rivastigmine, statins and sildenafil. The stakeholders included regional policy 
makers, pharmaceutical advisors, drug advisors, lay members, patient interest groups, the 
pharmaceutical industry and academics in health policy. The interviews captured two aspects of 
decision-making which are not usually captured in the rationales usually cited. The first dimension 
was 'subjectivity' that includes personal factors that influence the kind of evidence and 
interpretations of the evidence, such as personal experiences related to the disease or the novelty 
of the benefit of the technology. The second relate to the overall social and political functions of 
decision-making which relate to the importance of maintaining relationships, the achieving of 
politically and legally defensible decisions and the reduction of organisational burden. The 
researchers did not imply by referring to these dimensions that they were inappropriate but 
rather the opposite conclusions were drawn. The authors believe that including these factors 
helps to articulate the other unexplained elements of decision-making. The study concludes that 
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the factors identified were often buried under the rationales given to legitimise the decisions 
made. The authors suggest that personal and political factors should be recognised as a 
dimension of decision-making when it is done within a discourse of reasonableness. 
2.3.5.5 Qualitative studies of Finland reimbursement factors 
A study conducted in Finland examined different stakeholders perspectives through 18 interviews 
on the reimbursement decisions made in Finland with a specific focus on the higher 
reimbursement category (Vuorenkoski et aI., 2003). In Finland there is specific priority for some 
diseases and treatments that fall under a higher reimbursement category. In 2001, The 
Pharmaceutical Pricing Board of the Finish Ministry of Social Affairs and Health includes the drug 
in the reimbursement system if it considers the price of the drug to be reasonable. An expert 
opinion is provided from the Advisory Board for Social Medical Affairs (ABSMA) of the Social 
Insurance Institution of Finland (SIIF). If the proposal from SHIF is negative, it is unlikely that the 
pharmaceutical would be considered by the Ministry of Social Affairs and Health. The 
stakeholders discussed how the decision-makers tried to keep the decisions as evidence based 
and non-political but there appeared to be hidden non-technical rationales behind many decisions 
and this may be attributed to a lack of transparency. There has been indirect means by which 
some stakeholders have tried to influence decisions such as lobbying by media, parliament or 
other stakeholders. However, these stakeholder groups are seen to have restricted influence. 
• Process categorises diseases by serious and less serious; 
• Price; 
• Budget impact on the system; 
• The criteria taken into account in the decision-making process was unclear that led to 
stakeholder involvement in decision-making through lobbying and media attention. 
2.3.5.6 Qualitative studies of reimbursement factors In the Netherlands 
The search identified two qualitative studies conducted in relation to factors influencing Dutch 
reimbursement decision-making, one considering the revealed preferences of CVZ and ministry of 
health decision-makers for reimbursement of outpatient drugs during the period of 1999 and 
2002 (Pronk and Bonsel, 2004). This study identified a number of factors across the decision to list 
unique and valuable drugs (DPRS-list lb) and considered therapeutic value, budget impact and 
burden of disease as being considered. important by considering trends in the submissions 
considered. 
Chapter 2: Review of Empirical Evidence 77 
A second study focused on the role of budget impact in decision-making by conducting semi-
structured interviews of eleven key stakeholders. The interviews confirmed that budget impact 
did playa role In certain cases and gave examples such as clopidogrel and sildenafil. It was 
considered to have more of a role when there was uncertainty around other criteria such as cost-
effectiveness or severity of illness. The interviewees could not explain how this interacted with 
other criteria such as clinical effectiveness and cost-effectiveness and severity of illness. The study 
suggests rationales in favour of budget impact that include opportunity costs, loss aversion and 
endowment effects, uncertainty and equal opportunity (Niezen et aI., 2009). 
The following factors had evidence of importance across decision-making: 
• Clinical effectiveness/added therapeutic value; 
• Cost-effectiveness; 
• Burden of disease; 
• Budget impact; 
• Severity of disease. 
2.3.5.7 Qualitative studies of reimbursement factors In Sweden 
There were two studies that identified the trends in factors used in decision-making for the 
national Swedish Pharmaceutical Benefits Board (LFN) during 2002 to 2005 (Anell and Persson, 
2005, Jansson, 2007). The reimbursement decisions produced by the LFN are based on three main 
principles, the principle of human dignity where health care is provided equally for all Individuals, 
the principle of need and solidarity where those with the greatest medical need are provided 
more health care resources than others, the cost-effectiveness principle that includes the 
marginal utility principle where the costs must be reasonable from the medical, humanitarian and 
socioeconomic points of view. The two studies both consider 107 decisions and find that cost-
effectiveness supports decision-making and is used restrict by identify cost-effective subgroups in 
those areas with large patient groups and for rejected applications. The system produces 
unconditional, conditional, rejected and time limited decisions. The time limited reimbursement 
decision, is where the applicant is obliged in time to prove the cost-effectiveness shown In early 
modelling. The frequent use of economic analysis has been central to decision-making because 
the vaguer principles, such as need and solidarity and human dignity, do not discriminate well 
between individual products. The studies similarly found that the cost-effectiveness principle was 
less important for those drugs that were for an orphan indication. One of the studies also 
performed interviews with stakeholders to accompany the documented evidence and found that 
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cost-effectiveness is given a prominent role in decision-making and that a number of stakeholders 
have tried to exert direct influence on decision-makers. There have been a number of 
stakeholders that have been affected (patients, prescribers, pharmaceutical companies and 
patient associations) lobbied during the decision-making process sending official letters, 
contacting and visiting LFN. The influence of these processes may have had an effect through the 
appeal process but only one of these appeals revision of the decision occurred. The following 
themes were found to be important in LFN decision-making: 
• Cost-effectiveness principle has been given a prominent role in decision-making; 
• Proven marginal benefits of the treatment; 
• Consideration of cost-effectiveness in subgroups with high potential budget impact; 
• Disease type - orphan drug indication; 
• lack of alternative therapies; 
• Stakeholder lobbying. 
2.4 Critical appraisal of validity of results and risk of bias 
2.4.1 Quantitative studies using a revealed preference methodology 
The following domains were considered when appraising the quantitative regression analysis for 
the validity of the results and risk of bias: 
• Reporting of the definition of influence and statistical methods 
• Statistical Model Specification 
o Dependent variable and construct of independent factors; 
o Sample Size; 
o Sample Selection bias; 
o Omitted Relevant Variables; 
o Regression assumptions. 
• External validity of results 
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2.4.1.1 Reporting of the definition of influence and statistical methods 
The definition of influence or impact was not always explicitly stated in the studies design but all 
imply a linkage to association rather than causal influence of each of the factors. For example 
(Harris et aI., 2008) does not explicitly define influence but states the aim: 
This article examines the factors that influenced drug coverage decisions in the Australian 
Pharmaceutical Benefits Scheme (PBS) that since 1993 has required detailed evidence of 
both clinical effectiveness and value for money prior to coverage and price setting-the 
first and still the only national prescription drug insurance scheme to do so. (p.714) 
The influence of factors in reimbursement decisions has been studied by consideration of the 
statistical correlation of factors with the decision outcome using a number of different statistical 
approaches such as simple chi square tests, logistic regression, pro bit regression and multinomial 
logistic regression. These statistical techniques imply certain functional forms to the decision-
making processes that may be considered more or less appropriate depending on the behaviour 
of decision-makers. The factors have been considered influential in these studies if they were 
found to be statistically Significant at conventional levels, with occasional focus on the magnitude 
of effect for certain factors such as the leER value. The use of statistical significance of a factor 
rather than magnitude of the effect of a factor was the norm across studies for describing 
whether a factor was influential. It is, clearly, very difficult to collect experimental evidence of the 
impact of different reimbursement factors on decisions. The consideration of each factor with 
respect to the counterfactual (the effect on the decision had the factor not been present) is a 
challenging task for this research area. In other areas of economics, natural experiments have 
been used to examine the causal influence of economic variables (Angrist and Pischke, 2010, 
Deaton, 2010). For example, researchers conSidering the economics of education have used 
natural experiments to identify the causal impact of years of schooling on earnings (returns to 
education) (Devereux and Hart, 2010, Harmon and Walker, 1995). However, establishing methods 
for identifying random policy changes that allow instruments to develop may be a step too far, 
until studies have identified potential factors considered Important in larger observational 
datasets of decision-making that collect data on all factors potentially important. 
The majority of quantitative studies consider multiple factors and control for the influence across 
decisions but some studies consider one factor without a control for other factors in decision-
making (Clement et aI., 2009, George et aI., 2001, Mason and Drummond, 2009, Scuffham et aI., 
2008). There are a number of differences between the variables used in those studies that 
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consider multiple factors for the economic and clinical considerations. These present difficulties 
for making comparisons within countries and across the different country studies. The 
consideration of different factors in the regression analyses may legitimately reflect different 
considerations overtime within the countries and may reflect differences across countries with 
respect to the importance of such factors. However, they may also reflect the reporting of the 
considerations by the agency for the decision-making. This may explain why many of the studies 
are carried out for NICE, England and PBAC, Australia where there is sufficient reporting of the 
evidence to allow a more detailed understanding of the influential factors. There may therefore 
be potential for collection of data on the evaluation factors that are not directly reported in the 
documentation and which are influential factors such as stakeholder influence. The studies which 
only consider one or two factors in relation to decisions may be identifying the combined effect of 
all of the other factors and may not be very useful for considering the influence of such factors on 
decision-making. 
2.4.1.2 Statistical model specification 
Dependent Variable: Decision outcomes 
The decision outcomes for studies that consider factors for one country's reimbursement agency 
are classified into a number of different decision groups. For example in England and Wales, NICE 
decisions, have been classified as binary (recommended, not recommended) in some studies and 
in one study recommended for routine use, restricted and not recommended. This is in contrast 
to the definitions of recommendations used by NICE: recommended, recommended only in 
research, optimised and not recommended. In Australia, PBAC studies have classified decision-
making outcomes into classified as recommended and not recommended and grouped deferred 
decisions under not recommended decisions. The decision outcomes provided across countries 
are different for certain groups of drugs reflecting the process differences. The impact on the 
results of the different grouping of the variables is unknown and affects the interpretation and 
potential comparisons within and across country studies. 
Construct 0/ independent variables: Independent/actors 
The majority of quantitative studies consider factors that are directly documented and the 
documentation may not reflect all relevant factors. Further to this, some factors documented 
require subjective consideration of the guidance document to be able to construct the variables 
for the quantitative analysis. There were a number of different constructs of the variables to 
identify the clinical considerations and economic considerations for decision-making across 
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countries. For example, some studies considered evidence with regard to specific measures of the 
quantity and quality of the evidence such as the number of trials, RCT significance, type of 
evidence and appropriate comparator and population in combination with a composite indicator 
of quality. In contrast, some studies focused exclusively on a composite measure of the quality of 
evidence. The varieties of composite measures used to identify the quality of the clinical evidence 
were the Jadad score for RCTs, 12-item checklist and study specific measures such as clinical 
uncertainty (type of trial, comparator and endpoint) and quality of evidence (well designed and 
conducted RCTs). The application of each of these scales will introduce an element of subjectivity 
in the extraction of data from the documented evidence. These measures may not identify the 
relative weight that decision-makers considered trials to have in terms of the potential risk of 
bias. The potential differences observed across countries may be a true reflection of differences 
with regards to the importance of clinical considerations but may reflect the differences in the 
construct of the factors. Further to this, the Cochrane handbook distinguishes between bias and 
quality, recognising that a high quality study may have a high risk of bias and a low quality study 
may have a low risk of bias (Higgins and Green, 2011). The handbook advises against using rating 
summary scales (especially the Jadad scale) for consideration of the quality or risk of bias because 
such scales have been shown to provide an unreliable assessment of the validity. Instead the 
handbook proposes a tool across a number of domains where judgement is made of the risk of 
bias and the judgement Is provided in a qualitative table (Higgins and Green, 2011). 
The consideration of the specific cost-effectiveness estimate considered important for decision-
making may be subjective when the documentation does not specifically state the value deemed 
appropriate for decision-making. The consideration of pooled cost-effectiveness and cost-utility 
may also ignore differences between the uses of such evidence by decision-makers. The ICER 
should ideally be constructed so that the value and units (cost per life year gained (Cl Y) and cost 
per QAlY gained (CQG)) are specified and considered In relation to the decision. 
Sample Size: Total number of reimbursement decisions 
The studies that have performed regression analysis of the influence of factors on decision-
making have included a relatively small sample of between 33 and 243 decisions and a focus on 
NICE and PBAC decision-making in England/Wales and Australia. This was of course an 
unavoidable limitation for these studies because of the number of guidance documents available. 
However, it does limit the number of variables that can be considered and whether the analyses 
are sufficiently powered to detect differences between the decision outcomes and the factors 
considered. There are some factors noted in the analYSis that do not achieve statistical 
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significance, such as budget impact, that the authors suggest could be due to the small sample 
size of the study. One new study reported as a conference abstract described analysis which will 
consider 184 NICE technology appraisals covering 600 binary decisions which should provide more 
precise estimation of the influence of factors in England and Wales (Devlin et aI., 2010). 
Sample selection bias - missing data for the dependent variables: 
The characteristics of the samples of medicines were different within countries and across the 
country studies. This was not due to the researcher selecting certain medicines for their analysis. 
The types of medicines that were included in some studies were limited because of the remit of 
the agency such as NICE in England and Wales which only considers medicines referred by the 
Department of Health. This was illustrated in the cross country comparison that found that across 
the period of 2001 and 2008 that those countries using similar evidence only had 19 medicines 
that were commonly appraised across the three agencies (Clement et aI., 2009). The supply side 
incentives (patents, public funding of research and development, research environment) 
collectively present in each of the reimbursement systems are likely to impact upon the 
development of medicines for each disease area and partly determine alongside the pricing and 
reimbursement decisions the development of new medicines and the type of medicine appraised 
by each agency in each system. 
Omitted relevant variables - Missing (un) measurable factors 
The regression studies performed include a proportion of decision-making that is unexplained by 
the factors that are included. This could be related to the sample size of the studies but may also 
relate to the exclusion of other potential factors in the decision-making; some that could be 
measurable but others that are qualitative in nature and difficult to construct into a variable for 
analysis. Two studies consider stakeholder influence for NICE and this factor has had a more 
limited consideration in other studies and may be a potentially important consideration to 
analyse across other countries (Dakin et aI., 2006, Devlin et aI., 2010). There were fewer process 
factors and non-evidence factors controlled for across the studies and it is only possible to control 
for some process factors that are country specific within cross country comparison studies. There 
are also factors that cannot be measured from the documentation and would require observing 
each of the appraisal meetings to record details of the deliberations such as timing of evidence 
considerations and professional disciplines involved in decision-making. 
Regression model assumptions 
Endogenous Factors - relationships between reimbursement factors 
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The studies that included regression analyses were all retrospective observational analyses and 
some studies consider the potential relationships between the factors identified in the analyses. 
For example, the inclusion of both factors such as RCT size and RCT significance may be related 
(those trials with a larger number of patients are likely to be significantly powered to detect a 
significant treatment effect), the number of systematic reviews and number of RCTs (for example 
as more RCTs are available it likely that there will be more potential for systematic reviews of the 
effect of RCTs). Those studies that are found to have potentially weaker evidence of effect may 
also be found to be accompanied with lower quality economic evidence. The inclusion of both the 
effectiveness and cost-effectiveness in some of the included analyses may be inappropriate due 
to the potential relationship that exists between the price and effect (through the consideration 
of a value for money range) and the cost-effectiveness ratio. The cost-effectiveness ratio is a 
function of the effect and the price chosen by the manufacturer that will be to some extent a 
function of the threshold range. In these circumstances, an observed correlation between the 
cost-effectiveness and clinical effect would not be found because this is mediated by the price 
chosen by the manufacturer. The variable effect is a function of the CE ratio and would imply the 
problem of multi-collinearity and would not allow a meaningful separation of the influence of the 
two factors. The inclusion of endogenous factors across the studies may not allow identification of 
the actual influence of each of the factors in the regression analyses performed. 
Model specification tests 
Model specification tests were reported in four studies out of the seven multivariate factor 
regression studies (Chim et al., 2010, Dakin et aI., 2006, Devlin and Parkin, 2004, Harris et aI., 
2008). These studies all included a goodness of fit test in the form of the pseudo R2. Two of the 
studies considered regression model assumptions by either applying a formal test for 
multicollinearity called the VIF or by looking at the correlation between factors. One study looked 
at the impact of potential structural change through process overtime (see Table A2.9). 
2.4.1.3 External validity of results 
The generalisability of the influence of factors across studies for each countries reimbursement 
system will depend upon the consistency over time of the characteristics of the medicines that 
are assessed and appraised. The reforms to each reimbursement system over time may influence 
the extent by which factors are influential overtime. A number of the smaller sample quantitative 
studies viewed their results as generating a number of hypotheses that could be tested in future 
research using a larger sample of decisions. 
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2.4.2 Validity and reliability of qualitative studies 
The majority of studies were narrative analyses of reasons for retrospective decisions for national 
reimbursement agencies. These studies generally allow us to understand the processes that led to 
the consideration of factors in decision-making and generate hypotheses for the relative influence 
of factors. The influence upon decisions is generally not defined across studies and many of the 
studies consider examples that illustrate specific reasons and their impact upon decision-making. 
The use of documented evidence may be a poor representation of the actual considerations in 
decision-making or there maybe circumstances where the evidence may be used to justify a 
decision, even though other factors may have been the true explanation for the decision 
observed. The interpretation of the reasons for reimbursement decisions in the narrative studies 
is subjective and will be dependent on the backgrounds of the researchers undertaking such 
narrative analysis. 
The majority of studies identified that considered other forms of qualitative analysis were 
performed for NICE decision-making in England and used case studies, focus groups, semi-
structured interviews and observation of the committee meetings. Many of these studies consider 
the influence of one factor within decision-making with reference to other factors but do not 
necessarily gain insight into the relative influence of each factor in the deCision-making. There are 
difficulties in generalising whether the factors considered in England maybe important for other 
reimbursement decision-making because of the potential differences in processes for 
consideration of the evidence. There were a limited number of other studies that considered 
semi-structured interviews and focus groups for of decision-makers performed in Sweden, Finland 
and the Netherlands. 
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2.S Discussion 
The discussion will focus on the evidence for factors within countries to understand which are 
influential and then consider the factors commonly influential across countries. The discussion 
will then focus on the findings of studies that conduct cross-country comparisons and then any 
issues identified in the current literature. The discussion will be structured as follows: 
• Summary of quantitative and qualitative studies; 
• The influence of factors within countries; 
• The influence of factors in cross country comparisons; 
• Issues identified in the evidence and opportunities for further research. 
2.5.1 Summary of quantitative and qualitative studies 
Table A2.10 provides a summary of the quantitative factors and the validity of the results. The 
definition of influence in each study and the number of factors included depends upon the 
perspectives of the researchers. The table demonstrates that the majority of studies consider the 
statistical significance of the correlation/association of each factor with decisions and determine 
this to be the influence of a factor with occasional reference to the magnitude of effect of each 
factor. The search did not identify any experimental, quasi-experimental or natural experiment 
evidence for the influence of factors on reimbursement decisions and this possibly reflects the 
difficulties inherent in identifying the causal influence of factors on reimbursement decisions. If 
the meaning of Influence is to obtain the causal influence then this review has not identified any 
evidence on influence of factors for each reimbursement system. 
The majority of the quantitative studies identified focus on a retrospective analysis of the 
documented evidence (revealed preference) available for reimbursement agencies in Australia 
(PBAC), Belgium (National Insurance Agency), Canada (CADTH CDR), England (National Institute 
for Health and Clinical Excellence), Netherlands (CVZ) and USA (Medicare). Over half of the 
quantitative evidence was identified for Australia (PBAC) and England (NICE) decision-making. The 
majority of studies were based on one country and there was only one cross country comparison 
of national reimbursement agencies in Australia (PBAC), England (NICE) and Canada CDR (CADTH), 
perhaps reflecting the difficulties in collection of similar quantitative data and constructing similar 
variables across the countries reimbursement agencies. 
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The table shows the number of factors considered for each study and shows that nearly seventy 
percent of the factors considered were with respect to the clinical and economic evidence with 
more factors considered for the economic evidence across countries. The factors included by the 
researchers were all available or were separately constructed from the agency documentation of 
the assessment and appraisal of the medicine. Studies included multiple factors in their analysis 
for Australia, England, Canada and the Netherlands. A few studies included at least one factor 
across all the factor types (clinical evidence, economic evidence, non-evidence and process) for 
Australia and England which may indicate the lack of documentation of non-evidence and process 
factors in the other countries. Process factors were not frequently explored in the single country 
studies and none of these factors were included in the one cross country comparison. 
The sophistication of statistical analysis ranged from individual univariate analysis to a 
multinomial logistic regression analysis of factors. The analysis sample sizes ranged from 33 
decisions to 824 with many of the multivariate regression analyses including smaller sample sizes. 
There were four studies that included model specification tests with only two studies considering 
tests for multicollinearity and the relationships between included studies. Potential associations 
between the independent variables and potential endogeneity/confounding were rarely discussed 
in the studies included. 
The qualitative studies identified in the review focus on a descriptive narrative of retrospective 
reimbursement decisions, interviews, focus groups for national reimbursement decision-making. 
Eleven of the qualitative studies included descriptive narratives of retrospective reimbursement 
decisions for Australia (PBAC), England (NICE), Canada (CADTH CDR), Netherlands (CVl), New 
Zealand (PHARMAC), Scotland (SMC) and Sweden (TLV). Interviews, semi structured interviews 
and focus groups were methodologies used in eight studies to consider factors influential in 
national reimbursement decision-making in Canada (CADTH, CDR), England (NICE), Finland (PBB) 
and Netherlands (CVZ). Over half of the qualitative studies considered NICE decision-making in 
England and Wales. 
The studies explore the influence or support of types of evaluation on decision-making and define 
this with regards to the context of the study. The studies explore some factors already captured in 
the quantitative studies such as cost-effectiveness, clinical effectiveness, and severity of disease 
and identify other factors within countries that are not considered in the quantitative evidence 
such as stakeholder involvement, composition of the committee that makes the decision, 
approaches to consideration of evidence, process considerations and non-evidence factors such 
as end of life criteria and disease severity. 
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2.5.2 The influence of factors within countries 
There were a number of factors considered that were similar across some groups of countries and 
the influence of the factors considered in the quantitative analysis may be partly attributed to the 
design of study and other factors included. The majority of research to date has been conducted 
for established agencies with the majority of studies found in Australia (PBAC) and England (NICE). 
Table A2.11 Includes the factors that were found to be influential within countries and 
categorisation of the factors considered influential by quantitative and qualitative studies. The 
quantitative factors include those that were studied and were statistically significantly associated 
with the reimbursement decision in 'bold text' and those that were studied but there was no 
association between the factors in 'normal text'. 
The quantitative and qualitative studies all concurred that the incremental cost-effectiveness 
estimates were statistically significant in the regression models and therefore considered 
influential within Australia (PBAC decision-making), England (NICE decision-making), Canada (CDR 
decision-making) and the Netherlands (CVZ decision-making), regardless of the time period 
considered and the statistical methods used. The studies used a range of quantitative statistical 
analysis and different measures of cost-effectiveness such as ClG and CQG but all concluded that 
this was statistically significant and therefore influential in decision-making. There were two 
studies that identified a cost-effectiveness threshold estimate, one for the NICE decision-making 
and one for decision-making in the Netherlands. The magnitude of effect of the ICER estimate was 
Identified in some studies but these estimates are not comparable between studies because of 
the differences in study design. 
The qualitative studies of NICE decision-making highlighted the importance of cost-effectiveness 
for not just providing a single result for decision-making but presenting an analytic framework for 
elements of the decision problem that should be considered in the committee's deliberations. 
There was also evidence that different approaches to consideration of clinical and economic 
evidence with some citing concerns with the cost-effectiveness threshold and some citing the 
influence of other factors. 
The studies contained a mixture of variables to identify the other clinical considerations, 
economic considerations, non-evidence factors and effect of process in decision-making. The 
construct of variables used to describe factors and the different time periods of individual 
technology decisions across studies makes comparison of the similarities and differences in the 
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effects challenging. A discussion follows of the mix of evidence for factors within and across the 
countries considered in the review and potential explanations for these differences. 
The studies contained aspects of the clinical evidence such as the quality and quantity of evidence 
and explored a number of different measures using either a combination of composite quality 
indicators with specific indicators of quality and quantity or with only specific measures of quality 
and quantity of the clinical evidence. There was evidence of aspects of the quality of evidence 
found to be important in PBAC decision-making, CDR decision-making and Medicare decision-
making but no association for the studies that considered the quality of clinical evidence in NICE 
decision-making. The only attributes with respect to clinical evidence considered only in the 
context of NICE decision-making and found influential were the number of RCTs and the number 
of systematic reviews. A qualitative study of NICE decision-making that observed decision-making 
committees suggested that the 'clinical hurdle' was in some situations the most influential factor 
in the committee's deliberations and the perception of technology's clinical value and benefit 
could override the conclusions drawn from the reported evidence. In some reimbursement 
processes the economic analysts were found to be more important as they have the technical 
expertise to understand the evidence. One study suggested that it was controversial whether one 
such group should have disproportionate influence in such committees. 
There were differences observed across countries in the consideration of the robustness of 
economic evaluation and consistent findings of the influence of sensitivity analysis in studies 
conducted for NICE decision-making, PBAC decision-making and CVZ decision-making through the 
use of retrospective data and stated preference data with different constructs for providing a 
proxy measure of uncertainty. The studies find that those with higher levels of uncertainty using 
measures from the sensitivity analysis were more likely to be not recommended. The findings for 
NICE decision-making were supported by qualitative evidence of the importance of uncertainty 
being considered explicitly in decision-making and high levels of uncertainty being accompanied 
with negative decisions. The study highlights that there is a high level of variation in the univariate 
sensitivity analysis used, methods and ranges employed. These differences may not be found in 
the construct of the variables used in the quantitative data to consider the uncertainty around the 
estimates of cost-effectiveness. 
There is evidence of the influence of budget impact in studies for PBAC decision-making, CDR 
decision-making, NICE decision-making and CVZ decision-making. One study performed for NICE 
found no statistically significant influence of budget impact. However, Dakin et 01. notes that even 
though there was no significant effect in the regression model, it was shown that those restricted 
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for use had a significantly higher budget impact than those for routine and this factor additionally 
improved the explanatory power of the regression. The study suggested that this may be 
considered alongside the cost-effectiveness and requires further investigation for NICE decision-
making. One qualitative study performed in the Netherlands argue that budget impact is 
influential in decision-making and there are supporting rationales for this are opportunity costs, 
loss aversion, uncertainty and equal opportunity. 
The evidence with regards to lack of alternative therapies is mixed for the quantitative and 
qualitative studies performed for NICE decision-making. There was no association found in PBAC 
decision-making and one qualitative study suggested that this Is an influential factor in decision-
making for New Zealand. 
The severity of disease was found to be a significant influence of decisions in qualitative studies 
for NICE decision-making for cancer medicines, PBAC decision-making qualitatively, Finland, and 
CVZ decision-making in the Netherlands. There was one quantitative study that found an impact 
of severity of disease in one study for PBAC decision-making during 1994 and 2004 in contrast to 
another that did not find evidence of an impact in NICE decision-making, CDR decision-making 
and PBAC decision-making. This may be attributed to differences in the construct of the variables, 
Clement et 01. defined disease severity as those interventions with a mean 5 year survival of less 
than 50% whereas Harris et al. defined this as a survival of less than 5 years, differences in 
statistical analyses (control of other factors) or the different time periods of study (Harris et aI., 
2008). A study of the stated preferences of decision-makers in the Netherlands found that 
disease severity was positively associated with the choice of the intervention (Koopmanschap et 
aI., 2010).This factor could be a potential factor for consideration across studies quantitatively 
and qualitatively. 
Patient group involvement was only considered quantitatively in one study of NICE decision-
making and found to be influential in decision-making. This factor was found to be important In 
qualitative studies of decision-making in PBAC decisions, NICE decisions making and New Zealand 
decision-making, although all the other quantitative studies did not control for this factor. This 
factor could potentially be important for consideration across other contexts. 
There were then factors that were considered specific to the nature of the process and how the 
agency considered pharmaceuticals for decision-making in PBAC decision-making such as the 
number of resubmissions, composition of the decision panel for PBAC, CDR, PHARMAC and NICE 
decision-making, the introduction of STA in the NICE decision-making process, impact of third 
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party independent assessment in NICE decision-making and fitness for purpose of manufacturer . 
submission in SMC decision-making, categorisation of diseases by severity in Finland (PPB, 
Ministry of Health and Social Affairs) decision-making and other factors that relate to quality of 
life gains for decision-making in the Netherlands. 
2.5.3 The Influence of factors within cross country comparisons 
There were limited number of studies that considered comparisons of factors across countries 
and these focused on those countries with established agencies, one quantitative study 
performed for agencies that consider both clinical effectiveness and cost-effectiveness evidence 
which were for NICE decision-making, PBAC decision-making and CDR decision-making that 
included statistical univariate comparisons of similarly constructed variables across the three 
countries. 
There were differences observed across the countries with respect to the economic uncertainty 
and clinical uncertainty but regression analyses were not performed for each of the countries to 
identify the influence within countries. The study stated that statistical regression analyses were 
not possible due to the differences in processes but did not report such analyses, although 
univariate comparisons were made across the countries. The study also considered a qualitative 
investigation of common medicines similar to other studies that in addition considered SMC in 
Scotland and PHARMAC in New Zealand. The reasons suggested for differences between 
countries and suggested process differences such as differences in outcomes considered across 
the countries, different approaches to handling uncertainty in decision-making such as the 
consideration of subgroups in NICE decision-making rather than rejection, composition of the 
decision panel, number of drugs in the therapeutic class and the prevalence of the disease the 
drug is designed to treat. The generalisability of these findings across other pharmaceuticals may 
be limited but provide useful hypotheses for further quantitative empirical studies of the 
influence of factors within and across countries. 
2.5.4 The limitations of previous studies and opportunities for further research 
The review has identified a number of issues regarding the previous studies that could require 
further research to understand the factors influential within countries and across countries. The 
following main issues were identified and will be discussed: 
• lack of cross country comparisons of the influence of factors across countries 
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• Decision outcome categorisation 
• Process and other factors in decision-making 
• Construct of reimbursement factors and relationships between factors 
• Quantitative studies past decision sample size 
2.5.4.1 Lack of cross country comparisons of the Influence of factors across countries 
There are a limited number of comparisons (one quantitative study) across countries 
reimbursement agencies that consider the similarities and differences in the decision factors 
influencing decisions and the relative weight that these factors contribute. It is difficult to obtain 
comparisons across the current studies because of differences in the construct of the variables 
used, types of factors included and variation In the medicines considered. The results of the 
review demonstrate that a comparison may be limited by the details of the reporting of the 
factors that led to the final reimbursement decision but there is potential for some factors to be 
constructed across some of the developed countries. There would also need to be consideration 
of the different decision outcomes that were present across the countries and whether these can 
be categorised into certain similar outcomes given the process of the country. There are 
opportunities to explore the common factors that are important in those countries that share 
similarities in· processes and methods of assessment with similar construct of factors across 
countries. However, this would first require categorisation of the reimbursement systems and 
consideration of those agencies that share sufficient similarities in methods and processes to 
make a comparison of common factors meaningful. 
There are clear differences between some reimbursement agencies with respect to the 
methodologies used and processes followed. It would also be useful to explore how different 
processes and methods compare across countries with respect to the same medicine assessments 
and appraisals to consider whether differences in methods or process can explain these decisions. 
For example, the use of economic analysis in decision-making in comparison with a country that 
does not explicitly use economics in decision-making such as HAS In France. 
2.5.4.2 Decision outcome categorisation 
Decisions are commonly categorised as binary decision outcomes (recommend/not recommend) 
in the majority of the studies In this review. A more realistic approach to categorising decisions 
used in some studies identified in this review was to categorise the decision outcome as 
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recommended, not recommended and restricted. However, a very recent study on decision 
categorisation for a sample of decisions made by NICE in England and Wales recognises that 
'restricted decisions' include an entire range of degrees of access to those medicines (O'Neill and 
Devlin, 2010). The definition and levels of decision outcome are therefore not only important 
within countries but can have implications for comparisons of decisions made across countries. A 
balance needs to be therefore made in cross-country comparisons between having sufficient data 
for each level of decision outcome to understand the influence of each factor and providing 
comparative categories of the decision outcome across countries. 
2.5.4.3 Process and other factors In decision-making 
There were controls included in a few of the studies for the agencies process of decision-making. 
The factor was included as a time variable to control for evolution in process over time or by 
considering specific aspects of the process such as stakeholder involvement, the fact that the 
appraisal was a resubmission, the type of process followed by the agency (i.e. STA for NICE) or 
whether the assessment and appraisal resulted in an appeal. There are a limited number of 
process factors that can be identified and quantified at the individual technology decision level 
within the documentation provided for each of the decisions by each reimbursement agency. 
There is still considerable to be learnt about the influence/impact of differences in processes that 
exist between reimbursement agencies and systems. This first requires a categorisation of the 
reimbursement process differences at the policy level and the individual technology decision 
level. 
There is one element of decision-making that is unexplained by the model used to understand the 
influence of factors. The review has demonstrated across a number of the qualitative and 
quantitative studies that a number of stakeholders may have influence upon decision-making and 
these decisions take place within a political context. One quantitative study included a variable to 
identify whether a patient group submission was included in the submission and found to be 
influential on decision-making for NICE (Dakin et aI., 2006). It has been suggested that there are 
dimensions of decision-making that relate to the role of 'subjectivity' and how personal 
experiences of a condition or excitement about the 'novelty' can affect the way decision-makers 
interpret the evidence in practice. The perception of the evidence will be influenced by the actual 
evidence, subjectivity and personal knowledge of the condition. The other reasons for decision-
making maybe buried beneath rational factors that are reported by the agency. There may be a 
number of interpretations given by different stakeholders for the decision. The 'rational' decision-
making is often mediated through other factors in decision-making such as personal and political 
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factors that may reasonably influence decisions. The 'rational' and 'reasonable' may diverge and 
this may be a reason for differences in the perception of the evidence, actual evidence and the 
decisions made. There is also evidence from interviews and observation that the excitement of a 
novel technology can influence the evaluation and interpretation of the evidence (Wirtz et aI., 
2005). 
The influence of Patient Access Schemes (PAS) and risk sharing agreements has not been 
examined with respect to other factors on reimbursement decision-making in countries in the 
studies identified in this search. The review did not identify any studies because these are 
relatively new processes in each of the countries. Future datasets of decisions using PAS and risk 
sharing agreements in decisions in each country will be important when considering the influence 
of health economic analysis and other factors/criteria in decision-making. 
There were no factors included in studies that were generated from external sources other than 
the reimbursement agency (such as public interest influence, patient and other stakeholder 
lobbying, year of election, health policy priorities and other non-evidence factors). There are 
certain external forces upon a reimbursement agency identified in the qualitative evidence (public 
interest) that may influence and partly explain decisions even in the presence of explicitly stated 
criteria for decision-making. A study that attempts to measure such influences may help to 
further explain decision-making, some form of variable that considers the political or public 
interest in the treatment area may additionally explain how decisions are made. 
2.5.4.4 Quantitative studies past decision sample size 
There were a limited number of studies addressing the relative weight of decision criteria that 
varied within and across countries. The most established reimbursement agencies have only been 
producing sufficient documented evidence of the decisions over the last 15 years and the number 
of drugs that have been assessed using cost-utility analyses has been limited. This has meant that 
the sample sizes of studies using such techniques have ranged from between 33 and 243 
decisions. These studies include over 10 different factors in the analyses and some analyses are 
underpowered because of the lack of medicines falling into certain decision categories. Further to 
this, all analyses rely upon select samples; either because the reimbursement agency (NICE) has 
decided in the past which drugs to evaluate or the manufacturer has decided which of the drugs 
should be considered for reimbursement. This would require a first stage regression to 
understand why NICE chooses certain drugs to evaluate and why manufacturers choose certain 
. 
drugs to submit to an agency. There is potential for insufficient variation in some factors if these 
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are selected to explain the differences in decision-making between agencies. Additionally, the 
small sample size suggest that some factors may be shown to be influential because of the 
existence of a number of outliers in the data and no studies have considered the potential for 
outliers in the data because there is no view of the characteristics of all drugs that could have 
potentially been evaluated by agencies. The regression analyses provided also summarise older 
decisions that were conducted pre-2006 and this could be updated in relation to a number of new 
decisions and the process changes that these agencies have imposed over this period. There is an 
opportunity to produce a study that includes a larger sample size that includes a number of 
countries reimbursement systems and decisions 
2.5.4.5 Construct of reimbursement factors and relationships between factors 
The construct of the variables used to identify dimensions of the clinical considerations and 
economic considerations will depend on the detail of the evidence reported in the 
documentation. Interestingly, the only factor with consistent construct was that of the ICER and 
the direction and influence of this was found across the studies that considered this factor in their 
analysis. Those documents that are transparent and provide details of the considerations in the 
decision-making will provide sufficient evidence to construct variables. There were a number of 
variables used in the analyses that required subjective judgement and were based on some 
documentation that was limited and involved assumptions to enable data across the sample of 
decisions. 
The factors included in the studies assessing the clinical evidence considered bias in trials 
(composite scores such as the Jadad score), precision of clinical effect (statistical significance, RCT 
size and RCT significance) and type of evidence (type of study, appropriate comparator and 
number of RCTs) and one study introduced whether the drug was considered to have a clinically 
significant effect (Did the PBAC consider the size of the treatment effect to be clinically 
important?). The construct of these variables has relied on subjective assessment of the 
documents (clinical significant effect) and some assumptions where data is not reported for some 
decisions (Jadad score, RCT size, RCTs using a relevant comparator, RCTs showing a significant 
effect). For example where data was missing for RCT size across some trials the average number 
in the trial was extrapolated across those where this was not reported. 
The studies have aimed to understand the relative importance of decision factors by focusing on 
different elements of the considerations and defining a number of specific measures to identify 
these. The problem with this pursuit is that it very difficult to obtain a reliable direct measure 
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across countries that summarises the complexities with consideration of clinical uncertainty and 
economic uncertainty. It may be difficult to capture in one or a number of quantitative measures 
the complexities and perceptions of decision-makers with regards these factors. For example, 
considering the influence between clinical and economic considerations may be captured through 
using qualitative methods for identifying the differences in decision-making environments and 
this influence on the perceptions of the evidence. This review has shown that study results may 
be sensitive to the subjective judgements made by construction of variables and it would be 
better to minimise the researcher judgement when constructing such variables in the quantitative 
analysis. 
The difficulty in such analyses is to separate whether the clinical considerations obtain less/more 
weight than the overall economic considerations in decision-making. The studies have focused on 
measures of the quality of clinical evidence rather than the clinical effectiveness and its influence 
upon decisions. This maybe because the difficulties with separating the influence of clinical 
effectiveness from the influence of cost-effectiveness or the difficulties in the separation of other 
variables because whether a committee finds a medicine to have a clinically significant effect will 
be related to their judgements of the perceived type of evidence, quality and risks of bias within 
this evidence. 
There is discordance across studies using similar statistical methods in determining whether a 
threshold value can be observed for cost-effectiveness. This is perhaps because of the 
perspectives by which the researcher approaches the study because of the policy of the countries 
reimbursement agency and country with respect to the use of thresholds. But there is potentially 
no reason why methods could not have been used to imply a certain threshold in these countries 
through the analysis of retrospective decisions. 
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2.6 Conclusions 
The following main conclusions can be made from the review of the quantitative and qualitative 
evidence. 
• The majority of evidence identified includes quantitative and qualitative studies for NICE 
decision-making in England, PBAC decision-making in Australia and CDR decision-making in 
Canada. There is limited evidence for the influence of factors for other OECD countries' 
reimbursement decision-making and a lack of cross country comparisons of decisions and 
factors. 
• The quantitative regression analyses do not address causal influence only association of each 
factor based on relatively small sample sizes and further research should explore larger sample 
sizes and the relationships between factors included and the model specifications. 
• The quantitative studies most commonly explored factors were with respect to the evidence 
considerations with fewer variables to capture non-evidence factors and process. There were a 
number of qualitative factors that were identified that had not been explored in the 
quantitative research which mainly related to the non-evidence factors and agencies' 
processes of decision-making. 
• Cost-effectiveness was the most frequently explored factor across studies when this was 
included. This was the only factor to have a consistent construct and studies across and within 
countries found the same direction of effect but the magnitude of effect was not always 
comparable because of the different methodologies that were used. Some studies provided 
estimates of the cost-effectiveness threshold from the analysis of retrospective decisions but 
some authors did not produce an estimate. 
• Mixed evidence of the influence within reimbursement systems and across systems was found 
with respect to other factors clinical evidence factors, non-evidence factors and process 
factors when these were included in the studies within countries and across countries (when 
included). 
2.7 Further research opportunities 
A number of gaps in the literature were identified with respect to the influence of health 
economic appraisal and other factors on reimbursement decision-making across the OECD 
countries: 
• There was a lack of single country studies for many OECD countries' reimbursement systems 
and studies that compare the influence of factors on decisions across countries. There is an 
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opportunity to perform qualitative studies on systems that have not been studied and provide 
cross country comparisons of those systems not included using either a qualitative or 
quantitative methodology. 
• Process has been identified from the review as a potential factor that is missing from 
comparisons across countries and where possible for single country studies. The effect of 
process may explain differences found across countries reimbursement decisions. This factor 
appears to have been given little attention in the current literature. This would first require 
categorisation of the reimbursement systems before any qualitative or quantitative studies 
can be performed to explore the differences between countries due to process considerations 
and the other factors identified in this review as potentially important in decision-making; 
• It is no fault of the authors performing the studies that the samples are small because this is 
the number of decision that were available at the time of the study. There is potential to 
perform studies of larger sample size because the documented use of elements of HTA In 
reimbursement decision-making has grown over the last decade. Further studies could 
included new factors that have been highlighted in the qualitative evidence as potentially 
important In decision-making; 
• Further exploration of the construct of factors across the quantitative studies may partly 
explain some of the differences in influence upon decision observed within countries. The 
relationships between factors could also be more thoroughly studied to Identify whether It is 
possible to separate all factors into independent variables. The endogeneity problem has not 
been investigated in these types of regression modelling. 
• The Introduction of Value Based Pricing (VBP) schemes in countries reimbursement systems 
will require explicit definition of the criteria important for decision-making. This will require 
explicit documentation across the countries in the guidance for each reimbursement decision. 
This will allow more detailed examination of the factors and their weight in each of the 
countries and the desirability of the decisions and whether they are welfare improving. 
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Chapter 3: Categorisation of OECD Reimbursement 
Systems using Health Technology Assessment: Policy 
Implementation Level 
Abstract 
Objective: To apply a published analytical framework for describing and classifying 
pharmaceutical reimbursement decision-making systems using Health Technology Assessment 
(HTA) and to identify the similarities and differences between fourth hurdle systems at the policy 
implementation level. 
Methods: OECD countries with universal health care and institutionalised HTA were included. 
Systems were classified in four categories: establishment of the system, objectives of the system, 
implementation of the decision and accountability of the reimbursement system. The 
reimbursement institution(s) responsible for decision-making was identified and their websites 
searched for data on each element of the framework. When data were unavailable from the 
institution's websites, published and grey literature were searched and contact was made with 
the institution to identify missing data. 
Results: The sample included 24 DECO countries' reimbursement systems. Systems varied with 
respect to the institutions, their relationship with the Ministry of Health and the final 
reimbursement decision. The systems principle objective was categorised as affordability, access 
or cost-effective use of medicines and there was a degree of overlap and conflict between each 
objective, especially where multiple institutions were present. Systems implemented deCiSions 
through a sickness fund, Ministry of Health scheme, regional scheme or other schemes. Few 
detailed documents were identified with respect to the accountability of the reimbursement 
institutions. Where information was available this tended to be considered with respect to 
intermediate outcomes such as number of guidance rather than impact on final health outcomes. 
The ability of various stakeholders to appeal and processes of appeal varied widely across 
countries. 
Conclusion: Reimbursement systems are diverse with respect to their objectives, purpose and 
remit. This may explain differences in reimbursement decisions across countries and the use and 
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influence of HTA on decision-making. Public information was sparse in some countries for 
elements of the policy implementation level and this limited comparison. 
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3.1 Introduction 
Chapter 2 identified that many researchers have focused on the influence/impact of aspects of 
evidence such as the health economic analysis and clinical analysis upon reimbursement decision 
outcomes within a single country. The range of factors considered with respect to consideration 
of evidence displays some of the complexities involved in making comparisons between 
reimbursement systems that are complex and also contain other potentially important factors 
that affect the decisions made for new medicines in different countries. Few studies consider the 
characteristics of the entire reimbursement system in a more holistic approach that identifies the 
interdependencies between different elements of the system and the impact on how decision-
makers judge the evidence and the final decision outcomes. The impact of the differences on the 
decision outcomes can be understood by comparisons between countries. The first step in 
understanding the differences between the systems and their impact on the decision outcomes 
requires a descriptive categorisation of the different elements of a system. Hutton et 01. were the 
first to provide an analytical framework for classifying 'fourth hurdle' reimbursement systems that 
use HTA (Hutton et aI., 2006). The study defines the term fourth hurdle as: 
'The requirement to justify the reimbursement of pharmaceuticals by health systems has 
been labelled lithe fourth hurdle", as it is perceived by manufacturers to be an additional 
barrier to market access, after demonstration of product quality, efficacy, and safety to 
obtain a product license.' (p.ll) 
The framework for classifying decision processes for the reimbursement of health technologies 
can be considered a positive framework that allows all systems to be described and classified. It 
does not provide a normative framework which considers how things ought to be within each of 
the systems, whether one system is better than another or what are good practices for each 
element of the reimbursement system. Although there is an element of subjectivity in what 
constitutes each element of the framework for all countries, the systematic collection of data 
across countries will enable further investigation of the key characteristics of the system and the 
potential impact of these characteristics on the process of making medicine reimbursement 
decisions. The aim of the framework is to help understand which elements of the reimbursement 
system are important when considering the impact on the final decision. The framework allows 
the systems to be described and classified, making an important distinction between the policy 
implementation level and the individual technology decision level. 
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The differences in reimbursement systems partly reflect their objectives. These are determined by 
the political institutions and health care sectors in which they operate. The policy 
implementation level aims to consider the establishment of the fourth hurdle system as a policy 
decision of the government that has particular objectives and involves institutions and 
stakeholders such as the public, patient groups and industry (Hutton et aI., 2006). Hutton and 
colleagues define these as separate elements because they are likely to impact on the processes, 
methods and evidence requirements for the assessment and appraisal of individual medicines. 
The individual technology decision level categorises specific decisions regarding particular 
technologies, the processes and organisations involved in the detailed assessment and appraisal 
of each technology. The framework distinguishes between the assessment phase, decision phase 
and the outputs and implementation of the decisions made by the reimbursement system. 
The aim of this chapter is to describe the Fourth Hurdle framework and use it to classify the 
sample of OECD countries at the policy implementation level. The similarities and differences 
between countries can be identified within and across elements of the framework. This will 
provide a context within which the use and Impact of health economic analysis, and other 
analytical methods, at the technology decision level, within each of the countries, can be 
examined. 
3.2 Methods 
Chapter 2 identified limited evidence on OECD countries reimbursement factors and found limited 
evidence of the process factors. The thesis aims to consider those reimbursement systems that 
use elements of HTA to inform reimbursement decisions for pharmaceuticals. This sample has 
been identified by those systems where a formal HTA programme operates and produces 
recommendations and elements of HTA are used for the reimbursement of medicines. The OECD 
reimbursement systems were included if they met the following conditions: 
1. Countries with a reimbursement system for medicines that operates alongside an 
institutionalised HTA process. Formal HTA is defined as the institutionalisation of HTA 
provided either through a HTA agency or co-ordinated network of institutions 
undertaking HTA. The institutionalisation of HTA has been described as "promoting 
structures and processes that are suitable to produce technology assessments that will be 
powerful to guide policy and clinical practice towards the best possible health and cost 
outcomes", (WHO, 2000 - World Health Organisation. WHO Regional Office for Europe 
(2001). The institutionalisation of HTA will be identified by membership to the 
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International Network of Agencies for Health Technology Assessment (INAHTA). The. 
membership criteria require that institutions; (i) are responsible on an ongoing basis for 
the coordination and/or development and operation of HTA programs, and the 
production of assessment reports; (ii) have an officially recognised role in relation to 
national or regional government; (iii) are non-profit making and at least 50% of their 
income is obtained from public sources and (iv) members provide free access amongst 
members of any publications (INAHTA, 2011a). 
2. Countries with Universal Access to Health Care; 
3. Those countries with sufficient public information sources to be able to categorise the 
system. 
The sample includes 24 reimbursement systems including 25 countries (NICE covers medicine 
recommendations for England and Wales. Although Scotland is part of the UK its health service is 
separately organised and funded independently of UK government. Therefore it has been treated 
as a separate country): 
1. Australia 
2. Austria 
3. Belgium 
4. Canada 
5. Denmark 
6. Finland 
7. France 
8. Germany 
9. Ireland 
10. Israel 
11. Italy 
12. Hungary 
13. Korea 
14. Mexico 
15. Netherlands 
16. New Zealand 
17. Norway 
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18. Poland 
19. Portugal 
20. Spain 
21. Sweden 
22. Switzerland 
23. United Kingdom - England and Wales 
24. United Kingdom - Scotland 
The OECD countries excluded from the sample can be found in Table 3.1. 
Table 3.1: Countries excluded from the sample 
Countries without an Countries without universal Countries with Insufficient 
Institutionalised HTA process access to health care details across the system 
Czech Republic US Chile 
Estonia 
Greece 
Iceland 
Japan 
luxembourg 
Slovak Republic 
Slovenia 
Turkey 
The 24 countries' reimbursement systems institutions and websites were identified. The official 
publically available documentation was downloaded and used to complete the qualitative 
framework. Where the information was unavailable from official documents, published literature 
was used to provide information on the missing elements and when neither source was available 
email contact (where possible) was made with the staff of the Institution concerned. 
The framework was originally developed to categorise reimbursement systems for all types of 
technologies but in this chapter will only be applied to the systems for the reimbursement of 
medicines. The framework is comprised of sixteen elements which aim to describe and provide 
categorisation of the reimbursement systems. The elements considered within the framework 
cannot be completed by a (yes/no) binary consideration of each element and require a qualitative 
description of each element in each of the countries. The first level of the framework concerned 
the policy implementation level and this comprised four different elements, establishment of the 
system, objectives, implementation and the accountability of the system. The Elements of the 
Policy Implementation Level are provided in Table 3.2. 
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Table 3.2: Policy Implementation Level elements (Source: (Hutton et aI., 2006)) 
Establishment Objectives Implementation Accountability 
Relationship to health Broader political Directly by Health Managerial, political, 
ministry; number of objectives: Ministry; dependent on legal and obligations to 
health system Social, industrial, health other health system consult. 
organisations involved system objectives, cost organisations or 
control and health independent of 
improvement government 
3.2.1 Establishment of the reimbursement system 
The establishment of the system is important to identify the institutions involved and their legal 
basis. The dates of establishment of the main reimbursement institutions are identified at a 
national level and a timeline provided for the development of these institutions. The 
establishment of the systems are categorised by the relationship to the Ministry of Health, 
number and type of institution and whether the institution provides the final reimbursement 
decision or makes recommendations to another decision body. The remit of the reimbursement 
institution is considered with respect to whether it is solely established for consideration of 
medicines, or whether it has other functions. 
3.2.2 Objectives of the system 
The objectives of the system may not always be publically stated and the long-term publically 
available objectives of the institutions may be inconsistent with the short term political 
objectives. This element aims to characterise the overall policy objective of the reimbursement 
system but it is acknowledged that this may be more difficult when there are multiple institutions 
contributing to the final reimbursement decision for medicines. The objectives of the entire 
system will be identified when possible and where this is not possible the individual objectives of 
each element will be taken as a proxy for the overall objectives of the reimbursement system. 
3.2.3 Implementation 
This element of the framework concerns the Institutions responsible for the implementation of 
the reimbursement decision. The process and institutions responsible for the implementation of 
the decisions will be considered in each of the countries. This will be considered with respect to 
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the types of institutions and whether these operate at a centralised national level or regional 
level. 
3.2.4 Accountability 
The accountability of the reimbursement system relates to who monitors the performance of the 
system in meeting the stated objectives and who determines its budget. This may be an internal 
administrative process within the government or a more transparent democratic process with 
public involvement. Other considerations are the public availability of information on the 
assessment of performance and the opportunity for other stakeholders to hold the 
reimbursement institutions to account. 
106 Chapter 3 Policy Implementation Level 
3.3 Results 
The results are described for each of the four elements of the policy implementation level. A 
number of summary tables can be found for each element and a detailed summary of the data 
collected for each country can be found in the Table A3.2 and the references accompanying this 
data can be found in Box A3.1. 
3.3.1 Establishment of the system, institutions and relationship to Ministry of Health 
The reimbursement systems vary with respect to the relationship with the Ministry of Health and 
the institutes, organisations and committees involved in the reimbursement systems. The PBAC 
was the first reimbursement agency to be set up in 1954 under section 101 ofthe National Health 
Act 1953 which made recommendations to the Minister of Health on which medicines should be 
made available in the public system (Australian Government, 2011). The agency was also the first 
to require manufacturers to provide an economic analysis in the form of cost-effectiveness 
analysis (in 1993) to support reimbursement recommendations for medicines. Many OECD 
countries began to set up agencies or committees during the late 1990s and early 2000s, which 
covered different aspects of the reimbursement system, had varying remits, objectives and 
involved different stakeholders in the process of reimbursement decision-making. A time line of 
the reimbursement institutes, agencies and committees establishment is provided in Table 3.3. 
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Table 3.3: Time line of establishment of reimbursement body/agency 
Year Reimbursement Body established 
1953 Pharmaceutical Benefits Advisory Committee - Australia 
1980 Transparency Committee - France 
1989 Canadian Co-ordinating Office for Health Technology Assessment which is now known 
as the Canadian Agency for Drugs and Technologies in Health (CADTH) 
1993 National Authority of Medicines and Health Products (lNFARMED) - Portugal 
PBAC Economic Evaluation Committee - Australia 
1995 Federal Drug Commission - Switzerland 
1998 National Centre for Pharmacoeconomics (NCPE) - Ireland 
1998 Public National Advisory Committee (PNAC) -Israel 
1999 Health Insurance Board (evZ) - The Netherlands 
National Institute for Health and Clinical Excellence (NICE) - England and Wales 
2000 Health Insurance Review and Assessment (HIRA) - Korea 
2001 Scottish Medicines Consortium - Scotland 
Committee for Reimbursement of Medicines (CRM) - Belgium 
The Norwegian Medicines Agency (NoMA) - Norway 
Pharmaceutical Management Agency of New Zealand (PHARMAC) - New Zealand 
2002 Dental and Pharmaceutical Benefits Board (previously known as LFN) - Sweden 
2003 Directorate General of Pharmacy and Health Products - Spain 
General Health Council- Pharmacoeconomic evaluation - Mexico 
CADTH Common Drugs Review (CADTH) - Canada 
Reimbursement Committee (MTN) - Denmark 
2004 Haute Autorite de sante - France 
Institute for Quality and Efficiency in Health Care (IQWIG) - Germany 
Pharmaceutical Pricing Board (PPB) - Finland 
The Italian Medicines Agency (AFIA)-Italy 
2005 Medicines Evaluation Committee (HEK) - Austria 
2006 Agency for Health Technology Assessment in Poland (AHTAPol) - Poland 
The reimbursement systems vary with respect to the number of institutions and the 
establishment and relationship to the Ministry of Health are discussed by considering the 
countries in the following groups according to the final reimbursement decision (Table A3.1 and 
Table A3.2): 
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1. Systems with a single institute or agency using HTA to provide the final reimbursement 
decision; 
2. Systems with a national advisory agency providing recommendations to a regional final 
reimbursement decision-making body using HTA; 
3. Systems where the social insurance institution provides the final reimbursement decision; 
4. Systems where an national agency or committee provides advice to the final decision-
maker in the Ministry of Health 
5. Other systems. 
1. Systems with a single institute or agency using HTA to provide the final reimbursement 
decision; 
There are countries reimbursement systems where a single institute or government agency is 
established as the central body responsible for the national reimbursement process and decision 
that is either under the direction or accountable to the Ministry of Health. These include 
reimbursement agencies in countries where medicines are predominantly tax funded in Denmark 
through the establishment of the Danish Medicines Agency (DMA), the Italian Medicines Agency 
(AIFA) in Italy, Pharmaceutical Management Agency of New Zealand (PHARMAC), Dental and 
Pharmaceutical Board (TlV) in Sweden and the National Institute for Health and Clinical 
Excellence (NICE) in England and Wales. These are public bodies central to the reimbursement 
system and provide a mandatory decision for the use of the medicine which is made by a 
committee comprised of members that are independent of the Ministry of Health. The 
assessment of evidence for individual medicines is performed within each of these agencies and a 
separate committee convened by the agency provides judgement on the evidence and other 
factors that are specified as important in each of the systems. These agencies all consider only 
medicines with the exception of NICE and TlV. NICE also produces other guidance for diagnostics, 
interventional procedures, medical technologies for medical devices, public health guidance and 
clinical guidelines. TLV also provides guidance on the use of dental products. 
2. Systems with a national advisory agency providing recommendations to a regional final 
reimbursement decision-making body using HTA; 
In Scotland, Canada and Spain a national advisory body using HTA provides reimbursement advice 
to a regional decision-maker that uses HTA and other criteria to make the final reimbursement 
decision at the regional level. The Canadian reimbursement system involves mUltiple agencies 
with a remit to consider different types of medicines. 
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The SMC in Scotland was established in 2002 to avoid duplication by the Area Drug and 
Therapeutic Committees (ADlCs) and provide advice to the 14 local Boards and their ADTCs 
across Scotland with a remit for new medicines. The Scottish reimbursement system involves 
firstly advice from the SMC and then a final reimbursement decision by the local boards. The local 
boards are expected to follow the advice of the SMC but consider this with respect to other 
medicines available and individual patient requests for decisions (Health Policy and Strategy 
Directorate, 2010). 
The Canadian reimbursement system has the complexity that oncology and other medicines are 
assessed under different schemes but these schemes provide advisory recommendations to the 
provincial drug plans that provide the final recommendation. The Canadian Agency for Drugs and 
Technologies in Health (CADTH) which assesses medicine and devices established the Common 
Drug Review (CDR) in 2003 to provide formulary listing advice to 16 publically funded drug plans 
(12 provinces and territories) in Canada with the exception of Quebec that follows a separate 
process. The recommendations are advisory and the drug plans take into account other factors 
such as the laws governing the drug plans, the priorities of the jurisdiction and the financial 
resources that are available (CADTH, 2011a). The CADTH Common Drug Review does not include 
Oncology medicines which are considered within a separate process called pan Canadian 
Oncology Drug Review established In 2011, (pCODR, 2011). 
The Spanish health system is decentralised with 17 autonomous regions with health coverage 
financed from general taxation. The Ministry of Health makes the final reimbursement decision in 
Spain for Inclusion on either the positive list or negative list of medicines. There is an association 
of Spanish HTA agencies called AUnETS that aims to co-ordinate ten agencies representing regions 
in the Spanish National Health system (AUnETS, 2011). The Spanish regions have responsibility for 
their own health budgets (Vogler et aI., 2009) Some of these HTA agencies are responsible for 
creating prescribing guidelines for the regions but the Ministry of Health decides which medicines 
should be included in the national formulary. 
The health care systems of Austria, Italy, Portugal, Switzerland, Sweden, are all similarly 
decentralised systems. Decisions for the reimbursement of medicines are made at a national level 
In Austria by the Social Insurance Institutions, the Ministry of Health In Spain, TLV in Sweden, 
INFARMED and Ministry of Health in Portugal, the Federal Office of Public Health in Switzerland 
and AIFA In Italy. The reimbursement decisions are then implemented at a regional level in these 
systems. These systems fall into the other categorisations for the national systems. 
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3. Systems where the social insurance institution provides the final reimbursement decision; 
The body responsible for the final reimbursement decisions is provided by the social insurance 
institutions in Austria and Hungary. The Federation of Social Security Institutions (HBV) is a public 
self-governing body of social insurance institutions in Austria that consists of 22 social security 
institutions that fund medicines. In Hungary, the National Health Insurance Fund Administration 
(NHIFA) provides the funding for medicines and is a public social insurance body that provides the 
final reimbursement decision (PPRI, 2007b). There are other countries where the social insurance 
institutions are important in the process of decision-making but do not provide the final 
reimbursement decision such as the CVZ in the Netherlands and the Commission for 
Reimbursement that provide advice to the Ministry of Health (CVZ, 2009, Schafer et aL, 2010). 
4. Systems where an national agency or committee provides advice to the final decision-maker in 
the Ministry of Health 
The other OECD countries have established a reimbursement agency or committee that is 
advisory to the Ministry of Health. The Ministry of Health provides the final decision in these 
systems and generally one committee is involved in providing the reimbursement advice. The 
reimbursement committees are based within agencies that evaluate medicines and other 
technologies by the Haute Autorite de sante (HAS) in France, CVZ in the Netherlands, National 
Institute for Health and Disability Insurance (NIHDI) in Belgium, AHTAPol in Poland, HIRA in South 
Korea and solely medicines in Australia called the Pharmaceutical Benefits Advisory Committee, 
the Norwegian Medicines Agency (NoMA) in Norway, National Authority of Medicines and Health 
Products (lNFARMED) in Portugal. 
There are no separate agencies in Switzerland and Finland rather committees that advise the 
Ministry of Health. The Federal Office of Public Health (FOPH) is part ofthe Federal Department of 
Home Affairs in Switzerland and is the government department responsible for defining the 
benefit package made available in the social insurance system delivered by private insurers. The 
department is advised by the Federal Drugs Commission (FDe) that consists of scientific experts 
and wide range of stakeholders that include health insurers. In Finland, the Pharmaceutical Pricing 
Board is a committee that is based within the Pharmaceutical Services of the Ministry of Social 
Affairs and Health and makes the final reimbursement decision. 
In Israel the reimbursement system is operated entirely by the Ministry of Health and the process 
is uniquely setup to only update medicines included in the National list of Health Services (NlHS) 
once a year. The Medical Technology Administration (MTA) of the Ministry of Health provides an 
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assessment of the technology and then a committee with representatives of the Ministry of 
Health called the Public National Advisory Committee (PNAC) provides recommendations and the 
final decisions are provided by the Ministry of Heath in an act of government (Shemer et aI., 
2009). 
S. Other types of systems 
There are other types of systems where the final reimbursement decision is held by a self 
governing body in Germany, the responsibility of mUltiple insurance agenCies in Mexico and the 
Health Service Executive (HSE) responsible for running public health services in Ireland. 
In Germany, the Federal Joint Committee is a self governing independent body delegated by law 
in 2004 to decide the benefits provided under social health insurance with advice from the 
advisory agency the Institute for Quality and Efficiency in Health Care (IQWIG), (Federal Joint 
Committee, 2010).The body includes representation from the sickness funds, physicians and 
patients. 
A government decision-making body called the General Health Council (GHC) decides on the 
medicines that should be made available In accordance with the Presidential Agreement of 2002 
that specifies that the NHS in Mexico should only use medicines from the basic formulary for 
primary care and the catalogue of inputs for secondary and tertiary care. The public institutions In 
Mexico such as the social insurance Institutions, Mexican Social Security Institute (IMSS) and the 
Institute of Security and Social Services for Government Workers (lSSSTE) along with the voluntary 
Insurance programme operated by the Ministry of Health must consider these when making the 
decision on which medicines should be included in each of their respective formularies (Moise 
and Docteur, 2007). The public institutions are represented on the GHC. 
In Ireland, there Is no legal agreement applicable to reimbursement. There is an agreement which 
came into force in September 2006 between the Health Service Executive (HSE) and 
Pharmaceutical industry called the Irish Pharmaceutical Healthcare Association agreement (IHPE). 
The HSE is a public organisation which is accountable to the Minister of Health and Children. 
There is a General Medical Services (GMS) scheme and a Drugs Payment Scheme (DPS) provide 
reimbursement for those eligible in Ireland. The HSE is responsible for the operation and 
management of the public health services in Ireland on behalf of the Department of Health and 
Children. The Corporate Pharmaceutical Unit of the HSE makes final recommendations on the 
reimbursement and pricing of medicines. The final decision is informed by recommendations from 
a separate institution called the National Centre for Pharmacoeconomics (NCPE) for those high 
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cost or high budget impact medicines that require an economic evaluation established in 1998, 
(Tilson et aI., 2010). 
3.3.1.1 Other functions of reimbursement institutions/agencies 
These systems are developed alongside institutions that set the price through statutory price 
setting, price negotiations or other types of agreement. There are a number of separate 
institutions or bodies that may administer statutory pricing decision (prices are set on a legal 
basis) or perform price negotiations either before the reimbursement decision or in some cases 
after the decision. There is an entire literature on pricing of pharmaceuticals and this is not the 
topic of this thesis but the relationship with the reimbursement institutions and the use of HTA is 
important (Danzon and Furukawa, 2008, Danzon et aI., 2005, Goldman et aI., 2008, Vogler et aI., 
2009). Eight countries agencies have a dual role of considering both the price of pharmaceuticals 
and the reimbursement decision. These may be through the agreement of a statutory maximum 
price, negotiation of the price or both types of pricing policy (Table 3.4). 
Table 3.4: Countries systems agencies of dual remit of price and reimbursement 
Reimbursement System Type of pricing policy Reference 
(agency) 
Germany (Federal Joint FJC agrees maximum price and reimbursement (Leverkus, 2011) 
Committee) (Price negotiation follows with sickness funds) 
New Zealand PHARMAC negotiates price and reimbursement (PHARMAC, 2011a) 
(PHARMAC) 
Italy AIFA negotiates price and reimbursement (AI FA, 2011) 
(AI FA) 
Hungary NHIFA negotiates price and reimbursement (PPRI,2007b) 
(NHIFA) 
Ireland CPU agreement of price and reimbursement (CPU, 2011) 
(CPU) . 
Switzerland FOPH agrees maximum price and reimbursement (Paris and Docteur, 
(FOPH) 2007) 
Finland (PPB) PPB sets statutory maximum price and (Ministry of Social Affairs 
reimbursement and Health, 2011) 
Norway (NoMA) NoMA agrees maximum price and reimbursement (Norwegian MediCines 
Agency, 2011) 
Sweden TLV Is responsible for statutory pricing and (TLV, 2010) -
(TLV) reimbursement. 
3.3.2 Objectives of the reimbursement system 
The objectives of the systems vary overtime depending on the individual political priorities that 
exist at different pOints in time. A review was conducted of the stated objectives of the main 
schemes or institutions that are responsible for the reimbursement of medicines in each of the 
countries. The overall principle of all the health systems Is to improve the health of the population 
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but with respect to other policy objectives. The review revealed that the stated objectives of the 
agencies and institutions across the reimbursement system focus around improving health, access 
to care, quality of care, cost-effectiveness or value for money, need, solidarity, equity of access, 
equal access, reduce regional variation in access and to ensure a timely reimbursement decisions 
(Table A3.2). Interpreting the systems documented objectives it is possible to determine the 
principle objectives of the reimbursement systems. The systems can be broadly grouped into 
those systems where the central objective is cost-effective use of medicines, access to medicines 
or affordability of medicines. These objectives are considered in most systems with respect to 
other objectives, some of which are conflicting and overlapping objectives (Table 3.5). 
A central objective of some reimbursement systems is to obtain cost-effective use or value for 
money. These systems aim is to maximise health from a limited budget available that has been 
politically predetermined. This objective is stated alongside other objectives in 12 countries. A 
range of other objectives that accompany the cost-effective use of technologies are the need to 
produce consistent decisions across regions, affordability, stated objectives concerning equity, 
solidarity and need and objectives concerning process such as timely decisions. 
In England and Wales, Scotland and Canada cost-effective use of medicines is an objective 
alongside the requirement for consistency of reimbursement across regions is a main objective. 
NICE was set up on 1 April 1999 to ensure everyone has equal access to medical treatments and 
high quality care from the NHS, regardless of where they live in England and Wales. NICE's 
technology appraisals programme makes recommendations about the use of medicines in the 
NHS, based on how well a medicine works, and whether it offers value for money compared to 
existing treatments (cost-effectiveness) (NICE, 2011a). Similarly, the SMC in Scotland SMC is to 
accept those newly licensed drugs which clearly represent good value for money and reduce 
postcode prescribing (SMC, 2011a). In Canada the objective of the CDR process are to reduce 
duplication, to maximize the use of limited resources and expertise, and to enhance the 
consistency and quality of Drug reviews (CADTH, 2010). This objective is delivered by the 
consideration of clinical effectiveness and cost-effectiveness evidence for all new medicines with 
the exception of cancer medicines. The drug plans then have their own individual objectives. 
In the Netherlands and New Zealand, the cost-effective use of medicines is accompanied by the 
stated objective of affordability. That is the need to obtain medicines at low cost in order to 
contain costs within the system. The corporate brochure of the CVZ states that quality, 
accessibility and affordability are the three pillars of the Dutch Health Insurance system. The CVZ 
objective is to "safeguard and develop the public conditions for health care insurance system, so 
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that Dutch citizens can obtain their right to care." (CVZ, 2009). There are four stated package 
criteria of necessity, effectiveness, cost-effectiveness and feasibility that were developed from the 
funnel of Dunning. The first package principle called necessity is with reference to need and 
requires the committee to consider whether the illness or care given in the context of society 
justify a claim on solidarity. This criterion includes both the burden of disease and considerations 
relating to personal responsibility for the disease (CVZ, 2010a). The second criterion 
'effectiveness' refers to whether the medicine or care does what is expected of it. The third 
criterion 'cost-effectiveness' requires a consideration of whether the costs and benefits are 
broadly acceptable. The last criterion 'feasibility' aims to consider whether inclusion of the 
medicine in the care package is feasible in both the short and long term (CVZ, 2009). In New 
Zealand, PHARMAC's statutory objective is to "secure, for eligible people in need of 
pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical 
treatment and from within the amount offunding provided." (PHARMAC, 2010b). 
There are other principles with respect to equity of access that are stated objectives alongside 
cost-effective use in Sweden, Poland and Korea. The objective of the TLV is to examine which 
medicines, medical devices and dental care treatments will be subsidised by society in Sweden. 
This objective is achieved by consideration of three criteria, the human value principle, need and 
solidarity principle and the cost-effectiveness principle (LFN, 2007). The principles of human value 
which concerns the respect for equality of all human beings, need and solidarity which concerns 
agreement amongst the Swedish Society that those with more severe diseases are prioritised over 
less severe diseases must be taken into account alongside the cost-effective use of the mediCine. 
The Polish Constitution requires all citizens of the Republic of Poland to be entitled to equal 
access to health services from public providers of health services and these should be free of 
charge and provided by public funds.· The objective of the AHTAPol is to provide 
recommendations for the classification of health care services as guaranteed benefit (AHTAPol, 
2011). In Korea, HIRA is dedicated to maintaining and improving national health by fulfilling its 
commitment to health care review and quality assessment. HIRA aims to be an organisation that 
is recognised and respected by all physicians, patients, parties and people in the country. It is 
established under the National Health Insurance Act for improving the national health care and 
developing social security though fair and efficient heath care review and evaluation. HIRA is 
directed to deliver this efficiently and to monitor and assure medical necessity, appropriateness 
and quality of health care (HIRA, 2011). This Is delivered through a value based pricing scheme by 
considering the clinical usefulness and cost-effectiveness of medicines. 
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The Irish reimbursement system states that timely decisions are an important stated objective in 
addition to cost-effectiveness. The HSE in the Corporate Pharmaceutical Unit (CPU) in Ireland 
made an agreement with the pharmaceutical industry called the IPHA agreement in 2006. The 
objective was to ensure early access to and security of supply of new medicines for Irish patients 
and ensure that the medicine that best meets the patients' needs delivers best value for money 
(IPHA, 2006). The aim of the NCPE that provides recommendations to the HSE is to "promote 
expertise in Ireland for the advancement of the discipline of pharmacoeconomics through 
practice, research and education. Activities of the centre include economic evaluation of 
pharmaceutical products and the development of cost effective prescribing." (NCPE, 2011). 
The second group of countries includes those countries where the main objective of the 
reimbursement system can be categorised as delivering access on the basis of those medicines 
that are demonstrated to be clinically efficacious and/or clinically effective. The systems of 
Belgium, Denmark, France, Germany, Italy, Mexico, Portugal and Switzerland can be broadly 
classified into this group. There are a number of European systems which rely on a single 
institution to provide a judgement of the clinical efficacy in Denmark, France, Italy, Norway and 
Portugal. These systems include other objectives alongside providing access to medicines. There 
are some systems that include the objective of high quality care alongside accessible care, for 
example, in Belgium aims to "provide reimbursement of medical costs in order to make high 
quality health care accessible to as many people as possible", (NIHDI, 2011: The NIHDI: a closer 
look). The French systems reimbursement body adds equity alongside access to medical care 
stating the objective of the HAS lIa number of activities deSigned to improve the quality of patient 
care and to guarantee equity within the healthcare system" (HAS, 2011a). 
The German reimbursement system aims to provide timely decisions in addition to cost-
effectiveness. The objectives of the G-BA operate according to a legal basis through a code of 
procedure of the G-BA (Social Code (5GB V)). The services provided by the statutory health 
Insurance must be "adequate, expedient and cost-effective" (Federal Joint Committee, 2011: How 
Innovations Enter Statutory). The German Health reforms called the Pharmaceutical Market 
Restructuring Act (AMNOG) mean that an early benefit assessment will take place followed by 
negotiation on the price to provide access to medicines in Germany (Leverkus, 2011). IQWIG is 
contracted by the G-BA to provide early benefits assessments and an economic analysis only 
where necessary for medicines where agreement cannot be made on the price. The agency's 
stated aims are to "examine objectively the advantage and disadvantages of medical services for 
patients" (IQWIG, 2011a). 
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The final group of countries can be broadly defined as those that consider affordability with 
respect to other stated objectives. In Australia, the primary objective of the Pharmaceutical 
Benefit Scheme is to improve health (PBAC, 2008). The scheme's stated objectives are to focus on 
timely, reliable and affordable access to medicines (Department of Health and Ageing, 2011). The 
scheme achieves this through the advisory reimbursement body called Pharmaceutical Benefits 
Advisory Committee and the pricing body called the Pharmaceutical Benefits Pricing Authority 
(PBPA). The main objective is one of providing medicines that are value for money or cost-
effective by maximising health from a given budget (PBAC, 2008). The PBPA will then consider the 
price that should be recommended based on the PBAC analysis and expected budget impact. The 
Austrian reimbursement system aims to provide access but on the basis of affordability. The 
Austrian Health care system is built upon the principles of solidarity, affordability and universality 
(Federal Ministry of Health, 2010: The Austrian Health Care System). The system ensures high 
quality medical care for all citizens, independent of their social status or income. The Main 
Association of Austrian Social Insurance Institutions "provides customer-oriented and 
conscientious protection against the risks of diseases, old age and unemployment." (Main 
Association of Austrian Social Security Institutions, 2010). In Spain although accessibility is one 
objective, the introduction of two new laws in 2010 with respect to reducing expenditure through 
price reductions and reference price modification categorise place cost containment as the 
current principle objective of the system (Ferre, 2011). The Norwegian system has implemented a 
number of cost containment measures through price control after assessing the medicines clinical 
efficacy and effectiveness (H~konsen et aI., 2009). 
Chapter 3: Policy Implementation Level 117 
Table 3.5: Principle objectives of the reimbursement systems 
Affordability (cost Access (Principally based on Cost-effective use of medicines 
containment) providing reimbursement when (amongst other stated obJectives) 
clinically effective/clinical 
efficacy) 
Australia Belgium England and Wales 
Austria Denmark Scotland 
Israel france Canada 
Spain Germany Finland 
Norway Italy Ireland 
Mexico Hungary 
Portugal Netherlands 
Switzerland New Zealand 
Poland 
Sweden 
Korea 
3.3.3 Organisation of system and Implementation 
The reimbursement systems implement the final reimbursement decision through a social 
insurance institution or sickness fund, a regional decision-making body, through a Ministry of 
Health scheme or through other processes, some of which are more complex. 
3.3.3.1 Implementation by social Insurance Institutions or sickness funds 
There are reimbursement systems where the implementation of the reimbursement decision is 
made by the· social insurance institutions or sickness funds in systems where social health 
insurance is mandatory. The social Insurance funds operate and implement decisions through a 
positive list for all eleven social insurance countries included. A positive list contains medicines 
for which the system will automatically fund the medicine. 
The social insurance systems of Austria, Belgium, France, Germany, Mexico and Poland implement 
the decisions through a number of sickness or health insurance funds. In Austria, a list called the 
'Reimbursement Code' operates using a traffic light system for three main levels (red, yellow and 
green) of reimbursement where physicians are provided with the medicines that can be provided 
by general reimbursement by the 22 sickness funds of the statutory social insurance system 
(General Social Insurance Act, ASVG). The traffic light system provides conditions on the 
reimbursement of medicines where the red box includes those new medicines or medicine 
applying for reimbursement, the yellow box includes medicines with restrictions (criteria upon 
reimbursement) and the green box automatically qualify for reimbursement (PPRI, 2oo7a). In 
Belgium, the National Institute for Health and Disability Insurance is responsible for the 
supervision and managements of the compulsory health care and benefits (HCB) insurance. The 
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health insurance funds are responsible for implementation of the reimbursement decisions made 
by the CRM in the NIHDI. In Germany, the Federal Joint Committee (including representatives of 
the National Association for Statutory Health Insurance Funds) provides the directives for those 
medicines that can be provided by the statutory health insurance fund (GKV) and reimbursed by 
the health insurance funds. The reimbursement decisions in France are published in the Official 
Journal by the Ministry of Health and funded by the social insurance institutions through the 
mandatory social health insurance system. The National Union of Health Insurance Funds 
(UNCAM) co-ordinates the three national sickness funds (general scheme, agricultural scheme 
and social system of independent) and decides the rate of reimbursement following a listing 
decision by the HAS and the Economics Committee on Health Care Products (CEPS). Mexico has 
two main schemes that implement the decisions through a mandatory social insurance system by 
the Mexican Social Security Institute (IMSS) and the Institute for Security and Social Services for 
Government Workers (ISSSTE). 
In the Netherlands and Switzerland the positive lists for the mandatory social insurance system 
are delivered by regulated private health insurance organisations. The Swiss systems public 
reimbursement listings (SL medicines list) are implemented by the provision of these medicines by 
a number of private and public health insurers. In the Netherlands the institution appraising 
medicines, the CVZ is part responsible for implementation of decisions for the basic benefits 
package through providing the private health insurers with risk adjusted contributions according 
to the population served by the insurer. 
A single National Social Insurance body provides the reimbursement and implementation of 
decisions in Hungary (National Health Insurance Fund Administration (NHIFA)) Norway (National 
Insurance Scheme) and Korea (National Health Insurance Corporation (NHIC)). The Norwegian 
system is unique in that decisions can only be made by the Norwegian Medicines Agency for 
medicines that do not have a very large budget impact for coverage by the National Insurance 
Scheme (NIS). The decisions for medicines with an annual cost increase of more than 5 million per 
year cannot be made by the NoMA because further advice must be sought from other 
institutions. The Ministry of Health Care Services (HOD) may seek advice from another body called 
the National Council for Health Care Priorities which assesses whether reimbursing the medicine 
would be money well spent. The HOD can then decide whether to reject or favour approval of 
these high budget impact medicines. The HOD must then pass a parliamentary bill for the 
approval of these medicines and these can then be funded under the National Insurance Scheme 
(PPRI, 2008). 
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3.3.3.2 Implementation of national decisions at a regional level 
The reimbursement decisions for medicines by institutes/agencies in Denmark, Italy, New 
Zealand, Sweden, Denmark and those provided by the Ministry of Health in Portugal and Spain 
are implemented at the regional level. The institutions at a national level in Scotland and Canada 
provide advice to the respective regional decision-makers that are responsible for the final 
reimbursement decision and implementation. In Scotland, the fourteen Health Boards use the 
SMC advice and some NICE Multiple Technology Appraisal advice to determine the final decision 
in the form of a regional formulary and provide the funding for implementation of these 
decisions. Medicines accepted by the SMC are expected to be funded by the Health Boards but 
may receive a negative decision if there is already an equivalent treatment available on the Health 
Boards formulary (Health Policy and Strategy Directorate, 2010). In Canada the 16 publically 
funded health plans use CADTH CDR advice to provide their own decisions and implement these 
at a regional level. 
3.3.3.3 Implementation through a Ministry of Health scheme 
There are reimbursement systems where this is implemented directly by the Ministry of Health in 
Australia and Ireland. In Australia the Pharmaceutical Benefits Scheme (PBS) is part of the broader 
National Medicines Policy for which the government subsidises medicines and is administered 
through Medicare Australia. The scheme is eligible for those Australian residents who hold a 
Medicare card. The Irish system reimburses medicines through a voluntary agreement with the 
Pharmaceutical industry for which the Ministry of Health, Corporate Pharmaceutical Unit has 
decided are eligible either through the GMS, DPS, Long term illness scheme (LTI) or the Hi-Tech 
scheme. 
3.3.3.4 Other systems of Implementation 
In Finland the Social Security Institution called KELA provides implementation of the final 
reimbursement decision provided by the Pharmaceutical Pricing Board. KELA is an independent 
statutory social insurance institution (sometimes referred to as a social insurance institution even 
though it is funded by tax) for which 12 Trustees are appointed by parliament. KELA is confirmed 
in the Finnish constitution and provides reimbursement to patients for medicines provided out of 
the tax funded National Health Insurance scheme (KELA, 2011). 
The National Health Insurance Law (NLHS) specifies a list of medicines to be provided by publically 
tax funded Health Maintenance Organisations (HMOs) in Israel. The membership of one of the 
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four competing funds is mandatory and these provide the benefits approved by the Ministry of 
Health in the National list of Health Services (NlHS). 
The NICE recommendations apply to England and Wales and are enforceable within three months 
of the publication of the appraisal. The NHS providers are required by direction of the Secretary of 
State to provide funding for medicines recommended under the Single Technology Appraisal (STA) 
and Multiple Technology Appraisal (MTA) processes. NICE is not directly responsible for the 
implementation of the recommendations and this is undertaken through the NHS providers and 
funders. The NHS bodies need to assess how much the medicine guidance will cost to implement 
and must plan for implementing these by identifying and releasing funding. Those medicines that 
are not recommended can still be funded in individual cases or general cases if the physician and 
local provider decide that this is appropriate (Department of Health, 2011). 
3.3.4 Accountability 
The public reimbursement systems are accountable through reporting directly to the Ministry of 
Health, directly to the country's parliament or through legislation delegating powers and 
providing rules for the reimbursement of medicines. The complexity of the accountability of the 
systems varies by the number of institutions and committees involved in decision-making and 
whether separate institutions operate at both the national and regional level. The accountability 
of the system relates to the funding and accountability lines of the national institutions and the 
assessment of performance of the institutions or committees to meet the objectives of the 
system. The main problem is that many of the reimbursement systems have conflicting objectives 
of balancing access, cost-effectiveness and affordability which are difficult to attribute to the 
operation of the system. The objectives of the institution are not always solely with respect to 
these objectives and may be more procedural such as delivering a number of decisions per year, 
transparency of process or consistency in decision-making. In addition, the overall long term 
objectives may be in conflict with the shorter term political objectives of the government in 
power. Perhaps the ultimate judgement of the performance of the institutions in a 
reimbursement system may be demonstrated by the long term survival of an institution oVer 
time. 
An attempt was made to identify the budget of 20 reimbursement systems that included an 
institution which either provides an advisory decision or final decision (the other four countries' 
systems included a committee reporting to the Ministry of Health). The budgets of five countries' 
institutions could not be identified from the publically available information and contact by email 
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was made to each of these institutions to identify the budget but no response has been obtained. 
The details of the budget were identified from the institutions website or the annual report 
(where available for the institutions) and these were categorised as institutions paid for by the 
Ministry of Health through taxation, social insurance contributions or through mixed sources of 
funding. Seven of the institutions were directly funded through taxation and three were directly 
funded through social insurance contributions (Table 3.6). 
Table 3.6: Institutions funded by fully through taxation and social Insurance contributions 
Ministry of Health through Taxation Social Insurance Contributions 
Australia (PBAC) Austria (Federation of Social Insurance Institutions 
Ireland (HSE) Mexico (Social Insurance Institutions) 
The Netherlands (CVZ) Korea (HIRA) 
New Zealand (PHARMAC) 
Poland (AHTAPol) 
Sweden (TLV) 
England and Wales (NICE) 
There are then systems where the funding is from a mixture of sources. In Denmark the DMA 
receives income from the Danish Finance Act, fees set by the Danish Minister for Interior and 
Health for assessments and income from the work conducted for the European Medicines 
Agency. The HAS in France receives funding from a number of sources with a large proportion of 
funding from the social health insurance agencies and government subsidies. The German Federal 
Joint Committee has a unique system of funding through a system of surcharges. These are 
composed of a surcharge for each billable hospital visit and from an additional increase in fees. for 
outpatient's medical and dental care. The G-BA decides on a surcharge each year. In Canada the 
CDR Is financed through central and regional sources from the federal, provincial and territorial 
governments. Similarly, the regional/local NHS Boards of Scotland are required to fund the SMC 
from the funds allocated to them. 
The performance of the institution is reported in the annual reports of those that provide these 
on their websites (NICE, SMC, TLV, NoMA, PHARMAC, CVZ, HSE, HAS, DMA and CADTH). The focus 
of performance measures In the annual reports focus on procedural measures and intermediate 
outcomes or outputs such as the quantity or speed by which decisions are produced by each of 
the institutions. The focus on quantity and speed of deCiSions is linked to European Union Law 
that covers sixteen of the EU countries included in the OECD sample. The Transparency Directive 
of the EU lays down three major requirements for the individual pricing and reimbursement 
decisions that include that (i) decisions must be made within a specific timeframe (price within 
90/180 days when additional information requested); (iI) decisions must be communicated to the 
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application and contain a statement of the reasons based on objective and verifiable criteria and 
(iii) the decisions must be open to judicial appeal at the national level (European Commission, 
1989). The institutions do not tend to use quantitative measures of performance with respect to 
Improving health outcomes for patients or to measure performance on all of the objectives that 
are set by the agencies. 
The PHARMAC in New Zealand provides a section on the website devoted to accountability and 
the targets for the agency over the year period in relation to health outcome performance. The 
website provides a detailed section on accountability documents including a statement of intent 
(tabled at parliament) which summarises what the institutions plans to achieve over the year and 
then an annual report which describes what has been achieved with respect to the stated work 
plan. The system considers the intermediate outputs and the relation to the objectives of the 
system level final outcome of New Zealanders living longer, healthier and more independent lives 
(PHARMAC, 2010b). The outputs considered in 2011/2012 outputs and targets are as follows: 
• Decision-making, Community pharmaceutical schedule decisions: All funding decisions are 
supported by evidence and made using PHARMACs nine decision criteria - This is 
assessed by more than 90% of decisions on medicines being made within 6 months; 
• Influencing medicines use, Population health programmes: provide campaign materials on 
medicine use - This is assessed by 90% of the respondents rating their satisfaction as 
good (4 out of 5); 
• Supply management, Contract management: Respond to low medicine stock reports _ 
Ensure patients needs for medicines are met; 
• Policy advice: Survey of policy requesters indicates satisfaction with timeliness and quality 
of PHARMACs policy advice; 
• Rebates Distribution: All funds use is in accordance with PHARMAC policy (PHARMAC , 
2011b). 
The agency aims to measure the effectiveness of decision-making for the first time in 2010/2011 
using the QALY on system level outcomes. PHARMAC decision lead to an overall increase in the 
number of new patients treated compared with the previous 12 months and an increase in extra 
life years gained. The agency aims to consider the average value of the funding options available 
on the entire prioritisation list (some of which are not included because of limited budget) and 
compare this with average value of the funding decisions actually made. The value will be 
expressed in terms of QAl Ys gained per dollar. The institution highlights that the effectiveness of 
their work depend on the work of other in the New Zealand Medicines System such as optimal 
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prescribing decisions and use by patients to achieve the best health outcomes (PHARMAC, 
2010b). 
A further consideration with accountability is the ability of stakeholders to challenge the 
reimbursement system's decisions. The involvement of different stakeholders and ability to 
appeal varies across the reimbursement systems. The public and patients are represented in some 
systems and do not play any role in the decision-making process in other OECD systems. For 
example in England patients can participate in the committee deliberation and the public in 
specific committees such as the Citizens Council at NICE that provides advice to the committee on 
social value judgements. In the Netherlands views of patients and societal aspects of decision-
making are considered by a separate committee called the appraisal committee (ACP) at CVZ in 
the Netherlands. In contrast the French system provides no opportunities for patient participation 
in the reimbursement decision-making process. These differences will be discussed in further 
details at the technology decision level. 
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Chapter 4: Categorisation of OECD Reimbursement 
Systems • uSing Health Technology Assessment: 
Individual Technology Decision Level 
Abstract: 
Objective: To apply a published framework for describing and classifying pharmaceutical 
reimbursement decision-making systems using Health Technology Assessment (HTA) and to 
identify the similarities and differences between fourth hurdle systems at the individual 
technology decision level. 
Methods: OECD countries with universal health care and institutionalised HTA were included in 
the sample. Systems were categorised at the individual technology decision level: assessment of 
evidence, the decision and the output and implementation. The reimbursement institution(s} 
responsible for decision-making was identified and the websites searched for data on each 
element of the framework. When data were unavailable from the institution's website, published 
and grey literature were searched and contact was made with the institution to identify misSing 
data. 
Results: The sample included 24 OECD countries' reimbursement systems. Variation was present 
in the assessment and appraisal of clinical evidence. A health economic analysis was mandatory in 
17 ofthe OECD countries for some types of medicines but there was variation in the guidelines for 
the conduct of the analysis and the requirement for third party review. The appraisals were 
conducted by committees of varying size and composition. Forty-one stated decision-making 
factors were identified across countries and categorised into clinical evidence, economic evidence 
and non-evidence factors. Variation across countries was identified in the implicit/explicit use of 
cost-effectiveness thresholds and the interpretation of the threshold with respect to other 
factors. Final decision outcomes varied across countries with respect to the types of restrictions 
and the status of the decision. 
Conclusion: The influence of evidence on decision-making has been studied in some countries but 
less attention has been given to the impact of the reimbursement process upon the Use of 
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evidence and the decision. Further comparative studies designed to control for process may help 
to address some of the unexplained variation in reimbursement decisions across countries. 
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4.1 Introduction 
Chapter 3 categorised the reimbursement systems at a policy implementation level. This chapter 
categorises the process by which individual medicines are assessed and appraised to help 
understand how the objectives of the system influence the methods of assessment (use of health 
economic analysis) and the resulting reimbursement decisions by different systems. The 24 
reimbursement systems are described and categorised for each element of the technology 
decision level and where appropriate grouped by similarities with respect to each element. The 
individual technology decision level characterises how medicines are assessed, the appraisal and 
reimbursement decision-making and the output and implementation of decisions in countries 
(Hutton et aI., 2006). The aim of this chapter is to categorise the different reimbursement systems 
with respect to each of these elements to understand the stated use of health economic analysis 
within the context of the process and other stated factors. 
4.2 Methods 
Table A4.1 provides an overview of the elements of the technology decision level. This level 
distinguishes between the assessment of evidence, making the decision (which includes the 
appraisal of evidence and other factors) and the implementation of the decisions made by the 
system. 
4.2.1 Assessment 
The assessment of medicines is considered with respect to the consultation and involvement of 
stakeholders, methodological framework, source(s) of evidence for the assessment and 
presentation and communication of the results. The following elements and data are considered: 
• Process, institutions and stakeholder involvement: This considers the institution(s) and 
stakeholders involved in the assessment (manufacturer, review group, independent third 
party assessment), the points in the process at which they might contribute and whether 
there are specific committees with responsibility for the scientific assessment of the 
evidence. 
• Evidence and Methods of Synthesis: This considers the methods and elements of HTA 
used by the institution responsible for the assessment (source) of the medicines. The 
requirements and data sources are considered including: 
o The requirements for the manufacturer and the guidelines for the conduct of 
submissions by manufacturers; 
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o The requirements for health economic analysis in each of the reimbursement 
systems; 
o Independent third party assessment of the evidence. 
• Stakeholder consultation on evidence assessment: This describes the stages at which the 
manufacturer and other stakeholders can provide comments on the evidence assessment 
before this is considered within the decision-making process. 
• Communication of assessment of evidence: This section describes how the results of the 
assessment are communicated either by publication of the manufacturer submission or 
through the provision of reports of the assessment considered for the decision-making 
stage. This also considers whether other evidence is provided by other stakeholders and 
whether this is made publically available. 
4.2.2 Decision 
The decision is interpreted as the process and institutions involved in producing the final decision 
on whether a medicine is publicallY funded by the reimbursement system. The categorisation thus 
separates the assessment of the evidence by the institutions or committees involved from the 
appraisal of evidence by the final decision-making body. The appraisal involves the application of 
decision criteria to the synthesised evidence and the consideration of other factors (either 
explicitly stated by the institution or not). The characteristics of the decision are separated in the 
framework into the consideration of who makes the decision, decision-making process, evidence 
base and additional influences on the decision and the content and documentation of the 
decision: 
• Stakeholder involvement in deliberations: This considers the types of stakeholders 
involved on the committee(s) for the appraisal of medicines In relation to the final 
decision-maker In the reimbursement system. 
• Decision process and institutions: This describes the institutions involved in the appraisal 
and number of stages of the process. 
• Evidence base and additional Influences: This describes the evidence appraised and other 
stated factors considered by the institution responsible for the final reimbursement 
decision. This provides definitions of the stated factors and a consideration of how 
economic analysis is used in relation to the final decision. 
• Content and documentation of the decision: This describes the information that is made 
publically available by the decision body and whether justifications are provided for the 
interpretation of evidence in the deliberations. 
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4.2.3 Output and Implementation 
The outputs and implementation describes the opportunity for appeal and dissent, 
implementation and communication, monitoring and reappraisal and the evidence of the impact 
of the decision. 
• Appeal and dissent: This describes whether the system has a formal appeal mechanism 
against a decision, the types of options that are available for appeal, the grounds for 
appeal and the types of stakeholders that can appeal in the process. 
• Implementation and communication: This describes the types of decision outcomes 
produced, requirements or coverage with evidence development and the mechanisms 
and the status ofthe reimbursement decisions in practice. 
• Monitoring and reappraisal: This describes the reimbursement system's ability to monitor 
changes in the evidence base and activate reappraisal where necessary. The systems will 
be assessed with respect to whether there is a formal process to monitor and reappraise 
technologies and the mechanism which triggers reappraisal. 
• Evidence of impact of decisions: This refers to the systems accountability in assessing and 
documenting the impact of individual decisions. This concerns a review of the 
implementation and impact of decision by each of the reimbursement systems. 
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4.3 Results 
The following section summarise the results and the detailed data extraction can be found in 
Tables A4.14, A4.1S and A4.16. The references for the data collection tables can be found in Box 
A4.2. 
4.3.1 Assessment of medicines 
4.3.1.1 Process, Institutions and stakeholder Involvement 
The process of assessing the evidence in countries reimbursement systems is distinguished from 
the appraisal of evidence in the description of the countries processes. The assessment of 
evidence can be undertaken by the manufacturer, an independent group commissioned by the 
institution responsible for appraising the assessment or an analytical team within the appraising 
body. The assessment performed may be a full Health Technology Assessment which, as defined 
by HTAi, is "The systematic evaluation of properties, effects, and/or impacts of health care 
technology. It may address the direct, intended consequences of technologies as well as their 
indirect, unintended consequences. Its main purpose is to inform technology-related 
policymaking in health care. HTA is conducted by interdisciplinary groups using explicit analytical 
frameworks drawing from a variety of methods." (HTAi, 2011). HTA can be broadly considered to 
cover five main areas; clinical-effectiveness, cost-effectiveness, social, ethical and legal aspects. 
The reimbursement systems may require elements of HTA in the assessment such as safety, 
clinical effectiveness and cost-effectiveness of evidence rather than a full HTA. The requirements 
and methods for the assessment of evidence may reflect the policy objectives of the system and 
particular value judgements of the countries reimbursement system. 
The majority of the systems rely on the manufacturer to provide the assessment of the evidence 
regarding a medicine and to bear the majority of the cost. The manufacturers are required to 
provide a submission for new medicines to all of the reimbursement systems and the majority of 
these systems rely on the assessment of the evidence presented by the manufacturer (Table 
A4.2). There is an institution in each country which is responsible for reviewing the manufacturer 
submission. This review in different countries is either performed by the staff of the institution, a 
specific committee responsible for assessment within the Institution or by multiple committees 
within the institution. The assessment institution is not necessarily the same body as the appraisal 
institution, but is responsible for delivering the final assessment to the appraisers. 
Ther~ are single institutions responsible for processing the manufacturer submission and 
preparing an assessment for medicines in 17 of the countries (Table 4.1). The staff of the 
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institutions process the submissions made by the manufacturer in preparation for the appraisal by 
a separate committee within the same institution. Additionally an independent assessment of the 
clinical evidence is provided by a clinical review team at CADTH in Canada, independent 
assessment group in the NICE MTA process in England and by IQIWG in Germany. An independent 
economic analysis is provided by these groups in England (MTA only) and Germany. 
Table 4.1: Single Institution responsible for assessment and appraisal 
Country Institution/agency 
Belgium National Institute for Health and Disability Insurance (NIHDI) 
Canada (excluding cancer medicines) Canadian Agency for Drugs and Technologies in Health (CADTH) 
Denmark Danish Medicines Agency (DMA) 
England and Wales National Institute for Health and Clinical Excellence (NICE) 
Frances Haute Autorite de sante (HAS) 
Germany Institute for Quality and Efficiency in Health Care (IQWIG) 
Hungary Office for Health Technology Assessment (OHTA) 
Ireland National Centre for Pharmacoeconomics (NCPE) 
Israel Medical Technologies Administration (MTA) 
Mexico General Health Council (GHC) 
Norway Norwegian Medicines Agency (NoMA) 
Poland Agency for Health Technology Assessment in Poland (AHTAPol) 
Portugal National Authority of Medicines and Health Products (INFARMED) 
South Korea Health Insurance Review and Assessment (HIRA) 
Spain Ministry of Health, Directorate General for Pharmacy and Health 
Products 
Sweden Dental and Pharmaceutical Board (TlV) 
Switzerland Federal Office of Public Health (FOPH) 
Some reimbursement systems contain a specific institution and committee that is responsible for 
the scientific assessment of the evidence for delivery of a report to a committee or institution 
responsible for appraisal. There are committees which focus on the scientific assessment of the 
clinical evidence in Italy and New Zealand. The Technical and Scientific Committee (TSC) in the 
Italian Medicines Agency provides a classification of the therapeutic innovative value of the 
medicine. In New Zealand, the Pharmaceutical and Therapeutics Advisory Committee (PTAC) 
advises on the clinical evidence provided and critically reviews the clinical evidence provided. 
There are committees that focus on broader aspects of the assessment and provide a scientific 
assessment of the clinical and economic evidence in each institution. The committee's members 
include those with broad expertise including pharmacologists, medical physicians and health 
economists. These types of committees are established in the SMC called the New Drugs 
Committee (NDC), the Pharmaceutical Evaluation Board (HEK) in the Federation of Austrian SOCial 
Security Institutions (HVB) in Austria, the Pharmaceutical Assistance Commission (CFH) in CVZ in 
the Netherlands and the Expert Committee in the Pharmaceutical Benefits Board (PPB) in Finland. 
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The Australian reimbursement system is unique in that two committees advise the body 
responsible for providing the reimbursement recommendation caJled the Pharmaceutical Benefits 
Advisory Committee (PBAC). The PBAC is advised by the Economic Sub-Committee that was 
established in December 1993 to review and interpret the economic analysis submitted to PBAC, 
advises on technical aspects of economic evaluations and to provide advice with respect to the 
analysis submitted by the manufacturer. The Drug Utilisation Sub-Committee (DUSC) of PBAC 
coJlects and analyses data on medicine utilisation in Australia provide information on rational use 
and prescribing and to provide comparisons with other countries of use of medicines (Australian 
Government, 2011). 
4.3.1.2 Evidence and methods of synthesis for assessment 
AJI of the reimbursement systems recommend to the manufacturer the requirement for a 
description of the medicine's proposed use and pharmacological characteristics and details of the 
efficacy and safety from the regulatory marketing authorisation. AJI of the reimbursement 
agencies require clinical data on the safety and clinical efficacy of the medicine. The differences 
between the countries relate to the requirements for data on clinical benefit, either summary of 
the clinical efficacy, clinical effectiveness or a categorisation of the added therapeutic value of the 
medicine and other factors important In relation to the use of the medicine (Table A4.2). Actual 
effectiveness evidence is unlikely to be available at the initial reimbursement decision and 
systems have a variety of ways by which these uncertainties are considered either through 
economic modelling or the process by which medicines are appraised and reassessed/appraised. 
The majority of reimbursement systems require the manufacturer to include a health economic 
analysis in the submission for the reimbursement of the medicine. A health economic analysis by 
the manufacturer is mandatory in 17 countries, is optional in Denmark, New Zealand and 
Switzerland and not required in the initial submission in France, Germany and Spain (Table 4.2). 
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Table 4.2: Requirement for health economic analysis 
Mandatory for Mandatory for certain Optional Not required 
medicines medicines 
Australia Austria Denmark France 
Canada Belgium Italy Germany 
Finland Ireland New Zealand Spain 
Israel Netherlands Switzerland 
Hungary Norway 
Korea 
Mexico 
Poland 
Portugal 
Sweden 
England and Wales 
Scotland 
All of the countries, with the exception of Switzerland, provide guidelines for the submission of 
economic analyses. There is variation in the types of economic analysis, perspective, comparator 
definition, costs, discount rates and requirement for sensitivity analysis recommended or required 
in guidelines for manufacturers submissions The economic analysis guidelines are provided to 
manufacturers specifically by the body responsible for assessment and/or appraisal of the 
medicine in most countries and published manuscripts are available in Austria, Denmark, Italy, 
Hungary and Spain (Table A4.3). 
There are different recommendations with regards to type of economic analysis, such as the use 
of cost-benefit, cost-utility analysis, cost-effectiveness analysis, cost-value analysis and the 
efficiency frontier. A number of countries specify that cost-benefit analysis maybe presented but 
many have a preference for a different type of analysis. The majority of countries requesting 
manufacturers to provide formal health economic analysis recommend cost-effectiveness analYSis 
and cost-utility analysis as the approach to economic analysis. The use of cost-utility analysis is 
preferred over other types of economic analysis in Australia, Canada, Ireland, Israel, Italy, Korea, 
New Zealand, Poland, Portugal, Sweden, England and Wales, and Scotland in the manufacturers 
submissions for new medicines. This may reflect the desirable characteristics of the measure for 
practical decision-making for the reimbursement of medicines. Exceptions are Germany which 
recommends the use of the efficiency frontier, Norway which prescribes the use of cost-value 
analysis and England and Wales which require cost-utility analysis. 
In Norway the guidelines provided by the NoMA specify that cost-value analysis should 
supplement cost-utility analysis provided by the manufacturer (NoMA, 2005). Eric Nord and 
colleagues introduced the term 'cost-value analysis' to account for the degree of severity of the 
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disease and produces an equity adjusted cost-utility analysis (Nord et al., 1999). The approach 
follows two steps where the health gains are estimated using standard quality adjusted life years 
(QAlYs) and step two involves producing weights. The weights are produced from a 
representative sample of the general population that are required to make person trade-offs 
between movements that are equal in terms of utility gains but different in terms of the starting 
utility. The weights are combined multiplicatively with the standard utility data for cost-utility 
analysis to provide cost-value analysis for what Nord calls 'societal value', The technique adjusts 
estimates of cost-utility by considering how bad of the individual would be without the 
intervention (severity of disease). 
The IQWIG convened a panel of experts in 2007 to develop the economic methods for the 
assessment of technologies in Germany in line with the legal requirement (§ 3Sb Social Code Book 
(SGB) V). The panel produced a document on the general methods for evaluating the relation 
between cost and benefits in 2009 recommending the use of an alternative approach called the 
'Efficiency Frontier' in the evaluation of technologies (IQWIG, 2009). The method concerns finding 
a maximum price at which a medicine in a given therapeutic area should be recommended for 
reimbursement. The analysis aims to inform the decision-maker about the efficiency of a given 
medicine in the therapeutic area, but does not attempt to judge whether the condition deserves 
treatment or the willingness to pay for the medicine. The debate surrounding this methodology is 
provided in appendix Box A4.1. 
The Reorganisation Act of the Medicinal Products Market "Neuordnung des Arzneimittelmarktes" 
(AMNOG) law was introduced on the 1st of January 2011 for the new procedures for 
reimbursement (Federal Ministry of Health, 2011). The manufacturer will be free to set the price 
for the new medicine for a maximum of the first year after launch. The manufacturer must submit 
a dossier of the added therapeutic value and IQWIG maybe commissioned to provide an 
assessment. The G-BA will provide an appraisal within 3 months and an agreement on price 
should be made within 6 months with the health insurance funds. If no agreement is reached 
arbitration committee will set the price for the medicine for the period after 12 months. The 
manufacturer or insurer can request an economic analysis following the arbitration decision. The 
IQWIG will produce an analysis using the efficiency frontier which will be complete in a maximum 
of three years. It would therefore appear that the recent introduction of the regulation has 
reduced the potential use of the efficiency frontier methodology because the benefits assessment 
will have been produced including a choice of appropriate comparator rather than all of the 
comparators for the efficiency frontier (page 16 of the General Methods Guide) and the analysis 
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will not necessarily be mandatory for setting the maximum price because of the new process 
(IQWIG, 2009). The practical use of this approach and extent of the use of this approach are yet to 
be observed. 
4.3.1.3 Third party Independent assessment of evidence 
The processes used by some reimbursement systems do not rely solely on the manufacturer 
submission, in particular with respect to the review of clinical evidence. Few reimbursement 
systems' processes provide an independent health economic analysis for new medicines and 
these are normally provided in special circumstances or in the case of NICE in England and Wales, 
in the MTA process. There are independent assessments provided in Canada, Germany, New 
Zealand, Sweden, Netherlands and England/Wales to provide sufficient evidence for decision-
making. 
The CADTH CDR process for medicines (excluding oncology medicines) in Canada produces a 
separate independent clinical review of the evidence which draws on aspects of the manufacturer 
review which includes a systematic search. The review team develops a protocol for the review 
with inputs from the drug plans, CEDAC committee members and other members. It then designs 
and conducts an independent systematic review of the evidence from the protocol to supplement 
any data that has been provided by the manufacturer. The clinical review report is sent to the 
manufacturer for information. The CDR only provide a critical appraisal of the manufacturer's 
economic analysis and may provide revised estimates if the model is re-run but do not provide a 
separate economic analysis (CADTH, 2010). 
In Germany the new proposals in the AMNOG law will mean that if requested following 
arbitration by the manufacturer or the health funds the IQWIG will produce an independent 
economic analysis called a cost-benefit analysis by IQWIG (although not a conventional cost 
benefit analysis from an economists perspective) by constructing an 'Efficiency Frontier'. The 
analysis is provided in a maximum of three years period by the IQWIG. The benefit assessment 
evaluation is used in the provision of the economic analysis in those medicines demonstrating 
added therapeutic value using the efficiency frontier and a model may be used to perform this. 
The assessments may be performed by research organisations that may be subcontracted by 
IQWIG. There have to date been no formal referrals using this process using the Efficiency 
Frontier approach but two assessments have commenced which are due to report later in 2011 
(IQWIG, 2011b). 
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In New Zealand, PHARMAC expects to receive an economic analysis within the manufacturer's 
submission for reimbursement of new medicines and provision of analysis allows the submission 
to be prioritised earlier. The analysts may amend an economic analysis submitted and will report 
the manufacturers economic analysis and PHARMACs amended economic analysis with the 
differences explained between the two analyses. If this is not provided they will undertake an 
economic analysis and the stage at which this occurs will depend on the resources available and 
the priority of the new medicine. The process usually forms an iterative assessment process with 
more details added to the economic analysis as is required for decision-making. The extent of the 
analysis depends on the timeframes available for decision-making, the impact on the budget (high 
impact will require more detailed analysis), reliability of the results, extent of the information that 
is available, the extent of the expected impact of the economic analysis on the reimbursement 
decision and the availability of health economist resources. The economic analyses are normally 
published as "Technology Assessment Reports" that follow a template (PHARMAC, 2011d). 
In the Netherlands, the alZ prepares a pharmaco-therapeutic report from the claim of 
therapeutic value made in the manufacturer submission for outpatient medicines. The pharmaco-
therapeutic report is written in consultation with experts and provides a systematic report of the 
literature for use by the CFH. The CFH make a decision on the added therapeutic value of the 
medicine using criteria for this assessment and the decision and pharmaco-therapeutic report are 
published on the alZ website (CVZ, 2010b) 
In England and Wales, NICE uniquely operates a process that provides both an independent 
clinical review and an economic analysiS in the Multiple Technology Appraisal Process (MTA). The 
MTA process assesses several medicines used to treat the same condition. An Independent 
evidence report is commissioned through the National Institute for Health Research (NHIR) at 
Southampton to one of nine independent academic centres, which has recently included two 
organisations that are not University institutions (BMJ Evidence Centre and Kleijnen Systematic 
Reviews Ltd) (NICE, 2011b). The Assessment group develops a protocol for the assessment after 
the scope has been prepared. The group will prepare an assessment report that is an analysis of 
the clinical-effectiveness and cost-effectiveness of the medicines based on a systematic review of 
the literature, the manufacturers' submissions and advice from clinical experts. The assessment 
may include a new cost-effectiveness model that is separate from that of the manufacturers and 
will follow the NIHR template for production of the report. These are normally published as a HTA 
monograph (NICE, 2009a). 
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4.3.1.4 Stakeholder consultation on the assessment of evidence 
Consultation on the evidence assessment is defined as a stage or set of stages where stakeholders 
(such as manufacturers, organisations representing healthcare professionals, provincial funders, 
and national patient organisations) can comment or provide input to the assessment or comment 
on the draft reimbursement recommendations documentation. This does not include written or 
verbal appeals that follow after a reimbursement decision has been made. The consultation 
process was identified through the details and documents provided on each of the countries' 
websites. 
Table 4.3: Consultation on assessment of evidence 
Consultation with manufacturer Consultation with manufacturer No documented details 
and other stakeholders consultation process 
Netherlands (CVZ) Australia (PBAC)· Finland (PPB) 
New Zealand (PHARMAC) Austria (HEK) France (HAS) 
Norway (NoMA) Belgium (CRM) Israel (MTA) 
Sweden (TlV) Denmark (DMA) Italy (AI FA) 
England (NICE)· Ireland (NCPE) Hungary (TAC) 
Scotland (SMC) Korea (HIRA) Spain (Ministry of Health) 
Germany (G-BA) Poland (AHTAPol) Switzerland (FOPH) 
Canada (CADTH CDR)· Portugal (INFARMED) Mexico (GHC) 
·Multiple stages of consultation on the assessment of evidence. 
There is wide variation across countries with respect to consultation with stakeholders in the 
reimbursement process for new medicines. There were countries where the manufacturer and 
other stakeholders have the opportunity to comment on the assessment, countries where the 
manufacturer only has the opportunity to comment and those countries where there is no 
documentation of the consultation process (Table 4.3). There are some countries that only 
provide the manufacturer with the opportunity to consult with respect to providing comments 
and clarifications on the assessment report prepared for the decision-making (Austria, Belgium, 
Denmark, Ireland, Korea, Poland, Portugal). In Belgium and Denmark the manufacturer is only 
given the opportunity to comment if the draft recommendation is more restrictive than that 
requested in the original submission. 
There are then those countries that include other stakeholders in addition to the manufacturer in 
the reimbursement process. The type of stakeholders that are consulted depends on the nature 
of the funding system and number of levels of decision-making. In New Zealand medical groups 
and other interested parties are able to comment on the assessment report prior to the appraisal 
and similarly interested parties can comment in Norway. The most sophisticated processes for 
of 
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stakeholder consultation appear to be operating in Canada, England & Wales, Netherlands, 
Scotland and Sweden. 
In Canada the CDR process enables the manufacturer to comment on the review report produced 
by the CDR team and also have the opportunity to comment on the CEDAC recommendations and 
request reconsideration. The CADTH added a patient group input to the CDR process in May 2010 
(CADTH, 2011b). This integrates comments from patient groups in a formal process for organised 
patient groups to be consulted during the process. There is a template provided on the CADTH 
CDR website for patient input submissions. The patient input submission is included in the report 
prepared for recommendations performed by the CEDAC to consider the patient perspective on 
the drug's impact in comparison to other available therapies. 
The reimbursement process operated by the NICE in England has many stages in which a wide 
variety of stakeholders are consulted. The documents consulted on differ between the Single 
Technology Appraisal (STA) process and Multiple Technology Appraisal (MTA) process. The 
process defines two different types of stakeholders; consultees and commentators. Consultees 
include national groups representing patients and carers, bodies representing health 
professionals, manufacturer (s) or sponsor (s) of the technology in development, the Department 
of Health, the Welsh Assembly Government, Specialised commissioning groups. Primary care 
trusts and local health boards. Commentator organisations include manufacturers of comparator 
technologies, NHS Quality Improvement Scotland, the relevant National Collaborating Centre, 
research groups working in the area and other groups (NHS confederation, BNF etc). A wide 
variety of consultees and commentators are identified at the start of the process and may provide 
comments on the draft scope for the guidance. The consultees (excluding the manufacturer) are 
invited to provide an evidence submission with information about the potential clinical and cost-
effectiveness of a medicine using a template provide on the website. The Patient and Public 
Involvement Programme (PPIP) offer support (financial and non-financial) to patient organisations 
for their submissions to the process. NICE will release the manufacturer's submission (STA process 
only), statements from non-manufacturer consultees (STA process only), clarification letters (STA 
process only), Evidence Review Group Report and pre-meeting briefing (STA process only), 
assessment protocol (MTA process only), Evaluation report (MTA process only) to consultees and 
commentators with confidential information so long as they have signed a confidentiality 
agreement. The appraisal meeting includes nominated clinical specialists (usually two) and patient 
experts (usually two) and NHS commissioning experts (two) to attend and also prepare written 
statements. The manufacturer can have two representatives that attend to respond to any 
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questions from the committee. There is a session open to the general public and a closed session. 
of the meeting in which commercial in confidence information is considered prior to formulating 
the recommendation. The consultees and commentators have four weeks to comment on the 
Appraisal Consultation Document (ACD) which is prepared as a draft decision when more 
restrictive than initially proposed by the manufacturer in the STA process and always prepared in 
the MTA process (NICE, 2009b, NICE, 2009a). 
In the Netherlands the manufacturer, clinicians, patient associations and insurers are given the 
opportunity to comment on the draft reports produced by the Pharmaceutical Assistance 
Commission prior to this being provided to the CVZ board that produce the final reimbursement 
decision. There is a separate Appraisal Committee (ACP) that takes matters of social value 
judgements into account for medicines on an ad hoc basis (van Halteren, 2011). 
Health boards are consulted in addition to external clinical experts who answer 5 questions on 
each assessment by the SMC in Scotland. The SMC encourages members of the public to be 
involved in the process and has a Patient and Public Involvement Group (PAPIG) that ensures the 
patient and carer perspective are always taken into account in the reimbursement process. 
Patient interest groups can provide a formal patient evidence submission in Scotland which 
describes the experience of those that suffer from the health problems that the medicine treats. 
These are presented in the SMC board meetings. There is a template provided on the SMC 
website for the patient group evidence submission (SMC, 2011c). 
The TLV in Sweden consults with the manufacturer at various stages. The TLV will clarify the 
submission with the manufacturer and obtain any further information. The TlV may arrange a 
meeting with the manufacturer to do this if necessary (lFN, 2008). The documents that include 
the assessment and proposed decision are sent to the manufacturer for the opportunity to 
correct any factual errors and to comment on the justifications provided for the propOsed 
decision. The Pharmaceutical Benefits Group for the County Councils are given the opportunity to 
provide comments and put forward any issues with the documentation and proposed decision. 
Patient groups are represented in the process by two members of the Executive Board that 
provide the decision having involvement with patient organisations in the past (lFN, 2007). 
4.3.1.5 Communication of assessment of evidence 
The communication to stakeholders involves two aspects that include the involvement in the 
assessment (ex ante) and the communication of the assessment and decision (ex ante). The first 
type of communication with stakeholders was dealt with in the previous section. This section 
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considers the communication of the assessment. The communication of the manufacturer's 
submission and assessment varies considerably across the reimbursement systems from no 
publication through to almost complete publication of all assessment documentation used to 
inform the reimbursement decision-making (Table A4.4). There are many reimbursement systems 
that do not provide any details of the assessment provided by the agency or body in Finland, 
Israel, Italy, Hungary, Mexico, Portugal, Spain and Switzerland. In Korea, the HIRA does not 
provide the HTA report on the website but this is made available to the manufacturer throughout 
the process. Austria only provides reasons for the decisions on the website when these deviate 
from the manufacturers proposed use but do not provide the assessment report or the 
manufacturer submission. 
There are reimbursement bodies and institutions that do not provide the manufacturer 
submission but provide some details of the assessment and these are included in the appraisal 
and deliberation documentation that provides justification for the recommendation: 
• In Australia these can be found in the PBAC Public Summary Documents by Product 
which includes details of the cost-effectiveness and clinical effectiveness considerations; 
• In Belgium the CRM call this the Evaluation Report; 
• In Canada CDR call this the Canadian Expert Drug Advisory Committee (CEDAC) Final 
Recommendation; 
• In Denmark these are called the Minutes of the Reimbursement Committee; 
• In France the HAS document is called the Summary of Opinion; 
• In Ireland an NCPE Economic Evaluation is provided; 
• In the Netherlands the an report is called the Commission for Pharmaceutical Assistance 
(CFH) report; 
• In Norway these are called the Minutes of the Blue Prescription Committee; 
• In Poland these are called the Position of the Consultative Council; 
• In Sweden this is called the Decision document; and 
• In Scotland this is called the SMC advice document. 
The PHARMAC agency in New Zealand provides some Technology Assessment Reports (TARs) for 
a few of the reimbursement decisions but does not publish all of these on the website because of 
the confidential nature of the submissions. The manufacturer submission Is not provided 
alongside this information (PHARMAC, 2011d). The agency also provides the minutes of the 
Pharmacology and Therapeutics Advisory Committee that include some discussion around the 
assessment performed. 
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There are two systems that include elements of the manufacturer submission on the website 
which are the G-BA in Germany and NICE in England. The G-BA has a tracking system on the 
website for the status of early benefit assessments with the summary documentation, supporting 
reasons for the decision and the decision text. The details of the manufacturer submission are 
included but excluding any of the commercially in confidence information. The IQWIG also include 
the early benefits assessment on their website when they have been requested to conduct this on 
behalf of the Federal Joint Committee. 
NICE in England provide a number of documents in relation to the assessment of the medicine. A 
full manufacturer submission is provided on the website for the STA process excluding any 
confidential information and appendices if these include information that is commercially 
sensitive. The executive summaries of the manufacturer(s) submission(s) are provided for the 
MTA process. Any clarifications made with the manufacturer(s) for both of the processes are 
published on the website. There are date stamps provided on the website for when each of the 
documents was uploaded. The Assessment group report and Evaluation Report (MTA) and 
Evidence Review Group report and Pre-meeting briefing (ERG) are provided for the appraisal 
committee meeting and consultation. Any other statements from stakeholders are also provided 
on the NICE website. 
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4.3.2 The Decision 
4.3.2.1 Decision process and Institutions 
The appraisal stage involves value judgements about the evidence and its robustness and any 
other factors that are explicitly specified for consideration. The reimbursement systems vary in 
the number of institutions involved in the appraisal of medicines. The systems can be categorised 
by those that have established a separate institution that provides the final reimbursement 
decision or a separate institution that provides advice to the Ministry of Health. There are then 
reimbursement systems where a committee in the Ministry of Health is responsible for appraising 
medicines and either providing a final decision or advisory decision to the Minister of Health. 
There are other systems where multiple institutions are responsible for different stages of the 
appraisal and final decision. All of the OECD reimbursement systems in this study contain a 
committee that appraises the evidence using country specific criteria and that Is either 
responsible for the final reimbursement decision or provides an advice to the final decision-maker 
(Minister of Health or other decision-making body). 
A separate institution is responsible for the appraisal, using a committee to determine the final 
reimbursement decision in 11 of the countries. There are committees responsible for the 
appraisal of evidence and other factors in each of these countries' Institutions and the names of 
these are described in Table 4.4. 
Table 4 4: Country and reimbursement committee . 
Country (agency) Committee 
Austria (HVB) The Medicines Evaluation Committee (HEK) 
Denmark (DMA) Reimbursement Committee 
England & Wales (NICE) Technology Appraisal Committee (TAC) 
Germany (G-BA) Federal Joint Committee 
Hungary (NIHFA) Technology Appraisal Committee (TAC) 
Ireland (HSE) Products Committee 
Italy (AI FA) Pricing and Reimbursement Committee and Executive Board 
Mexico (GHC) General Health Council 
New Zealand (PHARMAC) PHARMAC Board 
Norway (NoMA) Blue Prescription Board 
Sweden (TLV) Dental and Pharmaceutical Board 
There is a separate institution which Includes a committee which appraises the medicine and 
provides an advisory recommendation to the Minister of Health in 6 of the countries. These 
systems involve a two stage appraisal where the agency provides a first appraisal and the Ministry 
of Health provides the final appraisal and decision. The Ministry of Health may draw on other 
institutions such as the pricing authorities in Australia called the Pharmaceutical Benefits Pricing 
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Authority (PBPA) and the Economics Committee (CEPS) in France. The other reimbursement 
systems committees that provide the two stage approach to appraisal are the CVZ Board in the 
Dutch Health Insurance Board (CVZ), the Consultative Council in the Agency for Health Technology 
Assessment in Poland (AHTAPol), INFARMED Board in INFARMED and the Drug and 
Reimbursement Committee (DREC) in the Health Insurance and Review and Assessment Service 
(HIRA) in Korea. 
A department or committee in the Ministry of Health is responsible for appraising medicines and 
providing the final reimbursement decisions in Belgium, Israel, Finland, Spain and Switzerland. A 
department called the Medical Technology Administration of the Ministry of Health and Finance 
has a committee called the Public National Advisory Committee (PNAC) which provides 
recommendations for which the government must approve in Israel. A Ministry of Health sub-
section is responsible for the reimbursement appraisal and final decision called the Directorate 
General of Pharmacy and Health Products (DGHP) in Spain and the Federal Office of Public Health 
(FOPH) in Switzerland. Both departments are advised by a committee called the Inter Ministerial 
Price Commission in the DGHP and the Federal Drugs Commission in the FOPH. The Ministry of 
Social Affairs and Health apPOints a committee called the Pharmaceutical Benefits Board that is 
responsible for appraising and providing the final reimbursement decision for medicines in 
Finland. Similarly in Belgium, the Ministry of Health and Social Affairs has a committee called the 
Committee for Reimbursement of Medicines (CRM). 
The reimbursement systems in Canada and Scotland contain a two stage appraisal performed by 
two separate institutions. In Canada the CEDAC provides an appraisal and recommendation for 
the Drug plans. The Drug plans will then provide an appraisal given local priorities and provide a 
final decision for inclusion in the plans formulary. Similarly, in Scotland the SMC Board provide 
advisory recommendations for the Health Boards. The Health Boards provide an appraisal and 
take the final decision to include the medicine in the Board's formulary. 
4.3.2.2 Stakeholder Involvement In deliberations 
The appraisal of the evidence was defined as the act of judging and valuing a medicine using 
stated criteria prior to the formal reimbursement decision for use or continued use in practice. 
The committees and types of stakeholders involved in deliberations were identified from the 
websites of the institutions conducting the appraisal of medicines for reimbursement. Table A4.S 
reports the types of stakeholders that are members of each committee. Committees that 
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appraised the evidence were identified in all reimbursement systems with the exception of Spain 
where the appraisal and reimbursement decision are made by the Ministry of Health. 
The size of reimbursement committees varied from between 5 members for the PHARMAC board 
in New Zealand to 38 members of the SMC in Scotland. There are variations in the types of 
stakeholder included in the reimbursement committees across the countries. All of the 
committees included medical practitioners which either included specialists or general 
practitioners with the exception of TLV in Sweden. Many of the committees included either a 
pharmacologist or a pharmacist with the exception of committees in Denmark, Germany, Israel, 
Mexico, Poland, Portugal and Spain. 
Health economists are represented on the reimbursement committee in just over half of the 17 
OECD countries reimbursement committees that require an economic analysis in the 
manufacturer submission. Health economists are members of the committees in Australia (PBAC 
committee), Finland (PPB committee), Ireland (NCPE committee), Israel (PNAC committee), Italy 
(CPR committee), on the scientific committee in Netherland's (CFH committee) but not in the 
appraisal committee, Korea (DREC committee), Sweden (LFN committee) and England and Wales 
(TAC). The health economic representation in Scotland is provided in a separate committee. The 
SMC committee has a sub-committee called the New Drugs Committee that includes health 
economists. The committee reviews the economic analysis presented from a purely scientific 
perspective and prepares advice to the SMC committee. In Germany a separate institution called 
IQWIG provides the Federal Joint Committee with an economic analysis on request following 
arbitration but health economists are not present In the reimbursement committee. 
Patients are represented in committees in Australia (PBAC), Germany (G-BA), Korea (OREC), 
Sweden (TLV), Scotland (SMC) and England and Wales (NICE). In Scotland, patients and carers are 
represented in by a Patient and Public Involvement Group (PAPIG) which consists of 6 members. 
Public Involvement Officers are represented on the SMC committee that makes the final decision 
for inclusion. Similarly, NICE has a PPIP to involve patients and carers in developing the NICE 
guidance. The committees contain at least two lay members either patients or members of the 
public. Patient experts are also nominated to attend an appraisal meeting to provide their 
personal knowledge and experience of the condition. Members of the public are represented on 
the CDR committee in Canada, Public National Advisory Committee in Israel and the Federal Drugs 
Commission in Switzerland. 
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The Pharmaceutical industry is represented in the SMC committee in Scotland, the CRM 
committee in Belgium and NICE committee in England. Then industry representatives are 
consultative members in the CRM but do not have any rights to vote in the reimbursement 
decisions. 
There are representatives of the insurers in many of those systems where the predominant 
funding system is that of social insurance. The other members represented across some of the 
committees included members of the Ministry of Health, other government department 
representatives, regional and health care planners and in a few representatives of the agency or 
institution. 
4.3.2.3 Stated factors In the appraisal of evidence 
The formal factors stated in the documentation provided by the reimbursement body or agency 
documentation provided on their website were considered in a table and grouped by types of 
factors. There were 41 factors identified across countries of which 17 were used within 2 or more 
countries and 24 were factors considered exclusively within one country. These factors were 
grouped into three categories clinical evidence factors, economic evidence factors and non-
evidence factors (Table A4.6). 
Appraisal of clinical factors 
The reimbursement systems all consider the medicines with respect to the clinical value/benefit 
focusing on different criteria for formal consideration depending on the processes of pricing and 
reimbursement. The agencies all require an appraisal of clinical factors which may either be by 
considering clinical-effectiveness, added therapeutic value or benefit, clinical efficacy or country 
specific criteria such as clinical usefulness. There are a number of criteria some of which are 
similar across countries, some overlapping and used to appraise the available clinical evidence. 
Clinical-effectiveness factor (some countries make the point of when this data ;s available) 
Clinical effectiveness is a formal criterion for medicines in Australia, Canada, Ireland, Netherlands , 
Mexico, Norway, New Zealand, Poland, Sweden, England and Scotland. The International Network 
of Agencies for Health Technology Assessment (INAHTA) defines clinical effectiveness as follows 
(INAHTA,2011b): 
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HThe extent to which a specific intervention, procedure, regimen, or service does what it is 
intended to do under ordinary circumstances, rather than controlled conditions. Or more 
specifically, the evaluation of benefit to risk of an intervention, in a standard clinical setting, using 
outcomes measuring issues of importance to patients (e.g. ability to do daily activities, longer life, 
etc.)." 
The definitions across these nine countries are similar but not identical. The definitions provided 
in these reimbursement systems generally relate to the benefit with respect to health gain of 
using the medicine in clinical practice within each specific country (Table A4.7). The clinical 
effectiveness evidence is used in all of these countries to inform the cost-effectiveness analysis. 
The cost-effectiveness analysis is required from manufacturers in the submissions to all these 
countries with the exception of New Zealand where it is optional but the agency will provide the 
analysis if this is not provided by the manufacturer. 
Added therapeutic value/Benefit factor 
The second most widely considered factor by the reimbursement systems is that of added 
therapeutic value or benefit. Eichler et al. highlights that payer bodies use the term "added 
therapeutic value" frequently but there is no widely accepted definition (Eichler et aI., 2010). The 
authors use European Medicines Agency Working Group with Patient Organisations (EMWGPO) 
definition. "A new medicinal product can be said to have added therapeutic value if sound clinical 
data show that it offers patients better efficacy, and/or better safety and/or simpler 
administration, than existing alternatives." 
The added therapeutic value or benefit factor is used in 10 of the countries Austria, Belgium, 
Denmark, Finland, France, Germany, Italy, Netherlands, Spain and Switzerland. The added 
therapeutic value is defined differently across these countries. The reimbursement bodies in 
Denmark, Finland, and Spain provide a broad statement on the meaning of Therapeutic Value 
which would appear to be consistent with the EMWGPO definition. Added therapeutic value is 
defined more widely in Belgium, France, Switzerland and Germany including other aspects of 
value (applicability, effectiveness and appropriateness). The CVZ in the Netherlands provides the 
widest definition . including efficacy, effectiveness, side effects, applicability, convenience, 
experience and quality of life. Germany defines this as any benefit demonstrated by any patient 
related outcome. The definitions provided in Austria focus on the efficacy and perception of 
innovation and similarly in Italy, the therapeutic benefit is considered as part of a composite 
innovation assessment for the level of 'therapeutic innovation' defined as either important, 
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moderate or modest (Table A4.8). The therapeutic innovation level is decided by an algorithm 
that takes into account the availability of existing medicines and the extent of the therapeutic 
benefit provided by the medicine. 
The factor is appraised descriptively in Denmark, Finland and Spain and in the other six countries 
is defined as a categorical scale. The scales have between 3 and 6 levels and depend on the 
committee's judgement of the extent of the therapeutic value of the medicine. In Belgium, 
Netherlands and Italy the medicines are categorised on three levels that are defined differently 
with respect to either type of medicine and the level of the benefit. The Swiss categorisation 
includes a 5 levels focusing on the level of therapeutic benefit and the economic savings by using 
the medicine, Level 1: therapeutic breakthrough, Level 2: Therapeutic progress, Level 3: Savings 
compared to other medicines, Level 4: No therapeutic progress and no savings, 5: Inappropriate 
for social insurance. The French, Swiss and German scales for categorisation of therapeutic value 
are similar with Germany having an additional sixth category of medicines with less therapeutic 
value than the appropriate comparator treatment. The categorisation used in Austria focuses on a 
6 point scale with categories based on the level and extent (patient subgroups or wider 
population) of the therapeutic value. 
Other clinical value factors 
The deliberations In Hungary consider clinical efficacy, the extent to which an intervention does 
more good than harm under ideal circumstances, alongside the cost-effectiveness when 
appraising the medicine. Israel specifies two criteria to consider when deliberating on the clinical 
evidence; the degree of extension of quality and length of life. Korea specifies clinical usefulness 
as the criterion considered in the deliberations for reimbursement and this includes an 
assessment of the therapeutic benefit (superior or inferior to .other relevant comparators), 
available alternatives and severity of disease. This is not measured on a categorisation scale. 
Additional clinical factors 
Australia has other formal stated criteria in addition to the clinical effectiveness which are 
likelihood of developing resistance to the medicine and the ability to target those patients that 
are most likely to benefit from the medicine. NICE in England and SMC in Scotland similarly 
consider those most likely to benefit and whether data on Health Related Quality of Life (HRQOL) 
sufficiently capture all of the benefits to patients. SMC has two further additional criteria to 
formally consider; the degree of extension of life and quality and whether the medicine provides a 
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bridging to another definitive therapy. Norway additionally considers whether the patients suffer 
from prolonged treatment or risk of prolonged treatment. 
Appraisal of economic evidence factors: 
Cost-effectiveness analysis in the form of cost-effectiveness, cost-utility or cost-minimisation is a 
stated decision-making criterion in 20 of the 24 OECD reimbursement systems. The other four 
countries' predominantly rely upon an initial assessment of the added therapeutic value provided 
by the new medicine amongst other factors. The German committee does not initially consider 
economic analysis but may request IQWIG to perform an alternative form of analysis - the 
efficiency frontier analysis on request of the manufacturer or the health funds. The French, 
Spanish and Swiss reimbursement systems do not use any formal economic analysis in the 
decision-making for new medicines. In France, the reimbursement agency does not perform 
economic analysis for new medicines but does have a department in HAS called the "Assessment 
of Health Economics and Public Health" (SEMESP) that performs economic evaluation. The 
department has produced 28 health economic assessment reports on a range of technologies, 
including a few medicines (HAS, 2011b). 
4.3.2.4 Cost-effectiveness thresholds 
The variation in the extent of the use of cost-effectiveness in decision-making across countries 
depends upon the acceptability of the assumptions and applicability of the values implied by the 
methodology. Cost-effectiveness analysis can be used to determine the most efficient allocation 
of resources after the budget has been allocated to the health sector (rather than describing the 
overall budget which is consistent with the efficient resource allocation across sectors). The 
effiCiency criteria in this approach depend on the type of outcome used in the approach - the 
QALY approach is a commensurate measure of health benefit that can be applied across 
technologies and relates an individual's length of life and an individual's quality of life (McGuire 
and Drummond, 2001). The general objective assumed is one of maximising the level of health 
benefits given the exogenously determined budget. The simplest form of QALY calculation is to 
aggregate the unweighted QAlY's and this assumes that a QAlY is regarded as equal value to 
everybody (Williams, 1996). Of course this is not the only means of aggregating QAl Ys and these 
may be weighted in a more complex calculation to take into account of characteristics of the 
patients and distributional principles. 
The central measure produced by cost-effectiveness analysis is the incremental cost-effectiveness 
ratio which represents the difference in costs between the two interventions divided by the 
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difference in effects. The measure of health effect can be expressed in a number of ways such as 
natural units, life years gained or quality adjusted life years (QAlYs). The use of cost-effectiveness 
analysis does not describe which interventions should be funded and requires a decision on the 
cut-off point at which interventions are judged as cost-effective or not cost-effective. Weinstein 
and Zeckhauser introduced the first discussion of the critical cut-off point in a study on public 
economics (Weinstein and Zeckhauser, 1973). The authors discussed the computation of a 
"critical ratio" or A cut-off in a constrained optimisation problem that became known as the 
"threshold" throughout the health economic literature. The determination of a threshold value 
relies on a number of assumptions such as a fixed budget, maximisation of health, perfect 
divisibility and constant returns to scale of all programs (Weinstein and Zeckhauser, 1973). The 
threshold has been further described by some authors as "hard and soft threshold" (Eichler et aL, 
2004). The "hard threshold" is where cost-effectiveness is the single criterion which leads to 
automatic acceptance or rejection of the medicine and a "soft threshold" where cost-
effectiveness is taken into account alongside other societal preferences with a lower and upper 
boundary or in other words a threshold range. 
Health Economists agree that the threshold value is an empirical question. There is disagreement 
between health economists by which the threshold value sholJld be estimated. Welfare 
economists argue that social benefits should be maximised and willingness to pay would be the 
best means to estimate this value. Whereas extra-welfarist's argue that the marginal productivity 
measured by the benefit gained from extra expenditure (cost per QAl Y of least efficient 
treatment) is the correct approach in budget constrained systems (Hutton, 2011). This has 
practical implications for each of the systems judgement of the cost-effectiveness threshold and 
the nature of the assumptions to the context of decision-making. 
A strict threshold cut-off point or "hard threshold" for below which a medicine is considered cost-
effective and above which is not recommended for use is not used in practice in any of the OECD 
countries reimbursement systems (Table A4.9). An explicit threshold range - where the agency or 
institutions responsible for decision-making have stated the threshold in the documentation 
provided for decision-making, operates in Scotland, England and the Netherlands for informing 
decision-making (CVZ, 2011a, NICE, 2008, SMC, 2011b). The ranges are used with respect to other 
stated factors that are considered important in each of the respective deciSion-making processes. 
There have been studies conducted in the medicine reimbursement systems of Australia, Canada, 
Ireland, Korea, Sweden that identify an implicit threshold through past decisions made in these 
countries. An implicit threshold is where a study that may be conducted independently from the 
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institution responsible for decision-making identifies a threshold value retrospectively. This may 
not be the actual threshold used formally by the committees responsible for decision-making but 
describes past decisions and the estimates of cost-effectiveness informing the reimbursement 
decision-making. 
The other 12 countries using economic analysis either do not refer to an explicit threshold range, 
state that an explicit threshold range is not required because of other factors in decision-making 
(New Zealand) or studies have not been performed to find an implicit threshold because of a lack 
of information. The previous sections of this thesis on communication of the assessment and 
appraisal of evidence, show that eight of the twelve countries do not provide this information 
publically which explains why no studies have been conducted to estimate an implied threshold. 
The lack of a threshold range in these countries may be explained by the prominence of other 
factors in decision-making (clinical evidence, budget impact and price), the use of economic 
evaluation in determining the price rather than the reimbursement status and the early 
development of the use of economic analysis in the reimbursement systems. 
Explicit Cost-effectiveness threshold ranges 
England and Wales, NICE: 
The use of a cost-effectiveness threshold range was not made explicit until five years after the 
setup of NICE where recommendations are mandatory for use in the NHS. In 2004, an Education 
and Debate article was written in the BMJ by Sir Michael Rawlins and Anthony Culyer that stated 
that NICE rejected the use of an absolute threshold for judging the level of acceptability of a 
technology in the NHS in England and Wales on the basis offour reasons which were: no empirical 
basis for deciding how this should be set, there may be exceptions where a threshold should be 
ignored, efficiency is not the primary priority over other objectives and price competition would 
be discouraged. The article stated: "The main considerations in making judgments about cost-
effectiveness for ratios of £2S,000-£3S,000/QALY are: The degree of uncertainty surrounding the 
estimate; The particular features of the condition and population using the technology; The 
innovative nature of the technology; When appropriate the wider societal costs and benefits; 
When appropriate, reference to previous appraisals." (Rawlins and Culyer, 2004). 
NICE has gained experience in using economic analysis as a central criterion in decision-making 
and evolved the use of methods in the process and transparency. The NICE methods guide 
published in 2004 stated that the threshold range to be £20,000 - £30,000 per QALY (NICE, 2004). 
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The range takes into account similar considerations as those made by Rawlins and Culyer for 
those technologies above a most plausible ICER of £20,000 but dropped with reference to 
previous appraisals. The methods guide in operation by NICE today includes a similar threshold 
range and there are differences in the stated other considerations (NICE, 2008). 
"Above a most plausible ICER of £20,000 per QALY gained, judgements about the acceptability of 
the technology as an effective use of NHS resources will specifically take account of the following 
factors: 
1. The degree of certainty around the ICER. In particular, the Committee will be more 
cautious about recommending a technology when they are less certain about the ICERs 
presented. 
2. Whether there are strong reasons to indicate that the assessment of the change in health 
related quality of life (HRQL) has been inadequately captured, and may therefore 
misrepresent the health utility gained. 
3. The innovative nature of the technology, specifically if the innovation adds demonstrable 
and distinctive benefits of a substantial nature which may not have been adequately 
captured in the QALY measure." 
The case must be explicit about the other factors when the ICER lies between the £20,000 to 
£30,000 range and must make a stronger case using these factors when the ICER is above a most 
plausible value of £30,000 per QALY gained. There has been an evolution in the guide to use of 
cost-effectiveness by NICE and the current 2008 guide appears to have tightened the criteria and 
definitions of each factor, possibly in an attempt to guard against the risk of benefit double 
counting. For example, the use of the cost-effectiveness criteria already rewards the 
manufacturer for the health benefit in the form of a premium price and to again consider the 
innovative nature of the technology would run the risk of double counting the benefit. This is 
unless the innovative nature of the technology provides benefits beyond the QALY measure. 
These have been proposed by some authors as larger dynamic benefits to society (Goldman et aI., 
2010), but examples are infrequently provided and these benefits are not clearly elucidated. 
Other benefits have been quoted as important such as severity of illness, unmet need and 
reduced care giver burden but the separate consideration of all of these remains controversial. 
These issues have been explored by the NICE Citizens Council and a report commissioned by NICE, 
published in 2009 (Kennedy, 2009). NICE established a Citizens Council in 2002, which is made up 
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entirely of members of the public to provide an advisory function with respect to the social value 
judgements made in the guidance and guidelines produced by NICE. NICE defines social value 
judgements to "relate to society rather than to basic clinical data: they take account of the ethical 
principles, preferences, culture and aspirations that should underpin the nature and extent of the 
care provided by the NHS" (NICE, 2005). The Council has produced 14 reports as of the January 
2011 and these include reports on innovation, rule of rescue, severity of illness, clinical need and 
departing from the threshold. The views of the council were taken in 2009 with respect to what 
makes an innovation valuable and the majority of citizens ranked increase in quality of life (26 out 
of 28) and other innovations may be developed from it in the future (11 out of 28) and a large 
number of people will benefit from it (10 out of 28), (NICE, 2009d). 
The Council acknowledged that there were many different definitions of severity of illness - some 
members defined this as a threat to life, the extent to which they can no longer carry on living life 
as normal, extent of suffering and presence of intolerable symptoms, illness on top of an impaired 
state of health and illness of long duration. However, the Council concluded 24 to 2 that the NICE 
advisory bodies should take into account of severity of illness and this should be taken into 
account alongside the QALY estimate rather than incorporating this within weights in the QALY 
estimate. 
In early 2009, supplementary guidance was published by NICE to take into account treatments at 
the end of life (NICE, 2009c). This was introduced to justify the use of medicines that are 
recommended when the estimate of cost-effectiveness was above a most plausible range. The 
supplementary guidance was produced with reference to the work of the Citizens council and 
previous appraisal committee decisions. The term end of life describes those technologies where 
the (i) the treatment is indicated for patients with a short life expectancy, normally less than 24 
months and; (ii) there is sufficient evidence to indicate that the treatment offers extension to life, 
normally of at least an additional 3 months, compared to current NHS treatment, and (iii) the 
treatment is licensed or otherwise indicated, for small patient populations. NICE does not 
operate a separate threshold range for those technologies meeting this criteria but considers the 
weight that must be applied in order that the most plausible ICER falls within the current 
threshold range used by NICE. 
The Kennedy report was commissioned to consider issues of innovation and other benefits of 
medical technologies later on in 2009 (Kennedy, 2009). The report recommended that NICE 
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should continue to use the explicit ICER approach but should consider relevant benefits. The 
report considered there may be some elements of other benefits such as severity of the illness 
and end of life that may not be taken into account in the current system and recommended that 
further research was undertaken to determine whether this was the case. The introduction of 
the new policy on value based pricing at the end of 2010 may result in criteria to weight a basic 
threshold depending on other considerations of benefit (Department of Health, 2010). The 
proposals include a basic threshold which would reflect the opportunity cost of the use of the 
new medicine and then three other criteria where a higher threshold would be given for; (i) 
Burden of illness - those disease with unmet need or that are severe would be given a higher 
threshold; (ii) Therapeutic innovation in comparison to other medicines would be provided with a 
higher threshold and (iii) Wider societal benefits. The final system will be introduced in 2014 and 
the final criteria are yet to be confirmed, including the value of the basic threshold. 
Scotland, SMC: 
The use of economic analysis is a central criterion in the SMC decision-making that provide 
advisory recommendations to the Health Boards in Scotland. The SMC does not operate a formal 
threshold and states that the cost per QALY is only part of a wider judgement of the value of a 
new medicine. The guide notes the importance of being transparent and explicit about the 
principles of decision-making but also must have flexibility to account for each individual 
particular case. The SMC makes note of the sections of the NICE guidance that state a plausible 
range for the threshold of between £20,000 to £30,000 which were reported in the previous 
section for England and Wales. 
The guide to manufacturers explicitly refers to other factors that are referred to as 'modifiers' of 
the decision when the committee considers the estimate of cost-effectiveness to be robust (SMC, 
2011b). The modifiers that are considered for approval of a high cost per QALYorphan medicines 
are: 
1. Evidence of substantial improvement in life expectancy (with sufficient quality of life to 
make the extra survival desirable). Substantial improvement in life expectancy would 
normally be a median gain of 3 months; 
2. Evidence of a substantial Improvement in quality of life; 
3. Evidence that a subgroup may derive specific extra benefit and the medicine can be 
targeted to that subgroup; 
4. No available therapeutic options provided by the NHS for the disease; 
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5. Potential bridging to another alternative therapy in a defined group of patients; 
6. Licensed alternative to an unlicensed therapy in Scotland for which the unlicensed 
therapy is the only option for the specific indication. 
The SMC committee may consider other special issues highlighted by the manufacturer, clinical 
experts or patient interest groups that do not fall into the other decision modifiers that are 
identified above. The VBP consultation by the Department of Health in England covers the SMC so 
it will be affected by the changes to the pricing and reimbursement system. 
The Netherlands, Dutch Health Insurance Board (CVZ): 
The principle of cost-effectiveness in the form of cost-utility analysis is one of four criteria used in 
the appraisal of medicines by the CVZ Board. The decision-making process separates the process 
for inpatient and outpatient medicines and the functions of appraisal and assessment. The 
assessment is provided by the CFH committee and the appraisal is provided by the CVZ Board and 
Appraisal Committee (ACP). The appraisal of economic analysis is only performed for those 
medicines that demonstrate an added therapeutic value and these are called class lB medicines. 
The Board provides advice to the Minister of Health, Welfare and Sport on the basic package of 
care to be included in the social health insurance. The Board can request consideration of the 
social impact by the Appraisal Committee (ACP) which was setup in 2008. The cost-effectiveness 
criterion must be weighted up in relation to the three other criteria which are necessity - whether 
the form of care delivers what is expected of it, effectiveness - whether the form of care delivers 
what is expected of it and feasibility - is inclusion in the package feasible, now and in the long 
term (CVZ, 2010b). 
The threshold has been made explicit by the Council for Public Health and Health Care (RVZ) that 
provides independent advice to the government on public health and care. The RVZ suggested 
that the cost-effectiveness should be weighted according to necessity in terms of burden of 
disease through a range or 'bandwidth'. The range varies from (10,000 for a limited burden of 
disease up to (80,000 for an extremely severe burden of disease (RVZ, 2006). These judgements 
were made on a number of observations including information from past decisions published for 
NICE in England and Wales (Devlin and Parkin, 2004). However, this has not been explicitly 
endorsed by the Ministry of Health, Welfare and Sport. 
A recent background study published by the CVZ provides guidance to the ACP on the meaning of 
cost-effectiveness in the appraisal in relation to the other three principles (CVZ, 2011a). The 
report was commissioned because of the lack of clarity with respect to the cost-effectiveness 
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criterion in decision-making. The report describes a list of factors that may be considered when 
weighting the role of cost-effectiveness in decision-making. Although the background study is not 
binding on the appraisal committee, it should be viewed as guidance for the criteria that are used. 
The table has been reproduced from the report (Table 4.5). 
Table 4.5: CVZ criteria that affect the retation of cost-effectiveness 
Criteria that affect the Interpretation of cost-effectiveness Increase the Make the cost- Should not be 
leniency with effectiveness included 
respect to the requirement 
cost- stricter 
effectiveness 
Source: (CVl, 20lla): Table. Criteria that playa role in assessing cost-effectiveness) 
The report stated that there is no threshold ceiling/cut-off point because there are other 
arguments in addition to cost-per QALY, to prevent manufacturer's strategic behaviour and a lack 
of consensus on how the price per QALY ought to be determined (a normative framework). 
However, it is suggested that many interventions lie within a range with a median value of 
(40,000 per QALY. The report states: 'cvz has set up a committee, the ACP, to examine per 
intervention, whether the value of the package principle 'cost-effectiveness' counterbalances the 
three other package principles (necessity, effectiveness and feasibility) and other possible 
arguments. In other words the committee does not determine cost-effectiveness, but assesses it 
with respect to all relevant arguments'. 
The criteria used in decision-making may relax the strictness of the cost-effectiveness criteria in 
the case of high burden of disease, rareness of condition, positive effect on informal care and 
when the condition is a public health risk. Burden of disease was not defined specifically under 
necessity because CVZ are yet to define this but the report refers back to the definition produced 
by the RVZ called 'proportional shortfall'. This makes a trade-off between the goals regarding 
equality in total and future health. It takes aspects of the fair innings argument that the size of the 
health gap is important but also considers the no treatment (severity) QALY expectation (Stolk et 
aI., 2005). There are then criteria that are considered to make the cost-effectiveness stricter 
when there is uncertainty about the appropriateness of the medicine. High risk behaviour and 
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certain patient characteristics should not be included in the interpretation of cost-effectiveness. 
The CVZ report suggests that there is a lack of clarity by which the budget is limited but suggests 
that there are a number of measures that restrict budget growth. The assumption of a limited 
budget will be at the discretion of the committee and states 'Cost-effectiveness could playa more 
prominent role if the committee feels that the budget growth is limited, than if the committee 
feels that budget growth is still possible. In the latter case, other arguments than cost-
effectiveness will gain the upper hand.' 
The appraisals of inpatient medicines follow a different process with respect to the appraisal of 
the economic analysis. The process was amended on the 1st of December 2010 and there is no 
initial analysis or appraisal of the cost-effectiveness at launch of the medicines included for 
hospital inpatient use (van Halteren, 2011). Those medicines that are either orphan medicines or 
expensive hospital medicines (at least (2.5 million to budget after 3 years) have provisional 
coverage (conditional coverage) for a period of four years and are initially appraised with respect 
to therapeutic value and budget impact. A proposal for outcomes research is produced. In this 
period data is collected in practice for the effectiveness of the medicine and is cost-effectiveness 
in usual practice. The economic model for real cost-effectiveness should be completed by the four 
year reassessment process. This is then appraised with consideration for the four principles 
referred to previously. The results of the first real cost-effectiveness assessments are due to be 
published at the end of 2011. 
Implied Cost-effectiveness threshold ranges: 
The documentation and search of the literature identified those reimbursement systems that do 
not explicitly provide a cost-effectiveness threshold but evidence has been provided of a cost-
effectiveness threshold. 
Australia, Pharmaceutical Benefits Advisory Committee (PBAC): 
There is no stated cost-effectiveness threshold or explicit range in Australia for use when 
appraising medicines. There are many factors taken into account and the guidance for submission 
categorises these as qualitative and quantitative factors (PBAC, 2008). The factors are not 
weighed equally and different factors may be more or less important depending on the situation. 
The quant~~ative factors include comparative cost-effectiveness, comparative health gain, patient 
affordability in the absence of the PBS and budget impact for the Pharmaceutical Benefits 
Schedule. Comparative cost-effectiveness includes both cost-minimisation analysis, incremental 
cost-effectiveness ratios including cost per natural outcome and cost-utility analysis. Comparative 
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health gain maybe included as both the effectiveness and toxicity and the magnitude of the effect 
and clinical importance. 
The qualitative factors include the uncertainty surrounding the evidence (types of studies, indirect 
comparisons, plausibility of assumptions), equity considerations such the equity implications of 
using cost per QALY analysis on a case by case basis, presence of effective alternatives, severity of 
the medical condition treated with respect to the nature and extent of the disease currently 
treated, ability to target the therapy in the proposed group of patients and the development of 
resistance. 
Henry et al. stated that although the Pharmaceutical Benefits Scheme does not operate a 
threshold value there is a correlative relationship between cost-effectiveness and the probability 
of rejection (Henry et al., 2005). The authors state that between 1994 and 2003 the highest cost 
per QALY at which a medicine was recommended was $52,400. However, PBAC does not solely 
consider QALYs as the only outcome measure and no comment is made about a threshold or 
range for other types of outcome. 
A report provided for the Commonwealth Fund states that t~e PBAC chair is on record as saying 
"That PBAC considers that an incremental cost-effectiveness ratio greater than AUS$SO,OOO per 
QALY a year would be on the high side." However, there have been a number of medicines with 
lower cost-effectiveness ratios that have not been approved because of the other factors that are 
taken into consideration in decision-making by PBAC (Lopert, 2009). 
Canada, Canadian Agency for Drugs and Technologies in Health Care (CADTH) Common Drug 
Review: 
The Canadian Expert Drug Advisory Committee (CEDAC) appraises both the clinical effectiveness 
evidence and the cost-effectiveness evidence for a new medicine to provide advisory 
recommendations. There is no explicit formal cost-effectiveness threshold for the Common Drug 
Review or details of how the appraisal of medicines is performed by the committee. The terms of 
reference for the CEDAC committee state that they are required to provide reasons for the 
recommendations in accordance with the procedure that has been established by CADTH (CADTH, 
2008). A common threshold figure that is cited is US $50,000 per QALY (Menon et al. 2009). 
Rocchi et al. considered whether an explicit or implicit threshold had been identified in the CEDAC 
deliberations of Canada's CDR process. However, ICERs were frequently not reported in the 
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recommendation guidance or the manufacturers estimate was not considered robust. There were 
25 recommendations included for which 12 were negative with a range of cost-effectiveness of 
between $32,000 to $137,000 per QALV and 13 were positive decisions with a range of ICERs of 
between $31,000 to $80,000 per QAl V (Rocchi et aI., 2008). 
Sweden, Pharmaceutical Benefits Board (TlV): 
There are three criteria that must be fulfilled if a medicine should be reimbursed (Health and 
Medical Services Act 15) which are the human value principle, need and solidarity principle and 
the cost-effectiveness principle. The Human Value principle considers the respect for equality of 
all human beings and the integrity of every individual. The TlV may not discriminate against 
people because of sex, race, age etc. when making a decision for reimbursement. The need and 
solidarity principle states that those in greatest need take precedence when considering 
reimbursement of pharmaceuticals. Individuals with more severe diseases are prioritised over 
people with less severe conditions. The cost-effectiveness principle states that the cost of using a 
medicine should be reasonable from a medical, humanitarian and social-economic perspective. 
The TlV Board must ensure that none of the three criteria are contravened. The Board primarily 
weighs up the need and solidarity principle with the cost-effectiveness principle. They must be 
weighed equally against each other as none of them have an absolute priority over each other. 
The cost-effectiveness criterion must be therefore weighed against the severity of disease 
(categorised on relevant, initial condition, risk of permanent injury or death without treatment 
with the medicine). The guidance states that the cost of the achieved relevant health benefit 
should be reasonable in proportion to the additional cost of the treatment (LFN, 2008). There is 
no formal explicit cost-effectiveness range. Persson et aL report that the principle of cost-
effectiveness requires determination ofthe willingness to pay for the health benefits (Persson et 
aI., 2010). The study reports that two different methods have been used to identify this, one using 
individual responses from a willingness to pay survey that resulted in a maximums of €40,OOO per 
QAl V, (Hjalte et aI., 2005) and one from a value of preventing fatality that resulted in a maximum 
of (70,000 per QAlV (Persson and Hjelmgren, 2003). 
Ireland, National Centre for Pharmacoeconomics (NCPE): 
There is no explicit cost-effectiveness threshold in practice in Ireland (Tilson et aI., 2010). The 
primary deCision criterion considered is that of cost-effectiveness. Although no threshold range is 
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stated, the experience of past decisions has demonstrated that medicines with an ICER of below 
€45,OOO per QALY have tended to be reimbursed by the Health Service Executive (HSE). Those 
medicines that have significantly higher cost-effectiveness estimates may have other factors that 
are taken into account. The other factors taken into account are the level of uncertainty 
associated with the clinical and cost-effectiveness evidence, the budget impact of the medicine, 
the innovative nature of the medicine and lack of available alternatives. 
Korea, Health Insurance Review and Assessment Service (HIRA): 
The DREC considers cost-effectiveness with respect to a number of other criteria which include 
clinical usefulness or value, international countries reimbursement status and guidelines and the 
budget Impact of the medicine. There is no explicit threshold reported in the HIRA documentation 
for the inclusion of medicines. The HIRA Reimbursement Committee has been reported to have 
drawn a discussion on the threshold and provided an implicit range of between 0.8 to 1.2 times 
that of GOP per capita (GOP per capita 2010 = 21.3million) which equates to a threshold of 
between 17 million to 26 million per QALY (Yang, 2009). Shiroiwa et al. reported the results of an 
international survey of willingness to pay for one additional QALY which included Korea. The WTP 
values for the Republic of Korea were estimated to be KWN 68 million (Shiroiwa et aI., 2010). 
New Zealand, Pharmaceutical Management Agency of New Zealand (PHARMAC): 
PHARMAC has no threshold below which a medicine will be considered cost-effective (Metcalfe 
and Grocott, 2010). This is because cost-effectiveness is only one of nine criteria (PHARMAC, 
2010a). The threshold is also likely to vary year on year with changes to the fixed budget. 
PHARMAC uses the following decision criteria: 
1. The health needs of all eligible people within New Zealand. 
2. The particular needs of Maori and Pacific peoples. 
3. The availability and suitability of existing medicines and related products 
4. The clinical benefits and risks of pharmaceuticals. 
s. The cost-effectiveness of meeting health needs by funding pharmaceuticals, rather than by 
using other publicly funded health and disability support services. 
6. The budgetary impact (in terms of the pharmaceutical budget and the Government's overall 
health budget) of any changes to the Pharmaceutical Schedule. 
7. The direct cost to health service users. 
8. The Government's priorities for health funding, as set out in any objectives notified by the 
Crown to PHARMAC, in PHARMAC's Funding Agreement, or elsewhere. 
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9. Any other criteria that PHARMAC thinks are relevant. The PHARMAC will conduct a consultation 
whenever taking into account other criteria. 
The past decisions have shown that the cost-effectiveness for those approved medicines has 
ranged between -NZ$40,OOO to NZ$200,OOO per QALY. The authors state that this would imply a 
threshold based on the estimates of NZ$200,ooO that they state is clearly not the case because of 
the other factors that are taken into account in decision-making (Metcalfe and Grocott, 2010, 
Simoens, 2009). 
No stated or observed threshold identified for countries using cost-effectiveness: 
There were 11 agencies or institutions websites that did not report an explicit threshold. A search 
of the literature was conducted to identify any studies conducted with implied a threshold for the 
reimbursement of medicines, where literature could not be identified the agency was contacted 
to identify whether an explicit or implicit threshold is in operation. 
The literature identified stated that threshold ranges were not in operation in: 
• Austria (KeE, 2010); 
• Belgium (KCE, 2008); 
• Denmark (Sorenson, 2oo9b); 
• Israel (Greenberg et aI., 2009); 
• Italy (Ettelt et aI., 2007); 
• Hungary (Sorenson, 2009a); 
• Poland (Sorenson, 2oo9a). 
There were responses from three of the countries emailed that confirmed that no explicit 
threshold range is in operation in Finland (Personal Communication: Blom, 2011), Norway 
(Personal Communication: Svanqvist, 2011), Portugal (Personal Communication: leite, 2011). No 
indication of either at threshold range could be identified from the literature and to date there 
has been no was obtained from the institutions in Mexico. 
4.3.2.5 Explicit and Implicit threshold ranges In relation to other factors 
There are differences between countries with respect to the stated threshold ranges, the 
methods of elicitation of implicit ranges and the time period and medicines from which these 
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were elicited (Table A4.10). England, Scotland and Ireland consider other factors when the 
threshold is in the upper end of the threshold ranges, whereas the Netherlands, Australia and 
Sweden weight cost-effectiveness evidence in relation to other factors regardless of the estimate 
of cost-effectiveness. The countries all recognise the fixed budget assumption but the 
Netherlands states that the committee may judge whether the budget is constrained for each 
individual decision. The uncertainty surrounding the evidence was a stated factor in Australia, 
Scotland, England, Ireland and Korea. 
A number of countries consider factors that relate to equity. Equity is an ethical concept and has 
no precise definition (Stolk et aI., 2005). These factors were grouped under equity concerns and 
concepts that include severity of medical conditions, need, human value principle of equality, end 
of life and general statements of the consideration of equity. Of those countries with evidence of 
a threshold range, these concepts were stated decision factors in England and Wales, the 
Netherlands, Australia, New Zealand, Korea and Sweden. 
There were other economic considerations such as budget impact and patient affordability. The 
other considerations were more country specific and included innovative nature of the medicine, 
alternative medicine present, international reimbursement status, feasibility, governments set 
priorities for health spending, patient perspective and other special criteria. 
4.3.2.6 Content and documentation of decision 
The appraisal documents are communicated on the website of the committee that is responsible 
for deliberations in many of the countries. There is no evidence of the details of the deliberations 
being publically available in Finland, Israel, Italy, Hungary, Mexico, Portugal, Spain, Korea and 
Switzerland. (See Table A4.4). 
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4.3.3 Output and implementation of the decision 
4.3.3.1 Reimbursement systems decision outcomes 
The systems decision outcomes are either mandatory decisions or advisory recommendations for 
prescription and reimbursement. These are considered with respect to the institution or 
committee that appraises the evidence and other factors and produces a decision for use in the 
system or recommendation to the Ministry of Health or other institution that decide the final 
decision. The reimbursement decision outcomes may be characterised with respect to a number 
of different dimensions, the type of list produced (negative/positive), the decision outcome and 
the level of copayments. 
Positive lists operate in 22 of the 24 OECD countries where medicines included in the positive list 
are only available for prescription and reimbursement by the public system. There are also 
individual reimbursement schemes that operate in Austria, Denmark and Norway. The individual 
reimbursement schemes allow the clinician to apply on behalf of the patient for reimbursement 
of a medicine that is not included within the positive list of medicines (Table A4.11). 
Negative lists operate in Germany and England and Wales and in addition to the positive list a 
negative list operates in Austria, Hungary, Scotland and Spain. Negative lists are lists of medicines 
that may not be prescribed by the clinician for funding by the public reimbursement system. In 
Scotland, England and Wales, the negative list can be described as more of a 'partial' negative list. 
This is because in Scotland the list is provided by the recommendations made by the SMC that 
should not routinely be made available by the NHS Boards. There may be exceptions where the 
Health Boards have a written policy for exceptions where individuals can receive reimbursement 
for the medicine (Health Policy and Strategy Directorate, 2010). Similarly, in England and Wales, 
NICE 'not recommended' medicines should not be routinely prescribed and reimbursed by the 
NHS and the ultimate decision lies with the clinician responsible for the patient. This means that a 
clinician can prescribe any licensed medicine if the local funder (currently the PCT) is willing to pay 
for the medicine (Department of Health, 2011). 
The restrictions may generally be classified according to a decision to list or recommend the 
medicine, restrictions as defined by the agency and either not listed or not recommended. 
However there are differences between the systems with respect to the numbers of types of 
restriction, . definition of the restrictions and requirements for outcomes based conditional 
reimbursement. There are a number of countries that include restrictions on the reimbursement 
decisions either with respect to the indication or characteristics of patients prescribed with 
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respect to the marketing authorisation or by prescription or authority of a specialist. The 
restrictions may sometimes be referred to as 'conditional reimbursement' or 'limited 
reimbursement' but to avoid confusion with other concepts (conditional outcome based 
coverage) these will be described as restricted decisions or recommendations in each 
reimbursement system. The recommendations for listing may be restricted by indication or the 
characteristics of the patient in reference to the marketing authorisation in nineteen countries 
and the use of restrictions was not identified in five of the countries national reimbursement 
systems (Table 4.6). 
Table 4.6: Systems decision outcomes 
Decision outcome may Include restrictions No restriction on decision outcome 
Australia France 
Austria Hungary 
Belgium Israel 
Canada Korea 
Denmark Mexico 
Finland Spain 
Germany 
Ireland 
Italy 
Netherlands 
New Zealand 
Norway 
Poland 
Portugal 
Sweden 
Switzerland 
England and Wales 
Scotland 
NICE in England and Wales did not provide a system for officially categorising the 
recommendations until 2010. The NICE decision outcomes have a type of restricted decision 
called 'optimised decisions' which were introduced in 2010 and are technically different to 
restricted decisions in other systems. The 'optimised decision' represents the case where the 
recommendation has a material effect on the use of the medicine and it is recommended in a 
smaller subset of patients than the marketing authorisation. The definition of materiality provided 
is "test of materiality takes into account advice from clinical experts on the anticipated use of the 
technology in routine practice" (NICE, 2011e). This means that a decision that there may be 
situations where a medicine categorised as a restricted listing decision in one of the other 
reimbursement systems would be categorised as a 'recommended' decision by NICE in England 
and Wales. 
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There are further restrictions that may apply for use or approval for reimbursement. The decision 
outcomes provided in Scotland and the Netherlands can require that only a specialist prescribes 
the medicine. There are further approval processes for some decisions in Australia, the 
Netherlands and New Zealand. In Australia the scheme is called 'authority required' where the 
medicine can only be prescribed once approval has been gained from either Medicare Australia or 
the Australian Government Department of Veterans' Affairs (PBAC, 2008). In New Zealand a 
similar process operates for some decision outcomes where 'special authority' may be required 
where an application is made for an individual for the listed medicine. The criteria for special 
authority are included alongside the listing of the medicine (PHARMAC, 20Uc). 
There are a number of systems where performance-based schemes are agreed between the 
reimbursement body and the manufacturer. These can be categorised as either non outcomes 
based schemes and health outcomes-based schemes (Carlson et aI., 2010). The health outcome-
based schemes can be further categorised into conditional coverage and performance linked 
schemes. Since the focus of the framework is to categorise the reimbursement decision outcomes 
the focus will be on the conditional coverage schemes rather than the performance-linked 
schemes which focus on the price of the medicine. There are a number of systems that have 
formal coverage with evidence development processes either by condition the decision on 
require further evidence to be collected or by only allowing prescription for those patients who 
are participating in research. 
Coverage with evidence development schemes operate where the decision allows the medicine to 
be prescribed on the condition that further evidence is provided in Belgium, Sweden, France, 
Netherlands and Poland. The use of coverage with evidence development is central to the 
process of reimbursement for inpatient medicines in the Netherland. Those medicines on the 
Expensive inpatient Medicines are assessed with evidence collected four years after launch for 
the real life cost-effectiveness. HAS in France requests post-listing studies as a condition for the 
reimbursement of medicines and reassesses the medical benefit (SMR) 5 years after their initial 
decision. In Sweden the recommendation can be conditioned with the requirement for the 
manufacturer to provide within a specific period a study to show how the medicine is used in real 
clinical practice with supplementary information on the clinical effect and the cost-effectiveness. 
Similarly, those recommendations provided in Belgium for Class 1 medicines that are claimed to 
demonstrate added therapeutic value may be required additional evidence to demonstrate the 
clinical effect and real life cost-effectiveness between 18 and 36 months. 
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The coverage with evidence development scheme in England and Wales is called 'Only in 
Research' and is the fourth category of NICE decisions in addition to recommended, optimised 
and not recommended. This is where insufficient evidence has been collected at the appraisal but 
the committee has judged the medicine to be promising but further research is required. The 
medicine may only be used in the context of a research study such as a clinical trial which is 
designed to reduce the evidence uncertainties (NICE, 2011e). PBAC1 in Australia and CADTH in 
Canada can also request that the decision is deferred while further information or clarification of 
the data on the medicine is provided. 
The level of copayment is important in determining the budget impact of the medicine on the 
public health system, implications for the equitable use of medicines depends on the payment 
and to prevent moral hazard in insurance based systems. There are no copayments required in 
Scotland (prescription fee recently abolished) and for medicines with added therapeutic value in 
the Netherlands (CVZ, 2011b). In other systems there are a number of types of copayments across 
systems where either a fixed prescription charge is paid, percentage of the price of the medicine 
or more complex systems where a percentage of the price of the medicine is paid up to a 
maximum ceiling level (Table A4.11). 
4.3.3.2 Status of the national reimbursement decision or recommendation outcome 
The decisions provided by the national institutions are final decisions with a legal basis for 
inclusion in the positive lists in Austria, Belgium, Denmark, Germany, Italy, Hungary, New Zealand, 
Norway, Sweden, Israel, Finland, Spain and Switzerland. 
The reimbursement recommendations are of an advisory nature by PBAC in Australia, HAS in 
France, CVZ in the Netherlands, AHTAPol in Poland, INFARMED in Portugal and HIRA in Korea. The 
final reimbursement decisions are made by the Ministry of Health taking into account the 
reimbursement bodies recommendations. These are then included within the positive list 
schemes in operation in each of these countries. 
In England and Wales the final decision for reimbursement depends on the NICE guidance and the 
clinician. The NHS in England and Wales is legally required to provide funding for medicines that 
are recommended for reimbursement normally within 3 months of the decision by NICE where 
the medicine is deemed appropriate by a clinician for a patient (NICE, 2011d). As discussed earlier 
the not recommended decisions should not normally be prescribed in routine practice but 
1 The Government has recently started to defer listing of medicines that have been judged to be recommended by the PBAC for listing 
because of the forthcoming budget cuts that are required. April 2011: http://parliamentflagpost.blogspot.com!2011!04!making-
~avings-from-pbs-Is-deferring.html 
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exceptions can be made when funding is available and it is considered appropriate by the 
clinician. NICE does not provide recommendations for all medicines and the decision for these 
medicines will depend on the clinical and local funder. The Scotland process of reimbursement 
partially overlaps with the recommendations provided by NICE for some MTAs. The NHS Quality 
Improvement in Scotland is involved in the NICE MTA process and reviews the guidance using 
experts for applicability in Scotland. The NHS QIS will validate whether the recommendations are 
appropriate for Scotland and Health Boards are required to normally provide these routinely (a 
SMC recommendation is therefore not required). The recommendations for other new medicines 
made by the SMC are considered by the NHS ADTC Boards in Scotland and will either provide the 
medicine in the formulary or not recommend if an existing equivalent treatment option is already 
available in the formulary (Health Policy and Strategy Directorate, 2010). 
The decisions made for the Basic Formulary and Catalogue of Inputs produced at the national 
level in Mexico must inform the basis of the social insurance institutions formularies and are only 
part of the final decision for inclusion in each of the positive lists. The Common Drug Review in 
Canada provides advisory recommendations to the drug plans and these can decide the formulary 
listings on the basis of their local priorities. 
4.3.3.3 Appeal and dissent 
The majority of countries have some form of mechanism of appeal or dissent for the 
reimbursement decisions but these differ in the number of stages, the stakeholders that are 
entitled to appeal and the grounds for appeal (Table A4.12). 
The manufacturer is the only stakeholder entitled to appeal the decisions made by many of the 
reimbursement bodies. The CDR process allows both the manufacturer and the drug plans for 
which the recommendations to request reconsideration by the CEDAC committee. The CVZ has a 
"participation procedure" where the manufacturer and those of that the chairman regards as 
stakeholders can respond to the draft advice before the final recommendation. The final decision 
made by the Ministry of Health maybe appealed on procedural grounds. There are three different 
types of stakeholders that can appeal in the NICE process in England and Wales which are 
referred to as consultees (National body representing patients, bodies representing health 
professionals and the manufacturer). 
There are· independent appeal committees that operate in separately providing the 
reimbursement decision in Austria (Independent Drug Commission UHK), Ireland (Expert 
Committee), Hungary (Appeal Committee) and Switzerland (Appeal Commission). The appeal 
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committee operates within the responsible agency in England and Wales, NICE (Appeal Panel) on 
procedural grounds and within the SMC (Independent Review Panel) to review the existing data 
and analyses. 
The NICE website contains the most detailed information on the appeals process for technology 
appraisals (NICE, 2011c). An appeals panel is appointed by the appeals committee. The consultees 
can make an appeal within 15 days of the release of the provisional guidance on any of the 
following three grounds; 1. The Institute has failed to act fairly where the appellant believes that 
they the process has not been followed as set out in the NICE technology appraisal process guide. 
This does not consider unfairness in the sense that it is unfair that the treatment is not provided 
to patients, 2. The Institute formulated guidance which cannot reasonably be justified in the light 
of the evidence submitted. This means that the recommendations produced are "unarguably 
wrong, illogical, or so absurd that a reasonable Appraisal Committee could not have reached such 
conclusions." 3. The Institute has exceeded its powers in relation to the directions and guidance 
issued by the Secretary of State for Health in England and Wales. There are three options for the 
outcome of the appeal; 1. Appeal upheld and Final Appraisal Documentation (FAD) returned to 
the Appraisal Committee, 2. Appeal Panel request alteration to the FAD but no further 
consideration by the Appraisal Committee or 3. The appeal is dismissed. There is no possibility for 
further appeal and the final guidance may be challenged by applying to the High Court in England 
and Wales for a judicial review. 
The manufacturers can provide a resubmission or request the formation of an Independent 
Review Panel (IRP) to appeal advice produced by the SMC (SMC, 2011d). The IRP route can be 
used when there is no significant new data or analyses but the manufacturer would like the SMC 
to look at the existing data and analyses. The IRP comprises 3 members not previously involved in 
the advice from the SMC and 4 members form the Scottish Area Drug and Therapeutic 
Committees). The IRP provides a review of the clinical and health economics assessment and will 
report back to the SMC Board that makes the final decision on these cases. 
In cases where the reimbursement body provided advisory recommendations in Australia (PBAC) 
and Canada (CDR on procedural grounds) the procedure allows the manufacturer to provide a 
resubmission or reconsideration rather than a formal appeal procedure. The HAS reimbursement 
agency is also advisory in France and provides manufacturers with hearings following a 
recommendation. They can then appeal a final decision by the Ministry of Health to the 
Administrative Courts. The manufacturer is able to resubmit to the GHC in Mexico, although there 
does not appear to be any other appeal process. In New Zealand and Korea, the manufacturer 
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may reapply and/or make an appeal to the countries respective Courts. The appeal procedure in 
Belgium (procedural grounds), Finland, Netherlands, Portugal and Sweden was by the countries 
Administrative Courts. The Ministry of Health is responsible for the appeal decision and process in 
Denmark (procedural grounds) and Norway. The German system is unique in that following the 
lack of a price being agreed in arbitration, the manufacturer and the sickness funds can request a 
cost-benefit analysis following a lack of agreement on price. There does not appear to be any 
formal mechanism for appeal in Germany. 
There were no mechanisms identified from the published process guides for reimbursement 
systems in Israel, Italy, Poland and Spain. 
4.3.3.4 Requirements for re-appraisal and monitoring of medicines 
The requirements for reappraisal are considered with respect to the agency or body that 
previously provided the reimbursement appraisal of the evidence amongst criteria for providing 
either reimbursement recommendations or decisions for the medicine. There are a variety of 
processes for the reappraisal of mediCines and these countries have been grouped into three 
broad categories; process allows the manufacturer to provide a resubmission but the 
reimbursement body does not have a procedure for reappraisal, the body responsible for 
reimbursement appraisal decides reimbursement overtime and does not specify a process time 
period for reappraisal and finally those countries that specify a time period for the reappraisal of 
medicines (Table A4.13). 
There are processes where the manufacturer may resubmit to the body responsible for 
reimbursement but the body does not specify a reappraisal procedure for medicines. This process 
operates mainly in reimbursement systems where the agency appraising the evidence provides 
advisory recommendations to the respective authorities, Ministry of Health in Australia (PBAC), 
Hungary (TAC) and Israel (Medical Technologies Administration), HSE in Ireland (NCPE) and local 
health boards or drug plans in Canada (CDR) and Scotland (SMC). The majority of these systems 
require the manufacturer to provide new evidence with the exception of the CDR process where 
in addition to new evidence the manufacturer may submit a new price during the embargo period 
(CADTH, 2010). 
There are syste~s where the body responsible for reimbursement appraisal does not specify a 
time period for the reappraisal but reviews the medicine over time. Those medicines that are 
perceived to no longer meet set criteria such as the medico therapeutic and health economic 
criteria are reappraised in Austria (HEK), are no longer prescribed or another product has been 
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included with greater efficacy or lower toxicity in Mexico (GHC), no longer meet criteria in New 
Zealand (PHARMAC) and Norway (NoMA). There are then countries that provide criteria for those 
medicines that should be prioritised for reappraisal. In Denmark, the DMA prioritises the 
medicines according to the significance of the medicine to the primary sector, public health 
considerations, new evidence and the medicine is found to have high costs or high consumption. 
In Korea, HIRA re-appraises medicines by therapeutic class and uses fewer prioritisation criteria 
that include growth in the use of the medicine and the budget impact of the medicine. The G-BA 
in Germany may reappraise medicines when significant new evidence becomes available. 
Additionally, PHARMAC in New Zealand, G-BA in Germany 12 months after the decision and HIRA 
in Korea also allow the manufacturer to resubmit when new evidence becomes available. 
In Sweden (TLV) medicines following conditional reimbursement are reappraised and a review of 
2,000 medicines was undertaken, reviewing one therapeutic area at a time to decide eligibility 
when the reimbursement system was reformed in 2002 (LFN, 2007). There is an ad-hoc review of 
medicines in the new system and the manufacturer is contacted with regards each case. 
In England and Wales (NICE) a proposed review date is provided on the guidance document. NICE 
decide the review date based upon the available evidence in the medicines guidance publication 
and any knowledge about when ongoing research will be reported (NICE, 2008). NICE may review 
the guidance earlier than the proposed date if significant new evidence becomes available. If a 
large amount of evidence is available the guidance will be reviewed by a guidance document or 
within a clinical guideline and if there is little evidence may be assigned as static guidance, 
deferred to a future date, or incorporated into a guideline. 
There is a time specific reappraisal process for which medicines are reviewed which ranges from 
between 1 year and 5 years in Belgium, Finland, France, Netherlands, Poland, Portugal, Spain and 
Switzerland. Some of these reimbursement systems operate processes of coverage with evidence 
development (CEO) for those medicines where there was judged to be uncertainty. Coverage with 
Evidence Development represents a specific approach to coverage for promising technologies, for 
which the evidence remains uncertain (Hutton et aI., 2007). The technologies are provided under 
conditions of generation of further evidence for a defined period after which these are reviewed. 
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Chapter 5: A retrospective analysis of factors 
commonly associated with reimbursement decisions 
in those • agencies • uSing clinical and cost-
effectiveness evidence for the appraisal of cancer 
and cardiovascular medicines 
Abstract 
Objectives: Clinical-effectiveness and cost-effectiveness evidence explicitly informs alongside 
other factors, the decision to recommend a medicine by committees in many established public 
national reimbursement agencies. National agencies stated factors and the details of past 
decisions, increasingly allow manufacturers to make more efficient investment decisions and 
develop new medicines that are determined to be of sufficient value to society. The objective of 
this study is to explore whether there are common factors used to consider the value of a 
medicine and determine reimbursement across countries with similarities in evidence 
requirements and objectives. 
Methods: A pooled sample of 189 appraisals for cardiovascular and cancer medicines for four HTA 
agencies were considered. This was analysed using mUlti-response models for all appraisals and a 
sub-sample that provided cost-utility estimates. 
Results: The results demonstrated that different factors were important for different types of 
decision. The number of RCTs, publication date and sensitivity analysis were found only to be 
important in a not recommended decision, whereas budget impact was only important for 
restricted decisions. The public interest and type of medicines were important for both restricted 
and not recommended decisions. The type of economic analysis and cost-utility estimate were 
not found to be statistically significant. 
Conclusions: The factors in this study explain some of the variation in reimbursement decisions 
across countries. Further variation may be explained by differences in the countries values, 
processes and institutions within which decisions are made. The type of quantitative analysis may 
not adequately be able to control for non-evidence factors and process which could potentially 
explain variability in decisions within and across these countries. 
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5.1 Introduction 
Over the last 20 years, national reimbursement agencies have been established in many 
developed countries with the complex task of assessing the value of a medicine and deciding 
whether this is sufficient to be recommended for use. Reimbursement agencies state factors for 
establishing the value of a medicine but differ in the transparency in the reporting of the 
considerations and the factors. The Pharmaceutical Benefits Advisory Committee (PBAC) in 
Australia, Common Drug Review (CDR) in Canada, National Institute for Health and Clinical 
Excellence (NICE) in England and Scottish Medicines Consortium (SMC) in Scotland provide the 
criteria informing decisions and are considered established agencies with respect to economic 
evaluation methods (Barbieri et aL, 2010). These established reimbursement agencies all consider 
whether a medicine can be considered value for money and in some circumstances will judge the 
medicine with respect to other criteria such as the innovativeness of the medicine, disease 
severity or high level of unmet need. The stated criteria of these agencies and an understanding 
of the factors that influence past actual decisions, increasingly allow manufacturers to make more 
efficient investment decisions and develop new medicines that are determined to be of sufficient 
value to society. The past decisions can be used to understand and establish the demand curve in 
those countries using health economic analysis. 
There is limited quantitative evidence of the factors influencing past decisions for the national 
reimbursement agencies in Australia, Canada, England and Scotland. Three quantitative studies 
have been conducted for the relative influence controlling for factors, two for NICE decision-
making (Dakin et aI., 2006, Devlin and Parkin, 2004), and one for PBAC decision-making (Harris et 
aL, 2008). One further mixed method study considers a comparison of CDR, PBAC and NICE 
decision-making, identifying some factors that were important across countries and some factors 
within countries but this was a univariate analysis without any analysis to control for the effect of 
each factor (Clement et aL, 2009). 
The studies have considered different aspects of the clinical considerations with respect to the 
characteristics of the clinical evidence finding these to be important (number of RCT's, clinical 
endpoint) (Dakin et aL, 2006, Harris et aL, 2008). One study demonstrates differences in the 
impact of uncertainty surrounding decision-making being important for CDR and PBAC but 
unimportant for NICE decision-making (Clement et aL, 2009). 
All of the studies reported that the cost-effectiveness estimate was important for decision-making 
(Clement et aL, 2009, Dakin et aL, 2006, Devlin and Parkin, 2004, Harris et aI., 2008). In addition, 
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the studies reported evidence of a cost-effectiveness threshold range for NICE, PBAC, CDR, with 
the exception of Harris et al. where the authors described the threshold range as mediated by 
other factors in decision-making. For NICE decision-making, a pooled sample of cost per QAlY 
gained (CQG) and cost per life year gained (ClG) demonstrated that the threshold based on 
previous decisions was between £35,000 and £57,000 per QAlY; higher than the currently 
declared threshold range of between £20,000 to £30,000 for NICE in England. The uncertainty in 
decision-making has been captured through a different variables relating to the outcomes of the 
sensitivity analysis (Devlin and Parkin, 2004, Harris et aI., 2008) or through a subjective 
assessment of whether the economic analysis was uncertain (no uncertainty, some uncertainty, 
considerable) (Clement et aI., 2009). 
There has been a focus on some common factors within each of these single country studies. 
These studies provide evidence that some factors are influential in decision-making, irrespective 
of whether the decision was made in Australia, Canada or England. However, the factors 
considered conceptually important for these countries national reimbursement agencies have low 
explanatory power. The low explanatory power maybe because of the studies small sample size or 
construct of quantitative variables that do not measure the decision-makers criteria applied or 
may legitimately indicate the actual relevance of each factor in the decision process for each 
country. 
5.2 Objectives 
The aim of this study is to examine the common factors influencing the past decisions for 
cardiovascular and cancer medicines used by fourth hurdle agencies that use cost-effectiveness 
and clinical effectiveness evidence. As described in chapter 3, Hutton et 01. (2006) explained the 
term 'fourth hurdle' as the manufacturers' perception of the value for money criterion as an 
additional market access barrier, after demonstrating the quality, efficacy and safety of a 
technology to obtain a marketing license. 
This study considers elements of the clinical and cost-effectiveness considerations and other 
factors that can be consistently obtained across a number of countries using broadly similar 
decision-making criteria. The rationale for the pooled analysis is to firstly explore whether there 
are factors in decision-making that are important for determining the value of a new medicine 
regardless of the country for which the decision was made when the agencies have broadly 
similar evidence and requirements. Secondly the pooled analysis will allow a larger sample size to 
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assess additional factors that have not been previously explored. Influence will be defined as the 
correlation or association between the factors and the decision outcomes. 
The technology appraisals included were undertaken to inform decisions taken by the National 
Institute for Health and Clinical Excellence (NICE) in England, the Common Drugs Review (CDR) 
and Joint Oncology Drug Review (JODR) in Canada (for non-supportive care cancer medicines) 
informed by the CDR, the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia and 
the Scottish Medicines Consortium (SMC) in Scotland. Those published prior to February 2008 
were included. 
The countries share the following similar characteristics: 
The agencies are established within similar economic environments with GOP per capita ranging 
from $32,961 in the UK to $36,814 per capita in Canada. Each country's health system is funded 
largely through a publicly-funded tax-based system with broadly similar objectives of making 
decisions on the basis of value for money; 
1. The agencies are established with processes and guides to their submission process with 
documentation of the decisions available, Australia (PBAC, 2008), Canada (CADTH, 2010), NICE 
(NICE, 2008), SMC (SMC, 2011b); 
2. The manufacturer makes an initial submission to the agency that includes an economic analysis. 
This is the primary source of the economic evidence. NICE is an exception where an independent 
assessment group or evidence review group produces an additional economic appraisal and/or a 
critical review of the manufacturer's model; 
3. The type of economic appraisal is broadly similar across the agencies. CADTH CDR, JODR 
(cancer medicines for which CDR contributes to reviews), PBAC and the SMC specify in their 
guides to submitting evidence that CUA Is the generally preferred form of economic analysis but 
they will consider other forms such as cost-effectiveness analysis using other measures of health 
benefit. Current NICE technology appraisal guidance stipulates that in their reference case the 
QALY should be the only measure of health effect (NICE, 2008). This agency has not always 
required this and some older appraisals of medicines contain other forms of economic analysis 
such as CEA. All agencies require their committees to consider whether they deem the medicine 
to be value for money with respect to other the appropriate alternative when making a decision. 
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5.3 Methods 
5.3.1 Sample of decisions 
The appraisals/evaluations were selected from reimbursement agencies which were known to 
make systematic use of economic analysis; had well-established processes; and provided 
sufficient public documentation to allow relevant data to be collected for the analysis. This 
reduced the heterogeneity with respect to the type of economic analysis used, although there 
was substantial variability in the detail of reporting between agencies and within agencies over 
time. 
Because the interest was in the influence of decision-making criteria and methods rather than the 
medicines themselves, appraisals were selected from two clinical areas. This limited the potential 
variation that would be seen in a study across disease areas, but the variation within the two 
disease areas should reflect how the decision-making criteria are applied across the countries. 
Medicines to treat cardiovascular disease and cancer were included as they provided a large 
sample of documented evidence for two disease areas that had been captured across all four of 
the agencies considered. This numerous pharmaceuticals appraised for these diseases reflected 
the fact that the two disease areas featured in the top 5 causes of death for these countries. 
5.3.2 Decision-making factors 
The decision-making factors were considered by the characteristics of reimbursement systems 
considered conceptually important by international decision-makers, (Hutton et aI., 2006), 
consideration of the stated criteria by each of the agencies by reference to their websites and 
guidelines and the factors that were commonly included across the previous retrospective 
studies. The research aimed to collect information on all conceptually important quantitative 
variables across countries but this depended upon sufficient similar documented evidence in the 
public reports and also how appropriate it was to transform some qualitative aspects of decision-
making into quantitative variables. The factors were categorised into three main groups: 
1. The first set of factors are described as the 'evidence factors' considered for each technology 
assessed at the "Individual technology decision level' (Hutton et aI., 2006). These include the 
clinical evidence, economic evidence and budget impact. 
2. The second set of factors relate to the policy context of the decision including the health 
system and country specific characteristics that are not related to the evidence called the 'non 
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evidence factors'. The non-evidence factors include the disease area, patient views and public 
interest. 
3. The third set of factors relate to the process of decision-making at the individual technology 
decision level called the 'process factors' that are common across the agencies processes such as 
review of previous appraisal, patient group involvement and time at which the decision was 
made. 
The definitions of the variables are given in Table AS.l. The dependent variables relate to the 
recommendation/decision outcome for each of the agencies. The multinomial regression was 
used to enable classification of the decisions into three categories rather than two 
(recommended/not recommended) as this was considered to be a more realistic representation 
of the decision outcome for the four agencies - recommended fully (as per licence), restricted 
recommendation (restricted to a patient subgroup of the regulatory licence) and not 
recommended. PBAC and SMC assess and appraise medicines following a single process whereas 
separate processes operate in SMC and a separate committee in Canada for cancer medicines 
called the Committee to Evaluate Drugs (CEO) which is informed by the CDR but is part of the 
JODR. NICE has two processes in operation, Multiple Technology Appraisal (MTA) and Single 
Technology Appraisal (STA). For the NICE, MTAs the recommendation for each medicine and 
indication was included as a separate decision, and the data relevant to each case was extracted 
from the reports. 
A factor can be considered either as an evidence, non-evidence factor or process factor that may 
influence the appraisal decision. Influence or impact will be defined as association between a 
factor measured by an independent explanatory variable and the decision controlling for other 
factors. Causation is therefore not assumed by this analysis. An 'evidence factor' - a characteristic 
of the medicines evidence (clinical efficacy, clinical effectiveness and cost-effectiveness), 'non-
evidence factor' - other value judgement applied because of a characteristics of the medicine that 
influences the decision (type of medicine) or 'process factor' - common characteristic shared with 
respect to the process of assessment within countries reimbursement processes (time period, 
review/resubmission of medicine). Sixteen explanatory variables were included in the analysis: 
1. Evidence Factors: 
• Evidence included RCTs 
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• RCT number 
• Evidence included observational studies 
• Type of economic analysis 
• ICER from economic analysis 
• Sensitivity analysis performed 
2. Non-evidence Factors: 
• Disease Area 
• Public Interest 
3. Process Factors 
• Time since guidance published 
• Patient group submission 
• Number of patient groups submissions 
• Review of previous appraisal 
• Country dummy variable (3 dummy variables) to control for other process factors unique 
to each countries reimbursement system 
Evidence factors 
Clinical evidence: The number of RCTs used in each technology appraisal was taken from the 
documentation available for the appraisal. This variable is a proxy for the strength of the clinical 
evidence and the willingness of the agency to use it to guide the decision-making. This does not 
necessarily mean the total number of RCTs of the technology, but those RCTs that the agency 
deemed important and appropriate for reporting in the appraisal. The effect size had been 
included as a separate factor in other studies but, as this has been captured within the estimate of 
the ICER value, we deemed this inappropriate and would be related to the CQG. 
The clinical evidence has been accounted for in other single country analysis by other variables 
such as the quality of the evidence and the judgements surrounding the uncertainty of the clinical 
evidence. However, the inclusion of these variables in this multi country analysis was problematic 
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for a number of reasons. The lack of reporting of information in the public documentation across 
these agencies does not allow a consistent objective variable to be constructed that can robustly 
captures the quality of evidence and uncertainty (with the exception of NICE) across the agencies. 
In the examination of quality of studies in the case of NICE, (Dakin et aI., 2006) found that the 
variables associated with characteristics of the RCTs, such as the quality, size and significance of 
effect were not found to be statistically associated with the decision and were also found to be 
correlated with each other and this could potentially bias the findings of the relative influence. 
The lack of association may be explained by the association between the quality variables or the 
fact that many elements of assessing clinical uncertainty require judgements which are difficult to 
summarise within a number of independent quantitative variables. The use of quality indices for 
RCTs, such as the Jadad score, has been explicitly discouraged by the Cochrane Collaboration for 
assessing the quality of trials and risk of bias. The Cochrane handbook (Higgins and Green, 2008) 
recommends that a domain based approach would be most appropriate for assessing the quality 
of RCT evidence, but this would be very difficult to introduce into this type of quantitative 
analysis. 
The uncertainty in clinical evidence has been captured explicitly in one other study by a subjective 
assessment by the authors of the uncertainty present from the documents and classifying this as 
none, some and considerable (Clement et aI., 2009). The construct of such a variable is flawed for 
a number of reason, firstly, the documentation for each of the countries does not provide 
sufficient information on the qualitative judgment of uncertainty nor to provide a subjective 
judgement of the uncertainty, the variable introduces a second level of uncertainty and bias by 
the researchers interpretation of the public documentation and the category of 'none' in the 
study is nonsensical because all clinical evidence is subject to some level of uncertainty. It was 
therefore considered inappropriate to construct such a variable across these agencies that would 
be sufficiently meaningful. 
Economic evidence: This study considers the type of economic analysis considered by the agencies 
in two groups; analyses using cost-effectiveness analysis (CEA) and those that use cost-utility 
analysis (CUA). CfA is one form of economic analysis where both the costs and consequences of 
the medicine are examined in the form of CLG or cost per unit of effect. CUA is related to CEA and 
considers the costs and benefits in terms of quantity and quality of life through the use of the 
quality adjusted life year (QALY). The type of economic analysis used can be regarded as an 
indicator of the quality of the outcome data available with three of the agencies stating a 
preference for cost-utility analyses. The size of our sample enabled an analysis of the differential 
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influence of (higher quality?) the presence of CUA and CEA. It would be expected that those using 
CUA would have a higher probability of recommendation or restriction in comparison to those 
using CEA. A variable was created for two subsamples of those analyses that included CUA and 
those that included CEA to capture the different ICER values by using the reported COG and 
reported ClG. 
Value for money is assessed and considered in the deliberations of these national agencies. 
Chapter 4 identified some evidence of the influence of COG in countries and the evidence shows 
that larger ICERs are associated with a higher probability of not recommending for these 
countries. The pooling of decisions across agencies would expect to show a statistically significant 
independent effect of a negative association between larger ICER values and the decision to 
recommend or restrict. However, average effects for each country may be different, indicating 
different threshold ranges for each of the countries. Higher ICERs might be expected to decrease 
the likelihood of recommendation in this group of countries with similar income levels, but 
differing rates of health expenditure and current health service configurations may produce 
differing decision threshold ranges. 
The incremental cost-effectiveness ratio (ICER) selected for use in this study was that ultimately 
used to make the decision, regardless of the source of the estimate. In Australia, Canada and 
Scotland the only ICER value is that from the manufacturer's submission to the agency. In the 
case of NICE, ICER values are presented by the manufacturer and then also either by an 
assessment group for an MTA or an Evidence Review Group (ERG) for an STA. Many of these 
ICERs relate to drug doses and patient populations which do not form part of the eventual 
recommendation. The value used in this study was that for the application of the technology on 
which NICE made its recommendation. In a number of cases, the specific ICER used for the 
decision was stated in the "Consideration of Evidence" section of the guidance. Where this was 
not the case (older NICE appraisals), the assessment group's ICER value was taken. The 
manufacturer's ICER was only used when there was no other ICER available in the guidance 
document for the indicated decision. 
The above protocol was adhered to in selection of the ICER values. Where the identification of an 
ICER value was unclear this was discussed by the two researchers extracting data to reach 
agreement on the 'appropriate decision ICER. The ICER values were then checked against the 
guidance by a separate researcher. The COG and ClG were converted by the exchange rate at the 
time of the technology appraisal into British pounds (GBP). The analyses used a pragmatic 
approach of using market prices rather than conversion by Purchasing Power Parity (PPP) for the 
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leER values in each country. The decision was made not to convert using PPP's because 
examination of the ppp's for the four countries revealed that there was small variation in the 
index for the years of guidance considered. It would be important to consider if the sample had 
included emerging markets or developing countries where there is generally a large gap between 
the market and PPP values. A further question which is not addressed here is whether GDP PPP 
indices are of the appropriate construct for the consideration of international cost-effectiveness 
estimates. 
Sensitivity analysis is a requirement across all of the agencies but there is variation of the 
reporting of such analysis across the agencies public documents. Ideally, the results of all the 
sensitivity analysis, summarised into a single quantitative variable to account for the uncertainty 
in the estimates provided would be the best variable to include. However, due to a lack of public 
documentation across all agencies reporting the results of sensitivity analysis performed and 
differential reporting within each country it was only possible to include the reporting of 
sensitivity analysis. The agencies reporting of sensitivity analysis may be used when committees 
provide justification for a restricted recommendation or a not recommended decision and its 
absence may indicate a high degree of confidence in the appraisal for those recommended 
deciSions. 
Non-evidence factors: 
Disease area and public interest were two non-evidence factors included. Public interest was a 
new variable identified through qualitative studies in the review in chapter 4 that had not been 
previously included in quantitative studies. Wirtz et al. focused on the broader personal and 
political factors which have Influenced decision-making but received less attention in previous 
empirical studies (Wirtz et aI., 2005). An understanding of the factors that influence the decision-
making environment (policy context) outside of the methods and process for which a medicine is 
assessed may be influential on national agencies decisions. The study referred to the subjective or 
political factors that were described as being appropriate and legitimate alongside other rational 
factors considered. This study aims to focus on public interest/pressure which may be considered 
a proxy measure for the political influence guiding processes and methods. There has been 
substantial pressure from manufacturers and patient groups for agencies to approve medicines 
prior to a reimbursement decision. In some cases there is wider public debate of the issues which 
may influence decision-making agencies which are ultimately subject to democratic control. A 
variable was added as a proxy measure of the public pressure for approval of a new medicine for 
the indication prior to the publication of the decision. This was based on the number of news 
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reports relating to the disease area and indication for each technology in the period prior to 
publication of the technology appraisal by the agency. This variable was not concerned with 
attempts to change a decision once it had been announced but as a proxy measure of the 
pressure prior to a decision. For each country, the counts were made in a broadsheet and a 
tabloid newspaper, selected from the highest circulation newspapers of each type. If the agencies 
were consistently implementing their stated criteria for decision-making there would not be 
expected to be any association between the public pressure prior to the decision and the actual 
decision made. However, it could be that medicines that receive substantial media interest prior 
to the decision may influence the decisions because the decision-makers focus on these decisions 
in more depth to provide greater justification because the agency and decision-makers are aware 
that they will be subject to greater public scrutiny. 
Process factors: 
Seven variables were included to identify aspects of process that may vary for each technology 
appraisal within each country (time since guidance, patient group submission, number of patient 
groups and review) and those aspects of process that only vary across the countries 
reimbursement systems (3 dummy variables for Australia, Canada and Scotland). A new variable 
called 'review' was added to identify whether the appraisal was either a review variable identified 
those decisions that were based on either a review of a previous guidance (NICE) or a 
resubmission by the manufacturer to the (CADTH, PBAC and SMC). 
5.3.3 Regression methods 
The type of qualitative response regression model used to analyse the factors commonly 
important in decision-making was the multinomial logit model (MNLM) regression. The model 
was chosen as it allowed the decision outcome to be categorised as a trichotomous variable -
either "recommended", "restricted recommendation" or "not recommended". This is a more 
realistic representation of decision-making outcomes for national agencies than the dichotomous 
logistic model. The. MNLM requires there to be sufficient observations in each category to ensure 
sufficient power to make statistical comparison between factors within each comparison group 
(Greene, 2003). The use of a pooled sample for the two disease areas in this study has the 
advantage of a larger sample size for each decision outcome. However, additional two-way 
tabulations were performed to check for perfect prediction of any variable and the dependent 
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variable (decision outcome) to make sure that there were sufficient observations within each 
category to produce meaningful results. 
The decision outcome will depend on the independent variables including the characteristics of 
each technology appraisal and the political and country specific factors in which decisions are 
made. The MNlM requires that decision outcomes are mutually exclusive and that there is no 
natural ranking for the three decision outcomes. In order for there to be a ranking of decisions a 
perspective (societal, manufacturer, patient, patient group) would need to be taken and an 
assessment of the relative desirability of each decision outcome. This analysis adopts a societal 
perspective and it is not clear that there would be a natural ranking for these decisions - sOciety 
would require an efficient and equitable decision depending on the evidence. The model also 
requires the implicit assumption of independence of irrelevant alternatives (IIA). The IIA 
assumption means that all other things being equal, a choice between two alternative outcomes 
(decision outcomes) is unaffected by the other (decision outcomes) available. This implies that the 
relative risk ratios are independent of one another for different comparison groups. 
The parameters were estimated using maximum likelihood (Ml) estimation in Stata 9.2 SE and 
robust standard errors were calculated. The result for each factor has been presented as a relative 
risk which is the ratio of the probability of choosing one decision outcome category over the 
reference category. The reference case group in the analysis is those decisions which were 
recommended. This means that the results for the two comparisons are interpreted separately as 
a comparison between restricted and recommended and not recommended and recommended. 
There is likely to be some intra cluster correlation between each of the reimbursement agencies 
in this sample. In other words it is likely that observations on an outcome variable 
(reimbursement decisions) are independent across groups (reimbursement agencies) but are not 
necessarily independent within the groups (decisions and factors driving the decisions). This was 
accounted for by using a cluster command for each of the agencies in Stata. 
5.3.4 Data collection 
Technology appraisals on cardiovascular and cancer medicines were identified by a systematic 
search of each of the agencies websites and through contact with the agencies. The data 
specifications and variable names were clearly specified in a table prior to extraction so that 
consistent extraction could take place between researchers. The data for each of the variables 
was extracted from full technology appraisal report documents and, where necessary, the public 
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appraisal reports that informed the decision process for each medicine. If there were any queries 
regarding missing documentation of the evidence clarification was gained before noting the 
information as not reported. Contact was not made with the agencies to consider whether the 
information reported reflected the information that they had thought they had taken into 
account in the technology appraisal. Those technology appraisals that were published prior to 
February 2008 were included within the sample. A record of each was collected within an Excel 
spreadsheet for all technology appraisals in the sample. The data for the public interest variable 
was obtained from the Nexis news source database (Nexis, 2008). 
5.4 Results 
5.4.1 Preliminary data analysis 
The pooled MNlM included a total of 189 appraisals of which 17 were reviews of previous 
technology appraisals. This sample had 48 (25%) decisions that were recommended, 78 (41%) that 
were restricted, and 63 (34%) not recommended decisions. There were 6 NICE MTA's which 
resulted in 17 individual medicine appraisals included within the analYSis (17 out of 189, 9%). The 
majority of recommendations were restricted, which demonstrates the importance of a 
trichotomous decision outcome (dependent variable). 
The descriptive statistics are provided in Table 5.1. There were 52 (28%) appraisals for Australia, 
19 (10%) appraisals for Canada, 45 (23%) appraisals for England and 73 (39%) appraisals for 
Scotland. The data included 129 cancer medicine technology appraisals and 60 cardiovascular 
medicine technology appraisals. The initial analysis showed that there were 34 SMC technology 
appraisals that did not report a number of the factors. These were either cases where the 
manufacturer did not submit evidence or cases for the early days of SMC when decisions were 
less fully reported. 
There was a statistically significant higher proportion of cancer medicines not recommended in 
comparison to cardiovascular medicines (p=O.OS). 
The technologies that were recommended were on average supported by 2 RCTs in comparison to 
3 for restricted decisions and 1 for not recommended decisions. Cardiovascular medicines were 
accompanled on average by 3 RCTs in comparison with cancer medicines which were supported 
by on average 2 RCTs. There was a statistically significant difference between the mean RCT 
number for recommended decisions in comparison to not recommended (p= 0.02). 
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The technology appraisals that were recommended were published on average 32 months ago, 
compared with 33 months for restricted decisions and 24 months for those decisions that were 
not recommended. The results were statistically significant between recommended and not 
recommended (p=O.Ol). On average the cardiovascular technology appraisals were 9 months 
older than those performed for cancer medicines. 
The data show that 85 (45%) of technology appraisals included CUA, and 35 included CEA. Cost-
utility values were presented in 78% of analyses for England, 43% for Scotland and 35% for 
Australia. 
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Table 5.1: Descriptive statistics for all drug decisions 
/Variable Recommended Restricted Not recommended All Decisions 
(n=48) (n=78) (n=63) (n=189) 
Months since guidance released 32.42 33 23.7 29.8 
timesincepub) (25.86, 38.97) (28.33, 37.67) (20.3, 27.2) (26.9, 32.6) 
Number of RCTs 2.44 2.68 1.40 2.2 
(1.60, 3.30) (1.78,3.58) (0.98, 1.81) (1.7,2.6) 
Proportion of studies: RCT 0.75 0.76 0.62 0.71 
studyrct) (0.62, 0.88) (0.66, 0.85) (0.50,0.74) (0.64,0.77) 
Proportion of studies: Observational 0.08 0.013 0.D3, 0.04 
studyobs) (0.002,0.16) (-0.013, 0.038) (-0.013,0.08) (0.01,0.06) 
Proportion of studies: Not Reported 0.17 0.23 0.35 0.25 
(0.06, 0.28) (0.14,0.33) (0.23, 0.47) (0.19, 0.32) 
Economic Analysis: CUA 0.54 0.45 0.38 0.45 
eccua) (0.40, 0.69) (0.34, 0.56) (0.26, 0.50) (0.38, 0.52) 
conomic Analysis: CEA 0.17 0.19 0.19 0.19 
eccea) (0.057,0.28) (0.10, 0.28) (0.09, 0.29) (0.13,0.24) 
conomic Analysis: CMA 0.063 0.14 0.05 0.09 
eccma) (-0.0090,0.14) (0.06, 0.22) (-0.006,0.10) (0.05,0.13) 
Economic Analysis: CC 0.0 0.013 0.D15 0.11 
ecce) (0.0,0.0) (-0.013, 0.038) (-0.016,0.05) (-0.004, 0.025) 
conomic Analysis: NR 0.23 0.21 0.37 0.26 
(0.11, 0.35) (0.11, 0.30) (0.24, 0.49) (0.20, 0.33) 
~ensitivity Analysis 0.46 0.39 0.17 0.33 
sensanalysis) (0.31, 0.61) (0.27, 0.50) (0.08, 0.27) (0.27, 0.40) 
CERvalue £11,597 £21,496 £26,491 £19,879 
icercua) (£7,838, £15,357) (£7,160, £35,832) (£17,473, £35,510) (£13,442, £26,315) 
Budget Impact 0.46 0.68 0.52 0.57 
budgetimpact) (0.31, 0.60) (0.57,0.79) (0.40, 0.65) (0.50,0.64) 
Patient group submission 0.38 0.30 0.19 0.28 
(patientgroupsub) (0.23, 0.52) (0.19, 0.40) (0.09, 0.29) (0.22,0.35) 
Number of patient group submissions 5.08 4.23 1.49 3.53 
(nopatientgroup) (2.80, 7.36) (2.24, 6.22) (0.09, 2.90) (2.42, 4.65) 
Public Interest 16.79 7.74 4.52 8.96 
(publicinterest) (4.52, 29.06) (4.10, 11.39 (1.72,7.32) (5.4,12.5) 
Note: (95% Confidence Interval), i) n=26, ii) n=35, iii) n=24, iv) n=8 
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Table 5.2: Cost per QALY by recommendation, country and common medicines and uncommon medicines appraised 
Country Recommended Restricted Recommended Not Recommended 
Mean Mean Mean Mean Mean Mean Mean Mean Mean 
All Common Uncommon All Common Uncommon All Common Uncommon 
Australia £12,270 £12,720 
-
£18,778 £14,910 £23,613 £23,475 £28,300 £18,651 
ngland £13,793 £11,641 £15,358 £19,664 £21,400 £19,086 £34,190 £36,885 £26,105 
Scotland £4,458 £5,687 £3,843 £24,814 £10,991 £32,453 £25,935 £39,281 £7,252 
Canada 
-
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In the subsample that presented CUA, the average ICER value was £26,491 per QALY for not 
recommended decisions, in comparison to £21,496 per QALY for restricted recommendations and 
£11,597 per QALY for recommended decisions. The difference between the recommended CQG 
mean and the not recommended was statistically significant (p=0.002). The technology which had 
the highest reported ICER was for an appraisal in Scotland where the reported ICER was £250,000 
per QALY for a PAH treatment. 
The mean ICER for each country can be found in Table 5.2 by all medicines appraised, medicines 
appraised commonly by counties agencies' and those that were uniquely appraised by each 
country agency. The ICER estimates were analysed in these groups to understand the differences 
across the decision groups. The average ICERs across Australia and England are similar for the a" 
recommended and restricted categories and the common recommended and restricted 
categories. The main differences occur between the not recommended group between Australia 
and England where the not recommended ICER across all decisions is £34,190 for England in 
comparison to £23,475 in Australia. This can be explained by the lower ICERs observed across the 
mean common medicines ICER and uncommon medicine ICER in Australia. The mean ICER values 
for Scotland are lower in all the recommended categories in comparison to Australia and England. 
This is the trend for the restricted ICER of common medicines appraised but a number of high 
ICERs for uncommon medicines result in a larger restricted ICER for all medicines appraised in 
Scotland in comparison to Australia and England. The Scottish common and uncommon medicines 
differ greatly with a mean ICER of £39,281 and £7,252, respectively. 
Budget impact was reported in 69% of restricted decisions in comparison with 46% of 
recommended and 52% of not recommended. There was a statistically significant difference 
between restricted decisions and recommended decisions (p=O.OOl). 
The analysis shows a higher level of public interest for recommended decisions, 16.8 articles per 
medicine in comparison with restricted decisions which had 7.7 articles per medicine and not 
recommended decisions where 4.5 articles per medicine were found. The differences from the 
reference decision were found to be statistically significant (p=0.03). 
5.4.2 Regression model results 
The results of three MNLM regressions are presented for the pooled sample of technology 
appraisals. The first regression included all decisions for the technology appraisals and the second 
model included a subset of technology decisions excluding the 34 SMC technology appraisals with 
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limited information discussed previously. The third model included those technology appraisals 
that included CQG. 
The first regression (Table 5.3) included the sample of 189 technology appraisals. The goodness of 
fit of the model was considered using the McFadden pseudo R2 and the percent correctly 
predicted. The pseudo R2 ranges from 0 to one and higher values indicate a better model fit. The 
McFadden pseudo R2 was 0.16 for model 1. The model correctly predicted 74% of restricted 
decisions, 62% of not recommended decisions and correctly classified 40% of recommended 
decisions. 
A technology appraisal that was performed on a cardiovascular medicine rather than a cancer 
medicine decreased the likelihood of not recommending by 74% which was statistically significant 
(p=O.Ol). There was a similar reduction for restricted decisions with reference to recommended 
but this was not found to be statistically significant. 
The older technology appraisals were associated with a statistically significant reduction in the 
probability of not recommending in comparison to recommending. The fact that a technology 
appraisal was a review of a previous decision did not make a statistically significant difference to 
the mean probability of not recommending or a restricted decision. 
An additional RCT statistically significantly reduced the probability of not recommending in 
comparison to recommending by 21% (p=0.046). The effect of the reduction in the probability of 
restriction in comparison to recommend was smaller and not statistically significant. Those 
technology appraisals that were accompanied by observational studies in addition to RCTs were 
associated with a larger decrease in the probability of not recommending and restriction in both 
comparisons with recommended decisions. 
The nature of the economic analysis supporting the decision was captured by two variables, CUA 
and CEA. CUA was associated with an increase in the probability of not recommending in 
comparison to recommending, whereas it was associated with a decrease in the probability of 
restriction rather than recommending. The use of CEA was associated with both a decrease in 
both comparison groups' probabilities. None of these effects were found to be statistically 
significant. The reporting of sensitivity analysis was statistically significant (p=0.03) in reducing the 
probability of being not recommended in comparison to recommended. This was not statistically 
significant In the restricted group comparison with recommended. 
The reporting of budget impact was associated with a large increase in the probability of 
restriction in comparison with recommended and was statistically significant (p=0.002). The 
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budget impact increased the probability of not recommending in comparison with recommending 
by a smaller magnitude but was not statistically significant. 
The public interest variable was found to be statistically significant in the pooled regression. 
Increases in the measure of public interest show a fall in the probability of not recommending in 
comparison with recommending (p=O.03) or restricting in comparison with recommending 
(p=O.07). Two supplementary regressions (results not shown here) were run to test the effect of 
excluding either public interest or the number of patient group submissions. These showed very 
small changes to the coefficients and small changes to the significance of the variables included. 
In a supplementary regression three dummy variables were included in model 1 to account for 
the country in which the decision on the technology was made and clustering was accounted for 
across the three countries (Table 5.5). Dummy variables and adjustment for clustering were 
introduced for Australia, Scotland and Canada with England as the reference case. The analysis 
showed both Scotland and Canada were statistically (1% significance level) more likely to make a 
restricted decision in comparison to a recommended decision and more likely to make a not 
recommended decision in comparison to a recommended. A number of the variables remained 
statistically significant and the magnitude of effect did not change greatly across the variables 
(disease area, public interest, RCT number, study observational). The introduction of country 
specific variables and adjustment for clustering did influence some of the other factors, making 
the time since guidance in the comparison of not recommended and recommended and type of 
economic analysis and budget impact in the comparison of restricted and recommended 
statistically insignificant. A number of variables in the restricted category in comparison to the 
recommended became statistically significant at the 5% and 1% level (time since guidance, patient 
group submission and public interest variable). 
The second analysis tested the effect of the limited information provided in the excluded SMC 
decisions. The second regression correctly predicted 69% of restricted decisions, 57% of not 
recommended decisions and 46% of recommended decisions. None of the coefficients swapped 
sign but there was a large change in the CUA coefficient for both outcome comparisons and the 
budget impact coefficient for the comparison of not recommended with recommended. The 
significance of some coefficients changed and this may be explained by the resulting reduction in 
the sample size to 155 (Table 5.3). 
The pooled sample included 85 technology appraisals that had estimates of CQG, 26 which were 
recommended, 35 restricted recommendation and 24 not recommended. A sub-sample 
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regression (Table 5.4) of those technologies was performed and the regression correctly predicted 
60% of restricted decisions, 63% of not recommended decisions and correctly classified 50% of 
recommended decisions. The pseudo R2 was 0.2006. 
Increases in the CQG estimates were associated with a decrease in the probability of both not 
recommending and restricting in comparison with recommended. The results were statistically 
significant In the not recommended versus recommended group at the 10% level but were not 
statistically significant in restricted recommended versus recommended. Those technology 
appraisals which reported budget impact, sensitivity analysis and higher levels of public interest 
were statistically significantly more likely to be restricted than recommended. The older decisions, 
cardiovascular medicines, those accompanied by sensitivity analysis and those with a patient 
group submission all statistically significantly reduced the probability of not recommending in 
comparison with recommended. 
The introduction of country specific dummy variables in model 3 changed the coefficients slightly 
and the CQG became statistically insignificant in the not recommended versus recommended 
group similar to the restricted recommended versus recommended in model 3. It should be 
noted that the results should be interpreted cautiously as the standard errors were large for the 
dummy variables in model 3 owing to few not recommended decisions in NICE decisions for 
cancer and cardiovascular drugs and the smaller subsample. The pseudo R2 demonstrated 
improved model fit with the introduction of the dummy variables in comparison to model 3. 
There were too few technology appraisals reporting cost per life-year gained to support a 
separate analysis of cost-effectiveness per outcome appraisals. 
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Table 5.3: Modell and Model 2 regression results 
lVariable 
Relative Risk Ratio (RR) 
Not recommended lIS Recommended 
diseasearea ~.2445058 
ctno (number) ~.7941144 
eccua 1.154654 
[eccea 0.8353286 
~tudvobs 0.1261477 
~ensanalvsis p.1869046 
imesinceguidance p.9701117 
[patientgroupsub ~.9678549 
publicinterest ~.9570102 
[budgetimpact 12·167374 
eview 1.099173 
~estricted recommended lIS Recommended 
~iseasearea p.486853 
ctno (number) p.9876587 
leccua p.328006 
leccea p.3847832 
~tudvobs b.0949439 
:.ensanalysis 0.8540079 
timesinceguidance 0.997945 
patientgroupsub 1.025246 
publicinterest p.9851029 
budgetimpact 14·626985 
review p.8930886 
Number of observations ~89 
Log pseudo-likelihood 171.68671 
Pseudo R~ 0.1585 
-- ---
Modell 
Robust s.d. 
~.1334756 
p.091661 
~.820358 
0.6644449 
0.1164031 
0.10649 
0.0114174 
0.0364941 
0.0190524 
1.166211 
~.9066001 
p.2396647 
P·0533437 
p.2164812 
p.2989747 
p.1293192 
P.4284739 
p.Ol00088 
0.0249569 
0.0081235 
2.257014 
0.6773815 
189 
Model 2 
p-value Relative Risk Ratio (RR) Robust s.d. p-value 
0.010··· ~.2584849 0.1629263 p.032·· 
0.046·· 0.8597941 0.0999217 0.194 
p.840 2.360742 1.787968 0.257 
p.821 1.908197 1.597382 0.44 
p.025·· 0.162627 0.1566555 0.059· 
p.003··· 0.192696 0.1140577 p.005··· 
p.01s·· 0.9602064 0.0120886 0.001··· 
p.386 0.9781417 0.0375047 0.564 
0.027·· 0.953032 0.0226686 0.043·· 
~.151 3.489901 1.978651 0.027·· 
p.909 1.246611 1.023834 0.788 
p.l44 0.5087713 p.277806 ~.216 
p.818 1.04193 P·073s524 p.561 
~.092· 0.6198758 P·4189568 0.479 
p.219 p.8199928 p.6447909 0.801 
p.084· p.l072556 p.1448021 0.098· 
p.753 p.8460304 p.4327981 0.744 
0.837 P·9814319 p.0113908 0.106 
p.306 1.03208 p.0254231 0.2 
~.069· 0.9850199 p.0069857 0.033·· 
p.002··· 6.566758 ~.33828 ~.OOO··· 
p.881 0.9117957 0.6832669 b.902 
155 
~9.989124 
p.1746 
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Table 5.4: Model 3 regression Model results 
Variable Model 3 Model 3 (Supplementary) I 
Relative Risk Ratio (RR) Robust s.d. p-value Relative Risk Ratio (RR) Robust s.d. p-value I 
Not recommended vs Recommended I 
Costperqaly (cqg) 1.000044 0.0000263 0.098· 1.000037 .0000294 0.203 ! 
diseasearea 0.3938765 0.217414 0.091· 0.5270375 .3873951 0.384 
rctno (number) 0.8957413 0.0713806 0.167 0.9887396 0.1003362 0.911 
sensanalysis 0.2440817 0.1716249 0.045·· 0.3772125 0.2669157 0.168 
timesinceguidance 0.9601926 0.0160943 0.015·· 1.015886 0.027151 p.555 
patientgroupsub 0.9328841 0.0106916 0.000··· 1.11299 0.0909948 0.190 
publicinterest 0.961838 0.0270538 0.167 p.9510433 p.0305308 P·118 
budgetimpact 1.751633 0.7729656 0.204 p.3689346 p.3877018 p.343 
review 2.119724 1.824898 0.383 3.283758 ~.287823 p.088· 
scotland 
- - -
83.13191 105.3851 p.OOO"· 
australia 
- - -
550.8798 ~19.7628 p.OOO"· 
Restricted recommended vs Recommended 
Costperqaly (cqg) 1.000043 0.0000341 0.205 1.000038 0.0000369 p.308 
diseasearea 0.889832 0.1329839 0.435 1.112464 0.4211866 p.778 
rctno (number) 1.008062 0.0931994 0.931 1.10356 0.1269025 p.391 
sensa na lysis 0.9735883 0.3376297 0.938 1.482655 p.6256125 0.351 
timesinceguidance 0.9783618 0.0107575 0.047·· 1.025357 p.0098049 0.009 
patientgroupsub 0.9975973 0.0288034 0.934 1.143655 p.0245178 0.000"· 
publicinterest 0.989338 0.0037129 0.004··· p.9816605 p.0118023 0.124 
budgetimpact 9.869959 4.76514 0.000··· ~.995473 p.8216106 b.ooo··· 
review 1.855619 2.195938 0.601 2.809609 3.407605 0.394 
scotland 
- - -
27.30291 24.71544 p.OOO··· 
australia 
- - - 165.2192 137.7452 p.OOO·" 
Number of observations 85 85 
og pseudo-likelihood -73.71167 -68.413167 
Pseudo RZ 0.2006 0.2580 
... = statistically significant at the 1% level, ·*=statistically Significant at the 5% level, *= statistically significant at the 10% level 
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Table 5.5: Supplementary regression country dummies 
\,'ariable Modell (Supplementary) 
Relative Risk Ratio (RR) Robust s.d. p-value 
Not recommended vs Recommended 
diseasearea 0.218361 0.170183 0.051· 
rctno (number) 0.845214 0.0670763 0.034·· 
eccua 1.449047 0.9681036 0.579 
eccea 1.573341 0.6770083 0.292 
studyobs 0.149174 0.1571916 0.071· 
sensanalysis 0.184905 0.1742794 0.073· 
timesinceguidance 0.979086 0.0167659 0.217 
patientgroupsub 1.09263 0.0387232 0.012 
publicinterest 0.964431 0.0077073 0.000··· 
budgetimpact 1.229409 0.2389235 0.288 
review 1.084773 1.052287 0.933 
australia 23.19655 24.22948 0.000··· 
scotland 32.38492 20.45078 0.000··· 
Canada 4.695003 6.226069 0.244 
Restricted recommended vs 
Recommended 
diseasearea 0.440805 0.2527405 0.153 
rctno (number) 1.033236 0.0541858 0.533 
eccua 0.489922 0.4223648 0.408 
ecce a 0.708912 0.414761 0.557 
studyobs 0.101917 0.1270261 0.067· 
sensanalysis 0.921645 0.503212 0.881 
tl mesi ncegu ida nce 1.015623 0.0074878 0.035·· 
patlentgroupsub 1.113824 0.0240655 0.000··· 
publicinterest 0.988429 0.0042842 0.007··· 
budgetimpact 2.291007 1.618887 0.241 
review 0.952992 0.5942747 0.938 
australia 13.95652 3.717845 0.000··· 
scotland 10.70257 5.200454 0.000··· 
Canada 2.304786 0.781788 0.014·· 
Number of observations 189 
og pseudo-likelihood -162.64696 
Pseudo R" 0.2028 
... = statistically Significant at the 1% level, ··=statistically significant at the 5% level, .= statistically significant at the 10% level 
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5.4.3 Regression diagnostics 
A number of diagnostic tests were performed on the regression models and the tests and a brief 
summary of the results can be found as follows: 
• Collinearity between variables was considered using pair wise comparisons and the only 
variables to show weak correlation were for between number of patient groups/public 
interest (r=O.21) and CQG/number of RCTs (r=-O.14). 
• Multicollinearity between variables was considered using Variance Inflation Factors (VIF). 
The mean values VIF values of 1.67 for model 1 and 1.43 for model 2 did not indicate 
multi-collinearity using this test. 
• The regression coefficients and statistical significance were not sensitive to changes in the 
structure of the model such as exclusion of number of patient groups. 
• Testing whether the MNML is an adequate specification by testing whether the IIA 
assumption holds using the Hausman test (Hausman and McFadden, 1984, McFadden et 
aL, 1976) and the Small-Hsaio test (Small and Hsiao, 1985). For model 1 we can conclude 
that we fail to reject the null hypothesis of IIA but for model 2 and 3 the results are 
inconclusive and depend on the specification test used. The details of these are reported 
in Table 5.6. 
Table 5.6: Hausman test and Small-Hsaio test 
Test Omitted outcome Chl2 P>chl2 
Hausman Test Not recommended -2.152 1.000 
.-f 
Resticted -6.379 1.000 
(jj Small-Hsiao Not recommended 12.482 0.408 
-0 
0 
~ Restricted 12.368 0.417 
Hausman Test Not recommended -4.554 1.000 
Resticted -9.914 1.000 
N 
(jj Small-Hsiao Not recommended 91.470 0.000 
-0 
0 
~ Restricted 61.553 0.000 
Hausman Test Not recommended 2.454 0.982 
Resticted 3.437 0.944 
rtI 
(jj Small-Hsiao Not recommended 374.935 0.000 
-0 
0 
~ Restricted 138.584 0.000 
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5.5 Discussion 
5.5.1 Common factors associated with decisions (non-context specific) 
The study found some evidence of the association of common factors with the reimbursement 
decision outcome across the four national agencies with respect to clinical evidence, two non-
evidence factors (disease area and public interest) and process (date of decision and country 
dummy variables). The results tended to show no common association across countries with 
respect to the cost-effectiveness estimate for each medicine appraised, although one 
specification of the model showed a significant result at the 10% level. Forty percent of decisions 
were categorised as restricted decisions and this proportion was found across the medicines 
considered for these four agencies demonstrating the importance of considering all three 
categories of decision rather than a binary categorisation (recommend/not recommend). 
The type of clinical evidence, and the number of studies from which it is derived, are commonly 
important for reimbursement decisions Internationally and similarly supports another study of the 
importance of clinical considerations that considered a univariate analysis of factors in national 
reimbursement decision-making (Clement et aI., 2009). There was on average, two main RCTs 
supporting the reimbursement decision for medicines appraised by the four agencies and those 
medicines with a larger number of RCTs were more likely to be recommended than not. Many of 
the manufacturer's submissions were based on one main RCT and therefore efficacy and 
modelling of the effectiveness over time. There tended to be a lack of observational data used to 
monitor the actual effectiveness because many of the decisions concerned the first 
reimbursement decision for the medicine. The agencies do not consistently review all the 
medicines and compare the modelled cost-effectiveness (efficacy) and resulting cost-
effectiveness at a later point in time. Where recommended decisions are made on health 
economic analysis supported by one RCT in the processes of single technology appraisal used by 
the four agencies this will be a partial basis for decision-making (Sculpher et al. 2006). When 
available, the influence of observational data could reflect that this type of study was 
complementary to the RCT evidence and allows the committees further understanding of the 
external validity issues surrounding a new medicine. 
The disease area for which the medicine is indicated to treat was found to be associated with the 
decision. The time element has been controlled for in the regression models so the Increased 
likelihood of cardiovascular medicines being recommended does not reflect the fact that many of 
the cardiovascular medicines are on average older than the cancer medicines and perhaps more 
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likely to be approved because of less stringent evidence requirements. The guidance included in 
this study was published prior to the introduction of new criteria such as the NICE end of life 
supplementary guidance. It is therefore interesting that across agencies cardiovascular medicines 
had a greater chance of being recommended in comparison to cancer medicines when there was 
no priority explicitly given in the agencies stated criteria (pre-2008). There are two possible 
related explanations for this finding, which relate to the selection of medicines assessed by these 
national agencies. Firstly, the cardiovascular medicines appraised may have been better at 
satisfying agencies requirements for demonstrating value in comparison to cancer medicines 
across these agencies. Secondly, differences in the composition of medicines appraised across the 
agencies may affect this, for example NICE select the medicines that are evaluated, whereas the 
manufacturer submits evidence to the CDR, PBAC and SMC for assessment and appraisal. 
The level of public interest was a newly introduced non-evidence factor that was found to have a 
moderate and statistically significant effect on the probability of decision outcome. This is 
consistent with the idea that political and institutional contexts of a technology appraisal decision 
are important in determining access to healthcare resources (Goddard et aI., 2006, Wirtz et aI., 
2005). The public pressure may have an impact on the evolution of the processes or the 
introduction of new factors (as has been seen with the introduction of the NICE end of life 
supplementary guidance) or could directly impact upon the extent of the deliberations or 
justification provided for a decision across these agencies. It is important to note that the level of 
public interest, as measured here, could be accounting for country specific factors which are not 
included in the analysis. However, it the variable remained statistically significant when country 
specific variables were introduced into the analysis. 
The results indicate that over time the fourth hurdle may have become tougher to pass and gain a 
recommended decision for cancer and cardiovascular medicines across the four countries. The 
results show that older medicines were more likely to be recommended in comparison to not 
recommended across the four agencies. This may reflect a combination of common evolution in 
the agencies processes and methods used to conduct HTAs including tougher evidence 
requirements overtime. 
5.5.2 Process and health economic analysis within and across countries 
There was no common association with the cost-effectiveness estimate and the decision across 
the four countries and categories in two of three regression models. This study was not designed 
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to assess the validity of the use of cost-effectiveness thresholds in decision-making, a topic on 
which there is an extensive literature both for and against (see for example (Birch and Gafni, 
2006), (Birch and Gafni, 1992) and (McCabe et aI., 2008)). This study concerns the 
influence/impact that the use of such thresholds might have on decision-making. Previous studies 
of NICE, pooled estimates of CLG and CQG enable a sufficient sample size to test the influence of 
the ICER (Dakin et aI., 2006, Devlin and Parkin, 2004). This study considered exclusively the effect 
of the value of the CQG ratio in a sub-sample that reported this information across the national 
agencies. Although the mean cost per QALY was higher in those appraisals which led to a not 
recommended decision, when other factors were controlled for, the absolute size of the CQG 
ratio had a small but statistically insignificant effect on decision-making. Even if agencies were 
using different thresholds, a positive significant impact between the ICER estimate and the 
decision would be expected. These results may be explained by the lack of an explicit threshold 
and differences in the interpretation and weighting of evidence in the countries, the impact of 
process on the use of health economic analysis and the mix of common medicines and 
uncommon medicines appraised across the agencies. 
NICE is the only agency to be explicit about its threshold range, which it specified to be in the 
range of £20,000 to £30,000 per QALY gained in 2004. There have been numerous studies on 
what the threshold is and should be for the NHS in England (Appleby et aI., 2009, Culyer et aI., 
2007, Devlin and Parkin, 2004, Grosse, 2008, McCabe et aI., 2008, Williams et aI., 2007) but little 
discussion of the foundations of a threshold and its use in other countries. It has been suggested 
that other authorities are operating implicit thresholds which are not public (George et aI., 2001). 
However, the absence of a significant relationship would suggest either that the other three 
agencies in this study were not operating impliCit thresholds for cancer and cardiovascular 
medicines for these medicines or there are factors that are not sufficiently controlled for in the 
analysis such as variation in process across countries. 
Controlling for the influence of process variation that occurs across agencies and systems is more 
complex in this type of quantitative study because it requires sufficient countries with sufficient 
similarities and differences in the reimbursement process. This analysis used simple intercept 
dummy variables to control for process across countries to understand whether this could be 
important and was found to be associated with the decision for some countries depending on the 
decision outcome comparison. Therefore the role of economic analysis on decisions may be 
dependent on the processes. Differences in process across countries may influence decisions in 
two ways, either independently of other factors such as economic analysis or by modifying the 
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way in which decision-makers within each reimbursement system consider factors such as 
economic analysis. The agencies processes may also evolve overtime and differences between 
agencies processes may converge or diverge depending on the time period at which the decision 
for the medicine was made. 
The inclusion of country specific dummy variables improved the predictive power of the 
regression and may demonstrate that process factors influence the way in which evidence is 
considered, even when there are similar evidence requirements, particularly with respect to 
restricted decisions. There are a number of process differences across the four countries that can 
be considered by the process variation within the agency providing the decision and variation in 
the entire reimbursement system process. 
The agencies all require the manufacturer to present evidence of the clinical and cost-
effectiveness but NICE also has two separate processes of appraisal including an academic 
assessment group for the MTA process and a evidence review group (ERG) for the STA process to 
review the evidence. The STA process was designed to speed up the assessment of medicines and 
has considered a number of new cancer medicines by only requiring a review of the evidence 
submitted by the manufacturer similar to the other reimbursement agencies. The use of the MTA 
process may provide decision-makers with more information on the appropriateness and 
uncertainty surrounding the evidence for committee deliberations and consideration of patient 
subgroups. This difference in process may result in the consideration of different patient 
subgroups from the manufacturer and result in different recommendations in comparison to 
those only considering the manufacturers assessment. 
The impact of third party assessment is illustrated in the data when considering the explanation 
for differences in the mean leER in the not recommended group for all medicines. The mean leER 
of both Australia and Scotland are lower than England which may be due to the fact that the 
submission is prepared by the manufacturer rather than reviewed by an independent group or 
provided by an independent assessment group. The wide difference in estimates between the 
common and uncommon medicines sample for Scotland can be explained by the plausibility of 
the manufacturers estimate. This was identified by considering the specific SMe guidance for the 
uncommon medicines, three of which were for cardiovascular medicines and one for a cancer 
medicine. The cancer medicine was topotecan for the treatment of relapsed small cell lung cancer 
(Sele). The economic analysis reported an leER of £21,582 per QAlY but the sensitivity of the 
leER to a number of key parameters led the SMe committee to decide that the leER would 
potentially be higher than the point estimate provided. The estimates provided in the 
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cardiovascular medicines SMC guidance were judged not plausible because of assumptions or the 
structure of the model. The lack of third party assessment and differences in the mix of medicines 
appraised by the agencies may explain the differences in mean ICER in the sample and also the 
lack of statistical significance of the common ICER on the reimbursement decision across 
countries. 
The process for cancer medicine reimbursement in Canada has been complex and continues to 
evolve and may explain cross country differences in decisions for these medicines. There have 
been a number of changes to the process for oncology medicine appraisal in Canada starting with 
a one year interim Joint Oncology Drug Review (JODR) process where the CDR provided clinical 
and pharmacoeconomics reviews for ambulatory new medicines in 2007 which form the basis of 
the sample in this study (Personal communication: Ministry of Health and Long term care, 2008). 
It was then expected that the JODR process would be made the responsibility of the CDR after the 
one year period (CADTH, 2011c). Instead, a new process has begun since 2010 called the pan-
Canadian Oncology Drug Review (pCODR) to consider the clinical and cost-effectiveness of 
medicines after the iJODR demonstrated the cross provincial value to provide decision-making for 
cancer care. The reviews have begun and the first one will be considered by the Expert Review 
Committee (pERC) published at the end of October 2011 (pCODR, 2011). 
The process by which a committee(s) considers the assessment and appraises the evidence and 
non-evidence factors varies across the reimbursement systems. There are single committees that 
assess and appraises the evidence for NICE (Technology Appraisal Committee), CDR (Canadian 
Expert Drug Advisory Committee) and JODR (Committee to Evaluate Drugs). There are two 
separate committees in PBAC and SMC, one with the task of providing the technical assessment 
and the other with providing an appraisal of the evidence and other factors. The PBAC (appraisal 
committee) is advised by the Economics Sub-Committee (ESC) advises on the economic analyses 
and technical aspects of these analyses which includes health economists, clinical specialists, 
epidemiologists, general practitioners, public health academics, Health Scientists, Pharmacologist 
and one industry representative (PBAC, 2011). The SMC board (appraisal committee) is advised by 
the New Drugs Committee (NDC) which consists of 21 members including clinicians, pharmacists, 
health economists, a statistician and two industry representatives. Medical practitioners, 
pharmacologists, pharmacists and Health economists are represented in at least one of the 
committees across all of the agencies but the SMC do not include a health economist on the SMC 
appraisal committee. Members of the public are represented across all committees although 
patient representatives are only present on the iJODR committee for cancer medicines in Canada. 
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The separation of the technical and appraisal committees and differences in the composition of 
committees across the agencies may result in differences in the role that economic analysis plays 
within each of the processes and subsequently different decisions. 
The NICE STA process is distinctive in that a published provisional decision stage occurs before the 
final decision is made by the agency, where subsequently there is no resubmission opportunity 
only appeal. The provisional recommendation is made at the Appraisal Consultation Document 
(ACD) stage and may either be a more 'restrictive recommendation', 'not recommended' or a 
'minded not recommended' (NICE, 2008). The minded not recommended allows the 
manufacturer to submit new cost-effectiveness analyses to reduce the uncertainty surrounding 
the decision. This is in contrast to the other four agencies processes where manufacturers can 
only resubmit following the final decision but the manufacturer may have the opportunity to 
request reconsideration of the recommendation in the CADTH CDR process if the CDR has not 
followed procedures or the recommendation is not supported in light of the evidence submitted 
(CADTH, 2010). The difference in NICE process may lead to identification of possibilities where a 
restrictive recommendation can be made in a subgroup rather than not recommending in 
comparison to the first decision made by the other reimbursement agencies. This may therefore 
technically mean that all submissions up to the final submission (whether this is the first 
submission or a resubmission) should be excluded from any comparison across reimbursement 
agencies. This is important because the ICERs included for the initial decisions may not have been 
considered plausible and this would explain the lack of common association between the ICER 
and the decision 
The second set of process differences are with respect to the entire reimbursement or fourth 
hurdle system in which the reimbursement agencies operate. The systems vary in the number of 
entities contributing to the reimbursement decision and the nature of the decisions, some 
containing a separate entity with a process for negotiating price and others allowing the 
manufacturer the freedom to set price. 
The reimbursement systems may provide different incentives for manufacturers submitting to the 
reimbursement agency that use HTA because of the other institutions involved in the 
reimbursement systems. Ultimately the final decision on access to a medicine in the systems 
depends on the decision of the clinician but the systems provide different complex processes by 
which this final decision is reached. NICE is a single institution that provides mandatory 
reimbursement decisions for which funds should be made available to provide the medicines in 3 
months. The other reimbursement agencies provide advisory recommendations where a second 
Chapter 5: Systems using Health Economic Analysis 199 
stage determines the formulary lists of those medicines that can be provided by clinicians, SMC to 
the health boards in Scotland, CADTH CDR, JODR to the health plans in Canada and PBAC to the 
Ministry of Health in Australia. The second stage may influence the manufacturers focus and 
preparation of evidence with respect to patient groups and details of the submissions 
(relationship between price and reimbursement) and therefore the initial decisions made by these 
reimbursement agencies. 
In England and Scotland manufacturers are free to set the prices of medicines and NICE and SMC 
signal their demand for the medicine at each price by an explicit indication of the threshold range. 
There are no explicit thresholds for cost-effectiveness evidence in Australia and Canada. Patented 
medicines prices are negotiated in Australia. The Pharmaceutical Benefits Pricing Authority (PBPA) 
makes recommendations to the Ministry of Health after the medicine has been recommended for 
listing in the Pharmaceutical Benefits Schedule in Australia (Australian Government, 2011b). In 
Canada prices are reviewed on introduction by the manufacturer by the Patented Medicine Price 
Review Board (PMPRB) and negotiated when found to be excessively priced. The PMPRB reviews 
whether a medicine is excessively priced by considering other medicines in the same therapeutic 
class and a comparison of the price sold in other countries. Further price regulations are in place 
across the health plans through volume agreements and rebates as a condition of inclusion in the 
health plans formulary (PMPRB, 2011). In the situation where price is negotiated ex post by a 
separate institution the result may result in different restrictions on reimbursement to those 
systems that allow manufacturers the freedom to set price. 
Further understanding of the impact of process differences on the decision would need to be 
explored in a number of single country studies with variables using similar constructs where 
possible. But of course this is limited by the transparency of the documentation of evidence and 
other factors reported in the documentation and the ability of a number of quantitative variables 
to control for some factors that are qualitative in nature. 
5.5.3 Limitations 
The data show that aspects of clinical evidence, some included non-evidence factors and process 
factors are commonly associated with the decision to recommend a medicine across countries. 
However, these findings should be considered cautiously, as the regression models were 
considered to have low predictive power, although this was similar to other studies using such 
methods and were better at predicting not recommended decisions and restricted decisions than 
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recommended decisions. There are potentially multiple reasons for the poor predictive power of 
the regression and this may be caused by lack of sufficient controls for process differences 
between countries as discussed previously, unmeasured factors through lack of reporting across 
countries agencies, qualitative nature of some factors in decision-making and relationships 
between factors. 
The extent of reporting and transparency of each agency limit the analysis of the factors 
influencing decisions. All the agencies provided some details for the evidence factors but the 
details varied across the agencies public documentation. NICE is the only agency that provides 
detailed documentation of the deliberations, stating other non-evidence factors. Therefore non-
evidence factors cannot be constructed directly from the public summaries of the decisions across 
all the agencies and characteristics of medicines or proxy measures such as public interest were 
used in this study to start to explore the influence of non-evidence factors on decisions. 
It would have been useful to explore other characteristics of the evidence that have been 
included in previous individual agency/country analysis where the quantitative evidence factors 
are tailored to the information publically available. The inclusion of all these factors was 
constrained in this study by the lack of common reporting across countries. This study excluded 
quantitative measures on both the clinical uncertainty (internal validity/external validity) and 
economic uncertainty (structural uncertainty and parameter uncertainty) and this may explain the 
lack of predictive power of the regression models. The measurement of such variables would have 
been included in this study if there had been sufficient public documentation to collect data 
across all of the countries agencies. However, even if such information had of been available 
there are further complexities because of the subjective nature of establishing a quantitative 
variable that can sufficiently and consistently capture the decision-makers deliberations on these 
evidence factors across the agencies. This is partly illustrated by the differences across agencies 
with regards to the guidelines for presenting sensitivity analysis (deterministic and probabilistic 
sensitivity analysis). 
A further explanation for the low explanatory power could be due to missing factors that are 
inherently qualitative in nature and cannot be easily summarised in a quantitative measure. There 
are some qualitative factors in the deliberations for decision-making that are difficult to 
summarise in a public document such as the nature of the meeting discussions, order of evidence 
consideration and balance of Input of different decision-makers in deliberations. 
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Factors that are found to be associated with decisions do not necessarily correspond with 
influence on decisions. For example, the observation that the conclusions of the economic 
analysis are associated with the decision outcome does not necessarily mean that the economic 
analysis has influenced the decision outcome. Buxton describes this with respect to the 
influence/impact of economic analysis on health policy in the UK. As (Buxton, 2006) emphasises: 
The consistency of subsequent policy with the conclusion of a study does not necessarily 
indicate that the study has influenced that policy. The consistency may be a happy 
coincidence, with the evaluation used rather as a drunken man may use a lamp post-
more for support than illumination. (p.1134) 
There may be situations in which the quantitative variables included in analysis cannot be 
considered independent and this could undermine the conclusions drawn on the association of 
factors. Cost-effectiveness and clinical effectiveness were excluded from the analysis because 
they should be considered endogenous - both will be related to the decision and clinical effect is 
directly related to the cost-effectiveness estimates through the pricing decision. However, even in 
those factors initially considered independent, there was for example, a weak relationship 
between the number of RCTs and the CQG ratio. These factors may be endogenous due to an 
unobserved variable which is correlated with both of these factors. For example, perceived 
potential cost-effectiveness of a medicine could increase the willingness to invest in trials. 
The main output of the reimbursement agencies in this study was the reimbursement decision 
outcome but this may be considered an intermediate outcome to the system level objectives. 
These systems all have the objective of improving the health of the population with respect to 
other objectives but the way in which the agency influences utilisation and the health of the 
population may ultimately be considered the final outcome of the agency. The intermediate 
decision outcome of the reimbursement agency may not necessarily translate to the final 
outcome in each country because the agency is only one of many entities with different objectives 
that influence the final outcomes. Research should therefore also consider the influence of 
economic analysis and other factors on actual use rather than the intermediate outcome of the 
reimbursement decision. 
5.6 Conclusions 
The results show that some factors are commonly important across systems and this may be an 
indication of a degree of international consensus on which elements of HTA are important in 
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determining reimbursement decisions in the selected countries. In spite of the introduction of 
non-evidence factors such as public interest the models had low predictive power. However, this 
was improved by the introduction of country specific dummy variables, indicating the importance 
of local process differences. Future research will need to focus on country specific models as 
larger samples of decisions become available to be able to identify process differences between 
countries. This will need to be coupled with more transparent public documentation by the 
agencies of the evidence and considerations, to be able to include all factors, to understand 
further how process can explain differences in decisions across countries. 
The desirability of a decision system from a societal perspective will depend on the context and 
the objectives (access, health maximisation, reducing inequalities, and cost-minimisation) which it 
has been designed to achieve. In countries with similar decision contexts, systems with similar 
institutional characteristics may develop with common methods and processes, as a result of 
similarities in their objectives. On the other hand apparently similar decision processes may reach 
different decisions if their context and objectives differ. The desire to define the "ideal" process in 
scientific terms must be tempered by the need for consistency between the system and the 
political decision context and objectives within which it operates. 
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Chapter 6: Pharmaceutical Reimbursement 
Decision-Making: Haute Autorite De Sante (HAS) use 
of Relative-Effectiveness versus Scottish Medicines 
Consortium (SMC) Use of Cost-Effectiveness 
Abstract 
Objectives: Chapter 3 and 4 categorised pharmaceutical reimbursement agencies' objectives, 
processes and methods of assessment and appraisal found this to vary significantly across 
countries. The aim of this study is to examine the impact of differences in process and methods 
upon reimbursement recommendations produced in France and Scotland. There is a particular 
focus on the contribution of health economic analysis. 
Methods: A framework for classifying reimbursement systems was used to analyse the two 
systems. Recommendations were compared for 2010 and a detailed qualitative analysis of the 
evidence and the issues reported for common medicines evaluated by both reimbursement 
agencies. Reasons for discrepancies in recommendations were analysed and case studies selected 
to illustrate the common reasons. 
Results: Thirty-nine common medicines were identified between 2006 and 2010, treating a 
variety of diseases for which the SMC tended to provide more restrictive, or did not recommend, 
listing. Similarities in clinical evidence submitted and the respective reimbursement committee's 
issues were reported. Differences in recommendation can be explained by a combination of the 
manufacturer's freedom to set price and incentives provided by the formal consideration of 
economic analysis and quality of life, process for addressing uncertainty in evidence, alongside 
differences in relevant comparators medicines, relevant outcomes, treatment guidelines, 
submission of network meta-analysis and the propensity to use such evidence synthesis methods 
in decision-making. 
Conclusion: This study identified some hypotheses and explanations for differences in 
recommendations such as agency organisational process factors, local differences in clinical 
guidelines and comparator treatments, methods of evidence synthesis and the use of health 
economic analysis. However, the differences may be associated with other contextual factors 
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such as politics, cultural traditions, and local physician prescribing patterns rather than the 
analytical methods used or the agencies' processes. Further research using larger datasets may 
allow stakeholders to assess the desirability of differences in some of these factors. 
Chapter 6: Comparison of a system using HE versus no use of HE 205 
6.1 Introduction 
Governments intervene in pharmaceutical markets to promote health and affordable access to 
pharmaceuticals, whilst balancing the R&D incentive for global pharmaceutical manufacturers to 
invest in future medicines (DECO, 2008). On the demand side, the collective systems of pricing 
and reimbursement are one means by which these objectives can be achieved. Health care 
systems differ in the processes they follow and the evidence they require from manufacturer's 
when evaluating new pharmaceuticals for inclusion on their public formulary. Chapter 4 
identified that many developed countries consider evidence on clinical effects and costs and 20 
out of 34 DECO countries report that they require cost-effectiveness analysis in the 
manufacturer's submission to the reimbursement entity. One exception is the French 
reimbursement system agency - Haute Autorite de sante (HAS) - which does not require health 
economic analysis for new medicines and separates pricing decisions from consideration of the 
clinical efficacy and relative-effectiveness of medicines. The law on financing and social security of 
2008 required HAS to consider medico-economic analysis in order to introduce wider methods of 
appraisal for medicines prior to the reimbursement and pricing decision. The agency established 
the Commission evaluation economique et de sante Publique (CEESP) to start considering the 
methods and provide appraisals for selected high priority medicines but is still deemed separate 
from the first listing assessment and appraisal of the clinical efficacy and effectiveness for new 
medicines. 
A number of studies have considered comparisons of the influences on reimbursement 
recommendations for systems that use similar processes and evidence requirements (Barbieri et 
aJ., 2009, Cairns, 2006, Clement et aJ., 2009, lexchin and Mintzes, 2008, Raftery, 2008). This 
literature has focused on comparisons of decisions at the individual technology assessment level 
for the evidence informing decisions by the National Institute for Health and Clinical Excellence 
(NICE) in England, Pharmaceutical Benefits AdviSOry Committee (PBAC) in Australia and the 
Canadian Agency for Drugs and Technologies in Health (CADTH) Common Drug Review in Canada. 
However, there are no studies that directly compare the processes and recommendations of 
agencies that use health economic analysiS with those that do not require such evidence for 
making reimbursement recommendations. 
, 
An und~.rstanding of the impact of different reimbursement processes and methods of evaluation 
will help to evaluate the desirability of such differences across countries and help stakeholders 
Identify best practices for these reimbursement systems given their objectives and health care 
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system context. The following sections describe the objectives, methods results and conclusions 
from the study. Limitations of the approach and the need for further research are discussed. 
6.2 Objective 
This study compared the reimbursement systems for pharmaceuticals in France and Scotland, in 
order to gain an understanding of the impact of process differences on the listing 
recommendations produced by each country. There was a particular focus on the contribution of 
health economic analysis to any differences as, in other respects, the systems are broadly similar 
with respect to requiring evidence on safety, efficacy and relative effectiveness to provide 
recommendations for reimbursement. Insights gained into the influence of health economic 
analysis from this qualitative analysis will be helpful in designing further studies of impending 
changes to the French and Scottish systems, and in wider studies of other agencies. 
6.3 Methods 
This study was based on detailed literature and documents, supplemented by consultations with 
staff members at the respective HTA agencies in Scotland and France - the Scottish Medicines 
Consortium (SMC) and the Haute Authorite de sante (HAS) and researchers active in the HTA field 
in France and Scotland. The first step was to obtain a clear picture of the operation of each 
reimbursement decision-making system from published commentaries and the publicly available 
documents of the agencies themselves. The differences in process and decision criteria were 
identified using a framework for describing and classifying reimbursement systems (Hutton et aI., 
2006). The framework classifies systems at a policy implementation level and technology decision 
level. From this any differences in processes and decision criteria were identified. 
The similarities and differences in listing recommendations for both agencies at the technology 
decision level were considered by collecting, for both agencies, for new medicine and extension of 
indications in 2010. This covered a narrower group of medicines assessed by HAS as they assess 
a" medicines and provide reassessment at 5 years. The listing recommendations of both agencies 
were classified by using a categorisation developed by Raftery et 01., which distinguishes between 
the different types of restriction. The classification included; recommend in line with marketing 
authorisation, minor restriction (specialist use/monitoring of patient), major restriction (limited to 
line of therapy, patient subgroup, intolerant to existing treatments) and not recommended 
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(Raftery, 2006). The classification additionally accounted for the type of HAS recommendation; 
National Insurance and hospital use or hospital use only and whether additional observational 
studies were requested. 
In order to provide explanations for differences in recommendations between the two agencies 
the HAS English language translated opinion documents were extracted from the HAS website for 
recommendations between 2005 and 1st of January 2010 and were matched with SMC advice for 
the same medicine and patient indication. The HAS agency prioritised the translation of advice by 
those medicines that had gained a European Marketing Authorisation (EMA) and there were no 
major changes to the agencies evidence requirements or processes during this period. The data 
extracted from the SMC and HAS recommendation documents are presented in Table 6.1. 
The characteristics of the evidence and committees perceptions of the fitness for purpose of the 
common medicines appraised were described. A qualitative analysis of the documentation was 
performed to identify themes for differences in the agencies' recommendations for medicines 
evaluated. The themes were considered with respect to differences in the clinical evidence and its 
interpretation and the conclusions resulting from the SMC's consideration of health economic 
analysis (cost utility, cost effectiveness and cost minimisation analysis). Three medicines were 
selected to illustrate some of the common themes for discrepancies between the 
recommendations of the two agencies. 
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Table 6.1: Data collected from documentation for medicines appraised 
Item Data Extracted: Notes regarding extracted evidence 
listing • listing recommendation reported in advice documents The recommendations for both agencies were extracted for classification 
Recommendation 
Type of recommendation for France (Hospital use or Social into one common classification provided by Raftery et 01. • 
Health Insurance) 
• Disease area 
Manufacturers • Clinical efficacy evidence (trial name and year); Data were collected from the recommendation documents to identify the 
submitted clinical 
clinical efficacy evidence and evidence synthesis. Trial names were 
evidence • Evidence Synthesis (meta-analysis, network meta-analysis); 
• Comparators; identified from Cochrane CENTRAL database. 
• Primary Outcome. 
Fitness for purpose • Reported issues with clinical evidence submitted The fitness for purpose of the manufacturer submission was considered by 
of clinical evidence 
and evaluation of • Conclusions regarding relative effectiveness of the medicine collecting data on the committees' issues with the evidence with respect to 
relative- • SMR (Medical Benefit) study design, quality, relevance to practice and robustness of network 
effectiveness: 
meta-analysis. The conclusions regarding the relative-effectiveness 
• ASMR (Improvement in Medical Benefit) 
through the description provided by the SMC and the HAS judgement of 
the ASMR resulting from the evidence. 
Manufacturers • Type of economic analysis; The estimates of cost-effectiveness analysis were recorded for those 
health economics 
specific to the indication recommended in the advice document. 
submission • Cost-effectiveness estimate reported; 
Fitness for purpose • Reported issues with health economic analysis submitted to the The fitness for purpose of the economic analysis was considered by the 
of health economic SMC; main issues reported in the documentation produced by the SMC. 
analysis. 
• Conclusion regarding cost-effectiveness. 
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6.4 Results 
The results are presented in two sections; the description of the two reimbursement systems 
using the framework for classifying reimbursement systems, Hutton et 01. (Part 1) and an analysis 
of the recommendations and characteristics for a series of medicines evaluated by both 
reimbursement agencies (Part 2). 
6.4.1 Part 1: Comparison of reimbursement systems 
A comparison of the two reimbursement systems is provided in Table AG.1 by using the data 
collected from chapters 3 and 4. 
Policy Implementation Level 
The Scottish health care system provides universal coverage, is mainly financed through taxation 
and national insurance contributions and a fixed £3 prescription charge is for those required to 
pay the charge (set to be abolished in Scotland from April 2011). In contrast, the French system is 
mainly financed through social health insurance (approx 7S%) paid for by the employer and 
employees and co-insurance rates vary for prescription medicines based on the review of 
effectiveness where between 0% and 100% is paid by the social health insurance fund. Prices for 
branded medicines are set freely within the Scottish reimbursement system prior to evaluation of 
the medicines' cost-effectiveness at the list price but are restricted by ex-post profit controls and 
price reductions through the UK wide Pharmaceutical Price Regulation Scheme (PPRS) 
(Department of Health, 200S). In France the HAS opinion informs the pricing and volume 
agreements that are negotiated between the manufacturer and the Economic Committee for 
Health Products (CEPS) for outpatient medicines and medicines on top of DRG. Prices for those 
medicines for hospital use included in the DRG are negotiated directly with the individual 
hospitals (Ministry of Health, 2010). 
The reimbursement systems of the two countries are compared in Figure 6.1. The most notable 
differences are the number of stages and remit of the agencies. The SMC only appraises 
medicines whereas the HAS remit is wider including medical device opinions, professional 
practices, certification of health facilities and guiding the management of long term illnesses. The 
two systems include agencies whose processes include HTA to provide advice on the 
reimbursement of medicines: SMC established in 2001 by Health Boards in Scotland and the HAS 
established in 2004 by the Ministry of Health and Solidarity in France. The French system includes 
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a second stage in which advice is produced by the CEPS department on the negotiation of price 
with the manufacturer using the assessment of clinical evidence provided by HAS. The agencies 
similarly provide advisory recommendations. The final reimbursement decisions are made by the 
15 Health Boards in Scotland and pricing and reimbursement decisions are made by CEPS and the 
Ministry of Health and Social Security in France. An Area Drug and Therapeutic Committee (ADTC) 
formulary list is produced by each Scottish Health Board and a positive formulary list is provided 
in the Official Journal of France (HAS, 2011c, SMC, 2011a). 
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Figure 6.1: French and Scottish reimbursement systems 
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Technology decision level 
1. Assessment of evidence 
HAS considers all pharmaceuticals whereas the SMC considers all newly licensed medicines, new 
formulations of existing medicines and new indications for established products (SMC excludes 
assessment of vaccines, branded generics, non-prescription-only medicines (POMs), blood 
products, plasma substitutes and diagnostic medicines) once marketing authorisation has been 
granted by the respective regulatory agencies. There is a fee charged to the manufacturers for 
submission of a dossier to HAS (2,875 EURO) but no fee required for submission of the New 
Product Assessment Form (NPAF) to the SMC. The two agencies similarly require the 
manufacturer to submit evidence of clinical efficacy, comparative safety and demonstrate the 
relative-effectiveness of the medicines but judge the evidence and associated uncertainty through 
different approaches. The SMC also includes a subgroup called the Public and Patient Involvement 
Group (PAPIG) which is comprised of members of the SMC and public partners. The PAPIG main 
purpose is to ensure that the patient/carer perspective is taken into account in all SMC advice. 
Patient interest groups can provide submissions for each medicine appraised by the SMC 
committee and a template and guidance is provided on the website (SMC, 2011e). Neither agency 
has a process for comments from external stakeholders on the assessment of evidence. 
(i) Efficacy and relative-effectiveness assessment 
The SMC requires the manufacturer to provide evidence assembled systematically for the 
indication(s) of the medicine including details of RCTs (active controlled most relevant), meta-
analyses, and most relevant effects of a medicine. The manufacturer provides evidence of clinical 
efficacy and is required to consider the medicine in terms of the applicability to clinical practice in 
Scotland, guidelines and relevant protocols for the most relevant active comparator medicines. In 
the absence of head to head evidence a network meta-analysis is required by the SMC. The 
network meta-analyses should be described with reference to a systematic review for studies 
included and the search strategy for trials included and clinical/statistical heterogeneity between 
data sources (SMC, 2011b). 
HAS requires the manufacturer to submit all relevant studies for the clinical efficacy of the 
medicine but there are no requirements for these to be identified by a systematic review of the 
evidence. In the absence of head to head trials a network meta-analysis is permitted. The HAS 
performs a separate literature review of the evidence. 
(ii) Cost-effectiveness assessment 
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The responsibility for demonstrating the cost-effectiveness and any further analysis relevant to 
Scottish practice rests with the manufacturer and failure to submit cost-effectiveness 
automatically results in a not recommended decision. A reference case is not provided but the 
SMC specifies that cost-utility analysis is the preferred form of economic evaluation and health 
effects should be expressed in Quality-Adjusted life Years (QAl Ys). Modelling is the main 
framework used to synthesise data of clinical and cost-effectiveness, in the absence of real-life 
effectiveness data. Manufacturers are required to provide sensitivity analysis in the form of single 
and multi-way analysis to allow the committee to explore the uncertainty in the estimates. 
HAS and SMC both provides summaries of the assessment of evidence within the document 
detailing the appraisal of evidence on their respective websites. HAS documents are known as 
'HAS Opinions' and the SMC documents are known as 'SMC advice'. The agencies do not provide 
the original manufacturer submission on their websites (HAS, 2011, SMC, 20lla). 
2. Decision process 
(i) Appraisal of clinical evidence 
The HAS committee is called the Transparency committee and considers the dossier from the 
manufacturer and a review of the literature. There are two committees in the SMC, the New 
Drugs Committee (NDC) that considers the evidence submitted and reports to the SMC 
Committee that makes the final recommendation decision. The NDC and Transparency 
committee solely receive a submission from the manufacturer of the relevant evidence and in 
contrast to NICE in England, do not commission a third party to provide a separate review of the 
clinical evidence and economic evidence (in the case of SMC). Both committees consider the 
fitness for purpose of the clinical efficacy evidence, relative-effectiveness and its generalisability 
to French and Scottish practice. 
The two committees report different outcomes from their respective appraisals; the NDC reports 
a qualitative description of the relative-effectiveness considerations, which has been taken from 
asking six standard questions from independent experts. In contrast, the Transparency 
committee is informed by a literature review and the manufacturers submission and reports a 
medical benefit (SMR) and the Improvement in Medical Benefit (ASMR) (including a 
manufacturers claimed score for both these criteria). A detailed summary of these 
considerations can be found in Table I. The SMR is determined by the absolute clinical effect and 
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the importance to public health and this determines whether the medicine should be reimbursed 
and the rate at which it should be reimbursed. 
The appraisal of the ASMR by the Transparency committee has implications for the price that is 
negotiated between the manufacturer and CEPS. A separate ASMR may be awarded to a 
medicine that has different benefits in different indications or patient subgroups. Medicines 
receiving an ASMR I-III are allowed free pricing relative to the maximum average of UK, Germany, 
Italy and Spain by the CEPS. Prices of medicines with an ASMR of IV and V are negotiated resulting 
In a price similar to or less than the comparator in France, along with a price-volume agreement. 
When there is uncertainty in the evidence, HAS requires the manufacturer to collect further 
observational data as a condition of the opinion for listing. 
(Ii) Appraisal of economic evidence 
The SMC aims to maximise health gain from a fixed NHS budget and cost-effectiveness provides a 
summary of these economic considerations (SMC, 2011a). Similar to consideration of the clinical 
evidence the committees must consider the fitness for purpose of the economic evidence and the 
interpretation of the estimate of cost-effectiveness in the context of the medicine's use in 
practice. The health economic analysis is one criterion considered in the draft advice by the NDC 
to the SMC and the threshold range reported in the NICE guide to appraisal is considered in the 
context of other criteria (NICE, 2008). Since 2009, manufacturers have been able to submit a 
Patient Access Scheme (PAS) to improve the cost-effectiveness of a medicine by reducing the cost 
of the new medicine and allowing patient access to clinically effective medicines. These schemes 
essentially provide a discount on the price whilst maintaining the list price of the medicine. 
Outputs and Implementation 
The details of the recommendations are provided in an advice document for the SMC within 120 
days (non-legally binding) and an opinion document for the HAS in 90 days (legally binding). 
Neither of the agencies publishes the manufacturer submission. Three categories of advice are 
provided by the SMC to the Area Drug and Therapeutic Committees (ADTe) for listing; accepted 
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for use; accepted for restricted use and not recommended 2• In contrast, HAS opinions are either 
positive or negative (conditions may also be imposed for additional studies or a target patient 
population) and are produced for the CEPS of the Ministry of Health where decisions are made on 
the price for outpatient medicines and hospital medicines that are not covered within the DRG 
(Ministry of Health, 2010). 
Manufacturers may resubmit to the SMC in the light of new evidence or a new analysis of existing 
evidence but the SMC does not periodically review existing advice. In contrast, HAS can self-refer 
medicines in the presence of new evidence, reviews all medicines at 5 years post-listing and 
assesses the evidence from any post-listing studies. The recommendations at the 5-year review 
may result in the SMR being revised and an opinion for de-listing the medicine. Manufacturers 
may submit new evidence for medicines at any point in a new dossier and the Transparency 
committee will provide reassessment of the medicine. 
6.4.2 Part 2: SMC and HAS recommendations for 2010 
The HAS published a total of 410 opinions on their website, reflecting the wider remit of 
medicines assessed by HAS including reassessment of SMR and renewal of registration but 
excluding those medicines following a simplified process (generics or different presentations of a 
medicine already listed). The SMC published 86 advices in 2010 on their website (including 
abbreviated submissions). The SMC considered 57 and HAS considered 122 new medicines 
including new indications and extensions of indications in this year. The HAS recommended 
listing in 115 (96%) and the SMC recommended listing for 32 (56%) of these medicines. Table 
A6.2 provides a tabulation of the listing recommendations and characteristics of the medicines 
assessed by each agency. 
6.4.2.1 Similarities and differences In medicine recommendations 
There were 39 English translated submissions that were matched between 2005 and the start of 
2010. The matched medicines were for treatment of a variety of diseases such as neoplasms, 
diseases of the nervous system, infection and parasitic, circulatory system, endocrine, nutritional 
and metabolic, skin and musculoskeletal system. The details of the recommendations can be 
2 
There is the facility for the SMC to designate an innovative medicine for a condition where there are no other treatment options 
as "unique". In the event that such a medicine for a specific condition was accepted by SMC, NHS Boards would be required to 
introduce it to an agreed national programme. 
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found in Table 6.2 and Table 6.3 and 6.4 present the medicines and diseases treated. The 
proportion of medicines recommended for listing for this selected sample of medicines were 85% 
for the SMC and 100% for HAS. The SMC recommended in 33%, minor restriction in 13%, major 
restriction in 39% and were not recommended in 15%. The HAS opinions were recommended in 
59%, minor restrictions in 28% and major restrictions in 13%. There were 14 concordant decisions 
made between the two agencies (Kappa Statistic=O.l1), which can be interpreted as poor 
agreement between the two agencies recommendations. In eight of the submissions, six 
concordant and two discordant decisions, the Transparency committee requested additional 
observational data as a condition of the recommendation to be presented for reassessment. 
There were some similarities with the disease areas treated by medicines appraised in 2010, 
although there were a more diverse number of diseases in this year and a higher rate of not 
recommended for both agencies in comparison to the matched sample. 
6.4.2.2 Manufacturers' clinical evidence submissions 
The majority of submissions contained one or two key trials that informed the submission for 
clinical efficacy and evidence of clinical effectiveness. There was at least one commonly reported 
trial in both the SMC and HAS recommendation document for the same medicine. In twelve of 
the recommendations there were additional studies presented by the manufacturers. There were 
six cases where no common comparators were shared between the submissions for SMC and 
HAS. Network meta-analyses were submitted on eight occasions to the SMC and three occasions 
to HAS. The manufacturer similarly submitted such analyses to both agencies in two common 
submissions. Few details were provided in the documents produced by both agencies with 
respect to the network meta-analyses such as trials included, whether the analysis was a mixed 
treatment comparison or indirect comparison and the type of statistical analysis. 
Chapter 6: Comparison of a system using HE versus no use of HE 217 
Table 6.2: Cross tabulation of matched SMC advice and HAS opinions 
HAS advice 
SMCadvice . To list advice To list Minor Restriction To list Major Restriction To not list Total (SMC) 
list advice 8 3 , 2 0 13 (33%) 
list Minor Restriction 1 4 0 0 5 (13%) 
list Major Restriction 11 2 2 0 15 (39%) i 
To not listed 3 2 1 0 6 (15%) 
Total (HAS) 23 (59%) 11 (28%) 5 (13%) 0(0%) 39 (100%) I 
---- - '------
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Table 6.3: Cross tabulation of medicines for matched SMC advice and HAS opinions 
HAS advice 
SMCadvice To list advice: 23 (59%) To list Minor Restriction: 11 To list Major Restriction: 5 To not List: 0 (0%) 
(28%) (13%) 
List advice: 13 (33%) (003: docetaxel (H) (002: ribavirin (NHI & H) (015: ibrandronic acid (NHI & 
COO4: candesartan cilexetil (NHI C016: pegylated interferon alfa H) 
&H) 2a (NHI & H) (040: testosterone 
(005: solifenacin succinate (NHI & (028: adalimumab (NHI & H) undecanoate (NHI & H) 
H) 
(018: posconazole (H) 
(026: levetiracetam (NHI, H) 
C032: nebivolol (NHI & H) 
(050: levetiractem (NHI & H) 
(051: palonosetron (NHI & H) 
List Minor Restriction: 5 (027: exemestane (NHI & H) (all: capecitabine (H) 
(13%) (014: sildenafil citrate (H)) 
(043: rituximab (H) 
(048: rituximab (H) 
List Major Restriction: 15 (009: lanthanum carbonate (NHI COlO: omalizumab (H) (038: pegaptanib (NHI & H) 
(39%) & H) C013: erlotinib (NHI & H) (047: parathyroid hormone 
C023: tipranavir (NHI & H) (NHI & H) 
(024: infliximab (H) 
(030: voriconazole (H) 
(033: daptomycin (H) 
C036: tigecycline (H) 
C037: tigecylcine (H) 
C045: ivabradine (NHI & H) 
C046: natalizumab (H) 
C049: levetiracetam (NHI & H) 
C052: posaconazole (H) 
To not Listed: 6 (15%) COOl: botulinum type A (H) C025: sodium oxybate (H) C034: alglucosiuidase alfa (H) 
(007: rasagiline (H) (029: sorafenib (H) 
C008: rasagiline (NHI & H) 
-----
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Table 6 4' Common medicines . . 
No. Drug Indication ICD-l0 Disease Category 
1 botulinum toxin type A Focal Spasticity Diseases of the nervous system 
2 ribavirin Children with Chronic Hepatitis C Certain infectious or parasitic diseases 
3 docetaxel Node-positive Breast Cancer Neoplasms 
4 candesartan cilexetil Heart Failure Diseases of the circulatory system 
5 solifenacin succinate Incontinence Diseases of the genitourinary system 
6 rasagiline Parkinson's Disease Indicationl Diseases of the nervous system 
7 rasagiline Parkinson's Disease Indication 2 Diseases of the nervous system 
8 lanthanum carbonate Chronic Renal failure Diseases of the genitourinary system 
9 omalizumab Asthma Control Diseases of the respiratory system 
10 capecitabine Colon Cancer Neoplasms 
11 erlotinib NSClC Neoplasms 
12 sildenafil citrate Pulmonary arterial hypertension Diseases of the circu latory system 
13 ibandronic acid Osteoporosis Diseases of the musculoskeletal system 
14 peginterferon alpha-2a Chronic Hepatitis B Certain infectious or parasitic diseases 
15 posaconazole Invasive Fungal Infection Certain infectious or parasitic diseases 
16 tipranavir HIV Certain infectious or parasitic diseases 
17 infliximab Psoriasis Diseases of the skin and subcuta neous tissue 
18 sodium Oxybate Narcolepsy Diseases of the nervous system 
19 levetiracetam Epilepsy Diseases of the nervous system 
20 exemestane Breast Cancer Neoplasms 
21 adalimumab Psoriatic Arthritis Diseases of the skin and subcutaneous tissue 
22 sorafenib Renal Cell Carcinoma Neopiasms 
23 voriconazole Candidemia Certain infectious or parasitic diseases 
24 nebivolol Chronic Heart Failure Diseases of the circulatory system 
25 daptomycin Soft Tissue Infections Diseases of the skin and subcutaneous tissue 
26 alglucosidase alfa Pompe Disease Endocrine, nutritional and metabolic diseases 
27 tigecycline Soft Tissue Infections Diseases of the skin and subcutaneous tissue 
28 tigecycline Intra-abdominal infections Diseases of the digestive system 
29 pegaptanib Age-related macular degeneration Diseases of the eyes and adnexa 
30 testosterone undecanoate Testosterone Deficiency Endocrine, nutritional and metaboliC diseases 
31 rituximab Lymphoma Neoplasms 
32 ivabradine Chronic Stable Angina Diseases of the circulat~ system 
33 natalizumab Multiple sclerosis Diseases of the nervous system 
34 parathyroid hormone Osteoporosis Diseases of the musculoskeletal system 
35 rituximab Rheumatoid arthritis Diseases of the musculoskeletal system 
36 levetiracetam Epilepsy Diseases of the nervous system 
37 levetiracetam Epilepsy Diseases of the nervous system 
38 palonosetron Cancer Chemotherapy Neoplasms 
39 posaconazole Invasive Fungal Infection Certain infectious or parasitic diseases 
6.4.2.3 Fitness for purpose and relative-effectiveness 
The two committees reported issues with the clinical evidence in 77% (30/39) submissions. The 
common issues reported by both committees were lack of direct comparison with active 
comparators (n=14), selection oftrial patient population (n=9), submission of uncontrolled studies 
(n=l) and lack of long-term efficacy data (n=l) (Table A6.7). The Transparency committee 
considered all the network meta-analysis submitted to be unreliable due to the lack of 
exchangeability between trials. In contrast, the SMC considered all of the network meta-analyses 
and these were used in the economic models submitted to the SMC. The source of a few meta-
analyses reported for the SMC were those previously informing NICE decision-making. 
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The Transparency committee considered 64% (24/39) of medicines submitted to demonstrate 
relative-effectiveness (ASMR = [1, 2, 3 innovative], 4) in comparison to French practice (Table 6.5). 
The SMC provided a description of the clinical-effectiveness and it was inferred from the 
description that the SMC judged improvement in relative-effectiveness with respect to the clinical 
outcome and health related quality of life for 30 medicines. 
Table 6.5: HAS medicine ASMR level 
ASMR Number of Medicines 
1- Major 2 
2 -Important 6 
3- Modest 11 
4-Minor 5 
5 -Inadequate 15 
Total 39 
6.4.2.4 Health economic evidence submitted 
The SMC reported issues with the economic evidence in 21 submissions. The main reasons for 
concerns with the economic evidence were consideration of a limited number of comparators 
(n=5), costing and resource use (n=5), model assumptions (n=4) and the use of appropriate clinical 
data (n=3). 
The manufacturer submitted cost-utility analysis in 31 cases claiming an improvement in health 
benefit in comparison to usual practice in Scotland. The manufacturer targeted a subgroup of the 
licensed population in 11 of the submissions. When costs had been modelled the estimates 
provided for the cost-utility analyses ranged from dominant (QALY benefit and cost-saving) to 
£318,283 per QALY. There was one submission including a cost-effectiveness analysis and 8 
submissions including cost-minimisation analysis. 
6.4.2.5 Qualitative analysis of reasons for differences In recommendations 
The reasons for differences in the recommendations are contained in Table A6.4 and Table A6.5. 
The most common reasons were differences In the comparators and committees judgement of 
the uncertainty in the evidence (n=4); both committees agreeing on uncertainties in the clinical 
evidence but uncertainties in the economic evidence leading SMC to be more restrictive or not 
recommend (n=4); both agreeing on equivalent relative-effectiveness but the use of cost-utility 
analysis resulting in either HAS or SMC being more restrictive (n=4); both agreeing on 
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improvement in relative-effectiveness but manufacturer submits in a subgroup where the SMC 
advises a major restriction (n=3); both agreeing on improvement in relative-effectiveness and 
manufacturers submission to the SMC demonstrates cost-effectiveness but either agency 
providing a minor restriction (n=3); both agreeing on improvement in relative-effectiveness but 
the price was too high to enable cost-effectiveness in Scotland (n=2) and other reasons (n=5). 
The following three case studies focus on the left hand side four quadrants of Table 6.3 where the 
SMC was more restrictive in comparison to HAS and illustrate some of the main common issues 
that may explain differences in the recommendations between HAS and SMC. 
Infliximab: Synthesis of evidence using network meta-analysis 
The Transparency opinion included judgements on two extensions of indications (psoriatic 
arthritis and psoriasis). The matched SMC advice focused on a single indication for the treatment 
of moderate to severe psoriasis in adults who have failed to respond to, or who have a 
contraindication to, or are intolerant of other systematic therapy. The clinical evidence submitted 
to the SMC and HAS contained the same clinical efficacy evidence for two double blind RCTs and 
one additional double blind RCT. Both submissions included an indirect comparison, which was 
judged by the Transparency committee to be unreliable due to the dosage of methotrexate in the 
included trials, other treatments, lack of tests for heterogeneity, length of follow-up and lack of a 
systematic review. The Transparency committee concluded that infliximab shared the same 
moderate improvement in actual benefit as etanercept (ASMR=3) for those patients with severe 
psoriasis. The Transparency committee additionally requested a representative observational 
,-
study of the benefit in practice over 5 years. The SMC judged the indirect comparison submitted· 
(previously been used in NICE decision-making) to be useful for the economic model but noted 
that there could be heterogeneity between trials. The results of the indirect comparison 
presented in the submission demonstrated infliximab to have a higher PASI75 response than 
etancercept and efalizumab. These estimates were included in the economic model producing an 
estimate of £27,354 per QAl Y for severe psoriasis. The SMC judged that the economic case had 
been made and advised a major restriction to this subgroup. 
Sorafenib: Clinically-effective and free pricing versus negotiation 
Sorafenib is indicated for the treatment of patients with advanced renal cell carcinoma who have 
failed prior interferon alpha or interleuken 2 based therapy or considered unsuitable for such 
therapy. The same clinical efficacy evidence was submitted to the agencies which included one 
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Phase II RCT placebo controlled and one Phase /II placebo controlled RCT. The trials 
demonstrated a progression free survival of approximately 3 months in comparison to placebo 
(relevant comparator in both countries), although evidence was unavailable at the time of 
recommendations for improvement in overall survival. HAS acknowledged this uncertainty and 
judged the medicine to be an important improvement in actual benefit (ASMR=2) and 
recommended listing. The SMC committee similarly judged an improvement in relative-
effectiveness and considered the manufacturer's Markov model to be well conducted, which 
produced a base case estimate of £35,523 per QALY. The committee were concerned with the 
uncertainty in the extrapolations from the available trial data and substantially reduced the 
confidence that could be placed in the longer-term estimates of cost-effectiveness. The SMC 
judged that in light of the uncertainty and price supplied by the manufacturers' cost-effectiveness 
had not been demonstrated. 
Erlotinib - Formal consideration of quality of life versus ASMR 
Erlotinib is indicated for the treatment of patients with locally advanced or metastatic Non-Small 
Cell Lung Cancer (NSCLC) after failure of at least one prior chemotherapy regimen (EGFR positive 
patients only). Both of the submissions included a Phase III double blind placebo controlled trial, 
in addition the submission to HAS included two phase I dose ranging studies and one phase II non-
comparative study of efficacy and safety. The primary outcome of overall survival demonstr~ted 
a 2 month improvement in actual benefit in comparison to placebo, but the main comparators in 
France and Scotland are docetaxel and pemetrexed for second line. The absence of evidence for 
these relevant comparators, led the Transparency committee to advise to recommend with no 
improvement in actual benefit for second line therapy. The SMC manufacturer's submission 
presented the economic case for those that would be eligible for docetaxel monotherapy. The 
submission presented a cost-utility analysis that was informed by the synthesis of evidence by an 
indirect comparison to enable a comparison with docetaxel. The analysis found a quality of life 
improvement in contrast to the Transparency committee, which could not judge the impact in the 
absence of direct comparisons. The estimate of £4,800 per QALY in the basecase was subject to 
uncertainty regarding the appropriate number of cycles for which expert advice considered 4 to 
be appropriate resulting in an estimate of £22,500 per QAlY. The medicine was recommended in 
this restricted group. 
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6.5 Discussion 
The agencies share similarities in their objectives of providing information and advice to their 
respective authorities to make final reimbursement decisions on the use of medicines but have 
different remits for medicines appraised. The HAS agency recommended listing in the majority of 
cases whereas the SMC was more likely to not recommend or place restrictions on the medicine 
in 2010. In those common medicines covering a variety of disease areas the trend remains, 
although there is a slightly higher proportion of listing recommendations for both agencies in this 
selected sample. The qualitative analyses show that similarities exist in the clinical trials 
submitted by the manufacturer and consideration of issues relating to the studies submitted 
(relative efficacy). Differences in recommendation may be explained by a combination of the 
manufacturer's freedom to set price and the incentives provided by the consideration of 
economic evidence by the SMC, alongside differences in relevant comparator medicines, relevant 
outcomes, country specific treatment guidelines, submission of network meta-analysis and the 
propensity to use such evidence synthesis methods in decision-making. 
Pricing approaches differ in both countries - price negotiations are performed by the CEPS after 
the HAS makes a judgement on the SMR and relative-effectiveness in France (ex-post price 
negotiation). In contrast, in Scotland prices are set freely (ex-ante free pricing) and an economic 
evaluation provided in addition to the clinical evidence. The systems provide different demand 
curves for global profit maximising manufacturers who consider the impact of the local listing 
price on international price referencing. In the common medicines evaluated there were cases 
where HAS recommended the medicine (obtaining a set maximum price defined by the ASMR) 
and the manufacturer chose to submit the cost-effectiveness evidence for a targeted subgroup to 
, 
the SMC. This may suggest a high price was more important for international price reference" 
purposes than the potential local revenue maximising position for the manufacturer given that 
the UK represents a relatively small 3.5% (Scotland represents cl0% of this proportion) of the 
global market (OECD, 2008). 
The consideration of economic evidence by the SMC rather than a score relating to improvements 
in relative-effectiveness (HAS) provides differences in the perceptions of value of some new 
medicines depending upon the medicines' characteristics. The requirement for manufacturers to 
present an economic evaluation may explain some of the variation in recommendations because 
in combination with free pricing it has provided incentives for the manufacturer to target a 
patient population, quantify and understand the uncertainty of the relative-effectiveness 
224 Chapter 6: Comparison of a system using HE versus no HE 
estimates in combination with the cost of the medicine and formally quantify the health related 
quality of life benefits for the medicine. 
The assessment of the medicines improvement in actual benefit using the primary clinical 
outcomes by HAS produced some examples where the HAS committee judged the medicine to 
have no improvement based on the same clinical evidence and relevant comparators. In these 
cases the manufacturer had presented cost-utility analysis to the SMC, and the committee judged 
this to be robust demonstrating modelled improvements in overall health related quality of life. 
The formal consideration of health related quality of life in some SMC submissions was rewarded 
by a premium price. In contrast, the Transparency committee judged no improvement (ASMR=5) 
leading to no premium price because there was no formal analysis of health related quality of life 
(HRQOL) provided. 
The SMC and HAS both assess the evidence around the point of marketing authorisation and HAS 
sometimes requires the manufacturer to collect additional observational evidence when the 
evidence is uncertain for the reassessment at 5-years. Network meta-analyses were more 
frequently submitted to the SMC and included in the respective economic analysis that included 
sensitivity analysis to explore the uncertainty in the treatment effect. This type of analysis maybe 
more frequently submitted to the SMC because of its use in the economic evaluation or because 
the Transparency committee tends to judge such analyses submitted by the manufacturer t~ not 
be sufficiently robust. The Transparency committee dealt with these uncertainties by judging and 
categorising the medicine as no improvement in relative-effectiveness; with the implications 
being that the price resulting would be similar or lower than the existing treatments. In contrast, 
the SMC considered the sensitivity and scenario analysis around the estimates of cost-
effectiveness and provided a restricted recommendation or not recommended decision 
depending on the degree of uncertainty. There were a few examples where the Transparency 
committee placed restriction on the use due to uncertainty in the clinical evidence on the first 
recommendation. The differences between the systems make price the main adjustment variable 
in France, as opposed to quantity in Scotland. 
There were examples where the maximum price setting and negotiation in France allowed the 
medicine to be available in France but not in Scotland because the medicines were not cost-
effective at the list price. Since 2009, a patient access scheme process has been made available to 
manufacturers In Scotland. This now enables manufacturers to propose a pricing discount that 
does not affect the list price, but improves the cost-effectiveness of a new medicine allowing 
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reimbursement. These clinically effective medicines may have been recommended if such a 
scheme had existed then. 
The reimbursement processes (free pricing, number of stages, medicines assessed, reassessment 
of decisions) could be just as important in explaining differences in decisions as the methods for 
evaluating the technologies at the technology decision level (use of economic evaluation). At 
launch, the Scottish system uses economic evaluation to understand the uncertainties and may 
restrict or not recommend when the committee judges there to be too much uncertainty given 
the price set by the manufacturer. Economic analysis is essential to control access where prices 
cannot be negotiated. The French system tends to more often recommend the medicine and will 
provide a price at launch that is reflective of the judgements of clinical efficacy and uncertainty in 
the evidence. The French process then requires the manufacturer to collect further real life 
evidence in the presence of uncertainty for reassessment of listing. This provides access to new 
medicines for patients, but lower financial incentives to innovative global manufacturers. 
This study provides some hypotheses and explanations for the differences observed in 
recommendations for a selected sample of medicines but does not identify whether one 
reimbursement system is better than the other in delivering health benefits, controlling health 
care costs or incentivising innovation. This would require further quantitative analysis of a larger 
sample of medicines for the two agencies and observation of utilisation rates and patient 
outcomes. Further research could explore the balance between the manufacturer (producer 
surplus) and patients (consumer surplus) by an analysis of prices and reimbursement decisions 
over the life cycle of the medicines in the two countries. Even if this were possible a study design 
which controlled for all system differences would be difficult to achieve. A further limitation is 
that the study relies on the documented evidence available where some of the considerations' 
may not have been documented. Additionally, the HAS recommendations for which English 
translations are available may not be representative. 
In December 2010, consultations were published in both countries for changes to the evaluation 
of medicines. The Department of Health in England3 has published a consultation on a new value 
based approach (VBP) to the pricing of branded medicines in the UK (Department of Health, 2010) 
consequently a number of suggestions have been made for the operation of VBP in the UK 
(Claxton et aI., 2011, NICE, 20l1f, Office of Fair Trading, 2007, Office of Health Economics, 2011). 
The HAS published a consultation on the procedures and methods for economic evaluation for 
3 
The PPRS Is a voluntary agreement between manufacturers In operation for over SO years and works In conjunction with other 
measures to encourage cost-effective prescribing of medicines. The Department of Health In England consulted on a proposal to 
modify this scheme through value based pricing for the entire UK. 
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technologies (HAS, 2010). The consultations propose the introduction of price negotiation for the 
SMC and the introduction of economic evaluation for HAS appraisal of medicines, which may 
result in more similarities between the two reimbursement systems in the future. The potential 
process changes may reduce the differences in recommendations and access to medicines in both 
countries using VBP informed by economic evaluation. The Scottish system will need to 
determine the details of price negotiations, agencies involved, other factors to be taken into 
account and reassessment of the price and any new evidence for medicines. The French system 
will need to determine whether health economic evaluation is used at launch and/or at 
reassessment, the opportunity cost of health care resources and other factors. The forthcoming 
details of these process changes will influence the extent to which variation in recommendations 
is reduced and health is maximised in each country given their respective budget constraints. 
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Chapter 7: Summary and Conclusions 
7.1 Overview summary 
In the earlier years of the development of health economic techniques, critics pointed out the 
difficulties that health economists had found in making an impact upon decision-making and 
developing techniques to be used by decision-makers (loomes and McKenzie, 1989, Ashmore et 
aI., 1989). Sociologists wrote a book about Health Economists in the late 1980s with a pessimistic 
outlook for the application of health economic techniques for practical purposes and wrote the 
following: 
' ... .few applied social scientists are likely to work in an environment as generally 
advantageous as that enjoyed by contemporary British Health economists. While their 
achievements should, quite legitimately, encourage other applied social scientists, their 
disappointments and failures must stand as a warning to us all of the inherent difficulty of 
using academic social science as a basis for practical assistance of others.' (p.3 (Ashmore 
et aI., 1989)) 
The development of health economic analysis since then has gained prominence in the appraisal 
and evaluation of health technologies. In the course of this thesis I have explored the contribution 
of health economic analysis to medicine reimbursement decision-making in a number of OECD 
reimbursement systems. One of the main aims of the thesis was to understand the similarities 
and differences in the use of health economic analysis and the influence upon reimbursement 
decisions for pharmaceuticals. The novelty of this thesis covers four main interlinked topics: 
1. The thesis identifies the current evidence base with respect to the influence of factors on 
OECD countries' reimbursement decisions. Chapter 2 identified few quantitative studies 
addressing the influence of factors on reimbursement decisions and even fewer country 
comparisons of reimbursement agencies and systems. There were a number of limitations 
with these studies. The studies focused on the evidence factors and fewer non-evidence 
factors and process factors were taken into account. 
2. There was little known about the operation of many OECD countries' entire 
reimbursement systems and the place of reimbursement institution(s) using HTA in the 
systems. The novelty of chapter 3 and 4 was to use a framework to systematically 
categorise OECD countries' reimbursement systems to identify the policy environment 
and process in which health economic analysis is used. Reimbursement systems are very 
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heterogeneous but some are more similar with respect to the evidence considered. 
Health Economic analysis is used in many reimbursement systems but there is variation in 
the extent of its use, the operation of a threshold range, committees and institutions 
involved in the system and the alignments with each system's policy objectives. 
3. Chapter 5 provides a comparison of reimbursement systems using formal health 
economic analysis. The chapter tests the hypothesis that some countries' reimbursement 
agencies using similar evidence requirements would display common association with the 
decision even though there is some heterogeneity in the process. The chapter considers 
factors across four established reimbursement agencies requiring similar clinical 
effectiveness and cost-effectiveness evidence using, regression analysis. There were 
elements of clinical evidence, non evidence factors and process factors that were 
correlated with decisions. Cost-effectiveness was not found to be statistically associated 
with the decisions and the magnitude of effect was small and surprisingly a measure of 
public interest was found to be associated with the decision. The findings require further 
research because some evidence factors could not be completely controlled for because 
of lack of reporting across the agencies and the methodology's lack of sufficient control 
for the process differences across the agencies. 
4. Chapter 6 provides a comparison of a reimbursement system using health economic 
analysis and one without the use of health economic analysis. The chapter contri~utes to 
the current knowledge on the contribution of health economics by comparing two 
reimbursement agencies' matched decisions, the SMC in Scotland and the HAS in France 
that provide advisory reimbursement decisions. There were differences in the 
recommendations for the same medicines with the SMC tending to restrict or not 
recommend in comparison to HAS. The chapter finds that the observed differences in the 
recommendations may be explained by price setting and process for dealing with 
uncertainty, relevant comparator medicines, relevant outcomes, treatment guidelines, 
use of network meta-analysis and formal consideration of HRQOL in the health economic 
analysis. 
The task of assessing the contribution of health economic analysis has required the use of both 
quantitative and qualitative methods of analysis and required consideration of new factors that 
may Influence medicines' reimbursement. Contribution can be considered in a number of ways 
and the thesis identified past research that had considered the contribution through the use of 
Health Economic analysis or by the association with decisions. The thesis has found the that there 
is a differential contribution through how Health Economic analysis Is used at the policy 
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implementation level and the individual technology decision level and has explored the influence 
on decisions in a comparison of Health Economic systems and the contribution through 
comparison with a system that does not use health economic analysis. Finally, the contribution 
through impact on the final outcomes in the reimbursement systems is discussed. 
7.2 The contribution Identified in previous research 
7.2.1 Contribution through use of health economic analysis 
Chapter 4 categorised medicines at the individual technology decision level and considered the 
use of health economic analysis in the decision process. If the contribution of health economic 
analysis is to be judged upon its use in reimbursement decision-making then it has made 
significant contribution in many systems. Health economic analysis is widely required across 
countries and a stated decision factor across twenty of the OECD countries studied. Cost-utility 
analysis is a preferred type of analysis across many of the countries using such evidence in 
decision-making. This has required Health Economists to be present on committees to interpret 
and make decisions in over half of those OECD countries committees where health economic 
analyses are required. There is variation with respect to the means of communication of the 
assessment to the committee and the documentation of the assessment of evidence. NICE in 
England and Wales is the only agency to communicate the manufacturer's submission on the 
website after the first appraisal meeting. Some agencies state the use of health economic analysis 
but do not provide documentation of the assessment of evidence for the medicine. This makes it 
difficult to interpret the contribution of such analysis to reimbursement decision-making in these 
countries. In contrast the willingness of the decision-maker to pay for independent analysis in a 
few of the countries such as NICE in England, PHARMAC in New Zealand and IQWIG in Germany 
(although there are no actual examples) may indicate the significant importance and value of such 
analysis to the decision-maker. 
7.2.2 Contribution through the association with reimbursement decisions 
Chapter two systematically reviewed the empirical studies that have considered the influence of 
health economics analysis and other factors on reimbursement decisions within and across 
countries. The majority of quantitative analysis focused on the correlation or association of the 
estimates of cost-effectiveness (cost per QALY, cost per effectiveness) and other factors on a cross 
sectional sample of decisions. The majority of evidence identified includes quantitative and 
qualitative studies for NICE decision-making in England, PBAC decision-making in Australia and 
CDR decision-making in Canada. There is limited evidence for the influence of factors for other 
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OECD countries' reimbursement decision-making and a lack of cross country comparisons of 
decisions and factors. Cost-effectiveness was the most frequently explored factor across studies 
when this was included. This was the only factor to have a consistent construct and studies across 
and within countries found the same direction of effect but the magnitude of effect was not 
always comparable because of the different methodologies used. Some studies provided 
estimates of the cost-effectiveness threshold from the analysis of retrospective decisions but 
some authors did not produce an estimate. Many of the studies included factors with respect to 
the clinical and economic evidence and few included other factors such as the influence of 
reimbursement process. Mixed evidence of the influence within reimbursement systems and 
across systems was found with respect to other factors, clinical evidence factors, non-evidence 
factors and process factors when these were included in the studies within countries and across 
countries (when included). There were a number of qualitative factors that were identified that 
had not been explored in the quantitative research which mainly related to the non-evidence 
factors and agencies' processes of decision-making. 
The samples of medicines included were generally only assessed and appraised at one point in 
time by the reimbursement agencies. The quantitative studies did not always define the meaning 
of influence, were often based on small samples of reimbursement decisions, and did not always 
explore the potential relationships between factors and the regression model specifications. The 
second chapter illustrated the need for both quantitative and qualitative studies for those single 
country analyses of the influence of factors when this had not been previously studied in OECD 
countries. There were few comparisons of reimbursement systems that identified the influence of 
health economic analysiS and process factors. One cross country comparison identified 
reimbursement process as a potential explanation but did not correlate differences directly with 
decisions or elucidate all the process factors potentially explaining differences in decisions 
(Clement et aI., 2009). 
7.3 Differential contribution of health economic analysiS through Its use In systems 
7.3.1 Health economic analysis use at the policy and Individual technology level 
Chapters three and four set out to understand and categorise the reimbursement systems using a 
framework to understand the institutions involved and the process of reimbursement decision-
making (Hutton et aI., 2006). The aims of these chapters were to help to understand the 
similarities and differences between the reimbursement systems before any empirical studies of 
factor influence were undertaken of reimbursement decisions across countries. Chapter 3 
Chapter 7: Summary and Conclusions 231 
categorised the systems at the policy implementation level and found varying objectives, types of 
financing and numbers of institutions involved in decision-making. The potential differences in 
principal objectives of the systems may explain the reimbursement processes and methods used 
at the individual technology decision level. The use and contribution of Health Economic analysis 
is most evident in NICE in England and Wales and this was established within the context of 
increasing health spending where the aims of such analysis were to reward innovation whilst 
gaining value for money. In contrast where the principal objective is cost containment such as 
Spain other primary methods and processes of reference pricing and price cuts are being used 
rather than health economic analysis and HTA. The principles primary objectives are important for 
the use and impact of such analysis across countries. However, these principle objectives vary 
overtime and depend on the political environment and those systems that frequently change the 
objectives and methods make study of the linkage of objectives and the use of health economic 
analysis challenging. 
Chapter 3 categorised systems by their implementation of decisions and found this can take place 
through a variety of mechanisms and a large number of the systems either operate through a 
social insurance sickness fund, through a Ministry of Health scheme or at a regional level where 
another decision-making body is responsible for the final decision and implementation. The 
variation in the mechanisms of implementation and other institutions involved affects the 
adherence to the recommendations made by the agencies and the ultimate impact of health 
economic analysis and HTA. Accountability of the reimbursement agencies was not well 
documented across the reimbursement systems. The accountability of reimbursement agencies 
was addressed by the existence of a formal appeal and consultation process or by reporting 
measures of performance against the objectives of the reimbursement agency. The performance 
of systems was often demonstrated by the reimbursement agency through the volume of 
decisions published and the rates of recommendations for medicines. Only the PHARMAC agency 
in New Zealand was identified to set targets for each year with respect to the influence of 
decision-making for medicines on health outcomes in a document that they call a 'statement of 
intent'. The agency estimates the health gain in terms of QALYs by considering the average values 
of the funding options available to them called the prioritisation list and comparing this with the 
average value of the funding decisions actually made. This attempt to consider the additional 
value is possible for PHARMAC in New Zealand because it is legally required to manage its 
spending within a community medicines budget unlike other systems where agencies are advisory 
or decisions are implemented by a different institution. The use of health economic analYSis 
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through the explicit and formal consideration of medicines impact on health of the population 
allows reimbursement agencies to be accountable for the decisions made. 
Chapter 4 identified variation in the application of HTA and the means by which Health Economic 
analyse are used in the reimbursement process with respect to the type of medicines requiring 
such analysis, process of assessment and appraisal, use of cost-effectiveness analysis in the 
appraisal alongside other stated factors. Manufacturers are required to produce clinical evidence 
and economic evidence for many of the countries and a few countries provide independent 
assessments of the medicine. These approaches have practical implications for the judgements 
regarding the nature of the cost-effectiveness threshold and the assumptions in the context of 
decision-making. 
Threshold ranges for cost-effectiveness have been explicitly stated in agency documentation in 
England and Wales, Scotland and the Netherlands but other criteria are applied differently during 
the appraisal of the medicine. The application of the cost-effectiveness is described as central to 
NICE decision-making and the impact with respect to other factors has evolved overtime with the 
introduction of supplementary guidance at the end of life. Factors such as degree of uncertainty, 
lack of capture of health improvement and innovative nature of the technology are taken 
increasingly within set ranges. The consideration of end of life is considered supplementary for 
this but implies a threshold even though a range is not stated explicitly. The SMC c0!lsider cost-
effectiveness as a central criterion similar to NICE but states that the NICE threshold is considered 
but there is no strict upper limit in the decision and refers to modifiers of the decision where a 
higher cost-effectiveness ratio may be accepted. In contrast health economic analysis is one of 
four principal factors (multiple criteria) in the Netherlands when considering cost-effectiveness 
analysis produced for CVZ and there are separate committees one for considering the therapeutic 
value a second and a medicines reimbursement committee. A further new committee called the 
appraisal committee is tasked with matters where wider social considerations should be 
addressed. The CVZ tend to include criteria that affect the strength by which the cost-
effectiveness criteria should be considered in decision-making, less strict consideration is taken 
for medicines that are for high burden of disease, rare and have a public health risk whereas cost-
effectiveness is a stricter criterion such as high budget impact, uncertainty about the 
appropriateness of the intervention. Details of the application of these multiple criteria are not 
explicitly provided In the decision documents as would be required if formal methods of Multiple 
Criteria Decision Analysis were applied (MCDA) (Goetghebeur et aL, 2011, Devlin and Sussex, 
2011). Other authors have reported the importance of being explicit about other factors such as 
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equity considerations in decision-making (Williams and Cookson, 2006, Shah et aI., 2011). This 
raises a question of whether these factors should be considered for each individual medicine by 
the committees responsible by providing explicit principles of equity that are determined by the 
political process or whether these should be made at the policy implementation level through the 
design of the systems processes to ensure that the objectives and the systems institutions are 
accountable. For example the involvement of stakeholders in the consultation of evidence, 
entitlement to appeal decisions and the grounds established for appeal. 
There are then those systems where implicit thresholds have been identified in the literature for 
Australia, Canada, Ireland, New Zealand, Korea and Sweden. Although there is debate on whether 
some of these countries actually appraise decisions using a cost-effectiveness threshold in mind 
because of other important factors. This calls into question the appropriateness of providing 
quantitative analyses of past decisions in these countries. The decision documentation tends to 
account for the evidence in these countries and statements of the other non-evidence 
considerations are generally lacking. 
7.3.2 Comparison of health economic analysis reimbursement systems 
The previous chapters considered the current evidence base and the categorisation of systems to 
allow more detailed analyses of the influence of factors across reimbursement systems. Chapter 5 
attempted to control for new factors in a larger sample in a pooled analysis across systems using 
similar evidence requirements from the manufacturer and found association with respect to the 
clinical evidence, non-evidence factors and within country process factors. Surprisingly there was 
a correlation with the number of citations of the medicine in the media prior to the decision 
across countries but no statistical correlation with the cost-effectiveness estimates. The 
introduction of specific dummies to control for country differences in the process and 
reimbursement systems improved the regression fit but these results remained. 
There are two possible explanations for these findings. The first explanation is that the influence 
of health economic analysis in these countries for the medicines studies is not as influential as 
believed by health economists in these countries and other factors can explain actual decision-
making. The second explanation is that it was inappropriate to pool countries because of the 
process differences across countries that cannot be sufficiently controlled for in this type of 
quantitative analysis. Through the different approaches used in this thesis I would tend to find the 
second explanation more plausible. There is a fundamental problem with these types of 
regression analyses in the consideration of past decisions that influence has only been studied 
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with respect to the correlation rather than causal association of a reduced set of factors that are 
provided by the agencies. It is likely that a number of factors are missing from the analyses 
because they have not been measured or there is an insufficient sample size to control for many 
other important factors that may explain differences in decisions within and across countries. This 
was one main problem in this analysis where there was sufficient information to produce new 
variables for NICE but insufficient to add these across all the other countries agencies. Differences 
in process across countries may influence decisions in two ways, either independently of other 
factors such as economic analysis or by modifying the way in which decision-makers within each 
reimbursement system consider factors such as economic analysis. The chapter identified a 
number of process differences that may moderate the use and interpretation of the health 
economic analysis such as the use of third party independent assessment by NICE, the process of 
implementation of decisions and interpretation of decision outcomes between the countries 
differs and is highly complex for some medicines in Canada, the number of committees involved 
in assessing and appraising the evidence and the composition of the committees, the use of 
provisional stages and incentives provided by the pricing of medicines and interaction with the 
provision of cost-effectiveness evidence. A second means to explore the influence of the use of 
health economic analysis is to consider a comparison of two systems decisions The understanding 
of such processes require qualitative study in comparisons of systems to understand the influence 
of process. 
7.3.3 Comparison of the use of health economic analysis versus no health economic analysis 
The final empirical chapter contributed to the knowledge on contribution of health economic 
analysis by comparing two reimbursement systems and matching reimbursement for those 
medicines considered for the same Indication (Bending et al., In press). The analysis compared 
recommendations of an agency that uses health economic with one that does not require 
economic analysis for decision-making. The French agency HAS considers safety, clinical efficacy 
and relative effectiveness but not consider health economic analysis at the first listing decision. 
There were similarities and differences identified in the policy implementation level and 
reimbursement processes of the two agencies. Medicines that were commonly assessed and 
appraised by the two agencies available in English language were compared with respect to the 
recommendations and evidence. There was poor agreement between the decisions made by the 
two agencies for the sample of medicines that were appraised by both agencies. The SMC tended 
to provide more restrictive listing or did not recommend in comparison with HAS in France. The 
observed differences in the matched recommendations may be explained by the process of price 
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setting and dealing with uncertainty, relevant comparator medicines, relevant outcomes, 
treatment guidelines, use of submitted network meta-analysis in the appraisal and formal 
consideration of HRQOl in health economic analysis by the SMC. The use of health economic 
analysis would appear to be important against a system that does not use such analysis because it 
provides differences in the perceptions of value of some new medicines depending upon the 
medicines characteristics. In combination with free pricing it can be observed that some 
differences in recommendations may be explained by the incentives for the manufacturer to 
target a patient population, quantify and understand the uncertainty of the relative effectiveness 
estimates in combination with the cost of the medicine and explicitly quantify the HRQOl benefits 
of a new medicine. 
7.3.4 Contribution through influence on final outcomes rather than the Intermediary 
decision 
This thesis has identified the current evidence base and has attempted to add to the current 
knowledge on the use and contribution of health economic evidence and other factors in 
heterogeneous reimbursement systems. The chapters have focused on the contribution of health 
economic analysis and other factors upon the intermediate outcome of the reimbursement 
decision in countries. One weakness of this thesis is the implicit assumption that final outcomes 
such as utilisation and improved health outcomes given the resources available are causally 
influenced by the decisions made by the agencies reimbursement decisions. For example, if the 
plausible estimate of a medicine is judged to be cost-effective against a threshold range and this 
subsequently leads to a recommended decision does this lead to appropriate use and an 
improvement in health outcomes. Chapter 3 and 4 displayed the complexities by which some 
systems operate and the different decision outcomes, the interpretation and review of medicines . 
within the systems. This makes the complexity of understanding the consistency of the agency 
decision, health economic analysis and other factors very difficult to analyse empirically. Further 
there has to be a good understanding of the objectives of the system at the time of the analysis 
because these will define the final outcomes that should be considered (cost-effectiveness/health 
improvement, access or cost containment). Studies have made assessment of the influence of 
decisions in England and Scotland. This would require a study conducted in two stages, firstly 
considering the consistency of the decision with the decision outcomes and the resulting 
consistency of the intermediate decision outcome with medicines utilisation and price. Little 
empirical evidence is known about the impact of decisions on final outcomes such as utilisation 
for decisions outside of the UK (Bennie et aI., 2011, Sheldon et aI., 2004). The recent study of 
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SMC decision-making in Scotland found that the effect of a not recommended decision is variable 
but suggests a number of limitations to the collection of prescribing data in Scotland. This study 
demonstrated the complexity in implementing advice from a reimbursement agency using health 
economic evidence and the changes in actual practice. 
Health economic analysis has contributed to the reimbursement system alongside the need of 
government agencies to be transparent by providing a framework to consider many aspects of the 
assessment and appraisal. The technique provides a means for agencies to measure the 
consequences of certain decisions and to be able to justify the value of considering evidence and 
other factors to the Ministry of Health which they are ultimately accountable. There are many 
factors influencing the end utilisation of medicines and the reimbursement agencies do not act 
alone in the process such as conflicting clinical guidelines, clinical decision-making and the 
potential for other countries decisions to influence use. Health Economic analysis has therefore 
been widely used in DECO reimbursement systems, there is evidence that it is associated with 
decisions in some countries and has provided structure by which other factors can be explicitly 
taken account and the agencies held accountable. But this only tells half of the story and the 
potential contribution to the end outcome of use and the impact of health outcomes is largely 
unknown in all systems. Using this criterion, there is some evidence suggesting the very opposite 
and potential lack of its end contribution to final decision-making. 
7.4 Policy Implications: Lessons for the use and implementation of VBP in countries 
This thesis has identified a number of key lessons for the implementation of VBP in those 
countries that have recently chosen to formally implement such methods of determining 
reimbursement and price of medicines. The key lessons are with respect to the objective of each 
reimbursement system, documentation of decision-making, use in the reimbursement process 
and the plans for Implementation of VBP. 
The first lesson Is with respect to the objective(s) of each system. There needs to be clarity of the 
reimbursement institution(s) objective (maximisation of health, other objectives) and how all the 
institutions involved within the process work together to be accountable for the objective(s) of 
the system. It Is clear that a lot more work needs to be done on the accountability of each of the 
agencies and how they contribute to the final outcomes of the system (for example has the 
decisions made by the agency improved health). This will be easier to consider in some systems 
more than others but this is likely to improve over time with the developing use of information 
technology to track decisions and use of the medicines by each population. 
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Once the objectives are clearly provided the criteria used in VBP need to be clearly stated and the 
decision-making clearly described within the guidance documentation. The criteria are likely to 
have some commonalities across countries because the review identified a number of common 
factors common to each country alongside the health economic analysis. But the review also 
identified a number of uniquely defined factors in each country some more easily quantifiable 
than others (need, severity, fairness in decision-making). A deliberative process is still important 
in systems but it is crucial that more subjective elements of decision-making are documented so 
that appropriate signals can be provided for manufacturers and accountability to the countries 
general public. This will not only help with accountability to the general public of each 
reimbursement system but also enhance the understanding of the decision-making and the 
desirability of the methods and processes of reimbursement decision-making. The formal use of 
MCDA would assist with this. 
The third key lesson from this thesis is that process is very important and this will effect the 
implementation of VBP. The framework analysis of each system would appear to suggest that the 
stakeholders involved may be very important. For example the balance between expert 
participation (and professional background of the expert) and public participation may not only be 
important factors in explaining differences in decisions across countries but also for identifying 
and mediating the criteria used for decision-making. The involvement of policy makers and 
stakeholders in design of the VBP scheme will be critical for the political sustainability of the 
institutions involved in providing the decisions. A number of different processes may result in 
different countries depending on the criteria used in VBP such as the stages by which criteria are 
considered, the setting of threshold values for certain criteria and the number of decision 
outcomes in each country. 
Finally, this thesis has found that many of the agencies have evolved their processes with respect 
to the use of HTA evidence and it appears some agencies have learnt a great deal over the years. 
It is therefore likely that an incremental process of implementation rather than a step change in 
process will allow each system to learn from practical experience. This will allow better 
accountability of the system to the public, provide stability in the signals of value to 
manufacturers and help to understand further how evidence improves the welfare of citizens in 
each country choosing to implement VBP. 
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7.S Limitations: What could have been done differently? 
A number of limitations have been identified in the previous chapters and this section summarises 
the main weaknesses that became apparent as study was undertaken. 
• language: There was decision documentation available in other countries that were not 
taken Into account in comparisons in this thesis because of the requirement for 
translation of this documentation. The thesis therefore only identified use for many OECD 
countries and conclusions regarding the influence of factors on decisions can only be 
drawn for a subset of the OECD countries. 
• Factor Causation: This study has identified no evidence that the association observed 
between factors and decisions are causal and ultimately whether this links to the final 
outcomes of the system. Although some studies have stated that they are natural 
experiments but it is questionable whether certain policy changes (third party 
assessment) are exogenous to the system or related to the processes and objectives of 
the system. There is no evidence on whether the contribution of Health Economic analysis 
is causal, although in some countries there is consistency between the association with 
the decision and the impact stated by decision-makers in qualitative studies. The use of 
the framework has attempted to identify the main similarities and differences between 
countries to allow comparison taking into account different aspects_of the reimbursement 
system. 
• Interview and questionnaire methodology: The study has not used a series of 
questionnaires and interviews to obtain responses directly from the decision-makers' in 
OECD countries. This has been studied in detail for the United Kingdom but there is scope 
to provide interviews in other countries where these were not identified in the current 
evidence base of Chapter 2. This would of required interviews and questionnaires in a 
number of languages to add sufficiently to the current body of evidence that exists for the 
United Kingdom. 
• Reflexivity: On reflection many of the studies considering the influence of health 
economic analysis have been conducted by individuals with an Economics, Health 
Economics, Health Sciences and the author of this thesis holds two degrees in Economics 
and is a student in Health Sciences. The author of this thesis has tried to be as objective in 
the construct of variables and avoid many subjective judgements made by other authors 
in the construct of variables in the quantitative analysis and interpretation of the findings. 
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However, it is likely that the perspectives of the researchers have affected the conclusions 
drawn. 
7.6 Further research recommendations 
The following further research recommendations have been identified: 
1. Individual Country Studies 
There is an opportunity for more individual country studies where a number of factors are 
considered in those countries where a lack of quantitative or qualitative studies identified in 
Chapter 2. The increased requirement for transparency across countries reimbursement 
systems may make this possible. 
2. Comparisons across countries 
Future research could conduct both qualitative and quantitative comparisons of decisions 
made by other reimbursement agencies that produce documented decisions such as in 
Sweden (TLV) and the Netherlands (CVZ). In order for there to meaningful quantitative 
comparisons across countries there needs to be consensus on the construct of variables used 
in future quantitative analyses. Many variables are formed from the data that is available by 
the agency requiring an assessment and appraisal. This will enable an understanding of the 
influence of the many different processes on the final decision outcome alongside the other 
factors such as Health Economic analysis. 
3. OECD country interviews 
A future study could interview decision-makers in systems where few studies were identified . 
in Chapter 2 of the importance of health economic analysis and other factors. 
4. Implementation 
Previous chapters identified that the mechanisms of implementation and pricing vary across 
the OECD countries. Further study of the influence of health economic analysis and other 
factors should not only focus on the reimbursement decision but other outcomes such as the 
price and use of the medicine following the recommendation. 
5. Contribution to health outcomes 
The value of using HTA and Health Economic analysis has not been assessed with respect to 
the improvement in health outcomes from limited resources in many of the systems. This 
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must be the ultimate purpose of such techniques and therefore further attempts such as that 
being undertaken in New Zealand are important to assess its contribution and value. 
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6 danish medicines agency.ti,ab. (28) 
7 haute autorit$ de sant$.ti,ab. (40) 
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37 college voor zorgverzekeringen.ti,ab. (1) 
38 (cvz adj20 netherlands).ti,ab. (2) 
39 norwegian medicines agency.ti,ab. (13) 
40 statens legemiddelverk.ti,ab. (0) 
41 "national institute for pharmacies and medicines".ti,ab. (0) 
42 instituto nacional da farmacia e do medicamento.ti,ab. (0) 
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43 agencia d'Avaluacio de tecnologia I recerca mediques de catalunya.ti,ab. (0) 
44 (federal office of public health adj20 switzerland).ti,ab. (18) 
45 (national institute adj6 clinical excellence).ti,ab. (811) 
46 scottish medicines consortium.ti,ab. (15) 
47 smc.ti,ab. (5532) 
48 nice.ti,ab. (2673) 
49 drug coverage.ti,ab. (427) 
50 drug approval/ (7704) 
51 decision$.tl,ab. (142933) 
52 allocation$.ti,ab. (17615) 
53 advice.ti,ab. (23015) 
54 list.ti,ab. (37580) 
55 lists.ti,ab. (15589) 
56 recomend$.ti,ab. (80) 
57 recommend$.ti,ab. (279492) 
58 apprais$.ti,ab. (20381) 
59 or/1-49 (29297) 
60 or/50-58 (512770) 
61 59 and 60 (3833) 
62 (comment or editorial).pt. (591648) 
63 61 not 62 (3754) 
64 Animals/ (4590194) 
65 Humans/ (11286508) 
66 64 not 65 (3409968) 
67 63 not 66 (3747) 
68 limit 67 to yr="1990-Current" (3423) 
Embase Search 
Date: Tue, 06 Jut 201009:21:51 GMT 
Server: OvidHTIPD/1.1.67 [libwww-perl-daemon/1.33] 
Database: EMBASE <1980 to 2010 Week 26> 
Search Strategy: 
------------------------------------------------------------------------------
1 (reimbursement or payer).ti,ab. (9616) 
2 Reimbursement mechanisms/ (13206) 
3 pharmaceutical benefits advisory committee.ti,ab. (37) 
4 pbac.ti,ab. (124) 
5 committee for drug reimbursement.tl,ab. (1) 
6 danish medicines agency.ti,ab. (27) 
7 haute autorit$ de sant$.ti,ab. (43) 
8 french national authority for health.ti,ab. (18) 
9 "reimbursement and medicinal products".ti,ab. (2) 
10 edaf.ti,ab. (1) 
11 "ministry of social affairs and health".ti,ab. (16) 
12 Italian medicines agency.tl,ab. (10) 
13 agenzia italiana del farmaco.ti,ab. (5) 
14 aifa.ti,ab. (35) 
15 health Insurance review agency.ti,ab. (10) 
16 national centS of excellence in health technology.ti,ab. (0) 
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17 centro nacional de excelencia tecnologica en salud.ti,ab. (0) 
18 cenetec.ti,ab. (0) 
19 pharmaceutical management agency.ti,ab. (12) 
20 pharmac.ti,ab. (168) 
21 health technology assessment agency.ti,ab. (3) 
22 aotm.ti,ab. (1) 
23 (ministry of health adj20 slovak republic).ti,ab. (16) 
24 (dental adj6 pharmaceutical benefits board).ti,ab. (0) 
25 (pharmaceutical adj20 tlv).ti,ab. (0) 
26 (social insurance agency adj20 turkey).ti,ab. (0) 
27 (medicare adj20 coverage advisory committee).ti,ab. (8) 
28 "Institute for Quality and Efficiency in Health Care".ti,ab. (49) 
29 Institut fur Qualitat und Wirtschaftlichkeit im Gesundheitswesen.ti,ab. (6) 
30 iqwig.ti,ab. (96) 
31 (national health insurance fund administration adj20 hungary).ti,ab. (8) 
32 national centre for pharmacoeconomics.ti,ab. (1) 
33 ncpe.ti,ab. (20) 
34 ("ministry of health" adj5 "labour and welfare ll adj20 Japan).ti,ab. (77) 
35 direction de la sant$.ti,ab. (2) 
36 national insurance health boards.ti,ab. (0) 
37 college voor zorgverzekeringen.ti,ab. (1) 
38 (cvz adj20 netherlands).ti,ab. (3) 
39 norwegian medicines agency.ti,ab. (12) 
40 statens legemiddelverk.ti,ab. (0) 
41 "national institute for pharmacies and medicines".ti,ab. (0) 
42 instituto nacional da farmacia e do medicamento.ti,ab. (0) 
43 agencia d'Avaluacio de tecnologia i recerca mediques de catalunya.ti,ab. (0) 
44 (federal office of public health adj20 switzerland).ti,ab. (18) 
45 (national institute adj6 clinical excellence).ti,ab. (887) 
46 scottish medicines consortium.ti,ab. (16) 
47 smc.ti,ab. (5111) 
48 nice.ti,ab. (2465) 
49 drug coverage.ti,ab. (333) 
50 drug approval! (15475) 
51 decision$.ti,ab. (114476) 
52 allocation$.ti,ab. (13673) 
53 advice.ti,ab. (18741) 
54 list.ti,ab. (30524) 
55 lists.ti,ab. (11512) 
56 recomend$.ti,ab. (227) 
57 recommend$.ti,ab. (242911) 
58 or (15770) 
59 or/1-49 (26989) 
60 or/50-58 (435739) 
61 59 and 60 (4142) 
62 (comment or editorial).pt. (259359) 
63 61 not 62 (4063) 
64 Animals/ (55517) 
65 Humans/ (7099174) 
66 64 not 65 (38607) 
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67 63 not 66 (4063) 
68 limit 67 to yr="1990-Current" (3837) 
EconLit 
Date: Tue, 06 Jul2010 13:34:51 GMT 
Database: Econlit <1969 to June 2010> 
Search Strategy: 
--------------------------------------------------------------------------
1 (health adj20 drug).ti,ab. (303) 
2 (health adj20 medicine).ti,ab. (199) 
3 (reimbursement or payer).ti,ab. (794) 
4 (drug adj20 pay$).ti,ab. (72) 
5 (medicine adj20 pay$).ti,ab. (16) 
6 pharmaceutical.ti,ab. (1612) 
7 (health adj20 agency).ti,ab. (131) 
8 drug coverage.ti,ab. (42) 
9 decision$.ti,ab. (42658) 
10 allocation$.ti,ab. (15528) 
11 advice.ti,ab. (1432) 
12 list.ti,ab. (1740) 
13 Iists.ti,ab. (677) 
14 recomend$.ti,ab. (14) 
15 recommend$.ti,ab. (7948) 
16 apprais$.ti,ab. (2861) 
17 or/1-8 (2919) 
18 or/9-16 (68771) 
19 17 and 18 (412) 
20 limit 19 to yr="1990-Current" (401) 
21 from 20 keep 1-401 (401) 
HMIC 
Database: HMIC Health Management Information Consortium <May 2010> 
Search Strategy: 
--------------------------------------------------------------------------
1 (reimbursement or payer).ti,ab. (619) 
2 (drug adj20 pay$).ti,ab. (75) 
3 (medicine adj20 pay$).ti,ab. (131) 
4 pharmaceutical.ti,ab. (2324) 
5 (health adj20 agency).ti,ab. (1099) 
6 drug coverage.ti,ab. (15) 
7 decision$.ti,ab. (10299) 
8 allocation$.ti,ab. (2656) 
9 advice.ti,ab. (5522) 
10 list.ti,ab. (4451) 
11 lists.ti,ab. (2706) 
12 recomend$.ti,ab. (20) 
13 recommend$.ti,ab. (12260) 
14 apprais$.ti,ab. (2232) 
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15 or/1-6 (4169) 
16 or/7-14 (35406) 
17 15 and 16 (749) 
NHSEED 
Search Name: NHSEED Search 06072010 
Comments: 
Save Date: 2010-07-0609:30:21 
10 Search Hits 
#1 
#2 
#3 
#4 
#5 
#6 
#7 
#8 
#9 
#10 
#11 
#12 
#13 
#14 
REPEC 
(reimbursement ):ti,ab,kw 
(payer):ti,ab,kw 228 
MeSH descriptor Reimbursement Mechanisms explode all trees 793 
(drug coverage):ti,ab,kw 
(decision* ):ti,ab,kw 
(allocation*):ti,ab,kw 
(advice):ti,ab,kw 
(list):ti,ab,kw 
(lists):ti,ab,kw 
(recommend):ti,ab,kw 14428 
(apprais*):ti,ab,kw 
(#1 OR #2 OR #3 OR #4) 1616 
(#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11) 55167 
(#12 AND #13) 
Reimbursement and decision -104 studies 
754 
170 
8590 
25023 
2129 
5906 
5906 
2344 
233 
249 
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Table A2.1: Study data collection table 
Study Details 
Study Name: 
Study 10: 
Review author 10: MWB 
Citation: 
Agency name: 
IV 
..... 
OJ Country: c 
> 
"0 
Study design: Quantitative / Qualitative ::J 
..... 
VI 
Total number of reimbursement decisions/interviews 
Decision time period 
Study type 
Decision outcomes 
Factors included 
Clinical evidence factor definition (quantitative) 
Economic evidence factor definition (quantitative) 
Non-evidence factor definition (quantitative) 
VI 
"0 Process factor definition (quantitative) 0 
.s:: 
..... 
OJ Other factor definition (quantitative) ~ 
> 
'"0 Definition of influence ::J 
..... 
VI 
Factors considered important 
~ 
"5 
VI 
OJ 
a: 
> 
't:I 
::J 
..... 
VI 
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Table A2.2: Study exclusion reasons 
Study Exclusion Reason 
(Anell, 2004) Description of the use of evidence rather than 
data on decisions and factors. (No data on 
decisions) 
(An is, 1998) Description on the influence of provincial 
decision-making. 
(Barham, 2008) length of time to complete the appraisal not 
investigated in relation to decision outcome 
(Factor not related to decision outcome) 
(Buxton, 2001) Discussion paper with no data on decisions (No 
data on decisions) 
(Claxton et aI., 2005) Discussion paper with no data on decisions (No 
data on decisions) 
(Dear et aI., 2007) The timing of production of guidance is not 
related to the influence on decisions (Factor not 
related to decision outcome) 
(Drummond et aI., 2009) Discussion paper with no data on decisions (No 
data on decisions) 
(Eddama and Coast, 2009) local decisions and health policy which do not 
relate to medicine formulary decisions. (local 
level decision making) 
(Harris et aI., 2001) A summary of potential influence without direct 
reference to decisions and data (No data on 
decisions) 
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Table A2.2: Study exclusion reasons Continued ...... ' 
(Hill et a!., 2000) 
(Ikegami et a!., 2002) 
(Jonsson, 1997) 
(Laupacis, 2002) 
(Miners et aI., 2004) 
(PausJenssen,2003) 
(Cohen et aI., 2008) 
(Scobie et al. 2010) 
This is a critique of past manufacturers 
submission without relation to decisions (Factor 
not related to decision outcome) 
This is summary of systems rather than data on 
decisions (No data on decisions) 
Summary of the Swedish system without data 
on decisions (No data on decisions) 
This is an essay on the Canadian system rather 
than an empirical study of decisions (No data on 
decisions) 
This study contains empirical analysis on the 
differences between the presentation of results 
by the manufacturer and assessment group for 
the economic analysis (Factor not related to 
decision outcome) 
Qualitative description of the factors influencing 
Ontario provincial decision-making in Canada. 
This study is a discussion of the theoretical use 
of budget impact analysis (Factor not related to 
decision outcome) 
This study considered a qualitative review of 
CDR decisions but did not directly consider the 
factors influencing decisions. The study 
considered the timeliness of CDR recommended 
and restricted decisions with respect to the 
decisions made by the provinces. 
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Table A2.2: Study exclusion reasons Continued ...... ! 
(Sloan et aJ. 1997) The use of economic analysis in the pharmacy 
setting (No data on decisions) 
(Summerhayes and Catchpole, 2006) The influence on one medicine decision (One 
medicine decision studied) 
(West, 2002) Qua Iitative study of the factors influencing 
reimbursement decisions in 5 provinces. 
(Williams and Bryan, 2007) Qualitative study on local formulary decisions. 
(Aaserud et aL, 2002) Not in English language 
(Persson and Ramsberg, 2007) Not in English language 
(Russo, 2008) Not in English language 
(Van Wilder and Dupont, 2009) Not in English language 
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Table A2.3: Quantitative studies data extraction 
Study 
(Clement et 
al.,2009) 
(Chim et aI., 
2010) 
(George et 
al.,2oo1) 
Country 
England, 
Australia and 
Canada 
Australia 
Australia 
Agency 
National Institute for 
Health and Clinical 
Excellence (NICE), 
Pharmaceutical Benefits 
Advisory Committee 
(PBAC), Common Drug 
Review CADTH CDR. 
Australia (PBAC) 
Pharmaceutical Benefits 
Advisory Committee 
(PBAC) 
Number of 
reimbursement 
decisions/lntervie 
ws 
CDR- n=121, NICE-
n=199, PBAC-
n=282, Total 
n=602 
Common 
submissions al 
three-n=19 
PBAC:243 
n=355, CUA=26, 
CElG=9 
Decision 
period/Study 
type 
2001-2008 
Mixed Method 
Retrospective 
analysis of 
decisions 
2005-2008 
Quantitative 
Retrospective 
Analysis 
1991-1996 
Quantitative 
Retrospective 
Analysis 
Decision 
outcomes 
Usted, not 
listed 
Approval, 
rejection/deferr 
al 
Recommended 
Reject 
Defer 
Factors considered 
• Resubmissions 
• ute threatening disease 
• Clinical evidence 
• Clinical Uncertainty 
• Economic evidence 
• Economic uncertainty 
• Medicine type 
• Application type 
• Estimated cost to the PBS 
• Economic model estimate 
• Cost-effectiveness analysis 
and cost-utility analysis 
were considered with 
respect to the decision 
outcome. 
Analysis 
Statistical 
differenc 
es across 
decisions 
by Chi2 
tests. 
logistiC 
regressio 
n of 
(cancer 
vs non 
cancer) 
Mann-
Whitney 
test to 
identify 
differenc 
e 
between 
the 
ClG/CEA 
for 
recomme 
nd/Rejec 
t 
Appendices 
Results: Factors considered important 
The three agencies face common issues 
with respect to the strength of 
experimental evidence. The results of the 
evaluation process are influenced by the 
context, agency processes, ability to 
engage in price negotiation and 
differences in the social values. 
The study aimed to assess whether cancer 
medicines were less likely to be approved 
than other medicines, controlling for other 
factors. The multivariable regreSSion 
found that application type (new 
indication/ new drug), estimated cost to 
the PBS per year and economic model 
estimate were statistically significantly 
associated with the decision. There was no 
statistical difference in the odds of 
approving cancer medicines. 
The study found that decisions to 
recommend drugs at a proposed price are 
associated with a lower cost per life year 
gained than decisions to reject is 
consistent with the use of economic 
efficiency as a criterion. The criteria of 
effiCiency alone cannot describe 
adequately the decisions, for example, 
uncertainty, scientific rigour of the 
evidence, lack of alternatives, perceived 
need in the community, drug is to be used 
in a hospital setting and seriousness of 
intended indication. 
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(Harris et aI., Australia Pharmaceutical Benefits n=103(CUA) 1994-2004 Usted • The variables included Probit The study found that the ICER, budget 
2008) Advisory Committee NotUsted were the ICER regressio impact, clinical Significance, relevance of 
(PBAC) Quantitative • Cost to government, n model evidence, life threatening, highest ICER, 
• Clinical significance, of previously considered and life threatening 
Retrospective • Precision of clinical interacted with clinical significance had 
Regression evidence statistically significant effects upon the 
Analysis 
• Level of evidence decision. The study concludes that the 
- • Quality of studies importance of the clinical effect. cost-
• Relevance of evidence effectiveness, budget impact are 
• ute th reaten i ng important factors influencing decisions. 
• Economic model validity The study concludes that there was no 
• Modelled outcome, evidence of a single threshold. The 
• Modelled cost authors acknowledge that the small 
• No alterative acceptable 
sample size may be too small to identify 
some differences across some of the 
therapy, 
variables included in the study. 
• Uncertainty given by the 
upper most sensitivity 
analysis 
• Whether the drug had 
been previously 
considered. 
(Scuffham et Australia Pharmaceutical Benefits n=49(CUA) 2002-2004 Recommended, • The approach to elicit Descripti The rejection rates were greatest for those 
al., 2008) Advisory Committee Rejected QALY weights through ve submissions including non-preference 
(PBAC) Quantitative Deferred either a multi attribute statistics based approaches, HSVs were more likely 
utility instrument (MAUl), of to be recommended whereas MAUls were 
Retrospective health state valuation decisions more likely to be deferred. 
analysis (HSV) or non preference 
measure. 
(Van Wilder Belgium National Insurance N=824, class I 2002-2004 Positive • The extent of the acquired Pearson The percentage of positive decisions to 
and Dupont, Agency submissions=67 Negative evidence with the chi reimburse is significantly lower for the 
2008) Quantitative compound square limited (68.4%) as compared to the 
• The approval of added extended evidence group (92.5%). 
value for class I The approval of the added value-label Is 
submissions only highly predictive of a positive decision. 
The authors conclude that both factors 
playa role in decision making. 
-_.-
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(Dakin et aI., I England 
2006) 
(Devlin and I England 
Parkin, 20(4) 
(Devlin et aI., I England 
2010) 
[conference 
abstract) 
National Institute for N=94, 
Health and Oinical N=60 for CEA 
Excellence (NICE) 
National Institute for I N=33 
Health and Clinical 
Excellence (NICE) 
National Institute for I N=l84 
Health and Clinical 
Excellence (NICE) 
1999-2005 
Quantitative 
Retrospective 
analysis 
1999-2002 
Quantitative 
Retrospective 
analysis 
1999-2009 
Quantitative 
Retrospective 
analysis 
Recommend 
Restricted 
recommend 
Not 
recommended 
Recommended 
Not 
recommended 
Recommend in 
patient 
subgroup/indic 
ation or Not 
recommend in 
patient 
subgroup/indic 
ation 
• Date of decision 
• Patient group submission 
• Number of RCTs 
• RCTsize 
• RCT quality 
• RCT relevance 
• RCT significance 
• Observational data 
• Systematic review 
• CUA estimate 
• CER and CQG estimate 
• No alternatives 
• Budget impact 
• Intervention type 
.ICERvalue 
• Uncertainty 
• Alternative treatment 
options 
• Other factors 
• Burden of disease 
• Budget impact 
• Clinical evidence 
• Economic evidence 
• No alternatives 
• Tvpe of disease 
• Children 
• Date of guidance 
• Involvement of 
stakeholders 
• STA process 
Multino 
mial 
logistic 
regressio 
n. 
Logistic 
regressio 
n 
Logistic 
regressio 
n 
Appendices 
The study found that the decisions were 
related to the number of RCTs, 
pharmaceuticals, the number of 
systematic reviews and the cost· 
effectiveness and there was a differential 
impact between the decision outcomes. 
For example higher cost-effectiveness was 
only found to be important in the 
comparison between not recommended 
and recommended for restricted use but 
did not Significantly affect the decision 
between recommended and restricted 
use. The study suggested that there was a 
differential impact of factors on the three 
decision outcomes. 
Cost-effectiveness, uncertainty and 
burden of disease were demonstrated to 
explain decisions. The results suggested a 
threshold of between £34,000 and 
£47,000 considering the model that 
included these explanatory factors. It was 
not possible to consider the budget 
impacts contribution to the decision 
because of the small sample size. The 
model assumes that the documented 
evidence is what NICE actuallv believed to 
be important in the decision making. 
Not reported - work in progress. 
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(Mason and England National Institute for N=56 (38 2000-2008 Positive • The impact of time period Generalis The results showed that relative to period 
Drummond, Health and Clinical appraisals) Restricted on decisions made by ed Fisher 1 the proportion of negative 
2009) Excellence (NICE) Quantitative Negative NICE for cancer exact test recommendations increased in period 2, 
treatments irrespective of whether the data was 
Retrospective analysed by appraisal or by drug 
analysis assessment. The study found similarities in 
the issues reported for restricted decisions 
-
but found a large variation in those citing 
the ICER as a reason for restriction 
between period 1 (27%) and period 2 
(100%) and NICE being unsure whether 
the drug represented value for money, 
period 1 (20%) than in period 2 (80%). The 
study concludes that the change to the 
STA process explains part of the observed 
changes, it is clear that the nature of the 
evidence base for cost-effectiveness has 
shifted from an absence of evidence to 
evidence of absence. 
(Tappenden England National Institute for N=664 (16 2007 Recommended • The study explored logistic The results suggest that increases in the 
etal.,2oo7) Health and Clinical respondents Not preferences for using the binary ICER, a high level of uncertainty and the 
Excellence (NICE) completing 18 Quantitative recommended incremental cost regressio availability of other therapies are 
choice scenarios) effectiveness n model associated with a statistically significant 
• The degree of uncertainty reduction in the odds of adoption. The 
surrounding the ICER and results were seen to support a 
health outcomes probabilistic adoption/rejection curve, 
• The age of beneficiaries rather than the operation of a single fixed 
• Baseline health related threshold. The results show that the 
quality of life committee is unlikely to adopt 
• The availability of technologies that have unfavourable 
alternative therapies. economic profiles, unless other factors are 
present. The study suggests that further I 
research should consider the criteria used J 
in other health care systems. 
258 
(Koopmansch I Netherlands 
ap et at, 
2010) 
(Neumann et I USA 
al., 2005) 
The use of evidence in 
reimbursement decision 
making 
Medicare 
Mixed methods: I 2007-2008 
N= 66 for DCE 
Quantitative 
Focus group 
N=69 of which n=5 I 1999·2003 
medications 
Quantitative 
Recommend 
Not 
recommended 
Determination: 
Completely 
covered 
Covered with 
conditions 
local contractor 
discretion 
No national 
coverage 
• Budget impact (national 
additional medical cost) 
• Productivity saving 
(savings in costs for 
absence from work) 
• Disease severity prior to 
treatment 
• Economic analysis (ICER-
cost per QALY) 
• The number of QALYs 
gained per patient 
• The composition of the 
health gain (longer life 
expectancy. purely 
improved Qol, 50:50 of 
these scena rios) 
• Uncertainty and risk 
aversion through the cost 
per QALY doubling from 
the average scenario. 
• Level clinical evidence-
well designed. well 
conducted studies in 
representative 
populations. 
• Limitations of evidence. 
limited number of studies. 
limited number of 
patients, lack of controls, 
relevance of outcomes. 
selection bias. lack of 
randomisation. length of 
study and other. 
Discrete 
ChOice 
Experime 
nt using 
Multino 
mial 
logistic 
Regressio 
n Models 
(MNLM) 
Descripti 
ve 
Statistics 
and 
narrative 
descripti 
on of 
documen 
ted 
evidence. 
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The regression model observed sign for 
each of the coeffiCients was as expected. 
an intervention with a higher budget 
impact. higher cost per QALY and more 
uncertainty was less likely to be preferred, 
whereas disease severity and the amount 
of individual health gain were positively 
linked with the probability of chOOSing the 
intervention. Productivity savings were 
not significant. There was near significance 
between the interaction of budget impact 
and higher cost-effectiveness. There were 
some subgroups that attracted more 
weight in decision making with particular 
emphasis on disease severity. The study 
found that respondents were generally 
more risk averse towards health effects 
than costs. The results were consistent 
with the low and high disease severity 
thresholds in the Netherlands of 
EUROSO.OOO and $10-$15.000 for low 
severity diseases. There were other factors 
identified that were not captured in the 
analysis. the number of patients covered 
by the intervention. health care cost per 
person. relative impact on budget and risk 
behaviour relating to the disease. 
The study considered commonly reported 
limitations that included a limited number 
of patients in studies and lack of controls. 
The majority of cases were covered with 
conditions (61%). no national coverage 
(32%). local contractor discretion (6%) and 
completely covered (1%). The 
technologies with good evidence were 
more likely to be covered than those with 
poor and fair evidence (RR=1.46. 
p=O.OO4}.The cost is not explicitly 
considered in coverage decisions but it has 
been acknowledged that those with a high 
budget impact receive a more careful 
evidence review. Cost-effectiveness 
analysis was not used to influence 
deciSions. 
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Table A2.4: Qualitative studies data extraction 
Study 
(Barbieri et 
al., 2009) 
(cairns, 
2006) 
(Clement et 
al., 2009) 
Countries 
compared 
England 
and 
Scotland 
England 
and 
Scotland 
England, 
Australia 
and Canada 
Agencies compared 
National Institute for 
Health and Clinical 
Excellence (NICE) and 
Scottish Medicines 
Consortium (SMC) 
National Institute for 
Health and Clinical 
Excellence (NICE) and 
Scottish Medicines 
Consortium (SMC) 
National Institute for 
Health and Clinical 
Excellence (NICE), 
Pharmaceutical Benefrts 
Advisory Committee 
(PBAC), Common Drug 
Review CADTH CDR. 
Number of 
reimbursement 
decisions/lntervie 
W5 
n=25 comparisons 
of the same 
medicines 
n=21 comparisons 
of the same 
medicine 
CDR- n=121, NICE-
n=199, PBAC-
n=282, Total 
n=602 
Common 
submissions al 
three-n=19 
Decision 
period/Study 
type 
2001-2006 
(supplementary 
information 
provided). 
Qualitative 
Retrospective 
analysis of 
decisions 
Decision outcomes 
Raftery classification 
for Recommended, 
Recommended with 
restriction. 
2001-2005 Recommended, 
restricted 
Qualitative recommendation 
and not 
Retrospective recommended. 
analysis of 
decisions 
2001-2008 listed, not listed 
Mixed Method 
Retrospective 
analysis of 
decisions 
Factors considered 
• Impact of Third Party 
Assessment (MTA vs 
STA) 
• length of process 
• Clinical effectiveness 
• Cost-effectiveness 
evidence 
• Uncertainty in cost-
effectiveness evidence 
• Consideration of 
subgroups 
• Characteristics of the 
technology considered. 
• Timing 
• length and detail of 
process 
• Quality of manufacturer 
submission 
• Cost-effectiveness 
• Clinical-effectiveness 
• Stakeholder 
involvement 
• Resubmissions 
• life threatening disease 
• Oinical evidence 
• Clinical Uncertainty 
• Economic evidence 
• Economic uncertainty 
Analysis 
Narrative 
descripti 
on of 25 
case 
studies 
Narrative 
descripti 
on of 21 
case 
studies 
Statistical 
differenc 
es across 
decisions 
by Chi2 
tests. 
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Factors considered important 
The study identifies a trend in 25 decision 
comparisons where NICE guidance tends to 
be more restrictive due to more information 
available for subgroups considered. The 
article argues that third party review may be 
important for reaching decisions when the 
evidence base is under the control of the 
manufacturer, manufacturer is unable to 
implement appropriate methods and failed 
to reflect all uncertainties. There may be 
situations where the use of a hybrid 
approach is most appropriate depending on 
the technology. 
The decisions that were made by both 
agencies were similar and the authors 
suggested that this indicates that the work 
of NICE and SMC are complementary. 
The three agencies face common issues with 
respect to the strength of experimental 
evidence. The results of the evaluation 
process are influenced by the context, 
agency processes, ability to engage in price 
negotiation and differences in the social 
values. 
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(Lexchin and I canada, Common Drug Review CDR-n=47, 1999-2006 
Mintzes, Australia CADTH CDR, PBAC=31. 
2008) and Pharmaceutical BenefItS SMC=29 Qualitative 
Scotland Advisory Committee 
(PBAq, Scottish Common Retrospective 
Medicines Consortium submissions by all analysis 
(SMq three-n=22 decisions 
(Raftery, England, National Institute for n=10 common 1996-2007 
2(08) Australia Health and Clinical decisions for NICE 
and New Excellence (NICE), top 10 least cost- Qualitative 
Zealand Pharmaceutical BenefItS effective drugs 
Advisory Committee 
(PBAq, Pharmaceutical 
Management Agency 
(PHARMAq 
(Hailey, Australia Pharmaceutical Benefits n=12 Not Reported 
1997) Advisory Committee 
(PBAC) Qua litative 
Case studies 
listed, restricted • Clinical evidence 
list, not listed • Qualityof 
Pharmacoeconomic 
studies, 
• Price and effectiveness 
of of competing products 
• Prevalence of disease 
• Perceived need for 
treatment 
• Composition ofthe 
panel making the 
decision 
listed, listed with • Clinical effectiveness 
major restrictions, • Cost effectiveness 
listed with minor • Uncertainty 
restrictions, not • Nature of condition 
listed. 
• Innovative technology 
• Precedents 
• Budget impact 
• Rule of rescue 
• Health benefits 
• Direct cost to users 
• Availability of 
alternative treatments 
listed • Clinical effectiveness 
Restricted listing 
• Safety 
Not listed • Cost effectiveness 
• Availability of 
alternatives 
• Budget impact 
• Minister over rule 
• Price negotiations 
• lobbying efforts by 
support groups 
Statistical 
differenc 
es in 
decisions 
consider 
ed Chi2 
test and 
kappa 
scores 
Narrative 
comparis 
on of 10 
case 
studies 
Case 
Study 
narrative 
descripti 
on 
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There was no difference across the 
proportion of all drugs recommended by the 
CDR and the other two agencies. However, 
when individual drugs were compared there 
was poor to moderate agreement between 
CDR and the other 2 agencies, as well as 
between PBAC and SMC. The poor level 
agreement was attributed to analyses of the 
pharmacoeconomic data by the agencies. 
Other considerations such as prevalence of 
disease, perceived need for treatment and 
composition of the panel making the 
decision was suggested but not directly 
tested with the data. 
The drugs deemed least cost-effective by 
NICE between 1996 and 200S were all 
approved for funding in the England, six 
were approved in Australia and five in New 
Zealand. It was suggested that it was difficult 
to avoid a conclusion that the reason that 
these drugs had been funded was because of 
the nature of the disease and it proved 
politically difficult not to fund them. 
Mechanisms such as patient access schemes 
were introduced to enable the funding of 
these drugs. The decision to fund drugs in 
the final decision depends on their political 
and social acceptability which are brought 
around by the public's perceptions. 
The study concluded that economic 
evaluation had played a valuable input and is 
used routinely in the decision making 
process. There have been other factors that 
have influenced the decisions such as 
political views, existing policies, 
administrative feaSibility, budget impact and 
political and societal factors. 
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(Rocchi et aI., canada Common Drug Review N=62 
- 2003-2007 Positive • Type of clinical outcome Documen In 37 submissions the only economic 
2(08) CfDAC documented Negative (surrogate, ted consideration mentioned was the price of 
evidence Qualitative intermediate, final) narrative the drug. Economic evidence beyond price 
N=17 
- focus • Magnitude of benefit and focus was considered in 25 out of the 62 cases. 
group versus comparators groups This included 12 negative recommendations 
• Choice of comparator and 13 positive recommendations. The ICER 
• Trial duration value was not routinely reported across the 
- • Generalisability of trial documented evidence for these decisions. 
population There was no clear indication of whether the 
• Trial size panel found the ICER attractive or not 
• Comparative safety attractive. The study considered a subset of 
• Price oncology drugs that were deemed to be an 
• Quality of model interesting subset. The ICERs for oncology 
• Effectiveness used in drugs constituted the upper limit of leERs for 
model versus efficacy recommendations ($80k per QAlY). 
• Historical factors In the round table focus groups the use of 
• Type of disease 
economic evidence provoked strong 
disagreement. The majority of participants 
• Prevalence of disease thought that economic evidence contributed 
• Equity to decision-making but clinical evidence was 
• Rule of rescue considered more important. The concept of 
• Lack of altematives equity is not addressed across decisions as in 
• Budget impact cancer not all health gains are valued 
• Appropriateness of equally. (Hierarchy of diseases) 
utilisation 
• Innovative drug 
(Andronis et England National Institute for n=15 2003-2004 Recommended • The impact of Retrospe In two decisions, the impact of uncertainty 
al.,2009) Health and Clinical (reimbursement Not recommended uncertainty and the use ctive of the cost-effectiveness estimates was 
Excellence (NICE) decisions) Qualitative of sensitivity analysis to narrative discussed with regards to the decision. The 
explore this uncertainty documents appear to indicate that 
n=28 semi Retrospective and the impact on the uncertainty is explicitly considered for 
structured analysis of decision outcome. decision making with a focus on parameter 
interviews documented • The impact of uncertainty. The interviews suggested that 
evidence parameter uncertainty PSA was important for decisions and is an 
and structural important factor for consideration when 
Interview uncertainty. NICE makes decisions 
• The identification of 
subgroups using I 
I sensitivity analysis. 
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(Bryan et al., England National Institute for N=28 semi 2003-2004 Not reported • The impact of economic Descripti The interviews confirmed that economiC 
2(07) Health and Oinical structured directly but analysis in NICE ve analysis is used in a direct way to inform 
Excellence (NICE) interviews Qualitative consideration of decision-making narrative decisions for new technologies with barriers 
impact on coverage • Use of economic to the use of research grouped under 
Semi-structured decision. analysis accessibility of the research evidence 
interviews • Understanding of CE (difficulties in accessing information, 
analysis interpretation and skills required) and 
• Cost-effectiveness acceptability of the research evidence 
threshold (whether decision makers are inclined to 
adopt the recommendations of the 
economic analysis). The study questions 
whether health maximisation is the only 
objective of the decision maker, and 
suggests that a number of other conflicting 
objectives which must be traded off in the 
decision making process. For example, the 
situation in which equity concerns were 
evoked or raised in decision-making given 
the unclear nature of the equity concerns. 
(Raftery, England National Institute for N=117 (86 1999-2005 Yes, routinely, Yes • Clinical evidence Narrative There were 22 (19%) no decisions, 27 yes 
2(06) Health and Oinical guidance with major (insufficient evidence descripti decisions (23%), 38 yes with major 
Excellence (NICE) published) Qualitative restrictions for use) on restrictions (32%) and 30 yes with minor 
Yes with minor • Economic evidence (do restrictions (30%). The negative decisions 
restrictions not use because of poor were explained by insufficient evidence in 
Not recommended cost-effectiveness). two thirds of the decisions and unacceptable 
cost-effectiveness in a third of the decisions. 
The highest ICER that NICE had accepted 
during this period was £39,000 per QALY. In 
this period there had been 25 appeals of 
which 15 were dismissed, 5 led to minor 
word changes and 5 were referred back to 
the appraisal committee. The study 
concluded that NICE rejections had been 
fairly rare and they were more likely to 
,--
recommend. 
--- -
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(Raftery, 
2009) 
(Williams et 
al., 2008) 
England 
England 
National Institute for 
Health and Clinical 
Excellence (NICE) 
National Institute for 
Health and Clinical 
Excellence (NICE) 
N=l1 1999-2009 
Qualitative 
Systematic review 2002-2004 
of influence of 
economics on Qualitative 
decision making. 
local formulary 
case studies (n=4) 
Documentary 
evidence of 
decisions (n=7) 
Interviews with 
decision makers 
(n=301 
Workshops (n=2) 
Not recommended 
decisions 
(overage decision 
as determined by 
the participant 
• The impact of end of life 
guidance on previous 
decisions to not 
recommend a 
treatment 
• To determine the 
influence of economic 
information in health 
policy decision making 
in England, considering 
local formulary 
decisions and national 
NICE decision making. 
Narrative 
descripti 
on 
Systemat 
ic 
literatur 
e Review, 
Case 
studies, 
Semi-
structure 
d 
interview 
sand 
worksho 
ps 
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Process changes resulted with respect to 
NICE because of legal action by patients, 
media publicity and political discomfort. This 
resulted in specific criteria. The study found 
that most of the previous studies would fail 
to meet the criteria of no alternative 
treatment with comparable benefits 
existing. Only two of the drugs would qualify 
if best supportive care were taken to 
indicate a lack of alternatives. It was 
concluded that the new arrangements were 
unlikely to improve the availability of new 
cancer drugs. The identification one group 
now sets precedence for other groups to be 
identified. 
The study found that at a local level the use 
of economic analysis was an exception to 
inform formulary decisions. The local level 
focused on clinical benefit and the cost 
implications. In contrast, at the national level 
economic analysis was seen to be highly 
integrated with an ordinal approach to 
consideration of clinical and cost-
effectiveness information. The analysis 
provided a framework for considering the 
decision problem but concern was raised 
about understanding of the economic 
analysis. The study concluded that further 
assessment is required into clarification of 
the objectives that society seeks from 
investments in health care. 
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(Williams and 
Bryan, 2007) 
(Wirtz et aI., 
2005) 
England 
England 
National Institute for 
Health and Oinical 
Excellence (NICE) 
National Institute for 
Health and Clinical 
Excellence (NICE) 
N=4 case studies 
H=30 semi 
structured 
interviews 
N=20 interviews 
on three drug 
therapies. 
2002-2004 
Qualitative 
2002 
Qualitative 
Coverage decision 
as determined by 
the participants 
Coverage decision 
as determined by 
the participants 
• The influence and use of 
health economic 
evaluation in the 
decision making 
process. 
• Cost-effectiveness 
• Equity considerations 
• Personal factors 
• Political factors 
Narrative 
descripti 
on of 
case 
studies 
and semi 
structure 
d 
interview 
s 
Narrative 
descripti 
on of 
interview 
5 
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The study found that there was an ordinal 
approach to how the evidence and analysis 
were considered, the clinical evidence 
followed by the economic evidence. A 
concern with cost-effectiveness was not 
apparent unless a clinical value had been 
demonstrated. The economics provided an 
analytical framework for the consideration 
of evidence, it is not just the overall 
outcome of the evaluation but it allows the 
discussion to be structured around the 
important aspects of the evidence and 
deliberations can be made. The study 
highlights that it is important to guard 
against one group on a committee being 
granted a dominant position. The use of one 
disciplines approach may mean that 
decisions are not aligned to social values. 
The interviews captured two aspects of 
decision-making which are not usually 
captured in the rationales usually cited. The 
first dimension was 'subjectivity' which 
includes personal factors which influence 
the kind of evidence, and interpretations of 
the evidence, such as personal experiences 
related to the disease or the novelty of the 
benefit of the technology. The second relate 
to the overall social and political functions of 
decision making which relate to the 
importance of maintaining relationships, the 
achieving of politically and legally defensible 
decisions and the reduction of organisational 
burden. The researchers did not imply by 
referring to these dimensions that they were 
inappropriate rather the opposite. The 
authors believe that including these type of 
factors helps to articulate the fuzzy elements 
of decision making. The study concludes that 
the factors identified were often buried 
under the rationales given to legitimise the 
decisions made. The authors suggest that 
personal and political factors should be 
recognised as a dimension of decision-
making is done within a discourse of 
reasonableness. 
Appendices 
(Vuorenkoski I Finland 
et al., 2003) 
(Niezen et I Netherland 
al.,2009) 5 
Pharmaceutical Pricing I N=18 interviews 
Board 
CVZ - Health insurance N=l1 
Board and Ministry of semistructured 
Health interviews 
2001 
Qualitative 
2006 
Qualitative 
As determined by 
the stakeholders 
interviewed. 
Recommendations 
for a new 
intervention 
• Disease areas prioritised 
for special higher 
reimbursement 
categories, 75% for 
chronic and serious 
diseases, 100% for 
severe and long term 
diseases. 
• Clinical effectiveness 
• Economic evaluation 
• Roles of stakeholders 
and influence in the 
reimbursement process 
• Pharmaceutical 
companies, patient 
organisations and 
medical speciality 
associations 
• Price and potential 
budget impact 
• Clinical effectiveness 
• Cost effectiveness 
• Severity of illness 
• Budget impact 
• Other implicit decision 
making factors 
Semi-
structure 
d 
interview 
s 
analysed 
using a 
thematic 
framewo 
rk 
approach 
Narrative 
descripti 
on of the 
interview 
themes. 
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The system in Finland in 2001 was to provide 
explicit prioritisation of disease areas. The 
nature of inclusions is believed to be of a 
technical nature but there are at least two 
non-scientific rationales used explicitly in 
decision making due to fiscal constraints and 
the difficulty of removing drugs in the higher 
reimbursement categories. The study found 
that it is difficult to base prioritisations solely 
on the wording of legislation and scientific 
data. The unofficial stakeholders were 
viewed to be conducive to provide a positive 
channel between stakeholders and public 
administration and may divert public policy 
to their narrow interests making the work of 
the public administration more difficult. 
However they were seen to have restricted 
influence. It is crucial to recognise 
stakeholders lobbying resources, interests 
and means of exerting influence so that 
decisions do not favour any particular 
individuals or groups of society. 
The interviews found that policy makers 
often rely on information gathered from 
cost-effectiveness analysis to justify their 
decision rather than explaining how budget 
impact had an effect on the decision. Budget 
impact is seldom used in an argument for 
denying a drug reimbursement outright or 
imposing conditions on reimbursement. The 
justifications for the use of budget impact 
collected from a literature review were 
opportunity costs, loss aversion and 
endowment effects, uncertainty and equal 
opportunity. Budget impact was found to 
playa role in decision making. 
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(Pronk and 
Bonsel,2004) 
(Anell and 
Persson, 
2005) 
Netherland 
5 
Sweden 
o/z - Health Insurance 
Board and Ministry of 
Health 
Pharmaceutical Benefits 
Board LFN 
N=139 
N=107 
1999-2002 
Qua litative 
2002-2005 
Qualitative 
Outpatient drugs 
recommended 
either for: 
List la subsititutable 
List Ib unique 
Other Refusal 
Unconditional 
reimbursement 
Conditional 
reimbursement 
Rejected 
• Therapeutic value 
• Budget impact 
• Burden of disease 
• Efficiency 
• Dynamic nature of 
decision making. 
• The principle of human 
dignity, whereby health 
care is provided equally 
for all individuals 
• The principle of need 
and solidarity, according 
to those with the 
greatest medical need 
are provide more health 
care resources than 
others. 
• The cost-effectiveness 
principle, according to 
which the costs of a 
pharmaceutical 
preparation must be 
reasonable. 
• The marginal utility 
principle which is a 
component of the cost-
effectiveness principle .. 
Descripti 
ve 
statistics 
and 
narrative 
descripti 
on of the 
decisions 
by the 
Ministry. 
of Health 
Narrative 
descripti 
on of the 
documen 
ted 
agency 
decisions 
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New drugs in the Dutch system in 1991 are 
excluded unless they pass legal 
requirements for clinical criteria and are 
grouped into two lists, DPRS-list la for 
substitutability with accepted drugs implying 
a reimbursement maximum, DPRS-list 1b 
which are unique and valuable with liberal 
price setting and those that are rejected as 
lack of value. The 8S DPRS-list Ib applicants 
were evaluated for the criteria finding 
therapeutic value, budget impact and 
burden of disease being important criterion. 
82 out of the 107 cases the drugs received 
unconditional reimbursement, 12 cases 
there was conditional reimbursement and 13 
cases where the drug was rejected. 
There were orphan drugs that were 
approved unconditionally even though their 
cost-effectiveness was weak. Those 
pharmaceuticals approved for limited 
reimbursement were found in the treatment 
of large patient populations where there was 
a large budget impact. The rejected 
applications were for low priority or deemed 
not to have demonstrated a clinically 
significant difference in benefit to receive a 
price premium. Reimbursement is limited to 
relevant subgroups when there is a high 
budget impact and varying cost-
effectiveness. There were often rejections 
where the manufacturer had not proved the 
benefits in comparison to existing 
alternatives. 
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(Jansson, Sweden Pharmaceutical Benefits N=107 2002-2005 Unconditional • Human dignity Oescripti 87 out of 107 received unlimited subsidy, 9 
2007) Board LFN documented subsidy • Need and solidarity ve out 107 received limited subsidy and 11 out 
decisions Qualitative Conditional subsidy • Cost-effectiveness statistics of 107 were rejected. The analysis of the 
Rejected • Based on the three and public documents and interviews confirmed 
N=23 interviews above principles Health narrative that cost-effectiveness had played an 
care is divided into four descripti important role in decision making. In those 
priority groups, priority I on of pharmaceuticals that received unconditional 
- for life threatening documen subsidy the cost-effectiveness was at an 
diseases or conditions, ted acceptable level. The economic analysis 
priority II for prevention evidence required for orphan drugs was seen to be 
and rehabilitation, and less stringent. The conditional subsidy have 
priority III for health interview been found in those treatments with 
care of less severe acute s. potentially large patient populations. The 
and chronic diseases rejections were based on the absence of 
and injuries and priority supporting evidence and low priority. 
IV for health care for In the case studies individual actors have 
other reasons than been found to directly influence decision 
disease or injury. makers through lobbying, contact to the LFN 
• Stakeholder and official letters. Six appeals have been 
involvement such as made out of the eleven rejected 
patients, applications. 
pharmaceuticals and 
---
patient associati()ns 
- -
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Table Al.S: Summary of quantitative studies 
Study Authors Country{s) Number of Methodology Decision Outcomes Time period of Factors Considered in 
(Institutions) Decisions (Statistical) decisions statistical analysis 
(Clement et aI., 2009) Canada (CADTH CDR) CDR: 121 Univariate Chi Square Binary (list/Do not CDR: 2004-2008 Resubmission 
England (NICE) NICE: 199 tests for characteristics list) NICE: 2001-2008 life threatening disease 
Australia (PBAC) PBAC:153 PBAC: 2005-2008 Clinical evidence 
Economic evidence 
(Chim et aI., 2010) Australia (PBAC) PBAC: 243 logistic regression Binary (Approval, PBAC: 2005-2008 Medicine type 
(cancer vs non-cancer) Rejection/Deferral) Application type 
Estimated cost to PBS 
Economic model estimate 
(George et aI., 2001) Australia (PBAC) PBAC:35 Univariate Mann Binary PBAC: 1991-1996 Economic model estimate 
Whitney test (Recommended, Not 
recommended) Defer 
decision discarded. 
(Harris et aI., 2008) Australia (PBAC) PBAC:103 Probit regression Binary PBAC: 1994-2004 Clinical evidence 
(Recommended, not Economic evidence 
recommended) Total financial cost 
Patient population 
characteristics 
History of drug submission 
(Scuffham et aI., Australia (PBAC) PBAC:49 Univariate comparison Binary (Recommend, PBAC: 2002-2004 Type of QAl Y weights 
2008) other) 
(Van Wilder and Belgium (CRM) CRM:824 Univariate Chi Square Binary (positive, CRM: 2002-2004 Clinical evidence 
Dupont, 2008) tests negative) Added therapeutic value 
(Dakin et aI., 2006) England (NICE) NICE: 94 Multinomial logistic Multinomial NICE: 1999-2003 Economic evidence 
regression (recommend, Clinical evidence 
restrict, not Budget Impact 
recommend) Characteristics of patient 
group 
Type of technology 
Other alternative 
Time of decision 
Stakeholder involvement 
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(Devlin and Parkin, England (NICE) NICE: 33 logistic regression Binary NICE: 1999-2002 Economic evidence 
2004) (recommended, not Other alternative 
recommended) Burden 
Budget Impact 
Other factors 
(Devlin et aI., 2010) England (NICE) NICE: 184 logistic regression Binary NICE: 1999-2009 Clinical Evidence 
-[Conference abstract] (recommended, not Economic evidence 
recommended) Characteristics of disease 
Characteristics of patients 
Patient group submission 
(Mason and England (NICE) NICE: 56 Fisher-Freeman-Halton Multinomial NICE: 2000-2006 STA process 
Drummond, 2009) test for comparison (Recommended, 
between two periods restricted, not 
recommended) 
(Neumann et aI., US (Medicare) Medicare: Univariate Comparison Multinomial Medicare: 1999-2003 Quality of clinical evidence 
2005) 69 (5 (Completely covered, Net benefit 
medicines) covered with Time to medicine decision 
conditions, local 
contractor discretion, 
i not covered) 
(Tappenden et aI., England (NICE) NICE Discrete choice Binary NICE: 2005 Economic evidence , 
2007) decision experiment using logistiC (Recommended, not Age 
makers: 37 regression analysis recommended Baseline Health related QOL 
Availability of other therapies 
(Koopmanschap et Netherlands (CVZ) Decision Discrete choice Binary CVZ: 2007-2008 Additional medical cost per 
al.,2010) makers experiment using logistic (Reimbursement, not year 
(including regression analysis reimbursement) Absence from work cost 
CVZ)66 saving 
Disease severity 
Economic evidence 
Number of QAl Ys 
, .. 
-
Composition of health gain 
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Precision of clinical evidence 
level of evidence 
Relevance of evidence 
Type of economic analysis 
Type of QALY weights used 
Cost-effectiveness estimate 
Economic analysis validity 
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Type of economic analysis 
Cost-effectiveness estimate 
Budget impact I The potential budget 
Uncertainty in 
effectiveness 
272 
Table A2.7: Characteristics of revealed preference quantitative studies in England and Wales 
Type of technology Pharmaceutical or other technology 
Other factors 
Burden of disease 
Type of disease 
Children 
Date of guidance 
Involvement of stakeholders 
Appeal 
STA process 
Appendices 
Introduction of the STA process in August 
2006. 
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Table A2.8: Description of each factor and direction of association 
Factor Considered Studies Countries Influence/Impact on Reimbursement decision 
Considered 
Clinical Evidence Factors 
Clinical uncertainty (type of trial, comparator and (Clement et aI., 2009) AU, CA, ENG Mixed - lower probability of listing for CA and AU, But no association 
endpoint) .- for ENG 
Added therapeutic value (Van Wilder and Dupont, BE Proven added value was positive associated with a listing decision 
2008) 
Relevant clinical endpoint (Clement et aI., 2009) AU, CA, ENG Increased probability of listing 
Number of RCTs (Dakin et aI., 2006) ENG One additional RCT reduced the probability of being restricted or not 
listed in comparison to listing. 
Size of treatment effect (Harris et aI., 2008) AU A large clinical effect was associated with a higher probability of listing 
Number of QALYs gained per patient· (Koopmanschap et aI., Nl A positive association between the number of QAlYs and choice of 
2010) intervention (listing) 
The composition of health gain (Koopmanschap et aI., Nl There was a preference for listing interventions with quality of life 
2010) improvements over extension of life with no improved quality of life 
Clinical claim (accepted/rejected or partially (Chim et aI., 2010) AU The acceptance of the manufacturers clinical claim is statistically 
accepted) associated with a positive listing. 
RCT Significance (Dakin et aI., 2006) ENG No association 
RCTsize (Dakin et al., 2006) ENG No association 
Precision of treatment effect (Harris et aI., 2008) AU No association 
Type of evidence (RCT) (Harris et aI., 2008) AU No association 
RCT quality (Jadad score) (Dakin et aI., 2006) ENG No association 
Quality of studies (12 item checklist) (Harris et aI., 2008) AU No association 
Quality of evidence (Well designed and (Neumann et aI., 2005) US Technologies with good evidence were more likely to be listed in 
conducted RCTs) comparison with poor evidence 
Comparator and population appropriate (Harris et aI., 2008) AU, ENG No association 
(Dakin et aI., 2006) 
Comparator claim (accepted/rejected or partially (Chim et aI., 2010) AU The acceptance of the comparator claim is statistically associated with 
accepted) a positive listing. 
Non randomised studies (Dakin et aI., 2006) ENG No association 
Number of systematic reviews (Dakin et aI., 2006) ENG The number of systematic reviews was positively associated with 
listing in comparison to not listing 
----- --------- - -
.-
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Economic Evidence Factors 
Type of economic analysis (CUA) (Dakin et al., 2006) ENG The use of CUA increased the probability of not listing in comparison 
(Chim et aI., 2010) to listing (ENG). Those with a CMA/no economic evaluation in the 
preliminary submission were more likely to lead to a positive listing 
than those with a CEA/CUA analysis (AU). 
ICER (cost per QAlY) (Clement et aI., 2009) AU, CA, ENG, Nl A negative association between higher ICER values and listing (AU, CA, 
(Harris et aI., 2008) ENG, Nl) 
(Tappenden et aI., 2007) 
(Koopmanschap et aI., 
2010) 
(Chim et aI., 2010) 
ICER (cost per lYG) (George et aI., 2001) AU A negative association between higher ICER values and listing 
ICE R (cost per l YG a nd cost per QAl Y) (Devlin and Parkin, 2004) ENG Mixed - A negative association between the ICER values and listing. A 
(Dakin et aI., 2006) negative association found between higher ICER values and restricted 
in comparison to not recommended 
Economic claim (PBAC committee accept the (Chim et aI., 2010) AU The PBAC accepting the manufacturers claim was associated with a 
manufacturers economic claim) positive recommendation. 
Economic uncertainty {major flaws in model, (Clement et aI., 2009) AU, CA, ENG Mixed - lower probability of listing for CA and AU, But no association 
assumptions and mapping) for ENG 
Degree of uncertainty concerning costs and (Tappenden et aI., 2007) ENG A high level of uncertainty is associated with a reduction in the 
effects probability of listing 
Probability that costs per QAl Y will be at least (Koopmanschap et aI., Nl A higher level of uncertainty was negatively associated with listing 
doubled as compared to the average CE 2010) choice. 
Range of cost-effectiveness divided by base case (Devlin and Parkin, 2004) ENG A negative association between a larger ratio and listing 
ICER 
Upper limit in model sensitivity analysis (Harris et aI., 2008) AU A higher upper cost per QAl Y was positively associated with listing 
Non preference based measure used for QAl Y (Scuffham et aI., 2008) AU Non preference based measures were associated with a lower 
weights probability of listing 
Model Structure appropriate (Harris et aI., 2008) AU No association 
Translation of clinical outcomes to quality of life (Harris et al., 2008) AU No association 
Modelled cost issues (Harris et aI., 2008) AU No association 
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Budget impact - cost to government (Harris et aL, 2008) AU, ENG, Nl Mixed - A negative association between higher budget impact and 
(Dakin et aL, 2006) listing in AU and Nl. No association in ENG. 
(Koopmanschap et aL, 
2010) 
(Chim et aL, 2010) 
Savings in costs of absence per year (Koopmanschap et aL, NL No association observed. 
2010) 
Non Evidence Based Factors 
Severity/life threatening (Clement et aL, 2009) AU, CA, ENG, Nl Mixed -No association observed for listing AU, CA, ENG. AU study 
(Harris et aL, 2008) found life threatening drugs to be positively associated with listing. Nl 
(Koopmanschap et aL, study found severity to be positively linked to choice of intervention. 
2010) 
Burden of disease (Devlin and Parkin, 2004) ENG A positive association between a higher burden of disease and listing 
No alternative therapy (Harris et aL, 2008) AU, ENG Mixed - No association found in AU. Two studies in ENG found an 
(Devlin and Parkin, 2004) alternative therapy lowers the probability of listing and one found no 
(Dakin et aL, 2006) association. 
(Tappenden et al., 2007) 
Type of intervention, pharmaceutical or other (Dakin et aL, 2006) ENG A pharmaceutical reduced the probability of not listing in comparison 
to listing 
Medicine type (cancer, non-cancer) (Chim et aL, 2010) AU No statistical association between cancer medicine and 
recommendation. 
Number of patients per year (Chim et aI., 2010) AU No statistically significant association with recommending 
Mean age of population who will benefit (Tappenden et aI., 2007) ENG No association observed. 
New medicines/indications in comparison with (Van Wilder and Dupont, BE Line extensions were more likely to be listed than new medicines and 
line extensions 2008) indications 
Baseline HRQol (Tappenden et aL, 2007) ENG A very low to a high baseline HRQoL was negatively associated with 
listing 
Reimbursement Process Factors 
Patient group submission (Dakin et aI., 2006) ENG The presence of a patient group submission decreased the probability 
of a restricted listing in comparison to listing. 
Previously considered (resubmission) (Harris et aI., 2008) AU Mixed evidence for AU. A previously considered drug had a higher i 
(Chim et aL, 2010) probability of listing. There was no association found in a second 
study. 
STA process impact on cancer medicines (Mason and Drummond, ENG Between 2006 to 2008 NICE, were more restrictive in comparison to 
2009) 2000 to 2006. 
-_ .. _---
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Date of decision (Dakin et aI., 2006) ENG A positive association was found between later guidance and not 
listing in comparison to listing 
Appeal (Dakin et aI., 2006) ENG No association with probability of recommending a medicine. 
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Table A2.9: Model specification tests reported 
Study Type of model specification test 
(Clement et aI., 2009) No statistical specification tests reported. 
(Chim et aI., 2010) Goodness of Fit test: Hosmer and Lemeshow 
Sensitivity analysis: Exclusion of factors from the regression model. 
(George et aL, 2001) No statistical specification tests reported. 
(Harris et aL, 2008) Goodness of fit: Pseudo RZ and Receiver Operating Characteristics 
(ROC) 
Regression model assumptions: Variance Inflation Factor (VIF) to 
consider potential multicollinearity. 
Omitted Relevant Variables: Dummy variable included to test for 
structural change. 
Consideration of outlier observations. 
(Scuffham et aL, 2008) No statistical specification tests reported. 
(Van Wilder and Dupont, No statistical specification tests reported. 
2008) 
(Dakin et aL, 2006) Goodness of fit: Pseudo RZ and regression predictive classification of 
decisions. 
Sensitivity analysis: robust versus conventional standard errors and 
impact of dropping factors. 
Regression model assumptions: multicollinearity considered 
between the variables. 
(Devlin and Parkin, 2004) Goodness of fit: Pseudo RZ. 
(Devlin et aL, 2010) Conference abstract: Not reported. 
(Mason and Drummond, No statistical specification tests reported. 
2009) 
(Neumann et aL, 2005) No statistical specification tests reported. 
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Table A2.10: Summary of quantitative reimbursement factors influence 
and Validity I ~ /:) p 0 m > m 0 Z 'J! I Validity of results n: c: c: n "0 n r+ 0 
AI AI AI 
:;- 0 
"0 0 ;r :::J 0 
:::J "r :::J .., :::J til I n r+ til 3 r+ ~ AI 0 0 0 .., til II' ;:i - 3 "0 3 m < II' til < 0 c: .., n a: :::J n or n 
-0 
-
:::J 0 til II> .... 
-
Q.. n II> .... til :::J :::J n til til :::J til < 0 n .... ~ !2 :;- ~ II> til a: 3 til 0 til 3· n II> <: n ~ n 0 til n 
-n II> 3· II' :::J II> .... 
- :::J n II> II> til r+ Ii> 0 n til QI - < til < ~nfluence jStudytype IStatistical method :::J til < ... 3 a: 0.. a: II> < c: < :::J "0 n :::J CD II' 
"0 a: til 0.. til n :::J .., 
til :::J C- II> II> til n til n :::J n :::J :::J ~ til 
Ii> n CD 0.. 0.. II> !!!. 
-til OQ <: II> 0 til .., II' :::J n 
:::J 3 til in· .:< .... II' Q til c: 
:::> ;::; II' 
... II' 
13 4 7 4 16 5 
(Devlin et al. 2010) as a conference abstract and the results could not be directly included with respect to direction of effect on the reimbursement decision. *3 factors were stated but influence was not reported 
and therefore not included in the count. 
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Table A2.11: Comparison of quantitative and qualitative studies by country 
Country/Type Australia Belgium Canada England Finland Netherlands New Zealand Scotland USA 
of evidence 
Reimbursement PBAC National CDR NICE Pharmaceutical Health care PHARMAC SMC Medicare 
agency Insurance Pricing Board insurance board 
Agency (PPB) (CVZ) 
Quantitative • Size of clinical effect • Size of • ainical uncertainty • Clinical uncertainty No studies • leER No studies identified No studies identified • Quality of 
studies Factors • Precision of clinical clinical • Weight of clinical • Weight of clinical identified • Uncertainty clinical 
Considered effect effect evidence evidence evaluated by evidence 
• Quality of studies • New • Relevant clinical • Relevant clinical sensitivity analysis 
• Comparator claim medicine endpoints endpoint • Budget impact 
• ainical claim line .ICER • Baseline HRQoL • Disease severity 
• leER extension • Type of economic • Number of RCTs • Number of QALYs 
• Economic claim analysis • Number of gained 
• Type of Economic • Economic Systematic reviews • Distribution of 
analysis uncertainty • Number of QoL improvement 
• Weight of clinical • ute threatening observational 
evidence • Resubmission studies 
• ainical uncertainty • RCT significance 
• Relevant clinical • RCTsize 
endpoint • RCT quality (Jadad) 
• Comparator • Comparator 
appropriate appropriate 
• Economic • Uncertainty 
uncertainty evaluated by 
• Uncertainty sensitivity analysis 
evaluated by .ICER 
sensitivity analysis • Type of economic 
• Type of utility evaluation 
elicitation • Economic 
• Budget Impact uncertainty 
• Severity of disease • ute threatening 
• Resubmlssion • Resubmission 
• Number of patients • Appeal 
per year • Burden of disease 
• Medicine type • Type of medicine 
• Patient group 
submission 
• Date of decision 
• Lack of altemative 
therapy 
- ------
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Table A2.11- Comparison of quantitative and qualitative studies by country Continued_.f 
Qualitative .Oinical- • Oinical benefit • Third party • Process .Oinical • Cost-effectiveness • Manufacturer No studies 
Studies Factors effectiveness • Cost-effectiveness Independent categorisation effectiveness • Proven marginal submission identified 
Considered • Cost-effectiveness • Quality of model assessment of severe • Cost-effectiveness benefit • Cost-effectiveness 
• Composition of the • Comparative • Cost-effectiveness diseases • Burden of disease • Cost-effectiveness • Composition of the 
decision panel effectiveness, type • Severity of disease, • Price • Budget Impact In subgroup decision panel 
• Prevalence of of outcome, rule of rescue • Budget Impact • Severity of disease • Disease type, • Prevalence of 
disease comparator choice, • End of life process Orphan drug disease 
• Severity of disease trial duration, trial • Approach to • Lack of alternative 
• Patient lobbying size & comparative decision making, therapies 
• Budget Impact safety ordinal • Stakeholder 
• Composition of the • Sensitivity analysis lobbying 
decision panel and uncertainty In 
• Prevalence of economic analysis 
disease • Stakeholder 
• Availability of Involvement In 
other therapies decision making 
• Budget Impact 
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Table A3.1: Policy implementation summary 
Country and 
agency/institu 
tion 
Australia 
{PBAC} 
Austria 
{HEK/HBV} 
Establishment of system 
Pharmaceutical Benefits Scheme 
{PBS} began in 1948 and provides a 
list of medicines that are publically 
funded. PBAC is required to provide 
advisory recommendations to the 
Ministry of Health and since 1993 
required an economic. analysis. A" 
Australian residents with a Medicare 
card are eligible and a co payment 
{up to $34.20 for PBS Medicines and 
$5.60 for concessions}. Public system 
predominately funded by taxation. 
PBAC only reviews medicines 
(Australian Government, 2011b). 
The regulation regarding 
pharmaceutical reimbursement is 
the responsibility of the Federal 
government specifically the Federal 
Ministry of Health, Family and Youth 
(BMFGJ). The health system is 
funded by social insurance based on 
the principles of statutory insurance, 
solidarity and self-governance, which 
includes 22 social security 
institutions. The Medicines 
Evaluation Committee {HEK} was 
established in 2005 and provides 
advice to the Federation of Social 
Security Institutions {HBV}. The 
Federation makes final 
reimbursement decisions. The 
System Institutions 
Requires a review by 1. Pharmaceutical 
Benefits Advisory Committee (PBAC), 
an independent statutory body that 
assesses new medicines established in 
1954; 2. Price negotiation by the 
Pharmaceutical Benefits Pricing 
Authority; 3. Final decision to list in the 
PBS by the Ministry of Health and 
Ageing (Australian Government, 
2011a). 
Price: Negotiated by separate 
institution called the PBPA. 
A traffic light system operates in the 
Reimbursement Code, "green", 
"yellow" and "red zone". The 
reimbursement code is determined by 
the rules of procedure (351g ASVG 
2004). The Reimbursement Code aims 
to provide physiCians with a 
transparent and clear understandable 
set of medicines that are available for 
general reimbursement. The process 
maybe initiated by the Federation of by 
the manufacturer submitting an 
application for marketing 
authorisation. The Federation will 
review the application for 
completeness and the manufacturer 
will be required to provide the 
Agency/I nstitutio 
n responsible for 
assessment 
PBAC {statutory 
body} 
HEK 
Agency/Committee 
responsible with 
appraisal and 
deliberation 
PBAC (statutory 
body) & Ministry of 
Health 
Main Association of 
Austrian Security 
Institutions {HBV} 
Reimbursement 
institution 
funding 
Ministry of Health 
and Ageing 
through taxation 
{Department of 
Health and 
Ageing, 2011}. 
Committee 
provides 
recommendation 
to the Main 
Association of 
Austrian Social 
Insurance 
Institutions (PPRI, 
2007a). 
281 
Annual Report 
Not identified 
Not identified 
282 
Belgium 
(CRM) 
canada 
(CADTH, CDR) 
BMFGJ takes the advice of the 
pricing committee (PK) for pricing 
decisions. The medicine maybe listed 
on the positive list for outpatient 
medicines called the reimbursement 
Code (EKO) or maybe included in the 
negative list (Federation of Social 
Security Institutions (HBV), 2011) 
The Committee for Reimbursement 
of Medicines (CRM) was established 
in 2001 in a legal act (Royal Decree 
21 December 2001). It is responsible 
for formulating proposals for the 
admission of pharmaceuticals for the 
list of reimbursable pharmaceuticals, 
advise the Minister on aspects of the 
policy on reimbursement of 
pharmaceutical products, formulate 
the insurance committee proposal 
interpretive rules for the 
reimbursement of pharmaceuticals. 
The CRM is located in the National 
Institute for Health and Disability 
Insurance which is a non-
governmental public body. The 
NIHDI is a federal institution, which 
organises, manages and supervises 
the correct application of 
compulsory insurance in Belgium 
(NIHDI, 2011). 
CADTH was established in 1989 and 
the Common Drug Review (CDR) 
started accepting submissions in 
2003 to standardise reviews across 
the country. CADTH is funded by the 
federal, provincial and territorial 
governments as an independent not 
for profit agency. The Common Drug 
information within 14 days otherwise 
the application will be rejected. The 
Independent Pharmaceutical 
Commission (UHK) functions as an 
appeal court for when a 
manufacturer's medicine is not 
approved for reimbursement, (PPRI, 
2oo7a) 
Price: Separate Pricing Committee 
The CRM formulates advice to the 
Minister of Health and Social Affairs 
whose decision may differ because of 
budget or social considerations 
(Adriaens and Soete, 2010). 
Price: Separate Pricing Committee at 
FPS Economy for maximum prices. 
The manufacturer submits to the 
CADTH CDR. The CEDAC committee 
provides the appraisal of evidence and 
the manufacturer may reduce the price 
during the process. The CDR process 
provides adviSOry recommendations to 
the drug plans. The provincial drug 
plans make the final decision on 
Committee for 
Reimbursement 
(CRM) in the 
NIHDI 
CADTH 
Minister of Health 
and Social Affairs 
CADTH - CEDAC 
and Provincial drug 
plans 
Not identified. 
(Emailed 
institution for 
funding source. 
National Institute 
for Health and 
Disability 
Insurance (NIHDI) 
Federal, 
provincial and 
territorial 
governments 
(CADTH,2010b). 
Appendices 
Not identified 
Yes - 2009 - Quantity 
of reports, 
transparency and 
number of website hits 
(CADTH, 2009). 
Appendices 
Denmark 
(DMA) 
Finland (PPB) 
Review (CDR) undertakes reviews of 
Drug Submissions and provides 
formulary listing recommendations 
to all Canadian publicly funded 
federal, provincial, and territorial 
(F/PIT) Drug Plans with the 
exception of Quebec. The drug plans 
make their own decisions based on 
the recommendations and plans 
mandate, priorities and resources. 
(CADTH, 2011b). 
The Danish Health Act of 2005 
Sections 144(1-3) and 152 (2&4) 
decides whether to grant 
reimbursement for medicinal 
products. The Danish Medicines 
Agency is an agency under the 
Ministry of Interior and Health and 
provides final reimbursement 
decisions and is advised by the 
reimbursement committee which is 
an independent authority. The 
Reimbursement Committee (MTN) 
was established in 2003 by the 
Danish Minister for the Interior and 
Health to provide advice to the DMA 
(Danish Medicines Agency, 2008). 
Pharmaceutical manufacturers have 
the freedom to set price and a 
patient can receive reimbursement 
through the KELA, the social security 
institution (sometimes referred to as 
social insurance institution even 
though predominantly funded 
through taxation). This can take 
place once the Pharmaceutical 
Pricing Board has made a decision on 
the reimbursement status and price 
under the Health Insurance Act 
(1224/2004). The conditions set out 
reimbursement (CADTH, 2011a). 
Price: Monitoring at the national level 
and provincial health plan negotiations. 
The recommendations provided by the 
Reimbursement Committee appointed 
by the Ministry of Health are advisory 
and the Danish Medicines Agency 
makes the final decision (Danish 
Medicines Agency, 2008). 
Price: Agreement between the Danish 
Association oj Pharmaceutical industry 
and the Ministry oj Health 
The PPB makes the final decision and 
patients can then receive 
reimbursement from the Social 
Insurance Institute, KELA for either 
basiC reimbursement or special 
reimbursement (Ministry of Social 
Affairs and Health, 2011). 
Price: The PPB sets the statutory 
maximum price and reimbursement. 
Danish Medicines 
Agency & 
Reimbursement 
Committee 
PPB 
Danish 
Agency 
PPB 
Medicines The income for 
the Danish 
Finance Act, fees 
set by the Danish 
Minister for 
Interior and 
Health and 
income from 
work carried out 
for the European 
Medicines Agency 
(Danish 
Medicines 
Agency, 2010). 
Government 
Department 
283 
Yes 2007 annual report 
(Danish Medicines 
Agency, 2007). 
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France (HAS) 
Germany (G-
SA) 
in the payment of reimbursement 
under the health insurance act for a 
medicinal product is that the 
medicine must have a 
reimbursement status confirmed by 
the Pharmaceutical Pricing Soard 
(PPS) (Ministry of Social Affairs and 
Health, 2011). 
The HAS was created in the health 
insurance Act of August 13 2004. 
HAS is an independent public 
scientific authority to assess medical 
technologies (HAS, 2011b). 
The Federal Joint Committee (G-BA) 
is a legal decision-making body in a 
self regulated statutory health 
insurance (SHI) system under the 
German Social Law (SGB V). It was 
established on 1st January 2004 as 
mandated by a federal health reform 
law (GKV Modernisation Act - GMG). 
The directives issued by the G-SA are 
legally binding for insured persons as 
well as for the providers and payers 
The manufacturer submits to the HAS 
agency. The HAS provides one of the 
two stages of advice regarding the case 
for reimbursement which includes 
consideration of clinical evidence. 
Economic considerations made by the 
Economic Committee for Health 
Products (CEPS). The HAS opinion 
informs the pricing and volume 
agreements that are negotiated 
between the manufacturer and the 
Economic Committee for Health 
Products (CEPS) for outpatient 
medicines and medicines on top of 
DRG. Prices for those medicines for 
hospital use included in the DRG are 
negotiated directly with the individual 
hospitals, (Rochaix and Xerri, 2009). 
Price: This ;s negotiated by a separate 
committee called the CEPS. 
The manufacturer sets price (can be 
prescribed) and then submits to the G-
SA and the social insurance system 
covers fully the medicine. The G-SA will 
consider the early benefit assessment 
and employs IQWIG to provide the 
assessment of the dossiers. If the 
medicine is deemed to have no 
additional benefit the price of the 
medicine is set in the reference price. If 
the medicine has additional benefit the 
HAS (independent 
authority/agency) 
IQWIG 
(independent 
authority) 
HAS - Transparency 
Committee & 
Ministry of Health 
G-BA 
making 
Federal 
(decision-
body) -
Joint 
Committee 
The budget of 
HAS is {62M in 
2009 and is 15% 
funded by 
government 
subsidies, Primary 
state social health 
insurance fund 
contributes 50% 
and 26% by 
French Social 
Security Agency. 
(HAS, 2011a) 
The Federal Joint 
Committee is 
funded by system 
surcharges. These 
are composed of 
a surcharge for 
each billable 
hospital visit and 
from an 
additional 
increase in fees 
Appendices 
Yes - 2009 - quantity 
of guidance produced 
and other tasks 
discussed (HAS, 2009). 
Not identified 
Appendices 
Ireland 
(Corporate 
unit and 
NCPE) 
of health care: physicians, hospitals 
and sickness funds. A new body was 
created in 2004 called the Institute 
for Quality and Efficiency in 
Healthcare (IQWIG) an independent 
scientific body which is responsible 
for the assessment of new medicines 
at the request of the G-BA. The Act 
for. the Restructuring of the 
Pharmaceutical Market in Statutory 
Health Insurance (AMNOG) in 2011 
has greatly changed the 
reimbursement system. G-BA aims to 
regulate SHI-wide issues of access, 
benefits and quality for medical 
technologies (Federal Joint 
Committee, 2010, leverkus, 2011) 
There is no legal agreement 
applicable for reimbursement 
decisions in Ireland. There is an 
agreement between the Health 
Service Executive and 
Pharmaceutical industry called the 
Irish Pharmaceutical Healthcare 
Association agreement. The HSE is a 
public organisation which is 
accountable to the Minister of 
Health and Children. There is a 
General Medical Services (GMS) 
scheme and a Drugs Payment 
Scheme (DPS) provide 
reimbursement for those eligible in 
Ireland. The Health Service 
Executive is responsible for the 
operation and management of the 
public health services in Ireland on 
behalf of the Department of Health 
and Children. The HSE reports 
directly to the Minister for Health. 
The Corporate Pharmaceutical Unit 
price is negotiated with the sickness 
funds at 6 months. No agreement on 
price results in an arbitration 
committee that will agree price. On 
dissatisfaction of the arbitration price, 
the manufacturer or funds can request 
IQWIG to provide an effiCiency frontier 
analysis. The reimbursement price is 
valid from one year onwards (leverkus, 
2011). 
Price: FJC agrees maximum price but on 
failure to agree prices are negotiated 
with the sickness funds. 
The CPU may request the NCPE to 
provide an economic analysis for those 
medicines that are high budget impact. 
The recommendation is provided to 
the CPU which makes the final deCision 
for reimbursement (IPHA, 2006, NCPE, 
2011, Tilson et a/., 2010). 
Price: A separate agreement is provided 
between the Irish Pharmaceutical 
Healthcare Association (lPHA) and the 
Irish government. 
NCPE 
(independent 
body) 
HSE (public body) 
for outpatient's 
medical and 
dental care. The 
G-BA fixes a 
surcharge each 
year (Federal 
Joint Committee, 
2011b). 
Ministers of 
Health and 
Children and 
Department of 
Health and 
Children through 
taxation (Health 
Service Executive, 
2010) The 
National Centre 
for 
Pharmacoeconom 
ics (NCPE) is 
funded by the 
Department of 
Health and 
Children. 
285 
Yes 2010 - Broader 
remit and medicines 
only mentioned in 
accounts (Health 
Service Executive, 
2010). 
286 
Israel 
(Medical 
Technologies 
Administratio 
n) 
Italy (Pricing 
and 
Reimburseme 
nt 
Committee) 
of the HSE makes 
recommendations 
reimbursement and 
on 
pricing 
final 
the 
of 
medicines. The final decision is 
informed by recommendations from 
the National Centre for 
Pharmacoeconomics (NCPE) 
established in 1998 (CPU, 2011, 
IPHA, 2006, NCPE, 2011). 
A list of Health Services that 
residents of Israel are entitled to 
called the National List of Health 
Services (NLHS) which introduced in 
1995. The list is updated annually 
and this is in line with the additional 
annual budget for technologies, 
specified by government for the 
year. In 1998 a process was 
established for the listing of 
medicines and a committee 
established called the Public National 
AdviSOry Committee (PNAC). The list 
specifies the benefits that residents 
are entitled to receive from the 
health plans (Greenberg et al., 2009). 
The Italian Medicines Agency (AI FA) 
was established in July 2004 and is 
the main agency responsible to the 
Ministry of Health for national 
reimbursement decisions regarding 
medicines in the National Healthcare 
System (SSN). The healthcare system 
is predominantly funded by taxation 
and largely decentralised and 
consists of a national level, regional 
level and local level (AIFA, 2011). 
The MTA provides an assessment that 
informs the PNAC decision for listing on 
the NLHS. The Ministry of Health makes 
the final approval of the list of new 
technologies approved. The list of 
technologies is only updated annually 
and this is a unique aspect of this 
fourth hurdle system (Greenberg et aI., 
2009, Rosen and Samuel, 2009). 
Price: Ministry of Health established 
the maximum price for all 
pharmaceuticals approved for sale. 
The manufacturer must first apply to 
the AIFA by submitting a dossier for 
pricing and reimbursement. The 
Technical and Scientific Commission 
(CTS) deal with the applications for 
marketing authorisation and provides 
an assessment of the efficacy of new 
drugs. The Price and Reimbursement 
Committee (CPR) evaluate the dossier 
and negotiate the prices of new drugs 
and set the reimbursement class of the 
medicine. The regions can decide on 
the copayments for these medicines 
which lead to price differences to the 
patient across the country. In 2010 a 
Ministry of Health 
Medical 
Technologies 
Administration 
AIFA CTS 
committee 
Ministry of Health -
PNAC committee 
and Ministry of 
Health through act 
of parliament. 
AIFA - Price and 
Reimbursement 
committee 
Government 
Department 
Not identified 
(Emailed 
Adrianna 
Gasparini at the 
AI FA. 
14/09/2011) 
Appendices 
Not identified 
Appendices 
Hungary 
(Technology 
Appraisal 
Committee) 
Mixed tax and 
social 
insurance 
Korea (HIRA) 
The National Health Insurance Fund 
Administration (NHIFA) provides 
reimbursement decisions for new 
medicines and a Technology 
Appraisal Committee was 
established in 2004 to perform this 
task. The TAC is informed by the 
National Institute for Strategic 
Health Research (NISHR) of the 
Ministry of Health which coordinates 
the HTA body that appraises 
submissions called the Office for 
Health Technology Assessment 
(OHTA) (PPRI, 2007b). 
The Ministry of Health and Welfare 
(MOHW) overseas the National 
Health System. The national health 
insurance system provides health 
care coverage to all citizens in the 
form of social insurance. The Health 
Insurance Review and Assessment 
Service (HIRA) conducts reviews and 
assessments for reimbursement and 
was established in July 2000 as an 
independent agency separated from 
new rule was introduced for hospital 
medicines that specified that within 30 
days of the AIFA reimbursement 
decision the medicine should be 
included on the regions hospital 
formulary. The regions and provinces 
are able to challenge the decision on 
the grounds of the medicine meeting 
the criteria specified by the AIFA 
(Jommi, 2009, Gianfrate, 2010). 
Price: Prices are negotiated and 
reimbursement decisions are made by 
theA/FA. 
The manufacturer submits to the 
NIHFA. The OHTA makes a critical 
appraisal of the submission and 
provides are report to the Technology 
Appraisal Committee (TAC). The Head 
of the Pharmaceutical Department of 
the NIHFA makes the reimbursement 
decision (PPRI, 2007b). 
Price: The NHIFA 
reimbursement decision 
negotiates price. 
decides 
and also 
The manufacturer must submit to the 
HIRA and a report is provided. The 
Drug Reimbursement Committee 
(DREC) makes the recommendation 
and then price negotiations are made 
by the National Health Insurance 
Corporation. The final decision is made 
by the Ministry of Health and Welfare, 
(Bae and Lee, 2009). 
Price: Price negotiations are made with 
OHTAofthe 
HIRA 
NIHFA-TAC 
HIRA - OREC & 
Ministry of Health 
and Welfare 
Not identified. 
The NHIFA has a 
health insurance 
fund that is a 
separate fund 
within the state 
budget which is 
approved by 
parliament each 
year. (Sent an 
email to the 
NHIFA Gyula 
Kiraly for how the 
administration is 
funded.) 
HIRA is funded by 
insurance 
contributions 
collected by the 
National 
Insurance 
Contribution 
(NHIC) 2011:WON 
223million (HIM. 
2011a) 
287 
Not identified 
Not identified 
288 
Mexico 
(General 
Health 
Council) 
Netherlands 
(CVZ) 
insurers, providers and other I the National Health Insurance 
interested parties. Economic Corporation. 
evaluation was introduced formally 
in 2006. The HTA assessment 
provided by HIRA is used by the 
National Insurance Corporation 
(NHIC) for negotiation of the price of 
reimbursed medicines (Bae, 2009) 
The General Health Council is the 
main government decision making 
body for the reimbursement of 
medicines. The Presidential 
Agreement of 2002 states that public 
institutions of the NHS should only 
use medicines from the basic 
formulary for primary care and the 
catalogue of inputs for secondary 
and tertiary care. The Council 
introduced a regulation in 2003 for 
the requirements including the use 
of pharmacoeconomic studies. There 
is a working group called the 
Interinstitutional Commission of the 
Basic Formulary of Inputs of the 
Health Sector that meets three times 
a year. Mixed system of financing 
with 50% covered by social insurance 
(General Health Council, 2011). 
Medicines in the outpatient setting 
are reimbursed by health insurers if 
they are included in the Drug 
Reimbursement System (GVS) which 
includes a reference price system. 
The Health Insurance Board (CVZ) is 
an independent non-governmental 
body that provides advice to the 
Minister of Health for the inclusion 
of medicines in the benefits package 
under the Health Insurance Act of 
The manufacturer submits and the 
interinstitution subcommittee 
evaluates the submissions. The General 
Health Council provides the decision 
and provides a GB code for inclusion on 
the Basic Formulary or catalogue of 
Inputs. The public institutions must use 
this as a basis for prescribing decisions 
but may produce their own formulary 
(Moise and Docteur, 2007). 
Price: There is a voluntary maximum 
price but the social insurance 
institutions can negotiate on price. 
The manufacturer submits to the CVZ 
and an assessment will be undertaken 
by the Pharmaceutical Assistance 
Commission (CFH committee). The CVZ 
Board may convene an appraisal 
committee (ACP) for those medicines 
with added therapeutic value. The final 
advice is sent to the Minister who 
makes the final decision for inclusion in 
the Drug Reimbursement System 
(GVS), (Schafer et al., 2010, CVZ, 2011, 
Interinstitution 
Sub Committee 
CVZ 
committee 
CFH 
General Health 
Council & Public 
institutions (Social 
insurers or social 
security agencies) 
CVZ - Board & 
Ministry of Health. 
The Social 
Insurance 
Institutions 
provide the 
formulary for the 
final 
reimbursement 
decision (Moise 
and Docteur, 
2007). 
The Dutch 
Ministry of Health 
through taxation 
(Personal 
Communication: 
Jacqueline 
Zwaap). 
Appendices 
Not identified 
Yes - Annual Review 
2010 - quantity of 
advice accounted for 
(CVZ, 2010). 
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New Zealand 
(PHARMAC) 
Norway 
(NoMA) 
I 2006 (Zorgverzekeringswet, Zvw). I evz, 2009) 
CVZ was established in 1999 and is 
responsible for technologies within 
the basic health care package (CVZ, 
2009). 
A Pharmaceuticals Schedule 
operates in New Zealand which 
includes a list of a" pharmaceuticals 
and related products. The 
Pharmaceutical Management Agency 
of New Zealand was established in 
1993. In June 2001 it was given legal 
duty under the Crown Entities Act 
2000 to perform its functions of 
managing the Pharmaceutical 
Schedule. PHARMAC is a government 
agency directly accountable to the 
Minister of Health and is part of the 
medicine system alongside Medsafe 
and the District Health Boards 
(DHBs). PHARMAC manages 
outpatient and inpatient medicines 
where national contracts have been 
negotiated (PHARMAC, 2011a). 
The residents of Norway are covered 
by a national social insurance 
scheme. The Norwegian Medicines 
Agency is responsible for the pricing 
and reimbursement of medicines 
and was established in 2001. The 
pricing and reimbursement process 
is regulated in Regulation No. 1559 
1999. This speCifies that a 
pharmacoeconomics evaluation 
should be provided for general 
reimbursement (Norwegian 
Medicines Agency, 2011). 
Price: There is statutory price setting 
for interchangeable medicines and 
generics set by the Ministry of Health, 
Welfare and Sport. 
The manufacturer submits to the 
PHARMAC. The Pharmacology and 
Therapeutics Advisory Committee 
(PTAC) reviews and provides a 
recommendation to the PHARMAC 
Board and price negotiations may take 
place. The PHARMAC Board then 
decide whether the medicine should be 
included in the schedule. (PHARMAC, 
2011c) 
Price: PHARMAC negotiates both price 
and reimbursement. 
The manufacturer initially submits to 
the Norwegian Medicines Agency for a 
blue prescription that covers the costs 
of essential medicines. The NoMA 
screens the application to make sure 
that it meets the requirements. A price 
application may be submitted 
simultaneously. The NoMA agency may 
request the Blue Prescription Board to 
consider the case for reimbursement 
and should be consulted if it is a major 
therapeutic innovation The Board 
provides an assessment within seven 
weeks of receiving the details of the 
manufacturer submission. The NoMA 
PHARMAC - PTAC 
NoMA 
PHARMAC Board 
NoMA Blue 
Prescription Board 
& Ministry of 
Health 
The Ministry of 
Health plan to pay 
$14m in 2011-
2012 output 
agreement 
through general 
taxation 
(PHARMAC, 
2011b). 
Not identified 
(Emailed 
Norwegian 
Medicines Agency 
no response to 
date) 
Yes - Annual Report 
2010 considers 
access and expenditure 
on pharmaceuticals 
(PHARMAC,2010b). 
Yes - Annual report 
2010, focus on 
regulatory tasks 
(Statens 
legemiddelverk, 2010). 
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Poland 
(AOTM) 
The Agency for Health Technology 
Assessment in Poland (AHTAPol) was 
established in 2006. In an Act of June 
2009, the agency became a state 
entity with legal responsibility for 
making recommendations for the 
reimbursement list. The agency is 
responsible for listing, removing 
medicines from the list of 
guaranteed benefits and changes in 
the level and funding of the benefits. 
It has responsibility for many 
can decide on the approval of the 
medicine in the list for provision by the 
National Insurance Administration. The 
NoMA cannot approve medicines with 
an annual cost increase of more than 5 
million annually. The NoMA must 
submit a report to the Blue Prescription 
Committee/Board and the 
manufacturer is given the opportunity 
to comment. A copy of the committee 
assessment will be forwarded to the 
Ministry of Health care Services (HOD) 
where advice maybe sought from the 
National Council for Health care 
Priorities. The National Council for 
Health care Priorities assesses whether 
the money spent on the medicine 
would be well spent with regards to 
other priorities. The Ministry can 
decide to reject the application 
following the further evaluation or it 
may favour approval and bring the case 
to parliament in the form of a 
parliamentary bill. (PPRI, 200Sb) 
Price: The NoMA is responsible for 
setting the maximum pharmacy 
purchase prices (PPP). 
The Ministry of Health refers the 
manufacturer submission to AHTAPol 
and the submission is analysed by the 
AHTAPol analytical team using the 
Polish Guidelines for the conduct of 
Health Technology Assessment. The 
Analytical Team will revise the 
submission and provide a report. The 
appraisal process is separate and 
performed by the Consultative Council 
that is chaired by the President of 
AHTAPol. The Consultative Council 
AHTAPol analytic 
team 
AHTAPol 
Consultative 
Council & Minister 
of Health 
Public institution 
that is financed 
from the 
government 
budget through 
taxation and 
partly by 
manufacturers 
contributions: 
EUR2.4Sm per 
year. (Personal 
Communication: 
Appendices 
Not identified 
Appendices 
Portugal 
(INFARMED) 
Spain 
(Ministry 
Health 
Directorate 
General) 
of 
technologies (AHTAPol, 2011). 
The reimbursement system is set 
within the National Health Services 
(SNS), which is funded through 
general taxation. The National 
Authority of Medicines and Health 
Products (INFARMED) is a 
government agency that was 
established in 1993. There is a legal 
framework for the reimbursement of 
medicines and this is set out in Law 
No.118/92 June 25. INFARMED 
assesses medicines only, (PPRI, 
2008a). 
The National Health Service was 
established in Spain in 1986 under 
the General Health Law. The health 
system is decentralised and control 
given by 17 autonomous regions. 
The reimbursement and pricing 
decisions are made at the national 
level involving the Ministry of Health, 
Directorate General of Pharmacy and 
Health Products role established in 
2003. The criteria considered by the 
Ministry of Health are contained in 
Art 89. Of Pharmaceutical Law -
Public financing procedure, 2006, 
(Vogler et aI., 2009b). 
takes into account the wider context 
specific judgements. The President of 
AHTAPol provides the final 
recommendation that is passed to the 
Ministry of Health. The Minister of 
Health decides the final decision for 
inclusion on the list, (Leopold and 
Vogler, 2009, AHTAPol, 2011). 
Price: The price is agreed with the 
Ministry of Health 
The manufacturer must agree a 
maximum price with the Directorate-
General for Economic Activities (DGEA). 
The manufacturer then applies to the 
Ministry of Health and INFARMED for 
reimbursement. The Ministry of Health 
makes the final decision (PPRI, 2008a). 
Price: The price is set by the Directorate 
Generol of Economic activities for a 
maximum price of new 
pharmaceuticals. 
The Ministry of Health, Directorate 
General of Pharmacy and Health 
Products initiates the reimbursement 
process and the Spanish Medicine 
Agency for Health Products provides a 
report on the clinical utility of the 
medicine. The manufacturer must 
provide information to the Inter-
ministerial Price Commission that 
agrees a maximum price. The Minister 
of Health makes the final decision and 
regions have responsibility for 
implementation of the decision, 
(Vogler et aI., 2009b). 
Price: The inter-ministerial price 
INFARMED 
Ministry of Health 
and Spanish 
Agency for 
Medicines and 
Health Products 
INFARMED & 
Ministry of Health 
Ministry of Health, 
Directorate General 
of Pharmacy and 
Health Products 
Gabriela Ofierska-
Sujkowska, Head 
of 
Reimbursement 
Recommendation 
s, AHTAPol). 
Not Identified 
(Emailed Laura at 
INFARMED.) 
Government 
Department 
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Not identified 
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Sweden (TLV) 
Switzerland 
(Federal 
Office for 
Public Health) 
The Dental and Pharmaceuticals 
BenefItS Board (TLV) was established 
in 2008 to integrate medicines and 
dental care in one agency. The 
agency use to be known as the 
Pharmaceutical Benefits Board (LFN), 
which was established in 2002. The 
TLV agency is a central government 
agency whose legal remit is to 
determine whether a pharmaceutical 
product or dental care procedure 
shall be subsidised by the state 
reimbursement scheme. The nv 
makes decisions for outpatient 
medicines and dental treatments. 
The Swedish public health system is 
funded by taxation (TLV, 2010a). 
The Federal Office of Public Health 
(FOPH) is part of the Department of 
Home Affairs (FDHA). The FOPH is 
the integrated centre for excellence 
for health. It is responsible alongside 
the 26 cantons for public health and 
development of the national health 
policy. The FOPH is responsible 
under the ACT 117FC to regulate 
health and accident insurance. The 
FOPH provides the final 
recommendation for inclUSion in the 
Pharmaceutical Specialities List (SL-
list) for reimbursement. The FOPH is 
informed by the Federal Drug 
Commission that was established in 
1995 and consists of scientific 
experts and stakeholders. It provides 
advice through conSideration of 
evidence for inclusion in the 
commission agrees a maximum price. 
The manufacturer must submit an 
application for pricing and 
reimbursement. The TLV determines 
whether the medicine should be 
eligible for inclusion in the -high-cost 
threshold-. There are many medicines 
included in the high-cost threshold and 
includes tax subsidised medicines 
where the state reimburses a 
proportion of the cost. The 
Pharmaceutical Benefits Board makes 
the final reimbursement decisions and 
these are mandatory. The County 
Councils implement the decisions for 
outpatient medicines (LFN, 2007). 
Price: Responsible for implementing 
statutory prlcmg but does not 
negotiate on price. 
The manufacturer submits an 
application to the FOPH which is then 
considered by the Federal Drug 
Commission (FOe). The FOPH makes 
the final decision (Paris and Docteur, 
2007). 
Price: The FOPH agrees maximum price 
and reimbursement 
TLV 
Foe (committee) 
TLV 
FOPH 
Department 
Health 
of 
of 
TLV is funded 
through central 
government 
budget decided 
by Swedish 
parliament 
through taxation. 
(Personal 
Communication: 
Martin Eriksson, 
nV) 
Government 
Department 
Appendices 
Yes - 2010, quantity 
and processing times 
(TLV,2010b). 
Appendices 
UK: 
and 
(NICE) 
England 
Wales 
UK: Scotland 
(SMC) 
speciality list (Federal Office of Public 
Health, 2011). 
The system is centred around NICE 
which was established in 1999 under 
direction of the Secretary of State. 
NICE reviews a number of 
technologies using different 
processes. Public system is 
predominantly funded through 
taxation (NICE, 2011). 
The provISion of health care is 
devolved to health boards. The 
Scottish Medicines Consortium 
(SMC) was established in 2001 by the 
15 Health Boards which today 
provides advice to the 14 health 
boards for funding of new medicines. 
Funding for public provision is 
funded through taxation in Scotland 
(SMC, 2011). 
NICE provides a recommendation. NICE 
recommendations require funding for 
the medicine 3 months after 
publication from taxation. They do not 
have responsibility for implementation, 
(Department of Health, 2011). 
Price: Indirect price control through the 
Pharmaceutical Price Regulation 
Scheme (PPRS) 
The SMC provides one stage advice to 
the health boards and Area Drug 
Therapeutic Committees with regards 
value for money. The health boards 
choose whether to include the 
medicine following advice from the 
SMC. Manufacturer is free to set price 
prior to the evaluation by the SMC, 
(SMC, 2011). 
Price: Indirect price control through the 
Pharmaceutical Price Regulation 
Scheme (PPRS) 
NICE (special 
health authority) 
ERG or 
Assessment 
Group 
SMC-NDC 
NICE (special health 
authority) 
Technology 
Appraisal 
Committee 
SMC & Area Drug 
Therapeutic 
Committees 
Department of 
Health through 
taxation (NICE, 
2010a). 
Funding from the 
Health Boards 
from the revenue 
allocated to them 
(Scottish 
Executive, 2003). 
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Yes previous annual 
report produced (NICE, 
2010b). 
Yes previously- Last 
annual report 
produced in 2008 
(quantity of guidance) 
(SMC, 2008). 
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Table A3.2 OECD countries' Policy Implementation Level 
Policy Implementation Level of OECD formal HTA 
Country I Establishment 
Australia I The Pharmaceutical Benefits 
Austria 
Advisory Committee was 
established in 1953 in the National 
Health Act 1953. The Economic 
Sub-Committee (ESC) was 
established in 1994 to assess the 
validity of the manufacturer 
economic submissions. PBAC is an 
advisory committee that reports to 
the Ministry of Health. The PBAC 
costs around $10 million per year 
to operate, (Lopert, 2009). 
The regulation regarding 
pharmaceutical reimbursement is 
the responsibility of the Federal 
government specifically the Federal 
Ministry of Health, Family and 
Youth (BMFGJ). The health system 
us funded by social insurance 
based on the principles of statutory 
insurance, solidarity and self -
governance, which includes 22 
social security institutions. The 
Medicines Evaluation Committee 
(HEK) was established in 2005 and 
provides advice to the Federation 
Objective 
The Pharmaceutical Benefits Scheme 
(PBS) aims to provide timely, reliable 
and affordable access to necessary 
medicines for Australians. The PBACs 
primary role is to recommend to the 
Minister for 
Health which drugs and medicinal 
preparations represent value for 
money and should be subsidised by 
the Australian 
Government under the PBS. The goal 
of Australian Government HTA 
processes is to maximise beneficial 
health outcomes to the Australian 
population within the overall funds 
available whilst being cognisant of 
the other important goals of the 
health system. PBAC provides 
recommendations for medicines and 
its remit was widened to include 
vaccines in 2006. 
The main principles of the Austrian 
Health Care system are solidarity, 
affordability and universality. The 
system ensures high quality medical 
care for all citizens, independent of 
their social status or income. The 
mission of the HBV states that they 
aim "provides customer-oriented and 
conscientious protection against the 
risks of diseases, old age and 
unemployment." 
Implementation 
In Australia the Pharmaceutical Benefits 
Scheme (PBS) is part of the broader 
National Medicines Policy for which the 
government subsidises and is administered 
through Medicare Australia. The PBAC 
committee provides advisory 
recommendations to the Ministry of 
Health. There is a two-stage process where 
the PBAC makes a recommendation and 
then the Pharmaceutical Benefits Pricing 
Authority (PBPA) considers this for price 
negotiations. 
The HVB and its 22 Sickness funds provide 
implementation of the decisions in the 
social insurance system using the 
reimbursement code. 
A traffic light system operates in the 
Reimbursement Code, "green", "yellow" 
and "red zone". The reimbursement code 
is determined by the rules of procedure 
(351g ASVG 2004). The Reimbursement 
Code aims to provide physicians with a 
transparent and clear understandable set 
of medicines that are available for general 
reimbursement. The process maybe 
initiated by the Federation of by the 
Accountability 
SubmiSSions are processed 
within 17 weeks and 
recommendations made. 
The recommendations by 
the PBAC are only adviSOry 
and the Minister for Health 
makes the final decision on 
listing. 
There is a legal framework 
governing the rules of 
procedure for inclusion in 
the code of reimbursement 
(351g of ASVG 2004). The 
HBV will provide a decision 
within 90 days of the 
original manufacturer 
submission. 
Appendices 
References 
(PBAC, 2008) 
(Lopert, 2009) 
(Department of 
Health and 
Ageing, 2011) 
(Australian 
Government, 
2011b) 
(Federation of 
Social Security 
Institutions (HBV), 
2011) 
(PPRI, 2007a) 
(Austrian 
Federation of 
Social Insurance 
Institutions, 2004) 
Appendices 
Belgium 
canada 
of Social Security Institutions 
(HBV). The Federation makes final 
reimbursement decisions. The 
BMFGJ takes the advice of the 
pricing committee (PK) for pricing 
decisions. The medicine maybe 
listed on the positive list for 
outpatient medicines called the 
reimbursement Code (EKO) or 
maybe included in the negative list. 
The Committee for Reimbursement 
of Medicines (CRMI was 
established in 2001 in a legal act 
(Royal Decree 21 December 2001). 
It is responsible for formulating 
proposals for the admission of 
pharmaceuticals for the list of 
reimbursable pharmaceuticals, 
advise the Minister on aspects of 
the policy on reimbursement of 
pharmaceutical products, 
formulate the insurance committee 
proposal interpretive rules for the 
reimbursement of pharmaceuticals. 
The CRM is located in the National 
Institute for Health and Disability 
Insurance. The NIHDI is a federal 
institution, which organises, 
manages and supervises the 
correct application of compulsory 
insurance in Belgium. 
CADTH was established in 1989 and 
the Common Drug Review (CDR) 
started accepting submissions in 
2003 to standardise reviews across 
the country. CADTH is funded by 
the federal, provincial and 
The NIHDI plays a key role in the 
Social Security System. It manages 
and organises the health care 
insurance for the reimbursement, 
payment of benefits and medical 
costs. Its objective is to provide 
reimbursement of medical costs in 
order to make high quality health 
care accessible to as many people as 
possible. The CRM has responsibility 
for providing advice to the Minister 
of Health and Social Affairs. 
The objectives of the CDR process are 
to reduce duplication, to maximize 
the use of limited resources and 
expertise, and to enhance the 
consistency and quality of Drug 
reviews. The CDR accepts 
manufacturer submitting an application for 
marketing authorisation. The Federation 
will review the application for 
completeness and the manufacturer will be 
required to provide the information within 
14 days otherwise the application will be 
rejected. The Independent Pharmaceutical 
Commission (UHK) functions as an appeal 
court for when a manufacturer's medicine 
is not approved for reimbursement. The PK 
advises the BMFGJ on the price of the 
medicine, (PPRI, 2007a) 
The NIHDI is responsible for the 
management and supervision of the 
compulsory health care and benefits (HCB) 
insurance. The health insurance funds are 
responsible for the reimbursement and 
payment of the benefits and medical costs. 
The CRM formulates advice to the Minister 
of Health and Social Affairs whose decision 
may differ because of budget or social 
considerations. 
The CADTH CDR recommendations are 
advisory and provided to each of the 
jurisdictions to make decisions on inclusion 
in their drug plans. CDR recommends 
whether a drug should be listed. 
Jurisdictions evaluate the impact of adding 
295 
NIHDI falls under the I (NIHDI,2011) 
responsibility of the 
Minister for Social Affairs. I (NIHDI,2007) 
listing decisions are made 
within 180 days of the I (Adriaens and 
application. Soete, 20101 
CADTH is owned by, and 
reports directly to, the 13 
Provincial/Territorial 
Deputy Ministers of Health 
and the Federal Deputy 
Minister of Health. 
(KCE,2010) 
(CADTH, 2010a) 
(CADTH, 2011a) 
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Denmark 
territorial governments as an 
independent not for profit agency. 
The Common Drug Review (CDR) 
undertakes reviews of Drug 
Submissions and provides 
formulary listing recommendations 
to all canadian publicly funded 
federal, provincial, and territorial 
(F/P/T) 
Drug Plans with the exception of 
Quebec. The drug plans make their 
own decisions based on the 
recommendations and plal1s 
mandate, priorities and resources. 
The Common Drug Review (CDR) 
undertakes reviews of Drug 
Submissions and provides 
formulary listing recommendations 
to all canadian publicly funded 
federal, provincial, and territorial 
(F/P/T) 
Drug Plans with the exception of 
Quebec. 
The Danish Health Act of 2005 
Sections 144(1-3} and 1S2 (2&4) 
decides whether to grant 
reimbursement for medicinal 
products. The Danish Medicines 
Agency is an agency under the 
Ministry of Interior and Health and 
provides final reimbursement 
decisions and is advised by the 
reimbursement committee which is 
an independent authority. The 
Reimbursement Committee (MTN) 
was established in 2003 by the 
Danish Minister for the Interior and 
Health to provide advice to the 
DMA. 
submissions for new medicines with 
the exception of cancer. medicines 
that are assessed by a different 
process. The Pan-Canadian Oncology 
Drug Review Process (pCODR) 
reviews all oncology medicines via a 
cross-jurisdictional process. 
The aim of the Danish Medicines 
Agency is to ensure the availability of 
effective and safe healthcare 
products - medicinal products, 
medical devices and new therapies 
and to promote the proper use of 
such products. According to section 
144(1)-{3) and section 152(2) and (4) 
of the Danish Health Act, the Danish 
Medicines Agency decides whether 
the Regional Council is to grant 
general, including general 
conditional, reimbursement, for a 
medicinal product. 
the drug to their formularies. Their 
considerations include: non-drug 
treatment options, policy, budget impact, 
and other economic considerations. Drug 
plans also assess drugs not covered by CDR 
(e.g. generics), monitor drug utilization, 
promote optimal prescribing, and manage 
the overall formulary. 
The recommendations provided by the 
Reimbursement Committee are adviSOry 
and the Danish Medicines Agency makes 
the final decision. 
The DMA is an agency 
under and accountable to 
the Minister of Interior and 
Health. In almost all cases 
the decision on 
reimbursement status for a 
given pharmaceutical is 
made in fewer than 90 days 
from the application date in 
accordance with the 
Transparency Directive. The 
process time may pause 
when consultation occurs 
with the manufacturer to 
clarify aspects of the 
submission. 
Appendices 
(Danish 
Medicines 
Agency, 2011) 
(Danish 
Medicines 
Agency, 2008) 
Appendices 
Finland 
France 
Pharmaceutical manufacturers 
have the freedom to set price and a 
patient can receive reimbursement 
through the KELA, the social 
security institution (sometimes 
referred to as social insurance 
institution even though 
predominantly funded through 
taxation). This can take place once 
the Pharmaceutical Pricing Board 
has made a decision on the 
reimbursement status and price 
under the Health Insurance Act 
(1224/2004). The conditions set 
out in the payment of 
reimbursement under the· health 
insurance act for a medicinal 
product is that the medicine must 
have a reimbursement status 
confirmed by the Pharmaceutical 
Pricing Board (PPB). 
Haute Autorite de sante (HAS) was 
established by the health insurance 
Act of August 13 2004 by the 
Ministry of Health and Solidarity. 
HAS is an independent public 
scientific authority to assess 
medical technologies. Health 
funding is raised through social 
health insurance in France. 
The chief objective of pharmaceutical 
service is to enable an efficient, safe, 
rational and cost-effective 
pharmacotherapy for all those in 
need of it. Inter-professional 
cooperation and agreeing on joint 
policies and goals regionally and 
locally are prerequisites for securing 
systematic and sustained operations. 
The utilisation of· information 
systems available In social welfare 
and healthcare and their 
compatibility should be enhanced. 
The goal is to deliver all prescriptions 
electronically. 
The aim of the agency is to improve 
the quality of care and guarantee 
equity within the healthcare system. 
The PPB makes the final decision and 
patients can then receive reimbursement 
from the Social Insurance Institute, KELA 
for either basic reimbursement or special 
reimbursement. KELA aims to secure the 
income and promote the health of the 
entire nation, and to support the capacity 
of individual citizens to care for 
themselves. 
The reimbursement decisions in France are 
published in the Official Journal by the 
Ministry of Health in France and provided 
by the social insurance institutions through 
the mandatory social health insurance 
system. The National Union of Health 
Insurance Funds (UNCAM) COoOrdinates the 
three national sickness funds (general 
scheme, agricultural scheme and SOCial 
system of independent) and decides the 
rate of reimbursement following a listing 
decision by the HAS and CEPS committee. 
The HAS provides one of the two stages of 
advice regarding the case for 
reimbursement which includes 
consideration of clinical efficacy. Economic 
considerations made by the Economic 
Committee for Health Products (CEPS). the 
HAS opinion informs the pricing and 
The Pharmaceutical Pricing 
Board is the responsible 
authority for decisions on 
medicines prices and 
reimbursement. The 
authority is responsible to 
the Ministry of Social 
Affairs and Health who are 
responsible for the 
administrative 
development of the 
pharmaceutical service. The 
reimbursement and pricing 
decisions take up to 180 
days. 
Legally required to provide 
advice to Ministry of Health 
in 90 days 
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(Ministry of Social 
Affairs and 
Health, 2011) 
(PPB,2011) 
(KELA, 2011) 
(HAS, 2011b) 
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Germany The Federal Joint Committee (G-
BA) is a legal decision-making body 
in a self regulated statutory health 
insurance (SHI) system under the 
German Social law (SGB V). It was 
established on 1st January 2004 as 
mandated by a federal health 
reform law (GKV Modernisation Act 
- GMG). The directives issued by 
the G-BA are legally binding for 
insured persons, providers and 
payers of health care (physicians, 
hospitals and sickness funds). A 
new body was created in 2004 
called the Institute for Quality and 
Efficiency in Healthcare (IQWIG) a 
independent scientific body which 
is responsible for the assessment of 
new medicines at the request of 
the G-BA. The institute provides 
independent reports for drugs, 
surgical procedures, methods of 
diagnosis and treatment guidelines 
and disease management 
programme (DMP). The agency 
provides an assessment of the 
medical benefit. It is required from 
2008 to produce a health economic 
assessment for the evaluation of 
costs and benefits of drugs. IQWIG 
provides advice to the Federal Joint 
Committee which makes the final 
The objectives of the G-BA operate 
according to a legal basis through a 
code of procedure of the G-BA (Social 
Code (SGB V)). The services provided 
by the statutory health insurance 
must be -adequate, expedient and 
cost-i!ffective" (Federal Joint 
Committee, 2011: How Innovations 
Enter Statutory). IQWIG is contracted 
by the G-BA to provide early benefits 
assessments and economic analysiS 
and the agencies stated aims are to 
-examine objectively the advantage 
and disadvantages of medical 
services for patients" 
volume agreements that are negotiated 
between the manufacturer and the 
Economic Committee for Health Products 
(CEPS) for outpatient medicines and 
medicines on top of DRG. Prices for those 
medicines for hospital use included in the 
DRG are negotiated directly with the 
individual hospitals. 
The Federal Joint Committee provides the 
directives for those medicines that can be 
provided by the statutory health insurance 
fund (GKV) and reimbursed by the health 
insurance funds. The National Association 
of Statutory Health Insurance Funds 
performs a central role in the German 
healthcare system from 1 July 2008, being 
the central association of the health 
insurance funds at federal level in 
accordance with section 217a of Book Vof 
the German Social Code (SGB V). The 
manufacturer sets price (can be 
prescribed) and then submits to the G-BA 
and the social insurance system covers 
fully the medicine. The G-BA will consider 
the early benefit assessment and employs 
IQWIG to provide the assessment. If the 
medicine is deemed to have no additional 
benefit the price of the medicine is set in 
the reference price. If the medicine has 
additional benefit the price is negotiated 
with the sickness funds at 6 months. No 
agreement on price results in an 
arbitration committee that will agree price. 
On dissatisfaction of the arbitration price, 
the manufacturer or social insurance funds 
can request IQWIG to provide an efficiency 
frontier analysis (2008). The 
reimbursement price is valid from one year 
onwards. 
The Federal Joint 
Committee assesses within 
three months after a new 
pharmaceutical accessed 
the market whether any 
claimed additional benefit 
in relation to the 
appropriate comparator is 
proven. Prices remain free 
for up to a year within 
which time a price maybe 
negotiated or a cost benefit 
analysiS requested from 
IQWIG. 
Appendices 
(IQWIG, 2011) 
(Federal Joint 
Committee, 
2011a) 
(Federal Joint 
Committee, 2010) 
(Leverkus, 2011) 
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Ireland 
reimbursement 
medicines. The 
decision for 
Act for the 
Restructuring of the 
Pharmaceutical Market in Statutory 
Health Insurance (AMNOG) in 2011 
has greatly changed the 
reimbursement system. G-BA aims 
to regulate SHI-wide issues of 
access, benefits and quality. 
There is no legal agreement 
applicable to reimbursement. 
There is an agreement between the 
Health Service Executive and 
Pharmaceutical industry. There is a 
General Medical Services· (GMS) 
scheme and a Drugs Payment 
Scheme (DPS) provide 
reimbursement for those eligible in 
Ireland. The Health Service 
Executive is responsible for the 
operation and management of the 
public health services in Ireland on 
behalf of the Department of Health 
and Children. The HSE reports 
directly to the Minister for Health. 
The Corporate Pharmaceutical Unit 
of the HSE makes final 
recommendations on the 
reimbursement and pricing of 
medicines. The final decision is 
informed by recommendations 
from the National Centre for 
Pharmacoeconomics (NCPE) 
established in 1998.The NCPE was 
established in 1998 by the 
Department of Health and Children 
to undertake health economic 
evaluation and provide advisory 
recommendations to the CPU. The 
The Health Service Executive (HSE) in 
the Corporate Pharmaceutical Unit in 
Ireland made an agreement with the 
pharmaceutical industry called the 
IHPA agreement in 2006. The 
objective was to ensure early access 
to, and security of supply of new 
medicines for Irish patients and 
ensure that the medicine that best 
meets the patients needs delivers 
best value for money, (lHPA,2006: 
IHPA agreement). The aim of the 
NCPE that provides 
recommendations to the HSE is to 
·promote expertise in Ireland for the 
advancement of the discipline of 
pharmacoeconomics through 
practice, research and education. 
Activities of the centre include 
economic evaluation of 
pharmaceutical products and tHe 
development of cost effective 
prescribing: (NCPE, 2011) It provides 
this through the evaluation of 
products and the development of 
cost-effective prescribing. 
The system of clinical assessment is similar 
to the French agency and the economic 
assessment similar to other European 
agencies using a different form of 
evaluation "efficiency frontier" 
The CPU can request a full 
pharmacoeconomic submission from the 
manufacturer for high cost/budget impact 
medicines. The recommendations from the 
NCPE are passed to a committee in the 
CPU that makes the final decision on the 
reimbursement. 
The reimbursement 
decisions are usually made 
within 90 days of the 
manufacturer submission 
(where there is no appeal 
against a not reimbursed 
decision). 
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Israel 
Italy 
NCPE has been required to provide 
pharmacoeconomic assessment for 
selected new medicines since 2006. 
A list of Health Services that 
residents of Israel are entitled to 
called the National list of Health 
Services (NLHS) which introduced 
into law in 1995. The list is updated 
annually by the Ministry of Health 
and this is inline with the additional 
annual budget for technologies, 
specified by government for the 
year. In 1998 a process was 
established for the listing of 
medicines and a committee 
established called the Public 
National Advisory Committee 
(PNAC). The list specifies the 
benefits that residents are entitled 
to receive from the health plans. 
The Italian Medicines Agency (AI FA) 
was established in July 2004 and is 
the main agency responsible to the 
Ministry of Health for national 
reimbursement decisions regarding 
medicines in the National 
Healthcare System (SSN). The 
manufacturer must first apply to 
the AIFA by submitting a dossier for 
pricing and reimbursement. The 
Technical and Scientific 
Commission (CTS) deal with the 
applications for marketing 
The Israeli National Health Insurance 
(NHI) system introduced in 1995, was 
based on the policy goals of 
containment of drug expenditures; 
sustainability and equity of financing 
for pharmaceuticals; efficiency of 
expenditure in the pharmaceutical 
sector; and availability and 
accessibility of pharmaceuticals. The 
Healthy Israel 2020 strategy is being 
led by the Ministry of Health and 
aims to improve the health of and 
reduce disparities in access to health 
care and health outcomes among the 
population. 
The objective of the AIFA is to 
promote good health through 
medicines, set fair pharmaceutical 
policies and assure their consistent 
application nationwide, manage the 
value and cost of medicines, promote 
pharmaceutical Research and 
Development and demonstrate 
leadership at home and 
internationally. 
The National Health Insurance Law (NLHS) 
specifies a list of medicines to be provided 
by publically tax funded Health 
Maintenance Organisations (HMOs) in 
Israel. The membership of one of the four 
competing funds is mandatory and these 
provide the benefits approved by the 
Ministry of Health in the National list of 
Health Services (NLHS). The process is 
based on two stages: i) A HT A process 
considering the clinical, epidemiology, 
economic, legal and ethical aspects and a 
(ii) decision processes undertaken by the 
Public National AdviSOry Committee that 
operates within the government specified 
additional budget allocation. 
The MTA provides an assessment that 
informs the PNAC decision for listing on the 
NLHS. The Ministry of Health makes the 
final approval of the list of new 
technologies approved. The list of 
technologies is only updated annually and 
this is a unique aspect of this fourth hurdle 
system. 
The medicines in the PFN are implemented 
at the regional level. The regions can 
decide on the copayments for these 
medicines which can lead to price 
differences to the patient across the 
country. In 2010 a new rule was introduced 
for hospital medicines that specified that 
within 30 days of the AIFA reimbursement 
decision the medicine should be included 
on the regions hospital formulary. The 
regions and provinces are able to challenge 
the decision on the grounds of the 
medicine meeting the criteria specified by 
The list is only updated 
annually. The PNAC is 
accountable to the Ministry 
of Health. The Health 
Maintenance Organisations 
are required by law to add 
the new medicines that are 
added to the NLHS. 
The listings are included in 
the official journal of Italy. 
The pricing and 
reimbursement decision 
should take no longer than 
180 days from the time of 
the initial submission. 
Appendices 
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Appendices 
Hungary 
Korea 
authorisation and provides an 
assessment of the efficacy of new 
drugs. The Price and 
Reimbursement Committe!! (CPR) 
evaluate the dossier and negotiate 
the prices of new drugs and set the 
reimbursement class of the 
medicine: 
The National Health Insurance 
Fund (NIHFA) provides 
reimbursement decisions for new 
medicines and a Technology 
Appraisal Committee was 
established in 2004 to perform this 
task. The TAC is informed by the 
National Institute for Strategic 
Health Research (NISHR) which 
coordinates the HTA body that 
appraises submissions called the 
Office for Health Technology 
Assessment (OHTA). 
The Ministry of Health and Welfare 
(MOHW) overseas the National 
Health System. The national health 
insurance system provides health 
care coverage to all citizens in the 
form of social insurance. The 
The aim of the NHIFA with regards to 
pharmaceuticals is "to provide access 
to new value added therapies by 
continuously recycling resources 
from off-patented products to 
innovative products with proven 
therapeutic effectiveness." The basic 
prinCiples of the financing of 
pharmaceuticals in Hungary includes, 
professional foundation within 
evidence based decision-making, 
consideration of budget framework, 
transparency, predictability, publicity 
with regards to access to data for 
stakeholders, transparency, 
enforcement of equality of access, 
needs based and cost-efficiency. 
The OHTA aims to determine 
guidelines of analysing technologies 
through a consideration of the 
clinical evidence, efficacy and cost-
effectiveness in comparison to 
alternative uses of resources. This 
facilitates the appropriate use of 
cost-effective health care 
technologies. 
HIRA is dedicated to maintaining and 
improving national health by fulfilling 
its commitment to health care review 
and quality assessment. HIRA aims to 
be an organisation that is recognised 
and respected by all phYSicians, 
theAIFA. 
The manufacturer submits to the NIHFA. 
The OHTA at the NISHR makes a critical 
appraisal of the manufacturer submission 
that informs the decision made by the 
Technology Appraisal Committee (TAC). 
The Head of the Pharmaceutical 
Department at the NIHFA makes the 
decision. An appeal must be submitted 
within 15 days of the deCision otherwise 
this becomes the final decision. Prices and 
reimbursement levels are published in the 
Official Journal of the Republic of Hungary 
before marketing can take place. 
The National Health Insurance Corporation 
(NHIC) implements the decisions and pays 
the health care institutions for the 
medicines provided in the positive Jist. The 
manufacturer must submit 
Pharmacoeconomic data to the HIRA and 
The reimbursement 
decision is provided within 
90 days of the application 
by the manufacturer. 
HIRA is a statutory public 
corporation under the 
direction of the Ministry of 
Health and Welfare. 
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Mexico 
Health Insurance Review and 
Assessment Service (HIRA) 
conducts reviews and assessments 
for reimbursement and was 
established In July 2000 as an 
independent agency separated 
from insurers, providers and other 
interested parties. Economic 
evaluation was introduced formally 
in 2006. The HTA assessment 
provided by HIRA is used by the 
National Insurance Corporation 
(NHIC) for negotiation of the price 
of reimbursed medicines. 
The General Health Council is the 
main government decision making 
body for the reimbursement of 
medicines. The Presidential 
Agreement of 2002 states that 
public institutions of the NHS 
should only use medicines form the 
basic formulary for primary care 
and the catalogue of inputs for 
secondary and tertiary care. The 
Council introduced a regulation in 
2003 for the requirements 
including the use of 
pharmacoeconomic studies. 
There is a working group called the 
Interinstitutional Commission of 
the Basic Formulary of Inputs of the 
Health Sector that meets three 
times a year. Mixed system of 
financing with 50% covered by 
social insurance. Centro Nacional 
de Excelencia Tecnol6gica en Salud 
(CENETEC) the HTA agency of 
Mexico may also provide advice to 
theGHS. 
CENETEC was established in 2004. 
patients, parties and people in the 
country. It is established under the 
National Health Insurance Act for 
improving the national health care ad 
developing social security though fair 
and efficient heath care review and 
evaluation. 
The General Health Councils main 
objective in Mexico is to provide co-
ordination for all institutions and 
entities comprised in the NHS in line 
with Article 4 of the Mexican 
Constitution which states that men 
and women are equal under law and 
every person has a right to receive 
medical treatment when deemed as 
necessary, (Vazquez, 2005) 
this is critiqued by members of staff. A HTA 
report is provided to the Drug 
Reimbursement Committee (OREC). The 
DREC makes recommendations for the 
second stage of the process, which involves 
price negotiations. The National Health 
Insurance Corporation using the 
information from the DREC report 
undertakes the price negotiation stage. 
The NHIC provides a maximum price for 
the medicine. The Ministry of Health and 
Welfare makes the final decision for 
reimbursement listing. 
There is the Basic formulary that is 
designed for primary care and the 
Catalogue of inputs that is designed for 
secondary and tertiary care. The 
Interinsitution sub committees review and 
evaluate the submissions and the General 
Health Council make the decision on 
inclusion on the Basic Formulary or 
Catalogue of Inputs. The institutions must 
use the Basic Formulary as a basis for there 
prescribing decisions. However, they may 
choose not to use some medicines and 
may produce their own formulary. As 
there are a number of different public 
institutions delivering care in Mexico such 
as Instituto Mexicano del Seguro Social 
(IMSS), Instituto de Seguridad y Servicios 
Sociales de los Trabajadores del Estado 
(ISSSTE), Seguro Popular (SP), IMSS 
Oportunidades, Petr61eos Mexicanos 
(Pemex), Secreta ria de Marina (Semar). 
These institutions make the final decision 
on access to the medicines. 
The General Health Council 
is a constitutional body that 
provides national guidance 
on health policy in Mexico. 
The listing 
recommendations should 
be made within 4 months 
of the initial manufacturer 
submission. 
Appendices 
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Netherland 
s 
New 
Zealand 
Medicines in the outpatient setting 
are reimbursed by health insurers if 
they are included in the Drug 
Reimbursement System (GVS) 
which includes a reference price 
system. The Health Insurance 
Board (CVZ) is an independent non-
governmental body that provides 
advice to the Minister of Health for 
the inclusion of medicines in the 
benefits package under the Health 
Insurance Act of 2006 
(Zorgverzekeringswet, Zvw). CVZ 
was established in 1999.The 
Pharmaceutical Assistance 
Commission (CFH) provides the 
assessment of the medicine. The 
ACP provides the appraisal of the 
medicine. There is a separate 
decision-making process for 
inpatient and outpatient 
medicines. 
A Pharmaceuticals Schedule 
operates in New Zealand which 
includes a list of all 
pharmaceuticals and related 
products. The Pharmaceutical 
Management Agency of New 
Zealand was established in 1993. In 
The Health Care Insurance Board 
(CVZ) tasks include providing advice 
and implementing the Dutch 
statutory health insurance. CVZ has a 
major role in the social insurance 
system of maintaining the quality, 
accessibility and affordability of 
health care in the Netherlands. CVZ:s 
advice is based not only or care-
related considerations, but also 
considerations relating to finance 
and society. CVZs missions are to 
"safeguards and develops the public 
conditions for the 
health care insurance system, so that 
Dutch citizens can obtain their right 
to care." There are four stated 
package criteria of neceSSity, 
effectiveness, cost-effectiveness and 
feasibility. 
PHARMAC's statutory objective is to 
"secure, for eligible people in need of 
pharmaceuticals, the best health 
outcomes that are reasonably 
achievable from pharmaceutical 
treatment and from within the 
amount of funding provided: 
The Dutch Health Care Insurance Board 
provides the assessment, appraisal and are 
involved in the implementation. The CVZ 
provides the risk adjusted contributions to 
the health insures for provision of those 
medicines included in the baSic health 
insurance package. 
There are two processes for deciding which 
outpatient and inpatient mediCines should 
be included. There are two related 
consecutive processes, assessment process 
and the CFH/CVD process management. 
The manufacturer submits to the CFH. The 
manufacturer submission is evaluated and 
reports prepared by consultants and CVD. 
This is then sent to the meeting by the CFH 
committee (a pharmacotherapeutic report 
and a pharmacoeconomic analysis). CFH 
discusses the report and manufacturers 
submission. After the CFH draft report the 
stakeholders are given the opportunity to 
comment. The CFH may require additional 
data. The comments from the stakeholders 
are discussed and a final report prepared. 
The CFH provides the report to the Health 
Board (CVZ) and this is considered. The 
Board may consider an ACP which takes 
into account other societal factors or may 
consider a public consultation (if procedure 
has not been followed appropriately). The 
final advice is sent to the Minister who 
makes the final decision. The decision is 
sent in a letter to the manufacturer. 
The District Health Boards of New Zealand 
are responsible for implementing the 
deCisions made by the PHARMAC agency. 
The manufacturer submits to PHARMAC 
using the guidance on funding applications 
to the agency. The Pharmacology and 
Therapeutics Advisory Committee (PTAC) 
CVZ is an independent 
organisation responsible for 
carrying out the task of 
government. The tasks are 
conducted under the 
guidance of the Ministry of 
Health, Welfare and Sport 
and within the AWBZ 
framework (Exceptional 
Medical Expenses Act). The 
Minister will make a 
decision within 90 days of 
receiving the application 
from the manufacturer. 
The PHARMAC is 
accountable to the Minister 
of Health. The Minister of 
Health can issue strategic 
directions to PHARMAC if 
required. 
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Norway 
June 2001 it was given legal duty 
under the Crown Entities Act 2000 
to perform its functions of 
managing the Pharmaceutical 
Schedule. PHARMAC is a 
government agency directly 
accountable to the Minister of 
Health and is part of the medicine 
system alongside Medsafe and the 
District Health Boards (DHBs). 
PHARMAC manages outpatient and 
inpatient medicines where national 
contracts have been negotiated. 
The Pharmaceutical schedule sets 
out the criteria for access to the 
pharmaceuticals in the community. 
It also includes hospital medicines 
where national contracts have 
been negotiated. Medicines are 
funded from the Community 
Pharmaceutical budget which is 
fixed each year by the Minister of 
Health in consultation with 
PHARMAC and the DHB's. 
The Norwegian Medicines Agency 
(NoMA) was established on the 1st 
of January 2001. The agency directs 
supervision of production, clinical 
trials and marketing of 
pharmaceuticals. It authorises and 
monitors the correct and 
The NoMA is responsible for 
supervising the production, trials and 
marketing of medicines. It approves 
medicines and monitors their use, 
and ensures cost-efficient, effective 
and well-documented use of 
medicines. The inspectorate also 
review and collate additional information 
on the medicine. It may also ask PHARMAC 
to undertake additional analysis if this has 
not been provided by the manufacturer. 
The PTAC provides a recommendation for 
prioritisation of the medicine by the 
PHARMAC board. At this stage price 
negotiations may take place with the 
manufacturer. The recommendations are 
then set out for consultation with 
interested parties. Once the consultation is 
received the PHARMAC board with deCided 
whether to approve the medicine based on 
the nine criteria. The PHARMAC is not 
bound by the process and may vary this 
when it is deemed appropriate. The 
recommendations by the PTAC are 
adviSOry and the recommendations by the 
PHARMAC board are mandatory with 
respect to funding. 
Applications can also be made for 
Exceptional Circumstances (EC) to fund 
medicines that are not funded in the 
community or hospitals. There are three 
types: 
1. Community EC - This is for rare 
clinical situations 
2. Hospital EC - This is to enable a 
quicker discharge from hospital 
3. cancer EC - This is for medicines 
not funded in the cancer 
medicine basket. 
The mandatory National Insurance Scheme 
which operates through the government 
provides coverage for those in 
employment and taxation provides funding 
for others provided by the reimbursement 
list in Norway. The manufacturer initially 
submits to the Norwegian Medicines 
The NoMA allocated time 
for dealing with the pricing 
and reimbursement 
decision is 180 days. 
Appendices 
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Appendices 
economical use of pharmaceuticals. 
It is responsible for reimbursement 
and pricing of medicines for the 
public list. 
supervises the supply-chain. NOMA 
also regulates the prices and trade 
conditions for pharmacies. The 
agency considers the reimbursement 
of medicines following Section 14 of 
the Norwegian Law Gazette. 
The Norwegian health systems 
fundamental aim is to give the 
citizens equal access to health 
services, irrespective of their 
location, gender, age, financial status 
and to prioritise those with greatest 
need (MlIlriand et aI., 2010). 
Price control through international 
reference priCing of prescription 
drugs and price revisions has been a 
strategy for pharmaceutical cost 
containment in Norway during the 
period 1994 to 2004 (Hakonsen et aI., 
2009). 
Agency for a blue prescription that covers 
the costs of essential medicines. Individual 
reimbursement may be made from a 
doctor or patient to the NoMA. The 
manufacturer may present the application 
either prior or after gaining marketing 
authorisation for the medicine. The NoMA 
screens the application to make sure that it 
meets the requirements. A price 
application may be submitted 
simultaneously. The NoMA agency may 
request the Blue Prescription Board to 
consider the case for reimbursement. The 
Board should be consulted if this is a major 
therapeutic innovation The Board provides 
an assessment within seven weeks of 
receiving the details of the manufacturer 
submission. The NoMA can decide on the 
approval of the medicine in the list for 
provIsion by the National Insurance 
Administration. The NoMA cannot approve 
medicines with an annual cost increase of 
more than 5 million annually. The NoMA 
must submit a report to the Blue 
Prescription Committee/Board and the 
manufacturer is given the opportunity to 
comment. A copy of the committee 
assessment will be forwarded to the 
Ministry of Health Care Services (HOD) 
where advice maybe sought from the 
National Council for Health Care Priorities. 
The National Council for Health Care 
Priorities assesses whether the money 
spent on the medicine would be well spent 
with regards to other priorities. The 
Ministry can decide to reject the 
application following the further evaluation 
or it may favour approval and bring the 
case to parliament in the form of a 
parliamentary bill. 
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Poland 
Portugal 
The Agency for Health Technology 
Assessment in Poland (AHTAPol) 
was established in 2006. In an Act 
of June 2009, the agency became a 
state entity with legal 
responsibility. The agency became 
responsible for listing, removing 
medicines from the list of 
guaranteed benefits and changes in 
the level and funding of the 
benefits. The Consultative Council 
(CC) acts as an advisory board and 
considers the evaluation report 
prepared by the AHTAPol analytic 
team, experts and representatives 
of the National Health Fund (NHF) 
on recommendations for new 
medicines. The President of the 
AHTAPol makes the final 
recommendation to the Minister of 
Health. The Minister of Health 
makes the final decision for listing 
of the medicine. 
The reimbursement system is set 
within the National Health Services 
(SNS), which is funded through 
general taxation. The National 
Authority of Medicines and Health 
Products (INFARMED) is a 
government agency that was 
established in 1993. There is a legal 
framework for the reimbursement 
of medicines and this is set out in 
Law No. 118/92 June 25. INFARMED 
concerns all elements of drug 
regulation with the exception of 
medicine prrclng, evaluating, 
authorising, regulating and control 
The objective of the AHT APol is to 
provide recommendations for the 
classification of health care services 
as guaranteed benefit. The Polish 
Constitution requires all citizens of 
the Republic of Poland to be entitled 
to equal access to health services 
from public providers of health 
services and these should be free of 
charge and provided by public funds. 
INFARMED's main aim is to ensure 
the quality, safety and efficacy of 
medicines and the quality, safety of 
health products in order to avoid the 
risks of their use while ensuring 
adequate standards of public health 
and consumer's protection. The 
Portuguese Constitution (Seventh 
Revision, 2005) states that -everyone 
has the right to health ... by means of 
a universal and general health service 
which with regard to the economic 
and social situation of citizens who 
use it, shall tend to be free of 
charge: 
The Polish health system is based on a 
social insurance system by a National 
Health Fund (Nfl) through 16 sickness 
funds. The manufacturer provides a 
submission to the Ministry of Health that 
provides details of the decision problem, 
clinical effectiveness, cost-effectiveness 
and impact on the health system. The 
Ministry of Health refers this to AHTAPol 
and the submission is analysed by the 
AHTAPol analytical team using the Polish 
Guidelines for the conduct of Health 
Technology Assessment. The Analytical 
Team will revise the submission and 
provide a report. The appraisal process is 
separate and performed by the 
Consultative Council that is chaired by the 
President of AHTAPol. The Consultative 
Council takes into account the wider 
context specific judgements. The President 
of AHTAPol provides the final 
recommendation that is passed to the 
Ministry of Health. The Minister of Health 
deCides the final decision for inclusion on 
the list. 
The manufacturer must submit to the 
Directorate-General for Economic Activities 
(DGEA) following marketing authorisation 
to obtain a maximum price for the 
medicine. The DGEA is a government 
organisation that has responsibility for its 
administrative tasks (self governance). 
Pricing is undertaken by DGEA and 
reimbursement recommendations are 
made by INFARMED, although these two 
processes are closely linked for outpatient 
medicines. The manufacturer agrees a 
maximum price and then applies to the 
Ministry of Hea/th/INFARMED for 
reimbursement. The application is screed 
The HT A process is 
stipulated by law to take 
only 45-60 days to final 
recommendation. 
INFARMED is required to 
process an application 
within 90 days for 
medicines, 75 days for 
generics. The deadline is 
suspended when the 
applicant is notified that 
they are required to submit 
additional information. 
INFARMED is accountable 
to the Ministry of Health. 
Appendices 
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Spain 
of human medicine products, 
including medicinal devices and 
cosmetics. Medicine pricing is 
performed by the Directorate-
General for Economic Activities 
(DGEA) prior to an application for 
reimbursement. 
The National Health Service was 
established in Spain in 1986 under 
the General Health Law. The health 
system is decentralised and control 
given by 17 autonomous regions. 
The reimbursement and pricing 
decisions are made at the national 
level involving the Ministry of 
Health, Directorate General of 
Pharmacy and Health Products role 
established in 2003. The criteria 
considered by the Ministry of 
Health are contained in Art 89_ Of 
Pharmaceutical Law Public 
financing procedure, 2006. The 
Spanish Agency for Medicines and 
Health Products was established in 
1998 and the Inter-ministerial 
Commission for Pharmaceutical 
Prices in 2003. 
The Spanish Constitution (1978) 
states that public authorities should 
maintain a public social security 
system for all citizens guaranteeing 
adequate social assistance and 
benefits in situations of need, 
recognising the right to protection of 
Health, through preventative services 
and the provision of benefits and 
services_ The law states that public 
authorities should co-operate with 
the common aims of providing 
citizens with the right to health 
protection, common goal of ensuring 
equity, quality and social 
participation (Law 16/2003 May 28). 
The Spanish Agency for Medicines 
and Health Products is a speCialised 
technical agency performing 
evaluation, registration, licensing, 
inspecting, monitoring and control of 
medicinal products for human and 
by INFARMED and if necessary clarification 
is gained from the manufacturer. The 
pharma-therapeutic submission is analysed 
by external pharmacologists to determine 
the added therapeutic value in comparison 
with existing alternatives. EconomiSts then 
review the pharmacoeconomic evaluation. 
If there is no therapeutic advantage the 
economic evaluation is based on an 
evaluation of the prices. If the medicine 
demonstrates an added therapeutic value, 
a economic evaluation is provided that has 
followed the INFARMED guideline. The 
INFARMED board makes a 
recommendation on whether to grant 
reimbursement. The Ministry of Health 
makes the final recommendation for 
inclusion on the list. 
The Ministry of Health initiates the 
procedure once they have received an 
application from the manufacturer on the 
technical and economic characteristics of 
the medicine. The Spanish Agency for 
Medicines and health Products provides a 
report on the clinical utility of the 
mediCine. The manufacturer must also 
provide all necessary information to the 
Inter-ministerial Price commission that has 
representatives from the autonomous 
regions. The Commission agrees a 
maximum price with the manufacturer. 
The Minister of Health makes the final 
listing decision (positive list or negative 
list.) The regions have responsibility for 
implication of these decisions at this level. 
The Directorate General of 
Pharmacy and Health 
Products, Ministry of 
Health is responsible for co-
ordinating the 
reimbursement decision. 
The Minister of Health 
makes the final 
reimbursement decision. 
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Sweden 
Switzerland 
The Dental and Pharmaceuticals 
Benefits Board was established in 
2008 to integrate medicines and 
dental care in one agency. The 
agency use to be known as the 
Pharmaceutical Benefits Board 
(lFN), which was established in 
2002. The TlV agency is a central 
government agency whose legal 
remit is to determine whether a 
pharmaceutical product or dental 
care procedure shall be subSidised 
by the state. The TLV makes 
decisions for outpatient medicines 
and dental treatments. 
The Federal Office of Public Health 
(FOPH) is part of the Department of 
Home Affairs (FDHA). The FOPH is 
the integrated centre for 
veterinary health products, cosmetics 
and personal care products, and 
conducting economic analysis for the 
assessment of these products, 
subject to the executive powers of 
the regions. 
Pharmaceutical coverage is 
characterised as a high coverage and 
rapidly accessible country. In 2010 
two new laws were issued to reduce 
expenditure to ensure NHS 
sustainability which included 
measures to reduce prices and 
reference price modifications (Ferre, 
2011). 
The mission of the TlV is to examine 
which medicines, medical devices 
and dental care treatments will be 
subsidised by society. The agency 
makes decisions on the 
reimbursement and price for 
substitutable medicines. The main 
consideration is with attaining value 
for money whilst considering other 
criteria The Swedish government 
subsidises medicines for various 
reasons but particularly to ensure 
universal access to high quality, 
effective medicines. 
The aim of the FOPH is to promote 
people's health skills and enable 
them to take responsibility for their 
own health and health behaviour. 
The manufacturer must submit an 
application for pricing and reimbursement. 
The TlV determines whether the medicine 
should be eligible for inclusion in the "high-
cost threshold". There are many medicines 
included in the high-tost threshold and 
includes tax subSidised medicines where 
the state reimburses a proportion of the 
cost. The Pharmaceutical Benefits Board 
makes the final reimbursement decisions 
and these are mandatory. The decisions 
made by the Board are on the basis of 
Praxis. Praxis is the process by which a 
theory, lesson or skill is enacted, realised 
or practices. Each decision made by the 
TlV allows further interpretation of the 
legislation and evolution through 
experience. The County Councils 
implement the decisions for outpatient 
medicines. 
In Switzerland, all of the population must 
purchase health insurance which provides 
reimbursement for medicines. The 
insurers will pay for medicines that are 
The TlV aims to provide 
notification ofthe price and 
reimbursement of a 
medicine within 180 days of 
the receipt of the 
application. The TlV 
generally aims to complete 
the process within 120 
days. The Tl V is 
accountable to the Ministry 
of Health and Social Affairs. 
The FOPH is accountable to 
the Federal Department for 
Home Affairs (FDHA). The 
reimbursement application 
Appendices 
(TlV,2011) 
(TlV,2010a) 
(lFN,2007) 
(lFN,2003) 
(Federal Office of 
Public Health, 
2011) 
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United 
Kingdom 
England 
excellence for health. It is 
responsible alongside the 26 
cantons for public health and 
development of the national health 
policy. The FOPH is responsible 
under the ACT 117FC to regulate 
health and accident insurance. The 
FOPH provides the final 
recommendation for inclusion in 
the Pharmaceutical Specialities List 
(SL-list) for reimbursement. The 
FOPH is informed by the Federal 
Drug Commission that was 
established in 1995 and consists of 
scientific experts and stakeholders. 
It provides advice through 
consideration of evidence for 
inclusion in the speciality list. 
The National Institute for Health 
and Clinical Excellence (NICE) 
provides guidance, sets standards 
and manages a national database 
to improve people's health and 
prevent and treat ill health. NICE 
was setup on the 1st of April 1999 
to ensure everyone has equal 
access to medical treatments and 
high quality care from the NHS 
regardless of where they live in 
England and Wales. The Centre for 
Health Technology Evaluation 
develops guidance for the use of 
new and existing medicines, 
treatment and procedures within 
the NHS. 
The FOPH also aims to shape the 
national structural framework in such 
a way that health promotion, 
prevention, health protection, care 
and palliation of illness and accidents 
can be implemented in an integrated 
way that provides the greatest 
possible health gains to everyone. 
The aims of the health insurance law 
(KVG) are to achieve high quality at 
the lowest possible cost to ensure 
access to medical care. 
NICE was set up on 1 April 1999 to 
ensure everyone has equal access to 
medical treatments and high quality 
care from the NHS, regardless of 
where they live in England and 
Wales. NICE's technology appraisals 
programme makes recommendations 
about the use of medicines in the 
NHS, based on how well a medicine 
works, and whether it offers value for 
money compared to existing 
treatments (cost-effectiveness). The 
NHS is legally obliged to found and 
resource treatments recommended 
by NICE's technology appraisals. The 
Chairman of NICE Sir Michael Rawlins 
states that "NICE is a national 
organisation for providing guidance 
on promoting good health and 
preventing ill health". 
included in the basic list of medicines 
reimbursed. The manufacturer submits an 
application to the Federal Office of Public 
Health (FOPH/BAG) which is then 
considered by the Federal Drug 
Commission. The Federal Drug Commission 
which is an expert body reporting initial 
recommendations to the FOPH. The FOPH 
provides the final decision for 
reimbursement and pricing applications for 
inclusion in the Pharmaceutical Specialities 
List (SL list). Citizens of Switzerland can 
access these medicines through their basic 
health insurance which can be used when 
the medicines are dispensed through 
community pharmacies, hospital 
pharmacies or dispensing doctors. 
The NICE recommendations apply to 
England and Wales and are enforceable 
within three months of the publication of 
the appraisal. The NHS providers are 
required by direction of the Secretary of 
State to provide funding for medicines 
recommended under the Single 
Technology Appraisal (STA) and Multiple 
Technology Appraisal (MTA) processes. 
NICE is not directly responsible for the 
implementation of the recommendations 
and this is undertaken through the NHS 
providers and funders. The NHS bodies 
need to assess how much the medicine 
guidance will cost to implement and must 
plan for provide these by identifying and 
releasing funding. There are two forms of 
technology appraisal for medicines: a 
Multiple Technology Appraisal (MTA) that 
covers more than one technology for more 
than one indications and the Single 
Technology Appraisal (STA) that covers one 
to final deciSion usually 
takes around 4 to 5 
months. 
The MTA process aims to 
complete in 54 weeks and 
the STA process aims to 
complete with 37 weeks. 
NICE is a Special Health 
Authority. They are an arms 
length body of the NHS. 
The Board and Senior 
Management Team set the 
strategic direction and 
ensure financial 
stewardship and corporate 
governance. 
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technology for one indication. 
5T A process: 
The Department of Health refers a list of 
appraisal topics and consultees and 
commentators are identified. Consultees 
can submit evidence during the appraisal, 
comment on the appraisal documents and 
appeal against the appraisal committee's 
final recommendations. Commentators are 
invited by NICE to take part in the appraisal 
process and comment on various 
documents produced during the process. 
The scope is prepared by the Department 
of Health and consultees and 
commentators are requested to comment 
on the draft scope. The manufacturer is 
invited to provide an evidence submission 
and consultees can also submit a 
statement on the potential clinical and cost 
effectiveness of the treatment. NICE 
commissions and independent academic 
centre to technically review the evidence 
submission and prepare an Evidence 
Review Group (ERG) report. An evaluation 
report is prepared for the appraisal 
committee that includes the ERG report, 
written submisSions, patient expert 
personal statements, clinical specialist 
personal statements and comments on the 
ERG report. The independent appraisal 
committee considers the evaluation report 
and evidence from nominated clinical 
experts, patients and carers. The 
committee discussions are held in public. 
The appraisal committee makes a 
provisional recommendation. An Appraisal 
Consultation Document (ACO) is produced 
if the recommendation is more restrictive 
than the licensed indication of the 
medicine. The consultees have four weeks 
Appendices 
Appendices 
United 
Kingdom -
Scotland 
The Scottish Medicines Consortium 
(SMC) was established in 2001 by 
the 15 Health Boards. Funding for 
public provision is funded through 
taxation in Scotland. 
The aim of the agency is to accept 
those newly licensed drugs which 
clearly represent good value for 
money and reduce postcode 
prescribing. 
to comment. The appraisal committee then 
considers the comments on the ACD and 
the final recommendation is made in the 
Final Appraisal Determination (FAD). 
Consultees can appeal against the final 
recommendations in the FAD. If there are 
no appeals and the appeal is not upheld 
the final mandatory recommendations are 
made by NICE. 
The MTA process is similar to the STA 
process up to the point of evidence 
submission. NICE commissions an 
independent academic centre (Assessment 
Group) to review the published evidence 
on the technology and prepare an 
assessment report. The Evaluation report 
includes the assessment report, written 
submissions, patient expert statements, 
clinical specialists and comments received 
on the assessment report. The appraisal 
committee holds its deliberation in public. 
The committee makes the provisional 
recommendation in an ACD. The appraisal 
committee considers the comments on the 
ACD and a Final Appraisal Determination 
(FAD) is produced. Consultees can appeal 
against the final recommendations. 
Provides one stage advice to the health 
boards and Area Drug Therapeutic 
Committees with regards value for money. 
The health boards choose whether to 
include the medicine following advice from 
the SMC. Manufacturer is free to set price 
prior to the evaluation by the SMC. 
NHS Scotland and 
Ministry of Health. 
the 
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Chapter 4 appendix 
Table A4.1: Technology Decision Level (source: reproduced from Hutton et al. 2006) 
Assessment Decision Outputs and Implementation 
(1) (2) (3) 
Constitution and Consultation and involvement of Who makes the decision Appeal and dissent 
governance stakeholders 
Methods, processes Methodology Decision-making process Implementation and 
communication ! 
Use of evidence Evidence-base for assessment Evidence base and additional influences Monitoring and reappraisal 
on decision 
Transparency, Presentation and communication of Content and documentation of the Evidence of impact of the decision 
accountability assessment results decision 
Appendices 
Table A4.2: Information required in Manufacturer submission 
Country. (Institutions). I Types of medicines assessed ; 3: Committee or Assessment team .c AI 
c '" ;" ~ 
Q.:::l. 
c 
iil 
., 
'" c cr 
3 ;;:;. 
!!!. 
0 
'" 
Australia (PBAC) I All new medicines including vaccines (IP & OP) Yes 
Austria (HVB) Pharmaceutical I New medicines for outpatient use (OP) [PPRI report] 
Evaluation Board (HEK) 
Yes 
Belgium (NIHDI CRM) NIHDI staff I New medicines (IP & OP) [PPRI Report] Yes 
Canada (CADTH CDR) - Clinical 
Review Team 
Denmark (DMA) - DMA staff 
Finland (PPB) Expert 
Committee 
France (HAS) - HAS staff 
Germany (G-BA) 
Ireland (Corporate 
Pharmaceutical Unit) and NCPE 
Israel 
Medical 
Administration 
of Health) 
Technologies 
New medicines excluding submissions for oncology I Yes 
medicines (IP & OP)-
New medicines (OP list) [PPRI Report] I Yes 
New medicines (OP list) [PPRI Report] I Yes 
All new medicines (IP & OP) including vaccines I Yes 
New medicines (IP & OP). excludes lifestyle medicines I Yes 
not available on prescription only. 
New prescription only medicines selected on basis of I Yes 
budget impact (IP & OP) 
New medicines submitted for inclusion in the Benefits I Yes 
Basket (IP & OP) 
Third party 
independent 
assessment 
No 
No 
No 
I Yes clinical 
review 
I No 
I No 
I No 
Yes economic 
analysis 
No 
No 
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Italy (Pricing and I All new medicines (IP & OP) [PPRI Report) I Yes 
Reimbursement Committee CPR) 
Hungary (Technology Appraisal I New medicines (IP & OP) [PPRI Reoortl I Yes 
Committee) Office for Health 
Assessment 
Korea (HIRA) - HIRA staff New medicines (IP & OP) I Yes 
Mexico (General Health Council) I New medicines (IP - Catalogue of inputs, OP - Basic I Yes 
Interinstitutional sub committee formulary) 
Netherlands (CVZ) - I New medicines (IP CVZ process and OP CVZ process) I Yes 
Pharmaceutical Assistance 
Commission 
New Zealand (PHARMAC) -
Pharmacology and Therapeutics 
Norway (NoMA) - NoMA staff 
Poland (AHTAPol) - AHTAPol 
Analytic team 
Portugal (INFARMED) External 
economists and Pharmacologists 
New medicines (OP & Some IP medicines) plus I Yes 
separate Pharmaceutical Cancer Treatments (PCTs) 
All new medicines (OP, not IP - decided by hospital I Yes 
formularies) [PPRI Report) 
All new medicines (OP, IP medicines includes but 
decision made within hospitals) [PPRI Report] 
New medicines (OP & IP) 
Yes 
Yes 
Spain (Ministry of Health) - I New medicines (OP & IP) Yes 
Directorate General for 
and Health Products 
Sweden (TlV) - TlV staff 
Switzerland (Federal Office 
Public Health) FOPH staff 
England (NICE) - NICE staff 
Evidence Review Group or 
assessment 
Scotland (SMC) - New Drugs 
Committee (NOC) 
by Pharmaceutical I Yes 
Yes 
New prescription only medicines selected for appraisal I Yes 
by the Secretary of State (excludes vaccines) (IP & OP) 
New prescription only medicines (excluding for I Yes 
diagnosis, vaccines, equivalent to generic at same cost, 
no patients eligible for treatment in Scotland, if NICE 
MTA imminentlllP & 
I No 
I No 
I No 
I No 
I No 
No 
No 
No 
No 
No 
Yes for 
process 
No 
ndices 
(AIFI\ 2011a) 
(Pekli-Novak et aI., 
2007) 
(Bae and lee, 2009, 
Kyung lee, 2011) 
(Hernandez. 2011) 
(CVZ and Ministry of 
Health Welfare and 
(PHARMAC, 2010) 
(NoMA, 2011c) 
(AHTAPol, 2011a) 
INFARMED,20llb) 
(Ferre, 2011) 
(lFN,2008) 
(FSIO, 2(08) 
(NICE,2008) 
(SMC, 20llb) 
·Joint Oncology Drug Review (JODR) based in Ontario reviews oncology medicines separately. ·Budget impact should be supplied if exempt, SMC template: 
http://www.scottishmedicines.org.uk/Submission Process/Submission Guidance and Templates for Industry/Templates-Guidance-for-Submissionflemplates-Guidance-for-Submission 
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Table A4.3: Guidelines for Health Economic analysis 
Reimbursem- Use of Pharmacoeconomics Perspecti- Comparat- Costs I Sensitivity I Reference 
ent System ve or cu CII analysis 
... ... 
• t IV IV !! ~ cc'?f!. cc . 1: :> 
:f. ~:l .... " . c: II ! c: ~ S~ :::l 0 l o '" .,. . u OJ u .... 
1;; 1;; u '" c: '" '" l!j .- OJ .- 0 0 8 Oce ou u 
Australia Mandatory for new medicines Societal Standard Direct 5 5 I Deterministic I (PBAC, (PBAC) treatment and SA 
indirect 
Austria (HEK) Mandatory for new medicines Justified Standard All direct 5 5 Deterministic (IPR,2006) 
with added therapeutic value or treatment and !probabilistic 
no alternative indirect SA 
Belgium Mandatory for new medicines HC Relevant Direct 1.5 3 Probabilistic I (KCE,2008) 
(CRM) with added therapeutic value alternative SA 
canada Mandatory for new medicines I I HC&SS Usual care Direct 5 5 Deterministic I (CADTH,2006) (CADTH CDR) costs +SS !Probabilistic 
SA 
Denmark Optional Societal Not Direct + d d Not reported I (Alban et al., 
(DMA) reported indirect 1997) 
Finland (PPB) Mandatory for new medicines Societal I Commonly Direct + 3 3 SA - type not I (Ministry of Social 
used indirect specified Affairs and 
France (HAS) Not required for HAS submission 
for new medicines 
Germany (G-I Only required if arbitration HC (SHI) All relevant Direct 3 3 Deterministic! I (IQWIG,2009) 
BA) cannot obtain an agreement on alternatives costs Probabilistic 
SA 
Ireland I Mandatory requirement for high I I I I I HC+SS I Routine Direct 4 4 Deterministic! I (HIQA, 2010) (CPU!NCPE) budget impact medicines care costs Probabilistic 
SA 
Israel (MTA) I Mandatory requirement for new I II I I I I I HC I Standard Direct 3 3 SA - type not I (Ministry of medicines care costs specified Health, 2010) 
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Italy (AIFA) Optional recommended for Societal Most Direct + 3 3 Deterministic (capri et al., 
medicines with added widespread indirect /Probabilistic 2001) 
therapeutic value care SA 
Hungary Mandatory for new medicines Justified Standard Perspectiv 5 5 Deterministic (Szende et al., 
(TAC) therapy e depend SA 2002) 
Korea (HIRA) Mandatory for new medicines Societal Most Direct + 5 5 Deterministic (HIRA, 2006) 
prevalent indirect /Probabilistic 
alternative SA 
Mexico (GHC) Mandatory for new medicines Routine Direct 5 5 Deterministic I (General Health 
care costs /Probabilistic Council, 2008) 
SA 
Netherlands Mandatory for medicines Treatment All Direct 1.5 4 Deterministic I (CVZ,2006) 
(CVZ) meeting criteria + in practice and /Probabilistic 
Indirect SA 
New Zealand Optional for manufacturer but is Treatment Direct 3.5 3.5 Deterministic I (PHARMAC, 2007) 
(PHARMAC) a requirement and PHARMAC will replaced costs /Probabilistic 
SAt 
Norway Mandatory pharmacoeconomics Most Direct + 2.5- 2.5- Deterministic I (NoMA, 2005) 
(NoMA) submission for new medicines prevalent indirect 5 5 SA 
treatment 
Poland Mandatory requirement for new Relevant 1 Direct + 1 3.51 5 1 
Deterministic I (AHTAPol,2009) 
(AHTAPol) medicines treatment indirect /Probabilistic 
SA 
Portugal Mandatory for new medicines Common Direct + 5 5 Deterministic (INFARMED, 
(INFARMED) practice productivi /Probabilistic 1998) 
treatment ty SA 
Spain Not required Standard Direct + 3 3 Deterministic (Lopez-Bastida et 
(Ministry of current indirect /Probabilistic al.,2010) 
SA 
Mandatory for new medicines 
-
Societal Most 1 Direct+ I 31 31 SA stated- (LFN,2003) 
appropriate indirect type not 
alternative 
Switzerland I Optional I I 
(FOPH) 
England Mandatory required for new I 
• I I I I I 
HC+SS I Routinely I Direct+ I 3.5 I 3.5 I Deterministic I (NICE, 2008) (NICE) medicines used best indirect and/Probabili 
stic SA 
Scotland 
(SMC) 
Mandatory required for new 
medicines 
HC+SS Treatment 
replaced 
Direct 
costs 
3.5 3.5 I Deterministic 
SA 
321 
(SMC, 2011b) 
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Table A4.4: Communication of assessment of evidence 
Country and Details of communication of assessment Details of Website address 
agency /institution appraisal 
Australia (PBAC) Details of the decision outcomes are provided Yes httQ:LLwww.health.gov.aulinternetlmainLQublishing.nsflConten!LQublic-summalY-
in documents alongside the recommendation docu ments-by-meeting 
but no separate assessment document. The 
decision outcome document is called the 
Public Summary Document (PBAC, 2011). 
Austria (HEK) The reasons for the decisions are provided Yes N/A 
when these deviate from the manufacturers 
proposed use (Austrian Social Security, 2011). 
Belgium (CRM) The evaluation report contains details of the Yes httQ:llwww.inami.fgov.belinami QrdlssQlcns2LQageslSQeciali1YCns.asQ 
assessment including therapeutic value and 
economic analysis (Class 1 added therapeutic 
value) is provided on the website alongside 
the Ministerial decision (NIHDI, 2011). 
canada (CADTH,CDR) CDR provides a summary of the assessment Yes httQ:LLcadth.calenlQroductslcdr 
that guides the decision outcome on the 
website of the CDR called the CEDAC Final 
Recommendation (CADTH, 2011b). 
Denmark (DMA) Details of the appraisal are provided on the Yes httQ:lllaegemiddels!yrelsen.d!sLenltoQicsLstatistics.-Qrices-and-
website in the minutes but not in the form of reimbursementlreimbursement-of-medicinesLthe-reimbursement-committeeLminutes 
a speCific report of the decision and these 
documents are called Minutes of the 
Reimbursement Committee (Danish 
Medicines Agency, 2011). 
Finland (PPB) The assessment report is not provided on the No N/A 
website and there are no details of the 
deliberations (Ministry of Social Affairs and 
Health, 2011b). 
France (HAS) Details of the assessment are provided by Yes httQ:LLwww.has-sante.frLQortailLicmsLc 5268Lmedicaments?cid=c 5268 
HAS alongside the appraisal of the evidence 
detailing the decision on the SMR and ASMR 
called the Summary Opinion (HAS, 2011a). 
Germany (G-BA) The Federal Joint Committee includes a Yes httQ:LLwww.g-ba.deLinformationenLbeschluesselzum-unterausschussL2Lsortiert-
tracking system which includes summary nachlbeschluss.DATUMLabsteigendLabLOL#1340l 
documentation, supporting reasons for the 
decision and the decision text. The details of 
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the manufacturer dossier are included but 
excluding any commercially confidential 
information (Federal Joint Committee, 
2011b). 
Ireland (Corporate unit and A summary of the deliberations and items Yes htt(;!:l1www.nc(;!e.ieLcatego!y.(;!h(;!?~id=33 
I NCPE) from the assessment are included in a report 
that is published on the NCPE website. This is 
called the Economic Evaluation (NCPE, 
2011b). 
Israel (Medical Technologies Details of the assessments and appraisal are No N/A 
Administration) not published only the decision and no details 
of the deliberations (Greenberg et al., 2009). 
Italy (Pricing and The assessment report for reimbursement is No N/A 
Reimbursement Committee) not published on the website or the 
deliberations (AI FA, 2011a). 
Hungary (Technology The assessment report is not published on the No N/A 
Appraisal Committee) website or the deliberations 
Korea (HIRA) The manufacturer submission nor the HTA is No N/A 
published on the website but details of the 
HTA report are shared with the manufacturer 
throughout the process.(Yang, 2009). 
Mexico (General Health The assessment report is not published and No N/A 
Council) details of the listing recommendation are only 
provided (General Health Council, 2011b). 
Netherlands (evZ) The advice is published on the website Yes htt~:LLwww.cvz.nIL~ublicatiesLdhra~l2orten 
including the Commission for Pharmaceutical 
Assistance (CFH) report of the added 
therapeutic value but no manufacturer 
submission is published (CVZ, 2011b). 
New Zealand (PHARMAC) The decisions are produced in a schedule. The Yes htt(;!:ilwww.(;!harmac.govt.nzLhealthl2rosLEconomicAnatllsisLCUAs 
Technology Assessment Reports are not all 
published because of the commercial 
sensitivity of some of the data. The agency 
provides some TARs. The Pharmacology and 
Therapeutics AdviSOry Committee publishes 
the minutes which include discussion of some 
of the details of the assessment in the 
discussion sections (PHARMAC, 2011c). 
Norway (NoMA) The minutes of the blue prescription Yes httQ:ilwww.slv.noLtemQlatesLlnterPage 16445.asl2x?filterBll=CoQllToMedecs 
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committee are provided on the website with 
discussions of details of the assessment 
(NoMA, 2011c). 
Poland (AOTM) The website contains a document Yes http://www.aotm.gov. pi/index. php ?id=112 
i 
summarising the considerations of the 
Consultative Council (CC) called the Position 
of the Consultative Council. This includes 
details of the assessment and 
recommendations (AHTAPol, 2011c). 
Portugal (lNFARMED) The assessment is not published on the No N/A 
website. The listing recommendations for the 
considerations are only published (Maria, 
2010). 
Spain (Ministry of Health) The manufacturer submission or assessment No N/A 
is not published on the website of the 
Ministry of Health 
Sweden (TLV) The assessment and deliberations are No http.:LLwww.tlv.seLbeslu1Lbeslut-lakemedeILgenerell-subventioni?page=3 
provided with the listing recommendation on 
the agency website and this is called the 
decision document (TLV, 2011a). 
Switzerland (Federal Office The assessment is not provided on the Yes N/A 
for Public Health) website nor is the manufacturer submission. 
England and Wales (NICE) Comprehensive details of the manufacturer Yes http:L[www.nice.org.ukle:uidanceLtaLpublishedLindex.jsp 
submission are provided for STA, executive 
summary for MTA. Assessment report and 
Evidence Review Group reports provided for 
the website which is published, other 
stakehOlder submission. These are date 
stamped and the process history is provided 
on the website (NICE, 2011e). 
Scotland (SMC) The details of the assessment are provided in Yes http:L[www.scottishmedicines.org.ukLSMC AdviceLAdvice Directorv/SMC Advice DirectorY 
the advice document that is presented on the 
website. This is called the SMC advice 
'------- ------
document(SMC,2011e). 
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Table A4.5: Composition of appraisal committees 
country and I Appraisal Committee name 
agency/institution 
Australia (PBAC) I Pharmaceutical Benefits 
ittee* 
Austria (HEK) I Medicines Evaluation 
Belgium (CRM) 
Canada (CADTH, CDR) 
Denmark (DMA) 
Finland (PPB) I Pharmaceutical Pricing Board I 
France (HAS) 
Germany (G-BA) Federal JOint Committee (G-BA) 
Ireland (Corporate Products Committee/NCPE -
Advisory 
Appraisal 
Committee 
Council 
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of Social Insurance 
(Adriaens and Soete, 2010) 
(CADTH,2011a) 
(DMA,2011b) 
(Ministry of Social Affairs and Health, 2011a) 
(HAS, 2011b) 
(Federal Joint Committee, 2010) 
(NCPE, 2011a) 
(Greenberg et aI., 2009) 
(AI FA, 2011b) 
(Gulacsi et aI., 2009) 
(General Health Council, 2011a) 
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Netherlands (CVZ) Appraisal Committee (ACP) 9 
New Zealand (PHARMAC) 
Norway (NoMA) (NoMA, 2011b) 
Poland (AHTAPol) Consultative Council (CC) (AHTAPol,2011b) 
Portugal (INFARMED) INFARMED Board (INFARMED,2011a) 
Spain (Ministry of Health) Ministry of Health (Vogler et aI., 2009) 
Korea (HIM) Drug (Bae and lee, 2009, Yang, 2009) 
Sweden (TLV) (TLV,2011b) 
(Paris and Docteur, 2007) 
(SMC,2011C) 
= 
England and Wales (NICE) Appraisal (NICE,2011a) 
Committee 
• There is also the Economics Sub-Committee (ESC) that advises on the economic analyses and technical aspects of these analyses which includes health economists, clinical speCialists, epidemiologists, general 
practitioners, public health academics, Health Scientists, Pharmacologist and one industry representative 
t These are consultative members but are not voting members. 
¥ The Economics Committee for Health Products (CEPS) assesses the price covered by the compulsory health insurance following the TC committee's appraisal. The CEPS consists of 26 members conSisting of 
representatives from Social Security, Health, Competition, Consumption and Fraud, Competitiveness industry and services, National Health Insurance, National Fund of Agricultural and Mutual Assistance 
Association, Union representatives, Health Care Delivery and Research. 
- The National Centre for Pharmacoeconomics provides an appraisal and recommendation and includes 10 members. The members include pharmacologists, pharmacists, epidemiologists, mathematicians, 
statisticians and health economists. 
§ The Scientific Technical Commission (STC) provides advice on the added therapeutic value and is composed of 17 members including medical practitioners and pharmacologists. 
9 The CFH advises the OIZ Board that consists of 3 board members and 6 expert members with knowledge of social security issues. The CFH committee is responsible for the assessment of medicines and consists of 
22 members including medical practitioners, pharmacologists, pharmacists, health economists and the Ministry of Health. The OIZ Board may seek advice from the new Appraisal Committee (ACP) which was setup 
in April 2008 to considers the appraisal of a medicine from a societal perspective. The ACP committee consists of nine members with knowledge in the field of social security, healthcare insurance, SCientific, practice 
and the patient perspective. 
IT The Pharmacology and Therapeutics Advisory Committee (PTAC) is a clinical advisory committee that has a role to provide objective clinical advice to the PHARMAC Board. The committee consists of 12 Medical 
Practitioners that are nominated by the professional medical bodies. 
• The New Drugs Committee consists of 21 members and provides advice to the SMC Board on the technical aspects of the assessment. The NDC includes cliniCians, pharmacists, health economists, a statistician and 
two industry representatives. 
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Table A4.7: Clinical-effectiveness criteria 
Clinical-
eftectiv 
eness 
definitl 
on 
Australia 
The comparative 
clinical 
effectiveness 
should be 
presented as 
both 
effectiveness 
(Australian 
practice) and 
toxicity with 
respect to the 
magnitude of the 
clinical effect and 
clinical 
importance in 
comparison with 
the relevant 
comparator in 
Australia. 
Canada 
The clinical 
effectiveness of 
the drug should 
be compared 
with alternatives 
in real 
practice 
canada 
available). 
clinical 
in 
(when 
Ireland 
HTA Economic 
Guidelines: 
"In the context of 
drugs, efficacy 
has been defined 
as 'clinical 
outcomes 
derived from 
patients' use of a 
pharmaceutical 
product in 
controlled 
settings, typically 
randomised 
control Phase I-III 
trials'. Expanding 
this 
definition to 
health 
in 
the 
of a 
technologies 
general, 
efficacy 
health 
technology 
relates to its 
performance 
under ideal 
circumstances. In 
contrast, 
effectiveness 
refers to the 
performance of I 
technology under 
normal 
circumstances, 
such as In routine 
clinical practice." 
New Zealand 
The term is 
defined as 
"Benefit of 
treatment In 'real 
world' setting." 
Mexico 
It is preferable to 
use measures of 
effectiveness of 
health products 
(E.g. 
improvements in 
health achieved 
In the real field) 
Instead of 
efficacy 
measures (E.g. 
improvements in 
health achieved 
in the context of 
a strictly clinical 
trial controlled) 
(if available) 
Norway 
The medicinal 
product has a 
scientifically well-
documented and 
clinically relevant 
effect In a 
defined, 
appropriate 
patient 
population 
Portugal 
Clinical effect 
should be 
assessed in terms 
of effectiveness 
whenever 
possible. If this 
Information is 
not available 
efficacy can be 
used. The 
economic 
guideline 
categorises this 
as: 
"Effectiveness is 
a measurement 
of the benefiCial 
effect of a 
technology or 
strategy assessed 
in normal clinical 
practice. It Is 
sometimes very 
difficult to 
reconcile the 
methodological 
precision of I 
clinical trial with 
the environment 
of 
real clinical 
practice. In the 
real world there 
are many health 
care providers 
with 
different 
prescribing 
profiles, writing 
prescriptions for 
heterogeneous 
groups of 
patients, who are 
normally not so 
well informed 
and more prone 
to co-morbidlty 
Poland 
The guideline 
speCifies that: 
"Effectiveness 
data are from 
pragmatic clinical 
trials. They can 
also be 
obtained from 
observational 
studies and 
databases 
(induding patient 
registers) 
coilecting 
information on 
the use of a given 
technology. The 
data should also 
be collected in 
the form of 
a systematic 
review." The 
comparators 
used in the 
comparison 
should reflect 
Polish practice. 
Sweden 
The 
effects 
clinical 
of the 
medicine should 
be 
demonstrated. 
The best 
evidence includes 
directly 
comparative 
studies with the 
most relevant 
comparison 
alternative. 
England 
The NICE glossary 
defines clinical 
effectiveness as: 
"How beneficial a 
test or treatment 
is under usual or 
everyday 
conditions, 
compared with 
doing nothing or 
opting for 
another type of 
care: 
329 
Scotland 
The SMC glossary 
defines clinical 
effectiveness as 
"The evaluation 
of benefit or risk, 
in a standard 
clinical setting, 
using outcomes 
of importance to 
the patient: 
330 
Oinical 
effectiv 
eness 
apprais 
ed 
This is appraised 
by a systematic 
search of the 
evidence and a 
qualitative 
interpretation of 
the magnitude 
and effect. A 
medicine may be 
more or at least 
as effective for 
consideration. A 
medicines that is 
less effective and 
more toxic 
maybe 
considered for 
listing. The data 
is then used in 
the cost-
effectiveness 
modelling. 
Referen I (PBAC, 2008) 
ce: 
A descriptive 
summary is 
provided in the 
decision 
documentation 
of the 
effectiveness 
when this is 
available. The 
data is used in 
the cost-
effectiveness 
modelling. 
(CADTH, 20l1e) 
A descriptive 
summary 
provided and the 
data on 
effectiveness is 
used in the cost-
effectiveness 
modelling. 
(HIQA, 2010) 
A descriptive 
summary of the 
dinicl!-
effectiveness is 
documented in 
the proposal for 
funding. 
(PHARMAC, 
2010) 
There is no 
categorisation 
scale for 
measuring 
effectiveness. 
The 
categorisation 
was not 
identified for the 
appraisal. 
(General Health I (NoMA,201la) 
Council, 2008) 
and! or the use of 
drugs that were 
not studied in the 
original dinical 
trials.· 
The descriptive 
assessment of 
effectiveness or 
efficacy is used in 
the economic 
modelling. 
(INFARMED, 
1998) 
A descriptive 
summary of the 
dinical 
effectiveness is 
considered. 
(AHTAPol,2009) 
A descriptive 
summary of the 
dinical 
effectiveness is 
provided in the 
decision 
document. 
(lfN,2008) 
The dinical 
effectiveness is 
provided in the 
dinical evidence 
section of the 
guidance. 
(NICE,20lld) 
Appendices 
A dinical efficacy 
and dinical 
effectiveness 
section is 
provided in the 
SMC guidance. 
(SMC, 201la) 
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Table A4.S Added therapeutic value criteria 
Added Benefit/ Added 
therapeutic ""Iue 
definition 
Levelof .......... nt 
Austria 
The mediall 
thetllpeutic ""Iue 
with ... poet to the 
efIiaIcy .nd 
perception of 
In""""tion os defined 
with .. spect to 
specific aroups of 
patients In .. iltlon to 
the thetllpeutic 
.hemotive .. 
The the",peutic 
benefit Is classtfied 
under the followlns 
Cltqories: 
1.Substantial 
the",peutic benefit In 
the majority of 
patients 
2.Substontial 
thetllpeutlc benefit 
for. subcroup 
3. Added the",peutic 
benefit for the 
majority of patients 
4. Added the",peutic 
benefit for • 
subpoup of patients 
5. SImilar the",peutlc 
benefit for patients 
6. No added 
therapeutic benefit. 
Belaium 
The the",peutic value 
of the medicine is the 
composite .".,Iuotlon 
of efficocy (tlial 
results of the",peutic 
effKt). effectiveness 
(If It Is effective In 
... 1 life practice). 
adverse side effects. 
.pplialbillty 
(different subsrouPs 
of the population) 
.nd .... of .... (by 
care liVers or 
ovoidlre mistakes 
.nd errors) Defined 
In the Royal Dec ... 
21 December 2001. 
Class 1: Medicines 
with . sWnlfialnt 
therapeutic ",,'ue 
Class 2: Medicines 
with modest or no 
therapeutic value. 
Class 3: Generic 
medicines. 
DenrMrk 
The therapeutic 
effKt (Vllue edded 
.nd adverse effects) 
... considerwd In • 
weH defined 
lndialtiDn. 
The,.. are no 
.. t .. _ of 
therapeutic volue 
defined by the D.nish 
Medicines Asency. 
Finland 
The therapeutic 
Vllue of the medicine 
should be .... ssed in 
comparison to other 
similar .hemotives 
provided by studies 
In the marketlre 
.uthorisltion .nd 
new studies of the 
cllniall efficocy of the 
medicine. 
The,.. is no 
cI!...,.-IsItionofthe 
therapeutic Vllue of 
the medicine by the 
PPB. 
FtlInce 
The Mediall Benefit 
Is .ssessed based on 
the severity of the 
disorder. the cliniall 
effective"".. of the 
medicine .nd impact 
on ""blic he.lth. 
Improvement In 
Mediall Benefit 
(ASMR). The ASMR Is 
• score of the added 
""I ... of the medicine 
comparwd to the 
medicine used In 
practice. 
The SMR Is defined 
IS: 
L Major 
2. Important 
3. Moderate 
4.lDw 
5. Insufficient 
The ASMR has five 
levels: 
II 
I.",...,..ment; 
Important; 
(III) Moderate; 
(IV) Minor.nd 
Major 
(III 
M No Improvement. 
Germany 
An .dditional 
the",peutlc benefit 
IS .ny patient ... illad 
outcome such os 
improvement of 
he.1th condition. 
shonenlre of the 
dutlltlon of dise .... 
improved survival 
.nd quality of life 
(etttwr qualitative or 
quantitative). 
1 Major 
Improvement In 
benefit: A swnificant 
addltlonal benefit, 
primarily • ...... for 
the diseu., I 
qnlfialnt survival 
time. • lore-term 
freedom/avoidolnce 
of .. rious side 
effects. 
2 Sicnificant 
Improvement In 
benefit: A swnificant 
add~ional benefit. 
moderate rift 
extension, 
substantial slow 
down In symptoms, __ of serious
side effects. 
3 - A sman additional 
benefit Is when one 
of the functional 
benefits shows • 
moderate rwduc!ion 
In non-fatal 
symptoms or side 
effects. 
4 - An edditional 
benefit exlsto but Is 
not quantifiable 
because there no 
scientific evidence 
base" possible 
5-The .. lsno 
demonst"'tlon of 
Italy 
The extent of the 
thetllpeutlc 
In""""tlon Is 
considered with 
.. spoet to avoilability 
of existine 
tro.tments .nd 
extent of therapeutic 
benefit. The edded 
the",peutic v.lue Is 
considered with 
respect to the 
effectiveness. 
efIiaIcy. 
pharmacolotliall 
innovation .nd 
technolOliall 
Innovation. 
The medicines .re 
considered In 
comparison to the 
relevant comparison 
.nd ranked: 
A. No adequate 
treatment 
8. Medicines 
developed for which 
subcroups ... 
Nsistant or non-
respond. 
e. Medicine for 
troatment where 
recosnised 
tre.tments .Ireldly 
exist. 
Scoro C ... 
considered under: 
0. Medidnos mo .. 
effective or safer 
medicine or 
medicines with 
better 
pharmacoldnetic 
profile comparod to 
existlnS mediclnos. 
C2. Mediclnos 
representire • simple 
phermacolotliall 
In""""tion, 
medicines with new 
mechanism of action 
with • therapeutic 
Netherland. 
The factors Included 
to ...... the 
the",peutic value .re 
the efficacy. 
effectiveness. sid • 
effects. .pplicabillty. 
convenience, 
__ rienee and 
quality of life. 
L Medicines with • 
therapeutic loss In 
comparison with 
other Included 
treatment options; 
2. Medicines which 
have equiv.lent 
therapeutic value 
compered to those of 
others In the packac-
3. Medicines with • 
therapeutic value in 
comparison to other 
medicines .Ireldly In 
the Insurance 
pacbp. 
Spain 
Thel'llpeutic value 
obt.ined but no 
definition found. 
No evidence of 
...... ment of levels 
of effectiveness. 
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Switzerland 
The therapeutic 
value Is .... ssed by 
considenne the 
efficacy .nd 
appropriateness 
The therapeutic 
value of the medicine 
should be classified 
by the Fedoral One 
Commission on the 
followins levels of 
innovation: 
L Therapeutic 
broakthroush 
2. The",peutic 
_ ....
3. Savinss compared 
to other medicines 
4. No therapeutic 
PI'OIress and no 
AVircs 
5. lnapproprilte for 
socill insul'llnc8 
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Implications 
reimbursement 
pricil1l 
Reference 
for 
Ind 
DemonstroUl added 
theropeutic ... 1 .. for 
Inclusion In the 
yellow or ''"'' box 
of the 
Reimbunement 
Code. Maximum 
pricll1l In relation to 
EU overo .. price. 
(Austrian Federation 
of Social Insuronee 
Inst~utions, 2004) 
Ooss 2 medicines .re 
set In cornporison 
with intemotionol 
prices ond 
compo,""" 
medicinos. Ooss 1 
can recetve I price 
premium ._ the 
comporotor 
medicines by supply 
of I 
pho~ics 
INtysfs. Maximum 
prices Ire set 
dependil1l on class, 
ClIISS 1: prwmium 
price, o.ss 2: no 
superior price, o.ss 
3: Lower price. 
(AdriHns and Soete, 
2010) 
The price of the 
medicine must be 
reasonable In relation 
'" the added 
therapeutic .. I ... 
F_ pricil1l operotes 
In Denmorlc. 
(Danish Medicines 
Aiency, 2008) 
The added 
therapeutic value 
and costs Ire token 
Into account when 
pricil1l Ind 
reimbursement 
decisions "" made. 
(PPB,2011) 
The ASMR levels 1-3 
re .. te to • premium 
price Ind Ire 
ateaorised as 
innovative whereas 
the other ,,,,,,po Ire 
..... orised similar 
price or lowe< by the 
CEPS institution. 
(Moyer, 2011, 
Roch.ix Ind X.ni, 
2009) 
.. I .. added benefit. 
6 • -n. benefits of 
the dnc '" be 
.... 1uotecI is less than 
the benefit of the 
appropr;.te 
-..-. 
tJeatment. 
If additional benerlt 
......... this will be 
quantified and the 
price neJotiated with 
the federol 
Issociation of heolth 
Insuronce fund.. If 
there is no 
documented 
additional benefit the 
medicines will be 
lilocated '" the 
phormoco-
theropeutic 
comperoble drup In 
the reference price 
system. 
(Fed .... 1 Joint 
Committee,2011a) 
role similar to 
eJCistq medicines 
e!. Medicines 
representil1l I simple 
technoIoIical 
irtnovwtion ..... new __ nce 
CO" medicine with I 
theropeutic: .... 
similar '" eJCistq 
med-. 
Medicines .,. 
considered with 
respect '" the .xtent 
of the theropeutic 
offKt: 
A. Greoter benefits 
on dinical enc\-j>oints 
(mortality, morbidity) 
or I ... Iidated 
surrapte endpoint 
B. pertill benefit on 
the disuse or limited 
..,ida_ of ,reeler 
benefit 
e. Mo- or 
temporlry benefit on 
..,..". aspects of 
disease (portial 
symptom) ... Iief. 
The dinicol 
theropeutic ... Iue 
determines the 
nelotiltion process 
for pricil1l In 
combiNition with • 
phormocoeconomics 
a""1ysis 
(AIFA, 2007) 
If medicines have 
similar benefits to 
existi,. medicines 
are catecorised in 1A 
of the medicines list. 
Those medicines with 
an Idded theropeutic 
benofit are 
catecorised In list 18 
Ind require an 
economic evaluation. 
(CVZ ond Ministry of 
Health Welfilre Ind 
SPOrt. 2010) 
Theropeutic .olue is 
tllke" into KCOUnt 
when dacidil1l to list 
• medicine or not list 
(neeltive list). 
(VOller et II., 2009) 
Appendices 
The medicine must 
be effective '" be 
Included on the 
reimbursement list. 
(Paris and Dod.ur, 
2007) 
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Table A4.9: Thresholds across countries 
Explicit threshold /lmPlicit threshold /lmPlicit threshold 
range range - past - WTP 
decisions 
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Table A4.11: Decision outcome and status 
Final Decision 
(Final Decisions) 
Institution I Advisory I List type 
Australia (PBAC) 
Austria (HVB) (Legal List) 
Belgium (CRM) (Legal List) 
Recommendation 
Advisory 
recommendation 
(Ministry of 
Health) 
Final Decision 
Final Decision 
Positive list 
Positive list 
& Negative 
list 
Positive list 
List Name 
Schedule of 
Pharmaceutical 
Benefits (SPB) 
Reimbursement 
Code (EKO) 
Positive 
chapter 
list by 
Listing Restrictions Outcome 
Conditional 
Reimbursement 
(CED/CTC) 
Based I Copayment 
Restricted benefit, 
authority required 
Red box initially 
referenced priced & 
Yellow box (disease or 
age group) require 
approval by head 
physician. Light Yellow 
box (disease or age 
group) freely prescribed 
by doctors. General and 
Individual 
reimbursement scheme. 
Defer listing pending the 
provision of certain 
information on the 
medicine. 
No scheme of 
conditional listing 
identified. 
Restricted Coverage with evidence 
reimbursement: development The 
Chapters II manufacturer must 
reimbursement for all clarify factors through 
common indications and additional data in the list 
prescribers keeps this on of factors at 18 and 36 
file and Chapter IV - months. 
reimbursement subject 
Concessional: 
Before safety net 
$5.60 (After safety 
net: $336 
prescription charge 
= $0) 
General patients: 
Before safety net: 
$34.20 (After 
safety net: 
$1317.20 
prescription charge 
= $5.60) 
Flat rate 
prescription is paid 
for all medicines 
5 categories of 
reimbursement 
cost sharing 
A(100%), B(85%, 
max EU7.20), 
C(50%, max 
EU8.90), Cs(40%), 
Cx(20%). 
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References 
(PBAC, 2008) 
(Austrian 
Federation of 
Social Insurance 
Institutions, 2004, 
PPRI,2007a) 
(Adriaens and 
Soete, 2010, 
Gerkens and 
Merkur, 2010, KCE, 
2010) 
336 Appendices 
to particular 
reimbursement 
conditions and requires 
prior approval by health 
insurance. 
(anada(CADTH,CDR) Advisory Positive list Individual Drug list with criteria to a Defer pending Copayments and (CADTH, 2010) 
recommendation plan formularies specific patient clarification of deductibles set at a 
(Drug plan) population information health plan level. 
Denmark (DMA) Final Decision Positive list General General conditional No scheme of Copayment (Danish Medicines 
Reimbursement reimbursement (patient conditional depending on Agency, 2008, 
list groups or disease reimbursement previous one year DMA,2011a) 
i 
specific), Individual identified. expenditure on 
reimbursement medicines. 
Finland (PPB) Law: Health Final Decision Positive list Positive list Restricted No conditional listing Three categories of (Kivioja, 2008, 
Insurance Act 1224/2004 (Ref: (Government reimbursement, either requirements identified, co payment Ministry of Social 
Website) Department) restricted basic or (100,72,42%) Affairs and Health, 
restricted special. 2005, PPB, 2011) 
France (HAS) Advisory Positive list List of Generally no restrictions Additional observational Copayment of (Meyer, 2011, 
recommendation Pharmaceuticals studies that cover the 100%,65%,35%, Rochaix and Xerri, 
(Ministry of Reimbursed by patient population 15% depending on 2009) 
Health) SoCial Insurance where uncertainty severity and 
and list of present. medical benefit 
Pharmaceuticals I 
Reimbursed by 
Hospitals 
Germany (G-BA) (Legal list Final Decision Negative list Benefits catalogue Prescribing restrictions No scheme of Basic co payment. (Federal Joint 
Fifth Social Code, § 92) Pharmaceutical can be set by the Federal conditional Committee, 2011a, 
Directive Drug Joint Committee (FJC) reimbursement Federal Joint 
POlicySGB V (patient group to be identified. Committee, 2011c, 
prescribed). leverkus, 2011) 
Hungary (NHIFA Technology Final Decision Positive list NHIFA Positive No restrictions stated No conditional Indication based (PPRI, 2007b, 
Appraisal Committee) (legal & Negative and Negative list reimbursement. reimbursement Dank6, 2010) 
list Decree of the Ministry of list Performance linked rates 100%, 90%, 
Health 32/2004) reimbursement schemes 70%&50%. 
operate alongside price 
volume agreements. 
Ireland (Corporate unit and Final Decision Positive list Community Drugs Restrictions to patient No scheme of Copayment (Tilson et al., 2010) 
NCPE) Scheme group (NCPE) conditional depends on 
reimbursement scheme from 100% 
----
Appendices 
Israel (Medical Technologies 
Administration) 
Italy (AIFA Board) Law no. 326 
of November 24, 2003 
Korea (HIRA) Established 
under article 55 of National 
Insurance Act 
Final Decision 
(Government 
Department) 
Final Decision 
Advisory 
recommendation 
(Ministry of 
Health) 
Positive Jist 
Positive list 
Positive list 
National list of 
Health Services 
(NLHS) 
National 
Pharmaceutical 
Formulary Group 
A 
Positive 
System (PLS) 
List 
No 
identified. 
restrictions 
AIFA Notes - guidelines 
for restrictions on 
patient population or 
characteristics of the 
disease 
No 
identified. 
restrictions 
identified. 
No conditional listing 
requirements identified 
No conditional 
reimbursement through 
coverage with evidence 
development. 
Conditional 
continuation 
(carlson 
treatment 
operates 
2010). 
linked Performance 
reimbursement 
introduced since 2006. 
A limited application of 
coverage with evidence 
development for off 
label medicines but no 
formal 
institutionalisation of 
CEO. 
reimbursed 
maximum 
payment. 
to 
Dependent on 
health plan. Three 
health plans charge 
15% of price 
minimum 13 NIS. 
The Clalit health 
plan charges a set 
12 NIS. 
Medications added 
before 1998 are 
charged 10% of 
maximum price 
minimum of 12 
NIS. There is a 
chronically ill 
ceiling of 250 NIS. 
{HiT, 2009) 
Fixed prescription 
charge called the 
'ticket' is present in 
some regions. 
Exemptions for 
100% 
reimbursement 
apply. 
Copayment for 
proportion of cost 
paid by patient in 
inpatient (10-20%) 
of cost, tertiary 
care and general 
hospital 50% 
treatment cost, 
hospital 40%, Clinic 
30% and pharmacy 
337 
(Greenberg et aI., 
2009) 
(Folino-Gallo et al., 
2008, Gori et al., 
2010, lommi, 2009) 
(Bae and Lee, 2009, 
lang, 2010, Kyung 
Lee, 2011, Moo 
Lee, 2011) 
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Mexico (General 
Council), Agreement 
Netherlands (CVZ) 
Health 
New Zealand (PHARMAC) 
Norway (NoMA) Legal 
Regulations FOR 2007-06-28 nr 
814 (Ref: Website) 
Final Decision 
Advisory 
recommendation 
(Ministry of 
Health) 
Final Decision 
Final DeCision 
Positive list 
Positive list 
Positive list 
Positive list 
Basic Formulary I No restrictions stated 
and Catalogue of 
Inputs provides 
basis for local 
formularies 
Drug 
Reimbursement 
System 1B and 2 
Pharmaceutical 
Schedule 
Blue Prescription 
list 
List 2: a particular 
condition, within a 
specific age group, by 
specialist doctor or 
special permission 
required. 
Restrictions and Special 
Authority (prescriber has 
to request subsidy from 
authority for a named 
person). 
Restrictions to indication 
or patient group and 
individual 
reimbursement can be 
made. 
No details of outcome 
based conditional 
reimbursement 
identified. 
Coverage with evidence 
development for 
inpatient medicines. 
No scheme of 
conditional outcomes 
based reimbursement 
identified. 
No scheme of 
conditional outcomes 
based reimbursement 
identified. 
30%. A threshold 
limit of 3 million 
WON) where no 
further payment 
required. 
Copayment 
dependent on 
social insurance 
institution. 
100%' covered for 
added therapeutic 
value medicines. 
Those medicines 
that are equivalent 
have a maximum 
reimbursement 
where some 
medicines may 
require an excess 
between the price 
and maximum 
reimbursable. 
A complex system 
depending on 
patient enrolment 
to a primary health 
organisation and 
eligibility depends 
on situation and 
base copayment 
can range from $3 
to $15 per 
prescription 
38% of the 
prescription but no 
more than 520 
million per 
prescription and 
individuals exempt 
Appendices 
(Moise and 
Docteur, 2007) 
(CVZ and Ministry 
of Health Welfare 
and Sport, 2010, 
van Halteren, 
2011) 
(PHARMAC, 2010, 
PHARMAC, 2011a, 
PTAC, 2010) 
(lovdata, 2009, 
Ministry of Health 
and Care Services, 
2004, PPRI, 2008b) 
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Poland (AOTM) (Journals of 
Laws 2008 No.164 item 1027) 
(Ref: Website, HAl, 2010, 
Matusewicz, 2009) 
Portugal (INFARMED) Legal 
Decree-Law No 129/2005 
August and Decree No. 
1474/2004, 21 December 
(outpatient) Decree-Law 
No.228/2oo8 25 November 
(inpatient) 
Spain (Ministry of Health -
Directorate General) Law: :aw 
26/2006 Guarantee and 
Rational Use of Medicines and 
Health Products) 
Advisory 
recommendation 
(Ministry of 
Health) 
Advisory 
recommendation 
(Ministry of 
Health) 
Final Decision 
(Government 
Department) 
Positive list 
Positive list 
Positive list 
& Negative 
list 
Reimbursement 
list 
Prontuario list 
Positive list 
Negative list 
Conditions for provision. 
Restrictions for 
therapeutic indications 
& No restriction evident 
Coverage with evidence 
development 
Temporary financing 
provided data gathered 
by AHTAPol 
recommendation. 
No conditional coverage 
schemes. Other non-
outcomes based 
schemes in operation. 
No conditional listing 
requirements identified 
at a national level. 
from charge. 
Certain medicines 
are covered for 
100% such as 
communicable 
diseases. 
The copayment 
depends on the 
condition and 
socioeconomic 
situation. There are 
four categories, 
100% reimbursed 
for some 
treatments and 
vulnerable groups, 
lump sum of PLN 
3.20, 70% 
reimbursed for 
non-life 
threatening 
disease and 50% 
for common 
ailments. (HAl, 
2010) 
Four types of 
copayment, 
category A 
100%,95%, 
category B 69%, 
category C: 37% 
and category D 
15% 
Cost sharing for 
patient under 65 is 
40% and free for 
over 65 years. 
Those medicines 
treating chronic 
diseases or life 
339 
(Upska, 2010, 
Matusewicz and 
Lipska, 2009, 
Personal 
Communication: 
Ofierska-
Sujkowska,2011) 
(PPRI, 2008a, 
Vogler and 
Leopold, 2009) 
(Noticias Juridicas, 
2011, Vogler et aJ., 
2009, Vallejo, 
2009) 
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Sweden (TLV) (Legal 2002:160 
on Pharmaceutical Benefits) 
Switzerland (Federal Office for 
Public Health) Law of Heath 
Insurance 1996 
United Kingdom England and 
Wales (NICE) (Ref: NICE 
Website) 
Final Decision 
Final Decision 
(Government 
Department) 
Final Decision 
Positive list 
POSitive list 
Negative list 
General Subsidy 
Decisions 
Pharmaceutical 
Specialities List (SL 
List) 
NICE 
Recommendations 
Restrictions limited to 
area or special patient 
group 
Limitations to a 
particular quantity or 
patient medical 
indication 
Optimised or only in 
research (OIR) 
Coverage with evidence 
development where 
reimbursement is 
limited in time to make 
it possible for new data 
to be provided for 
example on long term 
effects or follow up data 
to check that the 
medicine is being used 
according to the 
restriction. 
No conditional listing 
requirements identified 
Coverage with evidence 
development for those 
where recommended 
only in research .. 
Conditional patient 
access agreements for 
payment of medicines. 
threatening 10% 
contribution. 
There is a cost 
ceiling where the 
patient never pays 
more than SEK 
1,800 in a twelve 
month period. 
100% up to 900 
SEK, 900-1700 SEK, 
50% of the cost 
900-1300, 1700-
3300 SEL 25% of 
1300-1700, 3300-
4300 10% of cost 
1700-1800 SEK. 
More than 4300 
SEKO%. 
Deductable can 
range from CHF 
300 to CHF 2,500. 
10% of the cost of 
the medicine for 
outpatient after 
deductable. 
Inpatient 
medicines are 
covered. 20% for 
those where 
interchangeable 
generic is available 
up to 933 CHF. 
A flat prescription 
fee is paid for all 
medicines at £7.40 
per prescription. 
Appendices 
(LFN, 2007, LFN, 
2008, nv, 2011d) 
(Federal Office of 
Public Health, 
2011, Paris and 
Docteur, 2007) 
(NICE, 2009b, NICE, 
2009a, NICE, 2011f, 
NICE, 2011c) 
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United Kingdom Scotland Advisory Positive and Health Board Accepted for restricted No conditional listing No prescription (Health Policy and 
(SMC) (Ref: Website) recommendation Negative list Formulary use, patient indication, charge (abolished Strategy 
(Health Board group or authority to in March 2011) Directorate, 2010, 
prescribe. SMC, 20lle, SMC, 
- --
-_ .. -
- ---- -- -
2011dL 
_ J 
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Table M.12: Opportunity to appeal 
Country and I Ad I Appeal/Dissent Entitled 
Appeal/Dissent 
to I Grounds 
agency/institution mechanism 
Australia (PBAC) Resubmission to PBAC Manufacturer 
Austria (HEK/HBV) Appeal Committee Manufacturer 
Belgium (CRM) Council of State I Manufacturer 
Administrative Court 
Canada (CADTH, 
CDR) 
Request for I Stakeholders 
Reconsideration by (Manufacturer and Drug 
CEDAC 
Denmark (DMA) Danish Ministry of I Manufacturer 
Interior and Health 
Finland (PPB) Supreme I Manufacturer 
Administrative Court 
France (HAS) Reconsideration Manufacturer 
hearing by HAS by 
committee and 
Supreme 
Administrative Court 
Germany (G-BA) Verbal hearing for I Manufacturer & Sickness 
assessment. funds 
Appeal the arbitration 
for cost-effectiveness at 
Resubmission includes 
new data or modifies 
orevious submission. 
Negative decision 
Procedural only 
Procedural and 
recommendation is not 
su evidence 
Procedural only and 
cannot reassess evidence 
Negative decision 
Negative advice 
Price and therapeutic 
value 
Independent 
Appeal 
Committee 
No 
Independent 
Drug 
Commission 
(UHK) 
No 
No 
No 
No 
No 
No 
Independent 
Appeal 
Committee 
Members 
References 
No I (PBAC,2008) 
Public meetings I (PPRI, 2007a) 
8 independent 
expert members 
The 
commission can 
veto but not 
overall a 
decision by the 
HVB 
No 
No 
No 
No 
No 
No 
(KCE,2010) 
(CADTH,2010) 
(Danish 
Medicines 
(Rochaix and 
Xerri, 2009) 
(Leverkus, 2011) 
Appendices 
Ireland (Corporate 
unit and NCPE) 
Israel (Medical 
Technologies 
Italy (Pricing 
New Zealand 
(PHARMAC) 
Norway (NoMA) 
Poland (AOTM) 
Appeal 
Committee 
Expert I Manufacturer 
No procedure identified I No procedure identified 
No procedure identified I No procedure identified 
Resubmission to HIRA 
Resubmission to the 
GHS 
Participation procedure 
and Administrative 
Court 
Reapplication or Court 
of New Zealand 
Ministry of Health and 
Care Services 
No procedure identified 
Manufacturer 
Manufacturer 
Stakeholders 
Manufacturer 
Manufacturer 
No procedure identified 
decision 
Negative decision 
No procedure identified 
No procedure identified 
Committee 
Expert 
Committee 
No 
No 
Resubmission no appeal I No 
against DREC decision 
only final decision to 
Court 
Resubmission to the GHS 
after four months 
Participation procedure 
and administrative court 
on 
New data available or 
address issues previously 
raised. Court of New 
Zealand can consider 
where Public law 
breached. 
Not recommended 
decision 
No procedure identified 
No 
No 
No 
No 
No 
makes the 
decision. 
Members from 
government 
departments, 
Pharmacy, 
National 
insurance (7 
Details of the I (Tilson et al., 
committee could 2010) 
not be identified 
from 
documentation. 
NO 
No 
No 
No 
No 
No 
No 
No 
(Greenberg et 
al.,2009) 
(AIFA, 2010) 
(Kim & Chang, 
2011) 
(Moise 
Docteur 
(Overheid,2011) 
(PHARMAC, 
2006) 
(Lovdata, 2009) 
ils of 
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Spain (Ministry of 
Health 
Directorate 
Sweden (TLV) 
Switzerland 
(Federal Office for 
Public Health) 
England and Wales 
(NICE) 
Scotland (SMC) 
Supreme 
Administrative Court 
Not identified 
Manufacturer 
Not identified 
General Administrative I Manufacturer 
Court 
Reconsideration 
request or Appeal 
Committee 
Appeal Committee 
Resubmission and 
Appeal Committee 
Manufacturer 
Stakeholders (consultees 
-national body 
representing patients, 
body representing health 
professional and 
manufacturer) 
Manufacturer 
Negative decision No 
Not identified NO 
Reasons and proposed I No 
changes 
Negative decision 
3 procedural grounds 
Review existing data and 
analyses 
Appeal 
Commission 
Appeal Panel 
Independent 
Review Panel 
(IRP) & SMC 
arbitrator 
No 
NO 
No 
Details of the 
appeal 
committee not 
available in 
English language 
documentation. 
Non-executive 
directors of 
NICE, NHS 
representatives, 
representatives 
with experience 
of the relevant 
industry and lay 
members. 
3 members of 
SMC and 4 
members of the 
Scottish 
Drug 
Therapeutic 
Committees 
Area 
and 
(PPRI, 2008a) 
(Vogler et al., 
2009) 
(LFN,2007) 
(Federal Office 
of Public Health, 
2011) 
(NICE,20llb) 
(SMC, 20lld) 
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Table A4.13: Reappraisal requirements 
country and Reappraisal requirements Time after initial decision Coverage with evidence 
agency/institution process specifies reappraisal development 
Australia (PBAC) Resubmission by manufacturer- new evidence available (PBAC, 2008). 
- -
Austria (HEK/HVB) Reassessment by HVB if it believes no longer meets the criteria (medico-therapeutic or - -
health economic criteria and the manufacturer required to provide a case). This may result 
in delisting (PPRI, 2007a). 
Belgium (CRM) There are two reasons for reappraisal, that the initial appraisal was based on a number of 18 -36 months CEO, (KCE, 2010) 
hypothetical factors and new evidence was required. Those medicines that had concerns 
with uncertainty of evidence in class 1 medicines where the manufacturer claims added 
therapeutic value and is conducted between 18 and 36 months. The assessment report will 
contain new evidence and any real life cost-effectiveness evidence. The Minister may 
request a multiple appraisal. This can result in delisting (KCE, 2010). 
Canada (CADTH,COR) Resubmission by the manufacturer during the embargo period of a reduced price and in - -
the circumstance where new clinical evidence or cost information becomes available that 
significantly effects the cost-effectiveness of the medicine (CADTH, 2010). 
Denmark (OMA) Medicines are prioritised according to criteria to decide which medicines should reassessed - -
which includes, significance of the medicine to the primary sector, public health aspects, 
new evidence, high costs or high consumption (Danish Medicines Agency, 2008). 
Finland (PPB) The decisions provided by the PPB are for a fixed period of 3 years for new medicines. At 36 36 months 
-
months a renewed confirmation is required and this should document any changes that 
have taken place with respect to experience of use, clinical studies and treatment prices. 
The manufacturer may propose an increase in the price but these needs to be 
accompanied by evidence (Ministry of Social Affairs and Health, 2005). 
France (HAS) The HAS can self refer medicines in the presence of new evidence but reviews all medicines 60 months CEO, (Rochaix and Xerri, 
at 5 years post-listing. This may result in delisting of the medicine at 5 years and the 2009) 
manufacturer can submit new evidence at any point for reassessment of the medicine 
(Rochaix and Xerri, 2009). 
Germany (G-BA) After one year of the final G-BA decision, the manufacturer can request a new benefit - -
I 
assessment if there is new scientific knowledge. It is also possible that the G-BA decides 
that there is new scientific evidence that makes it necessary to perform a new assessment 
I (Federal Joint Committee, 2011c). 
Hungary (Technology Resubmission through the regular procedure (PPRI, 2007b). - -
Appraisal Committee) 
Ireland (Corporate unit and Resubmission by the manufacturer if new evidence becomes available that affects the - -
NCPE) pharmacoeconomics (Tilson et aI., 2010). 
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- -
Israel (Medical Technologies Resubmission by the manufacturer in the next cycle (one year) when new evidence 
- -
Administration) becomes available for adding to the list. The technologies already on the list have never 
been delisted and obsolete or ineffective treatments remain (Greenberg et aI., 2009). 
Italy (Pricing and On expiration of the terms the manufacturer or the agency can request reconsideration 24 months 
-
Reimbursement Committee) and negotiation. A variation on the reimbursement category can be applied for if new 
evidence is found. Conditional price reimbursement with respect to payment by outcome 
has been introduced since 2006 (Jommi, 2009). 
Korea (HIRA) Resubmission - The manufacturer can request a re-evaluation of the medicine. Existing 
- -
medicines are reviewed overtime to ensure that they meet the criteria for the PLS. The 
medicines are reassessed by therapeutic class and this is based on the growth in use of the 
medicines and the budget impact of the medicines. Those medicines that are not 
considered cost-effective are delisted (Bae and Lee, 2009). 
Mexico (General Health The basic inputs list is regularly reviewed to modify for inclusion and exclusion of 
- -
Council) medicines. A medicine maybe de-listed for a number of reasons 1.) It is not longer 
prescribed; 2.) Medicine will not be used; 3) Awareness of another product of greater 
efficacy or lower toxicity (Moise and Docteur, 2007). 
Netherlands (CVZ) There are two different processes where outpatient medicines can be reassessed by 48months· CEO, (van Halteren, 2011)· 
application by the manufacturer 6 months after the Ministers previous decision (CVZ and 
Ministry of Health Welfare and Sport, 2010). The inpatient medicines are assessed for real-
life cost-effectiveness four years after the decision (van Halteren, 2011). 
New Zealand (PHARMAC) Resubmission by the manufacturer following reasons, 1. New information or data becomes 
- -
available, 2. The manufacturer wishes to respond to previous issues. The PHARMAC can 
decide to delist the medicine (PHARMAC, 2010). 
Norway (NoMA) The NoMA may conSider whether the criteria are met for individual medicines in the list. 
- -
The manufacturer has the opportunity to submit new information to demonstrate the 
medicine still meets the criteria. The NoMA may include new conditions for these to be 
met or may delist the medicine if the criteria are no longer met (Lovdata, 2009, Ministry of 
Health and Care Services, 2004). 
Poland (AOTM) The Ministry of Health may review the medicine at 2 years. There is no explicit provision for 24 months 
-
the procedure on the expiry of the decision. The Ministry of Health may commission 
AHTAPol to reassess the medicine or may decide to prolong the terms of the decision 
(Personal Communication: Ofierska-Sujkowska, 2011). 
Portugal (INFARMED) The medicines are reviewed at 3 years to ensure that they meet the criteria set by law. The 36 months 
-
manufacturer is notified and given the opportunity to adjust price. The medicines may be 
delisted and the reason made publically available. The decision may be made due to 
excessive cost, therapeutic efficacy doubtful, comparative effectiveness lower than 
medicines reimbursed for same indication (PPRI, 2008a). 
Spain (Ministry of Health - Re-assessment may occur after one year of the reimbursement and price deCision. There 12 months 
-
J~ir!!ctorate General) may have been new medicines add~ to the list, which are at a lower price. The Directorate 
-----
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General for Pharmacy and Health Products may decide to de-list the medicine (Noticias 
Juridicas, 2011, Vallejo, 2009). 
Sweden (TlV) Medicines that have been given conditional reimbursement are reappraised. The TLV may - CEO, (LFN, 2008) 
decide to remove the medicine as either part of the reimbursement review (2002) by 
therapeutic group or by the ad hoc consideration of individual medicines. The 
manufacturer is contacted with regards to individual cases that are reviewed for 
reimbursement (LFN, 2008, TLV, 2011c). 
Switzerland (Federal Office Medicines are reviewed at 36 months after they have been included in the SL list. The 36 months -
for Public Health) medicine will be appraised to consider whether it still remains value for money. The 
documents must be submitted by the manufacturer 30 months prior to the review of the 
medicine. If the review shows the price is too high in comparison to the appropriate 
alternatives the FOPH can request a price reduction. Alternatively, if the medicine is found 
to be significantly cheaper in comparison to other countries, a price increase may occur. 
The FOPH also reviews the medicines listed for 15 years or after the expiration of the 
patent. The conditions of effectiveness, appropriateness and effiCiency will be assessed to 
ensure these are still met (Federal Office of Public Health, 2011, Paris and Docteur, 2007) . 
Scotland (SMC) Resubmission in the light of new evidence or a new analysis but no periodic review (SMC, - -
2011d) .. 
England and Wales (NICE) A review date is listed on the guidance for when the review process will commence and will - CEO, (NICE, 2011f) 
depend on the guidance, available evidence and knowledge on the topiC. Evidence is 
collected to inform the review process and the views of stakeholders are sought to identify 
additional evidence. If a large amount of new evidence is available the guidance will be 
reViewed, in contrast if there is little new evidence the review will be delayed (NICE, 
2011b). 
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Table A4.14 Technology Decision Level: Assessment of medicines 
Country 
Australia 
Austria 
Type of 
involvement 
stakeholder I Methods of evidence synthesis for assessment 
Manufacturer provides an 
assessment of the medicine 
meeting the criteria set out in a 
guideline for manufacturers. 
Two sutK:ommittees assess the 
manufacturer submission: the 
Drug Utilisation Sub Committee 
(DUSe) and the Economic Sub-
committee (ESq. The DUSC 
considers the pattern of drug 
uses and assesses the financial 
forecasts for future in use in 
major submissions. The ESC 
reviews the health economic 
analysis and assesses the 
quality, internal and external 
validity. The members include 
clinicians, clinical 
epidemiologists, health 
economists, biostatisticians and 
clinical pharmacologists 
(Australian Government, 2011). 
1. The manufacturer 
provides the application. 
2. The HEK provides an 
appraisal and 
recommendation to the 
Federation (HBV) (PPRI, 
2007a) 
Evidence of clinical effectiveness and cost-effectiveness is 
required for all manufacturer major submissions to the 
PBAC. These need to be relevant to the Australian context. 
Head to head trials are the most appropriate form of 
clinical evidence. If direct head to head evidence is 
unavailable then an indirect comparison maybe 
appropriate or non-randomised studies could be used. 
Cost-utility analysis is required. Supplementary analysis 
may take into account the broader impacts on costs and 
outcomes (For example: production changes and impacts 
on carers). 
The assessment should include the following: 
1. Description of new medicine 
2. Clinical Effectiveness 
3. Cost-effectiveness 
4. Budget impact 
5. Any other relevant information (PBAC, 2008) 
The manufacturer must include details of the 
pharmacology, medico-therapeutic advantage and health 
economic considerations. 
The comparison must consider the most frequent 
indication, appropriate dosage and the main groups of 
patients affected. 
1. Pharmacological evaluation. The classification 
and evaluation of the medicine from a pharmacological 
viewpoint in the context of available therapeutic 
alternatives 
2. Medical therapeutic evaluation - The therapeutic 
Appendices 
Consultation on assessment of I Communication of assessment 
evidence (e.g. manufacturers 
submission) 
The manufacturer has the opportunity 
to consult on the evidence on two 
occasions. The first occasion is prior to 
the technical committee where a 
detailed commentary of the 
manufacturer submission is provided. 
The manufacturer can then provide 
comments that are then passed to the 
technical details. The second 
opportunity to comment follows after 
the technical committees have 
assessed the evidence. (Lopert, 2009). 
The manufacturer can respond to 
clarification for comment on the 
submission and requests for further 
data. External experts are considered 
in the process of assessment 
nominated by the manufacturer 
(Austrian Federation of Social 
Insurance Institutions, 2004). 
The manufacturer's submission 
is not provided on the website. 
Specific details are provided in 
the decision documentation 
(PBAC, 2011). 
The manufacturer submission is 
not provided on the website. 
The reasons for decisions of the 
HEK are provided in the 
minutes when these deviate 
from the manufacturers 
proposed use (Austrian Social 
Security,2011a). 
Appendices 
Belgium 
canada 
The committee can appeal to 
internal and external experts 
that are either medical doctors 
or pharmacists. The experts 
provide a scientific judgement 
of the added therapeutic value 
of the medicine (KCE, 2010). 
The manufacturer provides the 
initial submission and this is 
reviewed by a team consisting 
of clinical reviewers, clinical 
experts. information speCialists. 
methodologists. administrative 
support and peer reviewers. 
This is input into the CDR 
clinical review section and also 
considered in the CEDAC 
benefit in comparison with the other therapeutic 
alternative and a review of the validity of the data 
submitted. The added therapeutic advantage should be 
assessed. The internal and external validity of the 
evidence should be considered in the application. A 
hierarchy of evidence is described,!. Prospective RCTs, 
2. Systematic Review of a large number of RCTs, 3. RCTs 
with smaller number of enrolled patients, 4. Non-RCT 
observational evidence 5. Professional committee 
opinion 6. Individual expert opinion (Austrian Federation 
of Social Insurance Institutions, 2004). 
3. A Health Economic Evaluation - This is based on 
the medical therapeutic evaluation. The perspective 
should be from the Social Insurance Programme. There 
are no official Guidelines for the conduct of economic 
evaluation but a consensus document is used (IPR, 
2006). 
The assessment of medicines is based on the therapeutic 
class. which can be categorised into Class I, Class II and 
Class III. Class I are specialities with increased therapeutic 
value, Class 2 are medicines with no increase in 
therapeutic value and Class III are generics. 
The following aspects should be assessed in the 
manufacturer submission: efficacy, safety, effectiveness, 
applicability, usability, level of evidence, price, budget 
impact and cost-effectiveness. The cost-effectiveness 
analysis should follow recent guidelines that are published 
in Value in Health (KCE, 2008. Adriaens and Soete, 2010) 
The CDR review seeks to answer the following critical 
questions: 1. How does it compare with alternatives? 2. 
Which patients will it benefit? 3. Will it deliver value for 
money? The manufacturer should achieve this by 
presenting evidence on the safety. efficacy and 
effectiveness of the new medicine. A systematic review of 
the evidence should be performed. RCTs. observational 
studies and expert opinion are all acceptable forms of 
evidence. 
The CDR requires the manufacturer to provide a 
An appraisal report is sent to the CRM 
and they can either approve or modify 
the report. If the appraisal outcome 
differs from the manufacturers original 
request this is then sent to the 
manufacturer for comment. The 
manufacturer then has 10 days within 
which they can respond to the 
provisional appraisal (KCE, 2010). 
There are two opportunities for 
comment: The review provided by the 
CDR review team is provided to the 
manufacturer for comment. 
The recommendation will be sent with 
the justification to the manufacturer in 
an embargo period prior to the 
announcement of the decision. The 
manufacturer may request a re-
consideration or a resubmission at a 
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The evaluation report and 
comments from the 
manufacturer can be obtained 
from the NIHDI website that 
includes the therapeutic value, 
other aspects of the appraisal 
and the ministerial decision 
(NIHDI,2011). 
The summary of the 
recommendation and 
outcomes are published on the 
CADTH website (CADTH, 
20llc). 
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Denmark 
Finland 
deliberations. The CDR 
produces an independent 
clinical review which uses 
aspects of the manufacturer 
review (CADTH, 2010). 
The manufacturer provides a 
submission for consideration by 
the reimbursement committee 
and the DMA. The 
manufacturer is free to set the 
price of the medicine (Danish 
Medicines Agency, 2008). 
There is an expert group 
consisting of seven members 
phanmacoeconomic submiSSion and the electronic mOdel 
used. The economic evaluation of health technologies 
(2006) states that a Cost-effectiveness or Cost-utility 
analysis should be provided if: 1. The medicine is the first 
available to the treat the disease or a new class of 
therapeutic effect; 2. Has demonstrated differences in 
efficacy and safety in head to head trials, manufacturer 
argues with evidence that there are differences between 
the relevant medicines in outcomes (CADTH, 2006). 
Those medicines demonstrating other outcomes (non-
clinical outcomes or surrogate outcomes) only require 
cost-consequence. All other medicines require details of 
price and cost. 
There is a reference case for the base case economic 
evaluation •• 
Budget impact analysis is required for each of the 
jurisdictions in which the medicines proposed use (CADTH, 
2010). 
The application provided by the manufacturer must 
include the following (Danish Medicines Agency, 2008): 
1. Marketing authorisation 
2. Infonmation about the expected expenditure of 
the medicine 
3. Pharmacological and clinical document 
4. Clinical assessment report 
5. Comparable clinical efficacy and safety 
6. Appropriate scientific studies 
A health economic analysis is optional. And a guideline is 
provided on the agency website. Price should be set 
proportionate to the therapeutic value. Health economic 
analysis should be valued against existing treatments or if 
the price is higher than other reimbursed medicines (Alban 
et al., 1997). 
The manufacturer application for basiC reimbursement 
and price should include the following elements (PPB, 
reduced price. Patient groups are also 
invited to submit a patient group 
submission (2010 onwards) (CADTH, 
2011e). 
The reimbursement committee 
provides a written recommendation to 
the Danish Medicines Agency. This 
includes a reasoned assessment 
provided for the opinion of the 
reimbursement committee. If the 
medicine is not granted general 
reimbursement it will be considered for 
conditional reimbursement. 
If the medicine is not granted either 
general or conditional reimbursement, 
the recommendation will be presented 
to the manufacturer for consultation 
before making its final decision. A copy 
of the medical assessment, price 
survey and appraisal of the health 
economic analysis is provided (Danish 
Medicines Agency, 2008). 
An appeal can be made at the end of 
the process. No formal consultation 
Appendices 
The manufacturer's submission 
is not provided on the website 
but details of the appraisal 
decisions are provided (Danish 
Medicines Agency, 2011). 
The manufacturer submission is 
not provided on the webSite. 
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France 
Germany 
that provides advice to the 
Pharmaceutical Pricing Board 
for the decision on whether the 
medicine should have special 
reimbursement 
before 
status or 
expanding 
reimbursement to a new 
indication. An expert group 
consisting of a maximum of 
seven members operates as 
part of the Pharmaceuticals 
Pricing Board. This expert 
group represents medical, 
pharmacological, health 
economics and social insurance 
expertise. The board decides on 
the reimbursement and 
reasonable wholesale price of 
medicinal products (Ministry of 
Social Affairs and Health, 
2011b). 
The assessment involves HAS 
staff and the committee of 
clinical experts. The pricing 
decision is linked to the ASMR 
assessment and this is provided 
by the CEPS following the SMR 
and ASMR assessment provided 
by the Transparency 
Committee (Meyer, 2011). 
The Federal Joint Committee 
2011): 
1. 
2. 
3. 
A proposal for reimbursement and a reasonable 
wholesale price 
The medicinal products therapeutic value and 
clinical assessment. 
Treatment costs 
4. Health economic evaluation demonstrating the 
cost-effectiveness of a new active substance 
medicine or selected by the PPB. 
5. Future sales forecast 
6. Prices in other European Economic Area 
Countries (EEA). 
A guideline for the development of economic evaluation 
was introduced on the 1st of May 2011. Cost-utility 
analyses are preferred except In the case of equivalence 
where cost minimisations may be used. There are no 
statements of a cost-effectiveness threshold used in 
decision-making (Ministry of Social Affairs and Health, 
2009). 
HAS considers all pharmaceuticals once marketing 
authorisation has been granted. The manufacturer is 
required to present relevant data on clinical efficacy, 
comparative safety and relative effectiveness. 
1. Clinical effectiveness: HAS requires the 
manufacturer to submit all relevant studies for 
the clinical efficacy of the medicine but there are 
no requirements for these to be identified by a 
systematic review of the evidence. In the 
absence of head to head trials a network meta-
analysis is permitted. The HAS commission a 
separate literature review of the evidence. The 
manufacturer provides a claimed score for the 
Service Medical Rendu (SMR) and L'amelioration 
du Service Medical (ASMR). The transparency 
committee is given information from a literature 
review and the manufacturer's submission 
(Rochaix and Xerri, 2009). 
A new early assessment has been introduced from 1st of 
process was identified from the 
literature or the Ministry of Social 
Affairs and Health website. 
There are no formal process for patient 
group Involvement in HAS decisions. 
The decisions are provided by clinical 
experts. (Falissard et aI., 2010). 
The pharmaceutical company has the 
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Notification of price and 
reimbursement are provided 
on the website but no details of 
assessment and appraisal were 
identified (Ministry of Social 
Affairs and Health, 2011c). 
The manufacturer submits a 
dossier to the HAS but this is 
not published on the website. A 
fee of 2,875 EURO is required 
for the processing of the 
submission, HAS provides a 
'opinion' document published 
on their webSite which contains 
an assessment of evidence, 
details of the appraisal and 
recommendation (HAS, 2011a). 
The manufacturer dossier is 
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Ireland 
(FJC) requires the manufacturer 
to submit on the new medicine 
The Federal Joint Committee 
can commission the Institute 
for Quality and Efficiency In 
Health care or third parties 
with assessing the benefits 
provided in the manufacturer 
submission (Federal Joint 
Committee, 2011a). 
The NCPE provides a rapid 
review of the medicine and will 
provide an appraisal of the 
manufacturers 
pharmacoeconomic analysis if 
this is required (referred by the 
products committee). The NCPE 
provides a critical appraisal of 
January 2011. An application for early assessment should 
include: 
1. 
2. 
3. 
Approved use 
Medical benefits (MTC and ITC are appropriate 
in the absence of head to head evidence to 
demonstrate benefit). 
Additional medical benefit for appropriate 
comparator treatment 
4. Number of patients and patient groups for which 
significant additional therapeutic benefit 
S. Cost for the statutory health insurance 
The extent of the therapeutic benefit should be assessed 
on a scale of 1-6: 
1 - Major improvement in benefit: A significant additional 
benefit, primarily a cure for the disease, a Significant 
survival time, a long-term freedom/avoidance of serious 
side effects. 
2 - Significant improvement in benefit: A significant 
additional benefit, moderate life extension, substantial 
slow down in symptoms, avoidance of serious Side effects. 
3 - A small additional benefit is when one of the functional 
benefits shows a moderate reduction in non-fatal 
symptoms or side effects. 
4 - An additional benefit exists but is not quantifiable 
because there no scientific evidence base is possible 
5 - There is no demonstration of value added benefit. 
6 - The benefits of the drug to be evaluated is less than the 
benefit of the appropriate comparison treatment. (Federal 
Joint Committee, 2011b) 
The effiCiency frontier is the approach adopted for 
economic analysis when this is required by the Federal 
Joint Committee (IQWIG, 2009). 
The rapid review template states that the following 
information should be provided for assessment (NCPE, 
2009): 
1. Reimbursement scheme 
2. Target indication and licensed group 
3. Clinical evidence (relevant trials and 
characteristics) 
4. Adverse events 
opportunity to have consultation prior 
to submitting to the FJC and this may 
be with regard to appropriate studies 
(prior to conducting the phase III trial) 
or selection of the appropriate 
comparator. 
The findings of the benefit assessment 
will be published in Internet and 
pharmaceutical companies, 
associations and experts are given the 
opportunity to make written and 
verbal hearings on the findings. Experts 
of medical science and practice, 
governing bodies of medical 
associations, patient representatives as 
well as umbrella organizations of 
manufacturers of medical products and 
devices in this way given the 
opportunity to respond (Federal Joint 
Committee,2011a). 
At the initial stages of the decision-
making process the manufacturer is 
invited to attend a meeting about the 
process and development of the scope 
for the assessment of the medicine 
(NCPE,2011b). 
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published simultaneously with 
the benefit assessment on the 
website of the Federal Joint 
Committee (Federal Joint 
Committee, 2011d). 
The manufacturer submission is 
not provided on the website 
but a summary of the 
deliberations can be found on 
the NCPE website (NCPE, 
2011d). 
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Israel 
Italy 
the health economic evaluation 
using the Drummond 10 pOint 
checklist (NCPE, 2011b). 
The manufacturer provides a 
submission using the guidelines 
provided by the Ministry of 
Health. The manufacturer's 
submission is assessed by the 
Medical Technologies 
Administration (MTA) to report 
on the clinical, epidemiology 
and economic considerations. 
This is then passed to the 
Medical Technologies Forum 
that grades the technologies on 
a scale of 1-10 using the stated 
criteria set out in the 
deliberations section of this 
framework. The MTF consists 
of experts in HTA (Greenberg et 
aI., 2009). 
The AIFA has a sub-committee 
that is responsible for the 
assessment of therapeutic 
innovation. The Technical 
Scientific Committee (TSC) 
assesses the national and 
European marketing 
authorisation applications, 
delivers a consultative opinion 
on these and provides 
5. Price 
6. Budget impact and Cost per patient 
7. Completed assessments and decision by other 
jurisdictions 
The pharmacoeconomics assessment must include cost-
effectiveness analysis (cost per life year or cost-utility) and 
this may be required for high budget impact medicines The 
guidelines state that probabilistic sensitivity analysis is 
mandatory to assess the uncertainty surrounding the 
evidence. Indirect comparisons may be required if no head 
to head comparisons are available. An assessment of the 
budget impact is required in the evaluation (HIQA. 2010). 
The manufacturer submission should include the following 
information (Ministry of Health, 2010): 
1. Indication and potential use of the technology 
2. Proof of its safety, efficacy and effectiveness. 
3. Advantage over a technology already in the 
NHLS 
4. Budget impact analysis 
5. As of 2007 a health economic evaluation. 
The manufacturer is required to submit details of the 
clinical studies and pharmacoeconomic studies for those 
medicines that are believed to be a therapeutic 
innovation. The manufacturer should provide details of 
(Folino-Gallo et al., 2008): 
1. Therapeutic value/Therapeutic Innovation 
2. Pharmacovigilance data 
3. Price in other EU countries 
4. Price of similar products within the same 
pharmacotherapeutic group 
There is no stated process for 
consultation following the MTA 
assessment of the evidence. The final 
recommendation on new medicines is 
made by the PNAC which has 
representation from the Ministry of 
Health, Health Maintenance 
Organisations and members of the 
public (Greenberg et al., 2009). 
The manufacturer can participate in 
the hearing performed for the price 
negotiations based on the findings of 
the CTS committee (AIFA, 2011a). 
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The decisions of the PNAC are 
published on the Ministry of 
Health webSite but details of 
the manufacturer submission 
are not provided (Greenberg et 
aI., 2009). 
The list of medicines 
reimbursed is provided on the 
website. The manufacturer 
submission is not published by 
the AIFA (AI FA, 2011b). 
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Hungary 
Korea 
classification for 
reimbursement (AIFA. 2011b). 
The NHIFA includes the 
Technology Appraisal 
Committee that makes the final 
decision on the reimbursement 
of the medicine. This· is 
informed by the critical 
appraisal provided by the OHTA 
(Office of Health Technology 
Assessment, 2011). 
The manufacturer makes a 
submission to H/RA and H/RA 
5. Internal market forecast 
6. Number of potential patients 
Guidelines are available in Italy for the conduct of 
pharmacoeconomic studies (Capri et aI., 2001). The AFIA 
CTS committee will assess the medicine for the 
therapeutic importance taking into account the following: 
1. Severity of disease: 
A :Treatment for serious diseases 
B: Treatment to eliminate the risk of serious diseases 
C: Treatment for non-seriOU5 diseases 
2. Availability of existing medicines: 
A: Medicine is for the treatment where there is currently 
no adequate treatment 
B: Medicine is designed for the treatment of diseases in 
subgroup of patients 
C: Medicine is for the treatment of diseases where no 
recognised treatment exists 
3. Main outcome criteria: 
A: Major benefits on clinical endpoints 
B: Partial benefit for the disease 
C: Minor or temporary benefit for the disease. 
Pharmacoeconomic studies are not a mandatory 
requirement. (AIFA, 2007) 
The manufacturer can submit under either a normal 
procedure or a simplified procedure. The normal 
procedure is for new active substances and this requires a 
Health Technology Assessment. The Simplified procedure 
is for the reimbursement of bioequivalent generiCS. The 
manufacturer submission should include details of (Pekli-
Novak et aI., 2007): 
1. Clinical efficacy 
2. Clinical effectiveness 
3. Cost-effectiveness of the new medicine 
There is a guideline for the conduct of pharmacoeconomic 
studies. There is a preference for cost-effectiveness 
analYSiS, cost-utility analysis and cost-minimisation 
analysis. Cost benefit analysis should not be submitted 
(Szende et aI., 2002). 
The application by the manufacturer should include the 
following (Kyung lee, 2011, Bae and lee, 2009): 
There does not appear to be any 
formal consultation stages in the 
process. Apart from the opportunity to 
appeal at the end of the decision-
making process. 
The manufacturer is given the 
opportunity to respond to questions 
Appendices 
The manufacturer's 
submissions could not be 
identified on the website. 
Neither the manufacturer 
submission nor the HTA 
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Mexico 
staff assesses this (Kyung Lee, 
2011). 
The manufacturer submits to 
the General Health Council 
(GHS). The sub-committees of 
the Interinstitutional 
commission meet once a 
month and reviews the 
applications for inclusion. The 
Technical Secretary of the 
Commission chairs the sub-
committee (Moise and Docteur, 
2007). 
1. A copy of the marketing authorisation 
2. Therapeutic Benefit 
3. Clinical data 
4. Evidence of comparative effectiveness. Head to 
head RCT data is strongly preferred and this 
should be obtained by a systematic search of the 
available evidence. 
5. Pharmacoeconomic analysis (KREP) guideline 
introduced in 2005. 
6. Reimbursement status in other countries. 
The recommendations for pharmacoeconomic analysis 
include that it should be performed from a societal 
perspective. Productivity costs should be assessed in a 
sensitivity analysis. Probabilistic analysis is encouraged 
(HIRA,2006). 
The following information should be submitted: a. Generic 
name; b. current health record; c. same trade name if any; 
d. Dosage form; e. Presentation; f. Quantitative formula or 
the active Ingredients and additives; g. cite recent 
scientific validity of each of the components of formula 
relating to pharmacokinetics, pharmacodynamics, clinical 
and therapeutic sustained controlled studies are useful for 
evidence-based medical practice; h. Schedule to the 
proposed generic description of the input requested 
update; i. Shelf life and storage conditions; j. 
Pharmacoeconomic studies that range from cost-
minimization analysis cost-effectiveness, cost-utility, cost-
benefit to unit prices (Hernandez, 2011). 
The manufacturer submission must contain a 
pharmacoeconomic assessment. A guide to Economic 
evaluation was published in 2008 and is available on the 
GHC website. The guidelines speCific that cost-
effectiveness or cost-utility analysis may be presented 
depending on the clinical problem. The results from a 
societal perspective can be presented separately if they 
are substantially different (such as lost productivity cost s 
and transportation costs for patients). Budget impact 
analysis is required. Probabilistic sensitivity analysis is 
recommended. A standard structure is provided in the 
regarding the submission and with 
respect to the final HTA report 
produced by HIRA staff. The DREC 
committee may hold public hearings 
where the manufacturer can attend 
and be involved in the discussions. This 
has more commonly occurred when a 
number of medicines are being re-
appraised (Yang. 2009, Bae and Lee, 
2009) 
If the medicine is accepted for inclUSion 
on the GHS informs the manufacturer. 
The decision is then placed on the GHS 
website where other stakeholders can 
then challenge the decision (General 
Health Council, 2011b). 
355 
informing the process is 
published on the website. 
However, the detailed HTA 
information is shared with the 
manufacturer throughout the 
process (Yang. 2009). 
The manufacturer's submission 
is not provided on the webSite. 
The GHS only provides details 
of the listing (General Health 
Council,2011b). 
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Netherlands The manufacturer submits to 
the CVD and a committee 
called the Pharmaceutical 
Assistance Commission (CFH) 
oversees the assessment 
report. There are two 
processes, one for outpatient 
medicines and one for inpatient 
medicines (van Halteren, 2011). 
guideline for the reporting of the pharmacoeconomic 
analysis (General Health Council, 2008). 
Outpatient Medicines: 
If exempt from provision of a economic analysis the 
following should be provided (CVZ and Ministry of Health 
Welfare and Sport, 2010): 
1. Indications 
2. Number of patients medicines treats 
3. The price of the medicine 
4. The budget impact of the medicine 
5. The availability of other treatments 
6. A motivation for not conducting an economic 
analysis 
7. Orphan status 
8. Cost-minimisation for medicines with similar 
therapeutic value. 
The assessment for outpatient medicines is summarised 
below for those requiring an economic analysis. The 
manufacturer submission should include the following. 
1. literature search (systematic) regarding the 
search strategy, terms, criteria and the date of 
search. This should identify all relevant studies, 
including reviews, meta-analysis and relevant 
guidelines. 
2. An assessment of therapeutic value by 
comparator and outcome measure 
3. SPC for licensed indication 
4. EPAR 
5. Cost-consequence analysis 
6. Pharmacoeconomic analysis (a guideline is 
provided on the website which was introduced 
in 1999). This should be structured in accordance 
with the guideline and the model should be 
attached. 
There are certain types of medicines that can be exempt 
from a pharmacoeconomic analysis: 
1.) Medicines for an Orphan indication 
2.) Medicines with a cost of less than £500,000 per 
year 
3.) Therapeutically equivalent and with no 
After the first meeting of the CFH to 
consider the draft reports, the 
stakeholders are given the opportunity 
to comment. Stakeholders may include 
clinicians, patients and insurers. A 
response time of 5 days to the 
consultation is provided. 
If the CFH decides additional data is 
required then this will be requested in 
writing to the manufacturer (the 
process time is suspended at this 
point). If the manufacturer does not 
submit the required data in 3 months 
the report will be automatically 
submitted to the Health Board (CVZ) 
unchanged (CVZ and Ministry of Health 
Welfare and Sport, 2010). 
Appendices 
CVZ advice and CFH report 
including annexes are 
published on the website of the 
CVD among publications of CFH 
reports (CVZ, 2011b). 
Appendices 
New Zealand The Pharmacology and 
Therapeutics Advisory 
Committee (PTAC) provides 
advice in relation to the 
community and hospital 
pharmaceuticals. PTAC 
comprises medical experts that 
have broad experiences of the 
medicines and indications. 
PTAC is the primary· clinical 
advisory body and there may 
be other specialist sub-
committees for certain clinical 
fields (oncology). 
PTAC critically reviews and 
appraises using the same 
criteria specified by PHARMAC. 
The group recommends priority 
ratings in the adviSOry notes to 
the PHARMAC (usually high, 
medium and low). The 
committee will also describe 
the criteria and the weight 
attached to each. A high 
priority cost-effective medicine 
is likely to be progressed faster 
than a low priority and not 
cost-effective medicine 
(PHARMAC, 2010). 
additional costs. 
Inpatient Medicines: 
The assessment for inpatient medicines includes 
therapeutic value and budget impact. There is a plan for 
the collection of real life data (coverage with evidence 
development) to conduct a real life cost-effectiveness at 
four years (van Halteren,_2011). 
The manufacturer should provide the following in a 
submission to PHARMAC (PHARMAC, 2010): 
1. Pharmacological information (e.g. forms, 
strength, indication and dose etc) 
2. Added therapeutic value (e.g. main therapeutic 
claims and advantages I disadvantages in 
comparison to other medicines) A systematic 
search should be performed and there is an 
evidence hierarchy grades 1-4 
3. Price information (e.g. proposed price and 
international prices) 
4. Epidemiological information 
S. Market information (expected sales) 
6. Detailed information on costs and benefits of the 
medicine 
7. Information regarding packaging and pack size 
PHARMAC will review and undertake either a cost-utility 
analysis (CUA) or a Budget Impact Analysis (BIA -
conducted over a five year period). The manufacturer 
should provide a CUA when submitting and should follow 
the guideline presented in the Prescription for 
Pharmacoeconomic Analysis (PFPA), published in 2007 
(PHARMAC, 2007). A PHARMAC analyst reviews the 
pharmacoeconomic analysis and will amend if required. 
Manufacturers are advised to provide a CD with a copy of 
the model. If the model is amended the PTAC will be 
supplied with note clearly explaining the differences 
between the two models. There is an iterative process 
with regards to the complexity of the economiC evaluation 
for each unique decision. The timeframes, impact on 
pharmaceutical budget, reliability of results, reporting, 
Prior to the PTAC committee, medical 
groups and other interested parties 
may be invited to comment on the 
pharmaceutical as part of the 
assessment. This allows parties to 
outline speCific issues relating to the 
medicine (PHARMAC, 2010). 
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The details of the funding 
applications are provided on 
the PHARMAC website. The 
agency does not publish most 
of the Technology Assessment 
Reports because of commercial 
sensitivity. It does provide 
some TARs that were used to 
inform the decisions on funding 
of medicines (PHARMAC, 
2011e). Details of the online 
schedule for the medicines 
funded are also available on 
the website. The Pharmacology 
and Therapeutics Advisory 
Committee publishes the 
minutes which include 
discussion of some of the 
details of the assessment. 
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Norway The manufacturer submits to 
NoMA and this can be 
approved by the NoMA 
depending on the budget and 
nature of the medicine. If this 
needs to be referred the Blue 
medicines Board a report will 
be prepared. The NoMA will 
create a background report 
that assesses the manufacturer 
submission. This will include 
data about the disease, 
possible alternative treatments, 
the new drug's possible place in 
the treatment image, drug 
efficacy. The NoMA will also 
analyze and provide comments 
on the application and the 
health economic analysis (PPRI, 
200Sb). 
impact of the CUA on the decision and availability of 
health economic resources determine this. Probabilistic 
Sensitivity analysis should be undertaken when more 
detailed analyses are required (PHARMAC, 2010). 
The PHARMAC states that a good assessment by the 
manufacturer will include: 
1. Critical appraisal of the key clinical evidence 
2. Information relating to all 9 of the PHARMAC 
decision criteria 
3. Market and epidemiological information 
4. Cost-effectiveness in the preferred form of a 
cost-utility analysis and budget impact analysis. 
5. Disclosure of information on ongoing trials and 
patents. 
The manufacturer should submit the following information 
to NoMA (NoMA, 2011a): 
1. The indication and any restrictions proposed 
from the marketing authorisation 
2. EU approval and SPC 
3. Description of the illness and epidemiology 
4. Treatment regime 
5. Overview of existing treatment programme and 
total number of patients for proposed indication 
6. Position of medicine in the treatment 
programme 
7. Current and predicted sales 
S. Description of clinical benefit 
9. Pharmacoeconomic analyses which should 
follow the NoMA guideline published in 2002. A 
probabilistic sensitivity analysis is not a 
requirement but is stated as an advantage. 
10. Budget consequences - the added expense 
should be included for the National Insurance 
Administration for a five year period. 
11. A reference list of published and unpublished 
studies supporting the application. 
Pharmacoeconomics is a requirement for the submission 
to the NoMA (NoMA, 2005). A cost-utility analysis should 
The NoMA gives interested parties the 
opportunity to comment before a final 
decision is made. The NoMA will 
outline the criteria for the decision. 
The manufacturer will be given four 
weeks to respond if the medicine does 
not meet the criteria because of the 
price. The manufacturer can provide 
feedback and any proposed changes. A 
final notice will be given if the medicine 
does not meet the criteria within which 
interested parties have four weeks to 
comment (Ministry of Health and care 
Services, 2004). 
Appendices 
The manufacturer's submission 
is not provided on the website. 
The decisions of the NoMA and 
minutes of the Blue 
prescription committee are 
provided on the website 
(NoMA, 20llc). 
Appendices 
Poland 
Portugal 
The manufacturer submits to 
the Ministry of Health. The 
Analytical Team of the AHTAPol 
assesses the manufacturer 
submission and may revise this 
before this is provided to the 
Consultative Committee 
(AHTAPol,201la). 
The manufacturer submits to 
INFARMED and external 
pharmacologists assess the 
added therapeutic value of the 
medicine. Economists assess 
the economic evaluation 
provided in accordance with 
the Portuguese guidelines for 
the conduct of economic 
be supplemented with a cost-value analysis. A cost-value 
analysis uses a set of alternative value for health 
conditions of various types (adjustment between health 
and disabled individuals, (Nord et al., 1999)). 
The assessment is performed by a review of the 
manufacturer submission and this includes the following 
elements: 
1. The decision problem 
2. Clinical analysis - The efficacy and safety in a 
specific population in comparison to the 
appropriate comparators. A systematic review 
should be performed including details of the 
search strategy, information selection, quality 
assessment (hierarchy of evidence provided in 
the guideline). Meta-analysis and indirect 
comparison can be performed in the case of lack 
of direct head to head comparisons. 
3. Economic analysis - This may either use a model 
structure that is relevant to the Polish context, 
an evaluation identified in a systematic review or 
a novo economic evaluation performed for the 
Polish context. 
4. Analysis of impact on the health system - This 
includes an assessment of the budget impact, 
assessment of the organisational consequences 
for the health care system and an assessment of 
the possible ethical and social implications of the 
new technology. 
A Guideline for Health Technology Assessment (2009) is 
provided on the AHTAPol website (AHTAPol, 2009). 
The manufacturer application should contain the following 
details (INFARMED, 201lc): 
1. The marketing authorisation 
2. The maximum price approval document 
provided by the Directorate-General of 
Economic Activities. The proposed 
reimbursement price maybe equal or below the 
price that was agreed by the DGAE. 
3. SPC 
The manufacturer is given the 
opportunity to provide comment when 
the Analytical Team have prepared 
their report. The Consultative council 
takes the opinions of Medical Schools 
and the National Health Fund into 
account. There does not appear to be a 
formal process for taking other 
stakeholders views into account such 
as patients (lipska, 2010). 
The manufacturer is given the 
opportunity for clarification of the 
pharmaco-therapeutic analysis and 
pharmaco-economic analysiS (PPRI, 
2008a). 
359 
The manufacturer submissions 
are not provided on the agency 
website but manufacturer 
commentaries are provided on 
the website. The website 
contains a document 
summarising the considerations 
of the Consultative Council 
(CC). This includes details of the 
assessment and 
recommendations (AHTAPol, 
201lc). 
The manufacturer submission is 
not published on the website. 
The listing recommendations of 
the INFARMED and the official 
Gazette annually (Maria, 2010). 
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Spain 
Sweden 
evaluation. The manufacturer 
has the opportunity to provide 
additional information and 
clarify elements of the 
assessment (PPRI, 2008a). 
The stakeholders involved are 
the Ministry of Health, 
Directorate General for 
Pharmacy and Health Products 
and the Spanish Agency for 
Medicines and Health Products 
(Vogler et aI., 2009). 
The manufacturer submits to 
the TlV. The TlV allocates an 
executive officer, health 
economist and a legal expert. 
The application is screened for 
completeness and then sent to 
4. The price and reimbursement status in member 
states of the EU 
S. Declaration of the manufacturer for inclusion in 
the reimbursement list 
6. Evidence of the added therapeutic advantage of 
the medicine 
7. The Pharmacoeconomic evaluation that 
demonstrates an economic advantage by the 
criteria set within the law. The 
Pharmacoeconomic evaluation should follow the 
Portuguese guideline 1995 (IN FARMED, 1998). 
The guideline specifies that any recognised 
scientific economic technique can be used 
including cost-benefit analysis. A cost-utility 
analysis is the preferable type of analysis. 
Probabilistic sensitivity analysis maybe used. A 
template is provided for the reporting of the 
economic analysis. 
S. Packaging size 
9. Status of registration in EU countries 
The application includes two analysis (PPRI, 200Sa): 
1. A pharmaco-therapeutic analysis 
2. A pharmaco-economic analYSis 
The manufacturer is required to submit details of the 
technical and economic characteristics of the medicine, 
(Ferre, 2011): 
1. Therapeutic utility report (place in therapy, 
alternatives, alternatives, applicability) 
2. Pharmacoeconomics assessment (Price of the 
medicine, cost comparison, budget impact) 
Pharmacoeconomic studies are not mandatory but are 
sometimes submitted by the manufacturer for the pricing 
process. There is a Guideline for Economic Evaluation 
originally published in 1995, (l6pez-Bastida et al., 2010) 
An application should include the following information 
(lFN, 200S): 
1. Information on patient groups 
2. Information on which other relevant products 
are already included in the pharmaceutical 
benefits for the indication 
No formal consultation process with 
other stakeholders could be identified 
in the reimbursement process. 
The stakeholders have a formal role in 
the deciSion process. The TlV in 
Sweden consults with the 
manufacturer at various stages. The 
TlV will clarify the submission with the 
manufacturer and obtain any further 
Appendices 
The manufacturer submission is 
not published on the Ministry 
of Health website. 
The manufacturer's submiSSion 
is not provided on the webSite. 
The details of the assessment 
and deliberations may be 
provided with the listing 
recommendations (TlV, 2011a). 
Appendices 
Switzerland 
United 
Kingdom 
the Pharmaceutical Benefits 
Group for County Councils 
(representing 18 county 
councils). The county councils 
have four weeks to prepare a 
case. The TLV may meet up 
with the manufacturer to gain 
clarification with regards to the 
application (LFN, 2003). 
The medicines regulatory 
agency, Swiss Agency for 
Therapeutic Products (SATP) 
informs the clinical efficacy 
assessment and the Federal 
Drug Commission assesses the 
submission presented by the 
manufacturer (Paris and 
Docteur, 2007). 
3. Estimated number of patients treated by the 
medicine 
4. Average cost of treatment per day 
5. Description of all relevant clinical studies 
6. Clinical effects and effects relevant to the health 
economics. The best available evidence will be 
that which directly compares studies with the 
most relevant comparator. Indirect comparison 
from a systematic review may be used if this is 
not possible. 
7. Health Economics in accordance to the guideline 
for Economic Evaluation 2003 should be 
conducted. The perspective should be societal, 
cost-effectiveness analysis using QALYs as a 
measure of effect, EQ5D is recommended and 
cost-benefit analysis using willingness to pay can 
be used when QALYs are not feasible (LFN, 
2003). 
The application for a new active substance should include 
the following (FSIO, 2008): 
1. A summary of the justification of the application 
broken down by effectiveness, appropriateness 
and efficiency. 
2. Comparative effectiveness - does the medicine 
fulfil the criteria for an innovation reward in 
comparison with the available alternatives. 
3. Number of patients treated by the mediCine 
4. The expiration date ofthe patent 
5. A foreign price comparison for the approved 
indications 
6. The three most important clinical studies usually 
published in the "Lancet" or "The New England 
Journal of Medicine". 
7. Pharmacoeconomic studies if these are 
available. 
8. Epidemiology data. 
l:! manufacturer, independent I The manufacturer is required to provide evidence of 
I assessment centre (ERG or clinical-effectiveness and cost-effectiveness and can be 
information. The TLV may arrange a 
meeting with the manufacturer to do 
this if necessary. The documents that 
include the assessment and proposed 
decision are sent to the manufacturer 
for the opportunity to correct any 
factual errors and to comment on the 
justifications provided for the proposed 
decision. The Pharmaceutical Benefits 
Group for the County Councils are 
given the opportunity to provide 
comments and put forward any issues 
with the documentation and proposed 
decision. Patient groups are 
represented in the process by two 
members of the Executive Board that 
provide the decision having 
involvement with patient organisations 
in the past (LFN, 2008). 
There is no formal consultation with 
other stakeholders on the evidence 
presented. One member of the insured 
are on the Federal Drug Commission 
committee but there does not appear 
to be any other means by which 
patients can comment on the 
documents. There is no formal process 
for stakeholders to comment on the 
assessment and appraisal provided by 
the Federal Drug Commission and 
BAG/FOPH (Paris and Docteur, 2007). 
There are several stages at which 
consultees and commentators can 
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The manufacturer submission is 
not provided on the website 
nor could the appraisal 
documentation provided bV 
Federal Drugs Commission be 
identified. 
The NICE website contains an 
audit of the process with time 
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England assessment group}, wide 
variety of stakeholders and 
patient representatives. NICE 
define the process in three 
stages which include seoping, 
assessment and appraisal (NICE, 
2008). 
found in the Guide to methods of technology appraisal 
(2008) (NICE, 2008). The assessment process is a 
systematic evaluation of the relevant evidence available 
on a technology. In general medicines can be considered 
clinically effective if, in normal clinical practice, they confer 
an overall health benefit taking account of any harmful 
effects when compared with relevant alternative 
treatments. Technologies can be considered to be cost-
effective if their health benefits are greater than the 
opportunity costs measured in terms of the health 
benefits are greater than the opportunity costs measured 
in terms of the health benefits associated with 
programmes that may be displaced to fund the new 
technology. 
The main submission should include at a minimum the 
following 
1. The aims of treatment and current approved 
indications for the technology 
2. An overview of the current treatment pathway, 
including how the technology is expected to fit 
into the treatment pathway 
3. An assessment of the clinical-effectiveness, 
containing a critical appraisal, interpretation and 
synthesis of the clinical effectiveness evidence 
4. A tabulation of the values and sources of the key 
parameters to be used in the assessment of cost 
effectiveness 
5. An assessment of the cost-effectiveness 
containing a reference-case analysis of the cost-
effectiveness based on the synthesis of clinical-
effectiveness evidence. A justification for any 
cost-effectiveness analysis not fulfilling the 
reference case requirement is essential. 
6. An assessment of the resource impact containing 
estimates of the impact of the technology on the 
NHS, including uptake/treatment rates, 
population health gain, resource implication and 
financial costs. 
Details with the requirements for clinical-effectiveness and 
cost-effectiveness; 
comment on the assessment of the 
medicine. A consultee includes national 
groups representing patients and 
carers, bodies representing health 
profeSSionals, manufacturer (s) or 
sponsor (s) of the technology in 
development. the Department of 
Health, the Welsh Assembly 
Government. Specialised 
commissioning groups. Primary care 
trusts and local health boards. 
Commentator organisations include 
manufacturers of comparator 
technologies, NHS Quality 
Improvement Scotland, the relevant 
National Collaborating Centre, research 
groups working in the area and other 
groups (NHS confederation. BNF etc). 
The consultees and commentators may 
provide comments on the draft scope. 
The consultees and commentators may 
provide a submission in a structured 
report. The committee can hear 
evidence from nominated clinical 
experts. patients and carers. The 
consultees and commentators have 
four weeks to comment on the 
Appraisal Consultation Document 
(ACD). Consultees can also appeal 
against the final recommendations in 
the FAD (NICE, 200gb, NICE, 2009a). 
Appendices 
stamped documents. The 
manufacturer submission is 
included, ERG report or 
Assessment Report, 
Clarification documents that 
are provided by the 
manufacturer of the 
independent assessment group 
and any stakeholder 
submissions or documents. The 
details of all the medicines 
assessment and appraisals are 
published on the website (NICE, 
2011e). 
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United 
Kingdom 
Scotland 
The manufacturer, SMC board, 
New Drugs Committee and 
Patient groups all input into the 
decision-making process. There 
is no third party review of the 
evidence or generation of an 
independent model (SMC, 
2011e). 
1. Evidence of relative treatment effects - There is 
no hierarchy of evidence. NICE has a strong 
preference for evidence from 'head-to-head' 
RCTs that direct compare the technology with 
the appropriate comparator in the relevant 
groups. Non-RCT evidence that is both 
experimental and observational maybe used 
when RCTs are not available or to substitute this 
information. A systematic consideration of the 
evidence should be included. 
2. Evidence for cost-effectiveness - A systematic 
review of economic evaluations should be 
performed and a new analysis of the cost-
effectiveness of the medicine. Evidence from 
other study designs other than RCTs may be 
necessary. 
3. Acceptability, appropriateness and preference 
4. Feasibility and impact 
5. Equity and equality 
The SMC considers all newly licensed medicines, new 
formulations of existing medicines and new indications for 
established products (SMC excludes assessment of 
vaccines, branded generics, non-prescription-only 
medicines (POMs), blood products, plasma substitutes and 
diagnostic medicines) once marketing authorisation has 
been granted. The manufacturer is required to submit 
evidence on clinical efficacy, comparative effectiveness, 
clinical effectiveness, cost-effectiveness and budget 
impact (SMC, 2011c): 
1. Clinical effectiveness: The SMC requires the 
manufacturer to provide evidence assembled 
systematically for the indication(s) of the 
medicine including details of RCTs (active 
controlled most relevant), meta-analyses, and 
most relevant effects of a medicine. The 
manufacturer provides evidence of clinical 
efficacy and is required to consider the medicine 
in terms of the applicability to clinical practice in 
Scotland, guidelines and relevant protocols for 
Patient Interest Groups are able to 
collect comments from a number of 
patients and carers and provide these 
in the form of a submission of evidence 
to the SMC. There is a submission 
guide and submiSSion template 
provided on the SMC website (SMC, 
2011f). The health boards and a 
number of experts are formally 
involved in the process of decision-
making. 
The manufacturer submits a 
New Product Assessment Form 
(NPAF) but no fee is required 
for the processing of the 
submission. The NPAF is not 
published on the SMC website. 
An advice document is 
published on the SMC website 
(SMC,2011h). 
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the most relevant active comparator medicines. I 
In the absence of head to head evidence a 
network meta-analysis is required by the SMC. 
The network meta-analyses should be described 
with reference to a systematic review for studies 
included and the search strategy for trials 
included and clinical/statistical heterogeneity 
between data sources. 
2. Cost-effectiveness: The responsibility for 
demonstrating the cost-effectiveness and any 
further analysis relevant to Scottish practice 
rests with the manufacturer and failure to 
submit cost-effectiveness automatically results 
in a not recommended decision. A reference 
case is not provided but the SMC specifies that 
cost-utility analysis is the preferred form of 
economic evaluation and health effects should 
be expressed in Quality-Adjusted Life Years 
(QAlYs). Modelling is the main framework used 
to synthesise data of clinical and cost-
effectiveness, in the absence of real-life 
effectiveness data. Manufacturers are required 
to provide sensitivity analysis in the form of 
single and multi-way analysis to allow the 
committee to explore the uncertainty in the 
estimates. 
Appendices 
Table A4.15: Technology assessment level: Deliberation of factors for decision 
country 
Australia 
Austria 
Institutions involved 
The PBAC provides an 
advisory recommendation 
which the Minister of 
Health with take into 
account alongside the price 
negotiations with the PBPA 
(PBAC, 2008). 
The HEK provides the 
reimbursement 
recommendation though a 
majority vote of the 
members providing that 
half of the members are 
present. The HBV 
(Federation) provides the 
reimbursement decision 
and the Pricing Committee 
(PK) advises the Ministry of 
Health, Family and Youth 
(BMFGJ) on the pricing of 
the medicine. The 
Federation only has to 
provide the reasons for 
rejecting the medicine and 
Type of stakeholders involved in 
appraisal 
The PBAC committee members are 
appointed by the Minister for 
Health, include medical 
practitioners (specialists, general 
practitioners and clinical 
pharmacologists), pharmacists, 
consumers and health economists 
(PBAC, 2008). 
The Medicines Evaluation 
Committee (HEK) is an advisory 
body to the Federation of Social 
Security Institutions (HBV) for 
inclusion of the medicines in the 
code of reimbursement (EKO). The 
members of the HEK and 
manufacturers holding the 
marketing authorisation must not 
discuss any aspects of the review. 
The committee consists of 20 
members and the agendas of the 
meetings are published on the HBV 
website. The HEK consists of 20 
members including ten members 
from the Social Insurance System 
including specialists from the 
Stated factors for the appraisal of medicines 
There is no stated cost-effectiveness threshold in Australia. There 
are many factors taken into account and the guidance for 
submission categorises these as qualitative and quantitative 
factors. The factors are not weighed equally and different factors 
may be more or less important depending on the Situation (PBAC, 
2008). 
Quantitative factors: 
1. Comparative cost-effectiveness 
2. Comparative health gain 
3. Patient affordabiJity in the absence of PBS 
4. Budget impact for PBS and government 
Qualitative factors: 
1. Uncertainty surrounding the evidence 
2. Equity considerations 
3. Presence of effective alternatives 
4. Severity of the medical condition treated 
5. Ability to target patients most likely to benefit 
6. Likely development of resistance 
The HEK conSider the following factors when considering an 
application (Austrian Federation of Social Insurance Institutions, 
2004): 
1. 
2. 
3. 
Pharmacological evaluation 
Medico-therapeutic assessment - the added therapeutic 
value of the medicine. The therapeutic benefit is 
classified under the following categories: 
1. Substantial therapeutic benefit in the majority of 
patients 
2. Substantial therapeutic benefit for a subgroup 
3. Added therapeutic benefit for the majority of 
patients 
4. Added therapeutic benefit for a subgroup of 
patients 
5. Similar therapeutic benefit for patients 
6. No added therapeutic benefit. 
The Health Economic evaluation. There is no explicitly 
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Communication of summary of 
appraisal and decision 
The PBS outcomes are presented in 
a summary document (around 4 
pages) on the Department of 
Health and Ageing website. This 
details the main deliberations and 
a summary of the evidence 
considered by the manufacturer 
(PBAC, 2011). 
The details of those medicines 
included in the reimbursement 
code can be found on the following 
website (Austrian Social Security, 
2011b). 
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Belgium 
must provide reasons in 
reference to points for 
which the manufacturer 
has had the opportunity to 
comment (PPRI, 2007a). 
The NIHDI CRM provides 
advice to the Minister of 
Health. The Ministry of 
Economy provides 
information on the 
maximum price (Adria ens 
and Soete, 2010). 
Federation, three independent 
Scientific representatives 
(pharmacologists and physicians 
from university institutions), two 
representatives from the Federal 
labour Board, two representatives 
from the Austrian Medical 
Association, one representative of 
the Austrian Chamber of 
Pharmacists. Each member of the 
committee has one deputy. The 
Federation appoints the members 
and their deputies for a period of 5 
years (Austrian Federation of Social 
Insurance Institutions, 2004). 
The CRM voting members consist 
of: seven members with an 
academic term in Belgian 
universities; eight members 
appointed by the insurers; four 
members appointed by the 
professional associations 
representing the medical 
profeSSion; three members 
appointed by professional 
associations representing the 
pharmacists - These all have voting 
rights. The members that are 
consultative with no voting rights 
are two members appointed by 
professional associations 
representing the pharmaceutical 
industry; one member nominated 
by the Minister responsible for 
Social Affairs in its attributions; one 
member nominated by the 
Minister responsible for Public 
Health in its attributions; one 
member nominated by the 
Minister in Economic Affairs in its 
reported cost-effectiveness threshold. 
Class 1 medicines are those with added therapeutic value, Class 2 
are those with comparable therapeutic value and Class 3 are 
generic medicines The decision to reimburse those medicines in 
class 1 depends on the following criteria: 
1. The therapeutic value, taking into account efficacy, 
effectiveness and the user-friendliness of the product 
2. The market price of the drug 
3. The clinical effectiveness and likely impact taking into 
account of the therapeutic and social needs 
4. The budget impact for national health insurance 
5. The cost-effectiveness of the product from a perspective 
of national health insurance. 
Class 2 and 3 drugs do not have to be assessed with regards to 
cost-effectiveness and further class 3 do not have to have an 
assessment of therapeutic value (Adriaens and Soete, 2010). 
Appendices 
The Ministers decisions are 
published on the NIHDI website 
alongside the evaluation reports 
(NIHDI,2011). 
Appendices 
Canada 
Denmark 
The PBAC makes 
recommendations to each 
of the provinces that make 
the final decision on the 
reimbursement and pricing 
given their local priorities 
(CADTH,20lla). 
The Danish Medicines 
Agency (DMA) makes the 
final decision on general 
reimbursement and the 
individual reimbursement 
status of medicines. The 
Reimbursement committee 
provides advisory 
recommendations to the 
DMA. The DMA's final 
deCisions may be appealed 
to the Ministry of Interior 
and Health (Danish 
Medicines Agency, 2008). 
attributions; one member 
representing the Department of 
the medical examination of the 
NIHDI(Adriaens and Soete, 2010). 
The canadian Expert Drug Advisory 
Committee (CEDAC) is an 
appointed, national, independent 
body of physicians, pharmacists 
and other health 
care professionals and public 
members (CADTH, 20llb). 
The Reimbursement Committee 
consists of a maximum of 7 people, 
of whom 2 must be general 
practitioners. Members are 
appointed by the Minister of the 
Interior and Health after 
recommendation by the Danish 
Medicines Agency. One member is 
appointed by the Minister of the 
Interior and Health after 
recommendation by the Regions' 
Board for Salaries and Rates 
(Regionernes L0nnings- og 
TakstnGevn). The committee's 
members are appointed for 4 years 
at a time and collectively possess a 
broad professional expertise (DMA, 
20llc). 
The DMA takes the advice from the 
professional medical 
recommendation from the 
reimbursement committee (MTN), 
other scientific societies, 
The CEDAC will consider in its deliberations the following factors 
(CADTH, 2010): 
1. Clinical studies, which assess safety and/or efficacy of the Drug 
in appropriate populations 
(Note: When available, effectiveness data will be compared with 
current accepted therapy) 
2. Therapeutic advantages and disadvantages relative to current 
accepted therapy 
3. Cost-effectiveness relative to current accepted therapy 
4. Patient perspectives obtained through Patient Group Input. 
The decision to provide the medicine under general 
reimbursement considers the following criteria (Danish Medicines 
Agency, 2008): 
1. Medicines therapeutic effect (Hierarchy of evidence 
considered) 
2. Value added proportionate to the price. 
3. Pharmacological documentation 
4. Side effects 
S. Price survey 
6. Optional health economic evaluation to determine that 
a premium price is reasonable in relation to the 
therapeutic effect. 
367 
The final recommendation and 
reasons for the recommendation 
are released publicly on the CADTH 
website (CADTH, 20llc). 
The recommendations are 
provided on the website. The 
details of any reappraisal are also 
provided on the webSite. The 
minutes of each of the 
reimbursement committees 
meetings are provided on the 
website (DMA, 20llb). 
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Finland 
France 
The PPB works in 
conjunction with the Social 
Health Insurance 
institution and the Ministry 
of Social Affairs and Health. 
PPB will request an opinion 
from Kela and from its own 
clinical expert group. Kela 
plays a role in evaluating 
the pharmacoeconomic 
reports on new medicines. 
Having received the expert 
opinions, PPB makes an 
independent decision 
(Ministry of Social Affairs 
and Health, 20lla). 
The HAS committee is 
called the Transparency 
committee and considers 
the dossier from the 
manufacturer and a review 
of the literature. A 
recommendation is 
produced along with a 
judgement of the ASMR 
and SMR are provided for 
the second stage where 
price is negotiated by the 
CEPS. The final 
reimbursement 
Pharmaceutical industry and 
patient organisations. 
The Pharmaceuticals Pricing Board 
consists of seven members and 
their deputies nominated by the 
Ministry of Social Affairs and Health 
for three years at a time. The board 
members have to be university 
graduates with at least a Masters 
Degree. At least one of the 
members has to represent medical, 
one pharmaceutical, one legal and 
one economic expertise. Two 
members of the Pharmaceuticals 
Pricing Board are from the Ministry 
of Social Affairs and Health, one 
from the Ministry of Finance, two 
from the Social Insurance 
Institution (Kela), one from the 
National Agency for Medicines and 
one from the National Research 
and Development Centre for 
Welfare and Health (STAKES 
(Ministry of Social Affairs and 
Health, 2011b)). 
Transparency committee includes 
physicians, pharmaCist, specialist in 
methodology and epidemiology. 
There is no third party synthesis of 
evidence (HAS, 20llb). 
There are different criteria dependent on the type of 
reimbursement, basic or special. On the basis of severity certain 
diseases are reimbursed in a list produced in 2005. 
Basic reimbursement focuses: 
Added therapeutic value of the medicine 
Special reimbursement focuses (PPB, 2011): 
1. Need - the necessity og a medical product and nature of 
disease 
2. Added therapeutic value 
3. Cost-effectiveness 
4. Economic considerations (cost of treatment and budget 
impact). 
The reimbursement decisions and 
reasonable wholesale prices are 
provided on the Ministry of Social 
Affairs and Health website 
(Ministry of Social Affairs and 
Health, 20llc). 
The committee judges the SMR and ASMR for the medicines. 
This is performed by a majority vote for the two criteria. 
The decisions are provided on the HAS 
website (HAS, 20lla). 
SMR: The score takes into account the severity of the 
condition and other data specific to the drug such as the 
effectiveness and adverse reactions, place in the therapeutic 
strategy, existence of other therapeutic alternatives and 
importance for public health. The SMR determines the level 
of cost-sharing paid by members of the health insurance 
system and whether the medicine justifies reimbursement. 
The SMR takes four categories; Major, Moderate, Low and 
insufficient (does not justify reimbursement). 
ASMR: The Improvement in Medical Benefit is first provided 
Appendices 
Germany 
recommendation and price 
is made by CEPS in the 
Ministry of Health (Rochaix 
and Xerri, 2009). 
The Federal Joint 
Committee decides 
whether a medicine should 
undergo an early benefit 
assessment. The IQWIG 
may be delegated to 
review the manufacturer's 
submission and the G-BA 
will make an early 
assessment of the benefit 
of the medicine. IQWIG 
may be asked to provide a 
cost-effectiveness analysis 
by the manufacturer 
following arbitration for 
the price of the medicine 
(Federal Joint Committee, 
2011d). 
The G-BA makes the final decision. 
The committee includes three 
impartial members (including a 
chairman), five representatives of 
payers (statutory health insurance) 
and five representatives of 
providers (doctors, dentists and 
hospitals). A patient representative 
has the right to observe 
deliberations but does not have the 
right to vote (Federal Joint 
Committee, 2010). 
in the manufacturer submission as a claimed score for the 
medicine. The ASMR is a score of the relative-effectiveness 
of the medicine compared to the medicine used in practice. 
There are five different levels of ASMR from Major 
Improvement (I), Important (II), Moderate (III), Minor (IV) 
and no improvement (V). The ASMR determines the pricing 
that is negotiated between the manufacturer and CEPS. A 
separate ASMR may be rewarded to a medicine that has 
different benefits in different indications or patient 
subgroups. The ASMR determines the price negotiated by 
the CEPS. CEPS negotiates price for outpatient medicines 
and those medicines that are used in hospital but not 
included in the DRG (those included in the DRG are 
negotiated with individual hospitals). Those rated on the 
ASMR of I, II or III are allowed to set a price higher than the 
comparator, IV depends on the context and V must be cost-
saving in relation to the relevant comparator (s). The CEPS 
also sets price volume agreements with the manufacturer 
where in the event that sales exceed the forecasts for the 
four years the company is required to provide a claw back 
for the additional costs (Grandfils, 2008). 
At early assessment the added therapeutic value is assessed 
(benefit). This will follow a 6 point assessment (Federal Joint 
Committee,2011b): 
1 - Major improvement in benefit: A significant additional 
benefit, primarily a cure for the disease, a significant survival 
time, a long-term freedom/avoidance of serious side effects. 
2 - Significant improvement in benefit: A significant 
additional benefit, moderate life extenSion, substantial slow 
down in symptoms, avoidance of serious side effects. 
3 - A small additional benefit is when one of the functional 
benefits shows a moderate reduction in non-fatal symptoms 
or side effects. 
4 - An additional benefit exists but is not quantifiable 
because there no scientific evidence base is possible 
5 - There is no demonstration of value added benefit. 
6 - The benefits of the drug to be evaluated is less than the 
benefit of the appropriate comparison treatment. 
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All decisions made by the G-BA are 
documented on the website (Federal 
Joint Committee, 2011c). 
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Ireland 
Israel 
The NCPE provides the 
critical appraisal, rapid 
reviews and 
pharmacoeconomic 
analYSiS, The Corporate 
Pharmaceutical Unit 
products committee selects 
medicines to be assessed 
by the NCPE and uses this 
information to appraise 
and provide the final 
reimbursement decision 
(Tilson et at, 2010). 
The manufacturer submits 
and the Medical 
Technologies 
Administration (MTA) of 
The NCPE review group critically 
appraises the manufacturer 
submission. The group consists of a 
clinician, pharmaCist, scientist, 
health economist and statistician. 
Local expert opinion is sought with 
regards the place of the new 
medicine (NCPE, 2011a). 
The manufacturer submits and 
PNAC makes the final decision for 
inclusion on the NLHS. The PNAC is 
appointed by the Ministry of Hea Ith 
This directly determines the price negotiations that are 
undertaken by the national confederation of statutory 
health insurance (orphan drugs are excluded from this 
process). An assessment of the cost-effectiveness can be 
requested by the manufacturer and this is performed by 
IQWIG using the efficiency frontier is used 15+ months post 
the initial marketing authorisation for the product (Federal 
Ministry of Health, 2011, Leverkus, 2011). 
Manufacturers must first submit for a rapid review and the 
criteria at this stage are as follows (NCPE, 2009): 
1. Number of eligible patients in the population 
2. Medicine replaces or adds to the available 
medicines 
3. Potential budget impact 
4. Price compared with available comparators 
5. Clinical-effectiveness 
6. Cost-effectiveness (if available) from other 
jurisdictions 
A recommendation maybe made for reimbursement or this 
maybe referred for a full pharmacoeconomic analysis if they 
are high cost medicines or are high budget impact. The 
economic evaluation is critically appraised using the 
Drummond 10 point checklist. The decision criteria 
considered for the recommendation are (NCPE, 2010): 
1. Cost-effectiveness - There is no fixed cost-
effectiveness threshold in practice and if the cost-
effectiveness estimate is significantly higher other 
factors will be considered. However previous 
recommendations have shown that a medicine 
with an ICER of less than €45,OOO/QALY is more 
likely to be reimbursed. 
2. The level of uncertainty associated with the clinical 
and cost-effectiveness evidence 
3. Budget impact 
4. Innovative nature of the medicine 
5. Lack of available alternatives. 
The committee takes into account the following factors: 
1. Life Saving technology 
2. Potential for the technology to prevent mortality and 
morbidity 
Appendices 
The summary of the recommendation 
provided by the NCPE is available on the 
website (NCPE, 2011c). 
The PNAC decisions and deliberations 
are available on the Ministry of Health 
website but the details with regards to 
the impact on the budget are not 
Appendices 
Italy 
the Ministry of Health 
screens the submission and 
provides a rapid 
assessment. A list of 
technologies is provided to 
the Medical Technologies 
Forum and they put 
together an evaluation and 
consider evidence from 
other professional bodies 
and other jurisdictions 
agencies. The MTA 
provides a prioritised list of 
medicines in three groups 
(A,B,C) for which the Public 
National AdviSOry 
Committee (PNAC) makes 
the final decision· on 
inclusion (Greenberg et aI., 
2009). 
The manufacturer, the two 
sub committees of the 
AI FA; Scientific technical 
committee (CTS) and the 
Pricing and Reimbursement 
Committee (CPR) make 
recommendations for 
provision on the PFN 
formulary. The Executive 
Board comprised of 5 
members makes the final 
decision on inclusion on 
the list (AIFA, 2011b). 
and is composed of twenty 
representatives, including the 
Ministry of Health, Ministry of 
Finance, Health Maintenance 
Organisation, experts in health 
economics and representatives of 
the public at large (Greenberg et 
al.,2009). 
The Scientific Technical 
Commission consists of 17 
members that include medical 
practitioners and pharmacologiSts. 
The Pricing and reimbursement 
committee (CPR) consists of 12 
expert members of 5 are 
nominated by the Ministry of 
Health, 5 are nominated by the 
regions, 1 representative of the 
Ministry of Economy and 1 
representative of the Ministry of 
Production Activity. These 
members have proven experience 
in negotiation of prices and 
particular expertise in health 
economics (AIFA, 2011d). 
3. Number of patients who might benefit from the 
technology 
4. Financial burden of illness 
S. The available treatment alternatives 
6. Degree of extension of life and quality of life 
7. Degree of financial savings 
8. Budget impact 
9. Economic evaluation (from 2007) 
A score is provided and if there is an estimate of cost/benefit 
of the new medicine in the form of cost-effectiveness (Cost 
per QALY) then this is also taken into account alongSide 
these other criterion. Cost-effectiveness is not however a 
specific criterion in the decision-making and is rarely 
provided by the manufacturer. The score is provided on a 
scale from 1 to 10 and the medicines are claSSified into three 
groups. Group 1 consists of high priority technologies 
(grades 8-10), group 2 consists of intermediate priority 
technologies (4-7) and group 3 consist of low priority 
technologies (grades 1 -3). Relative criteria of the decisions 
on the grades are not disclosed to the general public 
(Ministry of Health, 2010). 
The CTS takes into account the level of therapeutic 
innovation using an algorithm of defined characteristics, 
including (AI FA, 2007): 
1. Severity of disease, 
2. Availability of treatments 
3. Added therapeutic effect. 
The scores for each of these components is combined to 
assess whether the medicine represents an Important, 
moderate or modest therapeutic innovation. Those 
representing a therapeutic innovation undergo price 
negotiations with the CPR and those that are equivalent 
must be priced below or at a similar level to the other 
relevant available medicines. 
The manufacturer's negotiated price is based on the 
following criteria (Folino-Gallo et aI., 2008): 
1. The cost-effectiveness of the treatment, regarded as 
useful for treatment of the disease and whether the drug is 
more appropriate than those drugs already available for the 
same therapeutic indication. There is no cost-effectiveness 
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disclosed (Greenberg et aI., 2009). 
The final deCisions of the Executive 
Board are published in the Official 
Journal of Italy. The medicines lists are 
provided on the AIFA website (AI FA, 
2011C). 
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Hungary 
Korea 
The Office of Health 
Technology Assessment 
(OHTA) provides a critical 
appraisal of the 
manufacturer submission. 
The TAC committee of the 
NHIFA uses information 
from their 
recommendations to make 
a final deCision for the 
medicine (PPRI, 2007b). 
The Drug Reimbursement 
Committee of HIRA is 
responsible for reviewing 
the HT A report for 
recommendation in the 
positive list (Bae and Lee, 
2009). 
The TAC members include 
members from the HIFA, Ministry 
of Health, Ministry of Finance 
Ministry of Economy and 
Transport, Hungarian Chamber of 
Pharmacists, Hungarian Medical 
Association, College presidents that 
have voting rights. It also consists 
of members that do not have 
voting rights such as the secretary, 
National Institute for Heath 
Information and library (ESKI) and 
National Health insurance 
individual (Gulacsi et aI., 2009). 
The Drug Reimbursement 
Committee consists of 18 members 
that are appointed by the MOHW 
(Bae and Lee, 2009). The OREC 
includes healthcare professionals, 
academics, patient representatives, 
HIRA staff and other government 
department staff (Yang, 2009). 
threshold in Italy; 
2. The risk-benefit is ,pre favourable than drugs available for 
the same indication; 
3. Economic impact assessment on the National Health 
Service; 
4. Cost of treatment per day compared to medicines of the 
same effectiveness; 
S. Market shares of drug acquired; 
6. Comparison of prices and consumption in other European 
countries. 
The criteria for inclusion on the reimbursement list are as 
follows (PPRI, 2007b): 
1. Clinical efficacy 
2. Safety 
3. lack of alternative therapy 
4. Cost-effectiveness 
S. Price 
6. Budget Impact 
The Drug Reimbursement Committee considers the 
following factors (Bae and Lee, 2009): 
1. Clinical usefulness/value 
2. Pharmacoeconomics - there are Guidelines for 
Economic Evaluation of Pharmaceuticals in Korea 
(KPEG). There is no threshold reported for the 
inclusion of medicines. Although Yang (2008) 
reports discussion of a range of xO.8-1.2 of GOP. 
3. International countries reimbursement status 
4. International treatment guidelines 
S. Budget Impact. 
The NHIC considers the following factors in the price 
negotiations (Bae and Lee, 2009): 
1. The total cost of alternative medicines 
Appendices 
The appraisals are not published on the 
webSite. 
The appraisal documents are not 
available publically. 
Appendices 
Mexico 
Netherlands 
The General Health Council 
makes the final decision 
and is informed by the 
Interinstitutional working 
group (Moise and Docteur, 
2007). 
The CFH report is 
considered by the CVD 
board that prepare the 
final advice. The Board 
must also advise the 
Minister of Health of any 
social consequences as a 
result of the package 
recommendation. These 
meetings occur in public 
and are called AdviSOry 
Package (ACP) meetings. 
Other stakeholders such as 
clinician, patients and 
insurers may be consulted 
at other stages in the 
process (CVZ and Ministry 
of Health Welfare and 
Sport, 2010). 
The General Health Council of 
Mexico is composed of 
representatives of thirteen public 
health institutions as well as other 
government - -
governmental 
representatives 
professional's 
health-related 
offices, non-
organizations, 
from health 
academies and 
education 
representatives. The final decision 
is made on majority vote (General 
Health CounCil, 20lla). 
The CFH committee consists of 22 
external independent experts that 
can serve for a maximum term of 
eight years. The CFH membership 
includes pharmacist's physicians, 
health economists, health 
researchers/scientists, and 
representatives of the Ministry of 
Health. 
The Executive Board (CVZ) has 
three members that are appointed 
by the Minister of Public Health, 
Welfare and Sport. 
The ACP committee (Appraisal 
committee) includes the three 
executive board members and also 
has six expert members with 
practical knowledge of social 
security issues (CVZ and Ministry of 
Health Welfare and Sport, 2010). 
2. Budget impact 
3. Reference price 
4. The HIRA Drug Reimbursement Committee 
Evaluation. 
There are three criteria that all medicines must meet for 
inclusion into the Basic Formulary of Inputs (Moise and 
Docteur, 2007): 
1. The medicine must have a marketing authorisation 
2. The medicine must meet all safety and clinical 
tests. 
3. The medicines should be cost-effective. 
The CVZ has four criteria for assessing what should be 
included in the basic insured package: 
1. Necessity: does the illness or the required care - given the 
context in SOCiety - justify a claim on solidarity. This may 
include burden of disease or rarity of disease? 
2. Effectiveness: does the form of care deliver what is 
basically expected to do? 
3. Cost-effectiveness: is the relationship between 
costs/benefits broadly acceptable? This is appraised for 
medicines of added therapeutic value. 
4. Feasibility: is inclUSion in the package feaSible, now and in 
the long term? 
The Council are allowed to also take into account personal 
responsibility, incidental effects on society and temporary 
nature of the interventions. 
The appraisal must consider the therapeutic value provided 
by the medicine (CVZ and Ministry of Health Welfare and 
Sport, 2010). The therapeutic value is categorised into three 
groups depending on the properties of the medicine. The 
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The basic inputs table is published on the 
website with details of those medicines 
included. This does not include details of 
the deliberations for each of the 
medicines appraised (General Health 
Council, 2010). 
cvz advice and CFH report including 
annexes are published on the website of 
the CVD among publications of CFH 
Reports (CVZ, 2011b). 
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New Zealand The PTAC committee 
reviews and appraises the 
evidence provided by the 
manufacturer and 
The Pharmacology and 
Therapeutics Advisory Committee 
(PTAC) is a clinical advisory 
committee that has a role to 
properties included when assessing therapeutic value are 
the positive benefits provided (RCT evidence) and adverse 
events, experience (the use of the medicine in practice by 
patients), usability (administration time) and applicability 
(the medicine may benefit different groups of patients for 
the same disease). The criteria are assessed in relation to 
morbidity, chronic nature of the disease and availability of 
alternatives. The medicines are classified into three 
categories: 
1. Medicines with a therapeutic loss in comparison 
with other included treatment options; 
2. Medicines which have equivalent therapeutic 
value compared to those of others in the package 
3. Medicines with a therapeutic value in comparison 
to other medicines already in the insurance 
package. 
Budget impact is submitted but it is not a formal appraisal 
criteria. The appraisal phase is conducted by the Advisory 
Package CommisSion that considers the societal implications 
of any recommendation. 
The Minister makes the final decision and there is no 
explicitly stated threshold. However in 2009 the CVZ 
published guidance of a threshold range depending on 
severity of illness. (A background study on the 'cost-
effectiveness' package prinCiple for the benefit of the 
appraisal phase in package management CVZ report 2010). 
The threshold stated was EUROIO,OOO per QALY for less 
severe illness up to EUR080,OOO per QALY for severe illness. 
The Minister of Health has not confirmed this threshold. 
The Inpatient Expensive medicines are appraised for 
therapeutic value and a plan made for assessment of the 
real-life cost-effectiveness at four years. The medicine is 
temporarily listed during this period (van Halteren, 2011). 
PHARMAC uses the following decision criteria (PHARMAC, 
2010): 
1. The health needs of all eligible people within New 
Zealand. 
Appendices 
The minutes of the PTAC meetings are 
provided on the website (PHARMAC, 
2011b). 
Appendices 
Norway 
PHARMAC (when 
additional analysis 
undertaken). The 
PHARMAC board appraises 
the medicine following 9 
criteria (PHARMAC, 2010). 
The Drug Administration of 
NoMA can assess and 
approve applications that 
do not exceed certain 
budget restrictions. The 
application may be 
referred to the blue 
prescription board if the 
drugs budget impact 
exceeds NOK 5 million or is 
a major therapeutic 
innovation. The board help 
to ensure the quality of 
decision-making on 
important reimbursement 
issues. This will be 
provide objective clinical advice to 
the PHARMAC Board. The 
committee consists of 12 Medical 
Practitioners that are nominated by 
the professional medical bodies 
(PTAC, 2010). 
The PHARMAC board consists of 
five members (including the 
chairperson). The Board makes the 
final decisions for inclusion on the 
Pharmaceutical Schedule. The 
Minister of Health appoints each 
member of the Board for a period 
of 3 years (PHARMAC, 2011d). 
The Therapeutic Group Managers 
are responsible for negotiating the 
listing and commercial agreements 
which may include price 
negotiations special authority, 
expenditure caps, rebates on 
pharmaceutical price and multi-
product agreements (bundling). 
The negotiations may lead to a re-
prioritisation of the medicine. 
The Blue prescription board Is 
comprised of seven members that 
include health economists, 
pharmacists, physicians and GPs. 
The experts are appointed for a 
period of two years (NoMA, 
2011b). 
2. The particular needs of Maori and Pacific peoples. 
3. The availability and suitability of existing medicines and 
related products 
4. The clinical benefits and risks of pharmaceuticals. 
5. The cost-effectiveness of meeting health needs by funding 
pharmaceuticals, rather than by using other publicly funded 
health and disability support services. 
6. The budgetary impact (in terms of the pharmaceutical 
budget and the Government's overall health budget) of any 
changes to the Pharmaceutical Schedule. 
7. The direct cost to health service users. 
8. The Government's priorities for health funding, as set out 
in any objectives notified by the Crown to PHARMAC, in 
PHARMAC's Funding Agreement, or elsewhere. 
9. Any other criteria that PHARMAC thinks are relevant. 
PHARMAC conduct a consultation whenever taking into 
account other criteria. 
PHARMAC has no threshold below which a medicine will be 
considered cost-effective. This is because cost-effectiveness 
is only one of nine criteria. The threshold is also likely to vary 
year on year with changes to the fixed budget. 
The approval of a blue prescription relies on the following 
criteria being met. The Blue Board will consider these points 
for those medicines referred (PPRI, 2008b): 
1. The medicine is used to treat serious diseases or 
risk factors with high probability will lead to or 
aggravate a serious illness, 
2. There is prolonged treatment or risk of prolonged 
treatment, 
3. The medicinal product has a scientifically well-
documented and clinically relevant effect in a 
defined, appropriate patient population, and 
4. The cost of medicine is in a reasonable relation to 
the therapeutic value and the costs associated 
with alternative therapies. 
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The details of the available medicines are 
provided on the NoMA website: (NoMA, 
2011d). 
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Poland 
Portugal 
particularly relevant in 
cases of therapeutic 
innovations that can lead 
to significant changes in 
treatment and thus the use 
of resources. The Board 
should be consulted if the 
drug is claimed to 
represent a major 
therapeutic innovation 
(PPRI, 2oo8b). 
The Consultative council 
makes recommendations 
after considering the HTA 
analysis prepared by 
members of AHTAPol. The 
Ministry of Health makes 
the final recommendation 
(Lipska, 2010). 
The DGAE firstly makes the 
maximum pricing decision. 
The INFARMED board 
makes the final 
reimbursement 
recommendation 
2008a). 
(PPRI, 
The Consultative Council consists of 
12 members that are appointed by 
the Minister of Health for a period 
of 6 years. The members include 
Presidents of Medical Schools, the 
Supreme Medical Chamber, the 
Chief of the Pharmaceutical 
Council, the Supreme Council of 
Nurses and Midwives and the 
National Health Fund. The Council 
votes on the recommendations for 
new medicines. 
The AHTAPol consults National 
Organisations in the medical 
speCialism and the National Health 
Fund for any financial concerns. 
The two groups have 30 days to 
issues their opinions for 
consideration by the Consultative 
Council (AHTAPol, 2011b). 
The IN FARMED has an executive 
board that contains five members 
that are appointed by the Ministry 
of Health. External pharmacologists 
and economists are involved in the 
assessment but no other 
stakeholders are involved in the 
appraisal (INFARMED, 2011a). 
The Consultative Council takes into account the following 
factors: (Niewada et aI., 2011): 
1. Clinical effectiveness/efficacy 
2. Safety 
3. Cost-effectiveness 
4. Impact on health system (budget impact) 
5. Wider social and ethical aspects 
The appraisal of medicines for inclusion in the list of 
medicines reimbursed by the NHS is based upon scientifiC 
evidence demonstrating the efficacy and effectiveness of the 
medicine within the indication. A medicine maybe listed if it 
meets one of the following criteria (PPRI, 2008a): 
1. The medicine is a new substance or has an 
innovative mechanism of pharmacological action 
with greater efficacy or tolerance than the 
alternative listed treatment 
Appendices 
The appraisals are provided on the 
website (AHTAPol, 2011c). 
The listing recommendations are 
provided on the INFARMED webSite 
alongside the evaluation reports 
(INFARMED,2011b). 
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Spain 
Sweden 
The Ministry of Health is 
involved in the 
reimbursement decision 
and the Inter-ministerial 
Commission for 
Pharmaceutical Prices is 
involved in the pricing of 
medicines (Vogler, 2009) 
The Pharmaceuticals 
Benefit Board is 
responsible for making 
The Ministry of Health, Minister of 
Health and members of the Spanish 
Agency for Medicines and Health 
Products (Vogler et al., 2009). The 
composition skills could not be 
identified from the documentation 
and website. 
There are ten board members and 
chairman who is apPOinted by the 
government to serve on the expert 
2. The new medicine is of similar composition to the 
other reimbursed medicines with a price 5% lower 
than the non-reimbursed generics 
3. The new pharmaceutical form has a greater 
therapeutic benefit or cost-benefit ratio than 
those medicines that are already reimbursed 
4. The new medicine is not a therapeutic innovation 
but has an economic benefit with the same 
therapeutic benefit as those medicines already 
reimbursed 
5. A combination of medicines that are already 
reimbursed and demonstrate a therapeutic 
advantage but price does not exceed the sum of 
those already reimbursed. 
6. Combination of active substances that are not 
individually provided on the market but 
demonstrate an advantage over medicines in the 
same therapeutic group using RCT evidence. 
The following criteria are used when the Ministry of Health 
considers a medicine for reimbursement: 
1. The severity, duration and sequence of different 
pathologies for which the medicine is indicated 
2. The specific necessities of certain patient groups 
3. The therapeutic and social usefulness of the 
pharmaceutical 
4. The budget impact of the medicine and price of 
medicine 
5. The existence of alternative medicines to treat the 
disease 
6. The degree of innovation of the medicine 
A report is prepared by the Spanish Agency for Medicines 
and Health product, which summarises the clinical efficacy 
of the medicine (Vogler et aI., 2009). 
Pharmacoeconomic studies have been used by regional HTA 
agenCies but this is not a mandatory requirement for the 
reimbursement and pricing of medicines in Spain. 
There are three criteria that must be fulfilled if a medicine 
should be reimbursed. The criteria are provided in the 
Health and Medical Services Act IS (LFN, 2008): 
The details of the appraisal cannot be 
found on the agency website. A list of 
medicines approved can be found on the 
Ministry of Health website (Ministry of 
Health & Social Affairs, 2011). 
The minutes of the meetings are 
published on the TLV website. If the 
assessment can be made public (no 
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Switzerland 
decisions on the 
reimbursement of 
medicines. The Board may 
consult with expert advice 
from the 18 county 
councils and may require 
expert advice from the 
Swedish Council on 
Technology Assessment in 
Health care (SBU). 
However, SBU has no 
official influence on pricing 
and reimbursement. 
The manufacturer is invited 
to deliberations when they 
are proposing more 
restrictive or to not 
recommend the medicine. 
The manufacturer is sent 
the assessment prior to the 
meeting. The manufacturer 
may decide to verbally 
present the case to the 
Board. The manufacturer 
has 30 minutes to put 
forward the case on the 
assessment. There is no 
requirement for 
attendance at the 
deliberations and details 
maybe submitted by the 
manufacturer in writing 
(lFN, 2008). 
The Federal Drugs 
Commission reviews the 
manufacturer submission 
and makes an adviSOry 
recommendation. The 
Federal Office for Public 
Health (BAG) makes the 
board for two years (each has their 
own deputy appointed) (lfN, 2007) 
In 2010 the number of members on 
the board was reduced to six plus 
the chairperson (with deputies). 
The Director General is also able to 
attend the meeting but cannot 
vote. The Board includes one 
pharmacologist. One health 
economist one patient group 
representative and three members 
of the County councils. The 
Chairman must also be able to 
provide legal advice to the Board 
(nV,2011b). 
The Federal Drug Commission 
advices the FOPH on the 
Pharmaceutical Speciality list (Sl-
list). The FDC consists of 20 
members, four members of the 
faculty of medicine and pharmacy, 
three medical profeSSionals, three 
1. The Human Value Principle: Underlies the respect 
for equality of all human beings and the integrity 
of every individual. The nv may not discriminate 
against people because of sex, race, age etc. when 
making a decision for reimbursement. 
2. The need and solidarity principle: Those in greatest 
need take precedence when considering 
reimbursement of pharmaceuticals. Individuals 
with more severe diseases are prioritised over 
people with less severe conditions. 
3. The cost-effectiveness principle that states that 
the cost of using a medicine should be reasonable 
from a medical, humanitarian and social-economic 
perspective. There is no formal cost-effectiveness 
range. Budget impact is not formally assessed or 
appraised. 
Cost-effectiveness is a crucial principle and is analysed from 
a societal perspective. The Board must ensure that none of 
the three criteria are contravened. The Board primarily 
weights up the need and solidarity principle with the cost-
effectiveness principle. They must be weighed equally 
against each other. The Cost-effectiveness criteria must be 
therefore weighed against the severity of disease. The 
severity of the disease is considered using five categories, 
relevant, initial condition, prevent injury or death without 
treatment with the medicine. 
The framework for reimbursement and pricing sets out the 
following main elements to be considered: 
1. The price of the new applicant medicines in other 
countries - The ex-factory price of a listed medicine cannot 
exceed the average ex-factory price of a set of main 
countries (Germany, Denmark, United Kingdom and the 
Netherlands). 
f 
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commercially sensitive data) this will also 
be provided on the TlV website. The 
details of the not recommended decision 
may not be completely provided because 
the manufacturer requests removal of 
confidential information (nV,2011a). 
There are no summary details of the 
appraisals performed by the Federal 
Drug Commission. A press release is 
provided on the Federal Office of Public 
Health (Federal Office of Public Health, 
2011). 
, 
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United Kingdom 
- England 
final decision for inclusion 
in the list of medicines 
(Paris and Docteur, 2007). 
The manufacturer submits 
and an ERG or assessment 
group reviews the 
submission depending on 
the type of process 
followed The appraisal 
committee is responsible 
for the decisions. The 
Guidance Executive 
(consisting of the NICE 
Executive Directors) signs 
off the guidance and 
implementation for 
publication. The Secretary 
of State appointment 
individuals to the Guidance 
Executive and can provide 
direction to the Guidance 
Executive. The Guidance 
Executive provides final 
approval for the guidance 
and its implementation. 
The Guidance Executive 
can provide clarification on 
procedural issues prior to 
pharmacist, one hospital 
representative, three members 
from the health insurers, two 
people covered by the insurance, 
two pharmaceutical 
representatives, one person from 
the Cantons and one person from 
the medicine regulatory agency, 
Swiss Agency for Therapeutic 
Products (SATP) (Paris and Docteur, 
2007). 
There are four appraisal 
committees and each committee 
will normally consist of 33 voting 
members including the chair. The 
decisions of the committee will 
normally be arrived at by a 
consensus of the members. The 
members vote anonymously and a 
simple majority vote determines 
the decision. Committee members 
are appointed for a 3-year term 
and are drawn for the NHS, patient 
and carer organisations, academia 
(Health economists, statisticians, 
biostatisticians) and the 
pharmaceutical and medical device 
industries (NICE, 20lla). 
2. Relative effectiveness of the medicine - The 
relative effectiveness of the medicine should be classified by 
the Federal Drug Commission on the following levels of 
innovation: 
1. Therapeutic breakthrough 
2. Therapeutic progress 
3. Savings compared to other medicines 
4. No therapeutic progress and no savings 
S. Inappropriate for social insurance 
3. R&D costs - The medicines the either demonstrate 
(1) therapeutic breakthrough or (2) therapeutic progress are 
eligible to gain an "innovation premium". The price may be 
10% to 20% of the existing price of the therapeutic 
comparator (PariS and Docteur, 2007). 
The committee is expected to consider the following under 
the direction of the Secretary of State for Health (Secretary 
of State, 2005): 
1. Broad balance of clinical benefits and costs 
2. Degree of clinical need to patients with conditions 
or diseases under consideration 
3. Any guidance issued by the Secretary of State (End 
of life supplementary guidance 2009) 
4. The potential for long-term benefits to the NHS 
from the innovation. 
Social value judgements are elicited from a separate citizen's 
council. The committee is not able to make 
recommendations on price of technologies to the NHS. 
There are normally two appraisal meetings for each 
technology considered (NICE, 2008): 
1. Appraisal of clinical effectiveness -The committee 
may take into account with discretion to the 
weight of each factor: nature and quality of the 
evidence, uncertainty regarding the evidence 
differential benefits in different groups, the 
patient perspective on risks and benefits. 
2. Appraisal of cost-effectiveness - The strength of 
the supporting clinical effectiveness evidence, 
robustness of the economic model, plausibility of 
the inputs, preferred modelling, range and 
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The full details and documents of the 
appraisals are provided on the website. 
This is date stamped and includes the 
ACD document FAD document and the 
final guidance issued. NICE has detailed 
documentation provided of the entire 
process (NICE, 2011e). 
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United Kingdom 
-Scotland 
approval of the technology 
(NICE, 2008). 
The NOC 
submission 
manufacturer 
receive 
from 
of 
a 
the 
the 
relevant evidence and in 
contrast to NICE in 
England, do not 
commission a third party to 
provide a separate review 
of the clinical evidence and 
economic evidence (in the 
The SMC process includes two 
committees. The NDC includes 
clinicians and pharmacists 
nominated by the AOTCs a health 
economist, a statistician and two 
industry representatives. The SMC 
includes a wider representation 
including a Chief Executive, Finance 
Directors, patient and public 
representation, Association of 
plausibility of ICER's and the likelihood of decision 
error and consequences. 
The appropriate threshold to be considered by the appraisal 
committee is the opportunity cost of the programmes 
displaced by new more costly technologies. The committee 
uses an explicit threshold range: 
- Below a most plausible ICER of £20,000, the committee 
decision to recommend will normally be based on the cost-
effectiveness and the estimate and the acceptability of the 
medicine as an effective use of resources. When not 
recommended the committee will make reference to the 
robustness (inputs into the model) and certainty around the 
estimated ICER. This maybe demonstrated by sensitivity 
analysis. 
- Above a most plaUSible ICER of £20,000, judgements will 
take into account the following factors (These factors will be 
more explicitly referenced as the ICER increases within this 
range): 
1. The degree of certainty around the leER. In particular a 
committee will be more cautious to recommend when ICERs 
are uncertain. 
2. The assessment of changes in HRQL has been 
inadequately captured and may misrepresent the utility 
gained. 
3. The innovative nature of the technology, if it adds to the 
demonstrable and distinctive benefits that may not have 
been captured in the QALY measure. 
- Above a most plausible ICER of £30,000 the committee will 
need to Identify an Increasingly stronger case for supporting 
the technology as an effective use of NHS resources. 
Clinical effectiveness: The NDC reports a qualitative 
description of the efficacy and relative-effectiveness 
considerations. This has been informed by six questions 
asked to a number of independent experts on the following 
(SMC, 2011a): 
1. Are there guidelines, available or in preparation, which do 
(or could) influence Scottish prescribing in this area? 
2. Do you wish to highlight any areas of unmet need in 
relation to the relevant condition(s)? 
3. What are the current treatment options? In particular, 
Appendices 
The recommendations and the appraisal 
considerations can be found on the SMC 
website (SMC, 2011h). 
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case of SMC). The 
recommendation is advice 
and the final 
reimbursement decision is 
made by the Health 
Boards. 
British Pharmaceutical Industry 
(ABPI), together with the clinical 
and public health members. There 
is no third party synthesis of 
evidence and/or provIsion of 
economic evaluation (SMC, 2011d). 
what is the predominant treatment in Scotland? 
4. What is your preferred treatment (if different to 
predominant treatment)? Please explain? 
5. Disease prevalence: Please estimate how many patients 
currently receive treatment in your catchment area and/or 
in Scotland? (Please state population numbers if you have 
given an estimate for your catchment area.) 
6. If you have knowledge of this particular new product for 
this indication, please describe how it might fit into your 
treatment plan. 
Cost-effectiveness: The fitness for purpose of the economic 
evidence and the interpretation of the estimate of cost-
effectiveness in the context of the medicine's use in practice 
is considered. The economic evaluation is one criterion 
considered in the draft advice by the NOC to the SMC with 
respect to the threshold reported by NICE but other criteria 
are considered in the context of each decision such as the 
absence of alternatives, bridging to other therapies, 
emergence of other therapies and special issues that are 
specific to the medicine. The manufacturer may submit a 
Patient Access Scheme (PAS) to an independent group called 
the Patient Access Scheme Assessment Group (PASAG) to 
improve the cost-effectiveness of a medicine by reducing 
the cost of the new medicine and allowing patient access to 
clinica"yeffective medicines. 
Factors considered in the presence of a high cost per QALY 
(SMC, 2011c): 
1. More uncertainty in the economic analysis for 
Orphan drugs may be acceptable. 
2. Substantial improvement in life expectancy 
evidence (with sufficient quality of life to make the 
extra survival desirable). Substantial improvement 
in life expectancy would normally be a median 
gain of 3 months but the SMC assesses the 
particular clinical context in reaching its decision; 
3. A substantial improvement in quality of life (with 
or without survival benefit); 
381 
382 Appendices 
4. Evidence that a sub-group of patients may derive 
specific or extra benefit and that the medicine in 
question can, in practice, be targeted at this sub-
group; 
S. Absence of other therapeutic options of proven 
benefit for the disease in question and provided by 
the NHS; 
6. Possible bridging to another definitive therapy 
(e.g. bone marrow transplantation or curative 
surgery) in a defined proportion of patients; 
7. Emergence of a licensed alternative to an 
unlicensed therapy which is established in clinical 
practice in NHS Scotland as the only therapeutic 
option for a specific indication. 
8. SMC also looks at any other special issues which 
may have been highlighted by the manufacturer of 
the medicine, by clinical experts and/or by Patient 
Interest Groups. These special issues are usually 
very specific to the drug or disease under 
consideration and are thus not readily categorised. 
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Table A4.16: Technology assessment level: Outputs and Implementation of decision 
country 
Australia 
Austria 
Decision outcomes 
Positive list: 
List (unrestricted benefit): The medicine 
has no restriction on the therapeutic 
use 
List (restricted benefit): can only be 
prescribed for certain therapeutic uses 
List (authority required): Two 
categories; 1. Restricted benefit that 
requires approval from Medicare 
Australia or OVA; 2. Restricted benefit 
that does no require Medicare/OVA but 
requires recording of streamlined 
authority required code. 
Do not list: not recommended 
Defer listing: The listing can be deferred 
pending the provision of certain 
information on the medicine (PBAC, 
2008). 
Positive list: 
The Reimbursement Code (EKO) is 
categorised as a traffic light system 
(positive /ist). There is also a negative 
list for those not included for general 
reimbursement. The traffic light system 
is as follows (PPRI, 2007a): 
Red Box: 
Newly launched medicines that 
have applied for inclusion in the 
yellow or green box 
Medicines remain in the box for a 
period of 24-36 months 
Awaiting established price of EU 
countries and time taken depends 
on whether an EU price can be 
Status of decision 
The recommendation is advisory to the 
Minister of Health and Ageing. The 
Government cannot /ist a medicine on 
the PBS without a PBAC 
recommendation to do so. A PBAC 
decision not to recommend listing or 
not to recommend changing a listing 
does not represent a final PBAC view 
about the merits of the medicine and is 
subject to review whenever a new 
submission is lodged. If the listing is 
expected to add more than $AUSIO 
million the cabinet must provide 
approval (PBAC, 2008). 
The HEK provides an advisory 
recommendation. The Federation or 
Austrian SoCial Security Institutions 
(HVB) makes the final decision for 
inclusion on the Reimbursement Code 
(Austrian Federation of Social Insurance 
Institutions, 2004). 
Opportunity to appeal/dissent 
Manufacturers may resubmit to PBAC 
to reconsider matters from relevant 
previous submissions. Even if such a 
submission is based entirely on new 
data, modifies the previously requested 
restriction or changes the comparator, 
it will be regarded as a resubmission. 
This is because the information in the 
resubmission will have to provide the 
basis for any change to PBACs earlier 
decision (PBAC, 2008). 
The HVB will justify rejection decisions. 
The manufacturer can appeal to the 
Independent Drug Commission (UHK) 
on initial listing and if the Federation 
decides to de list the medicine. The UHK 
can veto decisions cannot amend 
decisions by the HVB. The manufacturer 
can present on the baSis of a negative 
decision. The UHK comprises 8 expert 
members each with their own deputies 
and is accountable to the BFGMJ. The 
sessions of the UHK are open to the 
public and meetings are scheduled 
monthly (PPRI, 2007a). 
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Requirements for re-appraisal of 
medicines 
The manufacturer may re-submit when 
new evidence or information becomes 
available. In the circumstances where 
no new evidence is available and the 
manufacturer submits an independent 
review is undertaken. The manufacturer 
must identify the main issue. A single 
independent reviewer, whose findings 
are submitted to the PBAC for 
consideration, generally reviews this. 
The PBAC will then amend if necessary 
the recommendation accordingly 
(PBAC, 2008). 
Amendments to the reimbursement 
code may be made with respect to the 
deletion from the code (de-listing) 
inclUSion in another area of the 
reimbursement code, change to the 
usage, or changes to the package size. 
The Federation will initiate this 
procedure either on request from the 
manufacturer or by itself. The 
Federation may decide to reassess if it 
believes the medicine to no longer 
meet the requirements of the medico-
therapeutic or health economic criteria. 
The Federation (HVB) gives the 
manufacturer 30 days to present the 
case when they have requested a 
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Belgium 
established 
Advice taken from the HEK board 
The Head Physician must approve 
the medicine for the doctor 
prescribing to the patient 
Yellow Box: 
Medicine considered an important 
therapeutic innovation 
Medicine is only reimbursed for a 
specific disease or age group, 
specialist doctor or limited 
quantities 
The Head Physician must approve 
the prescription 
light Yellow Box: 
Pharmaceuticals maybe freely 
prescribed by doctors of the 
Sickness fund. A schedule of the 
reasons for prescription should be 
kept for the lead physician 
Green Box: 
Medicines considered medically 
and health economically robust 
In general no conditions but 
maybe conditions in some 
circumstances (patient group, age 
etc.). 
A flat rate per prescription is paid for all 
medicines on the general 
reimbursement list. 
Negative list includes medicines that 
are unsuitable for outpatient care. 
Three classes of medicines (Adriaens 
and Soete, 2010): 
Class 1: added therapeutic value 
Class 2: comparable value 
The Minister of Health may make the 
following decisions within 30 days of 
receiving the CRM recommendation 
(Gerkens and Merkur, 2010): 
The decisions can be appealed at the 
relevant court on grounds that 
procedure was not correctly followed 
(KCE, 2010). 
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change to the Reimbursement Code. 
The manufacturer maybe requested to 
present a case to demonstrate that the 
medicine still meets these criteria. The 
HVB decides on the changes to the 
listing and justifies the decision. The 
manufacturer can appeal changes to 
the Reimbursement Code to the UHK 
(PPRI, 2007a). 
There are two reasons for reappraisal to 
occur across the medicine classes that 
the initial appraisal was based on a 
number of hypothetical factors and new 
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Canada 
Denmark 
Class 3: generics 
Positive list (Package list by chapter) for 
inclusion: 
Unrestricted reimbursement in line 
with the 5PC (chapter I) 
Restricted reimbursement: Chapters II -
reimbursement for all common 
indications and prescribers keeps this 
1. Positive decision for inclusion on the 
list of pharmaceuticals 
2.Negative decision. 
on file and Chapter IV - reimbursement 
subject to particular reimbursement I - -
conditions and requires prior approval 
by health insurance. 
Do not list. 
The recommendations also include 5 
categories of coverage with regards to 
cost-sharing (A(100%), 8(85%, max 
EU7.20), C(50%, max EU8.90), Cs(40%), 
Cx(20%)). 
The listing procedure is described in the 
procedure for common drug review 
(CADTH,2010): 
List: in line with licensed indication 
List with criteria: to a speCific patient 
population 
Do not list 
Defer: pending clarification of 
information. 
The drug plans make final benefit listing 
and coverage decisions based on the 
CADTH recommendations and other 
factors, such as drug plan mandates, 
jurisdictional priorities, and financial 
resources (CADTH, 2010). 
The manufacturer may request for 
reconsideration (CADTH, 2010). The 
request must comprise the reasons and 
grounds for the request, the relief 
sought and the supporting evidence. 
This cannot be made just because the 
manufacturer disagrees with the 
recommendation. The acceptable 
grounds are: the CDR/CEDAC failed to 
operate under the stated procedures, 
the CEDAC recommendation is not 
supported by the evidence in the 
reviewer's reports. The CEDAC 
reconsideration will result in a final 
recommendation. 
A drug plan can also request 
clarification of a recommendation 10 
working days following notification of 
the recommendation. 
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evidence was required to reduce the 
uncertainty and budgetary concerns. 
Those medicines that are categorised as 
class 1 follow a mandatory reappraisal 
between 18 and 36 months. The re-
assessment report is submitted along 
with any new evidence and real life 
cost-effectiveness evidence. The CRM 
decision may be modified and this can 
even result in the de-listing of the 
medicine. The Minister may also decide 
when there are budgetary concerns to 
provide a multiple medicine appraisal of 
those medicines covering similar 
indications (KCE, 2010). 
The manufacturer may re-submit with a 
reduced price during the embargo 
period and may provide a resubmission 
when new clinical evidence becomes 
available (CADTH, 2010). 
Details of general reimbursement are I The recommendations by the I A final decision provided by the Danish I The reimbursement status of medicines 
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Finland 
provided on the website (DMA, 2011a): 
Positive list: 
When a medicine has general 
reimbursement it means that all citizens 
receive reimbursement from the Danish 
regions. 
General reimbursement 
General reimbursement with conditions 
(To obtain reimbursement, it may be a 
condition that the medicine is 
prescribed to certain patient groups or 
for the treatment of specific diseases. 
Not eligible for general reimbursement 
Individual reimbursement 
There is a reimbursement co-payment 
rate depending on the previous 12 
months expenditure on medicines. 
There are three categories of 
reimbursement which have different 
levels of co-payment (Ministry of Social 
Affairs and Health, 2005). Basic: 58% 
copayment, Special (low): 28% 
co payment and Special (High): 0% 
co payment. The lower special category 
includes 10 diseases that are 
categorised as chronic illnesses. The 
high special category includes 26 
illnesses for severe diseases (PPB, 
2011). 
Basic reimbursement 
Basic restricted reimbursement 
Special (low) reimbursement 
Special (low) restricted reimbursement 
Special (high) reimbursement 
SpeCial (high) restricted reimbursement 
reimbursement committee are advisory 
and the final decision is made by the 
Danish Medicines Agency (Danish 
Medicines Agency, 2008). 
The recommendations by the experts 
are advisory and the PPB makes the 
final decision, which is implemented 
through the Social Insurance Institution, 
KELA. There is a positive list provided 
rather than those not recommended 
(Kivioja, 2008). 
Medicines Agency may be appealed to 
the Danish Ministry of Interior and 
Health. The Ministry cannot reassess 
the medicine agency scientific estimate 
(Danish Medicines Agency, 2008). 
If there are no appeals the decision of 
the PPB is final. Stakeholders unhappy 
with the decision of the PPB may appeal 
to the Supreme Administrative Court in 
Finland (Kivioja, 2008). 
Appendices 
is reassessed regularly because it is 
acknowledged that the status of a 
general reimbursement medicine may 
change over time. The reappraisal 
ensures that those medicines on the 
general reimbursement list are still 
meeting the criteria and those not do 
not satisfy the criteria. The reappraisal 
process was introduced in 2004. There 
is set prioritisation criteria to decide 
which medicines should be reassessed 
and this includes: significance of the 
medicines to primary sector, public 
health aspects, new evidence based 
recommendations and high costs or 
high consumption. The reimbursement 
committee then makes the 
recommendation to the Danish 
Medicines agency and details of the 
assessment are provided on the 
webSite (Danish Medicines Agency, 
2008). 
The decisions of the PPB are provided 
for a fixed term period (maximum of 5 
years and 3 years for a new active 
substance). A renewed confirmation is 
required when this period lapses and 
this should document any changes that 
have occurred during the 
reimbursement period with respect to 
experience of use, new clinical studies 
and treatment practices. 
A manufacturer may also propose an 
increase in the wholesale price but this 
must be accompanied by a grounded 
proposal to inform the proposed price 
changes (Ministry of Social Affairs and 
Health, 2005). 
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France 
Germany 
Hungary 
Positive list: 
HAS opinions are either positive or 
negative (conditions may also be 
imposed for additional studies or a 
target patient population) and are 
produced for the CEPS of the Ministry 
of Health where decisions are made on 
the price for outpatient medicines and 
hospital medicines that are not covered 
within the DRG (Meyer, 2011). 
The early benefits assessment details 
whether a medicine can be added to a 
reference price group (Federal Joint 
Committee, 2011b). The early benefit 
assessment will result in an assessment 
of added therapeutic value. This means 
that G-BA will not reject medicines 
outright because of the negotiations 
that occur with the price of the 
medicine. Prescribing restrictions can 
be set by the FJC. The G-BA can exclude 
items from reimbursement (negative 
list) if it does not show any 
improvement in benefit. 
Hungary operates both a positive and 
negative list for pharmaceuticals (PPRI, 
2007b). 
Recommended 
The recommended for subsidy category 
The CEPS of the Ministry of Health 
provides the final reimbursement 
decision. The recommendations of HAS 
are advisory (Meyer, 2011). 
Once a decision has been made on the 
therapeutic benefit the statutory health 
insurance funds and the speCific 
pharmaceutical company then 
negotiates the reimbursement price for 
pharmaceuticals that have proven 
additional benefit as a discount on the 
original selling price within six months. 
If negotiations do not achieve an 
agreement, an arbitration commission 
does not reach agreement then IQWIG 
will be commissioned to perform a Cost 
benefit analysis (leverkus, 2011). 
The Technology Appraisal Committee 
makes a recommendation and final 
recommendations are made in the 
National Health Insurance Fund's 
Pharmaceutical Division. These are 
The manufacturer has a period of eight 
days from receipt of the notice of the 
advice to request a hearing. At the end 
of the 8 days in the absence of 
comments the opinion becomes final. 
The manufacturer has 15 minutes to 
present its cases and reasons for the 
hearing should be submitted. The 
recommendation may then be 
amended and a final notice sent to the 
Ministry of Health and stakeholders 
(Rochaix and Xerri, 2009). 
Following the publication of the benefit 
assessment on the website of the 
Federal Joint Committee, medical and 
pharmaceutical experts, pharmaceutical 
companies and their associated 
organisations, the relevant 
pharmaceutical manufacturer, the 
professional representatives of the 
pharmacists and the 
relevant umbrella organisations of 
doctors' associations for special 
therapies at the federal level are 
consulted and given the opportunity to 
respond in writing to the benefit 
assessment of the pharmaceutical, 
using the templates on the website. The 
manufacturer can also provide verbal 
participation at the hearing for the 
deciSion (Federal Joint Committee, 
2011b). There is an arbitration stage if a 
price cannot be negotiated between 
the two parties (leverkus, 2011). 
The manufacturer has the right to 
appeal if the decision made by the 
NIHFA is to not recommend the 
medicine. The appeal Committee 
consists of a member from the Ministry 
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HAS can self-refer medicines in the 
presence of new evidence, reviews all 
medicines at 5 years post-listing and 
assess the evidence from any post-
listing studies. The recommendations 
at the 5-year review may result in the 
SMR being revised and an opinion for 
de-listing the medicine. Manufacturers 
may submit new evidence for medicines 
at any point in a new dossier and the 
Transparency committee will provide 
reassessment of the medicine (Rochaix 
and Xerri, 2009). 
After one year of the final G-BA 
decision, the manufacturer can request 
a new benefit assessment if there is 
new scientific knowledge. It is also 
possible that the G-BA decides that 
there is new SCientific evidence that 
makes it necessary to perform a new 
assessment (Federal Joint Committee, 
2011e). 
The manufacturer may resubmit for a 
price change through the regular 
procedure (PPRI, 2007b). 
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Ireland 
Israel 
involves a copayment by patients 
dependent on the disease severity. 
Not recommended 
Those products that cannot 
demonstrate cost-effectiveness or it is 
deemed not proven will not be 
recommended. 
Performance linked reimbursement 
schemes operate alongside price 
volume agreements (Dank6, 2010). 
There are three recommendation 
outcomes used by the NCPE (Tilson et 
aI., 2010): 
1. Recommended in line with marketing 
authorisation 
2. Recommended with restriction 
3. Not recommended 
Positive list (National List of Health 
Services) (Greenberg et al., 2009): 
There are three groups for which 
medicines maybe categorised for 
potential listing: 
Group A: consists of high priority 
technologies 
Group B: consists of intermediate 
priority technologies 
Group C: consists of low priority 
technologies. 
PNAC makes the final decision on 
whether the medicine is included in the 
annual list of new technologies. The 
yearly updating of the list is a unique 
aspect of this reimbursement system. 
then disseminated in the form of 
legislation by the Minister of health in 
agreement with the Minister of finance 
(PPRI,2007b). 
The recommendation by the NCPE is 
advisory and is sent to the HSE CPU unit 
which makes the final decision for the 
Community Drug Scheme (Tilson et al., 
2010). 
The Medical Technologies Forum lists 
are advisory but generally the PNAC 
only adds to the list those score A10 or 
A9. The Ministry of Health makes the 
final approval of the list produced for 
the additions for the year. All HMO's 
are required by law to provide those 
technologies that are added to the list 
(Greenberg et aI., 2009). 
of Health, one Minister of Finance, one 
member form the Ministry of Economy 
and Transport, a member of the 
National Institute of Pharmacy, 
President of the Health Insurance 
Supervisory body and the Director of 
the NIHFA. The decision will be made 
within 60 days of the appeal. The 
decision will be made by the appeal 
panel within 60 days of receiving the 
appeal (PPRI, 2007b). 
The reimbursement decision will be 
usually made within 90 days of receipt 
of the manufacturer submission. If 
reimbursement has been refused an 
appeal can be lodged with an expert 
committee (NCPE, 2011c). The expert 
committee will arranged by the Health 
Service Executive and the Irish 
Pharmaceutical Health care Association 
(IHPA). The expert committee will take 
the views of different stakeholders and 
a final decision provided within a 
further 90 days (Tilson et al., 2010). 
The stakeholders in the process are not 
allowed to appeal decisions made by 
PNAC on additions to the list of 
technologies. There is no process to 
resolve any disputes that stakeholders 
have with regards the decision or 
adherence to the specified procedure 
(Greenberg et aI., 2009). 
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If a new medicine is refused after 
appeal and the manufacturer finds new 
evidence, the manufacturer may 
provide a new submission for the 
pharmacoeconomics to the NCPE 
(Tilson et al., 2010). 
The manufacturer must resubmit to the 
next cycle (next year) when new 
evidence appears so that the medicine 
can then be considered for adding to 
the list. The technologies already on the 
list have never been delisted and 
therefore obsolete or 
treatments do not get 
(Greenberg et aI., 2009). 
ineffective 
removed 
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Italy 
Korea 
Mexico 
A positive list exists in Italy (Folino-Gallo 
et aI., 2008): The medicines maybe 
included in the National Pharmaceutical 
Formulary (PFN), a positive list. 
Special limitations can be applied by the 
AFIA committee called AFIA Notes. 
These are restrictions based on the 
patient population or characteristics of 
the disease. These are grouped as Class 
A medicines (essential medicines and 
medicines for serious and chronic 
diseases): 
1. Inclusion on the list 
2. Inclusion on the list with AIFA 
Notes. 
Class C: Diseases of slight importance. 
Theses medicines are not reimbursed 
by the NHS. 
Class H: Drugs that an! provided only by 
hospitals. 
There is Positive List System (PLS) in 
operation in South Korea (Kyung lee, 
2011, Moo lee, 2011): 
1. Reimbursed 
2. Not reimbursed 
HIRA classifies medicines as 
1. List 
2. Not Reimbursed 
Decisions may be based upon Coverage 
with evidence development but this is 
limited by the number of resources 
available (Moo lee, 2011). 
There are two positive lists is provided 
of recommendations for medicines 
called the Basic Formulary (Cuadro 
Basico) and the catalogue of Inputs 
(catcilogo de Insumos). The Basic 
The national decision is provided to the 
regions. Regions have to provide Class A 
medicines but may decide a different 
level of co-payment. In 2010 a new 
regulation was introduced for the 
mandatory listing of some medicines on 
regional hospital formularies to reduce 
variation In regions provision of 
innovative medicines. This was to 
promote equal access to these 
medicines regardless of the regional 
location of the patient (Gori et aI., 
2010). 
The reimbursement assessment is made 
by HIRA, price negotiations are 
undertaken by NHIC and the Ministry of 
Health makes final reimbursement 
listing decisions (Jang, 2010). 
The final listing decision made is 
published in the Official Journal of the 
Federation. The public institutions must 
observe the recommendations made in 
the basic table (Moise and Docteur, 
The regions can appeal against the 
compulsory listing of innovative 
medicines on the grounds that the 
criteria have not been followed. It is not 
clear whether manufacturers can 
submit an appeal in the process (AIFA, 
2010). Removal of the marketing 
authorisation can be appealed to the 
Regional Administrative tribunal. 
The manufacturer can request a re-
evaluation by the HIRA. The final 
reimbursement listing decision 
provided by the Ministry of Health can 
be appealed to the courts (Kim & 
Chang, 2011). There is no judicial 
system/law to enable an appeal of the 
intermediary recommendations of the 
DREC. 
The draft update of the table of Basic 
Inputs for mediCines is placed on the 
General Health Councils website and 
stakeholders may comment on this 
within 10 working days of the draft 
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The agreement between the 
manufacturer and the AIFA is for two 
years. On expiration of the term, each 
party can request a renegotiation. The 
manufacturer can apply for a variation 
in reimbursement category if new 
evidence is found following the initial 
assessment and also renegotiate for a 
change in the price. 
Conditional reimbursement was first 
introduced in 2006 either by a payment 
for performance or risk sharing. Data is 
collected in drug monitoring registries 
to monitor outcomes and provide 
payment on this basis (Jommi, 2009). 
The manufacturer can request a re-
evaluation of the medicine. Existing 
medicines are reviewed overtime to 
ensure that they meet the criteria for 
the PLS. The medicines are reassessed 
by therapeutic class and this is based on 
the growth in use of the medicines and 
the budget impact of the medicines. 
Those medicines that are not 
considered cost-effective are delisted 
(Bae and lee, 2009). 
The basic inputs list is regularly 
reviewed to modify for inclusion and 
exclusion of medicines. A medicine 
maybe de-listed for a number of 
reasons 1.) It is not longer prescribed; 
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Netherlands 
Formulary is designed for medical care I 2007). 
at the primary level and the Catalogue 
of Inputs is for medical care at the 
secondary and tertiary level. These 
provide the basis for the institution 
specific formularies (Moise and 
Docteur, 2007). 
There are two separate lists for 
outpatient medicines and hospital use 
medicines. Outpatient medicines fall 
under the Drug reimbursement System 
(GVS). The medicines are classified 
under: 
1A: Therapeutic equivalent value 
(equivalent price) 
1B: Therapeutic added value (fully 
reimbursed) 
2: Condition reimbursement 
(restrictions apply. The restrictions may 
be as follows: 
1. A particular condition 
2. Within a specific age group 
3. Delivery by specialist doctor 
or pharmacist 
4. Special permission is required. 
Those medicines for hospital use are 
categorised as normal medicines or 
expensive medicines. Expensive 
Medicines are temporarily admitted to 
the Expensive Drug list. This was 
introduced in 2006. Coverage with 
Evidence Development collects real life 
The CFH committee provides advice to 
the Board that will also consider the 
social consequences of the deciSion. 
The final advice of the Health Board 
(CVZ) is sent to the Minister of Health 
who makes the final decision (van 
Halteren, 2011). 
decision. The Commission will respond 
to the comments and inform of the 
technical justifICation for the comment 
received (Moise and Docteur, 2007). 
If a decision is unfavourable, the 
manufacturer cannot submit a new 
manufacturer submission until 4 
months after the previous decision. The 
manufacturer may then resubmit. 
A formal separate appeal process could 
not be identified from the 
documentation. 
If it is considered that there are possible 
procedural deficiencies in the conduct 
of the assessment the advice can be 
reconsidered. A consultation can be put 
in place where the interested parties 
are given the opportunity to comment. 
The Chairman of the council may also 
conSider a hearing appropriate. The 
intention of the hearing is not to discuss 
the medicines therapeutic value, or 
cost-effectiveness values (CVZ and 
Ministry of Health Welfare and Sport, 
2010). 
Any concerned party can appeal to the 
Administrative court with respect to the 
recommendation of the CVZ or the 
Minister on procedural grounds [Art 
116 of Health Insurance Act) (Overheid, 
2011). 
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2.) Medicine will not be used; 3) 
Awareness of another product of 
greater efficacy or lower toxicity (Moise 
and Docteur, 2007). 
The manufacturer may request a review 
of the deCision by writing to the 
Minister. The facts and new data should 
be provided. Only evidence after the 
previous decision can be considered. 
The manufacturer may also request a 
review if there are changes to the 
treatment guidelines within the 
indication. The request for re-
assessment cannot be any earlier than 6 
months after the Ministers previous 
decision (CVZ and Ministry of Health 
Welfare and Sport, 2010). 
Those medicines on the Expensive 
inpatient Medicines are assessed for 
real-life cost-effectiveness four years 
after the decision (van Halteren, 2011). 
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New Zealand 
Norway 
data so that real-life cost-effectiveness 
can be assessed at four years (van 
Halteren, 2011). 
Positive list (Pharmaceutical Schedule) 
(PHARMAC,2011a): 
1. Listing for medicines 
(community and hospital 
medicines subject to national 
contract. 
2. Listing of medicines with 
restrictions (conditions on 
prescribing and special 
authority required). 
There is cost-sharing for some 
medicines provided in the community. 
The listing schedule is provided on the 
PHARMAC website (PHARMAC, 2011c). 
Positive list (PPRI, 2008b): 
The listing decision for blue prescription 
may be as follows: 
List for indication of the marketing 
authorisation 
List with limited reimbursement - This 
includes limiting for certain parts of the 
indication or a particular patient group. 
The decision provided by the PTAC is 
advisory and the decision provided by 
the Executive Board of the PHARMAC 
provides a decision on listing which is 
mandatory (PTAC, 2010). 
The reimbursement decision for 
inclusion in the list can be made by 
NoMA for inclusion as long as the 
budget impact does not exceed 5 
million. The Minister of Health and 
Parliament must make a decision for 
the approval of medicines under law 
that exceed this value for inclusion by 
the National Insurance Administration 
(PPRI,2008b). 
The courts of New Zealand can review 
PHARMAC decisions where it has been 
alleged that PHARMAC has breached its 
public law obligations (PHARMAC, 
2006). 
Interested parties may appeal against 
decisions made by the NoMA and this 
will be forwarded to the Ministry of 
Health within 60 days of receiving the 
appeal. This can be extended by 30 days 
if the NoMA considers it necessary to 
consult with the Blue prescription 
committee. The Ministry of Health will 
make a deciSion on the appeal within 30 
days of receiving this from NoMA. This 
procedural timeframe maybe 
suspended if new information is 
requested from the complainant 
(Lovdata, 2009). 
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A manufacturer may provide a 
reapplication (resubmission) to the 
PHARMAC for the following reasons: 
1. New information/data 
becomes available (clinical 
trial or cost-utility analysis). 
2. The manufacturer wishes to 
respond to issues that were 
raised by the PTAC with 
regards to the original 
application. 
The PHARMAC can make decisions to 
delist medicine on the Pharmaceutical 
Schedule (PHARMAC, 2010). 
All medicines that are included in the 
list must meet the criteria which 
includes a) a mediCine which is used to 
treat a serious disease or risk factor, b) 
the disease or risk of disease requires 
prolonged treatment, c) the medicine 
has scientifically well documented 
evidence of the clinically relevant 
effect, d) the cost of the medicine is 
reasonable in terms of the therapeutic 
value. The NoMA may reconsider 
whether the requirements are met for 
individual mediCines in the list. The 
NOMA may include new conditions for 
these to be met or may delist the 
medicine because it can no longer meet 
the criteria. The manufacturer has the 
opportunity to submit documentation 
to demonstrate that the medicine still 
meets the criteria. The removal of a 
medicine from the list is justified and 
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Poland 
Portugal 
There are a number of 
recommendations provided by the 
President of AHTAPol (Matusewicz and 
lipska, 2009): 
1.' Finance 
2. Finance temporarily, provided 
that data are gathered for a 
final decision (coverage with 
evidence development) 
3. Finance provided if particular 
criteria are met in the 
particular condition 
4. Finance provided a cost-
effective way of financing was 
assessed following 
negotiations on price 
5. Not to Finance 
6. Increase Financing 
7. Decrease Financing 
8. Do not change Financing 
Positive list: 
There is a positive reimbursement list 
called the Prontuario list used in the 
outpatient setting. The positive list is 
updated on a monthly basis on the 
INFARMED website. (Vogler and 
leopold, 2009): 
1. list 
2. list with restriction for certain 
therapeutic indications which 
are set out in the order of 
reimbursement 
Medicines are categories under four 
types, which determine the level of co-
payment (Vogler, 2009): 
1. Category A: Includes life 
The recommendation provided by the 
President of AHTAPol is advisory. The 
Ministry of Health for inclusion in the 
formulary makes the final decision 
(lipska, 2010). 
The recommendations provided by the 
IN FARMED are advisory and the 
Minister of Health makes the final 
decision (PPRI, 2008a). 
No formal appeal process was identified 
from the website or literature. 
If the INFARMED committee decides 
not to list the medicine the 
manufacturer is informed of the 
decision and given the opportunity to 
present additional data. If the 
manufacturer has concerns with the 
final negative recommendation they 
can appeal to the Supreme 
Administrative Court in Portugal (PPRI, 
2008a). 
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documentation included on the agency 
website (Ministry of Health and Care 
Services, 2004, lovdata, 2009). 
The Ministry of Health provides the 
reimbursement decision for two years 
and may remove the medicine after 2 
years. There is no explicit provision in 
the reimbursement law for the 
procedure on expiry of the deCision. 
The Ministry of Health may commission 
AHTAPol to reassess the medicine or 
may decide to prolong the term of the 
decision provided. There may be new 
legislation very soon on the procedure 
for reassessment of medicines 
(Personal Communication: Gabriela 
Ofierska-Sujkowska Head of 
Recommendation Division AHTAPol). 
INFARMED reappraises medicines at 
three years to ensure that they still 
meet the criteria that are specified 
within the law. 
Price adjustment may take place if it is 
believed that the medicine is of excess 
costs. The manufacturer is notified and 
given the opportunity to adjust the 
price. Those medicines that do not 
meet the criteria can be delisted and 
the reasons are made publically 
available. The decision to exclude 
medicines is based on (PPRI, 2008a): 
1. Excessive cost 
2. Therapeutic efficacy doubtful 
or too expensive 
3. lower comparative 
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Spain 
Sweden 
2. 
3. 
4. 
saving medicines (100%) and 
reimbursed for chronic 
disease indications 
category B: Medicines for 
serious diseases (63%) 
category C: Non-priority 
medicine (31%) 
Category D: New medicines 
whose therapeutic value has 
not yet been determined 
(15%) 
There is both a positive and negative 
reimbursement list in Spain (Vogler et 
aI., 2009). 
There are four reimbursement 
categories: 
1. 100% reimbursement for 
hospital pharmaceuticals 
2. 90% reimbursement for 
pharmaceuticals for the 
management of chronic 
illnesses 
3. 60% reimbursement for the 
majority of prescription only 
pharmaceuticals 
4. 0% for pharmaceuticals on 
the negative list 
The following recommendations maybe 
made under the General Subsidy 
positive list (TlV, 20lld): 
1. Recommended as per license 
2. Restricted recommendation 
limited to area or special 
patient group 
3. Not recommended 
The recommendations may be 
conditioned: 
1. Reimbursement can be 
The reimbursement process is 
administered by the Directorate 
General for Pharmacy and Health 
Products in the Ministry of Health. The 
Ministry of Health makes the final 
listing decision (Vogler et al., 2009). 
The Pharmaceutical Benefits Board 
makes the decisions on reimbursement. 
These decisions are mandatory (lFN, 
2007). 
The Inter-ministerial commission on 
Pharmaceutical prices sets the price of 
the manufacturer medicine. A 
maximum price is set and 
manufacturers receive notification of 
this, which they can appeal if they 
disagree with the maximum price. An 
appeal can be made for the regional 
funding of medicines (Vogler et aI., 
2009). 
The deCisions maybe appealed against 
to the General Administrative Court, 
which is the county Administrative 
Court in the County of Stockholm. In 
the appeal, the manufacturer must 
indicate the reasons for the decision 
being appealed and the proposed 
changes to the decision. The appeal 
must be made within 3 weeks of the 
decision. An Individual private person 
cannot appeal against a decision made 
by the TlV (lFN, 2007). 
4. 
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effectiveness in relation to 
medicine reimbursed in 
comparison to those 
approved in the same 
indication 
Reduced therapeutic efficacy 
Re-assessment may occur after one 
year of the reimbursement and price 
decision. There may have been new 
medicines added to the list, which are 
at a lower price. The Directorate 
General for Pharmacy and Health 
Products may decide to de-list the 
medicine (Noticias Juridicas, 2011, 
Vallejo, 2009). 
The manufacturer may resubmit to the 
process with a different price or new 
evidence but will need to go through 
the entire process again (lFN, 2008). 
TlV will reappraise those medicines 
that have been given conditional 
reimbursement. The manufacturer may 
resubmit for a price change, which is a 
simple procedure for a lower price. A 
manufacturer must demonstrate that 
two criteria are met if it is to propose a 
price increase (lFN, 2008): 
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Switzerland 
limited in time to make it 
possible for new data to be 
provided to the TlV 
2. The company has to specify 
the restrictions set by the nv 
in the marketing of the 
medicine. 
A positive list (Federal Office of Public 
Health, 2011): 
called the Pharmaceutical Specialities 
List (SL-List): 
List recommended 
List recommended with limitations. The 
limitation can refer in particular to the 
quantity or patient medical indications. 
The listing recommendations result in a 
change in the Sllist within 30 days after 
the meeting by the Federal Drugs 
Commission. If the conditions for 
inclusion are not fulfilled the FOPH will 
provide reasons for why this has not 
been listed. The details are published in 
the Bulletin of the Federal Office of 
Public Health (Federal Office of Public 
Health, 2011). 
If the medicine is not judged to meet 
the criteria medicine will not be 
approved for listing. The manufacturer 
can submit a reconSideration request or 
it can appeal to the Federal Appeal 
Commission within 30 days of the 
decision. The manufacturer must 
prepare a letter with the reasons for 
disagreeing with the recommendation 
(Federal Office of PubliC Health, 2011) 
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1. Urgent treatment alternative 
for which the condition risks 
the patients life or future 
health 
2. There is considerable risk of 
the manufacturer removing 
the medicine from the 
Swedish market. 
The TLV may decide to remove the 
medicine as either part of the 
reimbursement review (2002) by 
therapeutic group or by the ad hoc 
consideration of individual medicines. 
The manufacturer is contacted with 
regards to individual cases that are 
reviewed for reimbursement (TlV, 
2011c). 
The manufacturer may apply for a price 
increase at least 2 years after the 
inclusion on the Sl list. The 
manufacturer should submit an 
application with the price increase 
request from a therapeutic comparison 
and a foreign price comparison. The 
manufacturer may also apply for a price 
decrease or change to the limitations 
on the listing. 
Medicines are reviewed at 36 months 
after they have been included in the Sl 
list. The medicine will be appraised to 
consider whether it still remains value 
for money. The documents must be 
submitted by the manufacturer 30 
months prior to the review of the 
medicine. If the review shows the price 
is too high in comparison to the 
appropriate alternatives the FOPH can 
request a price reduction. Alternatively, 
if the medicine is found to be 
significantly cheaper in comparison to 
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United Kingdom -
England 
NICE classifies each decision into one of 
four categories: 1. Recommended, 2. 
Optimised, 3. Only in Research and 4. 
Not Recommended in 2010 (NICE, 
2011f). There was an informal 
categorisation of decisions prior to 
2010 of Recommended in line with the 
marketing authorisation, Restricted and 
Not Recommended: 
1. Recommended - A medicine is 
recommended if the medicine is 
in line with the marketing 
authorisation from the European 
Medicines Agency (EMA) or 
Medicines and Healthcare 
Products Regulatory Agency 
(MHRA) OR inline with how it is 
used in clinical practice in the NHS; 
2. Optimised - The recommendations 
have a material effect on the use 
of the medicine and it is 
recommended in a smaller subset 
of the patient population than the 
marketing authorisation. The test 
of materiality takes into account 
advice from clinical experts on the 
anticipated use of the medicine in 
routine clinical practice. 
3. Only in Research - the medicine is 
recommended for use only in the 
NICE guidance for technology appraisals 
apply to England and Wales. When NICE 
guidance is published, health 
professional are expected to take if fully 
into account. The Secretary of State in 
England has states that the NHS is 
required to provide funding and 
resources for medicines recommended 
through Single Technology Appraisals 
and Multiple Technology Appraisals. It 
is normally enforceable three months 
from the date of publication of each 
technology appraisal (NICE, 2011c). 
The stakeholders have an involvement 
throughout the technology appraisal 
process. Consultees are invited to make 
submissions and comment on 
consultation documents. All consultees 
(national groups representing patients 
and carers, organisations representing 
health care profeSSionals, 
manufacturers and sponsors, the 
Department of Health, Welsh Assembly, 
speCialised commissioning groups and 
local health boards) may appeal against 
the FAD (NICE, 2009b, NICE, 2009a). 
The appeal process can take a total of 8 
weeks to complete (NICE, 2011b). There 
is a standing committee called the 
appeal committee which is chaired by 
the vice chair of NICE and non-
executive directors of NICE, NHS 
representatives, representatives with 
experience of the relevant industry and 
lay members. Consultees have 15 
working days from the FAD being issued 
to appeal. Appeals should be submitted 
in writing and must fall within the three 
specified procedural grounds for 
appeal. The appeal can be heard by oral 
submission or written submission and 
the decision will be made by the Chair 
of the appeal panel (Written 
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other countries, a price increase may 
occur. The FOPH also reviews the 
medicines listed for 15 years or after 
the expiration of the patent. The 
conditions of effectiveness, 
appropriateness and efficiency will be 
assessed to ensure these are still met 
(Federal Office of Public Health, 2011, 
Paris and Docteur, 2007) 
A review date is listed on the guidance 
for when the review process will 
commence. Evidence is collected to 
inform the review process and the 
views of stakeholders are sought to 
identify additional evidence. If a large 
amount of new evidence is available the 
guidance will be reViewed, in contrast if 
there is little new evidence the review 
will be delayed (NICE, 2009b, NICE, 
2009a). 
Only in research recommendations: The 
medicine or treatment is recommended 
for use only in the context of a research 
study, for example a clinical trial (NICE, 
2011f). 
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United Kingdom -
Scotland 
context of a research study for 
example a clinical trial. 
4. Not recommended The 
treatment is not recommended. It 
will not be recommended if there 
is a lack of evidence of its clinical 
effectiveness and cost-
effectiveness. 
Three categories of advice are provided 
by the SMC to the Area Drug and 
Therapeutic Committees (ADTC) for 
listing; accepted for use; accepted for 
restricted use and not recommended 
(SMC, 2011h). 
The details of the recommendations are 
provided in an advice document for the 
SMC within 12 weeks of the products 
being made available (non-legally 
binding) (SMC, 2011i). The Health 
Boards have the final decision with 
regards to reimbursement (Health 
Policy and Strategy Directorate, 2010). 
submissions are usually for where there 
are a limited number of appeal points). 
The appeal must relate to sections 1 to 
4 of the FAD. The grounds for appeal 
are: 
1. Ground one: The Institute has 
failed to act fairly. 
2. Ground two: The Institute has 
formulated guidance, which 
cannot reasonably be justified in 
the light of the evidence 
submitted. 
3. Ground three: The Institute has 
exceeded its powers. 
New evidence cannot be presented in 
the appeal hearing. Oral hearings are 
open to the public, consultees, 
commentators, members of the public 
and the press. If the appeal is upheld 
the FAD will be returned to the 
appraisal committee, the appeal panel 
may decide that small changes are 
required but this does not need to be 
sent to the appraisal committee or the 
appeal is dismissed. There are no 
further appeal possibilities. The 
decision maybe challenged by applying 
to the High Court for permission to 
apply for judicial review. This must be 
made within 3 months of the decision 
(NICE, 2011b). 
The manufacturer may ask the SMC to 
convene an Independent Review Panel 
(IRP) to look again over existing data 
and analyses. An IRP will review the 
original submission and views of the 
NDC and SMC. The IRP consists of three 
member of the SMC that were not 
involved previously with the submission 
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Manufacturers may resubmit to the 
SMC in the light of new evidence or a 
new analysis of existing evidence but 
the SMC does not periodically review 
existing advice (SMC, 2011g). 
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and four members of the Scottish Area 
Drug and Therapeutics Committees. 
The IRP reports back to the SMC who is 
the final judge following a review (SMC, 
2011g). 
-
~~--~-
398 Appendices 
Box A4.1: The Efficiency Frontier 
The Institute for Quality and Efficiency in Health Care (IQWIG) convened a panel of experts in 
2007 to develop the economic methods for the assessment of technologies in Germany in line 
with the legal requirement (§ 35b Social Code Book (5GB) V). The panel produced a document on 
the general methods for evaluating the relation between cost and benefits in 2009 recommending 
the use of an alternative approach called the 'Efficiency Frontier' in the evaluation of 
technologies. The method concerns finding a maximum price at which a medicine in a given 
therapeutic area should be recommended for reimbursement. The analysis aims to inform the 
decision maker about the efficiency of a given medicine in the therapeutic area, but does not 
attempt to judge whether the condition deserves treatment or the willingness to pay for the 
medicine. 
The efficiency frontier is an extension to the approach of incremental cost-effectiveness ratios 
and concerns the use of resources in a therapeutic area. The efficiency frontier approach is 
defined in the guide as follows: 
liThe efficiency frontier plot compares the therapeutic benefit of available interventions within a 
given therapeutic area with the outcome-related net costs of these interventions. The additional 
therapeutic benefit derived from a previous benefit assessment may be transferred into an 
approximately cardinally scaled measure. Interventions on the efficiency frontier denote the net 
cost for any given benefit that is consistent with the efficiency that can be achieved by the 
package of interventions on the current market. Prices can lead to health technologies being 
positioned on an already existing segment of the efficiency frontier, showing thereby consistent 
efficiency with already existing interventions. If a price results in an intervention being positioned 
below the efficiency frontier, this indicates a lower efficiency. This price is deemed too high and 
needs to be adjusted, or at least justified. Interventions above the efficiency frontier indicate 
improved efficiency and thus redefine the frontier.1I 
(General Methods for the Assessment of the Relation of Benefits to Costs - Version 1.0 
19/11/2009) 
The approach requires that the health effects of the medicines are considered in terms of actual 
clinical measures such as mortality, morbidity, health-related quality of life and validated 
surrogates meeting the IQWIG criteria. The key requirement in the definition above is that the 
benefits must be transformed to an approximately cardinal scale or interval properties because 
units along the scale have similar value (for example twice the benefit is twice as valuable). The 
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efficiency frontier allows the decision maker to examine the existing medicines in relation to each 
other in a given therapeutic area but does not establish what should be paid for a given level of 
benefit for the new medicine. The process of considering those medicines with added therapeutic 
benefit means that many of the medicines assessed by IQWIG are likely to lie in the right hand 
quadrant representing those with greater benefit at a higher cost compared with the most 
efficient comparator. There are three regions in this quadrant, (i) those to above the efficiency 
frontier line that represent more efficient medicines (more benefit at a lower cost); (ii) those on 
the efficiency frontier line which represent the same efficiency as the existing intervention and 
(iii) those below the efficiency frontier in this quadrant that represent lower efficiency than the 
previous intervention. The decision on medicines falling in areas (i) and (ii) are fairly 
straightforward whereas those in (iii) require an appraisal of the willingness to pay for the health 
benefit. In the cases where the medicine provides superior benefit but a lower efficiency than the 
next best intervention the decision maker would need to consider whether there is justification 
for the decrease. Caro et al. (2010) suggests that in many cases diminishing marginal returns will 
be operating and past decreases could be assessed to consider a reasonable level of decline. The 
authors also suggest that willingness to pay for the additional benefits could be used for each 
therapeutic area but this would be potentially challenging in practice (Caro et al. 2010 - The 
Efficiency Frontier Approach to Economic, Health Economics). 
The divergence from using standard cost-benefit or cost-effectiveness methods for using the 
efficiency frontier is justified by the panel on three grounds (Caro et al. 2010, Dintsios and Gerber 
2010): 
The evaluations perfo~med by IQWIG are not the same as other reimbursement systems because 
they have a narrower remit. IQWIG is required to consider the maximum reimbursement amount 
in a given therapeutic area and therefore there is not a need for prioritising across the health care 
system 
Those interventions should only be addressed that are judged as superior using the principles of 
Evidence Based Medicine (EBM) for the effectiveness of the medicine 
Patients should not be excluded from therapeutic benefits in cost grounds alone 
The introduction of this new approach for the economic analysis in the reimbursement of 
medicines have been controversial and subjected to criticism (Schulpher and Claxton (2010), 
Brouwer and Rutten (2010)) and the approach has been defended by the panel that 
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recommended the efficiency frontier and IQWIG - the agency responsible for implementing the 
approach (Dintsios and Gerber 2010, Caro et al. 2010). 
Brouwer and Rutten comment that the nature and origins of the restrictive approach to economic 
analysis is not clear in Germany, (Brouwer and Rutten, 2010). The authors point to the fact that 
there is no single 'universally accepted' method but there seems to be no statement in German 
law against the use of cost-effectiveness comparisons between diseases or therapeutic areas. It is 
pointed out that the conventional cost-effectiveness approach can be used to consider whether a 
specific medicine in a specific disease area offers value for money and does not necessarily have 
to be used across disease areas. 
Sculpher and Claxton emphasise the failure to define value because the methods fail to consider 
the implications of scarce resources and the concept of opportunity cost even if there is no 
explicit budget constraint. This is because additional costs will displace private consumption 
outside of the health sector. The authors explain that a lack of a definition of value across 
therapeutic area may have implications for providing appropriate signals of value and providing 
incentives for the development of future treatments. The authors suggest that the methods may 
be providing an indication of value through the 'going rate' - the additional cost per unit of health 
benefit implied by current clinical practice and this can only describe a lower bound on the value 
of health benefits If past decisions fully reflect health effects, costs and social values. If the going 
rate signals a lower bound then it is suggested that some sufficiently valuable medicines will be 
wrongly rejected. This is echoed by Brouwer and Rutten who comment that " ... an efficiency 
frontier only describes what is, not what should be. A relevant ceiling must be imposed 
separately." The efficiency frontier is therefore a good approach for identifying those inefficient 
interventions but cannot describe the necessary price for those more effective and more costly. 
Along the lines made by Sculpher and Claxton they describe the danger that decision makers may 
be misguided assuming resource constraints because they might accept unfavourable cost-
effectiveness ratios in some areas because the medicine is relatively inefficient (high prices), and 
reject some medicines in relatively efficient areas because of the fact that other relatively 
efficient medicines are available (low price). They also comment on the difficulties and 
complexities in constructing the efficiency frontier and both sets of authors do not perceive the 
approach to offer any value over conventional approaches. Schulpher and Claxton go on further 
to criticise the experts that developed the methods. "Even if the plea that the guidance reflects 
constraints imposed on them is credible, it poses the question of whether a group of independent 
experts should have accepted such a remit. Whether the critical constraints are exogenous or self 
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inflicted, they have failed to explore fully and to effectively communicate their severe limitations 
and often perverse implications." (Sculpher and Claxton, 2010). 
IQWIG defends the approach by criticising the commentators for considering the efficiency 
frontier in terms of their country specific setting (Dintsios and Gerber 2010). They state that "In 
Germany, however, best allocation of scarce resources is by law solely pursued within a 
therapeutic area." The authors state that there is no international standard because numerous 
authors, including prominent British health economists have commented that there are a number 
of differences in approaches across countries and no necessarily best approach internationally. 
They propose that the international standard is that these elements are transparently stated 
(perspective etc). They also refer to the arbitrary nature of explicit/implied threshold ranges in 
operation in countries using conventional cost-effectiveness and cost-utility analysis and the 
equity implications of using cost-utility analysis in rare diseases. 
The expert panel's response to these criticisms refers to the original aim of that was to outline a 
method that would allow a judgement of whether the price of a technology was reasonable in the 
therapeutic area. It reiterates that there is not a common standard for economic analysis because 
each country has its own procedures in line with each countries cultural and legal context. It goes 
onto state that the issue of whether the benefit is worth the price to society is something that 
remains unresolved by reimbursement agencies internationally, (Caro et al. 2010). 
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Chapter 5 appendix 
Table AS.l: Summary of variable definition and description 
Data Variable Description 
Dependent variables 
Decision outcome Dummy: Decision on reimbursement: The guidance for each of the decisions was 
multinomial Recommended, lassified into three categories of decision which were "recommended", 
regression) Restricted ~restricted recommended" or "not recommended". The guidance 
recommended, not ategorised as recommended were for all patients that met the licence 
recommended. indication. The restricted recommended were categorised as those 
recommended for a specific patient sub-group. Those studies that were no 
ecommended outside of clinical trials were categorised as "no 
ecommended". A small sample of countries gUidance that did not specify. 
~pecific decision. In these circumstances a decision was Inferred from the 
onclusion. 
Independent variables 
Diseasearea Dummy: Disease Area: This variable Identified whether the drug was fo 
Cardiovascular Disease, ardiovascular disease or cancer In the technology evaluation 
Cancer 
~imesinceguldance Numeric: Months Time since publication: The number of months since the guidance documen 
fNas published. This was taken as the number of months from the 
publication date to 20th May 2008. 
Review Dummy: Review of Review: This indicates that the technology evaluation was a review of a 
previous evaluation previous evaluation of the medicine. This was Identified by checking the 
echnology evaluation to see whether It explicitly Identified the evaluation 
~s a review or by considering each countries previous evaluations within the 
Indication. 
RCTno Numeric 'rJumber of RCTs: The RCT number are taken from the documents presented 
or each of the countries 
~tudyrct Dummy: RCT, no RCT ~CT studies included: This captures whether the document stated that the 
~ata on which the decision was based was taken from RCT data. 
~tudyobs Dummy: pbservational studies Included: This captures whether the document stated 
Observational, no hat the data on which the decision was based was taken frorr 
observational pbservational studies. 
Eccua Dummy: Cost-utility !rost-utility analysis; This variable identified whether cost-utility analysis wa 
analysis, no cost-utility ~sed within the technology evaluation. 
analysis 
!,-ccea Dummy: cost- !rost-effectiveness analysis; This variable identified whether cost 
effectiveness analysis, ~ffectiveness analysis was used within the technology evaluation. 
no cost-effectiveness 
analysis 
ccma Dummy: cost rost minimisation analysis; This variable identified whether cos 
minimisation analysis, minimisation analysis was used within the technology evaluation. 
no cost minimisation 
analysis. 
Ecce Dummy: cost rost consequence analysis; This variable identified whether cos 
consequence, no cost onsequence analysis was used within the technology evaluation. 
consequence analysis. 
Sensanalysis Dummy: Sensitivity ~ensitivity analysis: This identified whether sensitivity analysis was 
analysis, no sensitivity presented within the technology evaluation 
analysis 
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Table AS.1: Summary of variable definition and description Continued .... ! 
cercqg Numeric: cost per .... ost per QALY gained. The third model included the cost per QALV for the 
QALV (£) assessments where this was available. Where agencies reported ICER's In a 
different currency these were exchanged at the exchange rate for the date of the 
~uldance Into pounds (GBP). 
~he ICER value appropriate to the decision-making was selected when this was 
specified for the Indication and recommendation made. In the case of NICE 
~here there were a number of groups submitting evidence on the ICER, the firs 
holce was the one specified for the Indication either found In the discussion 0 
he 'consideration of evidence' section. In circumstances where this was no 
tated for NICE, the assessment group/ERG ICER dominated the sponsors ICER 
r-vith respect to the recommended Indication. Further to this In circumstances 
~here the appropriate decision ICER was not stated and a range of assessment 
~rouP/ERG leER's were presented the mid-point of the ICER range was taken fo 
~ssumptlons with regards to an Indication. Those drugs that were found tc 
~ominate the comparator were given an ICER of zero as a negative ICER I 
onsldered uninformative. 
Budgetimpact Dummy: Budget Budget Impact: This variable Identifies whether a budget Impact was reported In 
Impact reported, he analyses. This was used as an Indication of whether the committee explicitl~ 
no budget Impact onsldered the budget Impact of a medicine. 
reported. 
Patlentgroupsub Dummy: Patient Patient group submission: This variable Identifies whether any patient group 
group submission, ubmlssions were reported within the technology evaluation documentation. 
no patient group 
submission. 
Nopatientgroup Numeric: Number Number of patient groups: This was Identified by a count of the number 0 
of patient groups patient groups that were Included within the technology evaluation 
~ocumentatlon. 
Publiclnterest Numeric: No of ",ews coverage prior to technology evaluation publication: An assessment was 
Australia 
anada 
~cotland 
newspaper articles made of the news coverage In a sample of two newspapers in each of the 
reporting public ountrles for the generic and brand name of the drug within the specific 
Interest. ndlcation. 
Dummy: 0/1= 
Australia 
Dummy: 0/1= 
Canada 
Dummy: 0/1= 
Scotland 
wo newspapers were selected for the two highest circulation newspapers for 
each of the countries. The rationale for searching two newspapers was on a 
pragmatic basis because the number of newspapers In each country is different, 
ountries differ In size and not all papers are Indexed within databases. 
fI\ search of the Nexls database was conducted on the number of mentions 0 
~Ither the generic or brand name In the Indication reported prior to the date 0 
elease of the technology evaluation. This was to identify the level of media 
nterest prior to the publication of any decision on the drug. 
he number of appearances was then recorded for each of the medicines fo 
~ach technology evaluation. 
~ustralla HTA: The Impact of a Australian decision In comparison to England 
reference group.} 
.... anoda HTA: The Impact of a Canada decision In comparison to England 
reference group.} 
)cotland HTA: The Impact of a Scotland decision in comparison to England 
reference group.} 
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Chapter 6 appendix 
Table A6.1: Reimbursement system classification 
France Scotland 
Policy Implementation Level 
Establishment Haute Autorite de sante (HAS) was established in 2004 by the Ministry of The Scottish Medicines Consortium (SMC) was established in 2001 by the 
Health and Solidarity. Funding is raised through social health insurance in 15 Health Boards. Funding for public provision is funded through taxation 
France. in Scotland. 
Objectives The aim of the agency Is to improve the quality of care and guarantee The aim of the agency is to accept those newly licensed drugs which clearly 
equity within the healthcare system. represent good value for money and reduce postcode prescribing. 
Implementation Provides one of the two stages of advice regarding the case for Provides one stage advice to the health boards and Area Drug Therapeutic 
reimbursement which includes clinical efficacy. Economic considerations Committees with regards value for money. The health boards choose 
made lly the Economic Committee for Health Products (CEPS). the HAS whether to include the medicine following advice from the SMC. 
opinion informs the pricing and volume agreements that are negotiated Manufacturer is free to set price prior to the evaluation by the SMC. 
between the manufacturer and the Economic Committee for Health 
Products (CEPS) for outpatient medicines and medicines on top of DRG. 
Prices for those medicines for hospital use included in the DRG are 
negotiated directly with the individual hospitals. 
Accountability Legally required to provide advice to Ministry of Health in 90 days NHS Scotland and the Ministry of Health 
Technology Decision Level 
(i) Assessment 
Consultation and stakeholder Transparency committee includes physicians, pharmacist, specialist in The SMC process includes two committees. The NDC includes clinicians and 
involvement methodology and epidemiology. There is no third party synthesis of pharmacists - nominated by the ADTCs a health economist, a statistician 
evidence. and two industry representatives. The SMC includes a wider representation 
including a Chief Executive, Finance Directors, patient and public 
representation, Association of British Pharmaceutical Industry (ABPI), 
together with the clinical and public health members. There is no third 
party synthesis of evidence and/or provision of economic evaluation 
Evidence base for assessment HAS considers all pharmaceuticals once marketing authorisation has been The SMC considers all newly licensed medicines, new formulations of 
granted. The manufacturer is required to present relevant data on clinical existing medicines and new indications for established products (SMC 
efficacy, comparative safety and relative effectiveness. excludes assessment of vaccines, branded generics, non-prescription-only I 
medicines (POMs), blood products, plasma substitutes and diagnostic 
-_._-
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medicines) once marketing authorisation has been granted. The 
manufacturer is required to submit evidence on clinical efficacy, 
comparative effectiveness, clinical effectiveness, cost-effectiveness and 
budget impact. 
Clinical-effectiveness assessment HAS requires the manufacturer to submit all relevant studies for the clinical The SMC requires the manufacturer to provide evidence assembled 
efficacy of the medicine but there are no requirements for these to be systematically for the indication(s) of the medicine including details of RCTs 
identified by a systematic review of the evidence. In the absence of head (active controlled most relevant), meta-analyses, and most relevant effects 
to head trials a network meta-analysis is permitted. The HAS commission a of a medicine. The manufacturer provides evidence of clinical efficacy and 
separate literature review of the evidence. The manufacturer provides a is required to consider the medicine in terms of the applicability to clinical 
claimed score for the Service Medical Rendu (SMR) and l'amelioration du practice in Scotland, guidelines and relevant protocols for the most 
Service Medical (ASMR). The transparency committee is given information relevant active comparator medicines. In the absence of head to head ! 
from a literature review and the manufacturer's submission. evidence a network meta-analysis is required by the SMC. The network 
meta-analyses should be described with reference to a systematic review 
for studies included and the search strategy for trials included and 
clinical/statistical heterogeneity between data sources. 
Cost-effectiveness assessment Not required or presented by manufacturer. The responsibility for demonstrating the cost-effectiveness and any further 
analysis relevant to Scottish practice rests with the manufacturer and 
failure to submit cost-effectiveness automatically results in a not 
recommended decision. A reference case is not provided but the SMC 
specifies that cost-utility analysis is the preferred form of economic 
evaluation and health effects should be expressed in Quality-Adjusted Life 
Years (QALYs). Modelling is the main framework used to synthesise data of 
clinical and cost-effectiveness, in the absence of real-life effectiveness data. 
Manufacturers are required to provide sensitivity analysis in the form of 
single and multi-way analysis to allow the committee to explore the 
uncertainty in the estimates. 
Presentation and communication The manufacturer submits a dossier to the HAS but this is not published on The manufacturer submits a New Product Assessment Form (NPAF) but no 
of results the website. A fee of 2,875 EURO is required for the processing of the fee is required for the processing of the submission. The NPAF is not 
submission, HAS provides a 'opinion' document published on their website published on the SMC website. An advice document is published on the 
which contains an assessment of evidence, details of the appraisal and SMC website. 
recommendation. httQ:!Lwww.scottishmedicines.org.uklHome 
httQ:l[www.has-sante.frLQortailLicmslc 5268Lmedicaments?cid=c 5268 
(ii) Decision 
Who makes the decision The HAS committee is called the Transparency committee and conSiders The NDC and Transparency committee solely receive a submission from the 
the dossier from the manufacturer and a review of the literature. A manufacturer of the relevant evidence and in contrast to NICE in England, 
recommendation is produced along with a judgement of the ASMR and do not commission a third party to provide a separate review of the clinical 
SMR are provided for the second stage where price is negotiated by the evidence and economic evidence (in the case of SMC). The 
CEPS. The final reimbursement recommendation and price is made by CEPS recommendation is advice and the final reimbursement deCision is made by 
in the Ministry of Health, the Health Boards. 
Decisio~makil1g process The decision making process is summarised in Figure 1. The HAS is one The decision making process is summarised in Figure 1. The SMC is one 
Appendices 
Appraisal of clinical evidence 
Appraisal of economic evidence 
agency involved in the process of decision making, which also involves CEPS 
and the Ministry of Health. The HAS committee is called the Transparency 
committee and considers the dossier from the manufacturer and a review 
of the literature. There is no consultation with stakeholders prior to the 
final recommendation. 
The committee judges the SMR and ASMR for the medicines. This is 
performed by a majority vote for the two criteria. 
SMR (Medical Benefit): The score takes into account the severity of the 
condition and other data specific to the drug such as the effectiveness and 
adverse reactions, place in the therapeutic strategy, existence of other 
therapeutic alternatives and importance for public health. The SMR 
determines the level of cost-sharing paid by members of the health 
insurance system and whether the medicine justifies reimbursement. The 
SMR takes four categories; Major, Moderate, Low and insufficient (does 
not justify reimbursement). 
ASMR (Improvement in Medical Benefit): The Improvement in Medical 
Benefit is first provided in the manufacturer submission as a claimed score 
for the medicine. The ASMR is a score of the relative-effectiveness of the 
medicine compared to the medicine used in practice. There are five 
different levels of ASMR from Major Improvement (I), Important (II), 
Moderate (III), Minor (IV) and no improvement (V). The ASMR determines 
the pricing that is negotiated between the manufacturer and CEPS. A 
separate ASMR may be rewarded to a medicine that has different benefits 
in different indications or patient subgroups. The ASMR determines the 
price negotiated by the CEPS. CEPS negotiates price for outpatient 
medicines and those medicines that are used in hospital but not included in 
the DRG (those included in the DRG are negotiated with individual 
hospitals). Those rated on the ASMR of I, " or III are allowed to set a price 
higher than the comparator, IV depends on the context and V must be cost-
saving in relation to the relevant comparator (s). The CEPS also sets price 
volume agreements with the manufacturer where in the event that sales 
exceed the forecasts for the four years the company is required to provide 
a claw back for the additional costs. 
No appraisal performed of health economic evidence. 
415 
agency involved in the deciSion process. The Health Boards make the final 
reimbursement decision. The SMC process includes two committees. The 
NOC includes clinicians and pharmacists - nominated by the ADTCs a health 
economist, a statistician and two industry representatives. The SMC 
includes a wider representation including a Chief Executive, Finance 
Directors, patient and public representation, Association of British 
Pharmaceutical Industry (ABPI), together with the clinical and public health 
members. There is no consultation with stakeholders prior to the final 
recommendation. 
The NDC reports a qualitative description of the efficacy and relative-
effectiveness considerations. This has been informed by six questions asked 
to a number of independent experts on the following: 
1. Are there gUidelines, available or in preparation, which do (or could) 
influence Scottish prescribing in this area? 
2. Do you wish to highlight any areas of unmet need in relation to the 
relevant condition(s)? 
3. What are the current treatment options? In particular, what is the 
predominant treatment in Scotland? 
4. What is your preferred treatment (if different to predominant 
treatment)? Please explain? 
S. Disease prevalence: Please estimate how many patients currently 
receive treatment in your catchment area and/or in Scotland? (Please 
state population numbers If you have given an estimate for your catchment 
area.) 
6. If you have knowledge of this particular new product for this indication, 
please describe how it might fit into your treatment plan. 
The fitness for purpose of the economic evidence and the interpretation of 
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I the estimate of cost-effectiveness in the context of the medicine's use in 
practice is considered. The economic evaluation is one criterion considered 
in the draft advice by the NDC to the SMC with respect to the threshold 
reported by NICE but other criteria are considered in the context of each 
decision such as the absence of alternatives, bridging to other therapies, 
emergence of other therapies and special issues that are specific to the 
medicine. The manufacturer may submit a Patient Access Scheme (PAS) to 
an independent group called the Patient Access Scheme Assessment Group 
(PASAG) to improve the cost-effectiveness of a medicine by reducing the 
cost of the new medicine and allowing patient access to clinically effective 
medicines. 
(iii) Outputs and implementation , 
Appeal and dissent The manufacturer has a period of eight days from receipt of the notice of The manufacturer may ask the SMC to convene an Independent Review 
the advice to request a hearing. At the end of the 8 days in the absence of Panel (IRP) to look again over existing data and analyses. An IRP will review 
comments the opinion becomes final. The manufacturer has 15 minutes to the original submission and views of the NDC and SMC. The IRP consists of 
present its cases and reasons for the hearing should be submitted. The here member of the SMC that were not involved previously with the 
recommendation may then be amended and a final notice sent to the submission and four members of the Scottish Area Drug and Therapeutics 
Ministry of Health and stakeholders. Committees. The IRP reports back to the SMC who is the final judge 
following a review. 
Implementation and HAS opinions are either positive or negative (conditions may also be The details of the recommendations are provided in an advice document 
communication imposed for additional studies or a target patient population) and are for the SMC within 120 days (non-legally binding) and an opinion document 
produced for the CEPS of the Ministry of Health where decisions are made for the HAS in 90 days (legally binding). Neither of the agencies publishes 
on the price for outpatient medicines and hospital medicines that are not the manufacturer submission. Three categories of advice are provided by 
covered within the DRG. the SMC to the Area Drug and Therapeutic Committees (ADTC) for listing; 
accepted for use; accepted for restricted use and not recommended 
Monitoring and reappraisal HAS can self-refer medicines in the presence of new evidence, reviews all Manufacturers may resubmit to the SMC in the light of new evidence or a 
medicines at 5 years post-listing and assess the evidence from any post- new analysis of existing evidence but the SMC does not periodically review 
listing studies. The recommendations at the 5-year review may result in existing advice. 
the SMR being revised and an opinion for de-listing the medicine. 
Manufacturers may submit new evidence for medicines at any pOint in a 
new dossier and the Transparency committee will provide reassessment of 
the medicine. 
Evidence of impact of the HAS is an advisory body and only part of the reimbursement deCision There is one study that has identified the effect of a not recommended 
decision process. The authors are unaware of any published studies reporting the SMC on use within primary care and found the impact to be variable, 
impact of HAS advice on the final reimbursement decisions. Although the Bennie et al. An investigation into the effect of advice from the Scottish 
majority of reimbursement decisions made by the Ministry of Health are Medicines Consortium on the use of medicines in Scotland's Health Service 
positive. HAS influence the price through the judgement of ASMR. (2011). The study reported that there is a complex relationship between 
advice following an SMC recommendation and changes in clinical practice. 
France Scotland 
~~--
------- -- ----
~~-
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Policy Implementation Level 
Establishment Haute Autorite de sante (HAS) was established in 2004 by the Ministry of The Scottish Medicines Consortium (SMC) was established in 2001 by the 
Health and Solidarity. Funding is raised through social health insurance in 15 Health Boards. Funding for public provision is funded through taxation 
France. in Scotland. 
Objectives The aim of the agency is to improve the quality of care and guarantee The aim of the agency is to accept those newly licensed drugs which clearly 
equity within the healthcare system. represent good value for money and reduce postcode prescribing. 
Implementation Provides one of the two stages of advice regarding the case for Provides one stage advice to the health boards and Area Drug Therapeutic 
reimbursement which includes clinical efficacy. Economic considerations Committees with regards value for money. The health boards choose 
made by the Economic Committee for Health Products (CEPS). the HAS whether to include the medicine following advice from the SMC. 
opinion informs the pricing and volume agreements that are negotiated Manufacturer is free to set price prior to the evaluation by the SMC. 
between the manufacturer and the Economic Committee for Health 
Products (CEPS) for outpatient medicines and medicines on top of DRG. 
Prices for those medicines for hospital use included in the DRG are 
negotiated directly with the individual hospitals. 
Accountability Legally required to provide advice to Ministry of Health in 90 days NHS Scotland and the Ministry of Health 
Technology Decision Level 
(i) Assessment 
Consultation and stakeholder Transparency committee includes physicians, pharmacist, specialist in The SMC process includes two committees. The NDC includes clinicians and 
involvement methodology and epidemiology. There is no third party synthesis of pharmacists - nominated by the ADTCs a health economist, a statistician 
evidence. and two industry representatives. The SMC includes a wider representation 
including a Chief Executive, Finance Directors, patient and public 
representation, Association of British Pharmaceutical Industry (ABPI), 
together with the clinical and public health members. There is no third 
party synthesis of evidence and/or provision of economic evaluation 
Evidence base for assessment HAS considers all pharmaceuticals once marketing authorisation has been The SMC conSiders all newly licensed medicines, new formulations of 
granted. The manufacturer is required to present relevant data on clinical existing medicines and new indications for established products (SMC 
efficacy, comparative safety and relative effectiveness. excludes assessment of vaccines, branded generiCS, non-prescription-only 
medicines (POMs), blood products, plasma substitutes and diagnostic 
medicines) once marketing authorisation has been granted. The 
manufacturer is required to submit evidence on clinical efficacy, 
comparative effectiveness, clinical effectiveness, cost-effectiveness and I 
budget impact. 
Clinical-effectiveness assessment HAS requires the manufacturer to submit all relevant studies for the clinical The SMC requires the manufacturer to provide evidence assembled 
efficacy of the medicine but there are no requirements for these to be systematically for the indication(s) of the medicine including details of RCTs 
identified by a systematic review of the evidence. In the absence of head (active controlled most relevant), meta-analyses, and most relevant effects 
to head trials a network meta-analysis is permitted. The HAS commission a of a medicine. The manufacturer provides evidence of clinical efficacy and 
418 
Cost-effectiveness assessment 
Presentation and communication 
of results 
(ii) Decision 
Who makes the decision 
Decision-making process 
separate literature review of the evidence. The manufacturer provides a 
claimed score for the Service Medical Rendu (SMR) and L'amelioration du 
Service Medical (ASMR). The transparency committee is given information 
from a literature review and the manufacturer's submission. 
Not required or presented by manufacturer. 
The manufacturer submits a dossier to the HAS but this is not published on 
the website. A fee of 2,875 EURO is required for the proceSSing of the 
submission, HAS provides a 'opinion' document published on their website 
which contains an assessment of evidence, details of the appraisal and 
recommendation. 
http://www.has-sante.fr/portail/icrnsl~_52681medicaments?cid=c 5268 
The HAS committee is called the Transparency committee and considers 
the dossier from the manufacturer and a review of the literature. A 
recommendation is produced along with a judgement of the ASMR and 
SMR are provided for the second stage where price is negotiated by the 
CEPS. The final reimbursement recommendation and price is made by CEPS 
in the Ministry of Health, 
The decision making process is summarised in Figure 1. The HAS is one 
agency involved in the process of decision making, which also involves CEPS 
and the Ministry of Health. The HAS committee is called the Transparency 
committee and considers the dossier from the manufacturer and a review 
of the literature. There is no consultation with stakeholders prior to the 
final recommendation. 
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is required to consider the medicine in terms of the applicability to clinical 
practice in Scotland, guidelines and relevant protocols for the most 
relevant active comparator medicines. In the absence of head to head 
evidence a network meta-analysis is required by the SMC. The network 
meta-analyses should be described with reference to a systematic review 
for studies included and the search strategy for trials included and 
clinical/statistical heterogeneity between data sources. 
The responsibility for demonstrating the cost-effectiveness and any further 
analysis relevant to Scottish practice rests with the manufacturer and 
failure to submit cost-effectiveness automatically results in a not 
recommended decision. A reference case is not provided but the SMC 
specifies that cost-utility analysis is the preferred form of economic 
evaluation and health effects should be expressed in Quality-Adjusted Life 
Years (QALYs). Modelling is the main framework used to synthesise data of 
clinical and cost-effectiveness, in the absence of real-life effectiveness data. 
Manufacturers are required to provide sensitivity analysis in the form of 
single and multi-way analysis to allow the committee to explore the 
uncertainty in the estimates. 
The manufacturer submits a New Product Assessment Form (NPAF) but no 
fee is required for the processing of the submission. The NPAF is not 
published on the SMC website. An advice document is published on the 
SMC website. 
http://www.scottishmedicines.org.uk/Home 
The NDC and Transparency committee solely receive a submission from the 
manufacturer of the relevant evidence and in contrast to NICE in England, 
do not commission a third party to provide a separate review of the clinical 
evidence and economic evidence (in the case of SMC). The 
recommendation is advice and the final reimbursement decision is made by 
the Health Boards. 
The decision making process is summarised in Figure 1. The SMC is one 
agency involved in the decision process. The Health Boards make the final 
reimbursement decision. The SMC process includes two committees. The 
NDC includes clinicians and pharmacists - nominated by the ADTCs a health 
economist, a statistician and two industry representatives. The SMC 
includes a wider representation including a Chief Executive, Finance 
Directors, patient and public representation, Association of British 
Pharmaceutical Industry (ABPI), together with the clinical and public health 
members. There is no consultation with stakeholders prior to the final 
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Appraisal of clinical evidence 
Appraisal of economic evidence 
The committee judges the SMR and ASMR for the medicines. This is 
performed by a majority vote for the two criteria. 
SMR (Medical Benefit): The score takes into account the severity of the 
condition and other data specific to the drug such as the effectiveness and 
adverse reactions, place in the therapeutic strategy, existence of other 
therapeutic alternatives and importance for public health. The SMR 
determines the level of cost-sharing paid by members of the health 
insurance system and whether the medicine justifies reimbursement. The 
SMR takes four categories; Major, Moderate, Low and insufficient (does 
not justify reimbursement). 
ASMR (Improvement in Medical Benefit): The Improvement in Medical 
Benefit is first provided in the manufacturer submission as a claimed score 
for the medicine. The ASMR is a score of the relative-effectiveness of the 
medicine compared to the medicine used in practice. There are five 
different levels of ASMR from Major Improvement (I), Important (II), 
Moderate (III), Minor (IV) and no improvement (V). The ASMR determines 
the pricing that is negotiated between the manufacturer and CEPS. A 
separate ASMR may be rewarded to a medicine that has different benefits 
in different indications or patient subgroups. The ASMR determines the 
price negotiated by the CEPS. CEPS negotiates price for outpatient 
medicines and those medicines that are used in hospital but not included in 
the ORG (those included in the ORG are negotiated with individual 
hospitals). Those rated on the ASMR of I, II or III are allowed to set a price 
higher than the comparator, IV depends on the context and V must be cost-
saving in relation to the relevant comparator (s). The CEPS also sets price 
volume agreements with the manufacturer where in the event that sales 
exceed the forecasts for the four years the company is required to provide 
a claw back for the additional costs. 
No appraisal performed of health economic evidence. 
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recommendation. 
The NDC reports a qualitative description of the efficacy and relative-
effectiveness considerations. This has been informed by six questions asked 
to a number of independent experts on the following: 
1. Are there guidelines, available or in preparation, which do (or could) 
influence Scottish prescribing in this area? 
2. Do you wish to highlight any areas of unmet need in relation to the 
relevant condition(s)? 
3. What are the current treatment options? In particular, what is the 
predominant treatment in Scotland? 
4. What is your preferred treatment (if different to predominant 
treatment)? Please explain? 
s. Disease prevalence: Please estimate how many patients currently 
receive treatment in your catchment area and/or in Scotland? (Please 
state population numbers if you have given an estimate for your catchment 
area.) 
6. If you have knowledge of this particular new product for this indication, 
please describe how it might fit into your treatment plan. 
The fitness for purpose of the economic evidence and the interpretation of 
the estimate of cost-effectiveness in the context of the medicine's use in 
practice is considered. The economic evaluation is one criterion considered 
in the draft advice by the NDC to the SMC with respect to the threshold 
reported by NICE but other criteria are considered in the context of each 
decision such as the absence of alternatives, bridging to other therapies, 
emergence of other therapies and special issues that are specific to the 
medicine. The manufacturer may submit a Patient Access Scheme (PAS) to 
an independent group called the Patient Access Scheme Assessment Group 
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(PASAG) to improve the cost-effectiveness of a medicine by reducing the 
cost of the new medicine and allowing patient access to clinically effective 
medicines. 
(iii) Outputs and implementation 
Appeal and dissent The manufacturer has a period of eight days from receipt of the notice of The manufacturer may ask the SMC to convene an Independent Review 
the advice to request a hearing. At the end of the 8 days in the absence of Panel (IRP) to look again over existing data and analyses. An IRP will review 
comments the opinion becomes final. The manufacturer has 15 minutes to the original submission and views of the NDC and SMC. The IRP consists of 
present its cases and reasons for the hearing should be submitted. The here member of the SMC that were not involved previously with the 
recommendation may then be amended and a final notice sent to the submission and four members of the Scottish Area Drug and Therapeutics 
Ministry of Health and stakeholders. Committees. The IRP reports back to the SMC who is the final judge 
following a review. 
Implementation and HAS opinions are either positive or negative (conditions may also be The details of the recommendations are provided in an advice document 
communication imposed for additional studies or a target patient population) and are for the SMC within 120 days (non-legally binding) and an opinion document 
produced for the CEPS of the Ministry of Health where decisions are made for the HAS in 90 days (legally binding). Neither of the agencies publishes 
on the price for outpatient medicines and hospital medicines that are not the manufacturer submission. Three categories of advice are provided by 
covered within the DRG. the SMC to the Area Drug and Therapeutic Committees (ADTC) for listing; 
accepted for use; accepted for restricted use and not recommended 
Monitoring and reappraisal HAS can self-refer medicines in the presence of new evidence, reviews all Manufacturers may resubmit to the SMC in the light of new evidence or a 
mediCines at 5 years post-listing and assess the evidence from any post- new analysis of existing evidence but the SMC does not periodically review 
listing studies. The recommendations at the 5-year review may result in existing advice. 
the SMR being revised and an opinion for de-listing the medicine. 
Manufacturers may submit new evidence for medicines at any point in a 
new dossier and the Transparency committee will provide reassessment of 
the medicine. 
Evidence of impact of the HAS is an advisory body and only part of the reimbursement decision There is one study that has identified the effect of a not recommended 
deciSion process. The authors are unaware of any published studies reporting the SMC on use within primary care and found the impact to be variable, 
impact of HAS advice on the final reimbursement decisions. Although the Bennie et al. An investigation into the effect of advice from the Scottish 
majority of reimbursement decisions made by the Ministry of Health are Medicines Consortium on the use of medicines in Scotland's Health Service 
positive. HAS influence the price through the judgement of ASMR. (2011). The study reported that there is a complex relationship between 
-_._-_ ... _------ --- --------
advice following an SMC recommendation anc!~hanges in clinical_practice. 
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Table A6.2: 2010 recommendations by HAS and SMC 
HAS -2010 SMC-2010 
Recommendations (all submissions on website 410 86 
excluding HAS simplified procedure) 
Recommendations subset (Full submission for new 122 (30%) 57 (66%) 
medicine, indication, extension) 
Recommendations for new medicine, indication or 
extension 
Recommended listing (including major/minor 115 (94%) 32 (56%) 
restriction) i 
Not Recommended listing 7(6%) 25 (44%) 
Common medicines assessed 17 (14%) 17 (30%) 
Disease treated (lCD 10 codes by chapter) i 
Certain infectious and parasitic diseases 15 (12%) 1 (1%) 
Neoplasms 16 (13%) 17 (30%) 
Diseases of the blood and immune mechanism 6 (5%) 4 (7%) 
Endocrine, nutritional and metabolic diseases 9 (7%) 8 (14%) 
Mental and behavioural disorders 4(3%) 2 (4%) 
Diseases of the nervous system 9 (7%) 2 (4%) 
Diseases of the eye and adnexa 4(3%) 1 (2%) 
Diseases of the circulatory system 16 (13%) 5 (9%) 
Diseases of the respiratory system 5 (4%) 3 (5%) 
Diseases of the digestive system 7 (6%) 1 (2%) 
Diseases of the skin and subcutaneous tissue 3 (2%) 4 (7%) 
Diseases of the musculoskeletal system and 4 (3%) 6 (11%) 
connective tissue 
Diseases of the genitourinary system 2 (1%) 0(0%) 
Pregnancy, childbirth and the puerperium 1 (1%) 0(0%) 
Certain conditions originating in the perinatal period 1 (1%) 0(0%) 
Congenital malformations and chromosomal 1 (1%) 0(0%) 
abnormalities 
Symptoms, signs and abnormal clinical and laboratory 4 (4%) 2 (3%) 
findings 
_ .. _ .. - --
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- -
Injury, poisoning and certain other consequences of 2 (2%) 0(0%) 
external causes 
Factors influencing health status and contact with 13 (11%) 1 (1%) 
health services I 
Evidence judgments by HAS and SMC HAS -SMR HAS-ASMR SMC - Clinically- SMC 
-
Cost-
effectiveness effectiveness 
demonstrated demonstrated 
Substantial - 1 14 (12%) 1 3(3%) Yes 47 (82%) 32 (56%) 
Important - 2 83 (68%) 2 2(2%) No 10 (18%) 25 (44%) 
Moderate- 3 14 (11%) 3 9(7%) Type of Economic analysis performed 
low-4 4 (3%) 4 20 Cost utility 45 (79%) 
(16%) 
Insufficient - 7 (6%) 5 81 Cost 2 (3%) 
5 (66%) effectiveness 
Insufficient 7(6%) Cost 9 (16%) 
minimisation 
Not provided 1 (2%) 
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Table A6.3: Concerns with clinical evidence and economic evidence 
ID 
COOl 
C002 
C003 
Drug Efficacy Trials I SMC Clinical Evidence 
SMC: There are difficulties in assessing 
Bakheit (2000), Bakheit the benefits: 
units (2001) & Bakheit (2004) (1) Dosage - individualised 
Botulinum 
type A 
500 
powder 
solution 
injection 
for I HAS: 
for each patient 
according to muscle 
spasticity. 
Ribavirin 
200mg 
Docetaxel 
20mg/80mg 
concentrate 
and solvent 
Smith (2000), Bakheit 
(2001), Hesse (1998) 
The same 
supporting 
additional 
Phase III 
trial but 
different 
supporting trials. 
Same trials: 
Gonzalez-Peralta (2002) 
Fried (2002) 
Same trials 
Martin (2005), Roche 
(2006) 
(2) Comparators - no details 
for comparison with 
physiotherapy. 
(3) Patient population - short 
time period to post 
stroke. 
(4) Assessment of primary 
outcome by investigator 
assessment. 
(5) Clinical trial studies for 
post-stroke patients even 
though indication is 
wider. 
The clinical issues related to: 
(1) Dosage - for lighter 
patients where oral 
solution is unavailable. 
The clinical issues related to: 
(1) Comparator- The trial 
compared TAC with FAC. 
This is not the commonly 
used regime in France. 
An indirect comparison was 
considered against FEC. 
HAS Clinical Evidence 
The main issues reported were 
(1) No trials available 
comparing with active 
comparator drugs 
(phenol, alcohol, 
dantrolene or baclofen) 
or functional 
rehabilitation. 
(2) No safety or efficacy 
data lasting more than 
12 weeks. 
The clinical issues: 
(1) Uncontrolled design of 
trials not allowing 
demonstration of 
impact on morbidity or 
mortality. 
The clinical issues: 
(1) Comparator - The 
comparator used in the 
trial as according to 
American design rather 
than FECI00. 
ASMR 
5 
3 
2 
423 
SMC Economic Model Issues 
Not recommended - license 
The model structure was 
deemed appropriate and 
extensive sensitivity analysis. 
The issues reported were: 
(1) Improvement in MAS 
scores lead to 
improvements in 
quality of life. Clinical 
expert opinion 
confirmed that changes 
in MAS and quality of 
life are poorly reported. 
A Health Outcomes 
Data Repository 
(HODaR) was used but 
deemed a poor 
substitute for direct 
measurement. 
Recommended -license 
No issues reported. 
The analysis was well conducted 
and demonstrated ribavirin to 
be a cost-effective treatment 
option compared to no 
treatment. 
Recommended -license 
No issues reported. 
The economic study was well 
designed. An indirect 
comparison was used for the 
comparator regime. 
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COO4 Candesartan Same trials No issues reported. No issues reported. 2 Recommended - license 
cilexetil No issues reported. 
2,4,8,16 & CHARM-Alternative, The comparator reflected 
32mg CHARM-Added Scottish practice and 
demonstrated that candesartan 
is a cost-effective treatment 
when used as an alternative to 
ACE-inhibitors or when used as 
an add-on. 
COOS Solifenacin SMC: The issues reported were: The issues reported were: S Recommended - License 
succinate Chapple (2004), (1) Trial attrition. (1) lack of active Issues noted: 
tablets Smg, Cardozo (2004), Haab (2) Dosage - Dose reduction comparator studies- (1) The analysis was 
10mg (2005), xl unpublished, not permitted for those The committee does complicated by the 
Chapple (2005) intolerant. not have access to omission of lmg 
(3) Trial population - studies comparing with tolterodine which 
HAS: patients were an active comparator in would reduce the 
Chapple (2004), predominantly female France. average weighted cost. 
Cardozo(2004 ), x2 (4) Other comparators - (2) Trial representation -
unpublished, Chapple solifenacin has not been The trial population 
(2005) compared to other was not representative 
medicinal products. ofthe older patients 
C007 Rasagiline Same trials: The issues reported were: The issues reported were; 5 Not recommended - Subgroup 
lmg TEMPO study (1) Lack of comparator trials (1) The studies assessed Issues noted: 
- No trials compare with the short term benefit (1) Limited consideration 
selegiline or other of 6 to 12 months. of comparator regimes. 
dopamine agonists. (2) Lack of active (2) The interpolated 
(2) Delayed trial start design comparator trials - No transition probabilities. 
- There is no convincing trials compare with (3) Structure of the model 
evidence that it causes selegiline or other for first and second line 
disease modifying or dopamine agonists. therapy. 
neuroprotective effects. 
C008 Rasagiline Same trials: The issues reported were: The issues reported were; 5 Not recommended -license 
lmg LARGO study, PRESTO (1) Lack of active comparator (1) The studies assessed Issues noted: 
study trials - There were no the short term benefit (1) The most relevant 
trials directly comparing of 6 to 12 months. comparator was not 
_ .. _---- -
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rasagiline with other (2) lack of comparators- considered which was 
COMT inhibitors or No trials compare with considerably lower in 
" , selegiline. selegiline or other cost. 
dopamine agonists. The 
indirect comparison 
was not relevant 
C009 lanthanum Same trials: The issues reported were: The issues reported: 5 Restricted - Subgroup 
carbonate Joy (2003), Hutchison (1) lack of active comparator (1) The long term safety on No issues reported. 
250mg, , (2005) trials - There were no bone has not yet been The survival analysis was 
500mg, head to head studies with sufficiently established. deemed necessary and seems to 
750mg, other non-aluminium have been robustly performed 
1000mg phosphate binder, and sensitivity analysis gave the 
sevelamer committee confidence in the 
(2) long term effects on results given the uncertainty in 
bone have still to be fully the clinical evidence. 
established. 
COlO Omalizumab Same trials: The issues reported were: The issues reported: 4 Restricted - Subgroup 
150mg INNOVATE (2005) (1) lack of active comparator (1) Short-term study The issues reported were: 
trials - It has not been period of 28 weeks. 23 (1) Risk of death from 
shown whether month period would severe exacerbation 
omalizumab is clinically have been more episode may be an 
beneficial to slow release appropriate. overestimate 
theophyllines or anti- (2) Asthma severity was (2) The assumption of no 
leukotriene agents. markedly more drop out 
pronounced before the (3) The baseline assuming 
study. divisible dosage may 
I not always be feasible 
in clinical practice. 
CO 11 Capecitabine Same trial: The issues reported were: The issues reported were: 5 Recommended - license 
I 
150 and 500 X-ACT study (1) lack of direct (1) The main study showed No issues reported. ! 
mg comparisons - Whether that capecitabine was The evaluation was well 
I the tolerability of not inferior to 5FU/FA designed and seemed robust. It 
capecitabine would be regimen (bolus) but a was notable for the use of a 
sustained in comparison different number of comparators. 
to the de Gramont administration used in 
~-- ------~-
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regimen. Europe. 
CO 13 Erlotinib SMC: The issues reported were: The issues reported were: 5 Restricted - Subgroup 
25mg, lOOmg BR21 study (1) Comparator - Active (1) lack of comparator The issues reported were: 
& 150mg supportive care in al\ with second line (1) The group of patients 
Indirect comparison performance status. comparator drugs who would not be 
included. Indirect comparison was docetaxel and suitable to receive 
needed with docetaxel. pemetrexed. docetaxel was not 
HAS: (2) Patient Population - (2) Patient population - compared to the ! 
BR21 study and Trial Identification and pre- patients included in the appropriate 
A248-1007 Phase II. selection of patients most trial had to have comparator. 
likely to respond already received at (2) Weakness in the 
least one or two line of handling of resource 
chemotherapy and it use for the duration of 
was not stated whether treatment of 4-5 cycles 
the disease was of docetaxel may be 
progressing or had greater than standard 
stabilised. practice in Scotland. 
C014 Sildenafil SMC: The issues reported: Issues reported: 1 Restricted -license 
citrate 20mg Galie (2005) & SERAPH (1) Trial design with (1) The effect of the No issues noted. 
study meaningful endpoints. treatment on mortality 
Orphan (2) Patient population - only unknown and the 
Indication. HAS: 58% of the study benefit not established 
Galie(2005) population were of in more severe stages 
functional class 11\, ofPAH. 
although treatment 
effects were consistent 
across subgroups. 
(3) lack of data for second-
line - The study excluded 
patients who had 
previously failed 
bosentan therapy. 
C015 Ibrandronic Same trials: The issues reported: The issues reported: 5 Recommended - license 
acid 150mg Chesnut (2004) & Miller (1) lack of comparative trials (1) lack of comparative No issues reported 
(2005) - No comparative trials of trials with other 
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ibandronic acid with bisphosphonates 
HAS: Indirect other standard 
comparison includedc 
-
treatments for 
osteoporosis in 
postmenopausal women. 
(2) Patient population - the 
study included women 
that did not have 
osteoporosis. 
C016 Pegylated SMC: The issues reported were: The issues reported were: 5 Recommended - license 
interferon Lau (2004), Cooksley (1) Patient population - data (1) Lack of direct There were no issues reported. 
a If a 2a, (2001), Marcellin (2004) on patient subgroups and comparison with other 
180mcg the trials were based in comparators -
subcutaneous HAS: Australasia and the establishing benefit in 
injection Lau (2004), Marcellin proportion of Asian comparison to 
i (2004) patients exceeded 97%. standard alpha 
interferon 
C018 Posaconazole Same trials: The issues reported were: The issues reported were: 5 Recommended - license 
40mg/ml oral SCH56592 (1) The non-comparative (1) The uncontrolled study The issues reported were: 
suspension (unpublished) + study design and did not allow a (1) The comparison of 
retrospective data comparison with a comparison of costs is based on 
retrospectively identified posaconazole with median duration of 
SMC: Indirect control group. voriconazole. treatment with very 
comparison included. (2) Patient population - The wide range for each 
majority of the patients in drug. 
the posaconazole group 
had received prior 
treatment with 
amphotericin. 
C023 Tipranavir Same trials: The issues reported were: No issues reported. 3 Restricted - Subgroup 
2S0mg RESIST 1 study and (1) Long term safety issues No issues reported. 
RESIST 2 study. and adverse events The economic evaluation was 
profile require further well designed. 
information. 
C024 Infliximab SMC: The issues reported were: The issues reported were: 3 Restricted - Subgroup 
l00mg Gottlieb (2004), Reich (1) Lack of direct (1) Lack of a direct No issues reported. 
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(2005) & Menter (2006) comparison- in comparison - with 
comparison to etanercept etanercept and 
Indirect comparison or efalizumab. methotrexate. Indirect 
included. comparison submitted 
by manufacturer but 
HAS: not deemed suitable. 
Chaudhai (2001), 
Gottlieb (2004), Reich 
(2005) 
Indirect comparison 
included. 
C025 Sodium SMC: The issues reported were: The issues reported were: 4 Not recommended - license 
oxybate XYREM (2002), XYREM (1) lack of direct comparison (1) larger scale long term The issues reported were: 
500mg/ml (2003a), XYREM with other licensed trials are necessary to (1) The utility values may 
(2003b), XYREM (2005) products - A comparison clearly demonstrate not be representative 
between sodium oxybate the benefit of clomipramine 
HAS: and clomipramine which (2) The effects of treated patients 
XYREM (2002), XYREM is the only other licensed discontinuing sodium (2) The resource savings 
(2003a), XYREM product for the treatment oxybate therapy. (3) No costs for the 
(2003b), SXB-6, SXB-7 of cataplexy in adults with treatment of adverse 
narcolepsy. events were recorded 
(2) Dosing regimen - The (4) Non-responders maybe 
dosing regimen maybe on sodium oxybate for 
problematic in practice. more than 3 months. 
C026 levetiracetam Same trial: The issues reported were: No issues reported 3 Recommended - license 
250, 500, 750 Glauser (2006) (1) lack of direct The issues reported were: 
& 1000mg comparisons with other (1) There were some 
anti-epileptic drugs. weaknesses in the 
(2) Dosage mechanism - submission but these 
dose titration in practice are not expanded upon 
is unlikely to follow such a in the document. 
rigid titration as in the 
trials. 
C027 Exemestane Same trial: The issues reported were: The issues reported were: 3 Restricted use license 
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2Smg tablets Coombes (2004) (1) long term outcome (1) The exclusion of No issues reported. 
studies patients with early The choice of patient 
(2) Lack of direct comparison recurrences. population, comparator and 
, with other aromatase (2) Comparison with other economic modelling approach all 
inhibitors. comparator regimes- seem appropriate. 
A comparison of the 
benefit of sequential 
treatment compared 
with treatment with an 
aromatase inhibitor 
prescribed 
immediately. 
C028 Adalimumab Same trials: The issues reported were: The issues reported were: 2 Recommended - License 
40mg ATLAS study, (1) Patient population - Only (1) lack ota direct No issues reported. 
solution for Maksymowych (2005) 56% and 42% of the comparison with other The choice of comparator and 
injection patient populations in the TNF antagonists modelling approach were 
two trials had received etanercept and broadly acceptable. 
treatment with at least infliximab 
two DMARDs. The 
populations may differ 
from Scottish patients. 
(2) lack of direct 
comparisons - There are 
no direct comparisons of 
adalimumab with other 
TNF-antaginists for the 
treatment of arthritic and 
psoriatic symptoms in 
patients. 
C029 Sorafenib Same trials: The issues reported were: No issues reported. 2 Not recommended -license 
200mg Escudier (2007) phase (1) lack of studies against The issues reported were: 
III, Ratain (2006) the active comparator- (1) The extrapolation and 
sunitinib. reapplication of the 4th 
(2) Patient cross-over in trial. cycle transition 
probabilities 
substantially reduces 
-----
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the confidence in the 
long term cost-
effectiveness. 
C030 Voriconazole Same trials: The issues reported were: The issues reported were: 4 Restricted - Subgroup 
50mg & Kullberg (2005) (1) Dosage - The intravenous (1) Patient population - The issues reported were: 
200mg tablet, maintenance dose in the Patient characteristics (1) The use of the clinical 
40mg/ml oral clinical study was 3mg/kg at baseline were similar trial data, lower 
suspsension twice daily which is except for the mean maintenance dose and 
& 200mg vials inconsistent with the APACHE II score which patient weight in 
for infusion. maintenance dose, listed was higher in the clinical trials-
in the summary of amphotericin manufacturer asked to 
product characteristics B/fluconazole than produce additional 
(SPC) of 4mg/kg twice patients treated by analysis. 
daily. voriconazole. The 
(2) Submitted indication - incidence of renal 
the indication was for events was higher in 
second line following the amphotericin 
fluconazole where B/fluconazole group 
patients were fluconazole than in the 
resistant or refractory to voriconazole group. 
fluconazole. The study 
considered voriconazole 
with conventional 
amphotericin B followed 
by fluconazole for the 
primary treatment of 
non-neutropenic 
candidaemia. 
C032 Nebivolol SMC: The issues reported were: No issues reported 3 Recommended - License 
smg SENIORS (2005), Edes (1) lack of direct trials The issues reported were: 
(2005) comparing nebivolol with (1) The analysis compared 
other beta-blockers. nebivolol to carvedilol, 
Indirect comparison (2) Intention to treat analysis which is the more 
included. - The ITT analysis should expensive f the two 
include all patients available beta-blockers 
~ .. ---- JiAS: randomized, and no that could have been 
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SENIORS (2005) reason is given for the used in the comparison. 
exclusion of a study (2) The mean age in the 
centre. model was 70, which 
was 6 years less than 
the mean age in the 
clinical trials and likely 
age of the population of 
interest in Scotland. 
This is likely to 
overestimate the gain 
in life. 
C033 Daptomycin Same trial: The issues reported: The issues reported were: 5 Restricted - Subgroup 
350mg Arbeit (2004) (1) Other direct comparisons (1) Type of infections in No issues reported. 
- There are no directly the trials - The clinical It was appropriate to use a cost-
comparative clinical data efficacy of daptomycin minimisation approach because 
comparing daptomycin against Enterococcus the submitted clinical evidence 
with Iinezolid or faecalis and demonstrated equivalent 
quinupristin/dalfopristin. Enterococcus faecium efficacy of daptomycin and 
(2) Types of infections has not been Vancomycin. 
included - The numbers established. The 
of patients in some product cannot be 
groups were small and positioned in the 
these may affect the therapeutic 
extrapolation of the trial management of severe 
results in terms of clinical infections. 
success in the studies into 
practice. 
C034 Alglucosidase SMC: The issues reported were: The issues reported were: 2 Not recommended - license 
alfa 50mg Kishnani (2007), Trial (1) late onset - the available (1) There are no long-term No issues reported. 
Orphan Drug 1702, AGl02804 evidence does not efficacy and safety data The analysis was clear, concise 
demonstrate efficacy in available and well conducted but given 
HAS: this group of patients. It is (2) Data on late-onset the extremely high cost for the 
Kishnani (2007), Trial not clear if the data can Pompe disease is very health gain the economic case 
1702, AGl02804 be extrapolated from limited. was not demonstrated. 
infantile-onset disease. I 
(2) long term data - £244,450 - £318,283 per QAl V. 
----------
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uncertainty whether 
patients remain in good 
long term health. 
C036 Tigecycline Same trials: The issues reported were: This issues reported were: 5 Restricted - license 
SOmg Ellis-Grosse (200S), (1) Lack of other direct (1) Lack of other direct The issues identified: 
Sacchidanand (2005) comparisons. The trials comparisons. The (1) The evaluation 
compared to Vancomycin comparators used in considered clinical data 
and azetreonam. These the trials Vancomycin that does not represent 
antibiotics are not and azetreonam are 2nd or 3rd line treatment 
rountinely used in not the reference usage rather first line. 
Scottish practice for skin comparators. 
and soft tissue infections. (2) Patient population -
American study design. There were patient 
(2) Patient population - groups excluded which 
Patients were recruited in would be important in 
2 of 65 centres this context. 
participating in the global (immunodepressed 
trial. It is not possible to patients). 
determine from the data 
whether there are any 
differences between the 
Scottish population and 
I 
total trial population. 
C037 Tigecycline Same trials: The issues reported were: The issues reported were: 5 Restricted - License 
SOmg Olivia (2005) & (1) Patient population - (1) Patient population The issues reported were: 
Babinchak (2005) Patients from the UK included - The mean (1) The manufacturer's 
were recruited in 2 ofthe APACHE score was 6 analysis used clinical 
94 centres participating in and only 4% of patients effectiveness data from 
one of the trials. It is not had a score>lS. The 2nd line or 3rd line 
possible to determine number of patients therapy rather than 
whether there are any with a severe first line. 
differences between the underlying pathology (2) The possibility that 
Scottish population and was limited. The other factors other than 
the total trial population. patients not bacterial resistance 
(2) lack of other direct representative of those patterns might 
comparisons - The trials in practice. influence clinical 
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compared with (2) lack of other direct response has not been 
imipenem-cilastatin comparisons - with considered. 
which is not routinely other antibiotics. 
used in Scottish practice. 
(3) limited number of 
infections - The trials 
described in the evidence 
submission gave a limited 
number of pathogens 
resistant to other 
antibiotics which were 
isolated. 
C038 Pegaptanib Same trial: The issues reported were: The issues reported were: 3 Restricted - Subgroup 
O,3mg VISION study (1) Patient population - (1) Patient population - No issues reported. 
entry requirements in the caution should be The key strength of the 
trial defined subfoveal exercised in evaluation was that the clinical 
neovascular AMD, interpreting results as data has provided a targeted 
implying that patients 13-35% of patients, treat~ent option for Scottish I 
with extrafoveal or based on the groups in practice. 
juxtafoveal disease were both studies, also 
excluded from the trials. received verteporfin 
(2) long term efficacy - The FPT treatment during 
trial design may limit the the study. 
analysis of efficacy in the (2) lack of direct 
second year compared to comparison with 
the first year. verteporfin. The 
marketing 
authorisation was given 
6 years earlier. 
C040 Testosterone Same trial: The issues reported were: The issues reported were: 5 Recommended - license 
undecanoate Schubert (2004) (1) Dosage variations- (1) There was no No issues reported. 
1000mg/4ml comparative testosterone hypothesis formulated The economic evaluation was 
oily solution SMC: Indirect levels in the direct study of superiority or generally adequately designed, 
comparison included are difficult to interpret equivalence and no with a plausible comparator. 
because of variation in determination of 
-- '------- -
the dosing interv~~s and . sample size. The study _ 
--
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pharmacokinetic profile is exploratory and 
of different formulations descriptive and no 
relative to the sampling statistical tests 
points for assay performed. 
testosterone. (2) lack of comparison 
(2) The indirect comparison with other routes of 
had several weaknesses administration of 
but clinical experts did testosterone. 
not raise concerns about 
the comparative 
effectiveness. 
C043 Rituximab Same trial: No issues reported. No issues reported. 1 Restricted - license 
10mg/ml Van Oers [EORTC 20981 The issues reported were: 
study] (2006) (1) The model structure did 
not include adverse 
events. 
(2) Uncertainty stemming 
from the long-term 
nature of the disease 
C04S Ivabradine SMC: The issues reported were: The issues reported were: 3 Restricted - subgroup 
Smg& 7.Smg Tardif (2005), Ruzyllo (1) Patient Population - The (1) lack of other direct The issues reported were: 
(2007), [ x3 long term trial population may not comparisons - There is (1) The justification of 
studies] be representative of the no study available primary care resource 
Scottish population that versus other calcium use estimates were not 
HAS: would be eligible for inhibitors (especially provided and costs of 
Borer (2003), Tardif ivabradine. diliazem and managing ivabradine 
(2005), Ruzyllo (2007), (2) The robustness of the verapamil). related adverse events 
Cl03-018, [x3 long term non-inferiority trial (2) Patient population - were not estimated. 
safety studies] questioned by the EMEA. There were no studies (2) Concerns over the 
that enrolled patients comparator chosen of 
with contraindications no treatment for those 
or intolerance to beta- who are 
blockers. contraindicated or 
intolerant to beta-
blockers and calcium 
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channel blockers. No 
evidence for other 
possible treatment 
options. 
C046 Natalizumab Same trials: The issues reported were: The issues reported were: 3 Restricted - Subgroup 
300mg Polman [AFFIRM study] (1) The EMEA uncertainties (1) lack of other direct The issues reported were: 
(2006), Rudick (2006) highlighted with regards comparison study. The (1) The case was only made 
treating the trial committee regretted in rapidly evolving 
subgroup analysis with the absence of any severe RRMS. 
caution. There is no comparative study with (2) The data used was I 
documentation on the mitoantrone for the taken from the trials in 
severity of relapses, treatment of aggressive all patients with RRMS 
either by clinical course recurring-remitting rather than the RES 
or duration. forms of MS and the subgroup. 
(2) lack of controlled insufficient amount of (3) The assumption of 
comparative studies - data on natalizumab as assuming the treatment 
with existing therapies a monotherapy in the would continue 
such as beta-interferon or population defined by irrespective of the ti me 
glatiramer acetate. the indication. from start of treatment 
(2) long term safety or EDSS state. 
concerns. 
C047 Parathyroid SMC: The issues reported were: The issues reported were: 5 Restricted - license 
hormone PATH study, TOP study (1) Primary outcome - The (1) lack of direct There were no issues reported. 
100mcg trial comparing comparison - The The evaluation was presented 
Indirect comparison parathyroid hormone committee would of concisely, used a range of 
included. with alendronate liked to of been comparators and included 
assessed BMD but not presented with a direct adequate sensitivity analysis. 
HAS: fracture rates. However comparison with 
Top study, PATH study, anti-fracture efficacy is teriparatide or any 
OlES study, POWER not solely related to BMD other anti-osteoporosis I 
study and estimates of the drugs. 
relative benefits on 
Indirect comparison fracture rates with the 
included. drugs cannot be derived 
from this outcome. 
-
(2) lack of other cEl1lparator 
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trials - There are no trials 
directly comparing PTH 
with teriparatide. 
C048 Rituximab SMC: The issues reported were: The issues reported were: 2 Recommended - license 
lOOmg/10ml, REFLEX study (1) lack of other direct (1) lack of a direct There were no issues reported. 
SOOmg/50ml comparisons with other comparison with The model structure was 
Indirect comparison DMARDs or TNF- anotherTNF appropriate and the analysis was 
included. antagonists. antagonist. well described. 
HAS: 
REFlEX study, 
EDWARDS study, 
DANCER study. 
C049 levetiracetam Same trial: There were no issues reported. No issues were reported. 4 Restricted - license 
250, 500, Brodie (2007) The issues reported were: 
1000mg & (1) The manufacturers 
100mg/ml SMC: Indirect submission suffered 
oral solution, comparison included. from a lack of 
100mg/ml transparency and clarity 
diluted for (2) The use of a limited 
infusion. indirect comparison. 
COSO levetiracetam Same trial The issues reported were: No issues were reported 3 Recommended - license 
250, 500, Berkovic (2007) (1) lack of direct comparison There were some weaknesses 
1000mg & with other anti-epileptic raised with the submission. 
100mg/ml drugs for the licensed These were not explicitly raised. 
oral solution, indication. The sensitivity analysis gave 
100mg/ml (2) The selection criteria in reassurance. 
diluted for those patients from age 
infusion. of four. 
C051 Palonosetron Same trials: There were no main issues raised There were no issues reported. 4 Recommended -license 
250 mcg Gralla (2003), Eisenberg The issues reported were: 
(2003), Aapro (2003) (1) The reliance on non-
statistically significant 
treatment differences 
(2) The assumptions 
._-
L-. _ .. ________ .. ______ 
---
reg<.lrding dose and 
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efficacy of comparator I 
product I 
C052 Posconazole Same trials: The issues reported were: The issues reported were: 3 Recommended - License I 
40mg/ml oral Ullmann (2007), (l) Infection Type - The (l) The committee would The issues raised were: 
suspension Cornely (2007) comparative efficacy data of liked information on (l) Itraconazole may have 
relative to itraconazole, the method of isolation been the more 
are limited by small group of patients in the appropriate comparator 
sizes. studies. in the trial. 
(2) Patient population -
very few patients had 
grade 3-4 mucositis in 
the population studied. 
It is therefore difficult 
to draw conclusions on 
the efficacy of such 
prophylaxis in patients 
_ _ ,_ __ '----- ____ with se-"er~mu-=-co-,--s,---it_is_._,--___ --,--___________ __ 
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Table A6.4: Data and reasons for differences in recommendations 
Code Medicine Type Discrepa Trials similar Comparators Primary HAS 
-
SMC 
-
clinical Type of Economic Reason for 
nt rec Outcome ASMR effectiveness Economic estimate discrepancy 
Analysis 
COOl Botulinum C-C-C Yes Yes-add ev Different Modified 5 Clinical effective Cost utility Dominates Uncertainty 
type A Trials - placebo Ashworth for endpoints but surrounding the 
SMC - Three Score uncertainty about relative 
placebo RCT, 1 SMC (MAS) the effectiveness and 
Phase II, 2 Usual Care transformation to difference in 
Phase III QoL benefit comparators, HAS 
HAS - Active provides ASMR of 
comparator drugs 5 and list SMC not 
recommended 
C002 ribavirin C-c- Yes Yes Trials -placebo Sustained 3 Clinically effective Cost utility £490 Both agree 
NC Viral for endpoints and clinical 
Two SMC Response QoL effectiveness and 
uncontrolled Best supportive (SVR) improvement. Cost-
trials care effectiveness 
demonstrated -
HAS restriction 
~~ Best supportive imposed by HAS care (minor 
... 
restriction) on 
specialist and 
monitoring 
C007 rasagiline C-C-c Yes Yes Trials - placebo UPDRS 5 Uncertainty Cost Dominates Uncertainty in the 
2 double blind regarding the effectivene relative 
RCT SMC: Selegine, relative ss effectiveness for 
levodopa plus a effectiveness in SMC and issues 
dopa comparison with with fitness for 
decarboxylase other medicines purpose of model 
inhibitor and not sufficient to 
dopamine demonstrate 
receptor agonists. economics (not 
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recommended) 
HAS: Selegine, No improvement 
levodopa plus a in relative 
dopa effectiveness for 
decarboxylase HAS. 
inhibitor and 
dopamine 
receptor agonists. 
i 
C008 rasagiline C-C-C Yes Yes Trials: placebo, Average 5 Indirect Cost (£) saving Both agencies 
Two Double active change in comparison minimisati come to the same 
blind RCT (one comparator mean off No demonstrates on conclusion 
placebo (entacapone) time indirect improvement of regarding 
controlled, compar entacapone over uncertainty of 
one active SMC: Selegine, ison. other COMT relative 
comparator) levodopa plus a inhibitors but no effectiveness with 
dopa direct comparison selegiline. SMC 
decarboxylase of rasagline with does not 
inhibitor and selegiline. recommend 
dopamine Equivalence to because the 
receptor agonists. entacpone economic 
evidence includes 
HAS: Selegiline an inappropriate 
(MAO-B inhibitor) comparator. 
COOg lanthanu C-C- Yes Yes - Two Trials: placebo Serum 5 Broad Cost utility £6,741 Both agree on 
m NC Double blind and calcium Phosphate equivalence clinical 
carbonate RCTs Phase III carbonate levels between lanthum equivalence. The 
(one placebo, carbonate and manufacturer's 
one active SMC: Sevelamer, sevelamer even economic 
comparator) calcium though no direct evidence 
carbonate data. Modelled submission to the 
improvement in SMC is in a 
HAS: HrQol in subgroup of the 
Sevelamer comparison to licensed patient 
calcium group (second 
- carbonate. line) and 
--~--
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concludes cos-
effectiveness has 
been 
demonstrated in 
this group against 
one of the 
comparators 
(calcium 
carbonate). 
COlO omalizuma C-C-C Yes Yes - One Different Rate of 4 Relative Cost utility £30,995 Both agree on the 
b Double blind Trials: Placebo clinically effectiveness as relative 
Multi Centre significant an adjunctive effectiveness with 
RCT SMC: leukotriene asthma therapy but not regards to best 
receptor exacerbati determined in supportive care. A 
antagonist, SR ons relation to slow different relevant 
theophyline or ral release comparator in 
beta-2-agonist theophyllines or Scotland, which 
anti-Ieukotriene led to the analysis 
HAS: Best agents. focusing on a 
Supportive Care subgroup (all 
other treatments 
failed. 
COB erlotinib C-C-C Yes Yes add ev Trials: Placebo Overall 5 Indirect Cost utility £22,500 Uncertainty 
Survival comparison show regarding relative 
5MC: Double SMC: Docetaxel a comparable effectiveness for 
Blind RCT monotherapy, overall survival HAS (ASMR=5) 
Phase III pemetrexed, Best outcome with and judged 
(placebo) Supportive Care docetaxel and a equivalent for 
more favourable overall survival in 
HAS: Double HAS: Docetaxel, adverse event comparison to 
Blind RCT Permetrexed, profile. docetaxel. The 
Phase III Best Supportive economic 
(placebo) plus Care evidence is 
non- considered by the 
comparative SMC which 
Phase (( study. involved an 
- -- --------------- ----
-_ .. -
---
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indirect 
comparison show 
comparable 
overall survival 
outcomes and 
improvement in 
adverse events 
resulting in 
quality of life 
benefits. 
Recommended in 
a restricted group 
of those eligible 
for docetaxel. 
C015 Ibrandroni C-C- Yes Yes Trials: Placebo Rate of 5 - No active Cost (£15) Uncertainty 
cacid NC morpho me Indirect comparators with minimisati saving regarding clinical 
Two Double SMC: Oral tric compar other standard on efficacy for HAS. 
Blind Phase III bisphosphonates vertebral ison treatments. Clinical 
RCTs (Placebo) Alendronate, fractures provide Meta-analysis of equivalence 
risedronate d but 32 RCTs shows judged by a meta-
sodium, populat ibrandronic acid analysis for SMC 
raloxifene, ions of to be broadly and economic 
disodium trials equivalent to evidence 
etidronate, had other demonstrates 
calcitronin and differe bisphosphonates. cost-saving. HAS 
teripartide nt places restriction 
populat on reimbursed 
HAS: Oral ions indication. 
bisphosphonates. 
C016 Pegylated C-C-C Yes Yes-add ev Seroconve 5 Trial shows Cost utility £5,300 Both consider 
interferon Trials: (active rsion clinical common 
alfa 2a SMC: Two comparators, effectiveness in comparators and 
Phase III lamivudine) comparison to reach similar 
studies lamivudine which conclusions 
(Iamivudine SMC: is the most surrounding the 
monotherapy conventional commonly used clinical efficacy in 
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and interferon alfa 2a in clinical comparison to 
combination and alfa 2b. practice. Data conventional alfa 
of lamivudine lamivudine. limited to a Phase 2a and 
and pegylated Adefovir dipivoxil. II Australasian lamivudine. The 
interferon alfa study for economic 
2a) HAS: Interferon comparison with evidence 
One Phase II alfa 2a and alfa conventional modelled showed 
dose finding 2b. lamivudine. interferon alfa 2a. improvement in (pegylated quality of life and 
interferon alfa an acceptable 
2a versus cost-
conventional effectiveness. 
interferon alfa HAS minor 
2a) restriction 
(specialist and 
HAS: Two monitoring) 
Phase III 
studies 
(Iamivudine 
monotherapy 
and 
combination 
of lamivudine 
and pegylated 
interferon alfa 
2a) 
C023 Tipranavir C-NC- Yes Yes Trials: (active Reduction 3 Relative Cost utility £28,000 Both agencies 
NC comparator - pre in viral effectiveness agreed on the 
Two RCT selected protease load against other relative 
Phase III (pre inhibitors) protease effectiveness. The 
selected inhibitors was manufacturer 
protease SMC: Other established. submitted a cost-
inhibitor plus boosted effectiveness 
ritonavir) proteases analysis in highly 
inhibitors; pre-treated 
lopinavir /ritonavir patients. The 
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, cost -effectiven ess 
atazanavir/ritona was 
vir, demonstrated. 
saquinavir/ritona 
vir, 
amprenavir triton 
avir, 
fosamprenavir/rit 
onavir 
HAS: . Boosted 
protease 
inhibitors 
C024 infliximab C-C- Yes Yes-add ev Trials: placebo PASI75 3 - No active Cost utility £27,354 Both committees 
NC Indirect comparator trials concur on the 
SMC: SMC: etanercept com par comparing relative 
3 Double Blind and efalizumab ison infliximab with effectiveness. The 
RCTs (placebo) provide etanercept and economic model 
HAS: d but efalizumab. An used the indirect 
HAS: Etanercept and commit indirect comparison and 
X3 Double afalizumab tee comparison was extensive 
Blind trials judged performed by sensitivity 
(placebo) was NICE which analysis provided 
not demonstrated a demonstrated 
possibl greater response cost-effectiveness 
e to but this could be for patients with 
base due to differences severe plaque 
conclus in trial psoriasis. 
ions populations. (restricted) 
becaus 
e no 
assess 
ment 
of 
hetero 
....J -_._-
geneity 
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, not 
, conclus 
ive 
whethe 
r trials 
were 
compre 
hensive 
. A 
direct 
compar 
ison 
would 
be 
helpful. 
C025 Sodium C-C-C Yes Yes-add ev Different Change in 4 There is no direct Cost utility £65,980 The two agencies 
oxybate Trials: placebo Cataplexy comparison which considered 
SMC: Two attacks compares sodium different 
RCTs Double SMC: oxybate with comparators for 
Blind Clomipramine clomipramine, practice in France 
(placebo) uncertainty with and Scotland 
HAS: regards the The economic 
HAS: Two Best Supportive relative analysis was not 
RCTs Double Care effectiveness cost-effective at 
Blind the current price 
(placebo), and and there were 
6 month Open weaknesses with 
label RCT the submission. 
(not 
recommended) 
C027 exemestan c-c- Yes Yes Trial: (active Disease 3 Advantages in Cost utility £14,980 Both agencies 
e NC comparator, Free terms of disease agree on relative 
Double Blind tamoxifen, survival free survival. This effectiveness of 
RCT exemestane) translates into the medicine. 
(exemastane, QAlY gain Economic case 
tamoxifen) SMC:Tamoxifen, overtime in the demonstrated 
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anastrozole, economic model. through a robust 
letrozole. analysis (minor 
, 
restriction) 
HAS: Tamoxifen, 
anastrozole and 
letrozole. 
C028 adaJimuma C-e- Yes Yes Trials: Placebo ACR20 2 - Relative Cost utility £29,000 Both agree on 
b NC Indirect effectiveness in relative 
Two Double SMC: Etanercept, compar comparison with effectiveness with 
Blind RCT infliximab ison placebo but respect to 
(placebo) was uncertain with placebo but 
HAS: Etanercept, not regards other TNF uncertainty with 
infliximab adopte antagonists. respect to 
d etanercept. The 
becaus manufacturer's 
e of economic 
weakne submission to the 
sses SMC explores the 
with sensitivity of the 
the modelling and 
metho concludes cost-
dology effectiveness for 
adaJimumab. 
(Minor restriction 
for HAS) 
C029 Sorafenib C-NC- Yes Yes Trials: Placebo Progressio 2 Relative Cost utility £35,523 Both agencies 
C n Free effectiveness in agree on relative 
Double Blind SMC: Best Survival terms of PFS but effectiveness for 
RCT Phase 1/1 Supportive Care (PFS) uncertainty PFS but await 
(placebo) and regarding overall results of overall 
Phase" study. HAS: Best survival. survival (ASMR 
Supportive Care =2). Concerns 
with 
extrapolation 
after the trial 
- -
_._-
--
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periods and too 
high cost-
effectiveness (not 
recommended by 
SMC). C030 voriconazo C-e-e Yes Yes Trials: , (active Successful 4 Clinical study Cost (£1,436) HAS judge there Ie comparator) response shows relative minimisati saving to be an One open to effectiveness on improvement on 
label RCT ( SMC: treatment versus the active the basis of safety 
voriconazole Amphoericin B, comparator but in comparison to 
vs fluconazole and does not support Amphotericin 
amphotericin caspofungin. the submission second line 
B followed by for second line. (ASMR=4) 
fluconazole) HAS: Weaknesses in 
Amphotericin B, the model by use 
fluconazole, of clinical trial 
Caspofungin and data, patient 
Fluxytosine. weight and 
maintenance. 
There was a need 
for treatment in 
those that do not 
respond. 
(restriction to this 
patient group in 
SMC) 
C033 daptomyxi C-e- Yes Yes Trials Clinical 5 - Non-inferiority Cost (25) saving Both agree on 
n NC Different Success populat demonstrated to minimisati relative 
Two ion comparators on effectiveness with 
Investigator SMC: studies used. There are regards to non-
blind RCTs Vancomycin, did not no studies inferiority in trial (Daptomycin, teicoplanin, include comparing population but 
or linezolid, severe daptomycin with cannot be placed 
penicillinase- quinupristin/dalfo infectio linezolid or in HAS severe 
resistant pristin. ns quinupristin/dalfo infections 
penicillin or pristin which may because of lack of 
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- -
Vancomycin). HAS: Beta be used in severe infections I 
lactams, Scottish practice. in trial population • 
quinolines, which was also 
macrolides, highlighted by 
, 
glycopeptides, SMC. The 
aminoglycosides, manufacturer 
oxazolidinones submitted a cost-
and synergistins. minimisation 
analysis to the 
SMC in a 
subgroup of 
patients with 
suspected or 
confirmed MSRA 
infection. (Major 
restriction SMC). 
C034 Alglucosid C-e- Yes Yes - Three Trials: Proportion 2 Relative Cost utility £318,283 Both committees 
ase alfa NC non- (alglucosidase- of patients effectiveness concur on the 
comparative orphan drug) alive and demonstrated improvement of 
trials free of against Best relative 
matched with SMC: Best invasive Supportive Care. effectiveness 
a group Supportive Care ventilation (ASMR=4) 
without . A well conducted 
symptoms. HAS: Best analysis but not 
Supportive Care cost-effective at 
price (Not 
recommended). 
C036 tigecycline C-C-e Yes Yes Trials: (active Test of 5 Studies show Cost utility Not Both agree that 
comparators) Cure (TOC) tigecycline to be reported relative 
Two Double non-inferior to effectiveness 
Blind RCTs SMC: Vancomycin- shown in the 
(vancomycin Flucloxacillin and azetreonam. study 
followed by Benzylpenicillin, These are not comparisons but 
aztreonam) beta-Iacta routinely used in relevance to 
antibiotics and Scottish Practice clinical practice 
macrolides and no direct questionable. 
-_ .. _._-- -- ------_._.-
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comparisons with There are 
HAS: beta-Iactam, other antibiotic weaknesses in the 
quinolones, regimes. economic 
macrolides, evidence and use 
glycopeptides. of the clinical 
Aminoglycosides, evidence. 
oxazolidinones, Restricted to use I 
synergistins. for second and 
third line (Major 
restriction SMC). 
(037 ligecycline C-C-C Yes Yes Trials: (active Test of 5 The comparator (ost utility Not Both agree 
comparator) Cure (TOC) in the trials is not reported relative 
Two Double routine in Scottish effectiveness 
Blind RCT HAS: beta-Iactam, clinical practice. shown in the 
(tigecycline vs quinolones, Uncertainty study comparison 
imipenem- macrolides, regarding other but relevance to 
cilastatin) glycopeptides. direct clinical practice 
Aminoglycosides, comparisons. questionable. 
oxazolidinones, (ASMR=5). 
synergistins. There are 
weaknesses in the 
SM(: (efotaxime economic 
plus evidence and use 
metronidazole, of the clinical 
piperacillin- evidence. 
tazobactam, Restricted to use 
meropenem, for second and 
Vancomycin. third line (Major 
restriction SMC). 
(040 Testostero c-e- Yes Yes Trials (active Erthropoie 5 Similar relative (ost utility £2,019 The Transparency 
ne NC comparator) sis and efficacy in committee 
undecanoa One RCT Grip comparison to discounted the 
te (testosterone SM(: strength enanatate trial evidence 
undecanoate Testosterone (clinical because of 
vs enentate) enantate, equivalence). A methodological 
- --- --------
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Testosterone indirect weaknesses 
propionate, treatment (ASMR=5) and 
Testosterone comparison was restricted 
esters. provided that had reimbursement to 
I several non age related 
HAS: weaknesses. androgenic 
Testosterone deficiency. 
enanthate, Uncertainty in 
testosterone indirect 
esters comparison but 
sensitivity 
analysis confirms 
likely cost-
effectiveness. 
(Recommended 
listing) 
C045 ivabradine C-C-C Yes Yes-add ev Trials (active Total 3 Non-inferiority of Cost utility £15,021 Both agree 
comparator) Exercise ivabradine vs relative 
SMC: Two Duration atenolol and effectiveness 
Double blind SMC: Calcium- (TED) iva bra dine versus established in the 
RCT Phase 1/1 channel blockers, amlodipine was comparator drugs 
(ivabradine vs nitrates and shown. but ASMR (3) for 
atenolol) and potassium the same 
(ivabradine vs channel indication as 
amlodipine) activators SMC. 
Three 1 year M a nufactu rer 
safety studies. HAS: Calcium submitted within 
channel blockers, a subgroup of the 
HAS: Two nitrates , licensed 
Double blind nicrorandil population. 
RCT Phase III There were 
(ivabradine vs concerns over the 
atenolol) and comparator 
(iva bra dine vs chosen but there 
amlodipine), may be a small 
__ one Double group of patients 
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blind RCT 
with no other (placebo) treatment option. 
Phase II and (Major 
Double blind 
restriction) 
RCT (placebo) 
Phase III and 
three 1 year 
studies 
C046 natalizuma C-C-C Yes Yes Different Patient 3 There is a Cost-utility £22,500 Both agree b Trials: relapse clinically uncertainty with 
Two studies - important regards the active 
Double blind SMC; Beta- reduction in comparator of RCT (placebo) interferon, clinical relapse. mitoxantrone in 
Phase III, One glatiramer There are no France and beta-
RCT acetate active interferon in (natalizumab comparator Scotland. An 
vs beta HAS: studies resulting (ASMR=3) was 
interferon la) Mitroxanatrone in uncertainty. only provided for 
the RES group 
and requests an 
observational 
study be 
provided. 
Manufacturer 
submitted an 
economic analysis 
in the RES 
subgroup. There 
were concerns 
with model were 
explored through 
sensitivity 
analysis and 
considered cost-
effective. 
(Restricted) 
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C049 levetiracet NC- Yes Yes Trial: Active 6 month 4 Non-inferiority Cost utility £413 Both agree on the 
am NC-C comparator seizure demonstrated in non-inferiority in 
One Double freedom comparison to comparison with 
Blind RCT SMC: carbamazepine. A carbamazepine 
(Ievetiracetam oxacarbazepine, limited indirect and HAS provides 
vs gabapentin, comparison was a ASMR=4. 
carbamazepin topiramate, performed to Manufacturer 
e) sodium valproate, compartor. positioned as 
carbamazepine, second line. 
lamotrigine, There were a 
phenytoin. number of 
weaknesses with 
HAS: Phenytoin, indirect 
Primidone, comparison to 
Gabapentin, derive the 
lamotrigne, relative efficacy 
Phenobarbital, and high utility 
Carbazepine, values but 
Valporic acid, reassurance was 
Oxcarbazepine, provided by a 
Clonazepam number of 
sensitivity 
analyses (Major 
restriction). 
C052 posaconaz C-C-C Yes Yes Trials: Active Incidence 3 Posaconazole Cost utility £27,907 Both agree on the 
ole comparator of appears to be non-inferiority 
Two studies: probable/p more effective demonstrated 
One Double SMC: Fluconazole, roven than fluconazole, against the active 
Blind RCT itraconazole Fungal the comparative comparators in 
(posaconazole infection efficacy of the trials and 
vs posaconazole vs deemed an 
fluconazole), HAS: itraconazole, itraconazole is ASMR=3. 
one open fluconazole and more limited due The cost-
label amphotericin B to small sample effectiveness 
evaluator- sizes. modelling was J 
blind RCT uncertain and 
--
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(posaconazole sensitive to 
vs fluconazole changes in 
or parameters 
itraconazole) (provided when 
other therapies 
not tolerated). 
(Major 
Restriction). 
---- --------- -
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Table A6.5: Reasons for differences In recommendations 
Reason Codes Number 
The appropriate relevant comparators in France and Scotland are COOl, COlO 4 
different. -1 C025,C046 
Both agree on uncertainty in relative effectiveness (HAS: C007, C008, 4 
ASMR=S). There are uncertainties In the economic evaluation C036,C037 
resulting in the SMC advising either a not recommended/major 
restriction. - 3 
Both agree on improvement in relative effectiveness (HAS: C002, C027, 3 
ASMR~S). Manufacturers economic evidence demonstrates cost C028 
effectiveness and minor restriction between agencies -2 
Both agree on improvement in relative effectiveness (HAS: C023, C024, 3 
ASMR~S). Manufacturer submits a cost-utility analysis C049 
demonstrating cost-effectiveness in a subgroup where the SMC 
advises major restriction.- 4 
Both agree on improvement in relative effectiveness (HAS: C029,C034 2 
ASMR~S). The SMC advises to not recommended because the 
medicine is not cost-effective at the manufacturers supplied 
price. - 5 
Both agree on improvement in relative effectiveness (HAS: C045,C052 2 
ASMR~5). Manufacturer submits cost-utility analysis with 
weaknesses in the evaluation resulting in SMC advising a major 
restriction. - 7 
Both agree on uncertainty in relative effectiveness (HAS: C016,C040 2 
ASMR=5). Manufacturer submits a cost-utility analysis for a 
number of scenarios and sensitivity analysis demonstrating likely 
cost-effectiveness. HAS advises major/minor restriction. - 8 
Both agree on relative effectiveness (HAS: ASMR=5). C009, COB 2 
Manufacturer submits a cost-utility analysis in a subgroup 
demonstrating a quality of life benefit and cost-effectiveness. 
SMC advises major restriction. - 9 
Both agree uncertainty in relative effectiveness (HAS: ASMR=5). C033 1 
Manufacturer submits cost-minimisation in a subgroup resulting 
in SMC adviSing major restriction -6 
Both agree on relative effectiveness but ASMR=4 provided on C015 1 
ground of safety for HAS. The manufacturers economic 
submission to SMC contains weakness but advise listing in a 
restricted group because of no treatment alternative - 10 
Difference in judgement of clinical equivalence. HAS evaluates C030 1 
relative effectiveness to be uncertain in the presence of an 
indirect comparison whereas SMC considers a meta-analysis and 
find this to demonstrate equivalence in a restricted group. Cost-
minimisation demonstrates the economic case and SMC advises 
major restriction. - 11 
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Abbreviations 
ABSMA 
ACD 
ACP 
ADTC 
AHTAPol 
AIFA 
AMNOG 
ASMR 
AUnETS 
BMJ 
BNF 
CADTH 
CDR 
CEA 
CEDAC 
CEEPS 
CEPS 
CER 
CFH 
ClY 
CMS 
CPU 
CQG 
CRM 
CUA 
CVZ 
DGHP 
DPS 
DREC 
DUSC 
EBM 
EMA 
EMWGPO 
ERG 
ESC 
EUnetHTA 
FAD 
FDC 
FOPH 
G-BA 
GOP 
Advisory Board for Social Medical Affairs 
Appraisal Consultation Document 
Appraisal Committee 
Area Drug and Therapeutic Committees 
Agency for Health Technology Assessment in Poland 
The Italian Medicines Agency 
Pharmaceutical Market Restructuring Act 
Improvement in Medical Benefit 
The association ofthe Spanish HTA agencies 
British Medical Journal 
British National Formulary 
Canadian Agency for Drugs and Technologies in Health 
Common Drug Review 
Cost-effectiveness analysis 
Canadian Expert Drug Advisory Committee 
Commission for Economic Evaluation and Public Health 
Economics Committee on Health Care Products 
Comparative Effectiveness Research 
Pharmaceutical Assistance Commission 
Cost per Life year gained 
Centre for Medicare and Medicaid Services 
Corporate Pharmaceutical Unit 
Cost per QALY gained 
Committee for Reimbursement of Medicines 
Cost utility analysis 
Dutch Health Insurance Boards 
Directorate General of Pharmacy and Health Products 
Drugs Payment Scheme (DPS) 
Drug and Reimbursement Committee 
Drug Utilisation Sub-Committee 
Evidence Based Medicine 
European Marketing Authorisation 
European Medicines Agency Working Group with Patient Organisations 
Evidence Review Group 
Economic Sub-Committee 
European network for Health Technology Assessment 
Final Appraisal Determination 
Federal Drugs Commission 
Federal Office of Public Health 
Federal Joint Committee and IQWIG 
Gross Domestic Product 
Abbreviations 
GHC 
GMS 
HAS 
HEK 
HIRA 
HMO 
HOD 
HRQOL 
HSE 
HTA 
HTAi 
HVB 
ICER 
IIA 
IJODR 
IMSS 
INAHTA 
INFARMED 
IPHA 
IQWIG 
IRP 
ISSSTE 
KELA 
LTI 
MCDA 
ML 
MNLM 
MTA 
MTA 
MTN 
NCE 
NCPE 
NDC 
NHIC 
NHIFA 
NHS 
NICE 
NIHDI 
NLHS 
NoMA 
NPAF 
OECD 
OHTA 
OTA 
PAPIG 
General Health Council 
General Medical Services 
Haute Autorite de sante 
Medicines Evaluation Committee 
Health Insurance Review and Assessment 
Health Maintenance Organisations 
Ministry of Health Care Services 
Health Related Quality of Life 
Health Service Executive 
Health Technology Assessment 
Health Technology Assessment International 
Federation of Austrian Social Security Institutions 
Incremental Cost-effectiveness Ratio 
Independence of irrelevant alternatives 
Interim Joint Oncology Drug Review 
Mexican Social Security Institute 
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International Network of Agencies for Health Technology Assessment 
National Authority of Medicines and Health Products 
Irish Pharmaceutical Healthcare Association 
The Institute for Quality and Efficiency in Health Care 
Independent Review Panel 
The Institute of Security and Social Services for Government Workers 
Social Security Institutions 
Long term illness scheme 
Multiple Criteria Decision Analysis 
Maximum Likelihood 
Multiple Logistic Regression Model 
Multiple Technology Appraisal 
Medical Technology Administration 
Reimbursement Committee 
New Chemical Entities 
National Centre for Pharmacoeconomics 
New Drugs Committee 
National Health Insurance Corporation 
National Health Insurance Fund Administration 
National Health Service 
National Institute for Health and Clinical Excellence 
National Institute for Health and Disability Insurance 
National List of Health Services 
Norwegian Medicines Agency 
New Product Assessment Form 
Organisation for Economic Co-operation and Development 
Office for Health Technology Assessment 
Office of Technology Assessment 
Patient and Public Involvement Group 
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PBAC 
PBPA 
pCOOR 
PHARMAC 
PMPRB 
PNAC 
PPB 
PPIP 
QALYs 
R&D 
RCT 
RVZ 
SEMESP 
SIIF 
SMC 
SMR 
STA 
TAC 
TAR 
TLV 
TSC 
UK 
UNCAM 
VBP 
VIF 
WHO 
Pharmaceutical Benefits Advisory Committee 
Pharmaceutical Benefits Pricing Authority 
pan Canadian Oncology Drug Review 
Pharmaceutical Management Agency 
Patented Medicine Price Review Board 
Public National Advisory Committee 
Pharmaceutical Pricing Board 
Patient and Public Involvement Programme 
Quality Adjusted Life Years 
Research and Development 
Randomised Controlled Trial 
Council for Public Health and Health Care 
Assessment of Health Economics and Public Health 
Social Insurance Institution of Finland 
Scottish Medicines Consortium 
Medical Benefit 
Single Technology Appraisal 
Technology Appraisal Committee 
Technology Assessment Report 
Pharmaceutical Benefits Board (previously LFN) 
Technical and Scientific Committee 
United Kingdom 
National Union of Health Insurance Funds 
Value Based Approach 
Variance Inflation Factors 
World Health Organisation 
Abbreviations 
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